<SEC-DOCUMENT>0001842952-23-000054.txt : 20230510
<SEC-HEADER>0001842952-23-000054.hdr.sgml : 20230510
<ACCEPTANCE-DATETIME>20230510163458
ACCESSION NUMBER:		0001842952-23-000054
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		50
CONFORMED PERIOD OF REPORT:	20230331
FILED AS OF DATE:		20230510
DATE AS OF CHANGE:		20230510

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Context Therapeutics Inc.
		CENTRAL INDEX KEY:			0001842952
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				863738787
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-40654
		FILM NUMBER:		23907100

	BUSINESS ADDRESS:	
		STREET 1:		2001 MARKET STREET
		STREET 2:		SUITE 3915 UNIT #15
		CITY:			PHILADELPHIA
		STATE:			PA
		ZIP:			19103
		BUSINESS PHONE:		267-225-7416

	MAIL ADDRESS:	
		STREET 1:		2001 MARKET STREET
		STREET 2:		SUITE 3915 UNIT #15
		CITY:			PHILADELPHIA
		STATE:			PA
		ZIP:			19103

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Context Therapeutics LLC
		DATE OF NAME CHANGE:	20210128
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>cntx-20230331.htm
<DESCRIPTION>10-Q
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2023 Workiva--><!--r:25d0e2a1-022e-45ee-a4b8-2723f9a842c8,g:b681c287-491c-4187-8280-df3edb448dfa,d:bd14e01a97b1463b915192a9eff93f0c--><html xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns="http://www.w3.org/1999/xhtml" xmlns:us-gaap="http://fasb.org/us-gaap/2022" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:srt="http://fasb.org/srt/2022" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:cntx="http://www.contexttherapeutics.com/20230331" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:link="http://www.xbrl.org/2003/linkbase" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>cntx-20230331</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="ie35b115501ca468f8cadb8213304a30b_D20230101-20230331" name="dei:AmendmentFlag" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY180L2ZyYWc6YjZjY2Y5NDk4NDAwNDcwNzkzNjFjODFjMTRjNjk5Y2EvdGFibGU6YzU1NDc2MjFmMjIxNDJhOWFjNjBlMTBkZmVkY2I4OGIvdGFibGVyYW5nZTpjNTU0NzYyMWYyMjE0MmE5YWM2MGUxMGRmZWRjYjg4Yl8zLTEtMS0xLTY5OTQ5_ffe7bd93-01a8-4251-b365-68f6ba042ad5">FALSE</ix:nonNumeric><ix:nonNumeric contextRef="ie35b115501ca468f8cadb8213304a30b_D20230101-20230331" name="dei:DocumentFiscalYearFocus" id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY180L2ZyYWc6YjZjY2Y5NDk4NDAwNDcwNzkzNjFjODFjMTRjNjk5Y2EvdGFibGU6YzU1NDc2MjFmMjIxNDJhOWFjNjBlMTBkZmVkY2I4OGIvdGFibGVyYW5nZTpjNTU0NzYyMWYyMjE0MmE5YWM2MGUxMGRmZWRjYjg4Yl80LTEtMS0xLTY5OTQ5_d55726b2-fe29-401f-8316-1db6c693b16e">2023</ix:nonNumeric><ix:nonNumeric contextRef="ie35b115501ca468f8cadb8213304a30b_D20230101-20230331" name="dei:DocumentFiscalPeriodFocus" id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY180L2ZyYWc6YjZjY2Y5NDk4NDAwNDcwNzkzNjFjODFjMTRjNjk5Y2EvdGFibGU6YzU1NDc2MjFmMjIxNDJhOWFjNjBlMTBkZmVkY2I4OGIvdGFibGVyYW5nZTpjNTU0NzYyMWYyMjE0MmE5YWM2MGUxMGRmZWRjYjg4Yl81LTEtMS0xLTY5OTQ5_d4001128-e34e-4c90-b224-73590c75e5ea">Q1</ix:nonNumeric><ix:nonNumeric contextRef="ie35b115501ca468f8cadb8213304a30b_D20230101-20230331" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY180L2ZyYWc6YjZjY2Y5NDk4NDAwNDcwNzkzNjFjODFjMTRjNjk5Y2EvdGFibGU6YzU1NDc2MjFmMjIxNDJhOWFjNjBlMTBkZmVkY2I4OGIvdGFibGVyYW5nZTpjNTU0NzYyMWYyMjE0MmE5YWM2MGUxMGRmZWRjYjg4Yl82LTEtMS0xLTY5OTQ5_8829ec5b-3941-4cd8-b582-88978e032d39">0001842952</ix:nonNumeric><ix:nonNumeric contextRef="ie35b115501ca468f8cadb8213304a30b_D20230101-20230331" name="dei:CurrentFiscalYearEndDate" format="ixt:date-month-day" id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY180L2ZyYWc6YjZjY2Y5NDk4NDAwNDcwNzkzNjFjODFjMTRjNjk5Y2EvdGFibGU6YzU1NDc2MjFmMjIxNDJhOWFjNjBlMTBkZmVkY2I4OGIvdGFibGVyYW5nZTpjNTU0NzYyMWYyMjE0MmE5YWM2MGUxMGRmZWRjYjg4Yl83LTEtMS0xLTY5OTQ5_c27488d6-0f8f-477a-be0b-ce621837419b">12-31</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="cntx-20230331.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="ie35b115501ca468f8cadb8213304a30b_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001842952</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia277388742eb471f9d42d799adb36d70_I20230505"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001842952</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-05-05</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:context id="i9e6ffce2c2d247f491e046febe8251cd_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001842952</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:context id="i4b1713eab7d84494b3b43202a26fc3c4_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001842952</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="i3baf3250062d4a79a9b120fc56f1b18c_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001842952</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i943d13fd1b9f4197ae5a210a64adb3ab_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001842952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifaa2a5dd56c843d9a857de26b952bcfb_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001842952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic501c165e10e47e080880f65f01c1d5b_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001842952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icd5ebf0042ac4aac81eeac59d3a7522d_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001842952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8d193fa8f7974372bd0db6d8ebed8675_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001842952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9f9455c0d0e74c97a9a53955ed07377f_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001842952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib8f0e2696e0648f880780a1ad638027a_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001842952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if64ea5a878c145cdb5ea7e8156bc0335_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001842952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifd24ec169b5741408f1f292b74c4c8e7_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001842952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id6056ac1137049ecbf03cbd976238e74_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001842952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia7a50df0f70a4507a6bc3fee39e5d9c3_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001842952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7970953f78074175b146df53757b2465_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001842952</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic40bb4943d7c476c9169444151149747_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001842952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibf6fa1d37c03414bbe62bf55d335f4fe_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001842952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i81afc8f1d52c4facbecee4956dd23cfd_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001842952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3bf77d6bc24e42a48e050108be77d852_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001842952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6c6c3dc5639243a9bea9f8bc22ea83db_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001842952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iafab01d20e1847b5b62b10c7e70e7bc8_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001842952</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i426de1e79cbb451489bfc39d312e71c9_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001842952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0353d0309620461ab7aee7ea14ec31ba_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001842952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id8892bb22a7e45e7ab17a6a179589967_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001842952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cntx:IssuedForServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie79fb9e8979b4831b96adca175266f37_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001842952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cntx:IssuedForServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iacc367c186494022944e99aa683971ef_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001842952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i56a00969dd024778bc570050ee58a725_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001842952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8c99fb13d0f54109a9578b166514e149_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001842952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8db471e9da7749b2b45d29dfa213f4cc_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001842952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3062cc15f83f4cdfb396a7b04a1c52fc_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001842952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4d1a753ee70a4fd2bfd93f0e3636aa04_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001842952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibcafe063c5b44faf99d7d8aa71157121_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001842952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1badbe53200740efb2a4bd341a6746ea_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001842952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i32dbf7cfaa0f452aae81b03367cca49f_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001842952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id0fabbbc724b4914bb823640a0a66913_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001842952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i226a9d11b9184048a101065b542aff08_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001842952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i71991571d44349a9b2f3d9678cc16557_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001842952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i123230c41d4a4b6cb51151a89a8800c3_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001842952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cntx:IssuedForProfessionalConsultingServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1be90ca5530f4a1d914f1a6103d21bd1_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001842952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cntx:IssuedForProfessionalConsultingServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i68c87024c26f44ab8263dbd0a7fa6a4f_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001842952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cntx:IssuedToPlacementAgentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id3ed5205e2ed4995a41973b9bf8be2de_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001842952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cntx:December2021PrivatePlacementAgentWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4ab77790f64945ee9a78ac502ec36b66_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001842952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cntx:IssuedForProfessionalConsultingServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib10d0ed1d1274880b8a73ff00fe229ab_I20210430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001842952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i37c7d2f5e060456d835ba44ccd4b0c9b_D20210401-20210430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001842952</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:context id="i4ac2f469b04f49ea9a783619785adc82_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001842952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibac63907709f43e8bb17c649e92f3e4d_D20210401-20210430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001842952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i902a704c36e04459a8ef415c67f74f48_D20210401-20210430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001842952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i70f641b88b5a48aeb3fe1ce75baa1362_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001842952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4799146a2fb14bd8b37fc240a795004c_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001842952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaf92495d8d6b4b9a9ec33d201a161246_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001842952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7503ba5b2ff64139bbe478fa4ceedf80_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001842952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i56df8626827b4508b71d14c260351355_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001842952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia22a5f1f807740beb36572d3ab1f91c8_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001842952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i626f38146e594fbca5a1d17b96610d86_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001842952</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i247dcebb8f8f491b838555cf4a897045_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001842952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie4f3b47997974a9c92cf0116fb61189f_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001842952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cntx:TyligandBioscienceShanghaiLimitedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">cntx:ScaleUp100KilogramsOfGMPGradeCompoundMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4798e3c1b6ca496686ec4fd693e57cd8_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001842952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cntx:TyligandBioscienceShanghaiLimitedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">cntx:ScaleUp300KilogramsOfGMPGradeCompoundMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6b2d762a98f94d569b10a0723338a465_D20200301-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001842952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cntx:TyligandBioscienceShanghaiLimitedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-03-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icadec7fbbc8a431cbf67adac36bb34b1_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001842952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cntx:IntegralMolecularIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibffbea9aff4c4a0a9c67a9e90540390f_I20210430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001842952</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cntx:IntegralMolecularIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-30</xbrli:instant></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="ibd14e01a97b1463b915192a9eff93f0c_1"></div><div style="min-height:40.5pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;border-top:2pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="text-align:center;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:139%">UNITED STATES</span></div><div style="text-align:center;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:139%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:139%">Washington, D.C.&#160;&#160;20549</span></div><div style="text-align:center;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">___________________________________</span></div><div style="text-align:center;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:139%">FORM <ix:nonNumeric contextRef="ie35b115501ca468f8cadb8213304a30b_D20230101-20230331" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY18xL2ZyYWc6ZWRiMzM5MDJkYzdlNGY5NTllOGNkNjRiYTExZDQ0NWYvdGV4dHJlZ2lvbjplZGIzMzkwMmRjN2U0Zjk1OWU4Y2Q2NGJhMTFkNDQ1Zl8yMTU5_9ad6a1fc-7d74-4c3f-bb94-d6713f9be2ce">10-Q</ix:nonNumeric></span></div><div style="text-align:center;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">___________________________________</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">       (Mark one)</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.630%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.351%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:89.719%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</span></td><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:125%"><ix:nonNumeric contextRef="ie35b115501ca468f8cadb8213304a30b_D20230101-20230331" name="dei:DocumentQuarterlyReport" format="ixt:fixed-true" id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY18xL2ZyYWc6ZWRiMzM5MDJkYzdlNGY5NTllOGNkNjRiYTExZDQ0NWYvdGFibGU6ODBhZGExMGIwYWIzNDY2Yzk1ZTY4MjMxNzZiNTk5NTUvdGFibGVyYW5nZTo4MGFkYTEwYjBhYjM0NjZjOTVlNjgyMzE3NmI1OTk1NV8wLTEtMS0xLTY5OTQ5_4f173ca4-a011-407b-b21a-57369debc2ed">&#253;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div style="text-align:center;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:139%">For the quarterly period ended <ix:nonNumeric contextRef="ie35b115501ca468f8cadb8213304a30b_D20230101-20230331" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY18xL2ZyYWc6ZWRiMzM5MDJkYzdlNGY5NTllOGNkNjRiYTExZDQ0NWYvdGV4dHJlZ2lvbjplZGIzMzkwMmRjN2U0Zjk1OWU4Y2Q2NGJhMTFkNDQ1Zl8yMTM_6dd1a57d-adaf-4fa6-b47f-8611b2f92485">March 31, 2023</ix:nonNumeric> </span></div><div style="text-align:center"><span><br/></span></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.630%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.351%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:89.719%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</span></td><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:125%"><ix:nonNumeric contextRef="ie35b115501ca468f8cadb8213304a30b_D20230101-20230331" name="dei:DocumentTransitionReport" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY18xL2ZyYWc6ZWRiMzM5MDJkYzdlNGY5NTllOGNkNjRiYTExZDQ0NWYvdGFibGU6ZmY0ZmZkNmM3YzI3NGNjYzk0MjQ1NTc4ZDlkMmU3MzQvdGFibGVyYW5nZTpmZjRmZmQ2YzdjMjc0Y2NjOTQyNDU1NzhkOWQyZTczNF8wLTEtMS0xLTY5OTQ5_edb83cbd-5f79-4baf-838d-a8da54d71cd2">o</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">For the transition period from ___________ to ______________.</span></div><div style="text-align:center;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:80%">&#160;</span></div><div style="text-align:center;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:139%">Commission file number:  <ix:nonNumeric contextRef="ie35b115501ca468f8cadb8213304a30b_D20230101-20230331" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY18xL2ZyYWc6ZWRiMzM5MDJkYzdlNGY5NTllOGNkNjRiYTExZDQ0NWYvdGV4dHJlZ2lvbjplZGIzMzkwMmRjN2U0Zjk1OWU4Y2Q2NGJhMTFkNDQ1Zl8yMTYw_c51bd763-885f-4123-85ca-356849923e5c">001-40654</ix:nonNumeric></span></div><div style="text-align:center;text-indent:9pt"><span><br/></span></div><div style="text-align:center;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:22pt;font-weight:700;line-height:139%"><ix:nonNumeric contextRef="ie35b115501ca468f8cadb8213304a30b_D20230101-20230331" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY18xL2ZyYWc6ZWRiMzM5MDJkYzdlNGY5NTllOGNkNjRiYTExZDQ0NWYvdGV4dHJlZ2lvbjplZGIzMzkwMmRjN2U0Zjk1OWU4Y2Q2NGJhMTFkNDQ1Zl8yMTU0_30014f1f-7bb3-4ecc-a6a5-3bf861d4e30d">CONTEXT THERAPEUTICS INC.</ix:nonNumeric> </span></div><div style="text-align:center;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:139%">(Exact name of registrant as specified in its charter)</span></div><div style="text-align:center;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:80%">___________________________________</span></div><div style="text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:80%">&#160;</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%"><ix:nonNumeric contextRef="ie35b115501ca468f8cadb8213304a30b_D20230101-20230331" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY18xL2ZyYWc6ZWRiMzM5MDJkYzdlNGY5NTllOGNkNjRiYTExZDQ0NWYvdGFibGU6YzRjYzcwYTFkMTA0NDY0MGFmYWFhZWE4ZDc5ZDM0M2IvdGFibGVyYW5nZTpjNGNjNzBhMWQxMDQ0NjQwYWZhYWFlYThkNzlkMzQzYl8wLTAtMS0xLTY5OTQ5_8241fd1f-c417-4c75-bf60-0aab61c6cf8e">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%"><ix:nonNumeric contextRef="ie35b115501ca468f8cadb8213304a30b_D20230101-20230331" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY18xL2ZyYWc6ZWRiMzM5MDJkYzdlNGY5NTllOGNkNjRiYTExZDQ0NWYvdGFibGU6YzRjYzcwYTFkMTA0NDY0MGFmYWFhZWE4ZDc5ZDM0M2IvdGFibGVyYW5nZTpjNGNjNzBhMWQxMDQ0NjQwYWZhYWFlYThkNzlkMzQzYl8wLTEtMS0xLTY5OTQ5_3cace272-1a40-418b-9e66-f5be8779c348">86-3738787</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:125%">(State of other jurisdiction of incorporation or organization)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:125%">(I.R.S. Employer Identification Number)</span></td></tr></table></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:115%"><ix:nonNumeric contextRef="ie35b115501ca468f8cadb8213304a30b_D20230101-20230331" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY18xL2ZyYWc6ZWRiMzM5MDJkYzdlNGY5NTllOGNkNjRiYTExZDQ0NWYvdGV4dHJlZ2lvbjplZGIzMzkwMmRjN2U0Zjk1OWU4Y2Q2NGJhMTFkNDQ1Zl8yMTYx_c1ed7ca1-f5de-4df4-9673-051c7b1e21a6">2001 Market Street,</ix:nonNumeric> <ix:nonNumeric contextRef="ie35b115501ca468f8cadb8213304a30b_D20230101-20230331" name="dei:EntityAddressAddressLine2" id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY18xL2ZyYWc6ZWRiMzM5MDJkYzdlNGY5NTllOGNkNjRiYTExZDQ0NWYvdGV4dHJlZ2lvbjplZGIzMzkwMmRjN2U0Zjk1OWU4Y2Q2NGJhMTFkNDQ1Zl8yMTU2_97e44a65-6226-4609-98aa-f23684b0851e">Suite 3915, Unit #15</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:115%"><ix:nonNumeric contextRef="ie35b115501ca468f8cadb8213304a30b_D20230101-20230331" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY18xL2ZyYWc6ZWRiMzM5MDJkYzdlNGY5NTllOGNkNjRiYTExZDQ0NWYvdGV4dHJlZ2lvbjplZGIzMzkwMmRjN2U0Zjk1OWU4Y2Q2NGJhMTFkNDQ1Zl8yMTQ5_322c2f35-675d-4448-8e53-7b189d0bf4e4">Philadelphia,</ix:nonNumeric> <ix:nonNumeric contextRef="ie35b115501ca468f8cadb8213304a30b_D20230101-20230331" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY18xL2ZyYWc6ZWRiMzM5MDJkYzdlNGY5NTllOGNkNjRiYTExZDQ0NWYvdGV4dHJlZ2lvbjplZGIzMzkwMmRjN2U0Zjk1OWU4Y2Q2NGJhMTFkNDQ1Zl8yMTUw_17c4ddf8-9556-44a8-944f-5008b317b502">Pennsylvania</ix:nonNumeric> <ix:nonNumeric contextRef="ie35b115501ca468f8cadb8213304a30b_D20230101-20230331" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY18xL2ZyYWc6ZWRiMzM5MDJkYzdlNGY5NTllOGNkNjRiYTExZDQ0NWYvdGV4dHJlZ2lvbjplZGIzMzkwMmRjN2U0Zjk1OWU4Y2Q2NGJhMTFkNDQ1Zl81MTE_7d2b6e59-6fb3-415c-9ee3-d47a97fcb15d">19103</ix:nonNumeric> </span></div><div style="margin-bottom:0.05pt;margin-top:0.05pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:115%">(Address of principal executive offices, including zip code)</span></div><div style="text-align:center"><span><br/></span></div><div style="margin-bottom:0.05pt;margin-top:0.05pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:115%">(<ix:nonNumeric contextRef="ie35b115501ca468f8cadb8213304a30b_D20230101-20230331" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY18xL2ZyYWc6ZWRiMzM5MDJkYzdlNGY5NTllOGNkNjRiYTExZDQ0NWYvdGV4dHJlZ2lvbjplZGIzMzkwMmRjN2U0Zjk1OWU4Y2Q2NGJhMTFkNDQ1Zl81Nzg_9aae1081-4592-4282-91fd-8bbbbcc1323c">267</ix:nonNumeric>) <ix:nonNumeric contextRef="ie35b115501ca468f8cadb8213304a30b_D20230101-20230331" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY18xL2ZyYWc6ZWRiMzM5MDJkYzdlNGY5NTllOGNkNjRiYTExZDQ0NWYvdGV4dHJlZ2lvbjplZGIzMzkwMmRjN2U0Zjk1OWU4Y2Q2NGJhMTFkNDQ1Zl8yMTU4_1d10f036-964c-494e-a4c1-6496d64ebcfa">225-7416</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:115%">(Registrant&#8217;s telephone number, including area code)</span></div><div style="text-align:center"><span><br/></span></div><div style="margin-bottom:6pt;padding-left:8.52pt;padding-right:8.52pt;text-align:center;text-indent:45pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.953%"><tr><td style="width:1.0%"></td><td style="width:39.944%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.228%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:33.528%"></td><td style="width:0.1%"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:125%">Securities registered pursuant to Section 12(b) of the Act:</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:700;line-height:125%;text-decoration:underline">Title of Each Class</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:700;line-height:125%;text-decoration:underline">Trading Symbol(s)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:700;line-height:125%;text-decoration:underline">Name of Each Exchange on Which Registered</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:125%"><ix:nonNumeric contextRef="ie35b115501ca468f8cadb8213304a30b_D20230101-20230331" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY18xL2ZyYWc6ZWRiMzM5MDJkYzdlNGY5NTllOGNkNjRiYTExZDQ0NWYvdGFibGU6MGQxMmIyNGRlODQ0NDQyMDg0YmFlNTg1MGFkYmExZTkvdGFibGVyYW5nZTowZDEyYjI0ZGU4NDQ0NDIwODRiYWU1ODUwYWRiYTFlOV8yLTAtMS0xLTY5OTQ5_e877d5e2-5847-4c7d-98cf-a2a168645710">Common Stock, par value $0.001 per share</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:125%"><ix:nonNumeric contextRef="ie35b115501ca468f8cadb8213304a30b_D20230101-20230331" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY18xL2ZyYWc6ZWRiMzM5MDJkYzdlNGY5NTllOGNkNjRiYTExZDQ0NWYvdGFibGU6MGQxMmIyNGRlODQ0NDQyMDg0YmFlNTg1MGFkYmExZTkvdGFibGVyYW5nZTowZDEyYjI0ZGU4NDQ0NDIwODRiYWU1ODUwYWRiYTFlOV8yLTEtMS0xLTY5OTQ5_ee4edf38-a460-4a73-b16f-d9161943c7b6">CNTX</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:125%"><ix:nonNumeric contextRef="ie35b115501ca468f8cadb8213304a30b_D20230101-20230331" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY18xL2ZyYWc6ZWRiMzM5MDJkYzdlNGY5NTllOGNkNjRiYTExZDQ0NWYvdGFibGU6MGQxMmIyNGRlODQ0NDQyMDg0YmFlNTg1MGFkYmExZTkvdGFibGVyYW5nZTowZDEyYjI0ZGU4NDQ0NDIwODRiYWU1ODUwYWRiYTFlOV8yLTItMS0xLTY5OTQ5_2d833a4f-ce2e-4d72-9ce4-277dabe1ca25">The Nasdaq Stock Market LLC</ix:nonNumeric></span></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:139%">Indicate by check mark whether the registrant: (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12&#160;months (or for such shorter period that the registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90&#160;days. <ix:nonNumeric contextRef="ie35b115501ca468f8cadb8213304a30b_D20230101-20230331" name="dei:EntityCurrentReportingStatus" id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY18xL2ZyYWc6ZWRiMzM5MDJkYzdlNGY5NTllOGNkNjRiYTExZDQ0NWYvdGV4dHJlZ2lvbjplZGIzMzkwMmRjN2U0Zjk1OWU4Y2Q2NGJhMTFkNDQ1Zl8yMTUx_5ccc640b-d5c7-493e-9fee-4150586bcb9e">Yes</ix:nonNumeric>&#160; </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:400;line-height:139%">&#253;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:139%">&#160; No&#160; </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:400;line-height:139%">o</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:115%">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). <ix:nonNumeric contextRef="ie35b115501ca468f8cadb8213304a30b_D20230101-20230331" name="dei:EntityInteractiveDataCurrent" id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY18xL2ZyYWc6ZWRiMzM5MDJkYzdlNGY5NTllOGNkNjRiYTExZDQ0NWYvdGV4dHJlZ2lvbjplZGIzMzkwMmRjN2U0Zjk1OWU4Y2Q2NGJhMTFkNDQ1Zl8yMTYy_d23f6224-f41c-4bdb-bf88-ad3af5f68108">Yes</ix:nonNumeric>&#160; </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:400;line-height:115%">&#253;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:115%"> No&#160; </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:400;line-height:115%">o</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:115%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act. </span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:24.192%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.847%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.420%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:24.192%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.849%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:125%">Large&#160;accelerated&#160;filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:11pt;font-weight:400;line-height:125%">&#9744;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:125%">Accelerated&#160;filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:11pt;font-weight:400;line-height:125%">&#9744;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:125%"><ix:nonNumeric contextRef="ie35b115501ca468f8cadb8213304a30b_D20230101-20230331" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen" id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY18xL2ZyYWc6ZWRiMzM5MDJkYzdlNGY5NTllOGNkNjRiYTExZDQ0NWYvdGFibGU6YzRhNzhhMzE5N2E3NDYyM2JiZTEyMzA4MjViZTRhMjgvdGFibGVyYW5nZTpjNGE3OGEzMTk3YTc0NjIzYmJlMTIzMDgyNWJlNGEyOF8xLTAtMS0xLTY5OTQ5_05560ba9-56b6-44b4-8a4c-15bc7580036b">Non-accelerated filer</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:11pt;font-weight:400;line-height:125%">&#9746;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:125%">Smaller&#160;reporting&#160;company</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:11pt;font-weight:400;line-height:125%"><ix:nonNumeric contextRef="ie35b115501ca468f8cadb8213304a30b_D20230101-20230331" name="dei:EntitySmallBusiness" format="ixt:fixed-true" id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY18xL2ZyYWc6ZWRiMzM5MDJkYzdlNGY5NTllOGNkNjRiYTExZDQ0NWYvdGFibGU6YzRhNzhhMzE5N2E3NDYyM2JiZTEyMzA4MjViZTRhMjgvdGFibGVyYW5nZTpjNGE3OGEzMTk3YTc0NjIzYmJlMTIzMDgyNWJlNGEyOF8xLTQtMS0xLTY5OTQ5_7a158280-d9c7-4fd0-ac26-8408167ea694">&#9746;</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:125%">Emerging growth&#160;company</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:11pt;font-weight:400;line-height:125%"><ix:nonNumeric contextRef="ie35b115501ca468f8cadb8213304a30b_D20230101-20230331" name="dei:EntityEmergingGrowthCompany" format="ixt:fixed-true" id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY18xL2ZyYWc6ZWRiMzM5MDJkYzdlNGY5NTllOGNkNjRiYTExZDQ0NWYvdGFibGU6YzRhNzhhMzE5N2E3NDYyM2JiZTEyMzA4MjViZTRhMjgvdGFibGVyYW5nZTpjNGE3OGEzMTk3YTc0NjIzYmJlMTIzMDgyNWJlNGEyOF8yLTQtMS0xLTY5OTQ5_fc032777-bb4f-4b30-8ff1-ed548e0bf30c">&#9746;</ix:nonNumeric></span></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:139%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:139%"><ix:nonNumeric contextRef="ie35b115501ca468f8cadb8213304a30b_D20230101-20230331" name="dei:EntityExTransitionPeriod" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY18xL2ZyYWc6ZWRiMzM5MDJkYzdlNGY5NTllOGNkNjRiYTExZDQ0NWYvdGV4dHJlZ2lvbjplZGIzMzkwMmRjN2U0Zjk1OWU4Y2Q2NGJhMTFkNDQ1Zl8yMTUy_45038ad0-e47e-477f-9b94-41c5b1e065c6">&#9744;</ix:nonNumeric></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:115%">Indicate by check mark whether the registrant is a shell company (as defined in Rule&#160;12b-2 of the Act).Yes&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:400;line-height:115%"><ix:nonNumeric contextRef="ie35b115501ca468f8cadb8213304a30b_D20230101-20230331" name="dei:EntityShellCompany" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY18xL2ZyYWc6ZWRiMzM5MDJkYzdlNGY5NTllOGNkNjRiYTExZDQ0NWYvdGV4dHJlZ2lvbjplZGIzMzkwMmRjN2U0Zjk1OWU4Y2Q2NGJhMTFkNDQ1Zl8yMTYz_0f43825d-30ae-4c53-9743-8e180a7f55a5">o</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:115%">&#160;&#160;&#160;No&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:400;line-height:115%">&#253;</span></div><div style="text-indent:45pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:115%">The number of shares of common stock outstanding at May 5, 2023 was <ix:nonFraction unitRef="shares" contextRef="ia277388742eb471f9d42d799adb36d70_I20230505" decimals="0" name="dei:EntityCommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY18xL2ZyYWc6ZWRiMzM5MDJkYzdlNGY5NTllOGNkNjRiYTExZDQ0NWYvdGV4dHJlZ2lvbjplZGIzMzkwMmRjN2U0Zjk1OWU4Y2Q2NGJhMTFkNDQ1Zl8yMTM4_38a3734a-96fd-4aa6-9415-16defbc3058b">15,966,053</ix:nonFraction> shares.</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="height:40.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="ibd14e01a97b1463b915192a9eff93f0c_7"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#ibd14e01a97b1463b915192a9eff93f0c_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:139%"> INDEX TO FORM 10-Q </span></div><div style="text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#160;</span></div><div style="margin-bottom:6pt;text-indent:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:92.321%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.479%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%;text-decoration:underline">Page</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.08pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%;text-decoration:underline" href="#ibd14e01a97b1463b915192a9eff93f0c_10">NOTE REGARDING FORWARD-LOOKING STATEMENTS</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.08pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%;text-decoration:underline" href="#ibd14e01a97b1463b915192a9eff93f0c_10">3</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.08pt;text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%;text-decoration:underline" href="#ibd14e01a97b1463b915192a9eff93f0c_16">PART I &#8211; FINANCIAL INFORMATION</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.08pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%;text-decoration:underline" href="#ibd14e01a97b1463b915192a9eff93f0c_16">6</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.08pt;padding-left:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%;text-decoration:underline" href="#ibd14e01a97b1463b915192a9eff93f0c_19">Item 1.&#160;&#160;&#160;&#160;&#160;Financial Statements (unaudited)</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">:</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.08pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%;text-decoration:underline" href="#ibd14e01a97b1463b915192a9eff93f0c_19">6</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.08pt;padding-left:48pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%;text-decoration:underline" href="#ibd14e01a97b1463b915192a9eff93f0c_22">Condensed Consolidated Balance Sheets</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.08pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%;text-decoration:underline" href="#ibd14e01a97b1463b915192a9eff93f0c_22">6</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.08pt;padding-left:48pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%;text-decoration:underline" href="#ibd14e01a97b1463b915192a9eff93f0c_25">Condensed Consolidated Statements of Operations</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.08pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%;text-decoration:underline" href="#ibd14e01a97b1463b915192a9eff93f0c_25">7</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.08pt;padding-left:48pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%;text-decoration:underline" href="#ibd14e01a97b1463b915192a9eff93f0c_28">Condensed Consolidated Statement</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%;text-decoration:underline" href="#ibd14e01a97b1463b915192a9eff93f0c_28">s</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%;text-decoration:underline" href="#ibd14e01a97b1463b915192a9eff93f0c_28"> of Changes in Stockholders&#8217; Equity</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.08pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%;text-decoration:underline" href="#ibd14e01a97b1463b915192a9eff93f0c_28">8</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.08pt;padding-left:48pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%;text-decoration:underline" href="#ibd14e01a97b1463b915192a9eff93f0c_34">Condensed Consolidated Statements of Cash Flows</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.08pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%;text-decoration:underline" href="#ibd14e01a97b1463b915192a9eff93f0c_34">9</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.08pt;padding-left:48pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%;text-decoration:underline" href="#ibd14e01a97b1463b915192a9eff93f0c_37">Notes to the Unaudited Condensed Consolidated Financial Statements</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.08pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%;text-decoration:underline" href="#ibd14e01a97b1463b915192a9eff93f0c_37">10</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.08pt;padding-left:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%;text-decoration:underline" href="#ibd14e01a97b1463b915192a9eff93f0c_70">Item 2.&#160;&#160;&#160;&#160;&#160;Management's Discussion and Analysis of Financial Condition and Results of Operations</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.08pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%;text-decoration:underline" href="#ibd14e01a97b1463b915192a9eff93f0c_70">18</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.08pt;padding-left:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%;text-decoration:underline" href="#ibd14e01a97b1463b915192a9eff93f0c_100">Item 3.&#160;&#160;&#160;&#160;&#160;Quantitative and Qualitative Disclosures About Market Risk</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.08pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%;text-decoration:underline" href="#ibd14e01a97b1463b915192a9eff93f0c_100">25</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.08pt;padding-left:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%;text-decoration:underline" href="#ibd14e01a97b1463b915192a9eff93f0c_103">Item 4.&#160;&#160;&#160;&#160;&#160;Controls and Procedures</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.08pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%;text-decoration:underline" href="#ibd14e01a97b1463b915192a9eff93f0c_103">25</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.08pt;text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%;text-decoration:underline" href="#ibd14e01a97b1463b915192a9eff93f0c_106">PART II &#8211; OTHER INFORMATION&#160;</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.08pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%;text-decoration:underline" href="#ibd14e01a97b1463b915192a9eff93f0c_106">26</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.08pt;padding-left:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%;text-decoration:underline" href="#ibd14e01a97b1463b915192a9eff93f0c_109">Item 1.&#160;&#160;&#160;&#160;&#160;Legal Proceedings</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.08pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%;text-decoration:underline" href="#ibd14e01a97b1463b915192a9eff93f0c_109">26</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.08pt;padding-left:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%;text-decoration:underline" href="#ibd14e01a97b1463b915192a9eff93f0c_112">Item 1A.&#160;&#160;Risk Factors</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.08pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%;text-decoration:underline" href="#ibd14e01a97b1463b915192a9eff93f0c_112">26</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.08pt;padding-left:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%;text-decoration:underline" href="#ibd14e01a97b1463b915192a9eff93f0c_115">Item 2.&#160;&#160;&#160;&#160;&#160;Unregistered Sales of Equity Securities and Use of Proceeds</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.08pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%;text-decoration:underline" href="#ibd14e01a97b1463b915192a9eff93f0c_115">26</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.08pt;padding-left:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%;text-decoration:underline" href="#ibd14e01a97b1463b915192a9eff93f0c_118">Item 3.&#160;&#160;&#160;&#160;&#160;Defaults Upon Senior Securities</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.08pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%;text-decoration:underline" href="#ibd14e01a97b1463b915192a9eff93f0c_118">26</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.08pt;padding-left:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%;text-decoration:underline" href="#ibd14e01a97b1463b915192a9eff93f0c_121">Item 4.&#160;&#160;&#160;&#160;&#160;Mine Safety Disclosures</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.08pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%;text-decoration:underline" href="#ibd14e01a97b1463b915192a9eff93f0c_121">26</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.08pt;padding-left:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%;text-decoration:underline" href="#ibd14e01a97b1463b915192a9eff93f0c_124">Item 5.&#160;&#160;&#160;&#160;&#160;Other Information</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.08pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%;text-decoration:underline" href="#ibd14e01a97b1463b915192a9eff93f0c_124">26</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.08pt;padding-left:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%;text-decoration:underline" href="#ibd14e01a97b1463b915192a9eff93f0c_127">Item 6.&#160;&#160;&#160;&#160;&#160;Exhibits</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.08pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%;text-decoration:underline" href="#ibd14e01a97b1463b915192a9eff93f0c_127">27</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.08pt;padding-left:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%;text-decoration:underline" href="#ibd14e01a97b1463b915192a9eff93f0c_130">Signatures</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.08pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%;text-decoration:underline" href="#ibd14e01a97b1463b915192a9eff93f0c_130">28</a></span></div></td></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">         </span></div><div style="text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#160;&#160;&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">_________________________</span></div><div><span><br/></span></div><div style="margin-bottom:0.05pt;margin-top:0.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Unless the context otherwise requires, all references in this Form 10-Q to "Context," "Company," "we," "us," and "our" refer to Context Therapeutics Inc. and its subsidiaries.</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">_________________________</span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-bottom:0.05pt;margin-top:0.05pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:202%;text-decoration:underline">Trademark Notice</span></div><div style="margin-bottom:0.05pt;margin-top:0.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Context Therapeutics&#174; is a trademark of ours in the United States. All other trademarks, trade names and service marks appearing in this Form 10-Q are the property of their respective owners. We do not intend our use or display of other companies' trademarks, trade names or service marks to imply a relationship with, or endorsement or sponsorship of us by, any other companies.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">2</span></div></div></div><div id="ibd14e01a97b1463b915192a9eff93f0c_10"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#ibd14e01a97b1463b915192a9eff93f0c_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:139%">NOTE REGARDING FORWARD-LOOKING STATEMENTS</span></div><div style="margin-top:12pt;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">This Quarterly Report on Form 10-Q includes "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995.  These statements are based on our management's beliefs and assumptions and on information currently available to us. All statements other than statements of historical facts are forward-looking statements.  These statements relate to future events or to our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. Forward-looking statements include, but are not limited to, statements about: </span></div><div style="margin-bottom:0.05pt;margin-top:0.05pt"><span><br/></span></div><div style="margin-top:6pt;padding-left:55.05pt;text-indent:-18.35pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;&#160;&#160;&#160;&#160;the ability of our clinical trials to demonstrate safety and efficacy of our product candidates, and other positive results;</span></div><div style="margin-top:6pt;padding-left:55.05pt;text-indent:-18.35pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;&#160;&#160;&#160;&#160;the timing, progress and results of preclinical studies and clinical trials for CTIM-76 and other product candidates we may develop, including statements regarding the timing of initiation and completion of studies or trials and related preparatory work, the period during which the results of the trials will become available, and our research and development programs;</span></div><div style="margin-top:6pt;padding-left:55.05pt;text-indent:-18.35pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;&#160;&#160;&#160;&#160;the timing, scope and likelihood of U.S. and foreign regulatory filings and approvals, including timing of Investigational New Drug applications and final U.S. Food and Drug Administration (&#8220;FDA&#8221;) approval of CTIM-76 and any other future product candidates;</span></div><div style="margin-top:6pt;padding-left:55.05pt;text-indent:-18.35pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;&#160;&#160;&#160;&#160;our ability to develop and advance CTIM-76 and any other future product candidates, and successfully complete clinical studies;</span></div><div style="margin-top:6pt;padding-left:55.05pt;text-indent:-18.35pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;&#160;&#160;&#160;&#160;our manufacturing, commercialization, and marketing capabilities, implementations thereof, and strategy;</span></div><div style="margin-top:6pt;padding-left:55.05pt;text-indent:-18.35pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;&#160;&#160;&#160;&#160;our plans relating to commercializing our product candidates, if approved, including the geographic areas of focus, sales strategy, and our ability to develop a sales team;</span></div><div style="margin-top:6pt;padding-left:55.05pt;text-indent:-18.35pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;&#160;&#160;&#160;&#160;our intent to explore strategic options for onapristone extended release (&#8220;ONA-XR&#8221;);</span></div><div style="margin-top:6pt;padding-left:55.05pt;text-indent:-18.35pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;&#160;&#160;&#160;&#160;any disagreements or disputes with our licensees, licensors and other counterparties relating to the development and/or commercialization of ONA-XR, which may be time consuming, costly and could harm our efforts to pursue strategic options for ONA-XR;</span></div><div style="margin-top:6pt;padding-left:55.05pt;text-indent:-18.35pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;&#160;&#160;&#160;&#160;the impact of the COVID-19 pandemic and other economic uncertainties on our business and operations, including clinical trials, manufacturing suppliers, collaborators, use of contract research organizations and employees;</span></div><div style="margin-top:6pt;padding-left:55.05pt;text-indent:-18.35pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;&#160;&#160;&#160;&#160;the need to hire additional personnel and our ability to attract and retain such personnel;</span></div><div style="margin-top:6pt;padding-left:55.05pt;text-indent:-18.35pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;&#160;&#160;&#160;&#160;the size of the market opportunity for our product candidates, including our estimates of the number of patients who suffer from the diseases we are targeting;</span></div><div style="margin-top:6pt;padding-left:55.05pt;text-indent:-18.35pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;&#160;&#160;&#160;&#160;our competitive position and the success of competing therapies that are or may become available;</span></div><div style="margin-top:6pt;padding-left:55.05pt;text-indent:-18.35pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;&#160;&#160;&#160;&#160;the beneficial characteristics, safety, efficacy and therapeutic effects of our product candidates;</span></div><div style="margin-top:6pt;padding-left:55.05pt;text-indent:-18.35pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;&#160;&#160;&#160;&#160;our ability to obtain and maintain regulatory approval of our product candidates;</span></div><div style="margin-top:6pt;padding-left:55.05pt;text-indent:-18.35pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;&#160;&#160;&#160;&#160;our plans relating to the further development of our product candidates, including additional indications we may pursue;</span></div><div style="margin-top:6pt;padding-left:55.05pt;text-indent:-18.35pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;&#160;&#160;&#160;&#160;existing regulations and regulatory developments in the United States, Europe and other jurisdictions;</span></div><div style="margin-top:6pt;padding-left:55.05pt;text-indent:-18.35pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;&#160;&#160;&#160;&#160;our intellectual property position, including the scope of protection we are able to establish and maintain for intellectual property rights covering CTIM-76, ONA-XR, and other product candidates we may develop, including the extensions of existing patent terms where available, the validity of intellectual property rights held by third parties, and our ability not to infringe, misappropriate or otherwise violate any third-party intellectual property rights;</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">3</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#ibd14e01a97b1463b915192a9eff93f0c_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;padding-left:55.05pt;text-indent:-18.35pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;&#160;&#160;&#160;&#160;our continued reliance on third parties to conduct and support clinical trials of our product candidates, and for the manufacture of our product candidates for preclinical studies and clinical trials;</span></div><div style="margin-top:6pt;padding-left:55.05pt;text-indent:-18.35pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;&#160;&#160;&#160;&#160;our ability to obtain, and negotiate favorable terms of, collaboration, licensing or other arrangements that may be necessary or desirable to develop, manufacture or commercialize our product candidates;</span></div><div style="margin-top:6pt;padding-left:55.05pt;text-indent:-18.35pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;&#160;&#160;&#160;&#160;the pricing and reimbursement of CTIM-76 and other product candidates we may develop, if approved;</span></div><div style="margin-top:6pt;padding-left:55.05pt;text-indent:-18.35pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;&#160;&#160;&#160;&#160;the rate and degree of market acceptance and clinical utility of CTIM-76 and other product candidates we may develop;</span></div><div style="margin-top:6pt;padding-left:55.05pt;text-indent:-18.35pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;&#160;&#160;&#160;&#160;our estimates regarding expenses, future revenue, capital requirements and needs for additional financing;</span></div><div style="margin-top:6pt;padding-left:55.05pt;text-indent:-18.35pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;&#160;&#160;&#160;&#160;our current plans to seek additional capital in the future through equity and/or debt financings, partnerships, collaborations, licensing agreements or other strategic arrangements, or other sources and the availability of such future sources of capital;</span></div><div style="margin-top:6pt;padding-left:55.05pt;text-indent:-18.35pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;&#160;&#160;&#160;&#160;our financial performance;</span></div><div style="margin-top:6pt;padding-left:55.05pt;text-indent:-18.35pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;&#160;&#160;&#160;&#160;the period over which we estimate our existing cash and cash equivalents will be sufficient to fund our future operating expenses and capital expenditure requirements;</span></div><div style="margin-top:6pt;padding-left:55.05pt;text-indent:-18.35pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;&#160;&#160;&#160;&#160;the impact of laws and regulations;</span></div><div style="margin-top:6pt;padding-left:55.05pt;text-indent:-18.35pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;&#160;&#160;&#160;&#160;our expectations regarding the period during which we will qualify as an emerging growth company under the JOBS Act;</span></div><div style="margin-top:6pt;padding-left:55.05pt;text-indent:-18.35pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;&#160;&#160;&#160;&#160;our anticipated use of our existing cash and cash equivalents; and</span></div><div style="margin-top:6pt;padding-left:55.05pt;text-indent:-18.35pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;&#160;&#160;&#160;&#160;other risks and uncertainties, including those listed under the caption &#8220;Risk Factors&#8221;;</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">as well as other statements relating to our future operations, financial performance and financial condition, prospects, strategies, objectives or other future events. In some cases, you can identify forward-looking statements by terms such as &#8220;may,&#8221; &#8220;could,&#8221; &#8220;will,&#8221; &#8220;should,&#8221; &#8220;would,&#8221; &#8220;expect,&#8221; &#8220;plan,&#8221; &#8220;intend,&#8221; &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;estimate,&#8221; &#8220;predict,&#8221; &#8220;potential,&#8221; &#8220;project&#8221; or &#8220;continue&#8221; or the negative of these terms or other comparable terminology. These statements are only predictions. You should not place undue reliance on forward-looking statements because they involve known and unknown risks, uncertainties and other factors, which are, in some cases, beyond our control and which could materially affect results. Factors that may cause actual results to differ materially from current expectations include, among other things, those listed under the heading &#8220;Risk Factors&#8221; and elsewhere in this Form 10-Q. If one or more of these risks or uncertainties occur, or if our underlying assumptions prove to be incorrect, actual events or results may vary significantly from those implied or projected by the forward-looking statements. No forward-looking statement is a guarantee of future performance.  As a result, you should not place undue reliance on forward-looking statements. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Additionally, the forward-looking statements contained in this Form 10-Q represent our views only as of the date of this Form 10-Q (or any earlier date indicated in such statement). While we may update certain forward-looking statements from time to time, we specifically disclaim any obligation to do so, even if new information becomes available in the future. However, you are advised to consult any further disclosures we make on related subjects in the reports that we file with the U.S. Securities and Exchange Commission ("SEC").</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The foregoing cautionary statements are intended to qualify all forward-looking statements wherever they may appear in this Form 10-Q. For all forward-looking statements, we claim the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995.</span></div><div><span><br/></span></div><div id="ibd14e01a97b1463b915192a9eff93f0c_13"></div><div style="margin-bottom:0.05pt;margin-top:0.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:139%">Market, Industry and Other Data</span></div><div><span><br/></span></div><div style="margin-bottom:0.05pt;margin-top:0.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">This Form 10-Q may contain estimates, projections, market research and other data generated by independent third parties, by third parties on our behalf and by us concerning markets for our anti-CD3 x anti-Claudin 6 (&#8220;CLDN6&#8221;) antigen bispecific monoclonal antibody (&#8220;bsAb&#8221;), CTIM-76, and ONA-XR. Information that is based on estimates, projections, market research or similar methodologies is inherently subject to uncertainties and actual results, events or circumstances may differ materially from results, events and circumstances reflected in this information. As a result, you are cautioned not to give undue weight to such information.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">4</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#ibd14e01a97b1463b915192a9eff93f0c_7">Table of Contents</a></span></div></div><div style="margin-bottom:0.05pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">This Form 10-Q also may contain certain data and information, which we obtained from various government and private publications. Although we believe that the publications and reports are reliable, we have not independently verified the data. Statistical data in these publications include projections that are based on a number of assumptions. If any one or more of the assumptions underlying the market data is later found to be incorrect, actual results may differ from the projections based on these assumptions. </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">5</span></div></div></div><div id="ibd14e01a97b1463b915192a9eff93f0c_16"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#ibd14e01a97b1463b915192a9eff93f0c_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Part I - Financial Information</span></div><div id="ibd14e01a97b1463b915192a9eff93f0c_19"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Item 1. Financial Statements</span></div><div><span><br/></span></div><div id="ibd14e01a97b1463b915192a9eff93f0c_22"></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Context Therapeutics Inc. </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Condensed Consolidated Balance Sheets </span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:63.519%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.443%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.154%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">(Unaudited)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">(Note 3)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">Assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Current assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="i9e6ffce2c2d247f491e046febe8251cd_I20230331" decimals="0" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY18yMi9mcmFnOjAwMGYzZjEyOTA1NzRkM2ZhZmY0N2ZmZGFmY2YyNjRhL3RhYmxlOjQ4MDNhMzdjMjkzMDRkNDE4NDQ1ZTA5ZTY3ZGZlNmY1L3RhYmxlcmFuZ2U6NDgwM2EzN2MyOTMwNGQ0MTg0NDVlMDllNjdkZmU2ZjVfNC0xLTEtMS02OTk0OQ_4070c089-2066-4a2f-851b-dca5988c5370">29,768,990</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="i4b1713eab7d84494b3b43202a26fc3c4_I20221231" decimals="0" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY18yMi9mcmFnOjAwMGYzZjEyOTA1NzRkM2ZhZmY0N2ZmZGFmY2YyNjRhL3RhYmxlOjQ4MDNhMzdjMjkzMDRkNDE4NDQ1ZTA5ZTY3ZGZlNmY1L3RhYmxlcmFuZ2U6NDgwM2EzN2MyOTMwNGQ0MTg0NDVlMDllNjdkZmU2ZjVfNC0zLTEtMS02OTk0OQ_574ad9d5-7f63-46c8-8a7a-72445b497551">35,497,445</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="i9e6ffce2c2d247f491e046febe8251cd_I20230331" decimals="0" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY18yMi9mcmFnOjAwMGYzZjEyOTA1NzRkM2ZhZmY0N2ZmZGFmY2YyNjRhL3RhYmxlOjQ4MDNhMzdjMjkzMDRkNDE4NDQ1ZTA5ZTY3ZGZlNmY1L3RhYmxlcmFuZ2U6NDgwM2EzN2MyOTMwNGQ0MTg0NDVlMDllNjdkZmU2ZjVfNS0xLTEtMS02OTk0OQ_fa438ce4-f1ba-4fd6-8272-35d07e138b56">2,116,737</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="i4b1713eab7d84494b3b43202a26fc3c4_I20221231" decimals="0" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY18yMi9mcmFnOjAwMGYzZjEyOTA1NzRkM2ZhZmY0N2ZmZGFmY2YyNjRhL3RhYmxlOjQ4MDNhMzdjMjkzMDRkNDE4NDQ1ZTA5ZTY3ZGZlNmY1L3RhYmxlcmFuZ2U6NDgwM2EzN2MyOTMwNGQ0MTg0NDVlMDllNjdkZmU2ZjVfNS0zLTEtMS02OTk0OQ_b4a0f957-39ad-4090-9a9c-1e73a7fa6632">2,356,213</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Total current assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="i9e6ffce2c2d247f491e046febe8251cd_I20230331" decimals="0" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY18yMi9mcmFnOjAwMGYzZjEyOTA1NzRkM2ZhZmY0N2ZmZGFmY2YyNjRhL3RhYmxlOjQ4MDNhMzdjMjkzMDRkNDE4NDQ1ZTA5ZTY3ZGZlNmY1L3RhYmxlcmFuZ2U6NDgwM2EzN2MyOTMwNGQ0MTg0NDVlMDllNjdkZmU2ZjVfNi0xLTEtMS02OTk0OQ_6189e66a-a02a-4416-9f0b-0af6fb19cfab">31,885,727</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="i4b1713eab7d84494b3b43202a26fc3c4_I20221231" decimals="0" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY18yMi9mcmFnOjAwMGYzZjEyOTA1NzRkM2ZhZmY0N2ZmZGFmY2YyNjRhL3RhYmxlOjQ4MDNhMzdjMjkzMDRkNDE4NDQ1ZTA5ZTY3ZGZlNmY1L3RhYmxlcmFuZ2U6NDgwM2EzN2MyOTMwNGQ0MTg0NDVlMDllNjdkZmU2ZjVfNi0zLTEtMS02OTk0OQ_59f4397b-85a7-446c-b967-3e3154d7a3f9">37,853,658</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Operating lease right-of-use asset</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="i9e6ffce2c2d247f491e046febe8251cd_I20230331" decimals="0" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY18yMi9mcmFnOjAwMGYzZjEyOTA1NzRkM2ZhZmY0N2ZmZGFmY2YyNjRhL3RhYmxlOjQ4MDNhMzdjMjkzMDRkNDE4NDQ1ZTA5ZTY3ZGZlNmY1L3RhYmxlcmFuZ2U6NDgwM2EzN2MyOTMwNGQ0MTg0NDVlMDllNjdkZmU2ZjVfNy0xLTEtMS02OTk0OQ_a330497b-03dc-4e93-b9a9-bbb3fd2b3909">29,892</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="i4b1713eab7d84494b3b43202a26fc3c4_I20221231" decimals="0" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY18yMi9mcmFnOjAwMGYzZjEyOTA1NzRkM2ZhZmY0N2ZmZGFmY2YyNjRhL3RhYmxlOjQ4MDNhMzdjMjkzMDRkNDE4NDQ1ZTA5ZTY3ZGZlNmY1L3RhYmxlcmFuZ2U6NDgwM2EzN2MyOTMwNGQ0MTg0NDVlMDllNjdkZmU2ZjVfNy0zLTEtMS02OTk0OQ_2ba56837-5758-4f36-b324-41ca2c2a92be">51,967</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Property and equipment, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="i9e6ffce2c2d247f491e046febe8251cd_I20230331" decimals="0" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY18yMi9mcmFnOjAwMGYzZjEyOTA1NzRkM2ZhZmY0N2ZmZGFmY2YyNjRhL3RhYmxlOjQ4MDNhMzdjMjkzMDRkNDE4NDQ1ZTA5ZTY3ZGZlNmY1L3RhYmxlcmFuZ2U6NDgwM2EzN2MyOTMwNGQ0MTg0NDVlMDllNjdkZmU2ZjVfOC0xLTEtMS02OTk0OQ_9782a10e-4bf1-4b42-8dd0-f1af746cfab5">24,375</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="i4b1713eab7d84494b3b43202a26fc3c4_I20221231" decimals="0" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY18yMi9mcmFnOjAwMGYzZjEyOTA1NzRkM2ZhZmY0N2ZmZGFmY2YyNjRhL3RhYmxlOjQ4MDNhMzdjMjkzMDRkNDE4NDQ1ZTA5ZTY3ZGZlNmY1L3RhYmxlcmFuZ2U6NDgwM2EzN2MyOTMwNGQ0MTg0NDVlMDllNjdkZmU2ZjVfOC0zLTEtMS02OTk0OQ_eaceb49b-0123-4753-8527-067ec0938c9b">27,568</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Other assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="i9e6ffce2c2d247f491e046febe8251cd_I20230331" decimals="0" name="us-gaap:OtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY18yMi9mcmFnOjAwMGYzZjEyOTA1NzRkM2ZhZmY0N2ZmZGFmY2YyNjRhL3RhYmxlOjQ4MDNhMzdjMjkzMDRkNDE4NDQ1ZTA5ZTY3ZGZlNmY1L3RhYmxlcmFuZ2U6NDgwM2EzN2MyOTMwNGQ0MTg0NDVlMDllNjdkZmU2ZjVfOS0xLTEtMS02OTk0OQ_9fcc2f97-3e79-40ad-a747-67d275fe2bfd">26,188</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="i4b1713eab7d84494b3b43202a26fc3c4_I20221231" decimals="0" name="us-gaap:OtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY18yMi9mcmFnOjAwMGYzZjEyOTA1NzRkM2ZhZmY0N2ZmZGFmY2YyNjRhL3RhYmxlOjQ4MDNhMzdjMjkzMDRkNDE4NDQ1ZTA5ZTY3ZGZlNmY1L3RhYmxlcmFuZ2U6NDgwM2EzN2MyOTMwNGQ0MTg0NDVlMDllNjdkZmU2ZjVfOS0zLTEtMS02OTk0OQ_baaacad0-2707-4142-b58a-61b1278e4321">32,750</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Total assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="i9e6ffce2c2d247f491e046febe8251cd_I20230331" decimals="0" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY18yMi9mcmFnOjAwMGYzZjEyOTA1NzRkM2ZhZmY0N2ZmZGFmY2YyNjRhL3RhYmxlOjQ4MDNhMzdjMjkzMDRkNDE4NDQ1ZTA5ZTY3ZGZlNmY1L3RhYmxlcmFuZ2U6NDgwM2EzN2MyOTMwNGQ0MTg0NDVlMDllNjdkZmU2ZjVfMTEtMS0xLTEtNjk5NDk_2bcd2281-f4f7-496e-a9bf-d9e672e1e666">31,966,182</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="i4b1713eab7d84494b3b43202a26fc3c4_I20221231" decimals="0" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY18yMi9mcmFnOjAwMGYzZjEyOTA1NzRkM2ZhZmY0N2ZmZGFmY2YyNjRhL3RhYmxlOjQ4MDNhMzdjMjkzMDRkNDE4NDQ1ZTA5ZTY3ZGZlNmY1L3RhYmxlcmFuZ2U6NDgwM2EzN2MyOTMwNGQ0MTg0NDVlMDllNjdkZmU2ZjVfMTEtMy0xLTEtNjk5NDk_8dcd2d70-20b3-4bc8-8091-4244d6b94d53">37,965,943</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">Liabilities and Stockholders' Equity</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Current liabilities: </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Accounts payable</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="i9e6ffce2c2d247f491e046febe8251cd_I20230331" decimals="0" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY18yMi9mcmFnOjAwMGYzZjEyOTA1NzRkM2ZhZmY0N2ZmZGFmY2YyNjRhL3RhYmxlOjQ4MDNhMzdjMjkzMDRkNDE4NDQ1ZTA5ZTY3ZGZlNmY1L3RhYmxlcmFuZ2U6NDgwM2EzN2MyOTMwNGQ0MTg0NDVlMDllNjdkZmU2ZjVfMTQtMS0xLTEtNjk5NDk_05f476a7-10f3-43b1-abd1-dab007002eb0">1,210,261</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="i4b1713eab7d84494b3b43202a26fc3c4_I20221231" decimals="0" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY18yMi9mcmFnOjAwMGYzZjEyOTA1NzRkM2ZhZmY0N2ZmZGFmY2YyNjRhL3RhYmxlOjQ4MDNhMzdjMjkzMDRkNDE4NDQ1ZTA5ZTY3ZGZlNmY1L3RhYmxlcmFuZ2U6NDgwM2EzN2MyOTMwNGQ0MTg0NDVlMDllNjdkZmU2ZjVfMTQtMy0xLTEtNjk5NDk_77f9bb42-645d-4920-a282-0d68dc4ecb45">936,330</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Accrued expenses and other current liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="i9e6ffce2c2d247f491e046febe8251cd_I20230331" decimals="0" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY18yMi9mcmFnOjAwMGYzZjEyOTA1NzRkM2ZhZmY0N2ZmZGFmY2YyNjRhL3RhYmxlOjQ4MDNhMzdjMjkzMDRkNDE4NDQ1ZTA5ZTY3ZGZlNmY1L3RhYmxlcmFuZ2U6NDgwM2EzN2MyOTMwNGQ0MTg0NDVlMDllNjdkZmU2ZjVfMTUtMS0xLTEtNjk5NDk_d09b9cc6-5740-4026-8813-235b1b0e98ff">1,991,442</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="i4b1713eab7d84494b3b43202a26fc3c4_I20221231" decimals="0" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY18yMi9mcmFnOjAwMGYzZjEyOTA1NzRkM2ZhZmY0N2ZmZGFmY2YyNjRhL3RhYmxlOjQ4MDNhMzdjMjkzMDRkNDE4NDQ1ZTA5ZTY3ZGZlNmY1L3RhYmxlcmFuZ2U6NDgwM2EzN2MyOTMwNGQ0MTg0NDVlMDllNjdkZmU2ZjVfMTUtMy0xLTEtNjk5NDk_20bcd61a-ab25-4481-9a01-86e5c0d14aa7">2,216,169</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Operating lease liability - current</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="i9e6ffce2c2d247f491e046febe8251cd_I20230331" decimals="0" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY18yMi9mcmFnOjAwMGYzZjEyOTA1NzRkM2ZhZmY0N2ZmZGFmY2YyNjRhL3RhYmxlOjQ4MDNhMzdjMjkzMDRkNDE4NDQ1ZTA5ZTY3ZGZlNmY1L3RhYmxlcmFuZ2U6NDgwM2EzN2MyOTMwNGQ0MTg0NDVlMDllNjdkZmU2ZjVfMTYtMS0xLTEtNjk5NDk_80dfde25-c4a1-4462-a996-baf606a5fd34">31,669</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="i4b1713eab7d84494b3b43202a26fc3c4_I20221231" decimals="0" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY18yMi9mcmFnOjAwMGYzZjEyOTA1NzRkM2ZhZmY0N2ZmZGFmY2YyNjRhL3RhYmxlOjQ4MDNhMzdjMjkzMDRkNDE4NDQ1ZTA5ZTY3ZGZlNmY1L3RhYmxlcmFuZ2U6NDgwM2EzN2MyOTMwNGQ0MTg0NDVlMDllNjdkZmU2ZjVfMTYtMy0xLTEtNjk5NDk_4bc32cb6-b2ae-4e2e-8ef4-fd98a7c4d55d">55,078</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Total current liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="i9e6ffce2c2d247f491e046febe8251cd_I20230331" decimals="0" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY18yMi9mcmFnOjAwMGYzZjEyOTA1NzRkM2ZhZmY0N2ZmZGFmY2YyNjRhL3RhYmxlOjQ4MDNhMzdjMjkzMDRkNDE4NDQ1ZTA5ZTY3ZGZlNmY1L3RhYmxlcmFuZ2U6NDgwM2EzN2MyOTMwNGQ0MTg0NDVlMDllNjdkZmU2ZjVfMTctMS0xLTEtNjk5NDk_625dbac6-e920-4991-88dd-5cfdf70b6205">3,233,372</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="i4b1713eab7d84494b3b43202a26fc3c4_I20221231" decimals="0" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY18yMi9mcmFnOjAwMGYzZjEyOTA1NzRkM2ZhZmY0N2ZmZGFmY2YyNjRhL3RhYmxlOjQ4MDNhMzdjMjkzMDRkNDE4NDQ1ZTA5ZTY3ZGZlNmY1L3RhYmxlcmFuZ2U6NDgwM2EzN2MyOTMwNGQ0MTg0NDVlMDllNjdkZmU2ZjVfMTctMy0xLTEtNjk5NDk_c6d1eccb-670e-4dd5-b690-2b2c0387f742">3,207,577</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Total liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="i9e6ffce2c2d247f491e046febe8251cd_I20230331" decimals="0" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY18yMi9mcmFnOjAwMGYzZjEyOTA1NzRkM2ZhZmY0N2ZmZGFmY2YyNjRhL3RhYmxlOjQ4MDNhMzdjMjkzMDRkNDE4NDQ1ZTA5ZTY3ZGZlNmY1L3RhYmxlcmFuZ2U6NDgwM2EzN2MyOTMwNGQ0MTg0NDVlMDllNjdkZmU2ZjVfMTgtMS0xLTEtNjk5NDk_1d1907b7-ed3b-4dfa-9159-23159f170adb">3,233,372</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="i4b1713eab7d84494b3b43202a26fc3c4_I20221231" decimals="0" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY18yMi9mcmFnOjAwMGYzZjEyOTA1NzRkM2ZhZmY0N2ZmZGFmY2YyNjRhL3RhYmxlOjQ4MDNhMzdjMjkzMDRkNDE4NDQ1ZTA5ZTY3ZGZlNmY1L3RhYmxlcmFuZ2U6NDgwM2EzN2MyOTMwNGQ0MTg0NDVlMDllNjdkZmU2ZjVfMTgtMy0xLTEtNjk5NDk_a77cf86e-1544-44a8-aec0-a36f6edfeb76">3,207,577</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Commitments and contingencies (Note 8)</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="i9e6ffce2c2d247f491e046febe8251cd_I20230331" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY18yMi9mcmFnOjAwMGYzZjEyOTA1NzRkM2ZhZmY0N2ZmZGFmY2YyNjRhL3RhYmxlOjQ4MDNhMzdjMjkzMDRkNDE4NDQ1ZTA5ZTY3ZGZlNmY1L3RhYmxlcmFuZ2U6NDgwM2EzN2MyOTMwNGQ0MTg0NDVlMDllNjdkZmU2ZjVfMTktMS0xLTEtNjk5NDk_b2034094-3169-4886-9df2-acdbd396ad7f"></ix:nonFraction></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="i4b1713eab7d84494b3b43202a26fc3c4_I20221231" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY18yMi9mcmFnOjAwMGYzZjEyOTA1NzRkM2ZhZmY0N2ZmZGFmY2YyNjRhL3RhYmxlOjQ4MDNhMzdjMjkzMDRkNDE4NDQ1ZTA5ZTY3ZGZlNmY1L3RhYmxlcmFuZ2U6NDgwM2EzN2MyOTMwNGQ0MTg0NDVlMDllNjdkZmU2ZjVfMTktMy0xLTEtNjk5NDk_590b10d4-4d07-4e7a-8e6a-81d3568f0ffd"></ix:nonFraction></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Stockholders' equity:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.08pt;padding-left:19.5pt;text-indent:-13.51pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Preferred stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="i4b1713eab7d84494b3b43202a26fc3c4_I20221231" decimals="3" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY18yMi9mcmFnOjAwMGYzZjEyOTA1NzRkM2ZhZmY0N2ZmZGFmY2YyNjRhL3RhYmxlOjQ4MDNhMzdjMjkzMDRkNDE4NDQ1ZTA5ZTY3ZGZlNmY1L3RhYmxlcmFuZ2U6NDgwM2EzN2MyOTMwNGQ0MTg0NDVlMDllNjdkZmU2ZjVfMjEtMC0xLTEtNjk5NDkvdGV4dHJlZ2lvbjozOGE4NGUzMDJmMTM0MzJhYTM5YWI4NTExYTMzNmQ4OV8yMQ_7a038add-a5c5-4afb-b18d-cf84d017ef51"><ix:nonFraction unitRef="usdPerShare" contextRef="i9e6ffce2c2d247f491e046febe8251cd_I20230331" decimals="3" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY18yMi9mcmFnOjAwMGYzZjEyOTA1NzRkM2ZhZmY0N2ZmZGFmY2YyNjRhL3RhYmxlOjQ4MDNhMzdjMjkzMDRkNDE4NDQ1ZTA5ZTY3ZGZlNmY1L3RhYmxlcmFuZ2U6NDgwM2EzN2MyOTMwNGQ0MTg0NDVlMDllNjdkZmU2ZjVfMjEtMC0xLTEtNjk5NDkvdGV4dHJlZ2lvbjozOGE4NGUzMDJmMTM0MzJhYTM5YWI4NTExYTMzNmQ4OV8yMQ_98e23a0e-cef7-47ec-95be-3183a7456b6a">0.001</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction unitRef="shares" contextRef="i4b1713eab7d84494b3b43202a26fc3c4_I20221231" decimals="0" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY18yMi9mcmFnOjAwMGYzZjEyOTA1NzRkM2ZhZmY0N2ZmZGFmY2YyNjRhL3RhYmxlOjQ4MDNhMzdjMjkzMDRkNDE4NDQ1ZTA5ZTY3ZGZlNmY1L3RhYmxlcmFuZ2U6NDgwM2EzN2MyOTMwNGQ0MTg0NDVlMDllNjdkZmU2ZjVfMjEtMC0xLTEtNjk5NDkvdGV4dHJlZ2lvbjozOGE4NGUzMDJmMTM0MzJhYTM5YWI4NTExYTMzNmQ4OV8zNQ_251cb4f0-3e97-4a3b-bac1-4658107ae42a"><ix:nonFraction unitRef="shares" contextRef="i9e6ffce2c2d247f491e046febe8251cd_I20230331" decimals="0" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY18yMi9mcmFnOjAwMGYzZjEyOTA1NzRkM2ZhZmY0N2ZmZGFmY2YyNjRhL3RhYmxlOjQ4MDNhMzdjMjkzMDRkNDE4NDQ1ZTA5ZTY3ZGZlNmY1L3RhYmxlcmFuZ2U6NDgwM2EzN2MyOTMwNGQ0MTg0NDVlMDllNjdkZmU2ZjVfMjEtMC0xLTEtNjk5NDkvdGV4dHJlZ2lvbjozOGE4NGUzMDJmMTM0MzJhYTM5YWI4NTExYTMzNmQ4OV8zNQ_e5d60299-2060-40d1-9840-3271fb2aea1b">10,000,000</ix:nonFraction></ix:nonFraction> shares authorized; <ix:nonFraction unitRef="shares" contextRef="i9e6ffce2c2d247f491e046febe8251cd_I20230331" decimals="0" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY18yMi9mcmFnOjAwMGYzZjEyOTA1NzRkM2ZhZmY0N2ZmZGFmY2YyNjRhL3RhYmxlOjQ4MDNhMzdjMjkzMDRkNDE4NDQ1ZTA5ZTY3ZGZlNmY1L3RhYmxlcmFuZ2U6NDgwM2EzN2MyOTMwNGQ0MTg0NDVlMDllNjdkZmU2ZjVfMjEtMC0xLTEtNjk5NDkvdGV4dHJlZ2lvbjozOGE4NGUzMDJmMTM0MzJhYTM5YWI4NTExYTMzNmQ4OV81Nw_39ab2906-4f52-4864-8aa8-4a41c4eb443b"><ix:nonFraction unitRef="shares" contextRef="i4b1713eab7d84494b3b43202a26fc3c4_I20221231" decimals="0" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY18yMi9mcmFnOjAwMGYzZjEyOTA1NzRkM2ZhZmY0N2ZmZGFmY2YyNjRhL3RhYmxlOjQ4MDNhMzdjMjkzMDRkNDE4NDQ1ZTA5ZTY3ZGZlNmY1L3RhYmxlcmFuZ2U6NDgwM2EzN2MyOTMwNGQ0MTg0NDVlMDllNjdkZmU2ZjVfMjEtMC0xLTEtNjk5NDkvdGV4dHJlZ2lvbjozOGE4NGUzMDJmMTM0MzJhYTM5YWI4NTExYTMzNmQ4OV81Nw_4d9796fa-c968-4aef-8036-b29f64b3c466"><ix:nonFraction unitRef="shares" contextRef="i9e6ffce2c2d247f491e046febe8251cd_I20230331" decimals="0" name="us-gaap:PreferredStockSharesIssued" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY18yMi9mcmFnOjAwMGYzZjEyOTA1NzRkM2ZhZmY0N2ZmZGFmY2YyNjRhL3RhYmxlOjQ4MDNhMzdjMjkzMDRkNDE4NDQ1ZTA5ZTY3ZGZlNmY1L3RhYmxlcmFuZ2U6NDgwM2EzN2MyOTMwNGQ0MTg0NDVlMDllNjdkZmU2ZjVfMjEtMC0xLTEtNjk5NDkvdGV4dHJlZ2lvbjozOGE4NGUzMDJmMTM0MzJhYTM5YWI4NTExYTMzNmQ4OV81Nw_abbcea6b-23c8-41d2-bfe8-5be891aa85fd"><ix:nonFraction unitRef="shares" contextRef="i4b1713eab7d84494b3b43202a26fc3c4_I20221231" decimals="0" name="us-gaap:PreferredStockSharesIssued" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY18yMi9mcmFnOjAwMGYzZjEyOTA1NzRkM2ZhZmY0N2ZmZGFmY2YyNjRhL3RhYmxlOjQ4MDNhMzdjMjkzMDRkNDE4NDQ1ZTA5ZTY3ZGZlNmY1L3RhYmxlcmFuZ2U6NDgwM2EzN2MyOTMwNGQ0MTg0NDVlMDllNjdkZmU2ZjVfMjEtMC0xLTEtNjk5NDkvdGV4dHJlZ2lvbjozOGE4NGUzMDJmMTM0MzJhYTM5YWI4NTExYTMzNmQ4OV81Nw_bc1908e3-2dd7-4014-a2dd-6079d703127b">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> shares issued or outstanding</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="i9e6ffce2c2d247f491e046febe8251cd_I20230331" decimals="0" name="us-gaap:PreferredStockValue" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY18yMi9mcmFnOjAwMGYzZjEyOTA1NzRkM2ZhZmY0N2ZmZGFmY2YyNjRhL3RhYmxlOjQ4MDNhMzdjMjkzMDRkNDE4NDQ1ZTA5ZTY3ZGZlNmY1L3RhYmxlcmFuZ2U6NDgwM2EzN2MyOTMwNGQ0MTg0NDVlMDllNjdkZmU2ZjVfMjEtMS0xLTEtNjk5NDk_faa30cf5-4aab-4eaa-8275-1fad5eb0432d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="i4b1713eab7d84494b3b43202a26fc3c4_I20221231" decimals="0" name="us-gaap:PreferredStockValue" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY18yMi9mcmFnOjAwMGYzZjEyOTA1NzRkM2ZhZmY0N2ZmZGFmY2YyNjRhL3RhYmxlOjQ4MDNhMzdjMjkzMDRkNDE4NDQ1ZTA5ZTY3ZGZlNmY1L3RhYmxlcmFuZ2U6NDgwM2EzN2MyOTMwNGQ0MTg0NDVlMDllNjdkZmU2ZjVfMjEtMy0xLTEtNjk5NDk_ebca4a28-bf2d-4a0e-91ff-20be7b262722">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.08pt;padding-left:19.5pt;text-indent:-13.51pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Common stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="i9e6ffce2c2d247f491e046febe8251cd_I20230331" decimals="3" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY18yMi9mcmFnOjAwMGYzZjEyOTA1NzRkM2ZhZmY0N2ZmZGFmY2YyNjRhL3RhYmxlOjQ4MDNhMzdjMjkzMDRkNDE4NDQ1ZTA5ZTY3ZGZlNmY1L3RhYmxlcmFuZ2U6NDgwM2EzN2MyOTMwNGQ0MTg0NDVlMDllNjdkZmU2ZjVfMjItMC0xLTEtNjk5NDkvdGV4dHJlZ2lvbjo2MGFkYjdjNjA3OGU0ZGIxODI3ZTdjODZkYjQyMzViM18xOA_414e7e02-74fd-4aea-bbde-c798fc98bbf9"><ix:nonFraction unitRef="usdPerShare" contextRef="i4b1713eab7d84494b3b43202a26fc3c4_I20221231" decimals="3" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY18yMi9mcmFnOjAwMGYzZjEyOTA1NzRkM2ZhZmY0N2ZmZGFmY2YyNjRhL3RhYmxlOjQ4MDNhMzdjMjkzMDRkNDE4NDQ1ZTA5ZTY3ZGZlNmY1L3RhYmxlcmFuZ2U6NDgwM2EzN2MyOTMwNGQ0MTg0NDVlMDllNjdkZmU2ZjVfMjItMC0xLTEtNjk5NDkvdGV4dHJlZ2lvbjo2MGFkYjdjNjA3OGU0ZGIxODI3ZTdjODZkYjQyMzViM18xOA_c708108d-b32e-4990-964d-3e5937e0e4b4">0.001</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction unitRef="shares" contextRef="i4b1713eab7d84494b3b43202a26fc3c4_I20221231" decimals="0" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY18yMi9mcmFnOjAwMGYzZjEyOTA1NzRkM2ZhZmY0N2ZmZGFmY2YyNjRhL3RhYmxlOjQ4MDNhMzdjMjkzMDRkNDE4NDQ1ZTA5ZTY3ZGZlNmY1L3RhYmxlcmFuZ2U6NDgwM2EzN2MyOTMwNGQ0MTg0NDVlMDllNjdkZmU2ZjVfMjItMC0xLTEtNjk5NDkvdGV4dHJlZ2lvbjo2MGFkYjdjNjA3OGU0ZGIxODI3ZTdjODZkYjQyMzViM18zMg_9a485a77-dbb2-471c-96d7-0076153c0aac"><ix:nonFraction unitRef="shares" contextRef="i9e6ffce2c2d247f491e046febe8251cd_I20230331" decimals="0" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY18yMi9mcmFnOjAwMGYzZjEyOTA1NzRkM2ZhZmY0N2ZmZGFmY2YyNjRhL3RhYmxlOjQ4MDNhMzdjMjkzMDRkNDE4NDQ1ZTA5ZTY3ZGZlNmY1L3RhYmxlcmFuZ2U6NDgwM2EzN2MyOTMwNGQ0MTg0NDVlMDllNjdkZmU2ZjVfMjItMC0xLTEtNjk5NDkvdGV4dHJlZ2lvbjo2MGFkYjdjNjA3OGU0ZGIxODI3ZTdjODZkYjQyMzViM18zMg_e0a61d51-aeac-4981-a834-1060f20d82df">100,000,000</ix:nonFraction></ix:nonFraction> shares authorized; <ix:nonFraction unitRef="shares" contextRef="i9e6ffce2c2d247f491e046febe8251cd_I20230331" decimals="0" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY18yMi9mcmFnOjAwMGYzZjEyOTA1NzRkM2ZhZmY0N2ZmZGFmY2YyNjRhL3RhYmxlOjQ4MDNhMzdjMjkzMDRkNDE4NDQ1ZTA5ZTY3ZGZlNmY1L3RhYmxlcmFuZ2U6NDgwM2EzN2MyOTMwNGQ0MTg0NDVlMDllNjdkZmU2ZjVfMjItMC0xLTEtNjk5NDkvdGV4dHJlZ2lvbjo2MGFkYjdjNjA3OGU0ZGIxODI3ZTdjODZkYjQyMzViM181NA_2dab8fa4-a840-46fe-bd3d-6ed7895b75a1"><ix:nonFraction unitRef="shares" contextRef="i4b1713eab7d84494b3b43202a26fc3c4_I20221231" decimals="0" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY18yMi9mcmFnOjAwMGYzZjEyOTA1NzRkM2ZhZmY0N2ZmZGFmY2YyNjRhL3RhYmxlOjQ4MDNhMzdjMjkzMDRkNDE4NDQ1ZTA5ZTY3ZGZlNmY1L3RhYmxlcmFuZ2U6NDgwM2EzN2MyOTMwNGQ0MTg0NDVlMDllNjdkZmU2ZjVfMjItMC0xLTEtNjk5NDkvdGV4dHJlZ2lvbjo2MGFkYjdjNjA3OGU0ZGIxODI3ZTdjODZkYjQyMzViM181NA_5674aa2a-8ad6-4260-b1c5-e6e4a784648a"><ix:nonFraction unitRef="shares" contextRef="i9e6ffce2c2d247f491e046febe8251cd_I20230331" decimals="0" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY18yMi9mcmFnOjAwMGYzZjEyOTA1NzRkM2ZhZmY0N2ZmZGFmY2YyNjRhL3RhYmxlOjQ4MDNhMzdjMjkzMDRkNDE4NDQ1ZTA5ZTY3ZGZlNmY1L3RhYmxlcmFuZ2U6NDgwM2EzN2MyOTMwNGQ0MTg0NDVlMDllNjdkZmU2ZjVfMjItMC0xLTEtNjk5NDkvdGV4dHJlZ2lvbjo2MGFkYjdjNjA3OGU0ZGIxODI3ZTdjODZkYjQyMzViM181NA_69f43160-2d8d-4f8b-9ec7-1699b97d1368"><ix:nonFraction unitRef="shares" contextRef="i4b1713eab7d84494b3b43202a26fc3c4_I20221231" decimals="0" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY18yMi9mcmFnOjAwMGYzZjEyOTA1NzRkM2ZhZmY0N2ZmZGFmY2YyNjRhL3RhYmxlOjQ4MDNhMzdjMjkzMDRkNDE4NDQ1ZTA5ZTY3ZGZlNmY1L3RhYmxlcmFuZ2U6NDgwM2EzN2MyOTMwNGQ0MTg0NDVlMDllNjdkZmU2ZjVfMjItMC0xLTEtNjk5NDkvdGV4dHJlZ2lvbjo2MGFkYjdjNjA3OGU0ZGIxODI3ZTdjODZkYjQyMzViM181NA_84de4c18-0660-49a2-80d5-1657f319cf66">15,966,053</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> shares issued and outstanding at March&#160;31, 2023 and December&#160;31, 2022</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="i9e6ffce2c2d247f491e046febe8251cd_I20230331" decimals="0" name="us-gaap:CommonStockValue" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY18yMi9mcmFnOjAwMGYzZjEyOTA1NzRkM2ZhZmY0N2ZmZGFmY2YyNjRhL3RhYmxlOjQ4MDNhMzdjMjkzMDRkNDE4NDQ1ZTA5ZTY3ZGZlNmY1L3RhYmxlcmFuZ2U6NDgwM2EzN2MyOTMwNGQ0MTg0NDVlMDllNjdkZmU2ZjVfMjItMS0xLTEtNjk5NDk_633b2f1e-b1b7-4a34-aa97-6e91fde9e206">15,966</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="i4b1713eab7d84494b3b43202a26fc3c4_I20221231" decimals="0" name="us-gaap:CommonStockValue" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY18yMi9mcmFnOjAwMGYzZjEyOTA1NzRkM2ZhZmY0N2ZmZGFmY2YyNjRhL3RhYmxlOjQ4MDNhMzdjMjkzMDRkNDE4NDQ1ZTA5ZTY3ZGZlNmY1L3RhYmxlcmFuZ2U6NDgwM2EzN2MyOTMwNGQ0MTg0NDVlMDllNjdkZmU2ZjVfMjItMy0xLTEtNjk5NDk_a3e29b4e-96f9-4633-b7ce-641a4498cfb2">15,966</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Additional paid-in capital</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="i9e6ffce2c2d247f491e046febe8251cd_I20230331" decimals="0" name="us-gaap:AdditionalPaidInCapital" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY18yMi9mcmFnOjAwMGYzZjEyOTA1NzRkM2ZhZmY0N2ZmZGFmY2YyNjRhL3RhYmxlOjQ4MDNhMzdjMjkzMDRkNDE4NDQ1ZTA5ZTY3ZGZlNmY1L3RhYmxlcmFuZ2U6NDgwM2EzN2MyOTMwNGQ0MTg0NDVlMDllNjdkZmU2ZjVfMjMtMS0xLTEtNjk5NDk_87c65f55-4027-4f87-8b98-96190eadb3d4">79,115,541</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="i4b1713eab7d84494b3b43202a26fc3c4_I20221231" decimals="0" name="us-gaap:AdditionalPaidInCapital" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY18yMi9mcmFnOjAwMGYzZjEyOTA1NzRkM2ZhZmY0N2ZmZGFmY2YyNjRhL3RhYmxlOjQ4MDNhMzdjMjkzMDRkNDE4NDQ1ZTA5ZTY3ZGZlNmY1L3RhYmxlcmFuZ2U6NDgwM2EzN2MyOTMwNGQ0MTg0NDVlMDllNjdkZmU2ZjVfMjMtMy0xLTEtNjk5NDk_7d106c30-0b67-4b9e-b9ff-789992f77eaa">78,832,779</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Accumulated deficit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(<ix:nonFraction unitRef="usd" contextRef="i9e6ffce2c2d247f491e046febe8251cd_I20230331" decimals="0" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY18yMi9mcmFnOjAwMGYzZjEyOTA1NzRkM2ZhZmY0N2ZmZGFmY2YyNjRhL3RhYmxlOjQ4MDNhMzdjMjkzMDRkNDE4NDQ1ZTA5ZTY3ZGZlNmY1L3RhYmxlcmFuZ2U6NDgwM2EzN2MyOTMwNGQ0MTg0NDVlMDllNjdkZmU2ZjVfMjQtMS0xLTEtNjk5NDk_8cb4939c-d5d2-439b-9f63-d23cc91434d0">50,398,697</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(<ix:nonFraction unitRef="usd" contextRef="i4b1713eab7d84494b3b43202a26fc3c4_I20221231" decimals="0" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY18yMi9mcmFnOjAwMGYzZjEyOTA1NzRkM2ZhZmY0N2ZmZGFmY2YyNjRhL3RhYmxlOjQ4MDNhMzdjMjkzMDRkNDE4NDQ1ZTA5ZTY3ZGZlNmY1L3RhYmxlcmFuZ2U6NDgwM2EzN2MyOTMwNGQ0MTg0NDVlMDllNjdkZmU2ZjVfMjQtMy0xLTEtNjk5NDk_fc808d05-e40c-4fd0-8978-40d713885736">44,090,379</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Total stockholders' equity</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="i9e6ffce2c2d247f491e046febe8251cd_I20230331" decimals="0" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY18yMi9mcmFnOjAwMGYzZjEyOTA1NzRkM2ZhZmY0N2ZmZGFmY2YyNjRhL3RhYmxlOjQ4MDNhMzdjMjkzMDRkNDE4NDQ1ZTA5ZTY3ZGZlNmY1L3RhYmxlcmFuZ2U6NDgwM2EzN2MyOTMwNGQ0MTg0NDVlMDllNjdkZmU2ZjVfMjUtMS0xLTEtNjk5NDk_1be63065-388d-4029-befd-1f1292c4dee3">28,732,810</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="i4b1713eab7d84494b3b43202a26fc3c4_I20221231" decimals="0" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY18yMi9mcmFnOjAwMGYzZjEyOTA1NzRkM2ZhZmY0N2ZmZGFmY2YyNjRhL3RhYmxlOjQ4MDNhMzdjMjkzMDRkNDE4NDQ1ZTA5ZTY3ZGZlNmY1L3RhYmxlcmFuZ2U6NDgwM2EzN2MyOTMwNGQ0MTg0NDVlMDllNjdkZmU2ZjVfMjUtMy0xLTEtNjk5NDk_d960f2de-96c1-4a7f-a52e-12565aec0c2d">34,758,366</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Total liabilities and stockholders' equity</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="i9e6ffce2c2d247f491e046febe8251cd_I20230331" decimals="0" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY18yMi9mcmFnOjAwMGYzZjEyOTA1NzRkM2ZhZmY0N2ZmZGFmY2YyNjRhL3RhYmxlOjQ4MDNhMzdjMjkzMDRkNDE4NDQ1ZTA5ZTY3ZGZlNmY1L3RhYmxlcmFuZ2U6NDgwM2EzN2MyOTMwNGQ0MTg0NDVlMDllNjdkZmU2ZjVfMjYtMS0xLTEtNjk5NDk_945bbaff-fc40-40ad-921c-b4a1bb70b767">31,966,182</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="i4b1713eab7d84494b3b43202a26fc3c4_I20221231" decimals="0" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY18yMi9mcmFnOjAwMGYzZjEyOTA1NzRkM2ZhZmY0N2ZmZGFmY2YyNjRhL3RhYmxlOjQ4MDNhMzdjMjkzMDRkNDE4NDQ1ZTA5ZTY3ZGZlNmY1L3RhYmxlcmFuZ2U6NDgwM2EzN2MyOTMwNGQ0MTg0NDVlMDllNjdkZmU2ZjVfMjYtMy0xLTEtNjk5NDk_b2806cb5-6e15-4c42-a561-61c8c3a35379">37,965,943</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">6</span></div></div></div><div id="ibd14e01a97b1463b915192a9eff93f0c_25"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#ibd14e01a97b1463b915192a9eff93f0c_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Context Therapeutics Inc. </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Condensed Consolidated Statements of Operations </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">(Unaudited) </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#160;</span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:67.982%"><tr><td style="width:1.0%"></td><td style="width:64.061%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.889%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.660%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.890%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">Three months ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Operating expenses:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Research and development</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="ie35b115501ca468f8cadb8213304a30b_D20230101-20230331" decimals="0" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY18yNS9mcmFnOjA5ZGZjMGNmNmE4YjQ1Nzk5MzY0MTllYjNjYjczZGI3L3RhYmxlOmRlNzUzZDM1MGI1MDQzMGY5YTY4NjdkMjI1MTEwNjliL3RhYmxlcmFuZ2U6ZGU3NTNkMzUwYjUwNDMwZjlhNjg2N2QyMjUxMTA2OWJfNC0xLTEtMS02OTk0OQ_ee47d727-11ca-48d0-8764-ecf9b2359980">4,534,676</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="i3baf3250062d4a79a9b120fc56f1b18c_D20220101-20220331" decimals="0" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY18yNS9mcmFnOjA5ZGZjMGNmNmE4YjQ1Nzk5MzY0MTllYjNjYjczZGI3L3RhYmxlOmRlNzUzZDM1MGI1MDQzMGY5YTY4NjdkMjI1MTEwNjliL3RhYmxlcmFuZ2U6ZGU3NTNkMzUwYjUwNDMwZjlhNjg2N2QyMjUxMTA2OWJfNC0zLTEtMS02OTk0OQ_69c2e11e-d9d9-4a12-b188-53660d5027c5">1,351,495</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">General and administrative</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="ie35b115501ca468f8cadb8213304a30b_D20230101-20230331" decimals="0" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY18yNS9mcmFnOjA5ZGZjMGNmNmE4YjQ1Nzk5MzY0MTllYjNjYjczZGI3L3RhYmxlOmRlNzUzZDM1MGI1MDQzMGY5YTY4NjdkMjI1MTEwNjliL3RhYmxlcmFuZ2U6ZGU3NTNkMzUwYjUwNDMwZjlhNjg2N2QyMjUxMTA2OWJfNS0xLTEtMS02OTk0OQ_ff6ee6a5-ee08-410b-8005-c77200aa3469">2,131,872</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="i3baf3250062d4a79a9b120fc56f1b18c_D20220101-20220331" decimals="0" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY18yNS9mcmFnOjA5ZGZjMGNmNmE4YjQ1Nzk5MzY0MTllYjNjYjczZGI3L3RhYmxlOmRlNzUzZDM1MGI1MDQzMGY5YTY4NjdkMjI1MTEwNjliL3RhYmxlcmFuZ2U6ZGU3NTNkMzUwYjUwNDMwZjlhNjg2N2QyMjUxMTA2OWJfNS0zLTEtMS02OTk0OQ_da6359cd-0d6a-473c-a782-809f7530ba21">2,091,467</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Loss from operations</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(<ix:nonFraction unitRef="usd" contextRef="ie35b115501ca468f8cadb8213304a30b_D20230101-20230331" decimals="0" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY18yNS9mcmFnOjA5ZGZjMGNmNmE4YjQ1Nzk5MzY0MTllYjNjYjczZGI3L3RhYmxlOmRlNzUzZDM1MGI1MDQzMGY5YTY4NjdkMjI1MTEwNjliL3RhYmxlcmFuZ2U6ZGU3NTNkMzUwYjUwNDMwZjlhNjg2N2QyMjUxMTA2OWJfNi0xLTEtMS02OTk0OQ_27f5afb3-7773-40f3-9fbb-1f29f5bc63fa">6,666,548</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(<ix:nonFraction unitRef="usd" contextRef="i3baf3250062d4a79a9b120fc56f1b18c_D20220101-20220331" decimals="0" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY18yNS9mcmFnOjA5ZGZjMGNmNmE4YjQ1Nzk5MzY0MTllYjNjYjczZGI3L3RhYmxlOmRlNzUzZDM1MGI1MDQzMGY5YTY4NjdkMjI1MTEwNjliL3RhYmxlcmFuZ2U6ZGU3NTNkMzUwYjUwNDMwZjlhNjg2N2QyMjUxMTA2OWJfNi0zLTEtMS02OTk0OQ_b38c0909-ab13-47bc-8b0b-99b5dda42c3f">3,442,962</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Interest income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="ie35b115501ca468f8cadb8213304a30b_D20230101-20230331" decimals="0" name="us-gaap:InterestIncomeExpenseNet" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY18yNS9mcmFnOjA5ZGZjMGNmNmE4YjQ1Nzk5MzY0MTllYjNjYjczZGI3L3RhYmxlOmRlNzUzZDM1MGI1MDQzMGY5YTY4NjdkMjI1MTEwNjliL3RhYmxlcmFuZ2U6ZGU3NTNkMzUwYjUwNDMwZjlhNjg2N2QyMjUxMTA2OWJfNy0xLTEtMS02OTk0OQ_5bc9409b-dd47-4a6a-ab4f-487cf3586441">355,542</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="i3baf3250062d4a79a9b120fc56f1b18c_D20220101-20220331" decimals="0" name="us-gaap:InterestIncomeExpenseNet" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY18yNS9mcmFnOjA5ZGZjMGNmNmE4YjQ1Nzk5MzY0MTllYjNjYjczZGI3L3RhYmxlOmRlNzUzZDM1MGI1MDQzMGY5YTY4NjdkMjI1MTEwNjliL3RhYmxlcmFuZ2U6ZGU3NTNkMzUwYjUwNDMwZjlhNjg2N2QyMjUxMTA2OWJfNy0zLTEtMS02OTk0OQ_d4f47199-9885-448d-9bd2-888041ccf38a">5,864</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Other income (expense)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="ie35b115501ca468f8cadb8213304a30b_D20230101-20230331" decimals="0" name="us-gaap:NonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY18yNS9mcmFnOjA5ZGZjMGNmNmE4YjQ1Nzk5MzY0MTllYjNjYjczZGI3L3RhYmxlOmRlNzUzZDM1MGI1MDQzMGY5YTY4NjdkMjI1MTEwNjliL3RhYmxlcmFuZ2U6ZGU3NTNkMzUwYjUwNDMwZjlhNjg2N2QyMjUxMTA2OWJfOS0xLTEtMS02OTk0OQ_529b593b-d982-499c-b319-787bbb055448">2,688</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(<ix:nonFraction unitRef="usd" contextRef="i3baf3250062d4a79a9b120fc56f1b18c_D20220101-20220331" decimals="0" sign="-" name="us-gaap:NonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY18yNS9mcmFnOjA5ZGZjMGNmNmE4YjQ1Nzk5MzY0MTllYjNjYjczZGI3L3RhYmxlOmRlNzUzZDM1MGI1MDQzMGY5YTY4NjdkMjI1MTEwNjliL3RhYmxlcmFuZ2U6ZGU3NTNkMzUwYjUwNDMwZjlhNjg2N2QyMjUxMTA2OWJfOS0zLTEtMS02OTk0OQ_8b44c428-3142-4e55-834d-bc62b7fe2796">1,239</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Net loss</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(<ix:nonFraction unitRef="usd" contextRef="ie35b115501ca468f8cadb8213304a30b_D20230101-20230331" decimals="0" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY18yNS9mcmFnOjA5ZGZjMGNmNmE4YjQ1Nzk5MzY0MTllYjNjYjczZGI3L3RhYmxlOmRlNzUzZDM1MGI1MDQzMGY5YTY4NjdkMjI1MTEwNjliL3RhYmxlcmFuZ2U6ZGU3NTNkMzUwYjUwNDMwZjlhNjg2N2QyMjUxMTA2OWJfMTAtMS0xLTEtNjk5NDk_71955604-afa2-4f8e-805c-5e0d08e53572">6,308,318</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(<ix:nonFraction unitRef="usd" contextRef="i3baf3250062d4a79a9b120fc56f1b18c_D20220101-20220331" decimals="0" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY18yNS9mcmFnOjA5ZGZjMGNmNmE4YjQ1Nzk5MzY0MTllYjNjYjczZGI3L3RhYmxlOmRlNzUzZDM1MGI1MDQzMGY5YTY4NjdkMjI1MTEwNjliL3RhYmxlcmFuZ2U6ZGU3NTNkMzUwYjUwNDMwZjlhNjg2N2QyMjUxMTA2OWJfMTAtMy0xLTEtNjk5NDk_1b5e9a69-58f3-4d7c-a416-b6dd60171adc">3,438,337</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Net loss per common share, basic and diluted</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(<ix:nonFraction unitRef="usdPerShare" contextRef="ie35b115501ca468f8cadb8213304a30b_D20230101-20230331" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY18yNS9mcmFnOjA5ZGZjMGNmNmE4YjQ1Nzk5MzY0MTllYjNjYjczZGI3L3RhYmxlOmRlNzUzZDM1MGI1MDQzMGY5YTY4NjdkMjI1MTEwNjliL3RhYmxlcmFuZ2U6ZGU3NTNkMzUwYjUwNDMwZjlhNjg2N2QyMjUxMTA2OWJfMTEtMS0xLTEtNjk5NDk_407902ed-d759-4227-932b-27ef141c1e85"><ix:nonFraction unitRef="usdPerShare" contextRef="ie35b115501ca468f8cadb8213304a30b_D20230101-20230331" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY18yNS9mcmFnOjA5ZGZjMGNmNmE4YjQ1Nzk5MzY0MTllYjNjYjczZGI3L3RhYmxlOmRlNzUzZDM1MGI1MDQzMGY5YTY4NjdkMjI1MTEwNjliL3RhYmxlcmFuZ2U6ZGU3NTNkMzUwYjUwNDMwZjlhNjg2N2QyMjUxMTA2OWJfMTEtMS0xLTEtNjk5NDk_e7895dd6-2456-4b4b-9b37-0bc1ba53b741">0.40</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i3baf3250062d4a79a9b120fc56f1b18c_D20220101-20220331" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY18yNS9mcmFnOjA5ZGZjMGNmNmE4YjQ1Nzk5MzY0MTllYjNjYjczZGI3L3RhYmxlOmRlNzUzZDM1MGI1MDQzMGY5YTY4NjdkMjI1MTEwNjliL3RhYmxlcmFuZ2U6ZGU3NTNkMzUwYjUwNDMwZjlhNjg2N2QyMjUxMTA2OWJfMTEtMy0xLTEtNjk5NDk_7396cab6-1e12-4e87-a923-1a05b31cf986"><ix:nonFraction unitRef="usdPerShare" contextRef="i3baf3250062d4a79a9b120fc56f1b18c_D20220101-20220331" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY18yNS9mcmFnOjA5ZGZjMGNmNmE4YjQ1Nzk5MzY0MTllYjNjYjczZGI3L3RhYmxlOmRlNzUzZDM1MGI1MDQzMGY5YTY4NjdkMjI1MTEwNjliL3RhYmxlcmFuZ2U6ZGU3NTNkMzUwYjUwNDMwZjlhNjg2N2QyMjUxMTA2OWJfMTEtMy0xLTEtNjk5NDk_ba60692c-621e-419e-aab9-a08f34cd2aee">0.22</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Weighted average shares outstanding, basic and diluted</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="shares" contextRef="ie35b115501ca468f8cadb8213304a30b_D20230101-20230331" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY18yNS9mcmFnOjA5ZGZjMGNmNmE4YjQ1Nzk5MzY0MTllYjNjYjczZGI3L3RhYmxlOmRlNzUzZDM1MGI1MDQzMGY5YTY4NjdkMjI1MTEwNjliL3RhYmxlcmFuZ2U6ZGU3NTNkMzUwYjUwNDMwZjlhNjg2N2QyMjUxMTA2OWJfMTMtMS0xLTEtNjk5NDk_46ac0094-41af-4981-b4c6-2cd431a10fef"><ix:nonFraction unitRef="shares" contextRef="ie35b115501ca468f8cadb8213304a30b_D20230101-20230331" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY18yNS9mcmFnOjA5ZGZjMGNmNmE4YjQ1Nzk5MzY0MTllYjNjYjczZGI3L3RhYmxlOmRlNzUzZDM1MGI1MDQzMGY5YTY4NjdkMjI1MTEwNjliL3RhYmxlcmFuZ2U6ZGU3NTNkMzUwYjUwNDMwZjlhNjg2N2QyMjUxMTA2OWJfMTMtMS0xLTEtNjk5NDk_bb30c879-7bf3-463a-8a9e-1f0a08494d3e">15,966,053</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="shares" contextRef="i3baf3250062d4a79a9b120fc56f1b18c_D20220101-20220331" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY18yNS9mcmFnOjA5ZGZjMGNmNmE4YjQ1Nzk5MzY0MTllYjNjYjczZGI3L3RhYmxlOmRlNzUzZDM1MGI1MDQzMGY5YTY4NjdkMjI1MTEwNjliL3RhYmxlcmFuZ2U6ZGU3NTNkMzUwYjUwNDMwZjlhNjg2N2QyMjUxMTA2OWJfMTMtMy0xLTEtNjk5NDk_fa06dd43-ee69-4d8d-98b3-0989d2bcb762"><ix:nonFraction unitRef="shares" contextRef="i3baf3250062d4a79a9b120fc56f1b18c_D20220101-20220331" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY18yNS9mcmFnOjA5ZGZjMGNmNmE4YjQ1Nzk5MzY0MTllYjNjYjczZGI3L3RhYmxlOmRlNzUzZDM1MGI1MDQzMGY5YTY4NjdkMjI1MTEwNjliL3RhYmxlcmFuZ2U6ZGU3NTNkMzUwYjUwNDMwZjlhNjg2N2QyMjUxMTA2OWJfMTMtMy0xLTEtNjk5NDk_fb3695d2-eea5-4dea-8222-296c98cdbfbc">15,966,053</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">The accompanying notes are an integral part of these unaudited condensed consolidated financial statements. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:115%">&#160;</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">7</span></div></div></div><div id="ibd14e01a97b1463b915192a9eff93f0c_28"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#ibd14e01a97b1463b915192a9eff93f0c_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Context Therapeutics Inc. </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Condensed Consolidated Statements of Changes in Stockholders&#8217; Equity</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">(Unaudited) </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#160;</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.805%"><tr><td style="width:1.0%"></td><td style="width:62.027%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.662%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.256%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.151%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.256%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.635%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.256%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.548%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.256%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.553%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:125%">Three Months Ended March 31, 2023</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%">&#160;</span></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:125%">Common&#160;Stock </span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:125%">Additional<br/>Paid-in<br/>Capital </span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:125%">Accumulated<br/>Deficit </span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.08pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:125%">Total<br/>Stockholders&#8217;<br/>Equity</span></div></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:125%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:125%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%">Balance at January 1, 2023</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="shares" contextRef="i943d13fd1b9f4197ae5a210a64adb3ab_I20221231" decimals="0" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY18yOC9mcmFnOjVkNjAyMjg2NTk0NjQyZmU4M2ZmYmFmODZkYWVlMjc5L3RhYmxlOmExNWQ1Yjk0MTIzZDRjODNiYmQwYjdmMjJiZDkyOWJjL3RhYmxlcmFuZ2U6YTE1ZDViOTQxMjNkNGM4M2JiZDBiN2YyMmJkOTI5YmNfMy0xLTEtMS03MjMxMg_38bae8c2-a109-4049-974d-18732c646a28">15,966,053</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="i943d13fd1b9f4197ae5a210a64adb3ab_I20221231" decimals="0" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY18yOC9mcmFnOjVkNjAyMjg2NTk0NjQyZmU4M2ZmYmFmODZkYWVlMjc5L3RhYmxlOmExNWQ1Yjk0MTIzZDRjODNiYmQwYjdmMjJiZDkyOWJjL3RhYmxlcmFuZ2U6YTE1ZDViOTQxMjNkNGM4M2JiZDBiN2YyMmJkOTI5YmNfMy0zLTEtMS03MjMxMg_1920dc30-4596-4fa8-91a8-2b26c3f85e3b">15,966</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="ifaa2a5dd56c843d9a857de26b952bcfb_I20221231" decimals="0" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY18yOC9mcmFnOjVkNjAyMjg2NTk0NjQyZmU4M2ZmYmFmODZkYWVlMjc5L3RhYmxlOmExNWQ1Yjk0MTIzZDRjODNiYmQwYjdmMjJiZDkyOWJjL3RhYmxlcmFuZ2U6YTE1ZDViOTQxMjNkNGM4M2JiZDBiN2YyMmJkOTI5YmNfMy01LTEtMS03MjMxMg_78af1677-9767-4603-86ab-6e0a35d7eff5">78,832,779</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%">(<ix:nonFraction unitRef="usd" contextRef="ic501c165e10e47e080880f65f01c1d5b_I20221231" decimals="0" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY18yOC9mcmFnOjVkNjAyMjg2NTk0NjQyZmU4M2ZmYmFmODZkYWVlMjc5L3RhYmxlOmExNWQ1Yjk0MTIzZDRjODNiYmQwYjdmMjJiZDkyOWJjL3RhYmxlcmFuZ2U6YTE1ZDViOTQxMjNkNGM4M2JiZDBiN2YyMmJkOTI5YmNfMy03LTEtMS03MjMxMg_d2eb9377-2cd2-46d4-9658-628991d1e55f">44,090,379</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="i4b1713eab7d84494b3b43202a26fc3c4_I20221231" decimals="0" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY18yOC9mcmFnOjVkNjAyMjg2NTk0NjQyZmU4M2ZmYmFmODZkYWVlMjc5L3RhYmxlOmExNWQ1Yjk0MTIzZDRjODNiYmQwYjdmMjJiZDkyOWJjL3RhYmxlcmFuZ2U6YTE1ZDViOTQxMjNkNGM4M2JiZDBiN2YyMmJkOTI5YmNfMy05LTEtMS03MjMxMg_5d6e004c-b120-4302-b93b-5d6dec3c6c7a">34,758,366</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%">Share-based compensation expense</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="icd5ebf0042ac4aac81eeac59d3a7522d_D20230101-20230331" decimals="0" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY18yOC9mcmFnOjVkNjAyMjg2NTk0NjQyZmU4M2ZmYmFmODZkYWVlMjc5L3RhYmxlOmExNWQ1Yjk0MTIzZDRjODNiYmQwYjdmMjJiZDkyOWJjL3RhYmxlcmFuZ2U6YTE1ZDViOTQxMjNkNGM4M2JiZDBiN2YyMmJkOTI5YmNfNC01LTEtMS03MjMxMg_34e546e7-ecfe-4c06-9638-5164d9e717a5">282,762</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="ie35b115501ca468f8cadb8213304a30b_D20230101-20230331" decimals="0" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY18yOC9mcmFnOjVkNjAyMjg2NTk0NjQyZmU4M2ZmYmFmODZkYWVlMjc5L3RhYmxlOmExNWQ1Yjk0MTIzZDRjODNiYmQwYjdmMjJiZDkyOWJjL3RhYmxlcmFuZ2U6YTE1ZDViOTQxMjNkNGM4M2JiZDBiN2YyMmJkOTI5YmNfNC05LTEtMS03MjMxMg_df178b95-1e45-4edc-a8e4-81430127bf9d">282,762</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%">Net loss</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%">(<ix:nonFraction unitRef="usd" contextRef="i8d193fa8f7974372bd0db6d8ebed8675_D20230101-20230331" decimals="0" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY18yOC9mcmFnOjVkNjAyMjg2NTk0NjQyZmU4M2ZmYmFmODZkYWVlMjc5L3RhYmxlOmExNWQ1Yjk0MTIzZDRjODNiYmQwYjdmMjJiZDkyOWJjL3RhYmxlcmFuZ2U6YTE1ZDViOTQxMjNkNGM4M2JiZDBiN2YyMmJkOTI5YmNfNS03LTEtMS03MjMxMg_34d883ee-1512-47ba-a239-3984acc44a34">6,308,318</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%">(<ix:nonFraction unitRef="usd" contextRef="ie35b115501ca468f8cadb8213304a30b_D20230101-20230331" decimals="0" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY18yOC9mcmFnOjVkNjAyMjg2NTk0NjQyZmU4M2ZmYmFmODZkYWVlMjc5L3RhYmxlOmExNWQ1Yjk0MTIzZDRjODNiYmQwYjdmMjJiZDkyOWJjL3RhYmxlcmFuZ2U6YTE1ZDViOTQxMjNkNGM4M2JiZDBiN2YyMmJkOTI5YmNfNS05LTEtMS03MjMxMg_0a398734-ca5a-4dcb-80bf-26d16575b3bd">6,308,318</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%">Balance at March 31, 2023</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="shares" contextRef="i9f9455c0d0e74c97a9a53955ed07377f_I20230331" decimals="0" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY18yOC9mcmFnOjVkNjAyMjg2NTk0NjQyZmU4M2ZmYmFmODZkYWVlMjc5L3RhYmxlOmExNWQ1Yjk0MTIzZDRjODNiYmQwYjdmMjJiZDkyOWJjL3RhYmxlcmFuZ2U6YTE1ZDViOTQxMjNkNGM4M2JiZDBiN2YyMmJkOTI5YmNfNi0xLTEtMS03MjU5MQ_9a439f6c-451e-48da-a940-e78ca6566113">15,966,053</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="i9f9455c0d0e74c97a9a53955ed07377f_I20230331" decimals="0" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY18yOC9mcmFnOjVkNjAyMjg2NTk0NjQyZmU4M2ZmYmFmODZkYWVlMjc5L3RhYmxlOmExNWQ1Yjk0MTIzZDRjODNiYmQwYjdmMjJiZDkyOWJjL3RhYmxlcmFuZ2U6YTE1ZDViOTQxMjNkNGM4M2JiZDBiN2YyMmJkOTI5YmNfNi0zLTEtMS03MjU5MQ_9f1daffb-afea-47c2-817c-6e56bf7d7e21">15,966</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="ib8f0e2696e0648f880780a1ad638027a_I20230331" decimals="0" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY18yOC9mcmFnOjVkNjAyMjg2NTk0NjQyZmU4M2ZmYmFmODZkYWVlMjc5L3RhYmxlOmExNWQ1Yjk0MTIzZDRjODNiYmQwYjdmMjJiZDkyOWJjL3RhYmxlcmFuZ2U6YTE1ZDViOTQxMjNkNGM4M2JiZDBiN2YyMmJkOTI5YmNfNi01LTEtMS03MjU5MQ_c363b810-74fe-4e27-ae21-10b8b31142a2">79,115,541</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%">(<ix:nonFraction unitRef="usd" contextRef="if64ea5a878c145cdb5ea7e8156bc0335_I20230331" decimals="0" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY18yOC9mcmFnOjVkNjAyMjg2NTk0NjQyZmU4M2ZmYmFmODZkYWVlMjc5L3RhYmxlOmExNWQ1Yjk0MTIzZDRjODNiYmQwYjdmMjJiZDkyOWJjL3RhYmxlcmFuZ2U6YTE1ZDViOTQxMjNkNGM4M2JiZDBiN2YyMmJkOTI5YmNfNi03LTEtMS03MjU5MQ_066baac9-30a4-4e14-bf8b-3c16120a2ab4">50,398,697</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="i9e6ffce2c2d247f491e046febe8251cd_I20230331" decimals="0" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY18yOC9mcmFnOjVkNjAyMjg2NTk0NjQyZmU4M2ZmYmFmODZkYWVlMjc5L3RhYmxlOmExNWQ1Yjk0MTIzZDRjODNiYmQwYjdmMjJiZDkyOWJjL3RhYmxlcmFuZ2U6YTE1ZDViOTQxMjNkNGM4M2JiZDBiN2YyMmJkOTI5YmNfNi05LTEtMS03MjU5MQ_0295ed17-5eee-491f-8d54-047b81c5c293">28,732,810</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="27" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:125%">Three Months Ended March 31, 2022</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:125%">Common&#160;Stock</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:125%">Additional<br/>Paid-in<br/>Capital</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:125%">Accumulated<br/>Deficit</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:125%">Total<br/>Stockholders&#8217;<br/>Equity</span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:125%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:125%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%">Balance at January 1, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="shares" contextRef="ifd24ec169b5741408f1f292b74c4c8e7_I20211231" decimals="0" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY18yOC9mcmFnOjVkNjAyMjg2NTk0NjQyZmU4M2ZmYmFmODZkYWVlMjc5L3RhYmxlOmExNWQ1Yjk0MTIzZDRjODNiYmQwYjdmMjJiZDkyOWJjL3RhYmxlcmFuZ2U6YTE1ZDViOTQxMjNkNGM4M2JiZDBiN2YyMmJkOTI5YmNfMTItMS0xLTEtNzA3ODc_03aa510d-de77-4117-b3bd-30c4a2b16655">15,966,053</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="ifd24ec169b5741408f1f292b74c4c8e7_I20211231" decimals="0" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY18yOC9mcmFnOjVkNjAyMjg2NTk0NjQyZmU4M2ZmYmFmODZkYWVlMjc5L3RhYmxlOmExNWQ1Yjk0MTIzZDRjODNiYmQwYjdmMjJiZDkyOWJjL3RhYmxlcmFuZ2U6YTE1ZDViOTQxMjNkNGM4M2JiZDBiN2YyMmJkOTI5YmNfMTItMy0xLTEtNzA3ODc_a75c52e2-937d-4b40-9fca-ded93f85d85c">15,966</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="id6056ac1137049ecbf03cbd976238e74_I20211231" decimals="0" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY18yOC9mcmFnOjVkNjAyMjg2NTk0NjQyZmU4M2ZmYmFmODZkYWVlMjc5L3RhYmxlOmExNWQ1Yjk0MTIzZDRjODNiYmQwYjdmMjJiZDkyOWJjL3RhYmxlcmFuZ2U6YTE1ZDViOTQxMjNkNGM4M2JiZDBiN2YyMmJkOTI5YmNfMTItNS0xLTEtNzA3ODc_b762bf15-9d02-43e2-aeb5-60f34b02dc43">77,510,809</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%">(<ix:nonFraction unitRef="usd" contextRef="ia7a50df0f70a4507a6bc3fee39e5d9c3_I20211231" decimals="0" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY18yOC9mcmFnOjVkNjAyMjg2NTk0NjQyZmU4M2ZmYmFmODZkYWVlMjc5L3RhYmxlOmExNWQ1Yjk0MTIzZDRjODNiYmQwYjdmMjJiZDkyOWJjL3RhYmxlcmFuZ2U6YTE1ZDViOTQxMjNkNGM4M2JiZDBiN2YyMmJkOTI5YmNfMTItNy0xLTEtNzA3ODc_542fbc30-4f46-4f5c-9d8a-e45d664df3a4">29,254,440</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="i7970953f78074175b146df53757b2465_I20211231" decimals="0" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY18yOC9mcmFnOjVkNjAyMjg2NTk0NjQyZmU4M2ZmYmFmODZkYWVlMjc5L3RhYmxlOmExNWQ1Yjk0MTIzZDRjODNiYmQwYjdmMjJiZDkyOWJjL3RhYmxlcmFuZ2U6YTE1ZDViOTQxMjNkNGM4M2JiZDBiN2YyMmJkOTI5YmNfMTItOS0xLTEtNzA3ODc_9636ce17-360c-4e8b-bf2b-e92cdb267924">48,272,335</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%">Fair value of warrants issued for services</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="ic40bb4943d7c476c9169444151149747_D20220101-20220331" decimals="0" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY18yOC9mcmFnOjVkNjAyMjg2NTk0NjQyZmU4M2ZmYmFmODZkYWVlMjc5L3RhYmxlOmExNWQ1Yjk0MTIzZDRjODNiYmQwYjdmMjJiZDkyOWJjL3RhYmxlcmFuZ2U6YTE1ZDViOTQxMjNkNGM4M2JiZDBiN2YyMmJkOTI5YmNfMTMtNS0xLTEtNzIzMTk_7df1794b-d64b-483a-87bc-dba9570aeceb">345,530</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="i3baf3250062d4a79a9b120fc56f1b18c_D20220101-20220331" decimals="0" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY18yOC9mcmFnOjVkNjAyMjg2NTk0NjQyZmU4M2ZmYmFmODZkYWVlMjc5L3RhYmxlOmExNWQ1Yjk0MTIzZDRjODNiYmQwYjdmMjJiZDkyOWJjL3RhYmxlcmFuZ2U6YTE1ZDViOTQxMjNkNGM4M2JiZDBiN2YyMmJkOTI5YmNfMTMtOS0xLTEtNzIzMTk_7dcf0f58-a53a-4283-aa9a-430812f8f7f6">345,530</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%">Share-based compensation expense</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="ic40bb4943d7c476c9169444151149747_D20220101-20220331" decimals="0" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY18yOC9mcmFnOjVkNjAyMjg2NTk0NjQyZmU4M2ZmYmFmODZkYWVlMjc5L3RhYmxlOmExNWQ1Yjk0MTIzZDRjODNiYmQwYjdmMjJiZDkyOWJjL3RhYmxlcmFuZ2U6YTE1ZDViOTQxMjNkNGM4M2JiZDBiN2YyMmJkOTI5YmNfMTQtNS0xLTEtNzA5MTI_303fb82a-b98d-4917-a355-f21f7493de7a">214,958</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="i3baf3250062d4a79a9b120fc56f1b18c_D20220101-20220331" decimals="0" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY18yOC9mcmFnOjVkNjAyMjg2NTk0NjQyZmU4M2ZmYmFmODZkYWVlMjc5L3RhYmxlOmExNWQ1Yjk0MTIzZDRjODNiYmQwYjdmMjJiZDkyOWJjL3RhYmxlcmFuZ2U6YTE1ZDViOTQxMjNkNGM4M2JiZDBiN2YyMmJkOTI5YmNfMTMtOS0xLTEtNzA3ODc_2716e18e-b51d-4b7b-a2db-23a0a772b743">214,958</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%">Net loss</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%">(<ix:nonFraction unitRef="usd" contextRef="ibf6fa1d37c03414bbe62bf55d335f4fe_D20220101-20220331" decimals="0" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY18yOC9mcmFnOjVkNjAyMjg2NTk0NjQyZmU4M2ZmYmFmODZkYWVlMjc5L3RhYmxlOmExNWQ1Yjk0MTIzZDRjODNiYmQwYjdmMjJiZDkyOWJjL3RhYmxlcmFuZ2U6YTE1ZDViOTQxMjNkNGM4M2JiZDBiN2YyMmJkOTI5YmNfMTUtNy0xLTEtNzIzMTk_1984bc21-3423-47da-adad-995e3a8350ec">3,438,337</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%">(<ix:nonFraction unitRef="usd" contextRef="i3baf3250062d4a79a9b120fc56f1b18c_D20220101-20220331" decimals="0" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY18yOC9mcmFnOjVkNjAyMjg2NTk0NjQyZmU4M2ZmYmFmODZkYWVlMjc5L3RhYmxlOmExNWQ1Yjk0MTIzZDRjODNiYmQwYjdmMjJiZDkyOWJjL3RhYmxlcmFuZ2U6YTE1ZDViOTQxMjNkNGM4M2JiZDBiN2YyMmJkOTI5YmNfMTQtOS0xLTEtNzA3ODc_6efb316d-5081-4c82-908f-b16887ea3928">3,438,337</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%">Balance at March 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="shares" contextRef="i81afc8f1d52c4facbecee4956dd23cfd_I20220331" decimals="0" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY18yOC9mcmFnOjVkNjAyMjg2NTk0NjQyZmU4M2ZmYmFmODZkYWVlMjc5L3RhYmxlOmExNWQ1Yjk0MTIzZDRjODNiYmQwYjdmMjJiZDkyOWJjL3RhYmxlcmFuZ2U6YTE1ZDViOTQxMjNkNGM4M2JiZDBiN2YyMmJkOTI5YmNfMTUtMS0xLTEtNzA3ODc_937adab4-a993-4d9e-a987-847b77d5154d">15,966,053</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="i81afc8f1d52c4facbecee4956dd23cfd_I20220331" decimals="0" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY18yOC9mcmFnOjVkNjAyMjg2NTk0NjQyZmU4M2ZmYmFmODZkYWVlMjc5L3RhYmxlOmExNWQ1Yjk0MTIzZDRjODNiYmQwYjdmMjJiZDkyOWJjL3RhYmxlcmFuZ2U6YTE1ZDViOTQxMjNkNGM4M2JiZDBiN2YyMmJkOTI5YmNfMTUtMy0xLTEtNzA3ODc_ba6879a9-9bb1-41a6-841b-7ed23bd991e0">15,966</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="i3bf77d6bc24e42a48e050108be77d852_I20220331" decimals="0" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY18yOC9mcmFnOjVkNjAyMjg2NTk0NjQyZmU4M2ZmYmFmODZkYWVlMjc5L3RhYmxlOmExNWQ1Yjk0MTIzZDRjODNiYmQwYjdmMjJiZDkyOWJjL3RhYmxlcmFuZ2U6YTE1ZDViOTQxMjNkNGM4M2JiZDBiN2YyMmJkOTI5YmNfMTUtNS0xLTEtNzA3ODc_c6afff8d-eca7-4aa0-9378-458c4a72706f">78,071,297</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%">(<ix:nonFraction unitRef="usd" contextRef="i6c6c3dc5639243a9bea9f8bc22ea83db_I20220331" decimals="0" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY18yOC9mcmFnOjVkNjAyMjg2NTk0NjQyZmU4M2ZmYmFmODZkYWVlMjc5L3RhYmxlOmExNWQ1Yjk0MTIzZDRjODNiYmQwYjdmMjJiZDkyOWJjL3RhYmxlcmFuZ2U6YTE1ZDViOTQxMjNkNGM4M2JiZDBiN2YyMmJkOTI5YmNfMTUtNy0xLTEtNzA3ODc_d19d9539-eecc-481c-83f7-9057008369e8">32,692,777</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="iafab01d20e1847b5b62b10c7e70e7bc8_I20220331" decimals="0" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY18yOC9mcmFnOjVkNjAyMjg2NTk0NjQyZmU4M2ZmYmFmODZkYWVlMjc5L3RhYmxlOmExNWQ1Yjk0MTIzZDRjODNiYmQwYjdmMjJiZDkyOWJjL3RhYmxlcmFuZ2U6YTE1ZDViOTQxMjNkNGM4M2JiZDBiN2YyMmJkOTI5YmNfMTUtOS0xLTEtNzA3ODc_36655e70-445e-4024-8bdd-f9570a7984dc">45,394,486</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:12pt;padding-right:-7.1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">8</span></div></div></div><div id="ibd14e01a97b1463b915192a9eff93f0c_34"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#ibd14e01a97b1463b915192a9eff93f0c_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Context Therapeutics Inc. </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Condensed Consolidated Statements of Cash Flows</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">(Unaudited) </span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.876%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.621%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:125%">Three months ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:125%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:125%">2022</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">Cash flows from operating activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Net loss</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(<ix:nonFraction unitRef="usd" contextRef="ie35b115501ca468f8cadb8213304a30b_D20230101-20230331" decimals="0" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY18zNC9mcmFnOmE1Mjg2MzYzYjkyYjRjZGFhODllMjhiZjU0N2UyZTc3L3RhYmxlOjdiYmUwMjhjYmQ0MDRjZGViNWQyZTE2MzYwOTBjNDkxL3RhYmxlcmFuZ2U6N2JiZTAyOGNiZDQwNGNkZWI1ZDJlMTYzNjA5MGM0OTFfNC0xLTEtMS02OTk0OQ_bfbe42b3-e52c-4f62-b5a4-ff0350fd790f">6,308,318</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(<ix:nonFraction unitRef="usd" contextRef="i3baf3250062d4a79a9b120fc56f1b18c_D20220101-20220331" decimals="0" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY18zNC9mcmFnOmE1Mjg2MzYzYjkyYjRjZGFhODllMjhiZjU0N2UyZTc3L3RhYmxlOjdiYmUwMjhjYmQ0MDRjZGViNWQyZTE2MzYwOTBjNDkxL3RhYmxlcmFuZ2U6N2JiZTAyOGNiZDQwNGNkZWI1ZDJlMTYzNjA5MGM0OTFfNC0zLTEtMS02OTk0OQ_dccac528-3dd1-494d-93eb-16bff1e28528">3,438,337</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Adjustments to reconcile net loss to net cash used in operating activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Share-based compensation expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="ie35b115501ca468f8cadb8213304a30b_D20230101-20230331" decimals="0" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY18zNC9mcmFnOmE1Mjg2MzYzYjkyYjRjZGFhODllMjhiZjU0N2UyZTc3L3RhYmxlOjdiYmUwMjhjYmQ0MDRjZGViNWQyZTE2MzYwOTBjNDkxL3RhYmxlcmFuZ2U6N2JiZTAyOGNiZDQwNGNkZWI1ZDJlMTYzNjA5MGM0OTFfOC0xLTEtMS02OTk0OQ_71abd3c7-4057-4948-a73e-f362cc1cef84">282,762</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="i3baf3250062d4a79a9b120fc56f1b18c_D20220101-20220331" decimals="0" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY18zNC9mcmFnOmE1Mjg2MzYzYjkyYjRjZGFhODllMjhiZjU0N2UyZTc3L3RhYmxlOjdiYmUwMjhjYmQ0MDRjZGViNWQyZTE2MzYwOTBjNDkxL3RhYmxlcmFuZ2U6N2JiZTAyOGNiZDQwNGNkZWI1ZDJlMTYzNjA5MGM0OTFfOC0zLTEtMS02OTk0OQ_d5809538-241e-4e56-96c0-b924b97bb203">214,958</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Depreciation and amortization expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="ie35b115501ca468f8cadb8213304a30b_D20230101-20230331" decimals="0" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY18zNC9mcmFnOmE1Mjg2MzYzYjkyYjRjZGFhODllMjhiZjU0N2UyZTc3L3RhYmxlOjdiYmUwMjhjYmQ0MDRjZGViNWQyZTE2MzYwOTBjNDkxL3RhYmxlcmFuZ2U6N2JiZTAyOGNiZDQwNGNkZWI1ZDJlMTYzNjA5MGM0OTFfOS0xLTEtMS02OTk0OQ_1cc65b52-72c7-4df1-896a-253f2dc56d35">3,193</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="i3baf3250062d4a79a9b120fc56f1b18c_D20220101-20220331" decimals="0" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY18zNC9mcmFnOmE1Mjg2MzYzYjkyYjRjZGFhODllMjhiZjU0N2UyZTc3L3RhYmxlOjdiYmUwMjhjYmQ0MDRjZGViNWQyZTE2MzYwOTBjNDkxL3RhYmxlcmFuZ2U6N2JiZTAyOGNiZDQwNGNkZWI1ZDJlMTYzNjA5MGM0OTFfOS0zLTEtMS02OTk0OQ_a262c1b0-aa6d-4d16-8255-5393a78bd942">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Reduction in the carrying amount of operating lease right-of-use asset</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="ie35b115501ca468f8cadb8213304a30b_D20230101-20230331" decimals="0" name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY18zNC9mcmFnOmE1Mjg2MzYzYjkyYjRjZGFhODllMjhiZjU0N2UyZTc3L3RhYmxlOjdiYmUwMjhjYmQ0MDRjZGViNWQyZTE2MzYwOTBjNDkxL3RhYmxlcmFuZ2U6N2JiZTAyOGNiZDQwNGNkZWI1ZDJlMTYzNjA5MGM0OTFfMTItMS0xLTEtNjk5NDk_f6e42c13-783e-4b13-a301-62a3e2dccfae">22,075</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="i3baf3250062d4a79a9b120fc56f1b18c_D20220101-20220331" decimals="0" name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY18zNC9mcmFnOmE1Mjg2MzYzYjkyYjRjZGFhODllMjhiZjU0N2UyZTc3L3RhYmxlOjdiYmUwMjhjYmQ0MDRjZGViNWQyZTE2MzYwOTBjNDkxL3RhYmxlcmFuZ2U6N2JiZTAyOGNiZDQwNGNkZWI1ZDJlMTYzNjA5MGM0OTFfMTItMy0xLTEtNjk5NDk_79bc9915-3a54-4679-8f6f-55a1217ff68d">14,021</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Changes in operating assets and liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="ie35b115501ca468f8cadb8213304a30b_D20230101-20230331" decimals="0" sign="-" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY18zNC9mcmFnOmE1Mjg2MzYzYjkyYjRjZGFhODllMjhiZjU0N2UyZTc3L3RhYmxlOjdiYmUwMjhjYmQ0MDRjZGViNWQyZTE2MzYwOTBjNDkxL3RhYmxlcmFuZ2U6N2JiZTAyOGNiZDQwNGNkZWI1ZDJlMTYzNjA5MGM0OTFfMTUtMS0xLTEtNjk5NDk_8af7999f-c46d-4fa2-b0e9-b4c7b7126c0c">239,476</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="i3baf3250062d4a79a9b120fc56f1b18c_D20220101-20220331" decimals="0" sign="-" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY18zNC9mcmFnOmE1Mjg2MzYzYjkyYjRjZGFhODllMjhiZjU0N2UyZTc3L3RhYmxlOjdiYmUwMjhjYmQ0MDRjZGViNWQyZTE2MzYwOTBjNDkxL3RhYmxlcmFuZ2U6N2JiZTAyOGNiZDQwNGNkZWI1ZDJlMTYzNjA5MGM0OTFfMTUtMy0xLTEtNjk5NDk_345012e8-ef9c-4e20-be20-965ee963eac9">491,053</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Other assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="ie35b115501ca468f8cadb8213304a30b_D20230101-20230331" decimals="0" sign="-" name="us-gaap:IncreaseDecreaseInOtherNoncurrentAssets" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY18zNC9mcmFnOmE1Mjg2MzYzYjkyYjRjZGFhODllMjhiZjU0N2UyZTc3L3RhYmxlOjdiYmUwMjhjYmQ0MDRjZGViNWQyZTE2MzYwOTBjNDkxL3RhYmxlcmFuZ2U6N2JiZTAyOGNiZDQwNGNkZWI1ZDJlMTYzNjA5MGM0OTFfMTYtMS0xLTEtNjk5NDk_fee8c164-c29c-4822-be7f-11e28fe6f3c5">6,562</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(<ix:nonFraction unitRef="usd" contextRef="i3baf3250062d4a79a9b120fc56f1b18c_D20220101-20220331" decimals="0" name="us-gaap:IncreaseDecreaseInOtherNoncurrentAssets" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY18zNC9mcmFnOmE1Mjg2MzYzYjkyYjRjZGFhODllMjhiZjU0N2UyZTc3L3RhYmxlOjdiYmUwMjhjYmQ0MDRjZGViNWQyZTE2MzYwOTBjNDkxL3RhYmxlcmFuZ2U6N2JiZTAyOGNiZDQwNGNkZWI1ZDJlMTYzNjA5MGM0OTFfMTYtMy0xLTEtNjk5NDk_28403db4-aec6-4f0e-9012-c7fe34105827">24,000</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Accounts payable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="ie35b115501ca468f8cadb8213304a30b_D20230101-20230331" decimals="0" name="us-gaap:IncreaseDecreaseInAccountsPayable" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY18zNC9mcmFnOmE1Mjg2MzYzYjkyYjRjZGFhODllMjhiZjU0N2UyZTc3L3RhYmxlOjdiYmUwMjhjYmQ0MDRjZGViNWQyZTE2MzYwOTBjNDkxL3RhYmxlcmFuZ2U6N2JiZTAyOGNiZDQwNGNkZWI1ZDJlMTYzNjA5MGM0OTFfMTctMS0xLTEtNjk5NDk_b4556200-d048-4f1b-a42f-0277fe389b32">273,931</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(<ix:nonFraction unitRef="usd" contextRef="i3baf3250062d4a79a9b120fc56f1b18c_D20220101-20220331" decimals="0" sign="-" name="us-gaap:IncreaseDecreaseInAccountsPayable" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY18zNC9mcmFnOmE1Mjg2MzYzYjkyYjRjZGFhODllMjhiZjU0N2UyZTc3L3RhYmxlOjdiYmUwMjhjYmQ0MDRjZGViNWQyZTE2MzYwOTBjNDkxL3RhYmxlcmFuZ2U6N2JiZTAyOGNiZDQwNGNkZWI1ZDJlMTYzNjA5MGM0OTFfMTctMy0xLTEtNjk5NDk_9f70c36a-0130-4ad6-a361-f9b18415b748">1,269,389</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Accrued expenses and other current liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(<ix:nonFraction unitRef="usd" contextRef="ie35b115501ca468f8cadb8213304a30b_D20230101-20230331" decimals="0" sign="-" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY18zNC9mcmFnOmE1Mjg2MzYzYjkyYjRjZGFhODllMjhiZjU0N2UyZTc3L3RhYmxlOjdiYmUwMjhjYmQ0MDRjZGViNWQyZTE2MzYwOTBjNDkxL3RhYmxlcmFuZ2U6N2JiZTAyOGNiZDQwNGNkZWI1ZDJlMTYzNjA5MGM0OTFfMTgtMS0xLTEtNjk5NDk_663a0997-0be2-465b-9998-e9ce5665852d">224,727</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="i3baf3250062d4a79a9b120fc56f1b18c_D20220101-20220331" decimals="0" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY18zNC9mcmFnOmE1Mjg2MzYzYjkyYjRjZGFhODllMjhiZjU0N2UyZTc3L3RhYmxlOjdiYmUwMjhjYmQ0MDRjZGViNWQyZTE2MzYwOTBjNDkxL3RhYmxlcmFuZ2U6N2JiZTAyOGNiZDQwNGNkZWI1ZDJlMTYzNjA5MGM0OTFfMTgtMy0xLTEtNjk5NDk_4a547442-c8c9-4615-aacb-ac7c958b5653">198,324</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Operating lease liability</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(<ix:nonFraction unitRef="usd" contextRef="ie35b115501ca468f8cadb8213304a30b_D20230101-20230331" decimals="0" sign="-" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY18zNC9mcmFnOmE1Mjg2MzYzYjkyYjRjZGFhODllMjhiZjU0N2UyZTc3L3RhYmxlOjdiYmUwMjhjYmQ0MDRjZGViNWQyZTE2MzYwOTBjNDkxL3RhYmxlcmFuZ2U6N2JiZTAyOGNiZDQwNGNkZWI1ZDJlMTYzNjA5MGM0OTFfMTktMS0xLTEtNjk5NDk_956ae906-da2b-4b54-b044-cbd93d247207">23,409</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(<ix:nonFraction unitRef="usd" contextRef="i3baf3250062d4a79a9b120fc56f1b18c_D20220101-20220331" decimals="0" sign="-" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY18zNC9mcmFnOmE1Mjg2MzYzYjkyYjRjZGFhODllMjhiZjU0N2UyZTc3L3RhYmxlOjdiYmUwMjhjYmQ0MDRjZGViNWQyZTE2MzYwOTBjNDkxL3RhYmxlcmFuZ2U6N2JiZTAyOGNiZDQwNGNkZWI1ZDJlMTYzNjA5MGM0OTFfMTktMy0xLTEtNjk5NDk_7ad7b8c6-80d1-4011-a26f-1e4487b0b139">6,911</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Cash used in operating activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(<ix:nonFraction unitRef="usd" contextRef="ie35b115501ca468f8cadb8213304a30b_D20230101-20230331" decimals="0" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY18zNC9mcmFnOmE1Mjg2MzYzYjkyYjRjZGFhODllMjhiZjU0N2UyZTc3L3RhYmxlOjdiYmUwMjhjYmQ0MDRjZGViNWQyZTE2MzYwOTBjNDkxL3RhYmxlcmFuZ2U6N2JiZTAyOGNiZDQwNGNkZWI1ZDJlMTYzNjA5MGM0OTFfMjAtMS0xLTEtNjk5NDk_a9f09a81-43d5-48b5-9cab-3e4a5b70ba2d">5,728,455</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(<ix:nonFraction unitRef="usd" contextRef="i3baf3250062d4a79a9b120fc56f1b18c_D20220101-20220331" decimals="0" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY18zNC9mcmFnOmE1Mjg2MzYzYjkyYjRjZGFhODllMjhiZjU0N2UyZTc3L3RhYmxlOjdiYmUwMjhjYmQ0MDRjZGViNWQyZTE2MzYwOTBjNDkxL3RhYmxlcmFuZ2U6N2JiZTAyOGNiZDQwNGNkZWI1ZDJlMTYzNjA5MGM0OTFfMjAtMy0xLTEtNjk5NDk_0f2c1575-7f4d-4920-825e-560ae99290fc">3,820,281</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">Cash flows from investing activities:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Purchase of property and equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="ie35b115501ca468f8cadb8213304a30b_D20230101-20230331" decimals="0" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY18zNC9mcmFnOmE1Mjg2MzYzYjkyYjRjZGFhODllMjhiZjU0N2UyZTc3L3RhYmxlOjdiYmUwMjhjYmQ0MDRjZGViNWQyZTE2MzYwOTBjNDkxL3RhYmxlcmFuZ2U6N2JiZTAyOGNiZDQwNGNkZWI1ZDJlMTYzNjA5MGM0OTFfMjMtMS0xLTEtNjk5NDk_5b0d6139-9fbd-49a7-9737-248bd32dcc39">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(<ix:nonFraction unitRef="usd" contextRef="i3baf3250062d4a79a9b120fc56f1b18c_D20220101-20220331" decimals="0" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY18zNC9mcmFnOmE1Mjg2MzYzYjkyYjRjZGFhODllMjhiZjU0N2UyZTc3L3RhYmxlOjdiYmUwMjhjYmQ0MDRjZGViNWQyZTE2MzYwOTBjNDkxL3RhYmxlcmFuZ2U6N2JiZTAyOGNiZDQwNGNkZWI1ZDJlMTYzNjA5MGM0OTFfMjMtMy0xLTEtNjk5NDk_ff0c8dbb-146a-4cc3-9fcf-46c640fd9df7">34,999</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 31pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Cash used in investing activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="ie35b115501ca468f8cadb8213304a30b_D20230101-20230331" decimals="0" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY18zNC9mcmFnOmE1Mjg2MzYzYjkyYjRjZGFhODllMjhiZjU0N2UyZTc3L3RhYmxlOjdiYmUwMjhjYmQ0MDRjZGViNWQyZTE2MzYwOTBjNDkxL3RhYmxlcmFuZ2U6N2JiZTAyOGNiZDQwNGNkZWI1ZDJlMTYzNjA5MGM0OTFfMjQtMS0xLTEtNjk5NDk_b910060c-5b28-4c13-8c87-fafba6a8be16">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(<ix:nonFraction unitRef="usd" contextRef="i3baf3250062d4a79a9b120fc56f1b18c_D20220101-20220331" decimals="0" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY18zNC9mcmFnOmE1Mjg2MzYzYjkyYjRjZGFhODllMjhiZjU0N2UyZTc3L3RhYmxlOjdiYmUwMjhjYmQ0MDRjZGViNWQyZTE2MzYwOTBjNDkxL3RhYmxlcmFuZ2U6N2JiZTAyOGNiZDQwNGNkZWI1ZDJlMTYzNjA5MGM0OTFfMjQtMy0xLTEtNjk5NDk_4c8a01b8-9ce6-4c6f-bfaf-27340f94062b">34,999</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">Cash flows from financing activities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Payments for offering costs related to the private placement sale of common stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="i426de1e79cbb451489bfc39d312e71c9_D20230101-20230331" decimals="0" name="us-gaap:PaymentsOfStockIssuanceCosts" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY18zNC9mcmFnOmE1Mjg2MzYzYjkyYjRjZGFhODllMjhiZjU0N2UyZTc3L3RhYmxlOjdiYmUwMjhjYmQ0MDRjZGViNWQyZTE2MzYwOTBjNDkxL3RhYmxlcmFuZ2U6N2JiZTAyOGNiZDQwNGNkZWI1ZDJlMTYzNjA5MGM0OTFfMjYtMS0xLTEtNjk5NDk_fe7890ae-4260-4854-9a43-fc3450e04e4a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(<ix:nonFraction unitRef="usd" contextRef="i0353d0309620461ab7aee7ea14ec31ba_D20220101-20220331" decimals="0" name="us-gaap:PaymentsOfStockIssuanceCosts" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY18zNC9mcmFnOmE1Mjg2MzYzYjkyYjRjZGFhODllMjhiZjU0N2UyZTc3L3RhYmxlOjdiYmUwMjhjYmQ0MDRjZGViNWQyZTE2MzYwOTBjNDkxL3RhYmxlcmFuZ2U6N2JiZTAyOGNiZDQwNGNkZWI1ZDJlMTYzNjA5MGM0OTFfMjYtMy0xLTEtNjk5NDk_18877593-e060-47ff-8b49-9b8d2ed20704">102,071</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Cash used in financing activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="ie35b115501ca468f8cadb8213304a30b_D20230101-20230331" decimals="0" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY18zNC9mcmFnOmE1Mjg2MzYzYjkyYjRjZGFhODllMjhiZjU0N2UyZTc3L3RhYmxlOjdiYmUwMjhjYmQ0MDRjZGViNWQyZTE2MzYwOTBjNDkxL3RhYmxlcmFuZ2U6N2JiZTAyOGNiZDQwNGNkZWI1ZDJlMTYzNjA5MGM0OTFfMjktMS0xLTEtNjk5NDk_85f774f4-8c87-4b6c-bd2f-4d979eee991b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(<ix:nonFraction unitRef="usd" contextRef="i3baf3250062d4a79a9b120fc56f1b18c_D20220101-20220331" decimals="0" sign="-" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY18zNC9mcmFnOmE1Mjg2MzYzYjkyYjRjZGFhODllMjhiZjU0N2UyZTc3L3RhYmxlOjdiYmUwMjhjYmQ0MDRjZGViNWQyZTE2MzYwOTBjNDkxL3RhYmxlcmFuZ2U6N2JiZTAyOGNiZDQwNGNkZWI1ZDJlMTYzNjA5MGM0OTFfMjktMy0xLTEtNjk5NDk_a2477158-b25a-4171-9630-a5902b20f1db">102,071</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Net decrease in cash, cash equivalents and restricted cash</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(<ix:nonFraction unitRef="usd" contextRef="ie35b115501ca468f8cadb8213304a30b_D20230101-20230331" decimals="0" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY18zNC9mcmFnOmE1Mjg2MzYzYjkyYjRjZGFhODllMjhiZjU0N2UyZTc3L3RhYmxlOjdiYmUwMjhjYmQ0MDRjZGViNWQyZTE2MzYwOTBjNDkxL3RhYmxlcmFuZ2U6N2JiZTAyOGNiZDQwNGNkZWI1ZDJlMTYzNjA5MGM0OTFfMzAtMS0xLTEtNjk5NDk_c7b4ca77-d98a-4b2d-999e-d91094e5a2b7">5,728,455</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(<ix:nonFraction unitRef="usd" contextRef="i3baf3250062d4a79a9b120fc56f1b18c_D20220101-20220331" decimals="0" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY18zNC9mcmFnOmE1Mjg2MzYzYjkyYjRjZGFhODllMjhiZjU0N2UyZTc3L3RhYmxlOjdiYmUwMjhjYmQ0MDRjZGViNWQyZTE2MzYwOTBjNDkxL3RhYmxlcmFuZ2U6N2JiZTAyOGNiZDQwNGNkZWI1ZDJlMTYzNjA5MGM0OTFfMzAtMy0xLTEtNjk5NDk_cb230086-be4a-4690-832f-b89798ff6811">3,957,351</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Cash, cash equivalents and restricted cash at beginning of period</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="i4b1713eab7d84494b3b43202a26fc3c4_I20221231" decimals="0" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY18zNC9mcmFnOmE1Mjg2MzYzYjkyYjRjZGFhODllMjhiZjU0N2UyZTc3L3RhYmxlOjdiYmUwMjhjYmQ0MDRjZGViNWQyZTE2MzYwOTBjNDkxL3RhYmxlcmFuZ2U6N2JiZTAyOGNiZDQwNGNkZWI1ZDJlMTYzNjA5MGM0OTFfMzEtMS0xLTEtNjk5NDk_ee5584be-43b1-4b1f-bd62-d99751b1186f">35,497,445</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="i7970953f78074175b146df53757b2465_I20211231" decimals="0" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY18zNC9mcmFnOmE1Mjg2MzYzYjkyYjRjZGFhODllMjhiZjU0N2UyZTc3L3RhYmxlOjdiYmUwMjhjYmQ0MDRjZGViNWQyZTE2MzYwOTBjNDkxL3RhYmxlcmFuZ2U6N2JiZTAyOGNiZDQwNGNkZWI1ZDJlMTYzNjA5MGM0OTFfMzEtMy0xLTEtNjk5NDk_cd79887f-05b5-4009-91d2-00e8bd31c750">49,685,586</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Cash and cash equivalents at end of period</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="i9e6ffce2c2d247f491e046febe8251cd_I20230331" decimals="0" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY18zNC9mcmFnOmE1Mjg2MzYzYjkyYjRjZGFhODllMjhiZjU0N2UyZTc3L3RhYmxlOjdiYmUwMjhjYmQ0MDRjZGViNWQyZTE2MzYwOTBjNDkxL3RhYmxlcmFuZ2U6N2JiZTAyOGNiZDQwNGNkZWI1ZDJlMTYzNjA5MGM0OTFfMzItMS0xLTEtNjk5NDk_4d1afb00-cbde-4f8e-9e49-72acb41ece7e">29,768,990</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="iafab01d20e1847b5b62b10c7e70e7bc8_I20220331" decimals="0" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY18zNC9mcmFnOmE1Mjg2MzYzYjkyYjRjZGFhODllMjhiZjU0N2UyZTc3L3RhYmxlOjdiYmUwMjhjYmQ0MDRjZGViNWQyZTE2MzYwOTBjNDkxL3RhYmxlcmFuZ2U6N2JiZTAyOGNiZDQwNGNkZWI1ZDJlMTYzNjA5MGM0OTFfMzItMy0xLTEtNjk5NDk_c55daca7-33d5-4239-836e-26133f15529b">45,728,235</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:6pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">Supplemental disclosure of non-cash activities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Issuance of warrants for services provided</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="id8892bb22a7e45e7ab17a6a179589967_D20230101-20230331" decimals="0" name="cntx:WarrantsIssued" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY18zNC9mcmFnOmE1Mjg2MzYzYjkyYjRjZGFhODllMjhiZjU0N2UyZTc3L3RhYmxlOjdiYmUwMjhjYmQ0MDRjZGViNWQyZTE2MzYwOTBjNDkxL3RhYmxlcmFuZ2U6N2JiZTAyOGNiZDQwNGNkZWI1ZDJlMTYzNjA5MGM0OTFfMzktMS0xLTEtNjk5NDk_a046c390-e40a-413d-ab40-7cbb479084be">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="ie79fb9e8979b4831b96adca175266f37_D20220101-20220331" decimals="0" name="cntx:WarrantsIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY18zNC9mcmFnOmE1Mjg2MzYzYjkyYjRjZGFhODllMjhiZjU0N2UyZTc3L3RhYmxlOjdiYmUwMjhjYmQ0MDRjZGViNWQyZTE2MzYwOTBjNDkxL3RhYmxlcmFuZ2U6N2JiZTAyOGNiZDQwNGNkZWI1ZDJlMTYzNjA5MGM0OTFfMzktMy0xLTEtNjk5NDk_be63ef49-bbb6-403b-b0f3-74755a759d8f">345,530</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Right-of-use asset obtained in exchange for lease obligation</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="ie35b115501ca468f8cadb8213304a30b_D20230101-20230331" decimals="0" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY18zNC9mcmFnOmE1Mjg2MzYzYjkyYjRjZGFhODllMjhiZjU0N2UyZTc3L3RhYmxlOjdiYmUwMjhjYmQ0MDRjZGViNWQyZTE2MzYwOTBjNDkxL3RhYmxlcmFuZ2U6N2JiZTAyOGNiZDQwNGNkZWI1ZDJlMTYzNjA5MGM0OTFfNDAtMS0xLTEtNjk5NDk_8ec6386e-49fe-417c-b478-dd128d98316d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="i3baf3250062d4a79a9b120fc56f1b18c_D20220101-20220331" decimals="0" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY18zNC9mcmFnOmE1Mjg2MzYzYjkyYjRjZGFhODllMjhiZjU0N2UyZTc3L3RhYmxlOjdiYmUwMjhjYmQ0MDRjZGViNWQyZTE2MzYwOTBjNDkxL3RhYmxlcmFuZ2U6N2JiZTAyOGNiZDQwNGNkZWI1ZDJlMTYzNjA5MGM0OTFfNDAtMy0xLTEtNjk5NDk_9b02dc21-d2cc-4b12-8b44-b3a5f7b066ab">130,488</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">The accompanying notes are an integral part of these unaudited condensed consolidated financial statements. </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">9</span></div></div></div><div id="ibd14e01a97b1463b915192a9eff93f0c_37"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#ibd14e01a97b1463b915192a9eff93f0c_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">CONTEXT THERAPEUTICS INC. </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Notes to Unaudited Condensed Consolidated Financial Statements </span></div><div id="ibd14e01a97b1463b915192a9eff93f0c_40"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">(1) <ix:nonNumeric contextRef="ie35b115501ca468f8cadb8213304a30b_D20230101-20230331" name="us-gaap:NatureOfOperations" id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY180MC9mcmFnOjA5MGM5YjQyYzhlNzQyZjNiZmYxY2E1OTlkYTJhNTU4L3RleHRyZWdpb246MDkwYzliNDJjOGU3NDJmM2JmZjFjYTU5OWRhMmE1NThfMTIzMw_180bbc19-0a42-466c-a8b8-bb627d6be466" continuedAt="i1e0ebb657ede4e2496ecb89dc4ce6bb4" escape="true">Organization and Description of Business</ix:nonNumeric></span></div><ix:continuation id="i1e0ebb657ede4e2496ecb89dc4ce6bb4" continuedAt="i5ed28ea8548d40c085fc3438796c2d32"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Context Therapeutics Inc. (the &#8220;Company&#8221;) is a biopharmaceutical company dedicated to improving the lives of patients living with cancer. The Company&#8217;s preclinical product candidate, CTIM-76, is an anti-CD3 x anti-Claudin 6 (&#8220;CLDN6&#8221;) antigen bispecific monoclonal antibody (&#8220;bsAb&#8221;) that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company had also been developing onapristone extended release (&#8220;ONA-XR&#8221;). However, in March 2023, the Company announced its plan to discontinue the development of this product candidate and focus its efforts on the development of CTIM-76. All estimated closeout costs associated with the ONA-XR program were recognized in research and development expense during the first quarter of 2023. The Company does not expect to incur future material expenses related to this program.</span></div></ix:continuation><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:continuation id="i5ed28ea8548d40c085fc3438796c2d32">The Company was organized in April 2015 under the laws of the State of Delaware. The Company&#8217;s headquarters are located in Philadelphia, Pennsylvania.</ix:continuation> </span></div><div id="ibd14e01a97b1463b915192a9eff93f0c_43"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">(2) <ix:nonNumeric contextRef="ie35b115501ca468f8cadb8213304a30b_D20230101-20230331" name="cntx:RisksAndLiquidityTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY180My9mcmFnOjQxZDU2YmVjZjA4YzQ1NjQ5OTQ0YWM3MDc2ODJlMmEyL3RleHRyZWdpb246NDFkNTZiZWNmMDhjNDU2NDk5NDRhYzcwNzY4MmUyYTJfNDcxMQ_b2168143-d414-4042-8ad6-e19a533b96dc" continuedAt="i47cf0e1ca5ea4fa69227b23283c7a83b" escape="true">Risks and Liquidity </ix:nonNumeric></span></div><ix:continuation id="i47cf0e1ca5ea4fa69227b23283c7a83b" continuedAt="ic62a7f7194c04f60b37196e5ee9165ec"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company has incurred losses and negative cash flows from operations since inception and had an accumulated deficit of $<ix:nonFraction unitRef="usd" contextRef="i9e6ffce2c2d247f491e046febe8251cd_I20230331" decimals="-5" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY180My9mcmFnOjQxZDU2YmVjZjA4YzQ1NjQ5OTQ0YWM3MDc2ODJlMmEyL3RleHRyZWdpb246NDFkNTZiZWNmMDhjNDU2NDk5NDRhYzcwNzY4MmUyYTJfMTUy_bc35397d-78f8-4da7-8f0b-7eaf0c1eb991">50.4</ix:nonFraction>&#160;million as of March&#160;31, 2023. The Company anticipates incurring additional losses until such time, if ever, that it can generate significant revenues from its current or any future product candidates. The Company believes its cash and cash equivalents of $<ix:nonFraction unitRef="usd" contextRef="i9e6ffce2c2d247f491e046febe8251cd_I20230331" decimals="-5" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY180My9mcmFnOjQxZDU2YmVjZjA4YzQ1NjQ5OTQ0YWM3MDc2ODJlMmEyL3RleHRyZWdpb246NDFkNTZiZWNmMDhjNDU2NDk5NDRhYzcwNzY4MmUyYTJfMzkz_6066ee05-aa21-4bd2-8fe4-6d89cc46a15c">29.8</ix:nonFraction> million as of March&#160;31, 2023 are sufficient to fund its projected operations for at least the next 12 months from the issuance date of these condensed consolidated financial statements. However, substantial additional financing will be needed by the Company to fund its operations and to commercially develop its current and any future product candidates. There is no assurance that such financing will be available when needed or on acceptable terms.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company plans to seek additional capital in the future through equity and/or debt financings, partnerships, collaborations, or other sources to carry out the Company&#8217;s planned development activities. If additional capital is not available when required, the Company may need to delay or curtail its operations until such funding is received. Various internal and external factors will affect whether and when the Company&#8217;s current or any future product candidates become approved for marketing and successful commercialization. The regulatory approval and market acceptance of the Company&#8217;s current and any future product candidates, length of time and cost of developing and commercializing these product candidates and/or failure of them at any stage of the approval process will materially affect the Company&#8217;s financial condition and future operations. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company faces risks associated with companies whose products are in development. These risks include the need for additional financing to complete its research and development, achieving its research and development objectives, defending its intellectual property rights, recruiting and retaining skilled personnel, and dependence on key members of management, among others. </span></div></ix:continuation><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:continuation id="ic62a7f7194c04f60b37196e5ee9165ec">The spread of COVID-19 has caused worldwide economic downturn and significant volatility in the financial markets. There is significant uncertainty as to the likely effects of this disease should novel outbreaks emerge, which may, among other things, materially impact the Company&#8217;s planned clinical trials. This pandemic and/or periodic outbreaks could result in difficulty securing clinical trial site locations, contract research organizations, and/or trial monitors and other critical vendors and consultants supporting the trials. In addition, outbreaks or the perception of an outbreak near a clinical trial site location could impact the Company&#8217;s ability to enroll patients. These situations, or others associated with&#160;COVID-19,&#160;could cause delays in the Company&#8217;s clinical trial plans and could increase expected costs, all of which could have a material adverse effect on the Company&#8217;s business and its financial condition. At the current time, the Company is unable to quantify the potential effects of this pandemic on its future consolidated financial statements.</ix:continuation> </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">10</span></div></div></div><div id="ibd14e01a97b1463b915192a9eff93f0c_46"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#ibd14e01a97b1463b915192a9eff93f0c_7">Table of Contents</a></span></div></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">(3) <ix:nonNumeric contextRef="ie35b115501ca468f8cadb8213304a30b_D20230101-20230331" name="us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY180Ni9mcmFnOjhjODU4NmNiZTA4YzQ2MDA5Y2YzNDQyOWE5OGI4MzZkL3RleHRyZWdpb246OGM4NTg2Y2JlMDhjNDYwMDljZjM0NDI5YTk4YjgzNmRfMTI5MjA_dfbf2bfc-14f1-4d6b-88ee-befbad8c0efc" continuedAt="i4cc7eabf6bd34c7685f45bc50219487c" escape="true">Basis of Presentation and Summary of Significant Accounting Policies </ix:nonNumeric></span></div><ix:continuation id="i4cc7eabf6bd34c7685f45bc50219487c" continuedAt="ia4fedcacb3a24f4ebae83e9f5e9217b9"><ix:nonNumeric contextRef="ie35b115501ca468f8cadb8213304a30b_D20230101-20230331" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY180Ni9mcmFnOjhjODU4NmNiZTA4YzQ2MDA5Y2YzNDQyOWE5OGI4MzZkL3RleHRyZWdpb246OGM4NTg2Y2JlMDhjNDYwMDljZjM0NDI5YTk4YjgzNmRfMTI5MTQ_a5302759-12a4-4534-acb1-bc0236a83b60" continuedAt="i51735c4ad02b4d9e8adac4e6ccd9eb4d" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Basis of Presentation and Principles of Consolidation </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The accompanying unaudited condensed consolidated financial statements have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission (&#8220;SEC&#8221;). Certain information and note disclosures normally included in annual financial statements prepared in accordance with U.S. generally accepted accounting principles (&#8220;GAAP&#8221;) have been condensed or omitted pursuant to those rules and regulations, although the Company believes that the disclosures made are adequate to make the information not misleading. Any reference in these notes to applicable guidance is meant to refer to GAAP as found in the Accounting Standards Codification and Accounting Standards Updates (&#8220;ASU&#8221;) of the Financial Accounting Standards Board (&#8220;FASB&#8221;).</span></div></ix:nonNumeric><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:continuation id="i51735c4ad02b4d9e8adac4e6ccd9eb4d">In the opinion of management, the accompanying unaudited condensed consolidated financial statements include all normal and recurring adjustments (which consist primarily of accruals and estimates that impact the financial statements) considered necessary to present fairly the Company&#8217;s financial position as of March&#160;31, 2023, and its results of operations and cash flows for the three months ended March&#160;31, 2023 and 2022. Operating results for the three months ended March&#160;31, 2023 are not necessarily indicative of the results that may be expected for the year ending December&#160;31, 2023. The unaudited condensed consolidated financial statements, presented herein, do not contain the required disclosures under GAAP for annual financial statements. The accompanying unaudited condensed consolidated financial statements should be read in conjunction with the annual audited consolidated financial statements and related notes as of and for the year ended December&#160;31, 2022. The consolidated financial information as of December&#160;31, 2022 included herein has been derived from the annual audited consolidated financial statements.</ix:continuation> </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonNumeric contextRef="ie35b115501ca468f8cadb8213304a30b_D20230101-20230331" name="us-gaap:ConsolidationPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY180Ni9mcmFnOjhjODU4NmNiZTA4YzQ2MDA5Y2YzNDQyOWE5OGI4MzZkL3RleHRyZWdpb246OGM4NTg2Y2JlMDhjNDYwMDljZjM0NDI5YTk4YjgzNmRfMTI5MTU_1fe473fa-863a-444a-9bfa-683d438cfa03" escape="true">The unaudited condensed consolidated financial statements include the accounts of the Company, Context Therapeutics LLC, Context Biopharma, Inc. and Context Ireland Ltd., the Company&#8217;s wholly-owned subsidiaries. All intercompany accounts and transactions have been eliminated in consolidation.</ix:nonNumeric> </span></div><ix:nonNumeric contextRef="ie35b115501ca468f8cadb8213304a30b_D20230101-20230331" name="us-gaap:UseOfEstimates" id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY180Ni9mcmFnOjhjODU4NmNiZTA4YzQ2MDA5Y2YzNDQyOWE5OGI4MzZkL3RleHRyZWdpb246OGM4NTg2Y2JlMDhjNDYwMDljZjM0NDI5YTk4YjgzNmRfMTI5MDY_daf4b0a4-f3d1-4fe1-b618-5b5413176c01" continuedAt="if5415e483825489492fb19912b4e883e" escape="true"><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Use of Estimates </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The preparation of condensed consolidated financial statements in conformity with GAAP&#160;requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and contingent liabilities at the date of the condensed consolidated financial statements and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates. </span></div></ix:nonNumeric><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:continuation id="if5415e483825489492fb19912b4e883e">Estimates and assumptions are periodically reviewed, and the effects of the revisions are reflected in the accompanying unaudited condensed consolidated financial statements in the period they are determined to be necessary. Significant estimates and assumptions made in the accompanying unaudited condensed consolidated financial statements include, but are not limited to, share-based compensation arrangements, the fair value of warrants, and in recording the prepayments, accruals and associated expense for research and development activities performed for the Company by third parties.</ix:continuation> </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"><ix:nonNumeric contextRef="ie35b115501ca468f8cadb8213304a30b_D20230101-20230331" name="us-gaap:ConcentrationRiskCreditRisk" id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY180Ni9mcmFnOjhjODU4NmNiZTA4YzQ2MDA5Y2YzNDQyOWE5OGI4MzZkL3RleHRyZWdpb246OGM4NTg2Y2JlMDhjNDYwMDljZjM0NDI5YTk4YjgzNmRfMTI5MTY_0e53b7e4-6a36-4b2d-8153-1790563f9c8d" continuedAt="i5e4d5370244e421dbae8c2adec472bb5" escape="true">Concentrations of Credit Risk </ix:nonNumeric></span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:continuation id="i5e4d5370244e421dbae8c2adec472bb5">Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash and cash equivalents. The Company maintains deposits in federally insured financial institutions in excess of federally insured limits. The Company has not experienced any losses in such accounts.</ix:continuation> </span></div><div><span><br/></span></div><ix:nonNumeric contextRef="ie35b115501ca468f8cadb8213304a30b_D20230101-20230331" name="us-gaap:FairValueOfFinancialInstrumentsPolicy" id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY180Ni9mcmFnOjhjODU4NmNiZTA4YzQ2MDA5Y2YzNDQyOWE5OGI4MzZkL3RleHRyZWdpb246OGM4NTg2Y2JlMDhjNDYwMDljZjM0NDI5YTk4YjgzNmRfMTI5MjE_123fd042-e462-4954-868c-c69f415638ae" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Fair Value of Financial Instruments</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The carrying amount of the Company&#8217;s financial instruments, which include cash and cash equivalents, restricted cash, and accounts payable, approximate their fair values given their short-term nature.</span></div></ix:nonNumeric><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"><ix:nonNumeric contextRef="ie35b115501ca468f8cadb8213304a30b_D20230101-20230331" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY180Ni9mcmFnOjhjODU4NmNiZTA4YzQ2MDA5Y2YzNDQyOWE5OGI4MzZkL3RleHRyZWdpb246OGM4NTg2Y2JlMDhjNDYwMDljZjM0NDI5YTk4YjgzNmRfMTI5MTc_12b92361-03e2-497f-987c-dd6950aeadbf" continuedAt="ia5b0cab3cb06480dabc6b892debacccf" escape="true">Cash, Cash Equivalents and Restricted Cash</ix:nonNumeric></span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:continuation id="ia5b0cab3cb06480dabc6b892debacccf">The Company considers all highly liquid investments that have original maturities of three months or less when acquired to be cash equivalents. Cash equivalents consist of amounts invested in money market accounts.</ix:continuation> At March&#160;31, 2023, the Company's cash and cash equivalent balances exceeded federally insured limits by approximately $<ix:nonFraction unitRef="usd" contextRef="i9e6ffce2c2d247f491e046febe8251cd_I20230331" decimals="-5" name="us-gaap:CashUninsuredAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY180Ni9mcmFnOjhjODU4NmNiZTA4YzQ2MDA5Y2YzNDQyOWE5OGI4MzZkL3RleHRyZWdpb246OGM4NTg2Y2JlMDhjNDYwMDljZjM0NDI5YTk4YjgzNmRfMzI5ODUzNDg5NzI3Mg_7fdbe4f6-2f1c-46a4-931a-952c3b5556d3">29.5</ix:nonFraction> million.</span></div></ix:continuation><div><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">11</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#ibd14e01a97b1463b915192a9eff93f0c_7">Table of Contents</a></span></div></div><ix:continuation id="ia4fedcacb3a24f4ebae83e9f5e9217b9" continuedAt="i6df2fe565fc24d879ee6174310a00b42"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company maintained approximately $<ix:nonFraction unitRef="usd" contextRef="i7970953f78074175b146df53757b2465_I20211231" decimals="-3" name="us-gaap:RestrictedCashNoncurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY180Ni9mcmFnOjhjODU4NmNiZTA4YzQ2MDA5Y2YzNDQyOWE5OGI4MzZkL3RleHRyZWdpb246OGM4NTg2Y2JlMDhjNDYwMDljZjM0NDI5YTk4YjgzNmRfMTY0OTI2NzQ2MDUxOQ_7bff8df6-98da-4e64-93b8-257d045aeb70">50,000</ix:nonFraction> as collateral for the Company&#8217;s credit card program at December 31, 2021, which was previously reported as restricted cash on its consolidated balance sheets. There were <ix:nonFraction unitRef="usd" contextRef="i9e6ffce2c2d247f491e046febe8251cd_I20230331" decimals="0" name="us-gaap:RestrictedCashNoncurrent" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY180Ni9mcmFnOjhjODU4NmNiZTA4YzQ2MDA5Y2YzNDQyOWE5OGI4MzZkL3RleHRyZWdpb246OGM4NTg2Y2JlMDhjNDYwMDljZjM0NDI5YTk4YjgzNmRfMTY0OTI2NzQ2MDUyNw_3197330f-db6a-4e1f-a0fc-f4c608b8bcb1"><ix:nonFraction unitRef="usd" contextRef="i4b1713eab7d84494b3b43202a26fc3c4_I20221231" decimals="0" name="us-gaap:RestrictedCashNoncurrent" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY180Ni9mcmFnOjhjODU4NmNiZTA4YzQ2MDA5Y2YzNDQyOWE5OGI4MzZkL3RleHRyZWdpb246OGM4NTg2Y2JlMDhjNDYwMDljZjM0NDI5YTk4YjgzNmRfMTY0OTI2NzQ2MDUyNw_bd45b5d0-c519-4f53-98f2-af13a000d7d6">no</ix:nonFraction></ix:nonFraction> amounts restricted as of March 31, 2023 and December 31, 2022, as the collateral was released to the Company in the first quarter of 2022.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> <br/></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"><ix:nonNumeric contextRef="ie35b115501ca468f8cadb8213304a30b_D20230101-20230331" name="us-gaap:DeferredChargesPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY180Ni9mcmFnOjhjODU4NmNiZTA4YzQ2MDA5Y2YzNDQyOWE5OGI4MzZkL3RleHRyZWdpb246OGM4NTg2Y2JlMDhjNDYwMDljZjM0NDI5YTk4YjgzNmRfMTI5MjI_a6d9dedc-c935-4b5a-a36a-a0d8a65b7b2e" continuedAt="ic931805ad55d477abbbc430b5c47e70f" escape="true">Deferred Offering Costs </ix:nonNumeric></span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:continuation id="ic931805ad55d477abbbc430b5c47e70f">The Company capitalizes certain legal, professional, accounting and other third-party fees that are directly associated with in-process equity financings as deferred offering costs until such financings are consummated. After consummation of an equity financing, the costs are recorded as a reduction of additional paid-in capital generated as a result of such offering. Should an in-process equity financing be abandoned, the deferred offering costs will be expensed immediately as a charge to operating expenses in the condensed consolidated statements of operations.</ix:continuation> </span></div><div><span><br/></span></div><div><ix:nonNumeric contextRef="ie35b115501ca468f8cadb8213304a30b_D20230101-20230331" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY180Ni9mcmFnOjhjODU4NmNiZTA4YzQ2MDA5Y2YzNDQyOWE5OGI4MzZkL3RleHRyZWdpb246OGM4NTg2Y2JlMDhjNDYwMDljZjM0NDI5YTk4YjgzNmRfMTI5MDc_6a2caee9-642e-46fa-a600-f14f883bbf60" continuedAt="ia72efd6f1fb74ac4a876d7fae78bb937" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Property and Equipmen</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">t</span></ix:nonNumeric></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:continuation id="ia72efd6f1fb74ac4a876d7fae78bb937">Property and equipment consist of office equipment, furniture, and leasehold improvements and are recorded at cost. Property and equipment are depreciated on a straight-line basis over their estimated useful lives. Leasehold improvements are amortized over the shorter of their economic lives or the remaining lease term.</ix:continuation> </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"><ix:nonNumeric contextRef="ie35b115501ca468f8cadb8213304a30b_D20230101-20230331" name="us-gaap:InProcessResearchAndDevelopmentPolicy" id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY180Ni9mcmFnOjhjODU4NmNiZTA4YzQ2MDA5Y2YzNDQyOWE5OGI4MzZkL3RleHRyZWdpb246OGM4NTg2Y2JlMDhjNDYwMDljZjM0NDI5YTk4YjgzNmRfMTY0OTI2NzQ2MDUzNg_e57e41cc-a384-4a7c-a353-f4dace1d5c80" continuedAt="icbd972db99fc4e9984b0f9615a7c4e37" escape="true">Acquired In-Process Research and Development Costs</ix:nonNumeric></span></div><div><span><br/></span></div><div><ix:continuation id="icbd972db99fc4e9984b0f9615a7c4e37" continuedAt="i751abdacf22a45428a403005aab285a6"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Acquired in-process research and development (IPR&amp;D) expense consists of payments incurred in connection with the acquisition or licensing of products or technologies that do not meet the definition of a business under FASB ASC Topic 805, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Business Combinations</span></ix:continuation><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:continuation id="i751abdacf22a45428a403005aab285a6">. Payments for product development milestones are initially treated as the acquisition of an asset but then immediately expensed as there is no future alternative use for the asset. These development milestone payments are reflected as an investing activity outflow on the Company&#8217;s consolidated statements of cash flows due to the nature of the underlying acquisition of an asset.</ix:continuation> See Note 8 for further discussion.</span></div><div><span><br/></span></div><ix:nonNumeric contextRef="ie35b115501ca468f8cadb8213304a30b_D20230101-20230331" name="us-gaap:ResearchAndDevelopmentExpensePolicy" id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY180Ni9mcmFnOjhjODU4NmNiZTA4YzQ2MDA5Y2YzNDQyOWE5OGI4MzZkL3RleHRyZWdpb246OGM4NTg2Y2JlMDhjNDYwMDljZjM0NDI5YTk4YjgzNmRfMTI5MDg_8d3ac5e9-97a5-435e-bcc9-8e3af78249ff" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Research and Development Costs </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Research and development costs are expensed as incurred. Research and development costs include external costs of outside vendors engaged to conduct clinical studies and other research and development activities, salaries, share-based compensation, and other operational costs related to the Company&#8217;s research and development activities. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Costs for certain development activities, such as the provision of services for product candidate development, clinical and preclinical development and related supply and manufacturing costs, are estimated based on an evaluation of the progress to completion of specific tasks using data such as patient enrollment, clinical site activations or information provided to the Company by its vendors with respect to their actual costs incurred. Payments for these activities are based on the terms of the individual arrangements, which may differ from the pattern of costs incurred, and are reflected in the condensed consolidated financial statements as prepaid or accrued research and development expense, as the case may be. The estimates are adjusted to reflect the best information available at the time of the financial statement issuance. Although the Company does not expect its estimates to be materially different from amounts actually incurred, the Company&#8217;s estimate of the status and timing of services performed relative to the actual status and timing of services performed may vary.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Nonrefundable advance payments for goods and services, including fees for clinical trial expenses, process development or manufacturing and distribution of clinical supplies that will be used in future research and development activities, are deferred and recognized as expense in the period that the related goods are consumed or services are performed.</span></div></ix:nonNumeric><div><span><br/></span></div><ix:nonNumeric contextRef="ie35b115501ca468f8cadb8213304a30b_D20230101-20230331" name="cntx:PatentCostsPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY180Ni9mcmFnOjhjODU4NmNiZTA4YzQ2MDA5Y2YzNDQyOWE5OGI4MzZkL3RleHRyZWdpb246OGM4NTg2Y2JlMDhjNDYwMDljZjM0NDI5YTk4YjgzNmRfMTI5MTg_7ceb5688-7db3-4426-96bd-ebaf63fe8e05" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Patent Costs </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Costs related to filing and pursuing patent applications are recorded as general and administrative expense and expensed as incurred since recoverability of such expenditures is uncertain.</span></div></ix:nonNumeric><div><span><br/></span></div><ix:nonNumeric contextRef="ie35b115501ca468f8cadb8213304a30b_D20230101-20230331" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY180Ni9mcmFnOjhjODU4NmNiZTA4YzQ2MDA5Y2YzNDQyOWE5OGI4MzZkL3RleHRyZWdpb246OGM4NTg2Y2JlMDhjNDYwMDljZjM0NDI5YTk4YjgzNmRfMTI5MDk_8a659fe0-74ce-451c-bd5c-7a23677319d3" continuedAt="i47383f5e43f44ae691da5ac242635553" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Share-Based Compensation </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company measures and recognizes share-based compensation expense for both employee and non-employee awards based on the grant date fair value of the awards. The Company recognizes share-based compensation expense on a straight-line basis over the requisite service period of the awards, which is generally the vesting period. The Company recognizes forfeitures as they occur. </span></div></ix:nonNumeric></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">12</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#ibd14e01a97b1463b915192a9eff93f0c_7">Table of Contents</a></span></div></div><ix:continuation id="i6df2fe565fc24d879ee6174310a00b42" continuedAt="i64b8c067b77343788d607b077f984954"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:continuation id="i47383f5e43f44ae691da5ac242635553" continuedAt="ic34f2b1d380345dc80fac8d27c684dba">The Company classifies share-based compensation expense in its unaudited condensed consolidated statements of operations in the same manner in which the award recipients&#8217; payroll costs are classified or in which the award recipients&#8217; service payments are classified. </ix:continuation></span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:continuation id="ic34f2b1d380345dc80fac8d27c684dba">The Company estimates the fair value of employee and non-employee stock awards as of the date of grant using the Black-Scholes option pricing model. The Company lacks Company-specific historical and implied volatility information. Therefore, management estimates the expected share price volatility based on the historical volatility of a publicly traded set of peer companies and expects to continue to do so until such time as it has adequate historical data regarding the volatility of its own publicly traded share price. The expected term of the Company&#8217;s stock awards has been determined utilizing the &#8220;simplified&#8221; method for awards that qualify as &#8220;plain-vanilla&#8221; stock awards. The risk-free interest rate is determined by reference to the yield curve of a zero-coupon U.S. Treasury bond on the date of grant of the award for time periods approximately equal to the expected term of the award. Expected dividend yield is based on the fact that the Company has never paid cash dividends on common stock and does not expect to pay any cash dividends in the foreseeable future.</ix:continuation> </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"><ix:nonNumeric contextRef="ie35b115501ca468f8cadb8213304a30b_D20230101-20230331" name="us-gaap:EarningsPerSharePolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY180Ni9mcmFnOjhjODU4NmNiZTA4YzQ2MDA5Y2YzNDQyOWE5OGI4MzZkL3RleHRyZWdpb246OGM4NTg2Y2JlMDhjNDYwMDljZjM0NDI5YTk4YjgzNmRfMTI5MTI_740e3eea-3baa-423e-83fc-22dc77a8fb1d" continuedAt="iacbb1e0aa95049d9b4f80823c65898f2" escape="true">Net Loss Per Share </ix:nonNumeric></span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:continuation id="iacbb1e0aa95049d9b4f80823c65898f2">Basic net loss per share of common stock is computed by dividing net loss by the weighted-average number of shares of common stock outstanding during each period. Diluted net loss per share of common stock includes the effect, if any, from the potential exercise or conversion of securities, such as convertible promissory notes, preferred stock, warrants and share-based awards, which would result in the issuance of incremental shares of common stock. For diluted net loss per share, the weighted-average number of shares of common stock is the same for basic net loss per share due to the fact that when a net loss exists, dilutive securities are not included in the calculation as the impact is anti-dilutive.</ix:continuation> </span></div><ix:nonNumeric contextRef="ie35b115501ca468f8cadb8213304a30b_D20230101-20230331" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY180Ni9mcmFnOjhjODU4NmNiZTA4YzQ2MDA5Y2YzNDQyOWE5OGI4MzZkL3RleHRyZWdpb246OGM4NTg2Y2JlMDhjNDYwMDljZjM0NDI5YTk4YjgzNmRfMTI5MTM_af9f43d8-5017-4304-9974-8767b4e26074" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The following potentially dilutive securities have been excluded from the computation of diluted weighted-average shares of common stock outstanding, as they would be anti-dilutive:</span></div><div><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:59.210%"><tr><td style="width:1.0%"></td><td style="width:55.937%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.887%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.787%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.889%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:125%">March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:125%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:125%">2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Stock options</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="shares" contextRef="iacc367c186494022944e99aa683971ef_D20230101-20230331" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY180Ni9mcmFnOjhjODU4NmNiZTA4YzQ2MDA5Y2YzNDQyOWE5OGI4MzZkL3RhYmxlOmUxOGVjMzA1ZmJhNDQzMGJiN2EzMGUwYmM4NjE5ZGJkL3RhYmxlcmFuZ2U6ZTE4ZWMzMDVmYmE0NDMwYmI3YTMwZTBiYzg2MTlkYmRfNS0xLTEtMS02OTk0OQ_c1605c67-2baa-496e-87e1-cd379acbfc09">2,165,646</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="shares" contextRef="i56a00969dd024778bc570050ee58a725_D20220101-20220331" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY180Ni9mcmFnOjhjODU4NmNiZTA4YzQ2MDA5Y2YzNDQyOWE5OGI4MzZkL3RhYmxlOmUxOGVjMzA1ZmJhNDQzMGJiN2EzMGUwYmM4NjE5ZGJkL3RhYmxlcmFuZ2U6ZTE4ZWMzMDVmYmE0NDMwYmI3YTMwZTBiYzg2MTlkYmRfNS0zLTEtMS02OTk0OQ_0c22f84d-be25-435e-abc0-2a2afb14b059">1,180,222</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Warrants</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="shares" contextRef="i8c99fb13d0f54109a9578b166514e149_D20230101-20230331" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY180Ni9mcmFnOjhjODU4NmNiZTA4YzQ2MDA5Y2YzNDQyOWE5OGI4MzZkL3RhYmxlOmUxOGVjMzA1ZmJhNDQzMGJiN2EzMGUwYmM4NjE5ZGJkL3RhYmxlcmFuZ2U6ZTE4ZWMzMDVmYmE0NDMwYmI3YTMwZTBiYzg2MTlkYmRfNy0xLTEtMS02OTk0OQ_75d5d811-8dfb-4757-b017-55ca0e1524a7">5,860,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="shares" contextRef="i8db471e9da7749b2b45d29dfa213f4cc_D20220101-20220331" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY180Ni9mcmFnOjhjODU4NmNiZTA4YzQ2MDA5Y2YzNDQyOWE5OGI4MzZkL3RhYmxlOmUxOGVjMzA1ZmJhNDQzMGJiN2EzMGUwYmM4NjE5ZGJkL3RhYmxlcmFuZ2U6ZTE4ZWMzMDVmYmE0NDMwYmI3YTMwZTBiYzg2MTlkYmRfNy0zLTEtMS02OTk0OQ_c4f3e5df-7d2f-45e8-bd04-f8c59e13c186">5,860,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="shares" contextRef="ie35b115501ca468f8cadb8213304a30b_D20230101-20230331" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY180Ni9mcmFnOjhjODU4NmNiZTA4YzQ2MDA5Y2YzNDQyOWE5OGI4MzZkL3RhYmxlOmUxOGVjMzA1ZmJhNDQzMGJiN2EzMGUwYmM4NjE5ZGJkL3RhYmxlcmFuZ2U6ZTE4ZWMzMDVmYmE0NDMwYmI3YTMwZTBiYzg2MTlkYmRfOC0xLTEtMS02OTk0OQ_cfeb02c5-ccdf-4c90-af63-e4088c6b7bed">8,025,646</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="shares" contextRef="i3baf3250062d4a79a9b120fc56f1b18c_D20220101-20220331" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY180Ni9mcmFnOjhjODU4NmNiZTA4YzQ2MDA5Y2YzNDQyOWE5OGI4MzZkL3RhYmxlOmUxOGVjMzA1ZmJhNDQzMGJiN2EzMGUwYmM4NjE5ZGJkL3RhYmxlcmFuZ2U6ZTE4ZWMzMDVmYmE0NDMwYmI3YTMwZTBiYzg2MTlkYmRfOC0zLTEtMS02OTk0OQ_66097b0a-aad1-4061-98b8-88962a815a24">7,040,222</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Amounts in the above table reflect common stock equivalents.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Emerging Growth Company Status </span></div></ix:continuation><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:continuation id="i64b8c067b77343788d607b077f984954">The Company is an emerging growth company, as defined in the Jumpstart Our Business Startups Act of 2012 (the &#8220;JOBS Act&#8221;). Under the JOBS Act, emerging growth companies can delay adopting new or revised accounting standards issued subsequent to the enactment of the JOBS Act, until such time as those standards apply to private companies. The Company has elected to use this extended transition period for complying with new or revised accounting standards that have different effective dates for public and private companies until the earlier of the date that it (i)&#160;is no longer an emerging growth company or (ii)&#160;affirmatively and irrevocably opts out of the extended transition period provided in the JOBS Act. As a result, these condensed consolidated financial statements may not be comparable to companies that comply with the new or revised accounting pronouncements as of public company effective dates.</ix:continuation> </span></div><div id="ibd14e01a97b1463b915192a9eff93f0c_49"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">(4) <ix:nonNumeric contextRef="ie35b115501ca468f8cadb8213304a30b_D20230101-20230331" name="us-gaap:FairValueDisclosuresTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY180OS9mcmFnOmEyOGFhZmExODFjOTQxMGZhZTFiMjcyMTQxNWU5NTFhL3RleHRyZWdpb246YTI4YWFmYTE4MWM5NDEwZmFlMWIyNzIxNDE1ZTk1MWFfODQ0_cb617dea-c5f2-4644-8f25-0ec929196a69" continuedAt="iec836150ca5b4cd596d73a7f2afb0eae" escape="true">Fair Value Measurements </ix:nonNumeric></span></div><ix:continuation id="iec836150ca5b4cd596d73a7f2afb0eae" continuedAt="id2c69adc631a4682b8f94a45824b8fb6"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company utilizes a valuation hierarchy that prioritizes fair value measurements based on the types of inputs used for the various valuation techniques related to its financial assets and financial liabilities. The three levels of inputs used to measure fair value are described as follows: </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Level&#160;1 &#8211; Observable inputs such as quoted prices in active markets. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Level&#160;2 &#8211; Inputs, other than the quoted prices in active markets, that are observable either directly or indirectly. </span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">13</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#ibd14e01a97b1463b915192a9eff93f0c_7">Table of Contents</a></span></div></div><ix:continuation id="id2c69adc631a4682b8f94a45824b8fb6"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Level&#160;3 &#8211; Unobservable inputs for which there is little or no market data, which require the reporting entity to develop its own assumptions. </span></div><ix:nonNumeric contextRef="ie35b115501ca468f8cadb8213304a30b_D20230101-20230331" name="us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY180OS9mcmFnOmEyOGFhZmExODFjOTQxMGZhZTFiMjcyMTQxNWU5NTFhL3RleHRyZWdpb246YTI4YWFmYTE4MWM5NDEwZmFlMWIyNzIxNDE1ZTk1MWFfODQ1_f64b8169-f568-4130-9df5-07dfc3171b28" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In accordance with the fair value hierarchy described above, the following table sets forth the Company&#8217;s assets and liabilities measured at fair value on a recurring basis: </span></div><div style="margin-top:12pt"><span><br/></span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:34.237%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.829%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.386%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.495%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.386%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.589%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.386%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.592%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.57pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:125%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:125%">March 31, 2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.57pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:125%">Total </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:125%">Quoted&#160;Prices&#160;in&#160;Active<br/>Markets for Identical<br/>Assets (Level 1) </span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:125%">Significant&#160;Other<br/>Observable&#160;Inputs<br/>(Level 2) </span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:125%">Significant<br/>Unobservable&#160;Inputs<br/>(Level 3) </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">Financial assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 5.57pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 5.57pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 5.57pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 5.57pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.08pt;padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Cash equivalents <br/>(Money Market Accounts)</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 5.57pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="i3062cc15f83f4cdfb396a7b04a1c52fc_I20230331" decimals="0" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY180OS9mcmFnOmEyOGFhZmExODFjOTQxMGZhZTFiMjcyMTQxNWU5NTFhL3RhYmxlOmIzYWJiZmQ4ODM5NDQ3ZmFiZTZiM2QyM2UxODkyODgwL3RhYmxlcmFuZ2U6YjNhYmJmZDg4Mzk0NDdmYWJlNmIzZDIzZTE4OTI4ODBfMy0xLTEtMS02OTk0OQ_d96eddbe-08a1-4310-80c2-c5543c5011b3">2,150,810</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 5.57pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="i4d1a753ee70a4fd2bfd93f0e3636aa04_I20230331" decimals="0" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY180OS9mcmFnOmEyOGFhZmExODFjOTQxMGZhZTFiMjcyMTQxNWU5NTFhL3RhYmxlOmIzYWJiZmQ4ODM5NDQ3ZmFiZTZiM2QyM2UxODkyODgwL3RhYmxlcmFuZ2U6YjNhYmJmZDg4Mzk0NDdmYWJlNmIzZDIzZTE4OTI4ODBfMy0zLTEtMS02OTk0OQ_3b7b5277-d935-4afd-a298-9721aec85e22">2,150,810</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 5.57pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="ibcafe063c5b44faf99d7d8aa71157121_I20230331" decimals="0" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY180OS9mcmFnOmEyOGFhZmExODFjOTQxMGZhZTFiMjcyMTQxNWU5NTFhL3RhYmxlOmIzYWJiZmQ4ODM5NDQ3ZmFiZTZiM2QyM2UxODkyODgwL3RhYmxlcmFuZ2U6YjNhYmJmZDg4Mzk0NDdmYWJlNmIzZDIzZTE4OTI4ODBfMy01LTEtMS02OTk0OQ_e498e6ce-ed87-42c2-81ec-d8163fc7711e">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 5.57pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="i1badbe53200740efb2a4bd341a6746ea_I20230331" decimals="0" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY180OS9mcmFnOmEyOGFhZmExODFjOTQxMGZhZTFiMjcyMTQxNWU5NTFhL3RhYmxlOmIzYWJiZmQ4ODM5NDQ3ZmFiZTZiM2QyM2UxODkyODgwL3RhYmxlcmFuZ2U6YjNhYmJmZDg4Mzk0NDdmYWJlNmIzZDIzZTE4OTI4ODBfMy03LTEtMS02OTk0OQ_972524ba-c280-47c2-97de-d9ff55855a36">&#8212;</ix:nonFraction></span></td></tr></table></div><div><span><br/></span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:34.771%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.369%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.385%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.469%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.385%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.385%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.570%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.57pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%">&#160;</span></td><td colspan="3" style="padding:2px 1pt 2px 5.57pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.57pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:125%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:125%">Quoted&#160;Prices&#160;in&#160;Active<br/>Markets for Identical<br/>Assets (Level 1)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:125%">Significant&#160;Other<br/>Observable&#160;Inputs<br/>(Level 2)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:125%">Significant<br/>Unobservable&#160;Inputs<br/>(Level 3)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">Financial assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 5.57pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 5.57pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 5.57pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 5.57pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Cash equivalents </span><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(Money Market Accounts)</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 5.57pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="i32dbf7cfaa0f452aae81b03367cca49f_I20221231" decimals="0" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY180OS9mcmFnOmEyOGFhZmExODFjOTQxMGZhZTFiMjcyMTQxNWU5NTFhL3RhYmxlOjViYjE5NjkyYmQ1NjQ4MDhiZTFlYzdhNjYwMzIyY2FiL3RhYmxlcmFuZ2U6NWJiMTk2OTJiZDU2NDgwOGJlMWVjN2E2NjAzMjJjYWJfMy0xLTEtMS02OTk0OQ_47a0ae7a-1b54-4549-b8a2-b7c938e43ddb">1,723,893</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 5.57pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="id0fabbbc724b4914bb823640a0a66913_I20221231" decimals="0" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY180OS9mcmFnOmEyOGFhZmExODFjOTQxMGZhZTFiMjcyMTQxNWU5NTFhL3RhYmxlOjViYjE5NjkyYmQ1NjQ4MDhiZTFlYzdhNjYwMzIyY2FiL3RhYmxlcmFuZ2U6NWJiMTk2OTJiZDU2NDgwOGJlMWVjN2E2NjAzMjJjYWJfMy0zLTEtMS02OTk0OQ_537f4bab-3afe-4872-bfbd-7d04081fb348">1,723,893</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 5.57pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="i226a9d11b9184048a101065b542aff08_I20221231" decimals="0" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY180OS9mcmFnOmEyOGFhZmExODFjOTQxMGZhZTFiMjcyMTQxNWU5NTFhL3RhYmxlOjViYjE5NjkyYmQ1NjQ4MDhiZTFlYzdhNjYwMzIyY2FiL3RhYmxlcmFuZ2U6NWJiMTk2OTJiZDU2NDgwOGJlMWVjN2E2NjAzMjJjYWJfMy01LTEtMS02OTk0OQ_e55c5a7a-f76b-4335-bc3d-93af5195da52">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 5.57pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="i71991571d44349a9b2f3d9678cc16557_I20221231" decimals="0" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY180OS9mcmFnOmEyOGFhZmExODFjOTQxMGZhZTFiMjcyMTQxNWU5NTFhL3RhYmxlOjViYjE5NjkyYmQ1NjQ4MDhiZTFlYzdhNjYwMzIyY2FiL3RhYmxlcmFuZ2U6NWJiMTk2OTJiZDU2NDgwOGJlMWVjN2E2NjAzMjJjYWJfMy03LTEtMS02OTk0OQ_28b1ceee-36e3-4922-8994-9d50d7d00b52">&#8212;</ix:nonFraction></span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="margin-top:9pt"><span style="background-color:#ffff00;color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:115%">&#160;</span></div><div><span><br/></span></div><div style="margin-bottom:6pt;padding-left:51.29pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:80.116%"><tr><td style="width:1.0%"></td><td style="width:79.009%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.791%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.57pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:125%">&#160;</span></td><td colspan="3" style="padding:2px 1pt 2px 5.57pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:125%">&#160;</span></td></tr></table></div><div id="ibd14e01a97b1463b915192a9eff93f0c_52"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">(5) <ix:nonNumeric contextRef="ie35b115501ca468f8cadb8213304a30b_D20230101-20230331" name="us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY181Mi9mcmFnOmEzYWJjNmJkN2M1ZTQ4MjViNjFiMWRkMDUxY2RkNzAxL3RleHRyZWdpb246YTNhYmM2YmQ3YzVlNDgyNWI2MWIxZGQwNTFjZGQ3MDFfMTMz_3fbaf32c-3413-44b4-bcfd-f7ebb0d9130e" continuedAt="i496ce956452e4e21a55d3a2078e275ec" escape="true">Accrued Expenses and Other Current Liabilities</ix:nonNumeric></span></div><ix:continuation id="i496ce956452e4e21a55d3a2078e275ec"><ix:nonNumeric contextRef="ie35b115501ca468f8cadb8213304a30b_D20230101-20230331" name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY181Mi9mcmFnOmEzYWJjNmJkN2M1ZTQ4MjViNjFiMWRkMDUxY2RkNzAxL3RleHRyZWdpb246YTNhYmM2YmQ3YzVlNDgyNWI2MWIxZGQwNTFjZGQ3MDFfMTM0_c4dbdd85-26d7-410e-b261-261a23bec2aa" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Accrued expenses and other current liabilities consisted of the following:</span></div><div><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:77.046%"><tr><td style="width:1.0%"></td><td style="width:49.184%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.077%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.620%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">March 31, 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;text-indent:-12pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Compensation and benefits</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="i9e6ffce2c2d247f491e046febe8251cd_I20230331" decimals="0" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY181Mi9mcmFnOmEzYWJjNmJkN2M1ZTQ4MjViNjFiMWRkMDUxY2RkNzAxL3RhYmxlOmZjNzg2Mzc5YTI2MDQ1ODU5OTUzZWM0MTkzZmE4NzQwL3RhYmxlcmFuZ2U6ZmM3ODYzNzlhMjYwNDU4NTk5NTNlYzQxOTNmYTg3NDBfMS0xLTEtMS02OTk0OQ_fc2bd34a-f588-40b1-b9a0-a703927e6920">215,050</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="i4b1713eab7d84494b3b43202a26fc3c4_I20221231" decimals="0" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY181Mi9mcmFnOmEzYWJjNmJkN2M1ZTQ4MjViNjFiMWRkMDUxY2RkNzAxL3RhYmxlOmZjNzg2Mzc5YTI2MDQ1ODU5OTUzZWM0MTkzZmE4NzQwL3RhYmxlcmFuZ2U6ZmM3ODYzNzlhMjYwNDU4NTk5NTNlYzQxOTNmYTg3NDBfMS0zLTEtMS02OTk0OQ_cf321c9d-966a-44e3-8349-08377e6302ce">770,055</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;text-indent:-12pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Research and development costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="i9e6ffce2c2d247f491e046febe8251cd_I20230331" decimals="0" name="cntx:AccruedResearchAndDevelopmentCostsCurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY181Mi9mcmFnOmEzYWJjNmJkN2M1ZTQ4MjViNjFiMWRkMDUxY2RkNzAxL3RhYmxlOmZjNzg2Mzc5YTI2MDQ1ODU5OTUzZWM0MTkzZmE4NzQwL3RhYmxlcmFuZ2U6ZmM3ODYzNzlhMjYwNDU4NTk5NTNlYzQxOTNmYTg3NDBfMi0xLTEtMS02OTk0OQ_77178f09-0c25-48ae-97cd-72bb413e1aa7">1,629,014</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="i4b1713eab7d84494b3b43202a26fc3c4_I20221231" decimals="0" name="cntx:AccruedResearchAndDevelopmentCostsCurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY181Mi9mcmFnOmEzYWJjNmJkN2M1ZTQ4MjViNjFiMWRkMDUxY2RkNzAxL3RhYmxlOmZjNzg2Mzc5YTI2MDQ1ODU5OTUzZWM0MTkzZmE4NzQwL3RhYmxlcmFuZ2U6ZmM3ODYzNzlhMjYwNDU4NTk5NTNlYzQxOTNmYTg3NDBfMi0zLTEtMS02OTk0OQ_edabaa09-f349-43f0-aaa2-bc73705bb370">1,358,707</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;text-indent:-12pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Professional fees</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="i9e6ffce2c2d247f491e046febe8251cd_I20230331" decimals="0" name="us-gaap:AccruedProfessionalFeesCurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY181Mi9mcmFnOmEzYWJjNmJkN2M1ZTQ4MjViNjFiMWRkMDUxY2RkNzAxL3RhYmxlOmZjNzg2Mzc5YTI2MDQ1ODU5OTUzZWM0MTkzZmE4NzQwL3RhYmxlcmFuZ2U6ZmM3ODYzNzlhMjYwNDU4NTk5NTNlYzQxOTNmYTg3NDBfMy0xLTEtMS02OTk0OQ_77d0662f-c152-4c9b-8ad3-5197d2f3e5ab">103,131</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="i4b1713eab7d84494b3b43202a26fc3c4_I20221231" decimals="0" name="us-gaap:AccruedProfessionalFeesCurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY181Mi9mcmFnOmEzYWJjNmJkN2M1ZTQ4MjViNjFiMWRkMDUxY2RkNzAxL3RhYmxlOmZjNzg2Mzc5YTI2MDQ1ODU5OTUzZWM0MTkzZmE4NzQwL3RhYmxlcmFuZ2U6ZmM3ODYzNzlhMjYwNDU4NTk5NTNlYzQxOTNmYTg3NDBfMy0zLTEtMS02OTk0OQ_b389d6ed-c3f3-48c6-a88a-22c475176fd3">3,951</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;text-indent:-12pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="i9e6ffce2c2d247f491e046febe8251cd_I20230331" decimals="0" name="us-gaap:OtherAccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY181Mi9mcmFnOmEzYWJjNmJkN2M1ZTQ4MjViNjFiMWRkMDUxY2RkNzAxL3RhYmxlOmZjNzg2Mzc5YTI2MDQ1ODU5OTUzZWM0MTkzZmE4NzQwL3RhYmxlcmFuZ2U6ZmM3ODYzNzlhMjYwNDU4NTk5NTNlYzQxOTNmYTg3NDBfNC0xLTEtMS02OTk0OQ_5c92bb13-d70f-41fe-8699-3ddddb9482c0">44,247</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="i4b1713eab7d84494b3b43202a26fc3c4_I20221231" decimals="0" name="us-gaap:OtherAccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY181Mi9mcmFnOmEzYWJjNmJkN2M1ZTQ4MjViNjFiMWRkMDUxY2RkNzAxL3RhYmxlOmZjNzg2Mzc5YTI2MDQ1ODU5OTUzZWM0MTkzZmE4NzQwL3RhYmxlcmFuZ2U6ZmM3ODYzNzlhMjYwNDU4NTk5NTNlYzQxOTNmYTg3NDBfNC0zLTEtMS02OTk0OQ_c5749ccb-85b4-487d-8783-86b5f0d15c72">83,456</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;text-indent:-12pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="i9e6ffce2c2d247f491e046febe8251cd_I20230331" decimals="0" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY181Mi9mcmFnOmEzYWJjNmJkN2M1ZTQ4MjViNjFiMWRkMDUxY2RkNzAxL3RhYmxlOmZjNzg2Mzc5YTI2MDQ1ODU5OTUzZWM0MTkzZmE4NzQwL3RhYmxlcmFuZ2U6ZmM3ODYzNzlhMjYwNDU4NTk5NTNlYzQxOTNmYTg3NDBfNS0xLTEtMS02OTk0OQ_1accdba5-ccc7-4a2a-9488-022906feba02">1,991,442</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="i4b1713eab7d84494b3b43202a26fc3c4_I20221231" decimals="0" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY181Mi9mcmFnOmEzYWJjNmJkN2M1ZTQ4MjViNjFiMWRkMDUxY2RkNzAxL3RhYmxlOmZjNzg2Mzc5YTI2MDQ1ODU5OTUzZWM0MTkzZmE4NzQwL3RhYmxlcmFuZ2U6ZmM3ODYzNzlhMjYwNDU4NTk5NTNlYzQxOTNmYTg3NDBfNS0zLTEtMS02OTk0OQ_3d762f74-5881-43a0-ac4d-000ae057723b">2,216,169</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div><span><br/></span></div><div id="ibd14e01a97b1463b915192a9eff93f0c_58"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">(6) <ix:nonNumeric contextRef="ie35b115501ca468f8cadb8213304a30b_D20230101-20230331" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY181OC9mcmFnOmRhYTM0ODIxMjc2MjQ2YjBiY2ZiODBlY2E3YTQzYWUzL3RleHRyZWdpb246ZGFhMzQ4MjEyNzYyNDZiMGJjZmI4MGVjYTdhNDNhZTNfMjY1Mg_b7a1f568-fb8e-4048-818d-efec6a60d520" continuedAt="i337fe3130c2643afa8a3b5ca4fd30c5e" escape="true">Stockholders' Equity</ix:nonNumeric></span></div><ix:continuation id="i337fe3130c2643afa8a3b5ca4fd30c5e" continuedAt="icf187563977541b3b41d1f281f33506b"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Warrants for Common Stock </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In connection with the Company's initial public offering (&#8220;IPO&#8221;) and private placement in 2021, the Company issued warrants to purchase shares of common stock.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In March 2022, the Company issued <ix:nonFraction unitRef="shares" contextRef="i123230c41d4a4b6cb51151a89a8800c3_I20220331" decimals="0" name="us-gaap:ClassOfWarrantOrRightOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY181OC9mcmFnOmRhYTM0ODIxMjc2MjQ2YjBiY2ZiODBlY2E3YTQzYWUzL3RleHRyZWdpb246ZGFhMzQ4MjEyNzYyNDZiMGJjZmI4MGVjYTdhNDNhZTNfMTY0OTI2NzQ1MDI5OQ_b7c84d8f-a023-4836-8f46-f220cd5fc72b">360,000</ix:nonFraction> warrants to purchase common stock with an exercise price of $<ix:nonFraction unitRef="usdPerShare" contextRef="i123230c41d4a4b6cb51151a89a8800c3_I20220331" decimals="2" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY181OC9mcmFnOmRhYTM0ODIxMjc2MjQ2YjBiY2ZiODBlY2E3YTQzYWUzL3RleHRyZWdpb246ZGFhMzQ4MjEyNzYyNDZiMGJjZmI4MGVjYTdhNDNhZTNfMTY0OTI2NzQ1MDMyMw_48e3e72e-e392-416a-aaa7-5bd56e367791">10.00</ix:nonFraction> per share and a term of <ix:nonNumeric contextRef="i123230c41d4a4b6cb51151a89a8800c3_I20220331" name="us-gaap:WarrantsAndRightsOutstandingTerm" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY181OC9mcmFnOmRhYTM0ODIxMjc2MjQ2YjBiY2ZiODBlY2E3YTQzYWUzL3RleHRyZWdpb246ZGFhMzQ4MjEyNzYyNDZiMGJjZmI4MGVjYTdhNDNhZTNfMTY0OTI2NzQ1MDMwNw_0081463c-2a10-4d59-a0b2-77674454e1c4">5.76</ix:nonNumeric> years as compensation for professional consulting services performed in 2021. The estimated fair value of the warrants of $<ix:nonFraction unitRef="usd" contextRef="i1be90ca5530f4a1d914f1a6103d21bd1_D20210101-20211231" decimals="-5" name="us-gaap:FairValueAdjustmentOfWarrants" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY181OC9mcmFnOmRhYTM0ODIxMjc2MjQ2YjBiY2ZiODBlY2E3YTQzYWUzL3RleHRyZWdpb246ZGFhMzQ4MjEyNzYyNDZiMGJjZmI4MGVjYTdhNDNhZTNfMTY0OTI2NzQ1MDMwOQ_76a5b1bd-8612-4dae-bfc1-05ca0442d286">0.3</ix:nonFraction>&#160;million was recorded in general and administrative expense during the year ended December 31, 2021 and was also reflected as a liability on the condensed consolidated balance sheets as of December 31, 2021. The liability was reclassified into additional paid-in capital in March 2022 upon the issuance of the warrants.</span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">14</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#ibd14e01a97b1463b915192a9eff93f0c_7">Table of Contents</a></span></div></div><div><span><br/></span></div><ix:continuation id="icf187563977541b3b41d1f281f33506b"><ix:nonNumeric contextRef="ie35b115501ca468f8cadb8213304a30b_D20230101-20230331" name="us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY181OC9mcmFnOmRhYTM0ODIxMjc2MjQ2YjBiY2ZiODBlY2E3YTQzYWUzL3RleHRyZWdpb246ZGFhMzQ4MjEyNzYyNDZiMGJjZmI4MGVjYTdhNDNhZTNfMjY1Mw_8d32400c-5cb6-4936-9c4f-4328f15ddc35" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">At March&#160;31, 2023, the Company had the following warrants outstanding to acquire common stock: </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#160;</span></div><div style="margin-bottom:6pt;padding-left:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.274%"><tr><td style="width:1.0%"></td><td style="width:42.787%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.849%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.426%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.103%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.426%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:24.609%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:125%">Outstanding </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:125%">Exercise&#160;price </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:125%">Expiration&#160;dates </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Issued in connection with 2021 IPO</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 5.57pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="shares" contextRef="i68c87024c26f44ab8263dbd0a7fa6a4f_I20230331" decimals="0" name="us-gaap:ClassOfWarrantOrRightOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY181OC9mcmFnOmRhYTM0ODIxMjc2MjQ2YjBiY2ZiODBlY2E3YTQzYWUzL3RhYmxlOmMzYzQ5NTc0MzE4MzRjYmI5MGIxNmI4ZTc4NGQyMTg5L3RhYmxlcmFuZ2U6YzNjNDk1NzQzMTgzNGNiYjkwYjE2YjhlNzg0ZDIxODlfMS0xLTEtMS02OTk0OQ_50184511-15fc-4840-8926-50e006e9c550">250,000</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 5.57pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="usdPerShare" contextRef="i68c87024c26f44ab8263dbd0a7fa6a4f_I20230331" decimals="2" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY181OC9mcmFnOmRhYTM0ODIxMjc2MjQ2YjBiY2ZiODBlY2E3YTQzYWUzL3RhYmxlOmMzYzQ5NTc0MzE4MzRjYmI5MGIxNmI4ZTc4NGQyMTg5L3RhYmxlcmFuZ2U6YzNjNDk1NzQzMTgzNGNiYjkwYjE2YjhlNzg0ZDIxODlfMS0zLTEtMS02OTk0OQ_bfed624d-ec25-4392-b7bc-1876a2826a5c">6.25</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">October 2026</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Issued in connection with 2021 private placement</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 5.57pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="shares" contextRef="id3ed5205e2ed4995a41973b9bf8be2de_I20230331" decimals="0" name="us-gaap:ClassOfWarrantOrRightOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY181OC9mcmFnOmRhYTM0ODIxMjc2MjQ2YjBiY2ZiODBlY2E3YTQzYWUzL3RhYmxlOmMzYzQ5NTc0MzE4MzRjYmI5MGIxNmI4ZTc4NGQyMTg5L3RhYmxlcmFuZ2U6YzNjNDk1NzQzMTgzNGNiYjkwYjE2YjhlNzg0ZDIxODlfMi0xLTEtMS02OTk0OQ_d5051517-9768-4d1c-87a3-b3e2e84839bb">5,250,000</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 5.57pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="usdPerShare" contextRef="id3ed5205e2ed4995a41973b9bf8be2de_I20230331" decimals="2" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY181OC9mcmFnOmRhYTM0ODIxMjc2MjQ2YjBiY2ZiODBlY2E3YTQzYWUzL3RhYmxlOmMzYzQ5NTc0MzE4MzRjYmI5MGIxNmI4ZTc4NGQyMTg5L3RhYmxlcmFuZ2U6YzNjNDk1NzQzMTgzNGNiYjkwYjE2YjhlNzg0ZDIxODlfMi0zLTEtMS02OTk0OQ_9246c5cf-b4a2-4a2c-8637-2292f910a4f8">6.25</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">June 2027</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Issued in 2022 for consulting services</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 5.57pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="shares" contextRef="i4ab77790f64945ee9a78ac502ec36b66_I20230331" decimals="0" name="us-gaap:ClassOfWarrantOrRightOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY181OC9mcmFnOmRhYTM0ODIxMjc2MjQ2YjBiY2ZiODBlY2E3YTQzYWUzL3RhYmxlOmMzYzQ5NTc0MzE4MzRjYmI5MGIxNmI4ZTc4NGQyMTg5L3RhYmxlcmFuZ2U6YzNjNDk1NzQzMTgzNGNiYjkwYjE2YjhlNzg0ZDIxODlfMy0xLTEtMS02OTk0OQ_0be65e25-3e49-4262-a392-a4d8877f76ad">360,000</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 5.57pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="usdPerShare" contextRef="i4ab77790f64945ee9a78ac502ec36b66_I20230331" decimals="2" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY181OC9mcmFnOmRhYTM0ODIxMjc2MjQ2YjBiY2ZiODBlY2E3YTQzYWUzL3RhYmxlOmMzYzQ5NTc0MzE4MzRjYmI5MGIxNmI4ZTc4NGQyMTg5L3RhYmxlcmFuZ2U6YzNjNDk1NzQzMTgzNGNiYjkwYjE2YjhlNzg0ZDIxODlfMy0zLTEtMS02OTk0OQ_1fbfd698-b48a-4223-a772-cdcfb66ecc5a">10.00</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">December 2027</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 5.57pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="shares" contextRef="i9e6ffce2c2d247f491e046febe8251cd_I20230331" decimals="0" name="us-gaap:ClassOfWarrantOrRightOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY181OC9mcmFnOmRhYTM0ODIxMjc2MjQ2YjBiY2ZiODBlY2E3YTQzYWUzL3RhYmxlOmMzYzQ5NTc0MzE4MzRjYmI5MGIxNmI4ZTc4NGQyMTg5L3RhYmxlcmFuZ2U6YzNjNDk1NzQzMTgzNGNiYjkwYjE2YjhlNzg0ZDIxODlfNC0xLTEtMS02OTk0OQ_0775dbff-ace0-40cd-be5a-e1efe9b60104">5,860,000</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr></table></div></ix:nonNumeric></ix:continuation><div id="ibd14e01a97b1463b915192a9eff93f0c_61"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">(7) <ix:nonNumeric contextRef="ie35b115501ca468f8cadb8213304a30b_D20230101-20230331" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY182MS9mcmFnOmY0MWY3ZGYxZWMzYTQ3N2FhOWY1NmI1ZGJjMzIyOTMzL3RleHRyZWdpb246ZjQxZjdkZjFlYzNhNDc3YWE5ZjU2YjVkYmMzMjI5MzNfMjk4MA_ac717a96-ae8c-4906-ba14-65784d291d1b" continuedAt="id59b91ed01e8451ba42a926d984f9722" escape="true">Share-based Compensation</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"><ix:continuation id="id59b91ed01e8451ba42a926d984f9722" continuedAt="i45f8a5f7f10744d2b9648f9c5d76fcf9"> </ix:continuation></span></div><ix:continuation id="i45f8a5f7f10744d2b9648f9c5d76fcf9" continuedAt="if8a6cbc808e44cf0a9b8ec0ec69fd0e1"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In April 2021, the Company adopted the 2021 Long-Term Performance Incentive Plan (&#8220;2021 Incentive Plan&#8221;). Under the 2021 Incentive Plan, the Company can grant stock options, stock appreciation rights, restricted stock, restricted stock units (&#8220;RSUs&#8221;) and stock grants. The 2021 Incentive Plan allows for the issuance of up to <ix:nonFraction unitRef="shares" contextRef="ib10d0ed1d1274880b8a73ff00fe229ab_I20210430" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY182MS9mcmFnOmY0MWY3ZGYxZWMzYTQ3N2FhOWY1NmI1ZGJjMzIyOTMzL3RleHRyZWdpb246ZjQxZjdkZjFlYzNhNDc3YWE5ZjU2YjVkYmMzMjI5MzNfMzYx_63df7442-2c45-4565-b5a2-eab19add99a8">1,266,092</ix:nonFraction> shares of common stock (the &#8220;Share Limit&#8221;).  The Share Limit automatically increases on January 1st of each year, during the term of the 2021 Incentive Plan, commencing on January 1 of the year following the year in which the effective date occurs, in an amount equal to four percent (<ix:nonFraction unitRef="number" contextRef="i37c7d2f5e060456d835ba44ccd4b0c9b_D20210401-20210430" decimals="2" name="cntx:ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedAsAPercentageOfOutstandingStock" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY182MS9mcmFnOmY0MWY3ZGYxZWMzYTQ3N2FhOWY1NmI1ZGJjMzIyOTMzL3RleHRyZWdpb246ZjQxZjdkZjFlYzNhNDc3YWE5ZjU2YjVkYmMzMjI5MzNfNjUz_2f3faabf-71bd-4edc-9b0a-15c6d38ab7ef">4</ix:nonFraction>%) of the total number of shares of the Company&#8217;s common stock outstanding on December 31st of the preceding calendar year; provided that the Board may determine that there will be no such increase or a smaller increase for any particular year. As of March&#160;31, 2023, <ix:nonFraction unitRef="shares" contextRef="i4ac2f469b04f49ea9a783619785adc82_I20230331" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY182MS9mcmFnOmY0MWY3ZGYxZWMzYTQ3N2FhOWY1NmI1ZGJjMzIyOTMzL3RleHRyZWdpb246ZjQxZjdkZjFlYzNhNDc3YWE5ZjU2YjVkYmMzMjI5MzNfOTA5_dfaeb34f-687b-4512-93cc-89c66f461e86">361,035</ix:nonFraction> shares remained available for future grants. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:115%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Share-based awards generally vest over a period of <ix:nonNumeric contextRef="ibac63907709f43e8bb17c649e92f3e4d_D20210401-20210430" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY182MS9mcmFnOmY0MWY3ZGYxZWMzYTQ3N2FhOWY1NmI1ZGJjMzIyOTMzL3RleHRyZWdpb246ZjQxZjdkZjFlYzNhNDc3YWE5ZjU2YjVkYmMzMjI5MzNfMTAxMQ_383e6cd1-d847-417d-8ad5-e2d54df4277a">one year</ix:nonNumeric> to <ix:nonNumeric contextRef="i902a704c36e04459a8ef415c67f74f48_D20210401-20210430" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY182MS9mcmFnOmY0MWY3ZGYxZWMzYTQ3N2FhOWY1NmI1ZGJjMzIyOTMzL3RleHRyZWdpb246ZjQxZjdkZjFlYzNhNDc3YWE5ZjU2YjVkYmMzMjI5MzNfMTAxNw_268f54dd-73f5-4732-8350-60ace136fadf">four years</ix:nonNumeric>, and share-based awards that lapse or are forfeited are available to be granted again. The contractual life of all share-based awards is <ix:nonNumeric contextRef="i37c7d2f5e060456d835ba44ccd4b0c9b_D20210401-20210430" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY182MS9mcmFnOmY0MWY3ZGYxZWMzYTQ3N2FhOWY1NmI1ZGJjMzIyOTMzL3RleHRyZWdpb246ZjQxZjdkZjFlYzNhNDc3YWE5ZjU2YjVkYmMzMjI5MzNfMTE1Nw_741a0fea-72c4-4867-a298-e309d15622a0">ten years</ix:nonNumeric>. The expiration dates of the outstanding share-based awards range from January 2028 to February 2033. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company measures share-based awards at their grant-date fair value and records compensation expense on a straight-line basis over the service period of the awards. Share-based compensation is allocated to employees and consultants based on their respective departments. All board of directors&#8217; compensation is charged to general and administrative expense. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonNumeric contextRef="ie35b115501ca468f8cadb8213304a30b_D20230101-20230331" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY182MS9mcmFnOmY0MWY3ZGYxZWMzYTQ3N2FhOWY1NmI1ZGJjMzIyOTMzL3RleHRyZWdpb246ZjQxZjdkZjFlYzNhNDc3YWE5ZjU2YjVkYmMzMjI5MzNfMjk3Nw_f5c3cab1-263a-40f3-bedb-e82068235a9a" continuedAt="i8c85acfad8c94b8da83282c2caf3f169" escape="true">Share-based compensation expense related to the issuance of stock options was as follows for the three months ended March&#160;31, 2023 and 2022: </ix:nonNumeric></span></div><div><span><br/></span></div><div><ix:continuation id="i8c85acfad8c94b8da83282c2caf3f169"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:61.842%"><tr><td style="width:1.0%"></td><td style="width:49.018%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.540%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.745%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:24.197%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">Three months ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Research and development</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="i70f641b88b5a48aeb3fe1ce75baa1362_D20230101-20230331" decimals="0" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY182MS9mcmFnOmY0MWY3ZGYxZWMzYTQ3N2FhOWY1NmI1ZGJjMzIyOTMzL3RhYmxlOjZmNzZmYjQ2YzM4ZjQ2ZDc5YTI5OThhMGY5NDgyOTc5L3RhYmxlcmFuZ2U6NmY3NmZiNDZjMzhmNDZkNzlhMjk5OGEwZjk0ODI5NzlfMy0xLTEtMS02OTk0OQ_3dcd75bb-0022-4b51-85e2-91809f34f62b">21,087</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="i4799146a2fb14bd8b37fc240a795004c_D20220101-20220331" decimals="0" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY182MS9mcmFnOmY0MWY3ZGYxZWMzYTQ3N2FhOWY1NmI1ZGJjMzIyOTMzL3RhYmxlOjZmNzZmYjQ2YzM4ZjQ2ZDc5YTI5OThhMGY5NDgyOTc5L3RhYmxlcmFuZ2U6NmY3NmZiNDZjMzhmNDZkNzlhMjk5OGEwZjk0ODI5NzlfMy0zLTEtMS02OTk0OQ_a5662161-1ad9-435a-8e7f-748d765ef208">32,960</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">General and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="iaf92495d8d6b4b9a9ec33d201a161246_D20230101-20230331" decimals="0" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY182MS9mcmFnOmY0MWY3ZGYxZWMzYTQ3N2FhOWY1NmI1ZGJjMzIyOTMzL3RhYmxlOjZmNzZmYjQ2YzM4ZjQ2ZDc5YTI5OThhMGY5NDgyOTc5L3RhYmxlcmFuZ2U6NmY3NmZiNDZjMzhmNDZkNzlhMjk5OGEwZjk0ODI5NzlfNC0xLTEtMS02OTk0OQ_6c797015-d750-4559-9b6b-07747297d7af">261,675</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="i7503ba5b2ff64139bbe478fa4ceedf80_D20220101-20220331" decimals="0" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY182MS9mcmFnOmY0MWY3ZGYxZWMzYTQ3N2FhOWY1NmI1ZGJjMzIyOTMzL3RhYmxlOjZmNzZmYjQ2YzM4ZjQ2ZDc5YTI5OThhMGY5NDgyOTc5L3RhYmxlcmFuZ2U6NmY3NmZiNDZjMzhmNDZkNzlhMjk5OGEwZjk0ODI5NzlfNC0zLTEtMS02OTk0OQ_b75cd246-00c8-40c0-b049-bac4bd6d8280">181,998</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="ie35b115501ca468f8cadb8213304a30b_D20230101-20230331" decimals="0" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY182MS9mcmFnOmY0MWY3ZGYxZWMzYTQ3N2FhOWY1NmI1ZGJjMzIyOTMzL3RhYmxlOjZmNzZmYjQ2YzM4ZjQ2ZDc5YTI5OThhMGY5NDgyOTc5L3RhYmxlcmFuZ2U6NmY3NmZiNDZjMzhmNDZkNzlhMjk5OGEwZjk0ODI5NzlfNS0xLTEtMS02OTk0OQ_795f6362-7ca5-4638-9183-9f8702192ed7">282,762</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="usd" contextRef="i3baf3250062d4a79a9b120fc56f1b18c_D20220101-20220331" decimals="0" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY182MS9mcmFnOmY0MWY3ZGYxZWMzYTQ3N2FhOWY1NmI1ZGJjMzIyOTMzL3RhYmxlOjZmNzZmYjQ2YzM4ZjQ2ZDc5YTI5OThhMGY5NDgyOTc5L3RhYmxlcmFuZ2U6NmY3NmZiNDZjMzhmNDZkNzlhMjk5OGEwZjk0ODI5NzlfNS0zLTEtMS02OTk0OQ_a09226f2-6b6f-4ba5-be6a-feb817b1b446">214,958</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></ix:continuation><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> </span></div><ix:nonNumeric contextRef="ie35b115501ca468f8cadb8213304a30b_D20230101-20230331" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY182MS9mcmFnOmY0MWY3ZGYxZWMzYTQ3N2FhOWY1NmI1ZGJjMzIyOTMzL3RleHRyZWdpb246ZjQxZjdkZjFlYzNhNDc3YWE5ZjU2YjVkYmMzMjI5MzNfMjk4MQ_50134cef-5ff5-47aa-b9d5-34a63bd734ed" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The weighted average assumptions used in the Black-Scholes option pricing model to determine the fair value of share-based awards granted to employees during the three months ended March&#160;31, 2023 and 2022 were as follows: </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#160;</span></div><div style="margin-bottom:6pt;padding-left:51.3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:81.286%"><tr><td style="width:1.0%"></td><td style="width:66.525%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.519%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.367%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.519%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.370%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.57pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:125%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:125%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Expected stock price volatility</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="number" contextRef="i56df8626827b4508b71d14c260351355_D20230101-20230331" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY182MS9mcmFnOmY0MWY3ZGYxZWMzYTQ3N2FhOWY1NmI1ZGJjMzIyOTMzL3RhYmxlOmU3NDIyMTI5NjZmMDQyZWE5ODA2ZTA2YzJkZWEyY2Y0L3RhYmxlcmFuZ2U6ZTc0MjIxMjk2NmYwNDJlYTk4MDZlMDZjMmRlYTJjZjRfMS0yLTEtMS02OTk0OQ_64f166ee-935b-412f-a356-1c72ccfa118c">91.85</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="number" contextRef="ia22a5f1f807740beb36572d3ab1f91c8_D20220101-20220331" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY182MS9mcmFnOmY0MWY3ZGYxZWMzYTQ3N2FhOWY1NmI1ZGJjMzIyOTMzL3RhYmxlOmU3NDIyMTI5NjZmMDQyZWE5ODA2ZTA2YzJkZWEyY2Y0L3RhYmxlcmFuZ2U6ZTc0MjIxMjk2NmYwNDJlYTk4MDZlMDZjMmRlYTJjZjRfMS00LTEtMS02OTk0OQ_590027da-e916-4771-ba4a-abea22a4052d">86.86</ix:nonFraction>%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="number" contextRef="i56df8626827b4508b71d14c260351355_D20230101-20230331" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY182MS9mcmFnOmY0MWY3ZGYxZWMzYTQ3N2FhOWY1NmI1ZGJjMzIyOTMzL3RhYmxlOmU3NDIyMTI5NjZmMDQyZWE5ODA2ZTA2YzJkZWEyY2Y0L3RhYmxlcmFuZ2U6ZTc0MjIxMjk2NmYwNDJlYTk4MDZlMDZjMmRlYTJjZjRfMi0yLTEtMS02OTk0OQ_2dbafd88-18f7-499d-a7da-9b972d202a3e">3.88</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="number" contextRef="ia22a5f1f807740beb36572d3ab1f91c8_D20220101-20220331" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY182MS9mcmFnOmY0MWY3ZGYxZWMzYTQ3N2FhOWY1NmI1ZGJjMzIyOTMzL3RhYmxlOmU3NDIyMTI5NjZmMDQyZWE5ODA2ZTA2YzJkZWEyY2Y0L3RhYmxlcmFuZ2U6ZTc0MjIxMjk2NmYwNDJlYTk4MDZlMDZjMmRlYTJjZjRfMi00LTEtMS02OTk0OQ_30ae6e17-c4e9-4993-91b0-2680c4eca68f">1.91</ix:nonFraction>%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Expected term (in years)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"><ix:nonNumeric contextRef="i56df8626827b4508b71d14c260351355_D20230101-20230331" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY182MS9mcmFnOmY0MWY3ZGYxZWMzYTQ3N2FhOWY1NmI1ZGJjMzIyOTMzL3RhYmxlOmU3NDIyMTI5NjZmMDQyZWE5ODA2ZTA2YzJkZWEyY2Y0L3RhYmxlcmFuZ2U6ZTc0MjIxMjk2NmYwNDJlYTk4MDZlMDZjMmRlYTJjZjRfMy0yLTEtMS02OTk0OQ_98c038ca-bb79-443a-891b-a5ff03adb790">6.08</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"><ix:nonNumeric contextRef="ia22a5f1f807740beb36572d3ab1f91c8_D20220101-20220331" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY182MS9mcmFnOmY0MWY3ZGYxZWMzYTQ3N2FhOWY1NmI1ZGJjMzIyOTMzL3RhYmxlOmU3NDIyMTI5NjZmMDQyZWE5ODA2ZTA2YzJkZWEyY2Y0L3RhYmxlcmFuZ2U6ZTc0MjIxMjk2NmYwNDJlYTk4MDZlMDZjMmRlYTJjZjRfMy00LTEtMS02OTk0OQ_d87c2f33-29c7-4214-9d92-581a22647d7e">6.03</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Expected dividend yield</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="number" contextRef="i56df8626827b4508b71d14c260351355_D20230101-20230331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" format="ixt:fixed-zero" id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY182MS9mcmFnOmY0MWY3ZGYxZWMzYTQ3N2FhOWY1NmI1ZGJjMzIyOTMzL3RhYmxlOmU3NDIyMTI5NjZmMDQyZWE5ODA2ZTA2YzJkZWEyY2Y0L3RhYmxlcmFuZ2U6ZTc0MjIxMjk2NmYwNDJlYTk4MDZlMDZjMmRlYTJjZjRfNC0yLTEtMS02OTk0OQ_13cccaa5-fcc3-4962-9777-f06702cc2896">&#8212;</ix:nonFraction>&#160;&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="number" contextRef="ia22a5f1f807740beb36572d3ab1f91c8_D20220101-20220331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" format="ixt:fixed-zero" id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY182MS9mcmFnOmY0MWY3ZGYxZWMzYTQ3N2FhOWY1NmI1ZGJjMzIyOTMzL3RhYmxlOmU3NDIyMTI5NjZmMDQyZWE5ODA2ZTA2YzJkZWEyY2Y0L3RhYmxlcmFuZ2U6ZTc0MjIxMjk2NmYwNDJlYTk4MDZlMDZjMmRlYTJjZjRfNC00LTEtMS02OTk0OQ_57de793f-027b-4b22-a145-cc3724227bfa">&#8212;</ix:nonFraction></span></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">15</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#ibd14e01a97b1463b915192a9eff93f0c_7">Table of Contents</a></span></div></div><ix:continuation id="if8a6cbc808e44cf0a9b8ec0ec69fd0e1" continuedAt="i5251328037cd42a581e9576bca25eac0"><ix:nonNumeric contextRef="ie35b115501ca468f8cadb8213304a30b_D20230101-20230331" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY182MS9mcmFnOmY0MWY3ZGYxZWMzYTQ3N2FhOWY1NmI1ZGJjMzIyOTMzL3RleHRyZWdpb246ZjQxZjdkZjFlYzNhNDc3YWE5ZjU2YjVkYmMzMjI5MzNfMjk3OA_3e8e07c9-d4a2-4a0c-80bb-e0b598bc031b" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The following table summarizes the share-based award activity for the periods presented: </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#160;</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:53.870%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.524%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.57pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.08pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:125%">Number&#160;of&#160;Shares</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:125%">Weighted&#160;Average<br/>Exercise&#160;Price&#160;Per<br/>Share </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:125%">Weighted&#160;Average<br/>Remaining<br/>Contractual&#160;Term<br/>(years) </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Outstanding at January 1, 2023</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 5.57pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="shares" contextRef="i4b1713eab7d84494b3b43202a26fc3c4_I20221231" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY182MS9mcmFnOmY0MWY3ZGYxZWMzYTQ3N2FhOWY1NmI1ZGJjMzIyOTMzL3RhYmxlOjIxNDU5MjBhMDZlYzRkOGZiYzRhMjg5YmM1MTYwNThmL3RhYmxlcmFuZ2U6MjE0NTkyMGEwNmVjNGQ4ZmJjNGEyODliYzUxNjA1OGZfMS0xLTEtMS02OTk0OQ_00944b93-d5cc-4d95-99e6-f0b6e064b906">1,341,504</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="usdPerShare" contextRef="i4b1713eab7d84494b3b43202a26fc3c4_I20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY182MS9mcmFnOmY0MWY3ZGYxZWMzYTQ3N2FhOWY1NmI1ZGJjMzIyOTMzL3RhYmxlOjIxNDU5MjBhMDZlYzRkOGZiYzRhMjg5YmM1MTYwNThmL3RhYmxlcmFuZ2U6MjE0NTkyMGEwNmVjNGQ4ZmJjNGEyODliYzUxNjA1OGZfMS0zLTEtMS02OTk0OQ_a90736ae-25aa-4ad8-9f37-6343ab99a9f7">3.27</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 5.57pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"><ix:nonNumeric contextRef="i626f38146e594fbca5a1d17b96610d86_D20220101-20221231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY182MS9mcmFnOmY0MWY3ZGYxZWMzYTQ3N2FhOWY1NmI1ZGJjMzIyOTMzL3RhYmxlOjIxNDU5MjBhMDZlYzRkOGZiYzRhMjg5YmM1MTYwNThmL3RhYmxlcmFuZ2U6MjE0NTkyMGEwNmVjNGQ4ZmJjNGEyODliYzUxNjA1OGZfMS01LTEtMS02OTk0OQ_3880556f-eec1-4d6d-8973-e64dcb16dafb">8.9</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 5.57pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="shares" contextRef="ie35b115501ca468f8cadb8213304a30b_D20230101-20230331" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY182MS9mcmFnOmY0MWY3ZGYxZWMzYTQ3N2FhOWY1NmI1ZGJjMzIyOTMzL3RhYmxlOjIxNDU5MjBhMDZlYzRkOGZiYzRhMjg5YmM1MTYwNThmL3RhYmxlcmFuZ2U6MjE0NTkyMGEwNmVjNGQ4ZmJjNGEyODliYzUxNjA1OGZfMi0xLTEtMS02OTk0OQ_959c99f3-37e7-41c0-bdbe-2b8741b81ae6">824,142</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="usdPerShare" contextRef="ie35b115501ca468f8cadb8213304a30b_D20230101-20230331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY182MS9mcmFnOmY0MWY3ZGYxZWMzYTQ3N2FhOWY1NmI1ZGJjMzIyOTMzL3RhYmxlOjIxNDU5MjBhMDZlYzRkOGZiYzRhMjg5YmM1MTYwNThmL3RhYmxlcmFuZ2U6MjE0NTkyMGEwNmVjNGQ4ZmJjNGEyODliYzUxNjA1OGZfMi0zLTEtMS02OTk0OQ_3c9c47d0-21af-4b54-9072-80429f42efee">0.84</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 5.57pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.05pt;margin-top:0.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;&#160;&#160;&#160;&#160;Forfeited</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 5.57pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="shares" contextRef="ie35b115501ca468f8cadb8213304a30b_D20230101-20230331" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY182MS9mcmFnOmY0MWY3ZGYxZWMzYTQ3N2FhOWY1NmI1ZGJjMzIyOTMzL3RhYmxlOjIxNDU5MjBhMDZlYzRkOGZiYzRhMjg5YmM1MTYwNThmL3RhYmxlcmFuZ2U6MjE0NTkyMGEwNmVjNGQ4ZmJjNGEyODliYzUxNjA1OGZfMy0xLTEtMS02OTk0OQ_d771d579-d25a-4b58-b7de-c0a78951e99c">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="usdPerShare" contextRef="ie35b115501ca468f8cadb8213304a30b_D20230101-20230331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY182MS9mcmFnOmY0MWY3ZGYxZWMzYTQ3N2FhOWY1NmI1ZGJjMzIyOTMzL3RhYmxlOjIxNDU5MjBhMDZlYzRkOGZiYzRhMjg5YmM1MTYwNThmL3RhYmxlcmFuZ2U6MjE0NTkyMGEwNmVjNGQ4ZmJjNGEyODliYzUxNjA1OGZfMy0zLTEtMS02OTk0OQ_b3c99700-2ea9-4fc3-85b8-46ecc65c7441">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.08pt;padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Outstanding at March&#160;31, 2023</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 5.57pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="shares" contextRef="i9e6ffce2c2d247f491e046febe8251cd_I20230331" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY182MS9mcmFnOmY0MWY3ZGYxZWMzYTQ3N2FhOWY1NmI1ZGJjMzIyOTMzL3RhYmxlOjIxNDU5MjBhMDZlYzRkOGZiYzRhMjg5YmM1MTYwNThmL3RhYmxlcmFuZ2U6MjE0NTkyMGEwNmVjNGQ4ZmJjNGEyODliYzUxNjA1OGZfNC0xLTEtMS02OTk0OQ_04eb7f87-35a1-4c87-a2f8-5a47b6281b02">2,165,646</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="usdPerShare" contextRef="i9e6ffce2c2d247f491e046febe8251cd_I20230331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY182MS9mcmFnOmY0MWY3ZGYxZWMzYTQ3N2FhOWY1NmI1ZGJjMzIyOTMzL3RhYmxlOjIxNDU5MjBhMDZlYzRkOGZiYzRhMjg5YmM1MTYwNThmL3RhYmxlcmFuZ2U6MjE0NTkyMGEwNmVjNGQ4ZmJjNGEyODliYzUxNjA1OGZfNC0zLTEtMS02OTk0OQ_5ef0f588-0466-4a64-a05b-cb7613bb843b">2.35</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 5.57pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"><ix:nonNumeric contextRef="ie35b115501ca468f8cadb8213304a30b_D20230101-20230331" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY182MS9mcmFnOmY0MWY3ZGYxZWMzYTQ3N2FhOWY1NmI1ZGJjMzIyOTMzL3RhYmxlOjIxNDU5MjBhMDZlYzRkOGZiYzRhMjg5YmM1MTYwNThmL3RhYmxlcmFuZ2U6MjE0NTkyMGEwNmVjNGQ4ZmJjNGEyODliYzUxNjA1OGZfNC01LTEtMS02OTk0OQ_a5780a09-b803-4cb1-b029-f98709a2e7e5">9.1</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.08pt;padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Vested and exercisable at March&#160;31, 2023</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 5.57pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="shares" contextRef="i9e6ffce2c2d247f491e046febe8251cd_I20230331" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY182MS9mcmFnOmY0MWY3ZGYxZWMzYTQ3N2FhOWY1NmI1ZGJjMzIyOTMzL3RhYmxlOjIxNDU5MjBhMDZlYzRkOGZiYzRhMjg5YmM1MTYwNThmL3RhYmxlcmFuZ2U6MjE0NTkyMGEwNmVjNGQ4ZmJjNGEyODliYzUxNjA1OGZfNS0xLTEtMS02OTk0OQ_1397c8a5-bf7b-473c-a3bb-deaac7a296de">526,574</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="usdPerShare" contextRef="i9e6ffce2c2d247f491e046febe8251cd_I20230331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY182MS9mcmFnOmY0MWY3ZGYxZWMzYTQ3N2FhOWY1NmI1ZGJjMzIyOTMzL3RhYmxlOjIxNDU5MjBhMDZlYzRkOGZiYzRhMjg5YmM1MTYwNThmL3RhYmxlcmFuZ2U6MjE0NTkyMGEwNmVjNGQ4ZmJjNGEyODliYzUxNjA1OGZfNS0zLTEtMS02OTk0OQ_42e465c3-1f4c-49c7-b784-956da6643151">4.43</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 5.57pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"><ix:nonNumeric contextRef="ie35b115501ca468f8cadb8213304a30b_D20230101-20230331" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY182MS9mcmFnOmY0MWY3ZGYxZWMzYTQ3N2FhOWY1NmI1ZGJjMzIyOTMzL3RhYmxlOjIxNDU5MjBhMDZlYzRkOGZiYzRhMjg5YmM1MTYwNThmL3RhYmxlcmFuZ2U6MjE0NTkyMGEwNmVjNGQ4ZmJjNGEyODliYzUxNjA1OGZfNS01LTEtMS02OTk0OQ_e07aa49a-69ae-4713-9f52-f564b84e0511">8.3</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.08pt;padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Vested and expected to vest at March&#160;31, 2023</span></div></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 5.57pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="shares" contextRef="i9e6ffce2c2d247f491e046febe8251cd_I20230331" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY182MS9mcmFnOmY0MWY3ZGYxZWMzYTQ3N2FhOWY1NmI1ZGJjMzIyOTMzL3RhYmxlOjIxNDU5MjBhMDZlYzRkOGZiYzRhMjg5YmM1MTYwNThmL3RhYmxlcmFuZ2U6MjE0NTkyMGEwNmVjNGQ4ZmJjNGEyODliYzUxNjA1OGZfNi0xLTEtMS02OTk0OQ_13369237-d6e3-40e9-b802-2f4c0a00cef0">2,165,646</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"><ix:nonFraction unitRef="usdPerShare" contextRef="i9e6ffce2c2d247f491e046febe8251cd_I20230331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY182MS9mcmFnOmY0MWY3ZGYxZWMzYTQ3N2FhOWY1NmI1ZGJjMzIyOTMzL3RhYmxlOjIxNDU5MjBhMDZlYzRkOGZiYzRhMjg5YmM1MTYwNThmL3RhYmxlcmFuZ2U6MjE0NTkyMGEwNmVjNGQ4ZmJjNGEyODliYzUxNjA1OGZfNi0zLTEtMS02OTk0OQ_0c40f77b-5752-49e5-94a6-c71cc05c73d4">2.35</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 5.57pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"><ix:nonNumeric contextRef="ie35b115501ca468f8cadb8213304a30b_D20230101-20230331" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY182MS9mcmFnOmY0MWY3ZGYxZWMzYTQ3N2FhOWY1NmI1ZGJjMzIyOTMzL3RhYmxlOjIxNDU5MjBhMDZlYzRkOGZiYzRhMjg5YmM1MTYwNThmL3RhYmxlcmFuZ2U6MjE0NTkyMGEwNmVjNGQ4ZmJjNGEyODliYzUxNjA1OGZfNi01LTEtMS02OTk0OQ_c46c573d-7171-4f92-9266-2f39bfabe1be">9.1</ix:nonNumeric></span></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:continuation id="i5251328037cd42a581e9576bca25eac0">The weighted average fair value of share-based awards granted during the three months ended March&#160;31, 2023 and 2022 was $<ix:nonFraction unitRef="usdPerShare" contextRef="ie35b115501ca468f8cadb8213304a30b_D20230101-20230331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY182MS9mcmFnOmY0MWY3ZGYxZWMzYTQ3N2FhOWY1NmI1ZGJjMzIyOTMzL3RleHRyZWdpb246ZjQxZjdkZjFlYzNhNDc3YWE5ZjU2YjVkYmMzMjI5MzNfMjIwMw_a61973b9-0296-41ed-8aac-db0b2d4af307">0.65</ix:nonFraction> and $<ix:nonFraction unitRef="usdPerShare" contextRef="i3baf3250062d4a79a9b120fc56f1b18c_D20220101-20220331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY182MS9mcmFnOmY0MWY3ZGYxZWMzYTQ3N2FhOWY1NmI1ZGJjMzIyOTMzL3RleHRyZWdpb246ZjQxZjdkZjFlYzNhNDc3YWE5ZjU2YjVkYmMzMjI5MzNfMjIxMA_b3415585-b1e3-4568-8597-f501598f4410">1.33</ix:nonFraction>, respectively. As of March&#160;31, 2023, the unrecognized compensation cost related to outstanding share-based awards was $<ix:nonFraction unitRef="usd" contextRef="i9e6ffce2c2d247f491e046febe8251cd_I20230331" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY182MS9mcmFnOmY0MWY3ZGYxZWMzYTQ3N2FhOWY1NmI1ZGJjMzIyOTMzL3RleHRyZWdpb246ZjQxZjdkZjFlYzNhNDc3YWE5ZjU2YjVkYmMzMjI5MzNfMjMxOQ_72a1e4ed-a15a-4b30-bf1e-14f9e79bc194">1.9</ix:nonFraction>&#160;million and is expected to be recognized as expense over a weighted-average period of approximately <ix:nonNumeric contextRef="i247dcebb8f8f491b838555cf4a897045_D20230101-20230331" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY182MS9mcmFnOmY0MWY3ZGYxZWMzYTQ3N2FhOWY1NmI1ZGJjMzIyOTMzL3RleHRyZWdpb246ZjQxZjdkZjFlYzNhNDc3YWE5ZjU2YjVkYmMzMjI5MzNfMjQxNA_429e3698-6c94-4c1c-bf46-eb75202b6295">2.49</ix:nonNumeric> years.</ix:continuation> </span></div><div id="ibd14e01a97b1463b915192a9eff93f0c_64"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">(8) <ix:nonNumeric contextRef="ie35b115501ca468f8cadb8213304a30b_D20230101-20230331" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY182NC9mcmFnOjIwYTRiZDM4N2RmYjRiOGJhZTc0ZWY1MjNmZGYyY2M0L3RleHRyZWdpb246MjBhNGJkMzg3ZGZiNGI4YmFlNzRlZjUyM2ZkZjJjYzRfNjA1Mw_6e338bed-2e11-46f7-a579-390fbe87620b" continuedAt="i9ab107a44e094d87bacea43acefa128b" escape="true">Commitments and Contingencies </ix:nonNumeric></span></div><ix:continuation id="i9ab107a44e094d87bacea43acefa128b" continuedAt="i41e40612f61445d2a548ddf48a1391ff"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Operating Lease</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In January 2022, the Company entered into a noncancellable operating sublease for corporate office space in Philadelphia, Pennsylvania. The sublease for this space commenced on February 1, 2022 and is set to expire on July 31, 2023. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As of March&#160;31, 2023, the operating lease right-of-use asset and the operating lease liabilities were $<ix:nonFraction unitRef="usd" contextRef="i9e6ffce2c2d247f491e046febe8251cd_I20230331" decimals="0" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY182NC9mcmFnOjIwYTRiZDM4N2RmYjRiOGJhZTc0ZWY1MjNmZGYyY2M0L3RleHRyZWdpb246MjBhNGJkMzg3ZGZiNGI4YmFlNzRlZjUyM2ZkZjJjYzRfMzgy_7dcd5cd6-58a9-4c63-9339-b580497b9466">29,892</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i9e6ffce2c2d247f491e046febe8251cd_I20230331" decimals="0" name="us-gaap:OperatingLeaseLiability" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY182NC9mcmFnOjIwYTRiZDM4N2RmYjRiOGJhZTc0ZWY1MjNmZGYyY2M0L3RleHRyZWdpb246MjBhNGJkMzg3ZGZiNGI4YmFlNzRlZjUyM2ZkZjJjYzRfMzg5_89a4b63a-a436-4d69-b29d-cac2ba242637">31,669</ix:nonFraction>, respectively. The discount rate used to account for the Company&#8217;s operating leases was the Company&#8217;s estimated incremental borrowing rate of <ix:nonFraction unitRef="number" contextRef="i9e6ffce2c2d247f491e046febe8251cd_I20230331" decimals="2" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY182NC9mcmFnOjIwYTRiZDM4N2RmYjRiOGJhZTc0ZWY1MjNmZGYyY2M0L3RleHRyZWdpb246MjBhNGJkMzg3ZGZiNGI4YmFlNzRlZjUyM2ZkZjJjYzRfNTY2_8024d9bd-30ae-4e95-8b0f-4bbd1adc3e0e">5.0</ix:nonFraction>%. The remaining term of the Company&#8217;s noncancellable operating lease is <ix:nonNumeric contextRef="i9e6ffce2c2d247f491e046febe8251cd_I20230331" name="us-gaap:LesseeOperatingLeaseRemainingLeaseTerm" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY182NC9mcmFnOjIwYTRiZDM4N2RmYjRiOGJhZTc0ZWY1MjNmZGYyY2M0L3RleHRyZWdpb246MjBhNGJkMzg3ZGZiNGI4YmFlNzRlZjUyM2ZkZjJjYzRfNjQw_b1a8b410-9d43-4dd6-a119-ea5450053314">0.33</ix:nonNumeric> years. Future minimum lease payments under the sublease are $<ix:nonFraction unitRef="usd" contextRef="i9e6ffce2c2d247f491e046febe8251cd_I20230331" decimals="0" name="us-gaap:LessorOperatingLeasePaymentsToBeReceived" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY182NC9mcmFnOjIwYTRiZDM4N2RmYjRiOGJhZTc0ZWY1MjNmZGYyY2M0L3RleHRyZWdpb246MjBhNGJkMzg3ZGZiNGI4YmFlNzRlZjUyM2ZkZjJjYzRfMzg0ODI5MDcwMzQ2Mg_c779abe8-8845-4236-bbcb-ebf39ea88390">32,000</ix:nonFraction> at March&#160;31, 2023.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Rent expense related to the Company&#8217;s operating lease was approximately $<ix:nonFraction unitRef="usd" contextRef="ie35b115501ca468f8cadb8213304a30b_D20230101-20230331" decimals="0" name="us-gaap:OperatingLeaseCost" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY182NC9mcmFnOjIwYTRiZDM4N2RmYjRiOGJhZTc0ZWY1MjNmZGYyY2M0L3RleHRyZWdpb246MjBhNGJkMzg3ZGZiNGI4YmFlNzRlZjUyM2ZkZjJjYzRfNzE3_8596d5cd-9082-4766-bb46-7c7a76deaba9">23,000</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i3baf3250062d4a79a9b120fc56f1b18c_D20220101-20220331" decimals="0" name="us-gaap:OperatingLeaseCost" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY182NC9mcmFnOjIwYTRiZDM4N2RmYjRiOGJhZTc0ZWY1MjNmZGYyY2M0L3RleHRyZWdpb246MjBhNGJkMzg3ZGZiNGI4YmFlNzRlZjUyM2ZkZjJjYzRfNzI0_d979ffa6-5df7-4c17-b400-fd17c35a9ceb">15,000</ix:nonFraction> for the three months ended March&#160;31, 2023 and 2022, respectively. The Company recognizes rent expense on a straight-line basis over the lease period and accrues for rent expense incurred but not yet paid.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In March 2023, the Company entered into a direct lease for this same office space that commences on August 1, 2023 and is set to expire on August 31, 2024, pursuant to which the Company retains the right to renew the lease for an additional <ix:nonNumeric contextRef="i9e6ffce2c2d247f491e046febe8251cd_I20230331" name="us-gaap:LesseeOperatingLeaseRenewalTerm" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY182NC9mcmFnOjIwYTRiZDM4N2RmYjRiOGJhZTc0ZWY1MjNmZGYyY2M0L3RleHRyZWdpb246MjBhNGJkMzg3ZGZiNGI4YmFlNzRlZjUyM2ZkZjJjYzRfMTY0OTI2NzQ1MTcxNA_b75b2521-75c9-45e4-aca7-2f728257b3d9">one-year</ix:nonNumeric> term.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Employee Benefit Plans</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In the first quarter of 2022, the Company established a defined contribution 401(k) plan in which employees may contribute up to <ix:nonFraction unitRef="number" contextRef="ie35b115501ca468f8cadb8213304a30b_D20230101-20230331" decimals="0" name="us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY182NC9mcmFnOjIwYTRiZDM4N2RmYjRiOGJhZTc0ZWY1MjNmZGYyY2M0L3RleHRyZWdpb246MjBhNGJkMzg3ZGZiNGI4YmFlNzRlZjUyM2ZkZjJjYzRfMTE1NA_b833c3c7-824e-4215-8399-573f16091f7e">100</ix:nonFraction>% of their salary and bonus, subject to statutory maximum contribution amounts. The Company contributes a safe harbor minimum contribution equivalent to <ix:nonFraction unitRef="number" contextRef="ie35b115501ca468f8cadb8213304a30b_D20230101-20230331" decimals="2" name="us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY182NC9mcmFnOjIwYTRiZDM4N2RmYjRiOGJhZTc0ZWY1MjNmZGYyY2M0L3RleHRyZWdpb246MjBhNGJkMzg3ZGZiNGI4YmFlNzRlZjUyM2ZkZjJjYzRfMTMwOA_82c9a380-3a09-45cb-8f67-1630cc15ac2a">3</ix:nonFraction>% of employees&#8217; compensation. The Company generally assumes all administrative costs of the plan. For the three months ended March&#160;31, 2023 and 2022, the Company provided contributions of approximately $<ix:nonFraction unitRef="usd" contextRef="ie35b115501ca468f8cadb8213304a30b_D20230101-20230331" decimals="0" name="us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY182NC9mcmFnOjIwYTRiZDM4N2RmYjRiOGJhZTc0ZWY1MjNmZGYyY2M0L3RleHRyZWdpb246MjBhNGJkMzg3ZGZiNGI4YmFlNzRlZjUyM2ZkZjJjYzRfMTQ5OQ_bb5c0180-4c78-461c-9c1a-58530bf419a1">40,000</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i3baf3250062d4a79a9b120fc56f1b18c_D20220101-20220331" decimals="0" name="us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY182NC9mcmFnOjIwYTRiZDM4N2RmYjRiOGJhZTc0ZWY1MjNmZGYyY2M0L3RleHRyZWdpb246MjBhNGJkMzg3ZGZiNGI4YmFlNzRlZjUyM2ZkZjJjYzRfMTUwNg_50ac228b-e808-4dcd-b075-3014e43b16b6">25,000</ix:nonFraction>, respectively.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Collaboration Agreement with Tyligand Bioscience </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In March 2020, the Company entered into a process development agreement (the &#8220;Tyligand Process Development Agreement&#8221;) with Tyligand Bioscience (Shanghai) Limited (&#8220;Tyligand&#8221;) for the development, manufacturing, registration and future commercialization of ONA-XR. </span></div></ix:continuation><div><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">16</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#ibd14e01a97b1463b915192a9eff93f0c_7">Table of Contents</a></span></div></div><ix:continuation id="i41e40612f61445d2a548ddf48a1391ff"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Under the terms of the Tyligand Process Development Agreement, Tyligand was solely responsible for the design and optimization of an improved manufacturing process for ONA-XR. Upon completion of specific performance-based milestones, Tyligand and the Company entered into a license agreement (the &#8220;Tyligand License Agreement&#8221;) whereby Tyligand was granted the exclusive right to ONA-XR and is solely responsible for the development and commercialization of ONA-XR in China, Hong Kong and Macau (the &#8220;Territory&#8221;). The Company retains rights in the rest of the world to commercialize ONA-XR. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Under the Tyligand Process Development Agreement, the Company paid Tyligand certain milestone payments upon successful completion of the manufacturing development plan in 2021.  In addition, $<ix:nonFraction unitRef="usd" contextRef="ie4f3b47997974a9c92cf0116fb61189f_I20200331" decimals="-5" name="cntx:CollaborativeArrangementRightsAndObligationsMilestonePayment" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY182NC9mcmFnOjIwYTRiZDM4N2RmYjRiOGJhZTc0ZWY1MjNmZGYyY2M0L3RleHRyZWdpb246MjBhNGJkMzg3ZGZiNGI4YmFlNzRlZjUyM2ZkZjJjYzRfMjg4Mw_3555c3e6-bc20-41ee-bd65-3afcac3ac404">2.0</ix:nonFraction> million will be payable upon the completion of scale-up of the first cumulative 100 kilograms of the Good Manufacturing Practices (&#8220;GMP&#8221;)-grade compound and $<ix:nonFraction unitRef="usd" contextRef="i4798e3c1b6ca496686ec4fd693e57cd8_I20200331" decimals="-5" name="cntx:CollaborativeArrangementRightsAndObligationsMilestonePayment" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY182NC9mcmFnOjIwYTRiZDM4N2RmYjRiOGJhZTc0ZWY1MjNmZGYyY2M0L3RleHRyZWdpb246MjBhNGJkMzg3ZGZiNGI4YmFlNzRlZjUyM2ZkZjJjYzRfMzAzNQ_8b85cc74-39ad-4210-b8a2-3b5ec989f286">3.0</ix:nonFraction> million upon the Company&#8217;s completion of scale-up of the first cumulative 300&#160;kilograms of the GMP-grade compound. In consideration of and upon Tyligand&#8217;s successful completion of the development plan, within 30 days at the end of each calendar quarter, the Company shall pay Tyligand <ix:nonFraction unitRef="number" contextRef="i6b2d762a98f94d569b10a0723338a465_D20200301-20200331" decimals="2" name="cntx:CollaborativeArrangementRightsAndObligationsQuarterlySalesPaymentsPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY182NC9mcmFnOjIwYTRiZDM4N2RmYjRiOGJhZTc0ZWY1MjNmZGYyY2M0L3RleHRyZWdpb246MjBhNGJkMzg3ZGZiNGI4YmFlNzRlZjUyM2ZkZjJjYzRfMzMxNQ_40235db2-6cd6-4a52-9e50-c1621f90a494">1</ix:nonFraction>% of net sales of finished product utilizing the compound substantially manufactured in accordance with the process and specifications outlined in the Tyligand Process Development Agreement. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Per the Tyligand License Agreement, Tyligand shall pay the Company a non-refundable, non-creditable royalty at a rate in the mid-single digits of the net sales of each product in the Territory in each calendar quarter commencing with the first commercial sale of such product in the field in the Territory and ending upon the latest of (i) the sale of a generic product in the Territory and (ii) <ix:nonNumeric contextRef="i6b2d762a98f94d569b10a0723338a465_D20200301-20200331" name="cntx:CollaborativeArrangementRightsAndObligationsSalesPaymentPeriod" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY182NC9mcmFnOjIwYTRiZDM4N2RmYjRiOGJhZTc0ZWY1MjNmZGYyY2M0L3RleHRyZWdpb246MjBhNGJkMzg3ZGZiNGI4YmFlNzRlZjUyM2ZkZjJjYzRfMzkwNA_cdebf6e1-07c6-41ee-960f-0c58d6ca24d3">15</ix:nonNumeric> years after the date of the first commercial sale of product in the Territory. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Collaboration and Licensing Agreement with Integral Molecular </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In April 2021, the Company entered into a collaboration and licensing agreement with Integral Molecular, Inc. (&#8220;Integral&#8221;) (the &#8220;Integral License Agreement&#8221;) for the development of a CLDN6 bispecific monoclonal antibody for cancer therapy. Under the terms of the agreement, Integral and the Company will develop CLDN6 bispecific antibodies that trigger the activation of T cells and eliminate cancer cells displaying CLND6. The Company will conduct preclinical and all clinical development, as well as regulatory and commercial activities through exclusive worldwide rights to develop and commercialize the novel CLDN6 candidates. The payment for the initial upfront license fee as well as subsequent payments for milestones achieved were expensed to acquired in-process research and development. See Note 3. As a part of the agreement, Integral will be eligible to receive remaining development and regulatory milestone payments totaling approximately $<ix:nonFraction unitRef="usd" contextRef="icadec7fbbc8a431cbf67adac36bb34b1_I20230331" decimals="-5" name="cntx:CollaborativeArrangementRightsAndObligationsDevelopmentAndRegulatoryMilestonePaymentsMaximum" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY182NC9mcmFnOjIwYTRiZDM4N2RmYjRiOGJhZTc0ZWY1MjNmZGYyY2M0L3RleHRyZWdpb246MjBhNGJkMzg3ZGZiNGI4YmFlNzRlZjUyM2ZkZjJjYzRfNTA1Ng_8b4710d9-386b-4bb1-93d1-0a9c08e9c323">55</ix:nonFraction>&#160;million, sales milestone payments totaling up to $<ix:nonFraction unitRef="usd" contextRef="ibffbea9aff4c4a0a9c67a9e90540390f_I20210430" decimals="-6" name="cntx:CollaborativeArrangementRightsAndObligationsSalesMilestonePaymentsMaximum" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY182NC9mcmFnOjIwYTRiZDM4N2RmYjRiOGJhZTc0ZWY1MjNmZGYyY2M0L3RleHRyZWdpb246MjBhNGJkMzg3ZGZiNGI4YmFlNzRlZjUyM2ZkZjJjYzRfNTEwMA_67796fe2-95da-4a1d-bf88-91dd7cd4b255">130.0</ix:nonFraction> million, and tiered royalties of up to <ix:nonFraction unitRef="number" contextRef="ibffbea9aff4c4a0a9c67a9e90540390f_I20210430" decimals="2" name="cntx:CollaborativeArrangementRightsAndObligationsTieredRoyaltyPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY182NC9mcmFnOjIwYTRiZDM4N2RmYjRiOGJhZTc0ZWY1MjNmZGYyY2M0L3RleHRyZWdpb246MjBhNGJkMzg3ZGZiNGI4YmFlNzRlZjUyM2ZkZjJjYzRfNTEzNA_7806f709-8521-4839-b191-6a8fa5d92a74">12</ix:nonFraction>% of net sales of certain products developed under this agreement. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On March 20, 2023, the Company amended the Integral License Agreement to remove the previously agreed to second milestone payment and to change the amount of the third milestone payment to increase such payment by the amount of the prior second milestone payment and to add payment for third party research funding obtained and used by Integral in connection with the development of CTIM-76.</span></div><div><span><br/></span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Research and Development Arrangements</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In the course of normal business operations, the Company enters into agreements with universities and contract research organizations to assist in the performance of research and development activities and contract manufacturers to assist with chemistry, manufacturing, and controls related expenses. Expenditures to contract research organizations represent a significant cost in clinical development for the Company. The Company could also enter into additional collaborative research, contract research, manufacturing, and supplier agreements in the future, which may</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">require upfront payments and long-term commitments of cash.</span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">17</span></div></div></div><div id="ibd14e01a97b1463b915192a9eff93f0c_70"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#ibd14e01a97b1463b915192a9eff93f0c_7">Table of Contents</a></span></div></div><div style="margin-bottom:0.05pt;text-align:center"><span><br/></span></div><div style="margin-bottom:0.05pt;margin-top:0.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Item 2. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">You should read the following discussion of our financial condition and results of operations together with our unaudited  condensed consolidated financial statements and the notes thereto included elsewhere in this Quarterly Report on Form 10-Q and other financial information included in this report and our audited consolidated financial statements and related notes thereto and management&#8217;s discussion and analysis of financial condition and results of operations included in our Annual Report on Form 10-K for the year ended December 31, 2022 as filed with the Securities and Exchange Commission ("SEC"), on March 22, 2023. In addition to historical information, the following discussion contains a number of forward-looking statements, all of which are based on our current expectations and could be affected by the uncertainties and risks referred to under Part I, Item 1A. &#8220;Risk Factors&#8221; of our Annual Report on Form 10-K. Please also see the section entitled &#8220;Note Regarding Forward-Looking Statements.&#8221; </span></div><div id="ibd14e01a97b1463b915192a9eff93f0c_73"></div><div style="margin-bottom:0.05pt;margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Overview </span></div><div style="margin-top:6pt;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We are a biopharmaceutical company dedicated to improving the lives of patients living with cancer. </span></div><div style="margin-bottom:0.05pt;margin-top:0.05pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Our preclinical program, CTIM-76, is an anti-CLDN6 bsAb that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. CLDN6 is a tight junction membrane protein target expressed in multiple solid tumors, including ovarian, lung and testicular, and absent from or expressed at low levels in healthy adult tissues.  Investigational new drug ("IND")-enabling studies on CTIM-76 have been initiated, and we expect to submit an IND application to support human clinical trials to the FDA in the first quarter of 2024</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">.</span></div><div style="margin-bottom:0.05pt;margin-top:0.05pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On March 22, 2023, we announced a portfolio prioritization and capital allocation strategy, including discontinuing the development of ONA-XR and focusing on the development of CTIM-76. Based upon the challenging market conditions for emerging companies, the increasingly competitive landscape for breast cancer treatments, recent study findings, and other factors, we decided to cease development and explore strategic options for ONA-XR. As a result, we will no longer primarily focus on female cancers. By ceasing development of ONA-XR, we expect to have sufficient cash and cash equivalents to fund our operations into late 2024.</span></div><div style="margin-bottom:0.05pt;margin-top:0.05pt"><span><br/></span></div><div style="margin-top:0.5pt;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We were incorporated in April 2015 under the laws of the State of Delaware. Since inception, we have devoted substantially all of our resources to developing product and technology rights, conducting research and development, organizing and staffing our company, business planning and raising capital. We operate as one business segment and have incurred recurring losses, the majority of which are attributable to research and development activities, and negative cash flows from operations. We have funded our operations primarily through the sale of convertible debt, convertible preferred stock, common stock and warrants. Our net loss was $6.3 million for the three months ended March&#160;31, 2023. As of March&#160;31, 2023, we had an accumulated deficit of $50.4&#160;million.</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> Currently, our primary use of cash is to fund operating expenses, which consist primarily of research and development expenditures as well as general and administrative expenditures. Our ability to generate product revenue sufficient to achieve profitability will depend heavily on the successful development and eventual commercialization of one or more of our current or any future product candidates. We expect to continue to incur significant expenses and operating losses for the foreseeable future as we advance our current and any future product candidates through all stages of development and clinical trials and, ultimately, seek regulatory approval. In addition, if we obtain regulatory approval for any product candidates, we expect to incur significant commercialization expenses related to product manufacturing, marketing, sales and distribution. Furthermore, we have incurred and continue to incur significant costs associated with operating as a public company, including legal, accounting, investor relations and other expenses that we did not incur as a private company. Our net losses may fluctuate significantly from quarter-to-quarter and year-to-year, depending on the timing of our clinical trials and our expenses on other research and development activities. </span></div><div style="margin-top:12pt;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We expect to continue to incur net operating losses for at least the next several&#160;years, and we expect our research and development expenses, general and administrative expenses, and capital expenditures will continue to increase. We expect our expenses and capital requirements will increase significantly in connection with our ongoing activities as we: </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">18</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#ibd14e01a97b1463b915192a9eff93f0c_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt">continue nonclinical studies and initiate clinical trials for CTIM-76 and for any additional product candidates that we may pursue; </span></div><div style="margin-top:6pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt">continue to scale up external manufacturing capacity with the aim of securing sufficient quantities to meet our capacity requirements for clinical trials and potential commercialization; </span></div><div style="margin-top:6pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt">establish a sales, marketing and distribution infrastructure to commercialize any approved product candidate and related additional commercial manufacturing costs; </span></div><div style="margin-top:6pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt">develop, maintain, expand, protect and enforce our intellectual property portfolio, including patents, trade secrets and know how; </span></div><div style="margin-top:6pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt">acquire or in-license other product candidates and technologies, including related upfront, milestone and royalty payments; </span></div><div style="margin-top:6pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt">attract, hire and retain additional executive officers, clinical, scientific, quality control, and manufacturing management and administrative personnel; </span></div><div style="margin-top:6pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt">add clinical, operational, financial and management information systems and personnel, including personnel to support our product development and planned future commercialization efforts; </span></div><div style="margin-top:6pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt">expand our operations in the United States and to other geographies; and </span></div><div style="margin-top:6pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt">incur additional legal, accounting, investor relations and other expenses associated with operating as a public company. </span></div><div style="margin-bottom:0.05pt;margin-top:0.05pt;padding-left:9pt"><span><br/></span></div><div style="margin-bottom:0.05pt;margin-top:0.05pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As of March&#160;31, 2023, we had cash and cash equivalents of $29.8 million, which we expect will be sufficient to fund our operations into late 2024. If the Company is unable to obtain additional financing, the lack of liquidity could have a material adverse effect on the Company&#8217;s future prospects.</span></div><div style="margin-bottom:0.05pt;margin-top:0.05pt"><span><br/></span></div><div style="margin-bottom:0.05pt;margin-top:0.05pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We will need to raise substantial additional capital to support our continuing operations and pursue our growth strategy. Until such time as we can generate significant revenue from product sales, if ever, we plan to finance our operations through the sale of equity, debt financings and/or other capital sources, which may include collaborations with other companies or other strategic transactions. There are no assurances that we will be successful in obtaining an adequate level of financing as and when needed to finance our operations on terms acceptable to us, or at all. Any failure to raise capital as and when needed could have a negative impact on our financial condition and on our ability to pursue our business plans and strategies. If we are unable to secure adequate additional funding, we may have to significantly delay, scale back or discontinue the development and commercialization of one or more product candidates or delay our pursuit of potential in-licenses or acquisitions. </span></div><div id="ibd14e01a97b1463b915192a9eff93f0c_76"></div><div style="margin-bottom:0.05pt;margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">The COVID-19 Pandemic and its Impacts on Our Business </span></div><div style="margin-top:6pt;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The spread of COVID-19 has caused worldwide economic instability and significant volatility in the financial markets. There is significant uncertainty as to the likely effects of this disease should novel variants emerge, which may, among other things, materially impact our ongoing or planned clinical trials. This pandemic and/or periodic outbreaks could result in difficulty securing clinical trial site locations, contract research organizations (&#8220;CROs&#8221;), and/or trial monitors and other critical vendors and consultants supporting the trial. In addition, outbreaks or the perception of an outbreak near a clinical trial site location could impact our ability to enroll patients. These situations, or others associated with&#160;COVID-19,&#160;could cause delays in our clinical trial plans and could increase expected costs, all of which could have a material adverse effect on our business and financial condition. At the current time, we are unable to quantify the potential effects of this pandemic on our future consolidated financial statements. </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">19</span></div></div></div><div id="ibd14e01a97b1463b915192a9eff93f0c_79"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#ibd14e01a97b1463b915192a9eff93f0c_7">Table of Contents</a></span></div></div><div style="margin-bottom:0.05pt;margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Components of Our Results of Operations </span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Operating Expenses </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Research and Development Expenses </span></div><div style="margin-top:6pt;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Research and development expenses have consisted primarily of costs incurred in connection with the discovery and development of our product candidates. We expense research and development costs as incurred, including: </span></div><div style="margin-top:6pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt">expenses incurred to conduct the necessary discovery-stage laboratory work, preclinical studies and clinical trials required to obtain regulatory approval; </span></div><div style="margin-top:6pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt">personnel expenses, including salaries, benefits and share-based compensation expense for our employees and consultants engaged in research and development functions; </span></div><div style="margin-top:6pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt">costs of funding research performed by third parties, including pursuant to agreements with CROs that conduct our clinical trials, as well as investigative sites, consultants and CROs that conduct our preclinical and clinical studies; </span></div><div style="margin-top:6pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt">expenses incurred under agreements with contract manufacturing organizations, including manufacturing scale-up expenses, milestone-based payments, and the cost of acquiring and manufacturing preclinical study and clinical trial materials; </span></div><div style="margin-top:6pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt">fees paid to consultants who assist with research and development activities; </span></div><div style="margin-top:6pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt">expenses related to regulatory activities, including filing fees paid to regulatory agencies; and </span></div><div style="margin-top:6pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt">allocated expenses for facility costs, including rent, utilities and maintenance. </span></div><div style="margin-top:12pt;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We track outsourced development costs and other external research and development costs to specific product candidates on a program-by-program basis. However, we do not track our internal research and development expenses on a program-by-program basis as they primarily relate to compensation, early research and other costs which are deployed across multiple projects under development. </span></div><div style="margin-top:12pt;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Research and development activities are central to our business model. Product candidates in later stages of clinical development generally have higher development costs than those in earlier stages of clinical development, primarily due to the increased size and duration of later-stage clinical trials. We expect our research and development expenses to increase significantly over the next several years as we increase personnel costs, including share-based compensation, conduct our clinical trials, including later-stage clinical trials, for current and future product candidates and prepare regulatory filings for our product candidates. </span></div><div style="margin-top:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:115%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">General and Administrative Expenses </span></div><div style="margin-top:6pt;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">General and administrative expenses have consisted primarily of personnel expenses, including salaries, benefits and share-based compensation expense, for employees and consultants in executive, finance and accounting, legal, operations support, information technology and business development functions. General and administrative expense also includes corporate facility costs not otherwise included in research and development expense, including rent, utilities and insurance, as well as legal fees related to intellectual property and corporate matters and fees for accounting and consulting services. </span></div><div style="margin-top:12pt;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We expect that our general and administrative expenses will increase in the future to support our continued research and development activities, potential commercialization efforts and increased costs of operating as a public company. These increases will likely include increased costs related to the hiring of additional personnel and fees to outside consultants, legal support and accountants, among other expenses. Additionally, we will continue to incur significant costs associated with being a public company, including expenses related to services associated with maintaining compliance with the requirements of Nasdaq and the SEC, insurance and investor relations costs. If any of our current or future product candidates obtain U.S. regulatory approval, we expect that we would incur significantly increased expenses associated with building a sales and marketing team. </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">20</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#ibd14e01a97b1463b915192a9eff93f0c_7">Table of Contents</a></span></div></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Interest Income</span></div><div style="margin-top:6pt;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Interest income consists of interest earned on our cash and cash equivalents.</span></div><div style="margin-bottom:0.05pt;margin-top:0.05pt"><span><br/></span></div><div style="margin-bottom:0.05pt;margin-top:0.05pt"><span><br/></span></div><div id="ibd14e01a97b1463b915192a9eff93f0c_82"></div><div style="margin-bottom:0.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Results of Operations </span></div><div style="margin-bottom:0.05pt;margin-top:0.05pt"><span><br/></span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Comparison of the Three Months Ended March&#160;31, 2023 and 2022 </span></div><div style="margin-top:6pt;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The following table sets forth our results of operations for the three months ended March&#160;31, 2023 and 2022: </span></div><div style="margin-top:6pt"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.514%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.623%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:125%">Three months ended March 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:125%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:125%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:125%">$ Change</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:125%">% Change</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">Operating expenses:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">Research and development</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">4,534,676&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">1,351,495&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">3,183,181&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">236&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">General and administrative</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">2,131,872&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">2,091,467&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">40,405&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">Loss from operations</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">(6,666,548)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">(3,442,962)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">(3,223,586)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">94&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">Interest income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">355,542&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">5,864&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">349,678&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">5,963&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">%</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">Other income (expense)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">2,688&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">(1,239)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">3,927&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">(317)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">Net loss</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">(6,308,318)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">(3,438,337)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">(2,869,981)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">83&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">%</span></td></tr></table></div><div style="margin-bottom:0.05pt;margin-top:0.05pt"><span><br/></span></div><div style="margin-bottom:0.05pt;margin-top:0.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Research and Development Expenses </span></div><div style="margin-top:6pt;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Research and development expenses increased by approximately $3.2 million for the three months ended March&#160;31, 2023 as compared to the same period in 2022. The following table summarizes our research and development expenses for the three months ended March&#160;31, 2023 as compared to the same period in 2022: </span></div><div style="margin-bottom:0.05pt;margin-top:0.05pt"><span><br/></span></div><div style="margin-bottom:0.05pt;margin-top:0.05pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:39.619%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.288%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.375%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.288%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.375%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.288%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.375%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.292%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:125%">Three months ended March 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:125%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:125%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:125%">$ Change</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:125%">% Change</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">ONA-XR</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">2,088,763&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">861,311&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">1,227,452&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">143&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">CTIM-76</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">2,085,275&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">80,971&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">2,004,304&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">2,475&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">Personnel-related costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">345,255&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">352,340&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">(7,085)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">(2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">Other research and development</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">15,383&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">56,873&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">(41,490)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">(73)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">4,534,676&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">1,351,495&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">3,183,181&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">236&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">%</span></td></tr></table></div><div style="margin-bottom:0.05pt;margin-top:6pt;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The increase in ONA-XR expense of $1.2 million was primarily due to an increase of $1.0 million in clinical trial costs as a result of initiating our Phase 1b/2 ELONA trial and an increase of $0.2 million in contract manufacturing costs. CTIM-76 expenditures increased by $2.0&#160;million, primarily due to an increase of $1.6 million in contract manufacturing costs and $0.4 million in preclinical costs as a result of ongoing IND-enabling studies.</span></div><div style="margin-bottom:0.05pt;margin-top:0.05pt"><span><br/></span></div><div style="margin-bottom:0.05pt;margin-top:0.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">General and Administrative Expenses </span></div><div style="text-indent:24.5pt"><span><br/></span></div><div style="margin-bottom:0.05pt;margin-top:0.05pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">General and administrative expenses increased slightly for the three months ended March&#160;31, 2023 as compared to the same period in 2022. Increases in compensation and share-based compensation costs mainly due to higher headcount were partially offset by decreases in insurance premiums, professional fees and other administrative costs.</span></div><div style="margin-bottom:0.05pt;margin-top:0.05pt"><span><br/></span></div><div style="margin-bottom:0.05pt;margin-top:0.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Interest Income</span></div><div style="margin-top:6pt;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Interest income  increased by approximately $0.3 million for the three months ended March&#160;31, 2023 as compared to the same period in 2022 primarily due to higher interest income earned on cash and cash equivalent balances.</span></div><div style="margin-top:6pt;text-indent:24.5pt"><span><br/></span></div><div style="margin-top:6pt"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">21</span></div></div></div><div id="ibd14e01a97b1463b915192a9eff93f0c_85"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#ibd14e01a97b1463b915192a9eff93f0c_7">Table of Contents</a></span></div></div><div style="margin-bottom:0.05pt;margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Liquidity and Capital Resources </span></div><div style="margin-bottom:0.05pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Overview </span></div><div style="margin-bottom:0.05pt;margin-top:0.05pt"><span><br/></span></div><div style="margin-bottom:0.05pt;margin-top:0.05pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Since our inception, we have not recognized any revenue and have incurred operating losses and negative cash flows from our operations. We have not yet commercialized any product and we do not expect to generate revenue from sales of any products for several years, if at all.  Since our inception through March&#160;31, 2023, we have funded our operations through the sale of convertible debt, convertible preferred stock, common stock and warrants. As of March&#160;31, 2023, we had $29.8 million in cash and cash equivalents and an accumulated deficit of $50.4&#160;million. </span></div><div style="text-indent:27pt"><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We expect our existing cash and cash equivalents will be sufficient to fund our operations into late 2024. We have based these estimates on assumptions that may prove to be imprecise, and we could utilize our available capital resources sooner than we expect. </span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Funding Requirements </span></div><div style="margin-top:6pt;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our primary use of cash is to fund operating expenses, which consist of research and development expenditures and various general and administrative expenses. Cash used to fund operating expenses is impacted by the timing of when we pay these expenses, as reflected in the change in our outstanding accounts payable, accrued expenses and prepaid expenses. </span></div><div style="margin-top:12pt;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Because of the numerous risks and uncertainties associated with research, development and commercialization of pharmaceutical products, we are unable to estimate the exact amount of our operating capital requirements. Our future funding requirements will depend on many factors, including, but not limited to: </span></div><div style="margin-top:6pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt">the scope, timing, progress and results of discovery, preclinical development, laboratory testing and clinical trials for our current and any future product candidates that we may pursue; </span></div><div style="margin-top:6pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt">the costs of manufacturing our current and any future product candidates for clinical trials and in preparation for regulatory approval and commercialization; </span></div><div style="margin-top:6pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt">the extent to which we enter into collaborations or other arrangements with additional third parties in order to further develop our current and any future product candidates that we may pursue; </span></div><div style="margin-top:6pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt">the costs of preparing, filing and prosecuting patent applications, maintaining and enforcing our intellectual property rights and defending intellectual property-related claims; </span></div><div style="margin-top:6pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt">the costs and fees associated with the discovery, acquisition or in-license of additional product candidates or technologies; </span></div><div style="margin-top:6pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt">expenses needed to attract and retain skilled personnel; </span></div><div style="margin-top:6pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt">costs associated with being a public company; </span></div><div style="margin-top:6pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt">the costs required to scale up our clinical, regulatory and manufacturing capabilities; </span></div><div style="margin-top:6pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt">the costs of future commercialization activities, if any, including establishing sales, marketing, manufacturing and distribution capabilities, for our current and any future product candidates for which we receive regulatory approval; and </span></div><div style="margin-top:6pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt">revenue, if any, received from commercial sales of our current and any future product candidates, should any of our product candidates receive regulatory approval. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:115%">&#160;</span></div><div style="text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We will need additional funds to meet our operational needs and capital requirements for clinical trials, other research and development expenditures, and general and administrative expenses. We currently have no credit facility or committed sources of capital. </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">22</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#ibd14e01a97b1463b915192a9eff93f0c_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Until such time, if ever, as we can generate substantial product revenue, we expect to finance our operations through a combination of equity offerings, debt financings, collaborations, strategic alliances and/or marketing, distribution or licensing arrangements. To the extent that we raise additional capital through the sale of equity or convertible debt securities, the ownership interests of our stockholders will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect the rights of our common stockholders. Debt financing and preferred equity financing, if available, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making acquisitions or capital expenditures or declaring dividends. If we raise additional funds through collaborations, strategic alliances or marketing, distribution or licensing arrangements with third parties, we may have to relinquish valuable rights to our technologies, future revenue streams, research programs or product candidates, or grant licenses on terms that may not be favorable to us. If we are unable to raise additional funds through equity or debt financings or other arrangements when needed, we may be required to delay, limit, reduce or terminate our research, product development or future commercialization efforts, or grant rights to develop and market product candidates that we would otherwise prefer to develop and market ourselves. </span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Cash Flows </span></div><div style="margin-top:6pt;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The following table shows a summary of our cash flows for the periods indicated: </span></div><div style="margin-bottom:0.05pt;margin-top:0.05pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:86.111%"><tr><td style="width:1.0%"></td><td style="width:66.641%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.689%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.479%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.691%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:125%">Three  months ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:125%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:125%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Cash used in operating activities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">(5,728,455)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">(3,820,281)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Cash used in investing activities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">(34,999)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Cash used in financing activities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">(102,071)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Net decrease in cash, cash equivalents and restricted cash</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">(5,728,455)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">(3,957,351)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Comparison of the Three Months Ended March&#160;31, 2023 and 2022</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Operating Activities </span></div><div style="margin-top:12pt;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">During the three months ended March&#160;31, 2023, we used $5.7 million of cash in operating activities. Cash used in operating activities reflected our net loss of $6.3 million, partially offset by non-cash share-based compensation of $0.3 million and a change in our operating assets and liabilities of $0.3 million. The primary uses of cash were to fund our operations related to the development of our product candidates. </span></div><div style="margin-top:12pt;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">During the three months ended March&#160;31, 2022, we used $3.8 million of cash in operating activities. Cash used in operating activities reflected our net loss of $3.4 million and a net change in our operating assets and liabilities of $0.6 million. This was offset by non-cash share-based compensation of $0.2 million. The primary uses of cash were to fund our operations related to the development of our product candidates. </span></div><div style="margin-bottom:0.05pt;margin-top:0.05pt"><span><br/></span></div><div style="margin-bottom:0.05pt;margin-top:0.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Investing Activities </span></div><div style="margin-bottom:0.05pt;margin-top:0.05pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We did not have cash flows from investing activities during the three months ended March&#160;31, 2023.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">During the three months ended March&#160;31, 2022, we used $35,000 of cash to purchase property and equipment.</span></div><div style="margin-bottom:0.05pt;margin-top:0.05pt"><span><br/></span></div><div style="margin-bottom:0.05pt;margin-top:0.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Financing Activities </span></div><div style="margin-bottom:0.05pt;margin-top:0.05pt"><span><br/></span></div><div style="margin-bottom:0.05pt;margin-top:0.05pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We did not have cash flows from financing activities during the three months ended March&#160;31, 2023.</span></div><div style="margin-top:12pt;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">During the three months ended March&#160;31, 2022, cash used in financing activities was $0.1 million, consisting of the payment of offering costs related to our December 2021 private placement.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">23</span></div></div></div><div id="ibd14e01a97b1463b915192a9eff93f0c_88"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#ibd14e01a97b1463b915192a9eff93f0c_7">Table of Contents</a></span></div></div><div style="margin-bottom:0.05pt;margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Off-Balance Sheet Arrangements </span></div><div style="margin-top:6pt;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">During the periods presented, we did not have, nor do we currently have, any relationships with unconsolidated entities or financial partnerships, including entities sometimes referred to as structured finance or special purpose entities that were established for the purpose of facilitating off-balance sheet arrangements or other contractually narrow or limited purposes. We do not engage in off-balance sheet financing arrangements. In addition, we do not engage in trading activities involving non-exchange traded contracts. We therefore believe that we are not materially exposed to any financing, liquidity, market or credit risk that could arise if we had engaged in these relationships. </span></div><div style="margin-bottom:0.05pt;margin-top:0.05pt"><span><br/></span></div><div id="ibd14e01a97b1463b915192a9eff93f0c_91"></div><div style="margin-bottom:0.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Critical Accounting Policies </span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">During the three months ended March&#160;31, 2023, there were no material changes to our critical accounting policies and estimates from those described in our Annual Report on Form 10-K for the year ended December&#160;31, 2022, as filed with the SEC on March 22, 2023.</span></div><div id="ibd14e01a97b1463b915192a9eff93f0c_94"></div><div style="margin-bottom:0.05pt;margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Recent Accounting Pronouncements </span></div><div style="margin-top:6pt;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">See Note&#160;3 to our unaudited condensed consolidated financial statements found elsewhere in this Quarterly Report for a description of recent accounting pronouncements applicable to our condensed consolidated financial statements. </span></div><div id="ibd14e01a97b1463b915192a9eff93f0c_97"></div><div style="margin-bottom:0.05pt;margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Emerging Growth Company and Smaller Reporting Company Status </span></div><div style="margin-top:6pt;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In April 2012, the JOBS Act, was enacted. Section&#160;107 of the JOBS Act provides that an &#8220;emerging growth company&#8221; can take advantage of the extended transition period provided in Section&#160;7(a)(2)(B) of the Securities Act of 1933, as amended, for complying with new or revised accounting standards. Thus, an emerging growth company can delay the adoption of certain accounting standards until those standards would otherwise apply to private companies. We have elected to avail ourselves of this exemption from complying with new or revised accounting standards and, therefore, will not be subject to the same new or revised accounting standards as other public companies that are not emerging growth companies. As a result, our financial statements may not be comparable to companies that comply with new or revised accounting pronouncements as of public company effective dates. </span></div><div style="margin-bottom:0.05pt;margin-top:0.05pt"><span><br/></span></div><div style="margin-bottom:0.05pt;margin-top:0.05pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Other exemptions and reduced reporting requirements under the JOBS Act include, without limitation, the requirements for providing an auditor&#8217;s attestation report on our system of internal controls over financial reporting pursuant to Section 404(b) of the Sarbanes-Oxley Act of 2002, an exemption from any requirement that may be adopted by the Public Company Accounting Oversight Board regarding mandatory audit firm rotation, and less extensive disclosure about our executive compensation arrangements. We will remain an emerging growth company until the earlier to occur of (a) the last day of the fiscal year (i) following October 19, 2026, (ii) in which we have total annual gross revenues of at least $1.235 billion or (iii) in which we are deemed to be a &#8220;large accelerated filer&#8221; under the rules of the SEC, which means that we have been required to file annual and quarterly reports under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), for a period of at least 12 months and have filed at least one annual report pursuant to the Exchange Act and (b) either (i) the market value of our common stock that is held by non-affiliates exceeds $700.0 million as of the prior June 30th, or (ii) the date on which we have issued more than $1.0 billion in non-convertible debt during the prior three-year period.</span></div><div style="margin-bottom:0.05pt;margin-top:0.05pt"><span><br/></span></div><div style="text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We are also a &#8220;smaller reporting company,&#8221; meaning that the market value of our stock held by non-affiliates is less than $700.0&#160;million and our annual revenue is less than $100.0&#160;million during the most recently completed fiscal year. We will continue to be a smaller reporting company while either (i)&#160;the market value of our stock held by non-affiliates is less than $250.0&#160;million or (ii)&#160;our annual revenue is less than $100.0&#160;million during the most recently completed fiscal year and the market value of our stock held by non-affiliates is less than $700.0&#160;million. If we are a smaller reporting company at the time we cease to be an emerging growth company, we may continue to rely on exemptions from certain disclosure requirements that are available to smaller reporting companies. Specifically, as a smaller reporting company we may choose to present only the two most recent fiscal years of audited financial statements in our Annual Report on Form&#160;10-K and, similar to emerging growth companies, smaller reporting companies have reduced disclosure obligations regarding executive compensation. </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">24</span></div></div></div><div id="ibd14e01a97b1463b915192a9eff93f0c_100"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#ibd14e01a97b1463b915192a9eff93f0c_7">Table of Contents</a></span></div></div><div style="margin-bottom:0.05pt;margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Item 3. Quantitative and Qualitative Disclosures About Market Risk </span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We are a smaller reporting company as defined in Rule 12b-2 of the Exchange Act and are not required to provide the information otherwise required under this Item 3.</span></div><div id="ibd14e01a97b1463b915192a9eff93f0c_103"></div><div style="margin-bottom:0.05pt;margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Item 4. Controls and Procedures</span></div><div style="margin-bottom:0.05pt;margin-top:0.05pt"><span><br/></span></div><div style="margin-bottom:0.05pt;margin-top:0.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Evaluation of Disclosure Controls and Procedures</span></div><div style="margin-bottom:0.05pt;margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our management, with the participation of our principal executive officer and our principal financial officer, evaluated, as of the end of the period covered by this Quarterly Report on Form 10-Q, the effectiveness of our disclosure controls and procedures as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act. The term &#8220;disclosure controls and procedures,&#8221; as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act, means controls and other procedures of a company that are designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the SEC&#8217;s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is accumulated and communicated to the company&#8217;s management, including its principal executive and principal financial officers, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure. Management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives and management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures.</span></div><div style="margin-bottom:0.05pt;margin-top:0.05pt"><span><br/></span></div><div style="margin-bottom:0.05pt;margin-top:0.05pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Based on the evaluation of our disclosure controls and procedures as of March&#160;31, 2023, our principal executive officer and principal financial officer concluded that our disclosure controls and procedures as of such date were effective at the reasonable assurance level.</span></div><div style="margin-bottom:0.05pt;margin-top:0.05pt"><span><br/></span></div><div style="margin-bottom:0.05pt;margin-top:0.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Changes in Internal Control over Financial Reporting</span></div><div style="margin-bottom:0.05pt;margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">There were no changes in our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) during the quarter ended March&#160;31, 2023 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting. </span></div><div style="margin-bottom:0.05pt;margin-top:0.05pt"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">25</span></div></div></div><div id="ibd14e01a97b1463b915192a9eff93f0c_106"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#ibd14e01a97b1463b915192a9eff93f0c_7">Table of Contents</a></span></div></div><div style="text-align:center;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:139%">PART II &#8211; Other Information</span></div><div style="text-align:center"><span><br/></span></div><div id="ibd14e01a97b1463b915192a9eff93f0c_109"></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1. &#160;&#160;&#160;&#160;Legal Proceedings</span></div><div style="margin-top:6pt;padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, we may become involved in legal proceedings arising in the ordinary course of our business. We</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">are not presently a party to any material legal proceedings.</span></div><div id="ibd14e01a97b1463b915192a9eff93f0c_112"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1A. Risk Factors</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investing in our common stock involves a high degree of risk. In addition to the other information set forth in this quarterly report on Form 10-Q, you should carefully consider the factors described under the caption "Risk Factors" in our Annual Report on Form 10-K for the year ended December&#160;31, 2022, filed with the SEC on March 22, 2023. There have been no material changes to the risk factors described in that report. The occurrence of any of the events or developments described in our Risk Factors could adversely affect our business, financial condition, results of operations and growth prospects. In such an event, the market price of our common stock could decline, and you may lose all or part of your investment. Additional risks and uncertainties not presently known to us or that we currently deem immaterial also may impair our business operations.</span></div><div><span><br/></span></div><div id="ibd14e01a97b1463b915192a9eff93f0c_115"></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 2. Unregistered Sales of Equity Securities and Use of Proceeds</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">None.</span></div><div id="ibd14e01a97b1463b915192a9eff93f0c_118"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 3. &#160;&#160;&#160;&#160;Defaults upon Senior Securities</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None. </span></div><div id="ibd14e01a97b1463b915192a9eff93f0c_121"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 4. Mine Safety Disclosures</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div id="ibd14e01a97b1463b915192a9eff93f0c_124"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 5.  Other Information</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because we are filing this Quarterly Report on Form 10-Q within four business days after the triggering event, we are making the following disclosure under this Item 5 instead of filing a Current Report on Form 8-K under Item 2.05, Costs Associated with Exit or Disposal Activities:</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 22, 2023, the Company filed a Current Report on Form 8-K disclosing that on March 17, 2023, the Board of Directors of the Company approved a portfolio prioritization and capital allocation strategy, including discontinuing the development of ONA-XR and focusing on the development of CTIM-76. </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At this time, the Company has not incurred, nor does the Company expect to incur, material charges in connection with discontinuing the development of ONA-XR. </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">26</span></div></div></div><div id="ibd14e01a97b1463b915192a9eff93f0c_127"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="-sec-extract:summary"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#ibd14e01a97b1463b915192a9eff93f0c_7">Table of Contents</a></span></div></div><div style="-sec-extract:summary;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 6. Exhibits</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:10.143%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:74.429%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.128%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:125%">Exhibit<br/>No.</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:125%">&#160;<br/>Exhibit Description</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">3.1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.08pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0001842952/000119312521305465/d251040dex31.htm">Amended &amp; Restated Certificate of Incorporation of Context Therapeutics Inc. (incorporated by reference to Exhibit 3.1 to the Company's Current Report on Form 8-K (File No. 001-40654), as filed with the SEC on October 22, 2021).</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">3.2</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.08pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0001842952/000119312521305465/d251040dex32.htm">Amended and Restated Bylaws of Context Therapeutics Inc. (incorporated by reference to Exhibit 3.2 to the Company's Current Report on Form 8-K (File No. 001-40654), as filed with the SEC on October 22, 2021).</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.08pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">10.1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:125%;position:relative;top:-3.5pt;vertical-align:baseline">#</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.08pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1842952/000184295223000041/amendment1tointegralcollab.htm">Amendment No. 1, dated March 20, 2023, to that certain Research Collaboration and License Agreement, dated April 6, 2021, between Context Therapeutics LLC and Integral Molecular, Inc. (incorporated by reference to Exhibit 10.23 to the Company's Annual Report on Form 10-K (File No. 001-40654), as filed with the SEC on March 22, 2022)</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">10.2</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.08pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1842952/000184295223000041/context_menarinimutualterm.htm">Termination Agreement of the Clinical Trial Collaboration and Supply Agreement, dated March 21, 2023 between Context Therapeutics Inc. and Berlin-Chemie AG - Menarini Group (incorporated by reference to Exhibit 10.24 to the Company's Annual Report on Form 10-K (File No. 001-40654), as filed with the SEC on March 22, 2022)</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">31.1*</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.08pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%;text-decoration:underline" href="cntx2023-033110xqexhibit311.htm">Certification of Chief Executive Officer pursuant to Rule 13a-14(a) or 15a-14(a) under the Exchange Act.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">31.2*</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.08pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%;text-decoration:underline" href="cntx2023033110-qexhibit312.htm">Certification of Chief Financial Officer pursuant to Rule 13a-14(a) or 15a-14(a) under the Exchange Act.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">32.1*+</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.08pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%;text-decoration:underline" href="cntx2023033110-qexhibit321.htm">Certification Pursuant to 18 U.S.C. Section 1350 of principal executive officer and principal financial officer.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">101*</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The following financial statements from Context Therapeutics Inc.&#8217;s Quarterly Report on Form 10-Q for the fiscal quarter ended March 31, 2023, formatted in Inline XBRL (eXtensible Business Reporting Language): (i) Condensed Consolidated Balance Sheets; (ii) Condensed Consolidated Statements of Operations; (iii) Condensed Consolidated Statements of Changes in Stockholders&#8217; Equity; (iv) Condensed Consolidated Statements of Cash Flows; and (v) Notes to the Condensed Consolidated Financial Statements.</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">104*</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101 hereto)</span></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">*      Filed herewith </span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">#       Certain confidential information contained in this agreement has been omitted because it is both not material and is the type that the registrant treats as private or confidential</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">+    This certification is being furnished pursuant to 18 U.S.C. Section 1350 and is not being filed for purposes of Section 18 of the Exchange Act, and is not to be incorporated by reference into any filing of the Company, whether made before or after the date hereof.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">27</span></div></div></div><div id="ibd14e01a97b1463b915192a9eff93f0c_130"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#ibd14e01a97b1463b915192a9eff93f0c_7">Table of Contents</a></span></div></div><div style="text-align:center;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:139%">SIGNATURES</span></div><div style="text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#160;</span></div><div style="text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</span></div><div style="text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#160;</span></div><div style="text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">Date: May 10, 2023</span></div><div style="margin-bottom:5pt;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#160;</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:47.876%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.724%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:27.701%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.299%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</span></td><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</span></td><td colspan="6" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">CONTEXT THERAPEUTICS INC.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</span></td><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</span></td><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</span></td><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</span></td><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</span></td><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</span></td><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</span></td><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</span></td><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">By:</span></td><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;/s/ Martin Lehr</span></td><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</span></td><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Martin Lehr</span></td><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</span></td><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</span></td><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Chief Executive Officer (Principal Executive Officer)</span></td><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</span></td><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</span></td><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</span></td><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</span></td><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</span></td><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</span></td><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">By:</span></td><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">/s/ Jennifer Minai-Azary</span></td><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</span></td><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Jennifer Minai-Azary</span></td><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</span></td><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</span></td><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Chief Financial Officer (Principal Financial Officer and Principal Accounting Officer)</span></td><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</span></td></tr></table></div><div style="text-indent:9pt"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">28</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>2
<FILENAME>cntx2023-033110xqexhibit311.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i92444c94007a406bb76a757199c661ec_1"></div><div style="min-height:67.68pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:130%">Exhibit 31.1</font></div><div style="text-align:right"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:130%">CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:139%">PURSUANT TO SECTION 302 OF THE</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:139%">SARBANES-OXLEY ACT OF 2002</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">I, Martin Lehr, certify that&#58;</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;padding-left:10.5pt">I have reviewed this Quarterly Report on Form 10-Q of Context Therapeutics Inc.&#59;</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;padding-left:10.5pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;padding-left:10.5pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;padding-left:10.5pt">The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div><font><br></font></div><div style="padding-left:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="padding-left:72pt"><font><br></font></div><div style="padding-left:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="padding-left:72pt"><font><br></font></div><div style="padding-left:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">(c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="padding-left:72pt"><font><br></font></div><div style="padding-left:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">(d) Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;padding-left:10.5pt">The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions)&#58;</font></div><div><font><br></font></div><div style="padding-left:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information&#59; and</font></div><div style="padding-left:72pt"><font><br></font></div><div style="height:67.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:67.68pt;width:100%"><div><font><br></font></div></div><div style="padding-left:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.</font></div><div style="padding-left:72pt"><font><br></font></div><div style="padding-left:72pt"><font><br></font></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.314%"><tr><td style="width:1.0%"></td><td style="width:19.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:27.520%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; May 10, 2023</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Martin Lehr</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Martin Lehr</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Executive Officer</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal Executive Officer)</font></td></tr></table></div><div style="height:67.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>3
<FILENAME>cntx2023033110-qexhibit312.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i0c74d15c393e49089805c7f4a00332be_1"></div><div style="min-height:67.68pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:130%">Exhibit 31.2</font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:130%">CERTIFICATION OF PRINCIPAL FINANCIAL</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:139%">OFFICER PURSUANT TO SECTION 302</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:139%">OF THE SARBANES-OXLEY ACT OF 2002</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">I, Jennifer Minai-Azary, certify that&#58;</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;padding-left:10.5pt">I have reviewed this Quarterly Report on Form 10-Q of Context Therapeutics Inc.&#59;</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;padding-left:10.5pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;padding-left:10.5pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;padding-left:10.5pt">The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div><font><br></font></div><div style="padding-left:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="padding-left:72pt"><font><br></font></div><div style="padding-left:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="padding-left:72pt"><font><br></font></div><div style="padding-left:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">(c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="padding-left:72pt"><font><br></font></div><div style="padding-left:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">(d) Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;padding-left:10.5pt">The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions)&#58;</font></div><div><font><br></font></div><div style="padding-left:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information&#59; and</font></div><div style="height:67.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:67.68pt;width:100%"><div><font><br></font></div></div><div style="padding-left:72pt"><font><br></font></div><div style="padding-left:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.</font></div><div style="padding-left:72pt"><font><br></font></div><div style="padding-left:72pt"><font><br></font></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:18.771%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.771%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.771%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.803%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:24.384%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; May 10, 2023</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Jennifer Minai-Azary</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Jennifer Minai-Azary</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal Financial Officer)</font></td></tr></table></div><div style="height:67.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>4
<FILENAME>cntx2023033110-qexhibit321.htm
<DESCRIPTION>EX-32.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i5a9844a412e24812aa40040fe2276f8a_1"></div><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:161%">EXHIBIT&#160;32.1</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:161%">CERTIFICATIONS PURSUANT TO </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:139%">18 U.S.C. SECTION 1350, </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:139%">AS ADOPTED PURSUANT TO </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:139%">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 </font></div><div style="margin-top:12pt;text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (18 U.S.C. 1350, as adopted), Martin Lehr, Chief Executive Officer (Principal Executive Officer) of Context Therapeutics Inc. (the &#8220;Company&#8221;), and Jennifer Minai-Azary, Chief Financial Officer (Principal Financial Officer) of the Company, each hereby certifies that, to the best of his or her knowledge&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">(1) The Company&#8217;s Quarterly Report on Form 10-Q for the quarter ended March 31, 2023 (the &#8220;Quarterly Report&#8221;), and to which this Certification is attached as Exhibit 32.1, fully complies with the requirements of Section 13(a) or Section 15(d) of the Securities Exchange Act of 1934, as amended, and</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">(2) The information contained in the Quarterly Report fairly presents, in all material respects, the financial condition and results of operations of the Company for the periods presented therein.</font></div><div style="text-align:justify"><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:71.955%"><tr><td style="width:1.0%"></td><td style="width:57.029%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.771%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Martin Lehr</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; May 10, 2023</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Martin Lehr</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Executive Officer (Principal Executive Officer)</font></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Jennifer Minai-Azary</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; May 10, 2023</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Jennifer Minai-Azary</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer (Principal Financial Officer)</font></td></tr></table></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">&#8220;This certification accompanies the Quarterly Report on Form 10-Q to which it relates, is not deemed filed with the Securities and Exchange Commission and is not to be incorporated by reference into any filing of Context Therapeutics Inc. under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended (whether made before or after the date of the Form 10-Q), irrespective of any general incorporation language contained in such filing.&#8221;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>5
<FILENAME>cntx-20230331.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:25d0e2a1-022e-45ee-a4b8-2723f9a842c8,g:b681c287-491c-4187-8280-df3edb448dfa-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:cntx="http://www.contexttherapeutics.com/20230331" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.contexttherapeutics.com/20230331">
  <xs:import namespace="http://fasb.org/srt/2022" schemaLocation="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2022" schemaLocation="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2022" schemaLocation="https://xbrl.sec.gov/dei/2022/dei-2022.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="cntx-20230331_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="cntx-20230331_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="cntx-20230331_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="cntx-20230331_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="Cover" roleURI="http://www.contexttherapeutics.com/role/Cover">
        <link:definition>0000001 - Document - Cover</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedBalanceSheets" roleURI="http://www.contexttherapeutics.com/role/CondensedConsolidatedBalanceSheets">
        <link:definition>0000002 - Statement - Condensed Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedBalanceSheetsParenthetical" roleURI="http://www.contexttherapeutics.com/role/CondensedConsolidatedBalanceSheetsParenthetical">
        <link:definition>0000003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofOperationsUnaudited" roleURI="http://www.contexttherapeutics.com/role/CondensedConsolidatedStatementsofOperationsUnaudited">
        <link:definition>0000004 - Statement - Condensed Consolidated Statements of Operations (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofChangesinStockholdersEquityUnaudited" roleURI="http://www.contexttherapeutics.com/role/CondensedConsolidatedStatementsofChangesinStockholdersEquityUnaudited">
        <link:definition>0000005 - Statement - Condensed Consolidated Statements of Changes in Stockholders' Equity (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementofCashFlowsUnaudited" roleURI="http://www.contexttherapeutics.com/role/CondensedConsolidatedStatementofCashFlowsUnaudited">
        <link:definition>0000006 - Statement - Condensed Consolidated Statement of Cash Flows (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationandDescriptionofBusiness" roleURI="http://www.contexttherapeutics.com/role/OrganizationandDescriptionofBusiness">
        <link:definition>0000007 - Disclosure - Organization and Description of Business</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RisksandLiquidity" roleURI="http://www.contexttherapeutics.com/role/RisksandLiquidity">
        <link:definition>0000008 - Disclosure - Risks and Liquidity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasisofPresentationandSummaryofSignificantAccountingPolicies" roleURI="http://www.contexttherapeutics.com/role/BasisofPresentationandSummaryofSignificantAccountingPolicies">
        <link:definition>0000009 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurements" roleURI="http://www.contexttherapeutics.com/role/FairValueMeasurements">
        <link:definition>0000010 - Disclosure - Fair Value Measurements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccruedExpensesandOtherCurrentLiabilities" roleURI="http://www.contexttherapeutics.com/role/AccruedExpensesandOtherCurrentLiabilities">
        <link:definition>0000011 - Disclosure - Accrued Expenses and Other Current Liabilities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquity" roleURI="http://www.contexttherapeutics.com/role/StockholdersEquity">
        <link:definition>0000012 - Disclosure - Stockholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedCompensation" roleURI="http://www.contexttherapeutics.com/role/ShareBasedCompensation">
        <link:definition>0000013 - Disclosure - Share-Based Compensation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentandContingencies" roleURI="http://www.contexttherapeutics.com/role/CommitmentandContingencies">
        <link:definition>0000014 - Disclosure - Commitment and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies" roleURI="http://www.contexttherapeutics.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies">
        <link:definition>0000015 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasisofPresentationandSummaryofSignificantAccountingPoliciesTables" roleURI="http://www.contexttherapeutics.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesTables">
        <link:definition>0000016 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsTables" roleURI="http://www.contexttherapeutics.com/role/FairValueMeasurementsTables">
        <link:definition>0000017 - Disclosure - Fair Value Measurements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccruedExpensesandOtherCurrentLiabilitiesTables" roleURI="http://www.contexttherapeutics.com/role/AccruedExpensesandOtherCurrentLiabilitiesTables">
        <link:definition>0000018 - Disclosure - Accrued Expenses and Other Current Liabilities (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityTables" roleURI="http://www.contexttherapeutics.com/role/StockholdersEquityTables">
        <link:definition>0000019 - Disclosure - Stockholders' Equity (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedCompensationTables" roleURI="http://www.contexttherapeutics.com/role/ShareBasedCompensationTables">
        <link:definition>0000020 - Disclosure - Share-Based Compensation (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RisksandLiquidityNarrativeDetails" roleURI="http://www.contexttherapeutics.com/role/RisksandLiquidityNarrativeDetails">
        <link:definition>0000021 - Disclosure - Risks and Liquidity - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails" roleURI="http://www.contexttherapeutics.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails">
        <link:definition>0000022 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasisofPresentationandSummaryofSignificantAccountingPoliciesScheduleofAntidilutiveSecuritiesExcludedfromComputationofEarningsPerShareDetails" roleURI="http://www.contexttherapeutics.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesScheduleofAntidilutiveSecuritiesExcludedfromComputationofEarningsPerShareDetails">
        <link:definition>0000023 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies - Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsScheduleofassetsandliabilitiesmeasuredatfairvalueonarecurringbasisDetails" roleURI="http://www.contexttherapeutics.com/role/FairValueMeasurementsScheduleofassetsandliabilitiesmeasuredatfairvalueonarecurringbasisDetails">
        <link:definition>0000024 - Disclosure - Fair Value Measurements - Schedule of assets and liabilities measured at fair value on a recurring basis (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccruedExpensesandOtherCurrentLiabilitiesDetails" roleURI="http://www.contexttherapeutics.com/role/AccruedExpensesandOtherCurrentLiabilitiesDetails">
        <link:definition>0000025 - Disclosure - Accrued Expenses and Other Current Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityNarrativeDetails" roleURI="http://www.contexttherapeutics.com/role/StockholdersEquityNarrativeDetails">
        <link:definition>0000026 - Disclosure - Stockholders' Equity - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityScheduleofWarrantsOutstandingDetails" roleURI="http://www.contexttherapeutics.com/role/StockholdersEquityScheduleofWarrantsOutstandingDetails">
        <link:definition>0000027 - Disclosure - Stockholders' Equity - Schedule of Warrants Outstanding (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedCompensationAdditionalInformationDetails" roleURI="http://www.contexttherapeutics.com/role/ShareBasedCompensationAdditionalInformationDetails">
        <link:definition>0000028 - Disclosure - Share-Based Compensation - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SharebasedCompensationScheduleofSharebasedCompensationExpenseDetails" roleURI="http://www.contexttherapeutics.com/role/SharebasedCompensationScheduleofSharebasedCompensationExpenseDetails">
        <link:definition>0000029 - Disclosure - Share-based Compensation - Schedule of Share-based Compensation Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedCompensationScheduleofAssumptionsUsedtoDetermineFairValueofShareBasedAwardsDetails" roleURI="http://www.contexttherapeutics.com/role/ShareBasedCompensationScheduleofAssumptionsUsedtoDetermineFairValueofShareBasedAwardsDetails">
        <link:definition>0000030 - Disclosure - Share-Based Compensation - Schedule of Assumptions Used to Determine Fair Value of Share-Based Awards (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedCompensationScheduleofShareBasedActivityDetails" roleURI="http://www.contexttherapeutics.com/role/ShareBasedCompensationScheduleofShareBasedActivityDetails">
        <link:definition>0000031 - Disclosure - Share-Based Compensation - Schedule of Share-Based Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentandContingenciesOperatingLeaseDetails" roleURI="http://www.contexttherapeutics.com/role/CommitmentandContingenciesOperatingLeaseDetails">
        <link:definition>0000032 - Disclosure - Commitment and Contingencies - Operating Lease (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentandContingenciesEmployeeBenefitPlansDetails" roleURI="http://www.contexttherapeutics.com/role/CommitmentandContingenciesEmployeeBenefitPlansDetails">
        <link:definition>0000033 - Disclosure - Commitment and Contingencies - Employee Benefit Plans (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentandContingenciesCollaborationAgreementsDetails" roleURI="http://www.contexttherapeutics.com/role/CommitmentandContingenciesCollaborationAgreementsDetails">
        <link:definition>0000034 - Disclosure - Commitment and Contingencies - Collaboration Agreements (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="cntx_IssuedForProfessionalConsultingServicesMember" abstract="true" name="IssuedForProfessionalConsultingServicesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cntx_CollaborativeArrangementRightsAndObligationsSalesMilestonePaymentsMaximum" abstract="false" name="CollaborativeArrangementRightsAndObligationsSalesMilestonePaymentsMaximum" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cntx_WarrantsIssued" abstract="false" name="WarrantsIssued" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cntx_CollaborativeArrangementRightsAndObligationsTieredRoyaltyPercent" abstract="false" name="CollaborativeArrangementRightsAndObligationsTieredRoyaltyPercent" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="cntx_AccruedResearchAndDevelopmentCostsCurrent" abstract="false" name="AccruedResearchAndDevelopmentCostsCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cntx_CollaborativeArrangementRightsAndObligationsQuarterlySalesPaymentsPercent" abstract="false" name="CollaborativeArrangementRightsAndObligationsQuarterlySalesPaymentsPercent" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="cntx_CollaborativeArrangementRightsAndObligationsDevelopmentAndRegulatoryMilestonePaymentsMaximum" abstract="false" name="CollaborativeArrangementRightsAndObligationsDevelopmentAndRegulatoryMilestonePaymentsMaximum" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cntx_ScaleUp100KilogramsOfGMPGradeCompoundMember" abstract="true" name="ScaleUp100KilogramsOfGMPGradeCompoundMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cntx_IssuedForServicesMember" abstract="true" name="IssuedForServicesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cntx_RisksAndLiquidityAbstract" abstract="true" name="RisksAndLiquidityAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="cntx_IssuedToPlacementAgentsMember" abstract="true" name="IssuedToPlacementAgentsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cntx_RisksAndLiquidityTextBlock" abstract="false" name="RisksAndLiquidityTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="cntx_IntegralMolecularIncMember" abstract="true" name="IntegralMolecularIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cntx_CollaborativeArrangementRightsAndObligationsSalesPaymentPeriod" abstract="false" name="CollaborativeArrangementRightsAndObligationsSalesPaymentPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="cntx_PatentCostsPolicyPolicyTextBlock" abstract="false" name="PatentCostsPolicyPolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="cntx_TyligandBioscienceShanghaiLimitedMember" abstract="true" name="TyligandBioscienceShanghaiLimitedMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cntx_December2021PrivatePlacementAgentWarrantsMember" abstract="true" name="December2021PrivatePlacementAgentWarrantsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cntx_ScaleUp300KilogramsOfGMPGradeCompoundMember" abstract="true" name="ScaleUp300KilogramsOfGMPGradeCompoundMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cntx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedAsAPercentageOfOutstandingStock" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedAsAPercentageOfOutstandingStock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="cntx_CollaborativeArrangementRightsAndObligationsMilestonePayment" abstract="false" name="CollaborativeArrangementRightsAndObligationsMilestonePayment" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>6
<FILENAME>cntx-20230331_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:25d0e2a1-022e-45ee-a4b8-2723f9a842c8,g:b681c287-491c-4187-8280-df3edb448dfa-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.contexttherapeutics.com/role/CondensedConsolidatedBalanceSheets" xlink:type="simple" xlink:href="cntx-20230331.xsd#CondensedConsolidatedBalanceSheets"/>
  <link:calculationLink xlink:role="http://www.contexttherapeutics.com/role/CondensedConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_fb6a2788-6204-4e3d-9b85-1876744d2735" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_d51daf4e-2c46-46f3-8fe6-de2c8255130a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_fb6a2788-6204-4e3d-9b85-1876744d2735" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_d51daf4e-2c46-46f3-8fe6-de2c8255130a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_e2e2d326-b453-46f4-84a7-0d7bed4f6cab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_fb6a2788-6204-4e3d-9b85-1876744d2735" xlink:to="loc_us-gaap_AssetsCurrent_e2e2d326-b453-46f4-84a7-0d7bed4f6cab" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_bb337fc2-c37c-49a9-8a23-67d63e60271b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_fb6a2788-6204-4e3d-9b85-1876744d2735" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_bb337fc2-c37c-49a9-8a23-67d63e60271b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_851d4185-f36a-441f-9704-e7921b9abafe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_fb6a2788-6204-4e3d-9b85-1876744d2735" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_851d4185-f36a-441f-9704-e7921b9abafe" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_fa27ff02-ab69-4bbf-8ca1-81310491c353" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_eba42108-8c0c-4091-9fbf-c8e45e11e84f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_fa27ff02-ab69-4bbf-8ca1-81310491c353" xlink:to="loc_us-gaap_LiabilitiesCurrent_eba42108-8c0c-4091-9fbf-c8e45e11e84f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_c0cbe26d-e6f5-46ac-a0b5-04a04b8f8cea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_3577c586-06be-4743-a0cc-7431268fdeb8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_c0cbe26d-e6f5-46ac-a0b5-04a04b8f8cea" xlink:to="loc_us-gaap_Liabilities_3577c586-06be-4743-a0cc-7431268fdeb8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_8d1ef287-9313-411a-aa2f-3faadbfee1b3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_c0cbe26d-e6f5-46ac-a0b5-04a04b8f8cea" xlink:to="loc_us-gaap_CommitmentsAndContingencies_8d1ef287-9313-411a-aa2f-3faadbfee1b3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_d4de3fba-e815-4b19-8fac-7e5df5f2bbdd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_c0cbe26d-e6f5-46ac-a0b5-04a04b8f8cea" xlink:to="loc_us-gaap_StockholdersEquity_d4de3fba-e815-4b19-8fac-7e5df5f2bbdd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_0d8914d2-5aac-429e-a300-61b98823951c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_59584cfc-8be5-44e6-9348-f2db5da5eaca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_0d8914d2-5aac-429e-a300-61b98823951c" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_59584cfc-8be5-44e6-9348-f2db5da5eaca" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_0de3d0f1-b562-4137-b572-c407adf653d5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_0d8914d2-5aac-429e-a300-61b98823951c" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_0de3d0f1-b562-4137-b572-c407adf653d5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_88c7d95c-d3b1-481a-aa24-cdabd78f9fac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_0d8914d2-5aac-429e-a300-61b98823951c" xlink:to="loc_us-gaap_AccountsPayableCurrent_88c7d95c-d3b1-481a-aa24-cdabd78f9fac" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_fa959c73-7afd-4111-b51c-4f3459bfd609" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_6ae04aac-4db3-4fb0-a01d-c4982b738580" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_fa959c73-7afd-4111-b51c-4f3459bfd609" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_6ae04aac-4db3-4fb0-a01d-c4982b738580" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_9064769f-2946-4eb7-98ff-5fa8757bf3e7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_fa959c73-7afd-4111-b51c-4f3459bfd609" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_9064769f-2946-4eb7-98ff-5fa8757bf3e7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_d8e85c9b-1093-4761-8a4c-1b5fe41cdf47" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_3e3f54c3-f662-4fec-8d53-99ce6f4d4401" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_d8e85c9b-1093-4761-8a4c-1b5fe41cdf47" xlink:to="loc_us-gaap_PreferredStockValue_3e3f54c3-f662-4fec-8d53-99ce6f4d4401" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_b0ccfc29-4c73-449c-9ebc-8fa86b37e860" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_d8e85c9b-1093-4761-8a4c-1b5fe41cdf47" xlink:to="loc_us-gaap_AdditionalPaidInCapital_b0ccfc29-4c73-449c-9ebc-8fa86b37e860" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_070f9b02-30d5-45dc-a21d-f407e73dbafa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_d8e85c9b-1093-4761-8a4c-1b5fe41cdf47" xlink:to="loc_us-gaap_CommonStockValue_070f9b02-30d5-45dc-a21d-f407e73dbafa" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_c58eea71-ba6a-4632-b10b-55acf37f5140" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_d8e85c9b-1093-4761-8a4c-1b5fe41cdf47" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_c58eea71-ba6a-4632-b10b-55acf37f5140" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.contexttherapeutics.com/role/CondensedConsolidatedStatementsofOperationsUnaudited" xlink:type="simple" xlink:href="cntx-20230331.xsd#CondensedConsolidatedStatementsofOperationsUnaudited"/>
  <link:calculationLink xlink:role="http://www.contexttherapeutics.com/role/CondensedConsolidatedStatementsofOperationsUnaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_ac5c867b-c3a4-49d4-ae1e-9b204f0f996a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_e20440fa-2385-4710-8c48-cd376206e1ff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_ac5c867b-c3a4-49d4-ae1e-9b204f0f996a" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_e20440fa-2385-4710-8c48-cd376206e1ff" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_8622e084-1a66-4a5a-beb5-ca517a2edc81" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_ac5c867b-c3a4-49d4-ae1e-9b204f0f996a" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_8622e084-1a66-4a5a-beb5-ca517a2edc81" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_8c58111f-9ddd-4d37-b42a-97cc6c81de45" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_2ca0b436-1c9d-476b-9ae2-8a803a96b069" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_8c58111f-9ddd-4d37-b42a-97cc6c81de45" xlink:to="loc_us-gaap_OperatingIncomeLoss_2ca0b436-1c9d-476b-9ae2-8a803a96b069" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeExpenseNet_1665530c-e3c6-44d0-b370-eda5f12bec61" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestIncomeExpenseNet"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_8c58111f-9ddd-4d37-b42a-97cc6c81de45" xlink:to="loc_us-gaap_InterestIncomeExpenseNet_1665530c-e3c6-44d0-b370-eda5f12bec61" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_0a080813-8172-4995-a2b6-bedda8286732" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_8c58111f-9ddd-4d37-b42a-97cc6c81de45" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_0a080813-8172-4995-a2b6-bedda8286732" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.contexttherapeutics.com/role/CondensedConsolidatedStatementofCashFlowsUnaudited" xlink:type="simple" xlink:href="cntx-20230331.xsd#CondensedConsolidatedStatementofCashFlowsUnaudited"/>
  <link:calculationLink xlink:role="http://www.contexttherapeutics.com/role/CondensedConsolidatedStatementofCashFlowsUnaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_5d34ab92-96c7-4892-85c9-86120dd0881b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_8af93146-bcb7-43c9-a11e-b100a362ee91" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_5d34ab92-96c7-4892-85c9-86120dd0881b" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_8af93146-bcb7-43c9-a11e-b100a362ee91" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_2fa39e03-bb48-4607-a991-3ab31a24b90b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_0a2f8a78-a88d-429d-a669-82de7557cf4e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_2fa39e03-bb48-4607-a991-3ab31a24b90b" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_0a2f8a78-a88d-429d-a669-82de7557cf4e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_eb127543-4bb3-41c8-a947-ef3c4daee1bc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_d6ea9c3b-5af8-4759-919e-246c1c6d1784" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_eb127543-4bb3-41c8-a947-ef3c4daee1bc" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_d6ea9c3b-5af8-4759-919e-246c1c6d1784" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_1959eb1c-b8e6-4bc8-9a0f-365bbda468b3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_eb127543-4bb3-41c8-a947-ef3c4daee1bc" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_1959eb1c-b8e6-4bc8-9a0f-365bbda468b3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_e3b83701-1f1a-45bd-aabe-7e7bb15c908b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_eb127543-4bb3-41c8-a947-ef3c4daee1bc" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_e3b83701-1f1a-45bd-aabe-7e7bb15c908b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_54197a99-e7ff-4056-a9cf-f5a6a8125d1c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_eb127543-4bb3-41c8-a947-ef3c4daee1bc" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_54197a99-e7ff-4056-a9cf-f5a6a8125d1c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_509f065c-fc6a-49c6-8f5a-741a461c4422" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_eb127543-4bb3-41c8-a947-ef3c4daee1bc" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_509f065c-fc6a-49c6-8f5a-741a461c4422" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_df1b6bbe-6ce3-4bed-8e09-a74ec94fd745" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_eb127543-4bb3-41c8-a947-ef3c4daee1bc" xlink:to="loc_us-gaap_ShareBasedCompensation_df1b6bbe-6ce3-4bed-8e09-a74ec94fd745" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_c17d4d18-e16f-4fc4-9fa1-4681d8456ee2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_eb127543-4bb3-41c8-a947-ef3c4daee1bc" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_c17d4d18-e16f-4fc4-9fa1-4681d8456ee2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_c113ebb0-495e-4724-a1d8-3419b1d3ff76" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_eb127543-4bb3-41c8-a947-ef3c4daee1bc" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_c113ebb0-495e-4724-a1d8-3419b1d3ff76" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_3370dab7-73d5-410e-81ff-24fc9dd65938" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_eb127543-4bb3-41c8-a947-ef3c4daee1bc" xlink:to="loc_us-gaap_NetIncomeLoss_3370dab7-73d5-410e-81ff-24fc9dd65938" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_f8eb6434-c63a-4ed9-aefd-8caf1993ac78" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_b8851b07-86d3-4daa-81bc-569c6e1e7b75" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_f8eb6434-c63a-4ed9-aefd-8caf1993ac78" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_b8851b07-86d3-4daa-81bc-569c6e1e7b75" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_ded35e83-722b-4c3e-977c-b22c4d7993c4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_f8eb6434-c63a-4ed9-aefd-8caf1993ac78" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_ded35e83-722b-4c3e-977c-b22c4d7993c4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_fa61885f-a241-4af2-b7cc-dd4084dae45f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_f8eb6434-c63a-4ed9-aefd-8caf1993ac78" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_fa61885f-a241-4af2-b7cc-dd4084dae45f" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.contexttherapeutics.com/role/AccruedExpensesandOtherCurrentLiabilitiesDetails" xlink:type="simple" xlink:href="cntx-20230331.xsd#AccruedExpensesandOtherCurrentLiabilitiesDetails"/>
  <link:calculationLink xlink:role="http://www.contexttherapeutics.com/role/AccruedExpensesandOtherCurrentLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_d325ed2f-cc26-4087-aeae-d1e5108b8393" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_cntx_AccruedResearchAndDevelopmentCostsCurrent_b8615877-cabf-438f-9ef8-5a22d108fd92" xlink:href="cntx-20230331.xsd#cntx_AccruedResearchAndDevelopmentCostsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_d325ed2f-cc26-4087-aeae-d1e5108b8393" xlink:to="loc_cntx_AccruedResearchAndDevelopmentCostsCurrent_b8615877-cabf-438f-9ef8-5a22d108fd92" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_d9f80538-db51-425a-b989-e6bb42884f30" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_d325ed2f-cc26-4087-aeae-d1e5108b8393" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_d9f80538-db51-425a-b989-e6bb42884f30" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_00b9d4b5-045c-49b6-87a3-3272a11b2eb7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_d325ed2f-cc26-4087-aeae-d1e5108b8393" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_00b9d4b5-045c-49b6-87a3-3272a11b2eb7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent_ec9192f2-920c-4f8f-9c17-c56b269171ae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_d325ed2f-cc26-4087-aeae-d1e5108b8393" xlink:to="loc_us-gaap_AccruedProfessionalFeesCurrent_ec9192f2-920c-4f8f-9c17-c56b269171ae" xlink:type="arc"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>7
<FILENAME>cntx-20230331_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:25d0e2a1-022e-45ee-a4b8-2723f9a842c8,g:b681c287-491c-4187-8280-df3edb448dfa-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://www.contexttherapeutics.com/role/CondensedConsolidatedStatementsofChangesinStockholdersEquityUnaudited" xlink:type="simple" xlink:href="cntx-20230331.xsd#CondensedConsolidatedStatementsofChangesinStockholdersEquityUnaudited"/>
  <link:definitionLink xlink:role="http://www.contexttherapeutics.com/role/CondensedConsolidatedStatementsofChangesinStockholdersEquityUnaudited" xlink:type="extended" id="i0b498c8697dd4e909da0f47a1b2a5442_CondensedConsolidatedStatementsofChangesinStockholdersEquityUnaudited">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_1b60edcb-8343-4b26-8434-033566d99df0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2ae377b6-c93f-489d-9990-27bb7959b565" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1b60edcb-8343-4b26-8434-033566d99df0" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2ae377b6-c93f-489d-9990-27bb7959b565" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_f5460829-8975-4f0a-a279-c89b39879538" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2ae377b6-c93f-489d-9990-27bb7959b565" xlink:to="loc_us-gaap_SharesOutstanding_f5460829-8975-4f0a-a279-c89b39879538" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_90d6007d-339b-4585-9db9-2e4797da298c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2ae377b6-c93f-489d-9990-27bb7959b565" xlink:to="loc_us-gaap_StockholdersEquity_90d6007d-339b-4585-9db9-2e4797da298c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_eafb1765-17ee-4adb-9e26-c5543c9b3c2b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2ae377b6-c93f-489d-9990-27bb7959b565" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_eafb1765-17ee-4adb-9e26-c5543c9b3c2b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_12b5964e-00df-473f-b823-9d4d5fc469cc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2ae377b6-c93f-489d-9990-27bb7959b565" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_12b5964e-00df-473f-b823-9d4d5fc469cc" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_37982575-782e-4b99-9e12-45ce93400127" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2ae377b6-c93f-489d-9990-27bb7959b565" xlink:to="loc_us-gaap_NetIncomeLoss_37982575-782e-4b99-9e12-45ce93400127" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_291f7521-b216-4aa1-9117-fccf0cefadac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_d3320d32-5849-4756-8c73-78457c7a26b4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_2b6082cf-1288-4b01-83f4-f430683b437a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_1b60edcb-8343-4b26-8434-033566d99df0" xlink:to="loc_us-gaap_StatementTable_2b6082cf-1288-4b01-83f4-f430683b437a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_6a40173b-9e3d-48e4-95ec-c69232380aa8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_2b6082cf-1288-4b01-83f4-f430683b437a" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_6a40173b-9e3d-48e4-95ec-c69232380aa8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_6a40173b-9e3d-48e4-95ec-c69232380aa8_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_6a40173b-9e3d-48e4-95ec-c69232380aa8" xlink:to="loc_us-gaap_EquityComponentDomain_6a40173b-9e3d-48e4-95ec-c69232380aa8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_645a339b-7d98-4945-990d-98f24e72bc06" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_6a40173b-9e3d-48e4-95ec-c69232380aa8" xlink:to="loc_us-gaap_EquityComponentDomain_645a339b-7d98-4945-990d-98f24e72bc06" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_4f04df71-4112-4ff5-9ead-4350b474d8f2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_645a339b-7d98-4945-990d-98f24e72bc06" xlink:to="loc_us-gaap_CommonStockMember_4f04df71-4112-4ff5-9ead-4350b474d8f2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_a17f4dd1-163e-4af0-9a46-0e45cbf27864" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_645a339b-7d98-4945-990d-98f24e72bc06" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_a17f4dd1-163e-4af0-9a46-0e45cbf27864" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_2122a353-eef3-4d3b-b22d-dcd52546f9df" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_645a339b-7d98-4945-990d-98f24e72bc06" xlink:to="loc_us-gaap_RetainedEarningsMember_2122a353-eef3-4d3b-b22d-dcd52546f9df" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.contexttherapeutics.com/role/CondensedConsolidatedStatementofCashFlowsUnaudited" xlink:type="simple" xlink:href="cntx-20230331.xsd#CondensedConsolidatedStatementofCashFlowsUnaudited"/>
  <link:definitionLink xlink:role="http://www.contexttherapeutics.com/role/CondensedConsolidatedStatementofCashFlowsUnaudited" xlink:type="extended" id="i27e98729e9ad4e8d910df510b88421ef_CondensedConsolidatedStatementofCashFlowsUnaudited">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_7df31fe0-0ca7-4ec5-96ed-f5b1e39244c9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_cbd1358a-b482-4c09-a37b-17a7f26ac4a0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_7df31fe0-0ca7-4ec5-96ed-f5b1e39244c9" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_cbd1358a-b482-4c09-a37b-17a7f26ac4a0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_76fd16e2-4cbb-454f-b1dc-49c5adabe999" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_cbd1358a-b482-4c09-a37b-17a7f26ac4a0" xlink:to="loc_us-gaap_NetIncomeLoss_76fd16e2-4cbb-454f-b1dc-49c5adabe999" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_9c231c78-684b-4d5d-8d70-fe1218437f49" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_cbd1358a-b482-4c09-a37b-17a7f26ac4a0" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_9c231c78-684b-4d5d-8d70-fe1218437f49" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_654d117b-4be4-40bf-84fb-dc0e10556fde" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_9c231c78-684b-4d5d-8d70-fe1218437f49" xlink:to="loc_us-gaap_ShareBasedCompensation_654d117b-4be4-40bf-84fb-dc0e10556fde" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_9b041195-fb3a-4d4f-94a8-c91a5e515fb0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_9c231c78-684b-4d5d-8d70-fe1218437f49" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_9b041195-fb3a-4d4f-94a8-c91a5e515fb0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_746d78ce-fc90-41fe-98e7-cc7b7d31f602" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_9c231c78-684b-4d5d-8d70-fe1218437f49" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_746d78ce-fc90-41fe-98e7-cc7b7d31f602" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_89f1bf4a-9e7f-4214-9d5e-35097107d0ae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_9c231c78-684b-4d5d-8d70-fe1218437f49" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_89f1bf4a-9e7f-4214-9d5e-35097107d0ae" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_2f1a0519-5b20-4a18-9eca-d8f414a5c2c4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_89f1bf4a-9e7f-4214-9d5e-35097107d0ae" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_2f1a0519-5b20-4a18-9eca-d8f414a5c2c4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_5233180c-dbeb-4a1f-9047-9953ce8461cb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_89f1bf4a-9e7f-4214-9d5e-35097107d0ae" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_5233180c-dbeb-4a1f-9047-9953ce8461cb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_a46ae595-af45-486d-a66c-1617d1ce426b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_89f1bf4a-9e7f-4214-9d5e-35097107d0ae" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_a46ae595-af45-486d-a66c-1617d1ce426b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_d656d5c1-7602-4731-862f-53b950fd24b4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_89f1bf4a-9e7f-4214-9d5e-35097107d0ae" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_d656d5c1-7602-4731-862f-53b950fd24b4" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_b5f5de2e-9d6b-4a00-85fe-1ae6b63c2eb9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_89f1bf4a-9e7f-4214-9d5e-35097107d0ae" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_b5f5de2e-9d6b-4a00-85fe-1ae6b63c2eb9" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ca97b130-b43a-45e9-ae67-78e61b7ce93a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_cbd1358a-b482-4c09-a37b-17a7f26ac4a0" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ca97b130-b43a-45e9-ae67-78e61b7ce93a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_873174f6-c978-4a3c-891a-bddafa77b2fa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_7df31fe0-0ca7-4ec5-96ed-f5b1e39244c9" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_873174f6-c978-4a3c-891a-bddafa77b2fa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_23777791-d1c4-4ed0-ba92-8ba0206627c2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_873174f6-c978-4a3c-891a-bddafa77b2fa" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_23777791-d1c4-4ed0-ba92-8ba0206627c2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_fb7d9f21-cc8c-484c-8898-40f60c7b3911" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_873174f6-c978-4a3c-891a-bddafa77b2fa" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_fb7d9f21-cc8c-484c-8898-40f60c7b3911" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_e7a503c5-fff1-44d5-9519-5978a9e5c5de" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_7df31fe0-0ca7-4ec5-96ed-f5b1e39244c9" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_e7a503c5-fff1-44d5-9519-5978a9e5c5de" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_d972b4bf-37b6-4917-bdc1-cbeb86c940c0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_e7a503c5-fff1-44d5-9519-5978a9e5c5de" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_d972b4bf-37b6-4917-bdc1-cbeb86c940c0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_c41c7c7f-a7d6-49a7-85d0-204c0a08aaf6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_e7a503c5-fff1-44d5-9519-5978a9e5c5de" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_c41c7c7f-a7d6-49a7-85d0-204c0a08aaf6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_43fb8531-e639-482d-94b6-ceabb044d943" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_7df31fe0-0ca7-4ec5-96ed-f5b1e39244c9" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_43fb8531-e639-482d-94b6-ceabb044d943" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_4750824c-197e-4967-a244-dd888b19f6f5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_7df31fe0-0ca7-4ec5-96ed-f5b1e39244c9" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_4750824c-197e-4967-a244-dd888b19f6f5" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_4dbdbc93-4e5a-4bc3-b9fc-3332bbf22448" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowElementsAbstract_09347084-0d80-4a61-bb9e-0a239ddc64ab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalCashFlowElementsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_7df31fe0-0ca7-4ec5-96ed-f5b1e39244c9" xlink:to="loc_us-gaap_SupplementalCashFlowElementsAbstract_09347084-0d80-4a61-bb9e-0a239ddc64ab" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_cntx_WarrantsIssued_25e85e44-1139-49b0-a70f-6f91e5aac7d4" xlink:href="cntx-20230331.xsd#cntx_WarrantsIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SupplementalCashFlowElementsAbstract_09347084-0d80-4a61-bb9e-0a239ddc64ab" xlink:to="loc_cntx_WarrantsIssued_25e85e44-1139-49b0-a70f-6f91e5aac7d4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_a7235ff1-896c-4ec5-bea4-c925b3170292" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SupplementalCashFlowElementsAbstract_09347084-0d80-4a61-bb9e-0a239ddc64ab" xlink:to="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_a7235ff1-896c-4ec5-bea4-c925b3170292" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_9c74c0b3-0aad-4a46-bb25-1e74637004d9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_7df31fe0-0ca7-4ec5-96ed-f5b1e39244c9" xlink:to="loc_us-gaap_StatementTable_9c74c0b3-0aad-4a46-bb25-1e74637004d9" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_618758df-705f-49b5-9be8-4cda327bf059" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_9c74c0b3-0aad-4a46-bb25-1e74637004d9" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_618758df-705f-49b5-9be8-4cda327bf059" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_618758df-705f-49b5-9be8-4cda327bf059_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_618758df-705f-49b5-9be8-4cda327bf059" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_618758df-705f-49b5-9be8-4cda327bf059_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_368c93fb-60fd-4b71-8dbd-d026531c1836" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_618758df-705f-49b5-9be8-4cda327bf059" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_368c93fb-60fd-4b71-8dbd-d026531c1836" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cntx_IssuedForServicesMember_1bd3d01b-52a7-4fed-901b-2c5652a7e2e1" xlink:href="cntx-20230331.xsd#cntx_IssuedForServicesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_368c93fb-60fd-4b71-8dbd-d026531c1836" xlink:to="loc_cntx_IssuedForServicesMember_1bd3d01b-52a7-4fed-901b-2c5652a7e2e1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_c88cf3f9-d952-4fea-9767-09cede069bde" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_9c74c0b3-0aad-4a46-bb25-1e74637004d9" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_c88cf3f9-d952-4fea-9767-09cede069bde" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_c88cf3f9-d952-4fea-9767-09cede069bde_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_c88cf3f9-d952-4fea-9767-09cede069bde" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_c88cf3f9-d952-4fea-9767-09cede069bde_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_754d9f72-cad0-4cb8-9ef9-94e6bf4eb237" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_c88cf3f9-d952-4fea-9767-09cede069bde" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_754d9f72-cad0-4cb8-9ef9-94e6bf4eb237" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrivatePlacementMember_9808b80c-8f3e-4f07-b066-50049c371d18" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrivatePlacementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_754d9f72-cad0-4cb8-9ef9-94e6bf4eb237" xlink:to="loc_us-gaap_PrivatePlacementMember_9808b80c-8f3e-4f07-b066-50049c371d18" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.contexttherapeutics.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesScheduleofAntidilutiveSecuritiesExcludedfromComputationofEarningsPerShareDetails" xlink:type="simple" xlink:href="cntx-20230331.xsd#BasisofPresentationandSummaryofSignificantAccountingPoliciesScheduleofAntidilutiveSecuritiesExcludedfromComputationofEarningsPerShareDetails"/>
  <link:definitionLink xlink:role="http://www.contexttherapeutics.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesScheduleofAntidilutiveSecuritiesExcludedfromComputationofEarningsPerShareDetails" xlink:type="extended" id="i77a4c83abf6c457892984e5d08e6a262_BasisofPresentationandSummaryofSignificantAccountingPoliciesScheduleofAntidilutiveSecuritiesExcludedfromComputationofEarningsPerShareDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_ba5fa8bd-31e8-4bf3-8db9-cc1a7f0ef06f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_8d69ed6f-e996-418d-9f43-ad2a5e1f6fbe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_ba5fa8bd-31e8-4bf3-8db9-cc1a7f0ef06f" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_8d69ed6f-e996-418d-9f43-ad2a5e1f6fbe" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_56b9bfa4-27e8-4145-a9ef-020de88fbbeb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_ba5fa8bd-31e8-4bf3-8db9-cc1a7f0ef06f" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_56b9bfa4-27e8-4145-a9ef-020de88fbbeb" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_9b68a9ab-f811-4137-a4ae-970e6ba4d758" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_56b9bfa4-27e8-4145-a9ef-020de88fbbeb" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_9b68a9ab-f811-4137-a4ae-970e6ba4d758" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_9b68a9ab-f811-4137-a4ae-970e6ba4d758_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_9b68a9ab-f811-4137-a4ae-970e6ba4d758" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_9b68a9ab-f811-4137-a4ae-970e6ba4d758_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_c3e69ead-3fbd-4aea-8234-83455c538181" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_9b68a9ab-f811-4137-a4ae-970e6ba4d758" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_c3e69ead-3fbd-4aea-8234-83455c538181" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_6bcaa7d8-0512-45d3-b5ca-28118e520150" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_c3e69ead-3fbd-4aea-8234-83455c538181" xlink:to="loc_us-gaap_EmployeeStockOptionMember_6bcaa7d8-0512-45d3-b5ca-28118e520150" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_b3d0bf1f-8019-47c6-8e0d-f00cff4ae25b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_c3e69ead-3fbd-4aea-8234-83455c538181" xlink:to="loc_us-gaap_WarrantMember_b3d0bf1f-8019-47c6-8e0d-f00cff4ae25b" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.contexttherapeutics.com/role/FairValueMeasurementsScheduleofassetsandliabilitiesmeasuredatfairvalueonarecurringbasisDetails" xlink:type="simple" xlink:href="cntx-20230331.xsd#FairValueMeasurementsScheduleofassetsandliabilitiesmeasuredatfairvalueonarecurringbasisDetails"/>
  <link:definitionLink xlink:role="http://www.contexttherapeutics.com/role/FairValueMeasurementsScheduleofassetsandliabilitiesmeasuredatfairvalueonarecurringbasisDetails" xlink:type="extended" id="iec807af52df54a34bb224a90810f785b_FairValueMeasurementsScheduleofassetsandliabilitiesmeasuredatfairvalueonarecurringbasisDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_9081df33-7f4c-45db-b72d-9d19be029239" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract_85dbc12b-1699-407a-9fc2-8c6ec7d54bf0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_9081df33-7f4c-45db-b72d-9d19be029239" xlink:to="loc_us-gaap_AssetsFairValueDisclosureAbstract_85dbc12b-1699-407a-9fc2-8c6ec7d54bf0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_31107681-5bb9-42e3-83a3-5f1cbb669962" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_85dbc12b-1699-407a-9fc2-8c6ec7d54bf0" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_31107681-5bb9-42e3-83a3-5f1cbb669962" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_807d1e0c-d86a-4463-ae36-3e635da76a9d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_9081df33-7f4c-45db-b72d-9d19be029239" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_807d1e0c-d86a-4463-ae36-3e635da76a9d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_4feacef1-62e6-4141-8d44-f37e43443226" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_807d1e0c-d86a-4463-ae36-3e635da76a9d" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_4feacef1-62e6-4141-8d44-f37e43443226" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_4feacef1-62e6-4141-8d44-f37e43443226_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_4feacef1-62e6-4141-8d44-f37e43443226" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_4feacef1-62e6-4141-8d44-f37e43443226_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_5f8971b6-fa3a-4602-8b1f-1ef129528c8f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_4feacef1-62e6-4141-8d44-f37e43443226" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_5f8971b6-fa3a-4602-8b1f-1ef129528c8f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_a512699c-6701-4e13-a7dc-0d33a3b3abe7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_5f8971b6-fa3a-4602-8b1f-1ef129528c8f" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_a512699c-6701-4e13-a7dc-0d33a3b3abe7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAxis_f87ea966-de58-43f8-bc0f-3ba2272c032f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_807d1e0c-d86a-4463-ae36-3e635da76a9d" xlink:to="loc_us-gaap_CashAndCashEquivalentsAxis_f87ea966-de58-43f8-bc0f-3ba2272c032f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_f87ea966-de58-43f8-bc0f-3ba2272c032f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_f87ea966-de58-43f8-bc0f-3ba2272c032f" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_f87ea966-de58-43f8-bc0f-3ba2272c032f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_ad192453-e91e-401b-b160-013c19a851ba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_f87ea966-de58-43f8-bc0f-3ba2272c032f" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_ad192453-e91e-401b-b160-013c19a851ba" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_be0de5d7-c2c0-4696-8d6a-e886f56684b9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_ad192453-e91e-401b-b160-013c19a851ba" xlink:to="loc_us-gaap_MoneyMarketFundsMember_be0de5d7-c2c0-4696-8d6a-e886f56684b9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_0a72ab1a-bf5f-4c07-89a7-579891639283" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_807d1e0c-d86a-4463-ae36-3e635da76a9d" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_0a72ab1a-bf5f-4c07-89a7-579891639283" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_0a72ab1a-bf5f-4c07-89a7-579891639283_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_0a72ab1a-bf5f-4c07-89a7-579891639283" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_0a72ab1a-bf5f-4c07-89a7-579891639283_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_df3df4a5-61d1-46c7-8b8f-11939e892eee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_0a72ab1a-bf5f-4c07-89a7-579891639283" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_df3df4a5-61d1-46c7-8b8f-11939e892eee" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_48d9513e-4cd7-42b7-a4f6-26392391cb6c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_df3df4a5-61d1-46c7-8b8f-11939e892eee" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_48d9513e-4cd7-42b7-a4f6-26392391cb6c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_fe0f8af5-31e6-47ac-993c-b3c7bf3261bc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_df3df4a5-61d1-46c7-8b8f-11939e892eee" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_fe0f8af5-31e6-47ac-993c-b3c7bf3261bc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_cd6493c6-7436-47b0-89f9-8fd5fe8fc754" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_df3df4a5-61d1-46c7-8b8f-11939e892eee" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_cd6493c6-7436-47b0-89f9-8fd5fe8fc754" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.contexttherapeutics.com/role/StockholdersEquityNarrativeDetails" xlink:type="simple" xlink:href="cntx-20230331.xsd#StockholdersEquityNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.contexttherapeutics.com/role/StockholdersEquityNarrativeDetails" xlink:type="extended" id="i6e99b005f3ca45709a439796043074b4_StockholdersEquityNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightLineItems_d5a2cc6b-78af-4c0b-9206-2615c08cdd97" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_d2bd5d1c-4e0a-45cb-aa28-943d5ea6523b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_d5a2cc6b-78af-4c0b-9206-2615c08cdd97" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_d2bd5d1c-4e0a-45cb-aa28-943d5ea6523b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_18735b2a-9a3b-4ccf-aec7-b13521484ce9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_d5a2cc6b-78af-4c0b-9206-2615c08cdd97" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_18735b2a-9a3b-4ccf-aec7-b13521484ce9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingTerm_f2d47658-6733-40dd-ae54-02076d9adae5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantsAndRightsOutstandingTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_d5a2cc6b-78af-4c0b-9206-2615c08cdd97" xlink:to="loc_us-gaap_WarrantsAndRightsOutstandingTerm_f2d47658-6733-40dd-ae54-02076d9adae5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAdjustmentOfWarrants_62406061-f498-48ac-9df1-f61b45a9bc51" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAdjustmentOfWarrants"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_d5a2cc6b-78af-4c0b-9206-2615c08cdd97" xlink:to="loc_us-gaap_FairValueAdjustmentOfWarrants_62406061-f498-48ac-9df1-f61b45a9bc51" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightTable_fa3eb0b9-ce6c-48bb-96ad-2f1fae1e16bc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_d5a2cc6b-78af-4c0b-9206-2615c08cdd97" xlink:to="loc_us-gaap_ClassOfWarrantOrRightTable_fa3eb0b9-ce6c-48bb-96ad-2f1fae1e16bc" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_926e21c9-3d82-4fdc-befe-66a4271a9aaa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_fa3eb0b9-ce6c-48bb-96ad-2f1fae1e16bc" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_926e21c9-3d82-4fdc-befe-66a4271a9aaa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_926e21c9-3d82-4fdc-befe-66a4271a9aaa_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_926e21c9-3d82-4fdc-befe-66a4271a9aaa" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_926e21c9-3d82-4fdc-befe-66a4271a9aaa_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_8a07fd9d-f63d-489f-b9a6-241db22b6ef3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_926e21c9-3d82-4fdc-befe-66a4271a9aaa" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_8a07fd9d-f63d-489f-b9a6-241db22b6ef3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cntx_IssuedForProfessionalConsultingServicesMember_fb01f542-8e0f-4381-83b5-e9487bb9b275" xlink:href="cntx-20230331.xsd#cntx_IssuedForProfessionalConsultingServicesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_8a07fd9d-f63d-489f-b9a6-241db22b6ef3" xlink:to="loc_cntx_IssuedForProfessionalConsultingServicesMember_fb01f542-8e0f-4381-83b5-e9487bb9b275" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.contexttherapeutics.com/role/StockholdersEquityScheduleofWarrantsOutstandingDetails" xlink:type="simple" xlink:href="cntx-20230331.xsd#StockholdersEquityScheduleofWarrantsOutstandingDetails"/>
  <link:definitionLink xlink:role="http://www.contexttherapeutics.com/role/StockholdersEquityScheduleofWarrantsOutstandingDetails" xlink:type="extended" id="icef07795184e4f97b37cb6860e5f538a_StockholdersEquityScheduleofWarrantsOutstandingDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightLineItems_cec57d9b-9429-4e75-bc73-3839eabc2acf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_de616651-bfe5-4aa6-b350-4d7fa19f1fc9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_cec57d9b-9429-4e75-bc73-3839eabc2acf" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_de616651-bfe5-4aa6-b350-4d7fa19f1fc9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_a6c47959-d798-481d-950e-addc3be35fc6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_cec57d9b-9429-4e75-bc73-3839eabc2acf" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_a6c47959-d798-481d-950e-addc3be35fc6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightTable_1d7671b9-f37c-408c-8288-4aa42dd5d8fa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_cec57d9b-9429-4e75-bc73-3839eabc2acf" xlink:to="loc_us-gaap_ClassOfWarrantOrRightTable_1d7671b9-f37c-408c-8288-4aa42dd5d8fa" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_e3c96551-1b3a-4123-8f17-82109bfd7c89" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_1d7671b9-f37c-408c-8288-4aa42dd5d8fa" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_e3c96551-1b3a-4123-8f17-82109bfd7c89" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_e3c96551-1b3a-4123-8f17-82109bfd7c89_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_e3c96551-1b3a-4123-8f17-82109bfd7c89" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_e3c96551-1b3a-4123-8f17-82109bfd7c89_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_3201483b-839a-4fa2-abdb-c2943f78b1b4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_e3c96551-1b3a-4123-8f17-82109bfd7c89" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_3201483b-839a-4fa2-abdb-c2943f78b1b4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cntx_IssuedToPlacementAgentsMember_0a0418e6-bc59-458a-83d9-1888ab1bc5b1" xlink:href="cntx-20230331.xsd#cntx_IssuedToPlacementAgentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_3201483b-839a-4fa2-abdb-c2943f78b1b4" xlink:to="loc_cntx_IssuedToPlacementAgentsMember_0a0418e6-bc59-458a-83d9-1888ab1bc5b1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cntx_December2021PrivatePlacementAgentWarrantsMember_8b6f877c-33af-48d2-a3b7-d49033bcf61f" xlink:href="cntx-20230331.xsd#cntx_December2021PrivatePlacementAgentWarrantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_3201483b-839a-4fa2-abdb-c2943f78b1b4" xlink:to="loc_cntx_December2021PrivatePlacementAgentWarrantsMember_8b6f877c-33af-48d2-a3b7-d49033bcf61f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cntx_IssuedForProfessionalConsultingServicesMember_bb5bffde-46f3-4552-83af-fd5bf5fdef43" xlink:href="cntx-20230331.xsd#cntx_IssuedForProfessionalConsultingServicesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_3201483b-839a-4fa2-abdb-c2943f78b1b4" xlink:to="loc_cntx_IssuedForProfessionalConsultingServicesMember_bb5bffde-46f3-4552-83af-fd5bf5fdef43" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.contexttherapeutics.com/role/ShareBasedCompensationAdditionalInformationDetails" xlink:type="simple" xlink:href="cntx-20230331.xsd#ShareBasedCompensationAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.contexttherapeutics.com/role/ShareBasedCompensationAdditionalInformationDetails" xlink:type="extended" id="i6f3a4805b0044449a94b82f9a23f1e02_ShareBasedCompensationAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3629a71e-46f2-45ef-a2fa-1a3debc213f9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_947f10fd-46af-4f4f-afac-893f46c0da72" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3629a71e-46f2-45ef-a2fa-1a3debc213f9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_947f10fd-46af-4f4f-afac-893f46c0da72" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cntx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedAsAPercentageOfOutstandingStock_0a5fc451-4e87-49e4-a848-5af27a613861" xlink:href="cntx-20230331.xsd#cntx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedAsAPercentageOfOutstandingStock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3629a71e-46f2-45ef-a2fa-1a3debc213f9" xlink:to="loc_cntx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedAsAPercentageOfOutstandingStock_0a5fc451-4e87-49e4-a848-5af27a613861" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_769e98da-08d3-429a-b3a1-2b5474d85c6a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3629a71e-46f2-45ef-a2fa-1a3debc213f9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_769e98da-08d3-429a-b3a1-2b5474d85c6a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_f39233a8-4a2e-469b-84f0-1302455a864a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3629a71e-46f2-45ef-a2fa-1a3debc213f9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_f39233a8-4a2e-469b-84f0-1302455a864a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_e22b18ae-6806-4285-b1b0-5d6a86f0c63c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3629a71e-46f2-45ef-a2fa-1a3debc213f9" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_e22b18ae-6806-4285-b1b0-5d6a86f0c63c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_53561f42-f282-4330-b005-370e6b420352" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3629a71e-46f2-45ef-a2fa-1a3debc213f9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_53561f42-f282-4330-b005-370e6b420352" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_cdc0dbde-17c4-4615-95a3-019b1d90b95d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3629a71e-46f2-45ef-a2fa-1a3debc213f9" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_cdc0dbde-17c4-4615-95a3-019b1d90b95d" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_ba8b24c7-4a0c-4280-9c94-12623872e496" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3629a71e-46f2-45ef-a2fa-1a3debc213f9" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_ba8b24c7-4a0c-4280-9c94-12623872e496" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7745bcd3-ced1-4d68-9bf3-d62583b0c7a7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3629a71e-46f2-45ef-a2fa-1a3debc213f9" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7745bcd3-ced1-4d68-9bf3-d62583b0c7a7" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_76fb3c45-37e3-4d34-b1a8-d159f30db58d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7745bcd3-ced1-4d68-9bf3-d62583b0c7a7" xlink:to="loc_us-gaap_StatementClassOfStockAxis_76fb3c45-37e3-4d34-b1a8-d159f30db58d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_76fb3c45-37e3-4d34-b1a8-d159f30db58d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_76fb3c45-37e3-4d34-b1a8-d159f30db58d" xlink:to="loc_us-gaap_ClassOfStockDomain_76fb3c45-37e3-4d34-b1a8-d159f30db58d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_0a3bfbd4-c603-4ca2-a171-fc98e6605279" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_76fb3c45-37e3-4d34-b1a8-d159f30db58d" xlink:to="loc_us-gaap_ClassOfStockDomain_0a3bfbd4-c603-4ca2-a171-fc98e6605279" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassAMember_a8490597-4312-44f8-9555-f775dc1f0aa5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonClassAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_0a3bfbd4-c603-4ca2-a171-fc98e6605279" xlink:to="loc_us-gaap_CommonClassAMember_a8490597-4312-44f8-9555-f775dc1f0aa5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_81bfc743-701d-4eca-ab73-61c58201588c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_0a3bfbd4-c603-4ca2-a171-fc98e6605279" xlink:to="loc_us-gaap_EmployeeStockOptionMember_81bfc743-701d-4eca-ab73-61c58201588c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_eb230aab-ef98-4278-82ca-5e38cd40333a" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7745bcd3-ced1-4d68-9bf3-d62583b0c7a7" xlink:to="loc_srt_RangeAxis_eb230aab-ef98-4278-82ca-5e38cd40333a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_eb230aab-ef98-4278-82ca-5e38cd40333a_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_eb230aab-ef98-4278-82ca-5e38cd40333a" xlink:to="loc_srt_RangeMember_eb230aab-ef98-4278-82ca-5e38cd40333a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_5e3b10cb-755f-4afe-ac86-7b85c458b865" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_eb230aab-ef98-4278-82ca-5e38cd40333a" xlink:to="loc_srt_RangeMember_5e3b10cb-755f-4afe-ac86-7b85c458b865" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_fa92cfd7-7756-4500-be81-a7dd2c6a219f" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_5e3b10cb-755f-4afe-ac86-7b85c458b865" xlink:to="loc_srt_MinimumMember_fa92cfd7-7756-4500-be81-a7dd2c6a219f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_ac75b4e4-106a-4d3c-a204-57c8ce2ce74a" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_5e3b10cb-755f-4afe-ac86-7b85c458b865" xlink:to="loc_srt_MaximumMember_ac75b4e4-106a-4d3c-a204-57c8ce2ce74a" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.contexttherapeutics.com/role/SharebasedCompensationScheduleofSharebasedCompensationExpenseDetails" xlink:type="simple" xlink:href="cntx-20230331.xsd#SharebasedCompensationScheduleofSharebasedCompensationExpenseDetails"/>
  <link:definitionLink xlink:role="http://www.contexttherapeutics.com/role/SharebasedCompensationScheduleofSharebasedCompensationExpenseDetails" xlink:type="extended" id="i0f0ff2e002b74ae39362ce0d2fbb86e6_SharebasedCompensationScheduleofSharebasedCompensationExpenseDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_3d7adad0-161e-40cb-aa23-044bdf9a38c0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_16843367-da26-402d-85dd-d78cd64e0457" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_3d7adad0-161e-40cb-aa23-044bdf9a38c0" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_16843367-da26-402d-85dd-d78cd64e0457" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_94366b31-570b-4bd4-9f3b-a38ea72de285" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_3d7adad0-161e-40cb-aa23-044bdf9a38c0" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_94366b31-570b-4bd4-9f3b-a38ea72de285" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_3ffea33f-9eb3-49c1-8cee-9620884b3044" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_94366b31-570b-4bd4-9f3b-a38ea72de285" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_3ffea33f-9eb3-49c1-8cee-9620884b3044" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_3ffea33f-9eb3-49c1-8cee-9620884b3044_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_3ffea33f-9eb3-49c1-8cee-9620884b3044" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_3ffea33f-9eb3-49c1-8cee-9620884b3044_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_f76ebd7e-78e1-44a1-8b26-7efe40369620" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_3ffea33f-9eb3-49c1-8cee-9620884b3044" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_f76ebd7e-78e1-44a1-8b26-7efe40369620" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_a3f6fda1-6faa-457b-9cd3-a31c5d9b95e5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_f76ebd7e-78e1-44a1-8b26-7efe40369620" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_a3f6fda1-6faa-457b-9cd3-a31c5d9b95e5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_ebdf239a-456e-45fd-b273-f5cfe3915ca2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_f76ebd7e-78e1-44a1-8b26-7efe40369620" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_ebdf239a-456e-45fd-b273-f5cfe3915ca2" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.contexttherapeutics.com/role/ShareBasedCompensationScheduleofAssumptionsUsedtoDetermineFairValueofShareBasedAwardsDetails" xlink:type="simple" xlink:href="cntx-20230331.xsd#ShareBasedCompensationScheduleofAssumptionsUsedtoDetermineFairValueofShareBasedAwardsDetails"/>
  <link:definitionLink xlink:role="http://www.contexttherapeutics.com/role/ShareBasedCompensationScheduleofAssumptionsUsedtoDetermineFairValueofShareBasedAwardsDetails" xlink:type="extended" id="ife5729a09aa141118386356bb1ba6be1_ShareBasedCompensationScheduleofAssumptionsUsedtoDetermineFairValueofShareBasedAwardsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7888107b-e6a3-4300-8089-0493c9b70840" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_230fbb74-c852-41ab-a559-4651178873f3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7888107b-e6a3-4300-8089-0493c9b70840" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_230fbb74-c852-41ab-a559-4651178873f3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_6019963a-f783-4e0d-bae1-5978fbec0568" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7888107b-e6a3-4300-8089-0493c9b70840" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_6019963a-f783-4e0d-bae1-5978fbec0568" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_f4e9574e-8814-44c8-81fa-6cc107469005" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7888107b-e6a3-4300-8089-0493c9b70840" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_f4e9574e-8814-44c8-81fa-6cc107469005" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_8139351a-81cd-4b35-b9dd-bad693935605" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7888107b-e6a3-4300-8089-0493c9b70840" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_8139351a-81cd-4b35-b9dd-bad693935605" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_47759f05-c4e7-405d-85e8-059cb33e9649" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7888107b-e6a3-4300-8089-0493c9b70840" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_47759f05-c4e7-405d-85e8-059cb33e9649" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_58008832-b54b-4588-8f76-6e71179124fe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_47759f05-c4e7-405d-85e8-059cb33e9649" xlink:to="loc_us-gaap_AwardTypeAxis_58008832-b54b-4588-8f76-6e71179124fe" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_58008832-b54b-4588-8f76-6e71179124fe_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_58008832-b54b-4588-8f76-6e71179124fe" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_58008832-b54b-4588-8f76-6e71179124fe_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_fceab3a3-b9bd-49bc-ae2d-3578bf82fb44" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_58008832-b54b-4588-8f76-6e71179124fe" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_fceab3a3-b9bd-49bc-ae2d-3578bf82fb44" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_c2e55c19-0fef-4954-a22d-3d19e313a6d5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_fceab3a3-b9bd-49bc-ae2d-3578bf82fb44" xlink:to="loc_us-gaap_EmployeeStockOptionMember_c2e55c19-0fef-4954-a22d-3d19e313a6d5" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.contexttherapeutics.com/role/CommitmentandContingenciesCollaborationAgreementsDetails" xlink:type="simple" xlink:href="cntx-20230331.xsd#CommitmentandContingenciesCollaborationAgreementsDetails"/>
  <link:definitionLink xlink:role="http://www.contexttherapeutics.com/role/CommitmentandContingenciesCollaborationAgreementsDetails" xlink:type="extended" id="i3c45e7a47c6a48bdb834ed0794f375e9_CommitmentandContingenciesCollaborationAgreementsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_2c67f88e-1072-41c1-bf83-d887f8383632" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_cntx_CollaborativeArrangementRightsAndObligationsMilestonePayment_42404fc8-a8a4-4420-8213-76fd7e04cf3a" xlink:href="cntx-20230331.xsd#cntx_CollaborativeArrangementRightsAndObligationsMilestonePayment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_2c67f88e-1072-41c1-bf83-d887f8383632" xlink:to="loc_cntx_CollaborativeArrangementRightsAndObligationsMilestonePayment_42404fc8-a8a4-4420-8213-76fd7e04cf3a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cntx_CollaborativeArrangementRightsAndObligationsQuarterlySalesPaymentsPercent_a09ec128-46cb-4188-8f05-a5ff0261b0a3" xlink:href="cntx-20230331.xsd#cntx_CollaborativeArrangementRightsAndObligationsQuarterlySalesPaymentsPercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_2c67f88e-1072-41c1-bf83-d887f8383632" xlink:to="loc_cntx_CollaborativeArrangementRightsAndObligationsQuarterlySalesPaymentsPercent_a09ec128-46cb-4188-8f05-a5ff0261b0a3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cntx_CollaborativeArrangementRightsAndObligationsSalesPaymentPeriod_a3763cb8-4660-4287-8316-a47234ddb8a5" xlink:href="cntx-20230331.xsd#cntx_CollaborativeArrangementRightsAndObligationsSalesPaymentPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_2c67f88e-1072-41c1-bf83-d887f8383632" xlink:to="loc_cntx_CollaborativeArrangementRightsAndObligationsSalesPaymentPeriod_a3763cb8-4660-4287-8316-a47234ddb8a5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_cntx_CollaborativeArrangementRightsAndObligationsDevelopmentAndRegulatoryMilestonePaymentsMaximum_365b1b89-e414-4e51-b8f5-aa1eec82bb91" xlink:href="cntx-20230331.xsd#cntx_CollaborativeArrangementRightsAndObligationsDevelopmentAndRegulatoryMilestonePaymentsMaximum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_2c67f88e-1072-41c1-bf83-d887f8383632" xlink:to="loc_cntx_CollaborativeArrangementRightsAndObligationsDevelopmentAndRegulatoryMilestonePaymentsMaximum_365b1b89-e414-4e51-b8f5-aa1eec82bb91" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_cntx_CollaborativeArrangementRightsAndObligationsSalesMilestonePaymentsMaximum_88b8bf1a-53a4-4c29-aa85-e4cb78479835" xlink:href="cntx-20230331.xsd#cntx_CollaborativeArrangementRightsAndObligationsSalesMilestonePaymentsMaximum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_2c67f88e-1072-41c1-bf83-d887f8383632" xlink:to="loc_cntx_CollaborativeArrangementRightsAndObligationsSalesMilestonePaymentsMaximum_88b8bf1a-53a4-4c29-aa85-e4cb78479835" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_cntx_CollaborativeArrangementRightsAndObligationsTieredRoyaltyPercent_7a512ce4-88ac-4368-8445-b3807ffa21c4" xlink:href="cntx-20230331.xsd#cntx_CollaborativeArrangementRightsAndObligationsTieredRoyaltyPercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_2c67f88e-1072-41c1-bf83-d887f8383632" xlink:to="loc_cntx_CollaborativeArrangementRightsAndObligationsTieredRoyaltyPercent_7a512ce4-88ac-4368-8445-b3807ffa21c4" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_5e984f17-d8d4-4506-9fc1-0b70cff290fd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_2c67f88e-1072-41c1-bf83-d887f8383632" xlink:to="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_5e984f17-d8d4-4506-9fc1-0b70cff290fd" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_d0835cbb-2398-4e8e-aa91-1e90e51170a5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_5e984f17-d8d4-4506-9fc1-0b70cff290fd" xlink:to="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_d0835cbb-2398-4e8e-aa91-1e90e51170a5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProjectMember_d0835cbb-2398-4e8e-aa91-1e90e51170a5_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProjectMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_d0835cbb-2398-4e8e-aa91-1e90e51170a5" xlink:to="loc_us-gaap_ProjectMember_d0835cbb-2398-4e8e-aa91-1e90e51170a5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProjectMember_49b193da-a8cc-42f2-a63e-8332dd1e4192" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProjectMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_d0835cbb-2398-4e8e-aa91-1e90e51170a5" xlink:to="loc_us-gaap_ProjectMember_49b193da-a8cc-42f2-a63e-8332dd1e4192" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cntx_ScaleUp100KilogramsOfGMPGradeCompoundMember_620f7849-4065-4b23-98c1-be28ef20fde6" xlink:href="cntx-20230331.xsd#cntx_ScaleUp100KilogramsOfGMPGradeCompoundMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProjectMember_49b193da-a8cc-42f2-a63e-8332dd1e4192" xlink:to="loc_cntx_ScaleUp100KilogramsOfGMPGradeCompoundMember_620f7849-4065-4b23-98c1-be28ef20fde6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cntx_ScaleUp300KilogramsOfGMPGradeCompoundMember_e0ca2d72-8091-4f5b-8565-9fc1c335571f" xlink:href="cntx-20230331.xsd#cntx_ScaleUp300KilogramsOfGMPGradeCompoundMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProjectMember_49b193da-a8cc-42f2-a63e-8332dd1e4192" xlink:to="loc_cntx_ScaleUp300KilogramsOfGMPGradeCompoundMember_e0ca2d72-8091-4f5b-8565-9fc1c335571f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_86abd820-31a9-4925-b189-943eae080463" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_5e984f17-d8d4-4506-9fc1-0b70cff290fd" xlink:to="loc_srt_CounterpartyNameAxis_86abd820-31a9-4925-b189-943eae080463" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_86abd820-31a9-4925-b189-943eae080463_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_86abd820-31a9-4925-b189-943eae080463" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_86abd820-31a9-4925-b189-943eae080463_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_925b5ce6-f39b-4041-a92d-ddc89996c11b" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_86abd820-31a9-4925-b189-943eae080463" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_925b5ce6-f39b-4041-a92d-ddc89996c11b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cntx_TyligandBioscienceShanghaiLimitedMember_d1935e37-9eb4-4d74-bf97-5131627a6a2e" xlink:href="cntx-20230331.xsd#cntx_TyligandBioscienceShanghaiLimitedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_925b5ce6-f39b-4041-a92d-ddc89996c11b" xlink:to="loc_cntx_TyligandBioscienceShanghaiLimitedMember_d1935e37-9eb4-4d74-bf97-5131627a6a2e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cntx_IntegralMolecularIncMember_4e256769-b07a-40f2-bc7c-665ce54b75b4" xlink:href="cntx-20230331.xsd#cntx_IntegralMolecularIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_925b5ce6-f39b-4041-a92d-ddc89996c11b" xlink:to="loc_cntx_IntegralMolecularIncMember_4e256769-b07a-40f2-bc7c-665ce54b75b4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_16fa9325-8fb1-4891-b6bc-b4ad7a2b42fa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_5e984f17-d8d4-4506-9fc1-0b70cff290fd" xlink:to="loc_us-gaap_TypeOfArrangementAxis_16fa9325-8fb1-4891-b6bc-b4ad7a2b42fa" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_16fa9325-8fb1-4891-b6bc-b4ad7a2b42fa_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_16fa9325-8fb1-4891-b6bc-b4ad7a2b42fa" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_16fa9325-8fb1-4891-b6bc-b4ad7a2b42fa_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_adfc0a37-c585-42dc-82ca-207f31b1a8ae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_16fa9325-8fb1-4891-b6bc-b4ad7a2b42fa" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_adfc0a37-c585-42dc-82ca-207f31b1a8ae" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember_3c97a234-ed11-4d02-ad68-2b4756eae2fc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_adfc0a37-c585-42dc-82ca-207f31b1a8ae" xlink:to="loc_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember_3c97a234-ed11-4d02-ad68-2b4756eae2fc" xlink:type="arc" order="0"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>8
<FILENAME>cntx-20230331_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:25d0e2a1-022e-45ee-a4b8-2723f9a842c8,g:b681c287-491c-4187-8280-df3edb448dfa-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_c9dba290-a012-4496-9840-635d1add81ce_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_cdb96da8-dd5d-4c92-96de-c431ba9a6338_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_ca3a74f8-848d-4892-b847-35acc14b0db9_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and Equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_6db95591-979f-415f-8877-5f81d06edca4_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_f1c5685c-7dd2-44f3-9131-1ee175d43f8b_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted during the period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_54a0ffee-5faf-4461-8738-b41aa6129997_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_9b765415-fe35-463e-8650-cc29a508a04f_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_e9dd63d9-b9b1-4c9e-ad7c-b420aa07d32f_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashNoncurrent_b016f690-1ef7-4e55-82ed-225915bc1596_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted cash</link:label>
    <link:label id="lab_us-gaap_RestrictedCashNoncurrent_label_en-US" xlink:label="lab_us-gaap_RestrictedCashNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashNoncurrent" xlink:to="lab_us-gaap_RestrictedCashNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_fcda0579-c3fd-47e4-9d3d-e168eb9da351_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average common shares outstanding - diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_4d623825-08d5-40ea-abf4-6ca84bdcf0ca_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesOutstanding" xlink:to="lab_us-gaap_PreferredStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_cntx_CollaborativeArrangementRightsAndObligationsMilestonePayment_0d81e09e-6c00-45a6-a9a6-17ef0baf2871_terseLabel_en-US" xlink:label="lab_cntx_CollaborativeArrangementRightsAndObligationsMilestonePayment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone payment</link:label>
    <link:label id="lab_cntx_CollaborativeArrangementRightsAndObligationsMilestonePayment_label_en-US" xlink:label="lab_cntx_CollaborativeArrangementRightsAndObligationsMilestonePayment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Rights and Obligations, Milestone Payment</link:label>
    <link:label id="lab_cntx_CollaborativeArrangementRightsAndObligationsMilestonePayment_documentation_en-US" xlink:label="lab_cntx_CollaborativeArrangementRightsAndObligationsMilestonePayment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Rights and Obligations, Milestone Payment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cntx_CollaborativeArrangementRightsAndObligationsMilestonePayment" xlink:href="cntx-20230331.xsd#cntx_CollaborativeArrangementRightsAndObligationsMilestonePayment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cntx_CollaborativeArrangementRightsAndObligationsMilestonePayment" xlink:to="lab_cntx_CollaborativeArrangementRightsAndObligationsMilestonePayment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_a447ad58-65fb-41b5-a7d7-c54a39fa525b_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected term (in years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_ea1633ba-6025-411d-bea3-93de46aa65e3_terseLabel_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_label_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy_bf5fa8c0-1134-4ac8-b689-719fedfbe47a_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value of Financial Instruments</link:label>
    <link:label id="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy_label_en-US" xlink:label="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value of Financial Instruments, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:to="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValue_f9bcdb76-ab09-4bdb-9280-4ea8dc5b9806_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, $0.001 par value; 100,000,000 shares authorized; 15,966,053 shares issued and outstanding at March&#160;31, 2023 and December&#160;31, 2022</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_label_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_7c00df62-37eb-42d9-9a95-2cd571cf88d0_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid in Capital</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapital" xlink:to="lab_us-gaap_AdditionalPaidInCapital" xlink:type="arc" order="1"/>
    <link:label id="lab_cntx_TyligandBioscienceShanghaiLimitedMember_fd60888a-3dac-495f-b3c7-b8356bd2d9f3_terseLabel_en-US" xlink:label="lab_cntx_TyligandBioscienceShanghaiLimitedMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tyligand</link:label>
    <link:label id="lab_cntx_TyligandBioscienceShanghaiLimitedMember_label_en-US" xlink:label="lab_cntx_TyligandBioscienceShanghaiLimitedMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tyligand Bioscience (Shanghai) Limited [Member]</link:label>
    <link:label id="lab_cntx_TyligandBioscienceShanghaiLimitedMember_documentation_en-US" xlink:label="lab_cntx_TyligandBioscienceShanghaiLimitedMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tyligand Bioscience (Shanghai) Limited</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cntx_TyligandBioscienceShanghaiLimitedMember" xlink:href="cntx-20230331.xsd#cntx_TyligandBioscienceShanghaiLimitedMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cntx_TyligandBioscienceShanghaiLimitedMember" xlink:to="lab_cntx_TyligandBioscienceShanghaiLimitedMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_27471f13-16ca-4e40-9f5f-bb00dcce149a_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_0863fd9d-c0ba-4f84-95fd-95935ec2a298_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_13ba5e5b-7545-4da5-bdf2-5e85a1930a12_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_8ba61af4-4fc2-4ca7-881b-8d5c51ff949d_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average discount rate</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Discount Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrivatePlacementMember_cc46a11c-b988-40ce-a646-d3f3962977a6_terseLabel_en-US" xlink:label="lab_us-gaap_PrivatePlacementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Private Placement</link:label>
    <link:label id="lab_us-gaap_PrivatePlacementMember_label_en-US" xlink:label="lab_us-gaap_PrivatePlacementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Private Placement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrivatePlacementMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrivatePlacementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrivatePlacementMember" xlink:to="lab_us-gaap_PrivatePlacementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_3c48b0a4-aa97-4a63-b1dc-08b1cc6eac98_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_28d7a642-8ab4-4bda-ad1b-eb534f5f135f_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents and restricted cash at beginning of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_0d42f44d-9d2f-4f3e-8b3b-8827967c6acd_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents at end of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_e3b831b7-a862-4abb-b782-b2dc0b90565b_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_4f0b3361-ad2c-42b3-ae51-a128411e536f_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of warrants issued for services</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Additional Paid in Capital, Warrant Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_88d4bc64-d2fc-4619-972b-ce9b19730f29_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_715f1a69-98d6-4cb1-93e2-2e533ff42ace_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_cb0270c0-46f3-4f25-a726-0eacf07ec130_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested and expected to vest at March&#160;31, 2023</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_352e499e-b343-400e-9d9c-adcc29756b08_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_1ea9823d-14ef-4f8d-b7c2-47b1a07446a8_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_8dd96d5e-7d07-4b12-ab20-4a187b3b02e2_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_96ee9de7-4f35-41e4-933d-d905bd0f088e_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive securities excluded from computation of diluted weighted-average shares of common stock outstanding</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_6598479b-2161-49f9-a4ac-07a37f2ff642_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employer matching contribution, percent of employees compensation</link:label>
    <link:label id="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_label_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Contribution Plan, Employer Matching Contribution, Percent of Employees' Gross Pay</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:to="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_cntx_WarrantsIssued_9ff0f9cc-2820-429d-b7cd-5e8f522a00b5_verboseLabel_en-US" xlink:label="lab_cntx_WarrantsIssued" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of warrants for services provided</link:label>
    <link:label id="lab_cntx_WarrantsIssued_label_en-US" xlink:label="lab_cntx_WarrantsIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants Issued</link:label>
    <link:label id="lab_cntx_WarrantsIssued_documentation_en-US" xlink:label="lab_cntx_WarrantsIssued" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cntx_WarrantsIssued" xlink:href="cntx-20230331.xsd#cntx_WarrantsIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cntx_WarrantsIssued" xlink:to="lab_cntx_WarrantsIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_be040adc-62de-4bf2-97ff-ac3e18f4bd0f_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_us-gaap_IncomeStatementLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_35b37370-8a42-40e2-a803-205a27885dce_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_57396996-2db0-45b8-ab36-236802c33a22_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_9da258c0-4e45-429a-b55b-604f0f04c379_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_fffaed80-9161-471b-90dc-eae081490bd5_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Remaining lease term</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Remaining Lease Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseRemainingLeaseTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:to="lab_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_55a38746-b42f-4108-ad18-101c875183b7_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash used in investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseCost_bf3fb5f3-db89-4c0d-9770-af78231040eb_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rent expense</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseCost_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseCost" xlink:to="lab_us-gaap_OperatingLeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightLineItems_0284d231-d91b-42e6-9dc5-593e83630e0c_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Line Items]</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightLineItems_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="lab_us-gaap_ClassOfWarrantOrRightLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_21fe569f-adeb-4b66-bd06-bf823b356b0c_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_40410d9f-70d2-463d-96b7-ae1cc1f80482_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent" xlink:to="lab_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplementalCashFlowElementsAbstract_1f7e180b-b087-454c-b8d6-840c8185a147_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowElementsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental disclosure of non-cash activities:</link:label>
    <link:label id="lab_us-gaap_SupplementalCashFlowElementsAbstract_label_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowElementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Cash Flow Elements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowElementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalCashFlowElementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowElementsAbstract" xlink:to="lab_us-gaap_SupplementalCashFlowElementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_4081d35c-b3ad-4a27-b6c0-d5c1563b9ebe_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Remaining Contractual Term (years)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_86c6046d-c491-482e-b89f-dee34b5bd776_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercisable at period end (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_cntx_CollaborativeArrangementRightsAndObligationsQuarterlySalesPaymentsPercent_f17f494f-0557-4f1f-af72-7003db6a6ea1_terseLabel_en-US" xlink:label="lab_cntx_CollaborativeArrangementRightsAndObligationsQuarterlySalesPaymentsPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Quarterly sales payment due upon completion, percentage</link:label>
    <link:label id="lab_cntx_CollaborativeArrangementRightsAndObligationsQuarterlySalesPaymentsPercent_label_en-US" xlink:label="lab_cntx_CollaborativeArrangementRightsAndObligationsQuarterlySalesPaymentsPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Rights and Obligations, Quarterly Sales Payments, Percent</link:label>
    <link:label id="lab_cntx_CollaborativeArrangementRightsAndObligationsQuarterlySalesPaymentsPercent_documentation_en-US" xlink:label="lab_cntx_CollaborativeArrangementRightsAndObligationsQuarterlySalesPaymentsPercent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Rights and Obligations, Quarterly Sales Payments, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cntx_CollaborativeArrangementRightsAndObligationsQuarterlySalesPaymentsPercent" xlink:href="cntx-20230331.xsd#cntx_CollaborativeArrangementRightsAndObligationsQuarterlySalesPaymentsPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cntx_CollaborativeArrangementRightsAndObligationsQuarterlySalesPaymentsPercent" xlink:to="lab_cntx_CollaborativeArrangementRightsAndObligationsQuarterlySalesPaymentsPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_002a4444-0fb2-41c1-bdda-1b7837b40c83_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_cntx_December2021PrivatePlacementAgentWarrantsMember_40edc469-6223-4806-b58b-35905ae6d379_terseLabel_en-US" xlink:label="lab_cntx_December2021PrivatePlacementAgentWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issued in connection with 2021 private placement</link:label>
    <link:label id="lab_cntx_December2021PrivatePlacementAgentWarrantsMember_label_en-US" xlink:label="lab_cntx_December2021PrivatePlacementAgentWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">December 2021 Private Placement Agent Warrants [Member]</link:label>
    <link:label id="lab_cntx_December2021PrivatePlacementAgentWarrantsMember_documentation_en-US" xlink:label="lab_cntx_December2021PrivatePlacementAgentWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">December 2021 Private Placement Agent Warrants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cntx_December2021PrivatePlacementAgentWarrantsMember" xlink:href="cntx-20230331.xsd#cntx_December2021PrivatePlacementAgentWarrantsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cntx_December2021PrivatePlacementAgentWarrantsMember" xlink:to="lab_cntx_December2021PrivatePlacementAgentWarrantsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_e5f0e947-28c3-41ad-964f-0f78bd5fa7d2_terseLabel_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and amortization expense</link:label>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_label_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation, Depletion and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:to="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_9062f12a-7b53-4c23-9260-49e34e999aed_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_ae9d8d00-1b83-4a49-83ae-6f3ef813d6f8_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 1</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_9c9788cd-9794-4a11-8602-3f71774f51ea_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Project [Axis]</link:label>
    <link:label id="lab_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_label_en-US" xlink:label="lab_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Project [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis" xlink:to="lab_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CounterpartyNameAxis_9fc29be2-abac-4f54-9d95-e25578ae5646_terseLabel_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:label id="lab_srt_CounterpartyNameAxis_label_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CounterpartyNameAxis" xlink:to="lab_srt_CounterpartyNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_0fcfb04f-bd8b-4b88-bd8f-e44aa46e8c06_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding at beginning of period</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_2a77d723-385f-4267-ba66-28a1173a1875_verboseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding at end of period</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_314d0488-daa9-43e9-9ecf-a64e015e6b1e_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding at beginning of period ( in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_eadf16b7-7e6e-49c8-a029-7fa3a7b3ae3b_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding at period end (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAxis_dec2b417-fb36-4812-a79f-635204ea3eed_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Axis]</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAxis_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis" xlink:to="lab_us-gaap_CashAndCashEquivalentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InProcessResearchAndDevelopmentPolicy_60b2d9df-b4db-4e24-bed6-1a18a4db2485_terseLabel_en-US" xlink:label="lab_us-gaap_InProcessResearchAndDevelopmentPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquired In-Process Research and Development Costs</link:label>
    <link:label id="lab_us-gaap_InProcessResearchAndDevelopmentPolicy_label_en-US" xlink:label="lab_us-gaap_InProcessResearchAndDevelopmentPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">In Process Research and Development, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InProcessResearchAndDevelopmentPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InProcessResearchAndDevelopmentPolicy" xlink:to="lab_us-gaap_InProcessResearchAndDevelopmentPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_d8b8b3cf-4563-4b86-a29c-7a919db14244_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Expenses and Other Current Liabilities</link:label>
    <link:label id="lab_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_label_en-US" xlink:label="lab_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:to="lab_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardTypeAxis_1c93ec3d-2127-4017-ae33-f3a86514886d_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_cntx_AccruedResearchAndDevelopmentCostsCurrent_83a20a72-09f1-4dd2-b922-8d4f511328df_terseLabel_en-US" xlink:label="lab_cntx_AccruedResearchAndDevelopmentCostsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development costs</link:label>
    <link:label id="lab_cntx_AccruedResearchAndDevelopmentCostsCurrent_label_en-US" xlink:label="lab_cntx_AccruedResearchAndDevelopmentCostsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Research and Development Costs, Current</link:label>
    <link:label id="lab_cntx_AccruedResearchAndDevelopmentCostsCurrent_documentation_en-US" xlink:label="lab_cntx_AccruedResearchAndDevelopmentCostsCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Research and Development Costs, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cntx_AccruedResearchAndDevelopmentCostsCurrent" xlink:href="cntx-20230331.xsd#cntx_AccruedResearchAndDevelopmentCostsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cntx_AccruedResearchAndDevelopmentCostsCurrent" xlink:to="lab_cntx_AccruedResearchAndDevelopmentCostsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_91f52100-dd6f-4b07-b5b9-f989b39bee81_terseLabel_en-US" xlink:label="lab_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Presentation and Summary of Significant Accounting Policies</link:label>
    <link:label id="lab_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Presentation and Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_14724658-bb25-4e10-86e0-39a654e23321_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash used in operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_72a7b287-f9e4-42f7-90f4-541ce622d2e6_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_a4b6e7b2-670f-43d6-bfce-af9a770fcd27_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liability - current</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_629c4be7-ce21-4c42-9351-28b2a7fd71f5_terseLabel_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Presentation</link:label>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_2ca28dcd-3ecb-4c5b-9133-14072dad49e9_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_67fc9358-f75d-4755-aec4-7a366947523a_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_0ff014ee-80e2-4556-aaaa-82b06bb52dd1_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock options</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember" xlink:to="lab_us-gaap_EmployeeStockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_45b183ee-0399-49f4-99cb-7e0e89fdcfff_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_78e20c4a-79fc-4718-8ae1-0a52e32098a1_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Other Noncurrent Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_a48ba15e-803c-49ec-84bc-cd78911243f6_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum annual contributions per employee, percent</link:label>
    <link:label id="lab_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_label_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Contribution Plan, Maximum Annual Contributions Per Employee, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:to="lab_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_62d7b74a-369f-4294-89ce-fad1371e7560_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected stock price volatility</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_fc8d00b8-bfdd-4a98-b823-c3b7e9a86789_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_552af02d-0408-4f6a-b6b0-5c007c40ef84_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Liabilities_69d8482f-ae80-4e17-bd91-f605f9322f82_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_label_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5bb31418-39da-4b0e-8753-3e611da695b9_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightAxis_2a17b141-4acf-485f-b73b-3abf3201cedf_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Axis]</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightAxis_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis" xlink:to="lab_us-gaap_ClassOfWarrantOrRightAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_50b70c8d-1698-4c72-9b9f-45ee02c10363_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_266d6b72-fb09-416c-8e85-e29fcff07363_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from investing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonClassAMember_2fdd42ed-0509-47bf-bfa0-4505d458eced_terseLabel_en-US" xlink:label="lab_us-gaap_CommonClassAMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock</link:label>
    <link:label id="lab_us-gaap_CommonClassAMember_label_en-US" xlink:label="lab_us-gaap_CommonClassAMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Class A [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassAMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonClassAMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonClassAMember" xlink:to="lab_us-gaap_CommonClassAMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_b40d957f-b665-43e0-8d96-fa4242d98397_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_3c22a594-dfd8-4d15-bc91-6fefd3ceee67_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_63e3f641-014c-4cd5-b36b-729d0c0d12b6_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_4dd8a451-fc6c-4fff-8e83-29574acd6453_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember_f8f7ef52-3e54-42a2-b7b0-3d4ca990e07c_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Transaction with Party to Collaborative Arrangement</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Transaction with Party to Collaborative Arrangement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember" xlink:to="lab_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_7ef1ac0d-b706-4f1d-b736-f3123ebf66b9_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesIssued" xlink:to="lab_us-gaap_PreferredStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_47f4637c-a890-4569-8370-8e52a3c50290_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_5d966b94-a0b9-4a9a-b2d1-dd5ffa65cff1_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Exercise Price Per Share</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_50748d64-7796-4115-9c02-f73b55e2f135_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_6fb53db4-954a-4dfb-a628-4deb38308697_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Warrants Outstanding</link:label>
    <link:label id="lab_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:to="lab_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharesOutstanding_a8f21893-c3e8-48e0-952b-a1b6881cfc31_periodStartLabel_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesOutstanding_7fb1b269-13c6-442a-a06b-90b1218dfe36_periodEndLabel_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesOutstanding_label_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesOutstanding" xlink:to="lab_us-gaap_SharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_2c6056a5-c757-4a67-9e38-e6510e7d8be1_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_4257f867-dd05-46ab-9b29-3e9b8f7910b9_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Note Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_0323e573-45b3-44cb-8525-246d6502afd5_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reduction in the carrying amount of operating lease right-of-use asset</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset, Amortization Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosureAbstract_5e86d5fb-62d3-4e24-9b44-883b1bcbc4ad_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial assets</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Fair Value Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="lab_us-gaap_AssetsFairValueDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_88cacad2-b28e-4155-931c-b244a9c1939e_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_8c2bed87-3527-4aee-8a2b-274b5ad4aab5_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Options</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_27edfc5f-fd5f-4402-bf58-d5ed990109cd_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued expenses and other current liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_cntx_IntegralMolecularIncMember_afa04ad1-d1d2-46a7-b1e2-35cdfbadcd3c_terseLabel_en-US" xlink:label="lab_cntx_IntegralMolecularIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Integral</link:label>
    <link:label id="lab_cntx_IntegralMolecularIncMember_label_en-US" xlink:label="lab_cntx_IntegralMolecularIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Integral Molecular, Inc. [Member]</link:label>
    <link:label id="lab_cntx_IntegralMolecularIncMember_documentation_en-US" xlink:label="lab_cntx_IntegralMolecularIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Integral Molecular, Inc.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cntx_IntegralMolecularIncMember" xlink:href="cntx-20230331.xsd#cntx_IntegralMolecularIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cntx_IntegralMolecularIncMember" xlink:to="lab_cntx_IntegralMolecularIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_87d30e3a-b885-41e9-940f-9e3c81a1f566_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_f1bb41af-c710-4d11-a4f1-5888c50599e3_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PayablesAndAccrualsAbstract_label_en-US" xlink:label="lab_us-gaap_PayablesAndAccrualsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payables and Accruals [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract" xlink:to="lab_us-gaap_PayablesAndAccrualsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightTable_c9de2bb7-527c-4749-80e3-2c2307cb42d5_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Table]</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightTable_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable" xlink:to="lab_us-gaap_ClassOfWarrantOrRightTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_3f06e4de-f7e4-4d31-b9c6-506b8be84dc0_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiability" xlink:to="lab_us-gaap_OperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_0658eb2b-c523-4e02-b700-ff2cbecc5f01_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_56c09162-aa57-46a4-b50d-6c5d5166a9dd_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_dc89bf66-c104-495e-8ba6-9d03e6bcf6e4_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_us-gaap_IncomeStatementLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_cntx_IssuedToPlacementAgentsMember_d84d33f4-209d-4c5c-b954-4662a04fde43_terseLabel_en-US" xlink:label="lab_cntx_IssuedToPlacementAgentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issued in connection with 2021 IPO</link:label>
    <link:label id="lab_cntx_IssuedToPlacementAgentsMember_label_en-US" xlink:label="lab_cntx_IssuedToPlacementAgentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issued to Placement Agents [Member]</link:label>
    <link:label id="lab_cntx_IssuedToPlacementAgentsMember_documentation_en-US" xlink:label="lab_cntx_IssuedToPlacementAgentsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issued to Placement Agents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cntx_IssuedToPlacementAgentsMember" xlink:href="cntx-20230331.xsd#cntx_IssuedToPlacementAgentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cntx_IssuedToPlacementAgentsMember" xlink:to="lab_cntx_IssuedToPlacementAgentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceived_c9669485-2035-4826-be88-d9d0e8e360f4_terseLabel_en-US" xlink:label="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceived" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Future minimum payments due</link:label>
    <link:label id="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceived_label_en-US" xlink:label="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceived" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessor, Operating Lease, Payments to be Received</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceived" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceived"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceived" xlink:to="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceived" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_5b571550-a4c3-45e5-bdae-a8888bbdf42c_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashUninsuredAmount_8faa0573-76d4-4a9c-8e06-ebfd18fcfd0c_terseLabel_en-US" xlink:label="lab_us-gaap_CashUninsuredAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Uninsured amount</link:label>
    <link:label id="lab_us-gaap_CashUninsuredAmount_label_en-US" xlink:label="lab_us-gaap_CashUninsuredAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Uninsured Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashUninsuredAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashUninsuredAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashUninsuredAmount" xlink:to="lab_us-gaap_CashUninsuredAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_d83ea1de-1a2e-46eb-bae1-9d329ea11456_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Stockholders' Equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_d30e22e9-3263-4253-aacf-5ea3045b47a6_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued expenses and other current liabilities</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_0e6a4a9f-cea0-48d6-8741-8fdc5f989a1f_totalLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued expenses and other current liabilities</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_d1ca6401-589e-41dc-bb6b-13ba690d85b8_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_75a02f49-6efb-432b-ade3-a4fcd1640fbf_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="arc" order="1"/>
    <link:label id="lab_cntx_ScaleUp100KilogramsOfGMPGradeCompoundMember_108cd5af-d5fd-4030-b47a-79e884340c9c_terseLabel_en-US" xlink:label="lab_cntx_ScaleUp100KilogramsOfGMPGradeCompoundMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scale-up, 100 kilograms of GMP-grade compound</link:label>
    <link:label id="lab_cntx_ScaleUp100KilogramsOfGMPGradeCompoundMember_label_en-US" xlink:label="lab_cntx_ScaleUp100KilogramsOfGMPGradeCompoundMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scale-Up, 100 kilograms of GMP-Grade Compound [Member]</link:label>
    <link:label id="lab_cntx_ScaleUp100KilogramsOfGMPGradeCompoundMember_documentation_en-US" xlink:label="lab_cntx_ScaleUp100KilogramsOfGMPGradeCompoundMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scale-Up, 100 kilograms of GMP-Grade Compound</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cntx_ScaleUp100KilogramsOfGMPGradeCompoundMember" xlink:href="cntx-20230331.xsd#cntx_ScaleUp100KilogramsOfGMPGradeCompoundMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cntx_ScaleUp100KilogramsOfGMPGradeCompoundMember" xlink:to="lab_cntx_ScaleUp100KilogramsOfGMPGradeCompoundMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_47f7deae-28cc-4e27-8a03-8b1186e2aac0_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash used in financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_ed837638-ee67-472e-a4f1-65211898ab5f_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Compensation and benefits</link:label>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee-related Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_e7b10b6a-2f5d-4393-876e-e7cb34b4db93_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_e010d5e7-b899-4bb0-ac3b-45542fc9f748_verboseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' equity:</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract" xlink:to="lab_us-gaap_StockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_3c57ff93-ae5b-42b0-9041-efce02a13ca5_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expense and Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_6cc0b977-6e87-41ee-9a74-1bfae8fdc8ff_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Assumptions Used to Determine Fair Value of Share-Based Awards</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NatureOfOperations_f75395a4-a1bd-45eb-b2b0-3d90c714a223_terseLabel_en-US" xlink:label="lab_us-gaap_NatureOfOperations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization and Description of Business</link:label>
    <link:label id="lab_us-gaap_NatureOfOperations_label_en-US" xlink:label="lab_us-gaap_NatureOfOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nature of Operations [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NatureOfOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NatureOfOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NatureOfOperations" xlink:to="lab_us-gaap_NatureOfOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WarrantMember_04dac54b-4d3a-4816-9e1f-014dc03977f7_terseLabel_en-US" xlink:label="lab_us-gaap_WarrantMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants</link:label>
    <link:label id="lab_us-gaap_WarrantMember_label_en-US" xlink:label="lab_us-gaap_WarrantMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantMember" xlink:to="lab_us-gaap_WarrantMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_431de1b4-6f3b-49e6-93f0-f84b34c76336_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents and Restricted Cash</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_4ff1a6b7-6fc6-404e-b360-fdc0ff30a715_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liability</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_0359f716-7eb3-4e8b-93a6-5c7dfe3dc8e7_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_a9ab6d8d-a45f-419a-ad0c-476fc3f2b516_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average common shares outstanding - basic (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9dcd6be0-ab74-4888-937c-d2dfb5751841_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_1cbc908b-b1f5-445e-ae86-eb230b37c401_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected period for recognition</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_3ae9b7de-a0e9-418d-9b6c-7d5af0a2d285_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested and exercisable at March&#160;31, 2023</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_be589059-2d4f-452a-a738-d024edab5d9d_terseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation expense</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_00e16d15-50f2-431c-885e-edc0162b76a1_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies" xlink:to="lab_us-gaap_CommitmentsAndContingencies" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_99b3555d-e03b-4dda-a95a-e48a4b790528_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_f938780d-62af-40ef-882d-800da6bf2c0a_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_13b6bdaa-6ac7-4526-a35b-40b6e1b21304_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding at beginning of period (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_3d5bf26e-1db3-487b-9268-74f4896a77f8_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding at period end (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightDomain_0c1240b6-4ef7-4eb9-9a4a-e721e40d884c_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Domain]</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightDomain_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain" xlink:to="lab_us-gaap_ClassOfWarrantOrRightDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_02b8e22e-2368-4f2a-8281-072bc1fd4bdb_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others [Line Items]</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockValue_6d1e07a9-b109-4eb6-b527-e684e4733921_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, $0.001 par value; 10,000,000 shares authorized; no shares issued or outstanding</link:label>
    <link:label id="lab_us-gaap_PreferredStockValue_label_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockValue" xlink:to="lab_us-gaap_PreferredStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_a450e31e-2af7-4bc4-9eee-dafa1aff0ea6_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected dividend yield</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_3c90ec2f-622e-403a-8ddb-c33927ade015_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and Administrative Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_f9fbafff-cfd2-4181-8ed8-98e1e4b36af2_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeasesAbstract_6a6cef31-32a9-4a33-9526-6ddfdb3b66fa_terseLabel_en-US" xlink:label="lab_us-gaap_LeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:label id="lab_us-gaap_LeasesAbstract_label_en-US" xlink:label="lab_us-gaap_LeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeasesAbstract" xlink:to="lab_us-gaap_LeasesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_aefc2988-92b9-49f5-8940-21553dd23bac_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating expenses:</link:label>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpensesAbstract" xlink:to="lab_us-gaap_OperatingExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_b694c43e-713f-42e2-a1c0-076bb9264f9e_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 3</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member" xlink:to="lab_us-gaap_FairValueInputsLevel3Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_3c64dbe8-eec7-447f-ae83-5d5c5f8119dd_terseLabel_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Principles of Consolidation</link:label>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:to="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_4d375adc-bbcc-4cb9-a3c0-e38335d37694_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MinimumMember_7f8abf31-682a-436c-b1c3-dd18841d9e5a_terseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_label_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_1187a352-aea3-4320-8271-778e5ff7d97c_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_cc3ca8ee-66aa-412b-9ec1-e182b58fa9bc_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_6b4577a2-9fd6-4ff8-853a-66ccdebd6abf_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risk-free interest rate</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_7c3f4012-f1cb-41c2-9e1d-124b642347e3_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurements</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:to="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestIncomeExpenseNet_1f6fdc7d-1c46-42b2-a6b7-6cd0e5fd6af1_terseLabel_en-US" xlink:label="lab_us-gaap_InterestIncomeExpenseNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest income</link:label>
    <link:label id="lab_us-gaap_InterestIncomeExpenseNet_label_en-US" xlink:label="lab_us-gaap_InterestIncomeExpenseNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Income (Expense), Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeExpenseNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestIncomeExpenseNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestIncomeExpenseNet" xlink:to="lab_us-gaap_InterestIncomeExpenseNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_8c77db72-7654-40e9-bded-0d7a860fc152_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities and stockholders' equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_bb56d464-487f-46e9-9902-b656c5488797_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_c0089791-29c7-45be-b3a8-6af519ed3d16_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_5b12bd1e-e92b-4414-9574-ce35a56065c8_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_label_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfArrangementAxis" xlink:to="lab_us-gaap_TypeOfArrangementAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_1ccbe7ef-a013-46f6-9d25-48bf950a3f89_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_735adc81-10c2-4ae8-9366-f3437578a423_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 2</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_86568b0f-70e0-486a-9201-212ee132a076_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_cntx_RisksAndLiquidityTextBlock_85c37b85-391a-415e-8927-016a7f7d0035_terseLabel_en-US" xlink:label="lab_cntx_RisksAndLiquidityTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risks and Liquidity</link:label>
    <link:label id="lab_cntx_RisksAndLiquidityTextBlock_label_en-US" xlink:label="lab_cntx_RisksAndLiquidityTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risks And Liquidity [Text Block]</link:label>
    <link:label id="lab_cntx_RisksAndLiquidityTextBlock_documentation_en-US" xlink:label="lab_cntx_RisksAndLiquidityTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risks And Liquidity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cntx_RisksAndLiquidityTextBlock" xlink:href="cntx-20230331.xsd#cntx_RisksAndLiquidityTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cntx_RisksAndLiquidityTextBlock" xlink:to="lab_cntx_RisksAndLiquidityTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_f028447f-3b7b-4fb1-9d9e-5b1c6e5360c9_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income (loss) per share - diluted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted" xlink:to="lab_us-gaap_EarningsPerShareDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_13dad12e-371c-40fa-bf3d-12636fc6b010_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested and expected to vest at period end (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_cntx_PatentCostsPolicyPolicyTextBlock_f62193fe-6d9a-4d7d-b4f9-554068ec2277_terseLabel_en-US" xlink:label="lab_cntx_PatentCostsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Patent Costs</link:label>
    <link:label id="lab_cntx_PatentCostsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_cntx_PatentCostsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Patent Costs, Policy [Policy Text Block]</link:label>
    <link:label id="lab_cntx_PatentCostsPolicyPolicyTextBlock_documentation_en-US" xlink:label="lab_cntx_PatentCostsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Patent Costs, Policy</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cntx_PatentCostsPolicyPolicyTextBlock" xlink:href="cntx-20230331.xsd#cntx_PatentCostsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cntx_PatentCostsPolicyPolicyTextBlock" xlink:to="lab_cntx_PatentCostsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UseOfEstimates_c3ee21f3-4faf-4b8a-943f-7cafbdc7da09_terseLabel_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates</link:label>
    <link:label id="lab_us-gaap_UseOfEstimates_label_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UseOfEstimates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates" xlink:to="lab_us-gaap_UseOfEstimates" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_994d69a1-02f3-4d74-beea-4639ec8b1951_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_96fe4500-4382-4a9e-b21d-5c342ee878f7_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:to="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TemporaryEquityDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_TemporaryEquityDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquityDisclosureAbstract" xlink:to="lab_us-gaap_TemporaryEquityDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_670d93b1-a867-4273-b993-8882fdeeebcb_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based awards vesting period</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsOfStockIssuanceCosts_dc7cf7a5-7e1b-4673-86fc-8a227663ca3a_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfStockIssuanceCosts" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for offering costs related to the private placement sale of common stock</link:label>
    <link:label id="lab_us-gaap_PaymentsOfStockIssuanceCosts_label_en-US" xlink:label="lab_us-gaap_PaymentsOfStockIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments of Stock Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfStockIssuanceCosts" xlink:to="lab_us-gaap_PaymentsOfStockIssuanceCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_4c8484b1-ca44-4645-8b81-db15b2457f48_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_95245554-1b3f-43d6-a120-d0d774915cfc_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation expense</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">APIC, Share-Based Payment Arrangement, Increase for Cost Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAdjustmentOfWarrants_6d7f27d5-c328-495d-937f-f583ef25e652_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAdjustmentOfWarrants" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value adjustment of warrants</link:label>
    <link:label id="lab_us-gaap_FairValueAdjustmentOfWarrants_label_en-US" xlink:label="lab_us-gaap_FairValueAdjustmentOfWarrants" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Adjustment of Warrants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAdjustmentOfWarrants" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAdjustmentOfWarrants"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAdjustmentOfWarrants" xlink:to="lab_us-gaap_FairValueAdjustmentOfWarrants" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_50903c1e-843a-4661-96f7-988e1343eaf8_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_cntx_CollaborativeArrangementRightsAndObligationsDevelopmentAndRegulatoryMilestonePaymentsMaximum_415bd235-9797-4782-a391-7455cb52c0a8_terseLabel_en-US" xlink:label="lab_cntx_CollaborativeArrangementRightsAndObligationsDevelopmentAndRegulatoryMilestonePaymentsMaximum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum development and regulatory milestone payments</link:label>
    <link:label id="lab_cntx_CollaborativeArrangementRightsAndObligationsDevelopmentAndRegulatoryMilestonePaymentsMaximum_label_en-US" xlink:label="lab_cntx_CollaborativeArrangementRightsAndObligationsDevelopmentAndRegulatoryMilestonePaymentsMaximum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Rights and Obligations, Development And Regulatory Milestone Payments, Maximum</link:label>
    <link:label id="lab_cntx_CollaborativeArrangementRightsAndObligationsDevelopmentAndRegulatoryMilestonePaymentsMaximum_documentation_en-US" xlink:label="lab_cntx_CollaborativeArrangementRightsAndObligationsDevelopmentAndRegulatoryMilestonePaymentsMaximum" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Rights and Obligations, Development And Regulatory Milestone Payments, Maximum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cntx_CollaborativeArrangementRightsAndObligationsDevelopmentAndRegulatoryMilestonePaymentsMaximum" xlink:href="cntx-20230331.xsd#cntx_CollaborativeArrangementRightsAndObligationsDevelopmentAndRegulatoryMilestonePaymentsMaximum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cntx_CollaborativeArrangementRightsAndObligationsDevelopmentAndRegulatoryMilestonePaymentsMaximum" xlink:to="lab_cntx_CollaborativeArrangementRightsAndObligationsDevelopmentAndRegulatoryMilestonePaymentsMaximum" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_09e66093-ef9a-4122-8ae8-dfbf03518e72_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant exercise price (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Exercise Price of Warrants or Rights</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityExTransitionPeriod_bdfd5787-28c4-4f11-9d25-64182976ca05_terseLabel_en-US" xlink:label="lab_dei_EntityExTransitionPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Ex Transition Period</link:label>
    <link:label id="lab_dei_EntityExTransitionPeriod_label_en-US" xlink:label="lab_dei_EntityExTransitionPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Ex Transition Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityExTransitionPeriod" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityExTransitionPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityExTransitionPeriod" xlink:to="lab_dei_EntityExTransitionPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_40aec54a-674c-46f0-87b0-99711846ae1b_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income (loss) per share - basic (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_445f67a4-e94a-43ed-82af-5568e3fac9dc_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based award contractual life</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine2_a8c67af0-54da-4076-9dc9-6b7d8ab2f582_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine2_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine2" xlink:to="lab_dei_EntityAddressAddressLine2" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_c1735c9d-7109-40e1-b5c9-5995ba664dcb_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_a7cefda0-6167-4cce-9b8c-f33d31d235ab_terseLabel_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_label_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_4cf43e0f-ae22-4cbd-8d89-5022e67d9bd9_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total stockholders' equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_ca2a6855-7a04-4638-8603-2c54555c80a8_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_23dc4c3b-d71a-49e1-ab43-12f037a3ad54_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockDomain_9666154c-473e-4737-809f-d829e6fa6139_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockDomain_label_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockDomain" xlink:to="lab_us-gaap_ClassOfStockDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_cntx_IssuedForServicesMember_38bfe24e-eab7-4a45-80ef-69e03314c00c_terseLabel_en-US" xlink:label="lab_cntx_IssuedForServicesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issued for services</link:label>
    <link:label id="lab_cntx_IssuedForServicesMember_label_en-US" xlink:label="lab_cntx_IssuedForServicesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issued for Services [Member]</link:label>
    <link:label id="lab_cntx_IssuedForServicesMember_documentation_en-US" xlink:label="lab_cntx_IssuedForServicesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issued for Services</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cntx_IssuedForServicesMember" xlink:href="cntx-20230331.xsd#cntx_IssuedForServicesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cntx_IssuedForServicesMember" xlink:to="lab_cntx_IssuedForServicesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_d34a673b-002a-4569-94be-9844445bdc76_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_cntx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedAsAPercentageOfOutstandingStock_ca78ee86-a8b1-468f-920b-e849541abc8b_terseLabel_en-US" xlink:label="lab_cntx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedAsAPercentageOfOutstandingStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Annual rate at which authorized shares of common stock increase</link:label>
    <link:label id="lab_cntx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedAsAPercentageOfOutstandingStock_label_en-US" xlink:label="lab_cntx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedAsAPercentageOfOutstandingStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Additional Shares Authorized As A Percentage Of Outstanding Stock</link:label>
    <link:label id="lab_cntx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedAsAPercentageOfOutstandingStock_documentation_en-US" xlink:label="lab_cntx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedAsAPercentageOfOutstandingStock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Additional Shares Authorized As A Percentage Of Outstanding Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cntx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedAsAPercentageOfOutstandingStock" xlink:href="cntx-20230331.xsd#cntx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedAsAPercentageOfOutstandingStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cntx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedAsAPercentageOfOutstandingStock" xlink:to="lab_cntx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedAsAPercentageOfOutstandingStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_ccd62a0a-b563-4946-8f34-c5737732fbd6_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Research and Development Arrangement, Contract to Perform for Others [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Research and Development Arrangement, Contract to Perform for Others [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:to="lab_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_7ebb7971-2309-470e-93c8-caf74950fe32_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in operating assets and liabilities:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_555406fa-36f7-4c6b-a542-faabc5473093_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accrued Liabilities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accrued Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_7f2fad30-d28d-4d08-ad67-d2876eb2e283_terseLabel_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money market funds</link:label>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_label_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money Market Funds [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MoneyMarketFundsMember" xlink:to="lab_us-gaap_MoneyMarketFundsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_5618f430-410b-4e9b-ab24-b8b1d9be59fd_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Domain]</link:label>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_label_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_230c842d-60b6-478f-ab6b-e79da58c4b94_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employer contribution amount</link:label>
    <link:label id="lab_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_label_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Contribution Plan, Employer Discretionary Contribution Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:to="lab_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_105e0faf-a1c0-466a-8d74-b537c6274352_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_4bbd4f43-64cc-4649-a78c-84202f3678cd_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized compensation expense</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_5cb0b649-affb-4658-8b08-b8f701886462_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_d6a0fd87-f319-46d0-964e-08c6dfe8baf3_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total shares of common stock authorized for issuance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_e8666369-d483-4940-bc7d-5eefa7860831_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common&#160;Stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_2cb300bf-67a3-4b78-b3a3-bdd25ed49a70_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_cntx_ScaleUp300KilogramsOfGMPGradeCompoundMember_9c12935f-a79c-4eeb-abf2-1f4050bab3f8_terseLabel_en-US" xlink:label="lab_cntx_ScaleUp300KilogramsOfGMPGradeCompoundMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scale-up, 300 kilograms of GMP-grade compound</link:label>
    <link:label id="lab_cntx_ScaleUp300KilogramsOfGMPGradeCompoundMember_label_en-US" xlink:label="lab_cntx_ScaleUp300KilogramsOfGMPGradeCompoundMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scale-Up, 300 kilograms of GMP-Grade Compound [Member]</link:label>
    <link:label id="lab_cntx_ScaleUp300KilogramsOfGMPGradeCompoundMember_documentation_en-US" xlink:label="lab_cntx_ScaleUp300KilogramsOfGMPGradeCompoundMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scale-Up, 300 kilograms of GMP-Grade Compound</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cntx_ScaleUp300KilogramsOfGMPGradeCompoundMember" xlink:href="cntx-20230331.xsd#cntx_ScaleUp300KilogramsOfGMPGradeCompoundMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cntx_ScaleUp300KilogramsOfGMPGradeCompoundMember" xlink:to="lab_cntx_ScaleUp300KilogramsOfGMPGradeCompoundMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProjectMember_4f57fee8-5944-4535-bd34-760d4a06dbb2_terseLabel_en-US" xlink:label="lab_us-gaap_ProjectMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Project [Domain]</link:label>
    <link:label id="lab_us-gaap_ProjectMember_label_en-US" xlink:label="lab_us-gaap_ProjectMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Project [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProjectMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProjectMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProjectMember" xlink:to="lab_us-gaap_ProjectMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_4212f1de-a8c5-472e-9b69-6bcb6018fe4d_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares of common stock available for grant (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_b7d4a65c-1d5f-4758-b83c-fc1ddb254f25_terseLabel_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_label_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementClassOfStockAxis" xlink:to="lab_us-gaap_StatementClassOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_76e67d9b-df65-4703-8cbf-aa51a4d70854_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRenewalTerm_e0cb8db5-1155-4cbd-97de-b40767eae4cc_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional renewal term</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRenewalTerm_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Renewal Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:to="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentQuarterlyReport_79b5f5bf-115f-4ae7-8e73-cd5e5658c5bf_terseLabel_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:label id="lab_dei_DocumentQuarterlyReport_label_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentQuarterlyReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentQuarterlyReport" xlink:to="lab_dei_DocumentQuarterlyReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_027d061d-26a7-49d6-afca-fb22993f8d77_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_1f1270c0-f265-4f10-b8cb-0fd65c049657_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense (Excluding Acquired in Process Cost)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_0e098d4a-7bf7-47e3-874c-57650545042a_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_9a9b8a05-ea57-4b9f-86ec-d7ea39e4fa64_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net decrease in cash, cash equivalents and restricted cash</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_5996e013-b97e-4199-bba2-9c524576d2e1_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_ffcd66a2-a3ac-4891-95e2-f4e5244ffec0_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_8da1808c-83d3-4eba-86db-17d6d2c1f8b4_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_461adcd1-8e82-480b-86e0-976389683d3e_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_3b46dbd2-0513-4e07-bd4f-9f20132ebf9d_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_cntx_CollaborativeArrangementRightsAndObligationsTieredRoyaltyPercent_9f3564a6-98c3-41de-aae6-7a697530b648_terseLabel_en-US" xlink:label="lab_cntx_CollaborativeArrangementRightsAndObligationsTieredRoyaltyPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tiered royalty payment, percent (up to)</link:label>
    <link:label id="lab_cntx_CollaborativeArrangementRightsAndObligationsTieredRoyaltyPercent_label_en-US" xlink:label="lab_cntx_CollaborativeArrangementRightsAndObligationsTieredRoyaltyPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Rights and Obligations, Tiered Royalty, Percent</link:label>
    <link:label id="lab_cntx_CollaborativeArrangementRightsAndObligationsTieredRoyaltyPercent_documentation_en-US" xlink:label="lab_cntx_CollaborativeArrangementRightsAndObligationsTieredRoyaltyPercent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Rights and Obligations, Tiered Royalty, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cntx_CollaborativeArrangementRightsAndObligationsTieredRoyaltyPercent" xlink:href="cntx-20230331.xsd#cntx_CollaborativeArrangementRightsAndObligationsTieredRoyaltyPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cntx_CollaborativeArrangementRightsAndObligationsTieredRoyaltyPercent" xlink:to="lab_cntx_CollaborativeArrangementRightsAndObligationsTieredRoyaltyPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_05722653-869a-442b-85e7-9da78b2b64f2_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_16251b4c-3779-48c3-a52e-e55ad9447618_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Costs</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_3bd0dfa7-4d93-4316-91b1-aca329a04dda_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recurring</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:to="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_e34e6a8c-e856-4e75-b798-9c0e39ca73c5_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercisable at period end (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_3b8df0ed-ef6a-4355-8f72-6c83bb046be7_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskCreditRisk_863f09bd-3f0c-4188-abd8-ca17e2491df5_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentrations of Credit Risk</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskCreditRisk_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk, Credit Risk, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskCreditRisk" xlink:to="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_43e2c28c-327f-4df7-9790-1d5c1a3cfae2_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_7121ee02-8c84-4e11-b061-13a89052ad22_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_78dfa26d-42d1-46f4-8fc9-f3a3f4481298_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from operating activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_e5c32091-983b-40da-bf37-0ac38e639ea8_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedProfessionalFeesCurrent_099ac2ad-48b6-4474-aeb1-bcf1b36b0361_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedProfessionalFeesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Professional fees</link:label>
    <link:label id="lab_us-gaap_AccruedProfessionalFeesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedProfessionalFeesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Professional Fees, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedProfessionalFeesCurrent" xlink:to="lab_us-gaap_AccruedProfessionalFeesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_696c7919-d791-460d-a29c-c99f460358e5_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_4b61dc74-e586-42dd-bd34-f1b8f8e01bb2_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_c1201ea0-1d1e-492f-ba12-1c15689dd15d_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WarrantsAndRightsOutstandingTerm_a5145e87-99b2-4a0c-a207-28a5842bcbfa_terseLabel_en-US" xlink:label="lab_us-gaap_WarrantsAndRightsOutstandingTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants, term from date of issuance</link:label>
    <link:label id="lab_us-gaap_WarrantsAndRightsOutstandingTerm_label_en-US" xlink:label="lab_us-gaap_WarrantsAndRightsOutstandingTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants and Rights Outstanding, Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantsAndRightsOutstandingTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantsAndRightsOutstandingTerm" xlink:to="lab_us-gaap_WarrantsAndRightsOutstandingTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_cntx_IssuedForProfessionalConsultingServicesMember_07df091f-5fb0-4cbc-b89d-451ad0e015c0_terseLabel_en-US" xlink:label="lab_cntx_IssuedForProfessionalConsultingServicesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issued in 2022 for consulting services</link:label>
    <link:label id="lab_cntx_IssuedForProfessionalConsultingServicesMember_label_en-US" xlink:label="lab_cntx_IssuedForProfessionalConsultingServicesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issued for Professional Consulting Services [Member]</link:label>
    <link:label id="lab_cntx_IssuedForProfessionalConsultingServicesMember_documentation_en-US" xlink:label="lab_cntx_IssuedForProfessionalConsultingServicesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issued for Professional Consulting Services</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cntx_IssuedForProfessionalConsultingServicesMember" xlink:href="cntx-20230331.xsd#cntx_IssuedForProfessionalConsultingServicesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cntx_IssuedForProfessionalConsultingServicesMember" xlink:to="lab_cntx_IssuedForProfessionalConsultingServicesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredChargesPolicyTextBlock_8a87a864-be3c-4bd6-9f22-61426e83a911_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredChargesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Offering Costs</link:label>
    <link:label id="lab_us-gaap_DeferredChargesPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_DeferredChargesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Charges, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredChargesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredChargesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredChargesPolicyTextBlock" xlink:to="lab_us-gaap_DeferredChargesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_d6c8a151-7a89-476a-9dd6-21fb14ece590_terseLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other income (expense)</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpense" xlink:to="lab_us-gaap_NonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_737802dc-2334-4765-a820-229f89333bfe_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_62dc2cac-4aa4-4862-91c5-7f72a1acfcfc_terseLabel_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_label_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:to="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_cntx_CollaborativeArrangementRightsAndObligationsSalesMilestonePaymentsMaximum_49531973-f877-43f0-9dac-5c8e94324e9a_terseLabel_en-US" xlink:label="lab_cntx_CollaborativeArrangementRightsAndObligationsSalesMilestonePaymentsMaximum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum sales milestone payments</link:label>
    <link:label id="lab_cntx_CollaborativeArrangementRightsAndObligationsSalesMilestonePaymentsMaximum_label_en-US" xlink:label="lab_cntx_CollaborativeArrangementRightsAndObligationsSalesMilestonePaymentsMaximum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Rights and Obligations, Sales Milestone Payments, Maximum</link:label>
    <link:label id="lab_cntx_CollaborativeArrangementRightsAndObligationsSalesMilestonePaymentsMaximum_documentation_en-US" xlink:label="lab_cntx_CollaborativeArrangementRightsAndObligationsSalesMilestonePaymentsMaximum" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Rights and Obligations, Sales Milestone Payments, Maximum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cntx_CollaborativeArrangementRightsAndObligationsSalesMilestonePaymentsMaximum" xlink:href="cntx-20230331.xsd#cntx_CollaborativeArrangementRightsAndObligationsSalesMilestonePaymentsMaximum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cntx_CollaborativeArrangementRightsAndObligationsSalesMilestonePaymentsMaximum" xlink:to="lab_cntx_CollaborativeArrangementRightsAndObligationsSalesMilestonePaymentsMaximum" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_271ab1df-e072-48ae-8782-aabc5490f2c7_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from financing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_6d213b04-e11d-43a8-9fda-4e8a85f300b4_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease right-of-use asset</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_662513b2-de06-4449-a7a3-fe435495566a_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Loss Per Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_11f43f3d-a547-4e56-9b7e-a74b92486271_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation expense</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_526b49aa-7bf5-40be-a2d3-5edc014193b8_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average fair value of grants during period (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightOutstanding_658b9c4c-c5ff-4fbc-8d56-57b78ff80a6e_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants prior to conversion (in shares)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightOutstanding_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:to="lab_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_d9c0c542-6636-4cdf-9e77-3cd61124e14b_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested and expected to vest at period end (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_55c7cbb2-36a5-42b0-82da-15ca340a2222_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_c8d3b76b-a124-4fd8-b618-e5b63e1319d8_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_587afcd0-9f7f-4f4e-b5b9-91864883d7ac_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase of property and equipment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_a5c5b4e1-70a4-401f-9897-8d7a3fb46870_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-Based Award Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Option, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_358d9d02-892e-4e21-ac03-00b0104d24d8_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss from operations</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_29dc9db8-da03-411c-bc0c-a018677b061c_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_cntx_CollaborativeArrangementRightsAndObligationsSalesPaymentPeriod_ecd35afc-f616-45df-828a-8c4e948d9923_terseLabel_en-US" xlink:label="lab_cntx_CollaborativeArrangementRightsAndObligationsSalesPaymentPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Quarterly sales payment due upon completion, period of payment</link:label>
    <link:label id="lab_cntx_CollaborativeArrangementRightsAndObligationsSalesPaymentPeriod_label_en-US" xlink:label="lab_cntx_CollaborativeArrangementRightsAndObligationsSalesPaymentPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Rights and Obligations, Sales Payment Period</link:label>
    <link:label id="lab_cntx_CollaborativeArrangementRightsAndObligationsSalesPaymentPeriod_documentation_en-US" xlink:label="lab_cntx_CollaborativeArrangementRightsAndObligationsSalesPaymentPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research And Development Arrangement, Contract To Perform For Others, Upon Completion, Sales Payment Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cntx_CollaborativeArrangementRightsAndObligationsSalesPaymentPeriod" xlink:href="cntx-20230331.xsd#cntx_CollaborativeArrangementRightsAndObligationsSalesPaymentPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cntx_CollaborativeArrangementRightsAndObligationsSalesPaymentPeriod" xlink:to="lab_cntx_CollaborativeArrangementRightsAndObligationsSalesPaymentPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_fedfbe97-3a8b-4638-87fc-16f854658bc1_terseLabel_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-use asset obtained in exchange for lease obligation</link:label>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-Use Asset Obtained in Exchange for Operating Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_6de36680-3f76-406c-be24-ade5c7b42310_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_38b756c4-28e8-433d-9aed-d37389b15f70_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_cntx_RisksAndLiquidityAbstract_label_en-US" xlink:label="lab_cntx_RisksAndLiquidityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risks And Liquidity [Abstract]</link:label>
    <link:label id="lab_cntx_RisksAndLiquidityAbstract_documentation_en-US" xlink:label="lab_cntx_RisksAndLiquidityAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risks And Liquidity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cntx_RisksAndLiquidityAbstract" xlink:href="cntx-20230331.xsd#cntx_RisksAndLiquidityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cntx_RisksAndLiquidityAbstract" xlink:to="lab_cntx_RisksAndLiquidityAbstract" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>9
<FILENAME>cntx-20230331_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:25d0e2a1-022e-45ee-a4b8-2723f9a842c8,g:b681c287-491c-4187-8280-df3edb448dfa-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.contexttherapeutics.com/role/Cover" xlink:type="simple" xlink:href="cntx-20230331.xsd#Cover"/>
  <link:presentationLink xlink:role="http://www.contexttherapeutics.com/role/Cover" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_fe9515a6-6e63-4ba2-94ab-9edae1461828" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_e7c41320-5ef4-48a6-ab25-0ab555b6a759" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_fe9515a6-6e63-4ba2-94ab-9edae1461828" xlink:to="loc_dei_DocumentType_e7c41320-5ef4-48a6-ab25-0ab555b6a759" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport_7cfc4212-968b-4613-a8b0-d3e13a036725" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentQuarterlyReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_fe9515a6-6e63-4ba2-94ab-9edae1461828" xlink:to="loc_dei_DocumentQuarterlyReport_7cfc4212-968b-4613-a8b0-d3e13a036725" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_60c13078-2db3-492c-bc75-b61be0c856fe" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_fe9515a6-6e63-4ba2-94ab-9edae1461828" xlink:to="loc_dei_DocumentPeriodEndDate_60c13078-2db3-492c-bc75-b61be0c856fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_4966cae2-c668-43e9-973a-4c76ace20d28" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_fe9515a6-6e63-4ba2-94ab-9edae1461828" xlink:to="loc_dei_DocumentTransitionReport_4966cae2-c668-43e9-973a-4c76ace20d28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_1f495a1d-8299-4228-b6ba-29ccc1dd18ea" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_fe9515a6-6e63-4ba2-94ab-9edae1461828" xlink:to="loc_dei_EntityFileNumber_1f495a1d-8299-4228-b6ba-29ccc1dd18ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_f7c17368-e3ba-45d3-9f4b-1b0f952074d6" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_fe9515a6-6e63-4ba2-94ab-9edae1461828" xlink:to="loc_dei_EntityRegistrantName_f7c17368-e3ba-45d3-9f4b-1b0f952074d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_ddb9c5d9-a019-4e35-a1b1-3dbd31dfa563" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_fe9515a6-6e63-4ba2-94ab-9edae1461828" xlink:to="loc_dei_EntityIncorporationStateCountryCode_ddb9c5d9-a019-4e35-a1b1-3dbd31dfa563" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_35131b77-841d-4b7d-ac4b-f8fa31b21495" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_fe9515a6-6e63-4ba2-94ab-9edae1461828" xlink:to="loc_dei_EntityTaxIdentificationNumber_35131b77-841d-4b7d-ac4b-f8fa31b21495" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_3a9e2808-e4ed-4504-ab16-3b27dee83ffb" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_fe9515a6-6e63-4ba2-94ab-9edae1461828" xlink:to="loc_dei_EntityAddressAddressLine1_3a9e2808-e4ed-4504-ab16-3b27dee83ffb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2_493f3bf1-5c71-43b5-8350-da8050db727b" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine2"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_fe9515a6-6e63-4ba2-94ab-9edae1461828" xlink:to="loc_dei_EntityAddressAddressLine2_493f3bf1-5c71-43b5-8350-da8050db727b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_dc8bd536-d012-480e-8199-54227d785030" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_fe9515a6-6e63-4ba2-94ab-9edae1461828" xlink:to="loc_dei_EntityAddressCityOrTown_dc8bd536-d012-480e-8199-54227d785030" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_073cecdf-35e7-437e-b279-373bea48603a" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_fe9515a6-6e63-4ba2-94ab-9edae1461828" xlink:to="loc_dei_EntityAddressStateOrProvince_073cecdf-35e7-437e-b279-373bea48603a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_3dfdfecb-5620-4fbd-95f4-7cc74c59934c" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_fe9515a6-6e63-4ba2-94ab-9edae1461828" xlink:to="loc_dei_EntityAddressPostalZipCode_3dfdfecb-5620-4fbd-95f4-7cc74c59934c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_dca5b3a1-147a-40bb-a1f2-0960a0db8756" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_fe9515a6-6e63-4ba2-94ab-9edae1461828" xlink:to="loc_dei_CityAreaCode_dca5b3a1-147a-40bb-a1f2-0960a0db8756" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_e1af7006-e274-488e-b1b1-d8cdee6a0482" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_fe9515a6-6e63-4ba2-94ab-9edae1461828" xlink:to="loc_dei_LocalPhoneNumber_e1af7006-e274-488e-b1b1-d8cdee6a0482" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_27364193-6e4d-4b6d-97e0-6d0593984c0e" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_fe9515a6-6e63-4ba2-94ab-9edae1461828" xlink:to="loc_dei_Security12bTitle_27364193-6e4d-4b6d-97e0-6d0593984c0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_527a28dc-04e9-42d1-bee3-fd25b6c9acac" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_fe9515a6-6e63-4ba2-94ab-9edae1461828" xlink:to="loc_dei_TradingSymbol_527a28dc-04e9-42d1-bee3-fd25b6c9acac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_9366c773-64e9-4152-9195-a99f7bf7ea21" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_fe9515a6-6e63-4ba2-94ab-9edae1461828" xlink:to="loc_dei_SecurityExchangeName_9366c773-64e9-4152-9195-a99f7bf7ea21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_ae1117d1-2b8c-4d37-9c76-b1a82a6ddd94" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_fe9515a6-6e63-4ba2-94ab-9edae1461828" xlink:to="loc_dei_EntityCurrentReportingStatus_ae1117d1-2b8c-4d37-9c76-b1a82a6ddd94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_e3e7bfe7-1a60-42f8-a05d-aa2b7218a199" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_fe9515a6-6e63-4ba2-94ab-9edae1461828" xlink:to="loc_dei_EntityInteractiveDataCurrent_e3e7bfe7-1a60-42f8-a05d-aa2b7218a199" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_e7fc5963-6587-4cef-b4c9-f546c8d799ee" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_fe9515a6-6e63-4ba2-94ab-9edae1461828" xlink:to="loc_dei_EntityFilerCategory_e7fc5963-6587-4cef-b4c9-f546c8d799ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_7b7eb9c3-bc07-4578-9790-f271e20ca4d2" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_fe9515a6-6e63-4ba2-94ab-9edae1461828" xlink:to="loc_dei_EntitySmallBusiness_7b7eb9c3-bc07-4578-9790-f271e20ca4d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_ace9b5bb-ff9e-4148-99b4-354397a70999" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_fe9515a6-6e63-4ba2-94ab-9edae1461828" xlink:to="loc_dei_EntityEmergingGrowthCompany_ace9b5bb-ff9e-4148-99b4-354397a70999" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityExTransitionPeriod_5d366d6e-12ad-497f-83ba-7d1d55c9576d" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityExTransitionPeriod"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_fe9515a6-6e63-4ba2-94ab-9edae1461828" xlink:to="loc_dei_EntityExTransitionPeriod_5d366d6e-12ad-497f-83ba-7d1d55c9576d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_5ddd1d4a-2bf3-42de-9d5e-9c8164bd7438" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_fe9515a6-6e63-4ba2-94ab-9edae1461828" xlink:to="loc_dei_EntityShellCompany_5ddd1d4a-2bf3-42de-9d5e-9c8164bd7438" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_f77f84da-e17c-47ec-8faa-583819583d1b" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_fe9515a6-6e63-4ba2-94ab-9edae1461828" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_f77f84da-e17c-47ec-8faa-583819583d1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_97674263-a59b-4f70-b6bd-2fc26a11d8ea" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_fe9515a6-6e63-4ba2-94ab-9edae1461828" xlink:to="loc_dei_AmendmentFlag_97674263-a59b-4f70-b6bd-2fc26a11d8ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_68938d6f-b47d-4b9b-b24c-e4aca4d66208" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_fe9515a6-6e63-4ba2-94ab-9edae1461828" xlink:to="loc_dei_DocumentFiscalYearFocus_68938d6f-b47d-4b9b-b24c-e4aca4d66208" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_7947ae8a-415a-4baa-bd54-85425d5b777f" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_fe9515a6-6e63-4ba2-94ab-9edae1461828" xlink:to="loc_dei_DocumentFiscalPeriodFocus_7947ae8a-415a-4baa-bd54-85425d5b777f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_8a694afe-8e36-49bd-ac83-596d6a342999" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_fe9515a6-6e63-4ba2-94ab-9edae1461828" xlink:to="loc_dei_EntityCentralIndexKey_8a694afe-8e36-49bd-ac83-596d6a342999" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_143cbf56-19b7-478b-a95a-9e318a6357e3" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="31" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_fe9515a6-6e63-4ba2-94ab-9edae1461828" xlink:to="loc_dei_CurrentFiscalYearEndDate_143cbf56-19b7-478b-a95a-9e318a6357e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.contexttherapeutics.com/role/CondensedConsolidatedBalanceSheets" xlink:type="simple" xlink:href="cntx-20230331.xsd#CondensedConsolidatedBalanceSheets"/>
  <link:presentationLink xlink:role="http://www.contexttherapeutics.com/role/CondensedConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_1c988bea-acec-4c41-8242-a19cd883703b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_a93c5d26-d700-4c32-a5d9-752680d9b82b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_1c988bea-acec-4c41-8242-a19cd883703b" xlink:to="loc_us-gaap_AssetsAbstract_a93c5d26-d700-4c32-a5d9-752680d9b82b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_4a28832c-ebbe-4441-8078-55967e4e8f89" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_a93c5d26-d700-4c32-a5d9-752680d9b82b" xlink:to="loc_us-gaap_AssetsCurrentAbstract_4a28832c-ebbe-4441-8078-55967e4e8f89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_10f97f03-aafd-4889-8380-7bbead348532" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_4a28832c-ebbe-4441-8078-55967e4e8f89" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_10f97f03-aafd-4889-8380-7bbead348532" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_ca62d912-d365-4fbf-a94a-9556e7d8f42b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_4a28832c-ebbe-4441-8078-55967e4e8f89" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_ca62d912-d365-4fbf-a94a-9556e7d8f42b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_09c88b79-5b22-4bdb-8d1a-6748fa8937ee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_4a28832c-ebbe-4441-8078-55967e4e8f89" xlink:to="loc_us-gaap_AssetsCurrent_09c88b79-5b22-4bdb-8d1a-6748fa8937ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_96304a70-d209-4f9f-8038-8daaef15f0d5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_a93c5d26-d700-4c32-a5d9-752680d9b82b" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_96304a70-d209-4f9f-8038-8daaef15f0d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_642c4b90-9baf-4481-b586-49a4f40a9591" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_a93c5d26-d700-4c32-a5d9-752680d9b82b" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_642c4b90-9baf-4481-b586-49a4f40a9591" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_4a7ed700-9a47-4fe1-a724-c4ebd00bf571" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_a93c5d26-d700-4c32-a5d9-752680d9b82b" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_4a7ed700-9a47-4fe1-a724-c4ebd00bf571" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_c69b1c83-2612-4257-81fd-b1e5008fcc62" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_a93c5d26-d700-4c32-a5d9-752680d9b82b" xlink:to="loc_us-gaap_Assets_c69b1c83-2612-4257-81fd-b1e5008fcc62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_a70e64f4-2dd6-48bb-a99a-2c9314b2b4e0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_1c988bea-acec-4c41-8242-a19cd883703b" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_a70e64f4-2dd6-48bb-a99a-2c9314b2b4e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_3a43344e-4e34-47fa-a68f-193f1353ff75" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_a70e64f4-2dd6-48bb-a99a-2c9314b2b4e0" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_3a43344e-4e34-47fa-a68f-193f1353ff75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_95d05b65-ee17-4acb-bb8a-c1c4c78f7ca7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_3a43344e-4e34-47fa-a68f-193f1353ff75" xlink:to="loc_us-gaap_AccountsPayableCurrent_95d05b65-ee17-4acb-bb8a-c1c4c78f7ca7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_5395f5c7-7db3-4927-90e8-8cc9f2e4f06d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_3a43344e-4e34-47fa-a68f-193f1353ff75" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_5395f5c7-7db3-4927-90e8-8cc9f2e4f06d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_c8f4af39-8dd5-4cd4-94bb-d36058844f0a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_3a43344e-4e34-47fa-a68f-193f1353ff75" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_c8f4af39-8dd5-4cd4-94bb-d36058844f0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_f55f114e-409d-4918-9620-30a9ce7b4c12" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_3a43344e-4e34-47fa-a68f-193f1353ff75" xlink:to="loc_us-gaap_LiabilitiesCurrent_f55f114e-409d-4918-9620-30a9ce7b4c12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_2aee3283-01d7-44b2-9c66-9c4324033d51" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_a70e64f4-2dd6-48bb-a99a-2c9314b2b4e0" xlink:to="loc_us-gaap_Liabilities_2aee3283-01d7-44b2-9c66-9c4324033d51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_37361bfe-0705-4697-a61d-3fcb48404aff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_a70e64f4-2dd6-48bb-a99a-2c9314b2b4e0" xlink:to="loc_us-gaap_CommitmentsAndContingencies_37361bfe-0705-4697-a61d-3fcb48404aff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_c7f89981-7d0d-497b-8018-16c0f6822771" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_a70e64f4-2dd6-48bb-a99a-2c9314b2b4e0" xlink:to="loc_us-gaap_StockholdersEquityAbstract_c7f89981-7d0d-497b-8018-16c0f6822771" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_83bf64ae-5383-45da-b5b7-2508ddbb2774" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_c7f89981-7d0d-497b-8018-16c0f6822771" xlink:to="loc_us-gaap_PreferredStockValue_83bf64ae-5383-45da-b5b7-2508ddbb2774" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_4c016820-468a-4135-992f-90cfc04c3018" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_c7f89981-7d0d-497b-8018-16c0f6822771" xlink:to="loc_us-gaap_CommonStockValue_4c016820-468a-4135-992f-90cfc04c3018" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_587ea306-b3d9-492b-ba6a-18278e437010" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_c7f89981-7d0d-497b-8018-16c0f6822771" xlink:to="loc_us-gaap_AdditionalPaidInCapital_587ea306-b3d9-492b-ba6a-18278e437010" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_93507750-82e4-429f-a997-0af87886fb2b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_c7f89981-7d0d-497b-8018-16c0f6822771" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_93507750-82e4-429f-a997-0af87886fb2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_7cadd0a4-b2b2-47b1-97e9-02bf0387a0df" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_c7f89981-7d0d-497b-8018-16c0f6822771" xlink:to="loc_us-gaap_StockholdersEquity_7cadd0a4-b2b2-47b1-97e9-02bf0387a0df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_35bb430e-1c95-48b3-b080-7077b27a400f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_a70e64f4-2dd6-48bb-a99a-2c9314b2b4e0" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_35bb430e-1c95-48b3-b080-7077b27a400f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.contexttherapeutics.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="simple" xlink:href="cntx-20230331.xsd#CondensedConsolidatedBalanceSheetsParenthetical"/>
  <link:presentationLink xlink:role="http://www.contexttherapeutics.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_1953d1ef-0617-4c73-b506-c6b9af97f3f6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_8fec1f63-bb8f-4fba-a13b-dc1a077ca080" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_1953d1ef-0617-4c73-b506-c6b9af97f3f6" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_8fec1f63-bb8f-4fba-a13b-dc1a077ca080" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_ceb1e6dd-3b70-48e9-bc7f-80dc1213133a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_1953d1ef-0617-4c73-b506-c6b9af97f3f6" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_ceb1e6dd-3b70-48e9-bc7f-80dc1213133a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_9a931b16-a4bb-474c-b242-4a841d7efbf8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_1953d1ef-0617-4c73-b506-c6b9af97f3f6" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_9a931b16-a4bb-474c-b242-4a841d7efbf8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_2dc27e90-11e8-4340-b25c-8eef587f45b9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_1953d1ef-0617-4c73-b506-c6b9af97f3f6" xlink:to="loc_us-gaap_PreferredStockSharesIssued_2dc27e90-11e8-4340-b25c-8eef587f45b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_97f485af-efab-47ab-95c8-a8a8b63c65a5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_1953d1ef-0617-4c73-b506-c6b9af97f3f6" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_97f485af-efab-47ab-95c8-a8a8b63c65a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_d269d409-d312-45eb-ae3f-af2780202356" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_1953d1ef-0617-4c73-b506-c6b9af97f3f6" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_d269d409-d312-45eb-ae3f-af2780202356" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_3bcd4aa7-702a-4bbb-8fa6-6167747d550d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_1953d1ef-0617-4c73-b506-c6b9af97f3f6" xlink:to="loc_us-gaap_CommonStockSharesIssued_3bcd4aa7-702a-4bbb-8fa6-6167747d550d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_cbca961d-9b04-4d26-9325-b5e85ab2a704" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_1953d1ef-0617-4c73-b506-c6b9af97f3f6" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_cbca961d-9b04-4d26-9325-b5e85ab2a704" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.contexttherapeutics.com/role/CondensedConsolidatedStatementsofOperationsUnaudited" xlink:type="simple" xlink:href="cntx-20230331.xsd#CondensedConsolidatedStatementsofOperationsUnaudited"/>
  <link:presentationLink xlink:role="http://www.contexttherapeutics.com/role/CondensedConsolidatedStatementsofOperationsUnaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_d33eb45d-230f-407d-a7d9-3f106c5406bd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_f0bcefe1-00a4-41de-beb6-04504eeb30bd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_d33eb45d-230f-407d-a7d9-3f106c5406bd" xlink:to="loc_us-gaap_OperatingExpensesAbstract_f0bcefe1-00a4-41de-beb6-04504eeb30bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_0fc14999-a686-4854-85b5-f6239cb62533" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_f0bcefe1-00a4-41de-beb6-04504eeb30bd" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_0fc14999-a686-4854-85b5-f6239cb62533" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_d710d813-5502-4f8c-99c8-a71aefd8007f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_f0bcefe1-00a4-41de-beb6-04504eeb30bd" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_d710d813-5502-4f8c-99c8-a71aefd8007f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_6999208b-9ce4-4d21-a41d-881c6e3d5049" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_d33eb45d-230f-407d-a7d9-3f106c5406bd" xlink:to="loc_us-gaap_OperatingIncomeLoss_6999208b-9ce4-4d21-a41d-881c6e3d5049" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeExpenseNet_00b27d5c-93c3-4444-a33e-7698f27620ef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestIncomeExpenseNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_d33eb45d-230f-407d-a7d9-3f106c5406bd" xlink:to="loc_us-gaap_InterestIncomeExpenseNet_00b27d5c-93c3-4444-a33e-7698f27620ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_f2556781-ea7a-4ef3-834a-3a0f13b6f99c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_d33eb45d-230f-407d-a7d9-3f106c5406bd" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_f2556781-ea7a-4ef3-834a-3a0f13b6f99c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_0f305266-7f94-4e7b-94f0-0ce540ac1b74" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_d33eb45d-230f-407d-a7d9-3f106c5406bd" xlink:to="loc_us-gaap_NetIncomeLoss_0f305266-7f94-4e7b-94f0-0ce540ac1b74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_12e0e38a-002d-4d54-a7f1-00dbe994eac2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_d33eb45d-230f-407d-a7d9-3f106c5406bd" xlink:to="loc_us-gaap_EarningsPerShareBasic_12e0e38a-002d-4d54-a7f1-00dbe994eac2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_78e22e70-839c-46dc-87d7-1eb82962b3e5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_d33eb45d-230f-407d-a7d9-3f106c5406bd" xlink:to="loc_us-gaap_EarningsPerShareDiluted_78e22e70-839c-46dc-87d7-1eb82962b3e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_b7431e8c-03da-445f-a858-85f890a2902f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_d33eb45d-230f-407d-a7d9-3f106c5406bd" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_b7431e8c-03da-445f-a858-85f890a2902f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_8226fed9-baa2-4087-aa80-3c243088e335" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_d33eb45d-230f-407d-a7d9-3f106c5406bd" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_8226fed9-baa2-4087-aa80-3c243088e335" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.contexttherapeutics.com/role/CondensedConsolidatedStatementsofChangesinStockholdersEquityUnaudited" xlink:type="simple" xlink:href="cntx-20230331.xsd#CondensedConsolidatedStatementsofChangesinStockholdersEquityUnaudited"/>
  <link:presentationLink xlink:role="http://www.contexttherapeutics.com/role/CondensedConsolidatedStatementsofChangesinStockholdersEquityUnaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_898ae74a-94f6-4ef9-b3b9-78d7b7bd6ad5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_2b6082cf-1288-4b01-83f4-f430683b437a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_898ae74a-94f6-4ef9-b3b9-78d7b7bd6ad5" xlink:to="loc_us-gaap_StatementTable_2b6082cf-1288-4b01-83f4-f430683b437a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_6a40173b-9e3d-48e4-95ec-c69232380aa8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_2b6082cf-1288-4b01-83f4-f430683b437a" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_6a40173b-9e3d-48e4-95ec-c69232380aa8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_645a339b-7d98-4945-990d-98f24e72bc06" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_6a40173b-9e3d-48e4-95ec-c69232380aa8" xlink:to="loc_us-gaap_EquityComponentDomain_645a339b-7d98-4945-990d-98f24e72bc06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_4f04df71-4112-4ff5-9ead-4350b474d8f2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_645a339b-7d98-4945-990d-98f24e72bc06" xlink:to="loc_us-gaap_CommonStockMember_4f04df71-4112-4ff5-9ead-4350b474d8f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_a17f4dd1-163e-4af0-9a46-0e45cbf27864" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_645a339b-7d98-4945-990d-98f24e72bc06" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_a17f4dd1-163e-4af0-9a46-0e45cbf27864" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_2122a353-eef3-4d3b-b22d-dcd52546f9df" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_645a339b-7d98-4945-990d-98f24e72bc06" xlink:to="loc_us-gaap_RetainedEarningsMember_2122a353-eef3-4d3b-b22d-dcd52546f9df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_1b60edcb-8343-4b26-8434-033566d99df0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_2b6082cf-1288-4b01-83f4-f430683b437a" xlink:to="loc_us-gaap_StatementLineItems_1b60edcb-8343-4b26-8434-033566d99df0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2ae377b6-c93f-489d-9990-27bb7959b565" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1b60edcb-8343-4b26-8434-033566d99df0" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2ae377b6-c93f-489d-9990-27bb7959b565" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_f5460829-8975-4f0a-a279-c89b39879538" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2ae377b6-c93f-489d-9990-27bb7959b565" xlink:to="loc_us-gaap_SharesOutstanding_f5460829-8975-4f0a-a279-c89b39879538" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_90d6007d-339b-4585-9db9-2e4797da298c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2ae377b6-c93f-489d-9990-27bb7959b565" xlink:to="loc_us-gaap_StockholdersEquity_90d6007d-339b-4585-9db9-2e4797da298c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_eafb1765-17ee-4adb-9e26-c5543c9b3c2b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2ae377b6-c93f-489d-9990-27bb7959b565" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_eafb1765-17ee-4adb-9e26-c5543c9b3c2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_12b5964e-00df-473f-b823-9d4d5fc469cc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2ae377b6-c93f-489d-9990-27bb7959b565" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_12b5964e-00df-473f-b823-9d4d5fc469cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_37982575-782e-4b99-9e12-45ce93400127" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2ae377b6-c93f-489d-9990-27bb7959b565" xlink:to="loc_us-gaap_NetIncomeLoss_37982575-782e-4b99-9e12-45ce93400127" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_291f7521-b216-4aa1-9117-fccf0cefadac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2ae377b6-c93f-489d-9990-27bb7959b565" xlink:to="loc_us-gaap_SharesOutstanding_291f7521-b216-4aa1-9117-fccf0cefadac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_d3320d32-5849-4756-8c73-78457c7a26b4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2ae377b6-c93f-489d-9990-27bb7959b565" xlink:to="loc_us-gaap_StockholdersEquity_d3320d32-5849-4756-8c73-78457c7a26b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.contexttherapeutics.com/role/CondensedConsolidatedStatementofCashFlowsUnaudited" xlink:type="simple" xlink:href="cntx-20230331.xsd#CondensedConsolidatedStatementofCashFlowsUnaudited"/>
  <link:presentationLink xlink:role="http://www.contexttherapeutics.com/role/CondensedConsolidatedStatementofCashFlowsUnaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_08392850-0139-4ec8-bbab-3f63e1b8dcb4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_9c74c0b3-0aad-4a46-bb25-1e74637004d9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_08392850-0139-4ec8-bbab-3f63e1b8dcb4" xlink:to="loc_us-gaap_StatementTable_9c74c0b3-0aad-4a46-bb25-1e74637004d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_618758df-705f-49b5-9be8-4cda327bf059" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_9c74c0b3-0aad-4a46-bb25-1e74637004d9" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_618758df-705f-49b5-9be8-4cda327bf059" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_368c93fb-60fd-4b71-8dbd-d026531c1836" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_618758df-705f-49b5-9be8-4cda327bf059" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_368c93fb-60fd-4b71-8dbd-d026531c1836" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cntx_IssuedForServicesMember_1bd3d01b-52a7-4fed-901b-2c5652a7e2e1" xlink:href="cntx-20230331.xsd#cntx_IssuedForServicesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_368c93fb-60fd-4b71-8dbd-d026531c1836" xlink:to="loc_cntx_IssuedForServicesMember_1bd3d01b-52a7-4fed-901b-2c5652a7e2e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_c88cf3f9-d952-4fea-9767-09cede069bde" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_9c74c0b3-0aad-4a46-bb25-1e74637004d9" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_c88cf3f9-d952-4fea-9767-09cede069bde" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_754d9f72-cad0-4cb8-9ef9-94e6bf4eb237" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_c88cf3f9-d952-4fea-9767-09cede069bde" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_754d9f72-cad0-4cb8-9ef9-94e6bf4eb237" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrivatePlacementMember_9808b80c-8f3e-4f07-b066-50049c371d18" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrivatePlacementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_754d9f72-cad0-4cb8-9ef9-94e6bf4eb237" xlink:to="loc_us-gaap_PrivatePlacementMember_9808b80c-8f3e-4f07-b066-50049c371d18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_7df31fe0-0ca7-4ec5-96ed-f5b1e39244c9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_9c74c0b3-0aad-4a46-bb25-1e74637004d9" xlink:to="loc_us-gaap_StatementLineItems_7df31fe0-0ca7-4ec5-96ed-f5b1e39244c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_cbd1358a-b482-4c09-a37b-17a7f26ac4a0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_7df31fe0-0ca7-4ec5-96ed-f5b1e39244c9" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_cbd1358a-b482-4c09-a37b-17a7f26ac4a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_76fd16e2-4cbb-454f-b1dc-49c5adabe999" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_cbd1358a-b482-4c09-a37b-17a7f26ac4a0" xlink:to="loc_us-gaap_NetIncomeLoss_76fd16e2-4cbb-454f-b1dc-49c5adabe999" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_9c231c78-684b-4d5d-8d70-fe1218437f49" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_cbd1358a-b482-4c09-a37b-17a7f26ac4a0" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_9c231c78-684b-4d5d-8d70-fe1218437f49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_654d117b-4be4-40bf-84fb-dc0e10556fde" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_9c231c78-684b-4d5d-8d70-fe1218437f49" xlink:to="loc_us-gaap_ShareBasedCompensation_654d117b-4be4-40bf-84fb-dc0e10556fde" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_9b041195-fb3a-4d4f-94a8-c91a5e515fb0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_9c231c78-684b-4d5d-8d70-fe1218437f49" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_9b041195-fb3a-4d4f-94a8-c91a5e515fb0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_746d78ce-fc90-41fe-98e7-cc7b7d31f602" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_9c231c78-684b-4d5d-8d70-fe1218437f49" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_746d78ce-fc90-41fe-98e7-cc7b7d31f602" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_89f1bf4a-9e7f-4214-9d5e-35097107d0ae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_9c231c78-684b-4d5d-8d70-fe1218437f49" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_89f1bf4a-9e7f-4214-9d5e-35097107d0ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_2f1a0519-5b20-4a18-9eca-d8f414a5c2c4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_89f1bf4a-9e7f-4214-9d5e-35097107d0ae" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_2f1a0519-5b20-4a18-9eca-d8f414a5c2c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_5233180c-dbeb-4a1f-9047-9953ce8461cb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_89f1bf4a-9e7f-4214-9d5e-35097107d0ae" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_5233180c-dbeb-4a1f-9047-9953ce8461cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_a46ae595-af45-486d-a66c-1617d1ce426b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_89f1bf4a-9e7f-4214-9d5e-35097107d0ae" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_a46ae595-af45-486d-a66c-1617d1ce426b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_d656d5c1-7602-4731-862f-53b950fd24b4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_89f1bf4a-9e7f-4214-9d5e-35097107d0ae" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_d656d5c1-7602-4731-862f-53b950fd24b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_b5f5de2e-9d6b-4a00-85fe-1ae6b63c2eb9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_89f1bf4a-9e7f-4214-9d5e-35097107d0ae" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_b5f5de2e-9d6b-4a00-85fe-1ae6b63c2eb9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ca97b130-b43a-45e9-ae67-78e61b7ce93a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_cbd1358a-b482-4c09-a37b-17a7f26ac4a0" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ca97b130-b43a-45e9-ae67-78e61b7ce93a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_873174f6-c978-4a3c-891a-bddafa77b2fa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_7df31fe0-0ca7-4ec5-96ed-f5b1e39244c9" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_873174f6-c978-4a3c-891a-bddafa77b2fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_23777791-d1c4-4ed0-ba92-8ba0206627c2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_873174f6-c978-4a3c-891a-bddafa77b2fa" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_23777791-d1c4-4ed0-ba92-8ba0206627c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_fb7d9f21-cc8c-484c-8898-40f60c7b3911" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_873174f6-c978-4a3c-891a-bddafa77b2fa" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_fb7d9f21-cc8c-484c-8898-40f60c7b3911" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_e7a503c5-fff1-44d5-9519-5978a9e5c5de" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_7df31fe0-0ca7-4ec5-96ed-f5b1e39244c9" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_e7a503c5-fff1-44d5-9519-5978a9e5c5de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_d972b4bf-37b6-4917-bdc1-cbeb86c940c0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_e7a503c5-fff1-44d5-9519-5978a9e5c5de" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_d972b4bf-37b6-4917-bdc1-cbeb86c940c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_c41c7c7f-a7d6-49a7-85d0-204c0a08aaf6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_e7a503c5-fff1-44d5-9519-5978a9e5c5de" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_c41c7c7f-a7d6-49a7-85d0-204c0a08aaf6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_43fb8531-e639-482d-94b6-ceabb044d943" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_7df31fe0-0ca7-4ec5-96ed-f5b1e39244c9" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_43fb8531-e639-482d-94b6-ceabb044d943" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_4750824c-197e-4967-a244-dd888b19f6f5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_7df31fe0-0ca7-4ec5-96ed-f5b1e39244c9" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_4750824c-197e-4967-a244-dd888b19f6f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_4dbdbc93-4e5a-4bc3-b9fc-3332bbf22448" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_7df31fe0-0ca7-4ec5-96ed-f5b1e39244c9" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_4dbdbc93-4e5a-4bc3-b9fc-3332bbf22448" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowElementsAbstract_09347084-0d80-4a61-bb9e-0a239ddc64ab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalCashFlowElementsAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_7df31fe0-0ca7-4ec5-96ed-f5b1e39244c9" xlink:to="loc_us-gaap_SupplementalCashFlowElementsAbstract_09347084-0d80-4a61-bb9e-0a239ddc64ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cntx_WarrantsIssued_25e85e44-1139-49b0-a70f-6f91e5aac7d4" xlink:href="cntx-20230331.xsd#cntx_WarrantsIssued"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowElementsAbstract_09347084-0d80-4a61-bb9e-0a239ddc64ab" xlink:to="loc_cntx_WarrantsIssued_25e85e44-1139-49b0-a70f-6f91e5aac7d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_a7235ff1-896c-4ec5-bea4-c925b3170292" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowElementsAbstract_09347084-0d80-4a61-bb9e-0a239ddc64ab" xlink:to="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_a7235ff1-896c-4ec5-bea4-c925b3170292" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.contexttherapeutics.com/role/OrganizationandDescriptionofBusiness" xlink:type="simple" xlink:href="cntx-20230331.xsd#OrganizationandDescriptionofBusiness"/>
  <link:presentationLink xlink:role="http://www.contexttherapeutics.com/role/OrganizationandDescriptionofBusiness" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_65efee21-c3f6-41be-b8fa-a45b7343a549" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NatureOfOperations_ad26042d-25f2-45b7-8a54-09ebd0b67e9a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NatureOfOperations"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_65efee21-c3f6-41be-b8fa-a45b7343a549" xlink:to="loc_us-gaap_NatureOfOperations_ad26042d-25f2-45b7-8a54-09ebd0b67e9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.contexttherapeutics.com/role/RisksandLiquidity" xlink:type="simple" xlink:href="cntx-20230331.xsd#RisksandLiquidity"/>
  <link:presentationLink xlink:role="http://www.contexttherapeutics.com/role/RisksandLiquidity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_cntx_RisksAndLiquidityAbstract_ac4de726-b878-4360-83c3-49d6972cbc92" xlink:href="cntx-20230331.xsd#cntx_RisksAndLiquidityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_cntx_RisksAndLiquidityTextBlock_d4337b7e-13e0-42f3-8581-785f8b7f7743" xlink:href="cntx-20230331.xsd#cntx_RisksAndLiquidityTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cntx_RisksAndLiquidityAbstract_ac4de726-b878-4360-83c3-49d6972cbc92" xlink:to="loc_cntx_RisksAndLiquidityTextBlock_d4337b7e-13e0-42f3-8581-785f8b7f7743" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.contexttherapeutics.com/role/BasisofPresentationandSummaryofSignificantAccountingPolicies" xlink:type="simple" xlink:href="cntx-20230331.xsd#BasisofPresentationandSummaryofSignificantAccountingPolicies"/>
  <link:presentationLink xlink:role="http://www.contexttherapeutics.com/role/BasisofPresentationandSummaryofSignificantAccountingPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_c5ff9852-5a4d-46f0-b4b6-4b4f3e3c9e95" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_565caa9b-3457-469c-945c-246f1faa0ab8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_c5ff9852-5a4d-46f0-b4b6-4b4f3e3c9e95" xlink:to="loc_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_565caa9b-3457-469c-945c-246f1faa0ab8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.contexttherapeutics.com/role/FairValueMeasurements" xlink:type="simple" xlink:href="cntx-20230331.xsd#FairValueMeasurements"/>
  <link:presentationLink xlink:role="http://www.contexttherapeutics.com/role/FairValueMeasurements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_832ca1f9-5f45-407a-afa7-f578910b2e6e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_004eb34a-7373-4a35-9666-47a7e8d44f0c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_832ca1f9-5f45-407a-afa7-f578910b2e6e" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_004eb34a-7373-4a35-9666-47a7e8d44f0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.contexttherapeutics.com/role/AccruedExpensesandOtherCurrentLiabilities" xlink:type="simple" xlink:href="cntx-20230331.xsd#AccruedExpensesandOtherCurrentLiabilities"/>
  <link:presentationLink xlink:role="http://www.contexttherapeutics.com/role/AccruedExpensesandOtherCurrentLiabilities" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_253ca342-c006-4c8c-a12a-087a78a290c1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_8aef318d-3a0a-4895-8667-058f12fe51dc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_253ca342-c006-4c8c-a12a-087a78a290c1" xlink:to="loc_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_8aef318d-3a0a-4895-8667-058f12fe51dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.contexttherapeutics.com/role/StockholdersEquity" xlink:type="simple" xlink:href="cntx-20230331.xsd#StockholdersEquity"/>
  <link:presentationLink xlink:role="http://www.contexttherapeutics.com/role/StockholdersEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityDisclosureAbstract_899a3d3a-5910-47f5-a233-b526518cd30c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_03463f93-2318-4b0f-942d-121288f5247d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TemporaryEquityDisclosureAbstract_899a3d3a-5910-47f5-a233-b526518cd30c" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_03463f93-2318-4b0f-942d-121288f5247d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.contexttherapeutics.com/role/ShareBasedCompensation" xlink:type="simple" xlink:href="cntx-20230331.xsd#ShareBasedCompensation"/>
  <link:presentationLink xlink:role="http://www.contexttherapeutics.com/role/ShareBasedCompensation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_5781ba9d-0a60-4541-97ed-55a33c71cc7a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_c191f13c-5639-4663-8026-b750b91598f6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_5781ba9d-0a60-4541-97ed-55a33c71cc7a" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_c191f13c-5639-4663-8026-b750b91598f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.contexttherapeutics.com/role/CommitmentandContingencies" xlink:type="simple" xlink:href="cntx-20230331.xsd#CommitmentandContingencies"/>
  <link:presentationLink xlink:role="http://www.contexttherapeutics.com/role/CommitmentandContingencies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_9c50125b-6b5f-43cb-96b4-9a3e63f6dd40" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_a7d0efce-fcba-4d6b-910b-e9aff0ef12c6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_9c50125b-6b5f-43cb-96b4-9a3e63f6dd40" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_a7d0efce-fcba-4d6b-910b-e9aff0ef12c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.contexttherapeutics.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="cntx-20230331.xsd#BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"/>
  <link:presentationLink xlink:role="http://www.contexttherapeutics.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_2e895909-6b2b-4554-90ec-f1878ccdce60" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_f76c5136-5e1d-487a-97ec-646b09b8abae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_2e895909-6b2b-4554-90ec-f1878ccdce60" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_f76c5136-5e1d-487a-97ec-646b09b8abae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock_77900b2b-fdd8-4c63-a55b-eb6d9a16728c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_2e895909-6b2b-4554-90ec-f1878ccdce60" xlink:to="loc_us-gaap_ConsolidationPolicyTextBlock_77900b2b-fdd8-4c63-a55b-eb6d9a16728c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates_717db407-7cd0-43bb-ac52-6c26011ec71a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UseOfEstimates"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_2e895909-6b2b-4554-90ec-f1878ccdce60" xlink:to="loc_us-gaap_UseOfEstimates_717db407-7cd0-43bb-ac52-6c26011ec71a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk_6393ccf4-9f59-410b-bf38-9e8e6f313557" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_2e895909-6b2b-4554-90ec-f1878ccdce60" xlink:to="loc_us-gaap_ConcentrationRiskCreditRisk_6393ccf4-9f59-410b-bf38-9e8e6f313557" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_c8a3084c-7e8d-4525-a6be-188f691ec4b9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_2e895909-6b2b-4554-90ec-f1878ccdce60" xlink:to="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_c8a3084c-7e8d-4525-a6be-188f691ec4b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_8d633b3b-ddc3-4c08-bfe6-474e29f926ec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_2e895909-6b2b-4554-90ec-f1878ccdce60" xlink:to="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_8d633b3b-ddc3-4c08-bfe6-474e29f926ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredChargesPolicyTextBlock_36673b8c-6cac-4a11-a5ab-95adb02d9d49" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredChargesPolicyTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_2e895909-6b2b-4554-90ec-f1878ccdce60" xlink:to="loc_us-gaap_DeferredChargesPolicyTextBlock_36673b8c-6cac-4a11-a5ab-95adb02d9d49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_7b09722a-5ba0-4b3e-ab94-b5e92e9c9477" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_2e895909-6b2b-4554-90ec-f1878ccdce60" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_7b09722a-5ba0-4b3e-ab94-b5e92e9c9477" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentPolicy_1d17f834-c167-45a0-b5b5-3081444b7f64" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InProcessResearchAndDevelopmentPolicy"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_2e895909-6b2b-4554-90ec-f1878ccdce60" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentPolicy_1d17f834-c167-45a0-b5b5-3081444b7f64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_92de3e43-22ea-4a62-add4-5b6273fd985a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_2e895909-6b2b-4554-90ec-f1878ccdce60" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_92de3e43-22ea-4a62-add4-5b6273fd985a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cntx_PatentCostsPolicyPolicyTextBlock_7c39a631-d0b4-4467-8729-b15555f153a7" xlink:href="cntx-20230331.xsd#cntx_PatentCostsPolicyPolicyTextBlock"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_2e895909-6b2b-4554-90ec-f1878ccdce60" xlink:to="loc_cntx_PatentCostsPolicyPolicyTextBlock_7c39a631-d0b4-4467-8729-b15555f153a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_6349dc8d-1873-4cea-9bb5-dc41ce78f059" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_2e895909-6b2b-4554-90ec-f1878ccdce60" xlink:to="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_6349dc8d-1873-4cea-9bb5-dc41ce78f059" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock_e6fe141e-f67d-44b7-ad6f-28a808ff21be" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_2e895909-6b2b-4554-90ec-f1878ccdce60" xlink:to="loc_us-gaap_EarningsPerSharePolicyTextBlock_e6fe141e-f67d-44b7-ad6f-28a808ff21be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.contexttherapeutics.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesTables" xlink:type="simple" xlink:href="cntx-20230331.xsd#BasisofPresentationandSummaryofSignificantAccountingPoliciesTables"/>
  <link:presentationLink xlink:role="http://www.contexttherapeutics.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_5438e2c6-633d-474b-8156-e8d3ebdff214" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_07682b38-1cdb-4400-af5e-ce34d8c05f76" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_5438e2c6-633d-474b-8156-e8d3ebdff214" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_07682b38-1cdb-4400-af5e-ce34d8c05f76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.contexttherapeutics.com/role/FairValueMeasurementsTables" xlink:type="simple" xlink:href="cntx-20230331.xsd#FairValueMeasurementsTables"/>
  <link:presentationLink xlink:role="http://www.contexttherapeutics.com/role/FairValueMeasurementsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_64a71cf1-d1e9-4a65-979a-0ed83ce6dd35" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_31508bba-e226-4424-aba4-12d26d5b26b2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_64a71cf1-d1e9-4a65-979a-0ed83ce6dd35" xlink:to="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_31508bba-e226-4424-aba4-12d26d5b26b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.contexttherapeutics.com/role/AccruedExpensesandOtherCurrentLiabilitiesTables" xlink:type="simple" xlink:href="cntx-20230331.xsd#AccruedExpensesandOtherCurrentLiabilitiesTables"/>
  <link:presentationLink xlink:role="http://www.contexttherapeutics.com/role/AccruedExpensesandOtherCurrentLiabilitiesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_40d8ae42-1eeb-4a9c-a53d-9c64639c61af" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_4e76bedd-1ba1-4113-a926-7b21c3d3dbe4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_40d8ae42-1eeb-4a9c-a53d-9c64639c61af" xlink:to="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_4e76bedd-1ba1-4113-a926-7b21c3d3dbe4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.contexttherapeutics.com/role/StockholdersEquityTables" xlink:type="simple" xlink:href="cntx-20230331.xsd#StockholdersEquityTables"/>
  <link:presentationLink xlink:role="http://www.contexttherapeutics.com/role/StockholdersEquityTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityDisclosureAbstract_93e768bb-06ae-41ac-9625-4f3ca659a096" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_66d2986a-6057-4ca1-ae82-32e9c0333d29" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TemporaryEquityDisclosureAbstract_93e768bb-06ae-41ac-9625-4f3ca659a096" xlink:to="loc_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_66d2986a-6057-4ca1-ae82-32e9c0333d29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.contexttherapeutics.com/role/ShareBasedCompensationTables" xlink:type="simple" xlink:href="cntx-20230331.xsd#ShareBasedCompensationTables"/>
  <link:presentationLink xlink:role="http://www.contexttherapeutics.com/role/ShareBasedCompensationTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_cdabf298-b1e0-499f-a7f5-58ea2993468d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_e2dd11a8-97d0-44d9-9f81-7c4b259c4619" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_cdabf298-b1e0-499f-a7f5-58ea2993468d" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_e2dd11a8-97d0-44d9-9f81-7c4b259c4619" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_9f94a951-d637-4131-b79e-3d9fc4f3b50a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_cdabf298-b1e0-499f-a7f5-58ea2993468d" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_9f94a951-d637-4131-b79e-3d9fc4f3b50a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_e01379e5-e2e5-4a5b-96b5-e4eeec327805" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_cdabf298-b1e0-499f-a7f5-58ea2993468d" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_e01379e5-e2e5-4a5b-96b5-e4eeec327805" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.contexttherapeutics.com/role/RisksandLiquidityNarrativeDetails" xlink:type="simple" xlink:href="cntx-20230331.xsd#RisksandLiquidityNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.contexttherapeutics.com/role/RisksandLiquidityNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_cntx_RisksAndLiquidityAbstract_165d13b2-d7d0-4e86-85b1-5ba6fc767cc7" xlink:href="cntx-20230331.xsd#cntx_RisksAndLiquidityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_559b81ef-501b-4095-a541-fa4e482d1b90" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cntx_RisksAndLiquidityAbstract_165d13b2-d7d0-4e86-85b1-5ba6fc767cc7" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_559b81ef-501b-4095-a541-fa4e482d1b90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_20ee2592-f527-4799-b49d-f841e26456ab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cntx_RisksAndLiquidityAbstract_165d13b2-d7d0-4e86-85b1-5ba6fc767cc7" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_20ee2592-f527-4799-b49d-f841e26456ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.contexttherapeutics.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails" xlink:type="simple" xlink:href="cntx-20230331.xsd#BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.contexttherapeutics.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_14a2e7aa-b25f-4b55-8f19-a3adbaccf1f4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashUninsuredAmount_f00776a1-0c91-46a4-8b53-dca195a51264" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashUninsuredAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_14a2e7aa-b25f-4b55-8f19-a3adbaccf1f4" xlink:to="loc_us-gaap_CashUninsuredAmount_f00776a1-0c91-46a4-8b53-dca195a51264" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashNoncurrent_cd4c1dc6-6cb7-4eab-8abf-4237dbf7b486" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_14a2e7aa-b25f-4b55-8f19-a3adbaccf1f4" xlink:to="loc_us-gaap_RestrictedCashNoncurrent_cd4c1dc6-6cb7-4eab-8abf-4237dbf7b486" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.contexttherapeutics.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesScheduleofAntidilutiveSecuritiesExcludedfromComputationofEarningsPerShareDetails" xlink:type="simple" xlink:href="cntx-20230331.xsd#BasisofPresentationandSummaryofSignificantAccountingPoliciesScheduleofAntidilutiveSecuritiesExcludedfromComputationofEarningsPerShareDetails"/>
  <link:presentationLink xlink:role="http://www.contexttherapeutics.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesScheduleofAntidilutiveSecuritiesExcludedfromComputationofEarningsPerShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_72557dd5-8d50-4623-ae7e-1cb29dbc2dd0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_56b9bfa4-27e8-4145-a9ef-020de88fbbeb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_72557dd5-8d50-4623-ae7e-1cb29dbc2dd0" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_56b9bfa4-27e8-4145-a9ef-020de88fbbeb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_9b68a9ab-f811-4137-a4ae-970e6ba4d758" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_56b9bfa4-27e8-4145-a9ef-020de88fbbeb" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_9b68a9ab-f811-4137-a4ae-970e6ba4d758" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_c3e69ead-3fbd-4aea-8234-83455c538181" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_9b68a9ab-f811-4137-a4ae-970e6ba4d758" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_c3e69ead-3fbd-4aea-8234-83455c538181" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_6bcaa7d8-0512-45d3-b5ca-28118e520150" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_c3e69ead-3fbd-4aea-8234-83455c538181" xlink:to="loc_us-gaap_EmployeeStockOptionMember_6bcaa7d8-0512-45d3-b5ca-28118e520150" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_b3d0bf1f-8019-47c6-8e0d-f00cff4ae25b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_c3e69ead-3fbd-4aea-8234-83455c538181" xlink:to="loc_us-gaap_WarrantMember_b3d0bf1f-8019-47c6-8e0d-f00cff4ae25b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_ba5fa8bd-31e8-4bf3-8db9-cc1a7f0ef06f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_56b9bfa4-27e8-4145-a9ef-020de88fbbeb" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_ba5fa8bd-31e8-4bf3-8db9-cc1a7f0ef06f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_8d69ed6f-e996-418d-9f43-ad2a5e1f6fbe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_ba5fa8bd-31e8-4bf3-8db9-cc1a7f0ef06f" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_8d69ed6f-e996-418d-9f43-ad2a5e1f6fbe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.contexttherapeutics.com/role/FairValueMeasurementsScheduleofassetsandliabilitiesmeasuredatfairvalueonarecurringbasisDetails" xlink:type="simple" xlink:href="cntx-20230331.xsd#FairValueMeasurementsScheduleofassetsandliabilitiesmeasuredatfairvalueonarecurringbasisDetails"/>
  <link:presentationLink xlink:role="http://www.contexttherapeutics.com/role/FairValueMeasurementsScheduleofassetsandliabilitiesmeasuredatfairvalueonarecurringbasisDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_ec06d411-2f08-4869-8553-17d18a75408d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_807d1e0c-d86a-4463-ae36-3e635da76a9d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_ec06d411-2f08-4869-8553-17d18a75408d" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_807d1e0c-d86a-4463-ae36-3e635da76a9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_4feacef1-62e6-4141-8d44-f37e43443226" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_807d1e0c-d86a-4463-ae36-3e635da76a9d" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_4feacef1-62e6-4141-8d44-f37e43443226" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_5f8971b6-fa3a-4602-8b1f-1ef129528c8f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_4feacef1-62e6-4141-8d44-f37e43443226" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_5f8971b6-fa3a-4602-8b1f-1ef129528c8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_a512699c-6701-4e13-a7dc-0d33a3b3abe7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_5f8971b6-fa3a-4602-8b1f-1ef129528c8f" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_a512699c-6701-4e13-a7dc-0d33a3b3abe7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAxis_f87ea966-de58-43f8-bc0f-3ba2272c032f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_807d1e0c-d86a-4463-ae36-3e635da76a9d" xlink:to="loc_us-gaap_CashAndCashEquivalentsAxis_f87ea966-de58-43f8-bc0f-3ba2272c032f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_ad192453-e91e-401b-b160-013c19a851ba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_f87ea966-de58-43f8-bc0f-3ba2272c032f" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_ad192453-e91e-401b-b160-013c19a851ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_be0de5d7-c2c0-4696-8d6a-e886f56684b9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_ad192453-e91e-401b-b160-013c19a851ba" xlink:to="loc_us-gaap_MoneyMarketFundsMember_be0de5d7-c2c0-4696-8d6a-e886f56684b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_0a72ab1a-bf5f-4c07-89a7-579891639283" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_807d1e0c-d86a-4463-ae36-3e635da76a9d" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_0a72ab1a-bf5f-4c07-89a7-579891639283" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_df3df4a5-61d1-46c7-8b8f-11939e892eee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_0a72ab1a-bf5f-4c07-89a7-579891639283" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_df3df4a5-61d1-46c7-8b8f-11939e892eee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_48d9513e-4cd7-42b7-a4f6-26392391cb6c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_df3df4a5-61d1-46c7-8b8f-11939e892eee" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_48d9513e-4cd7-42b7-a4f6-26392391cb6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_fe0f8af5-31e6-47ac-993c-b3c7bf3261bc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_df3df4a5-61d1-46c7-8b8f-11939e892eee" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_fe0f8af5-31e6-47ac-993c-b3c7bf3261bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_cd6493c6-7436-47b0-89f9-8fd5fe8fc754" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_df3df4a5-61d1-46c7-8b8f-11939e892eee" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_cd6493c6-7436-47b0-89f9-8fd5fe8fc754" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_9081df33-7f4c-45db-b72d-9d19be029239" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_807d1e0c-d86a-4463-ae36-3e635da76a9d" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_9081df33-7f4c-45db-b72d-9d19be029239" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract_85dbc12b-1699-407a-9fc2-8c6ec7d54bf0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_9081df33-7f4c-45db-b72d-9d19be029239" xlink:to="loc_us-gaap_AssetsFairValueDisclosureAbstract_85dbc12b-1699-407a-9fc2-8c6ec7d54bf0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_31107681-5bb9-42e3-83a3-5f1cbb669962" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_85dbc12b-1699-407a-9fc2-8c6ec7d54bf0" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_31107681-5bb9-42e3-83a3-5f1cbb669962" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.contexttherapeutics.com/role/AccruedExpensesandOtherCurrentLiabilitiesDetails" xlink:type="simple" xlink:href="cntx-20230331.xsd#AccruedExpensesandOtherCurrentLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.contexttherapeutics.com/role/AccruedExpensesandOtherCurrentLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_45266271-a604-4964-835d-30c53dc41309" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_0454fba0-e90c-42b2-9e2f-094328964562" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_45266271-a604-4964-835d-30c53dc41309" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_0454fba0-e90c-42b2-9e2f-094328964562" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cntx_AccruedResearchAndDevelopmentCostsCurrent_39e40f9f-090b-4840-af9b-463f6e9cba06" xlink:href="cntx-20230331.xsd#cntx_AccruedResearchAndDevelopmentCostsCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_45266271-a604-4964-835d-30c53dc41309" xlink:to="loc_cntx_AccruedResearchAndDevelopmentCostsCurrent_39e40f9f-090b-4840-af9b-463f6e9cba06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent_fe24f9a0-fe2b-47ad-aad1-88b7fcbd9534" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_45266271-a604-4964-835d-30c53dc41309" xlink:to="loc_us-gaap_AccruedProfessionalFeesCurrent_fe24f9a0-fe2b-47ad-aad1-88b7fcbd9534" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_1a55258d-d1d8-4509-9a23-f533536f565b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_45266271-a604-4964-835d-30c53dc41309" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_1a55258d-d1d8-4509-9a23-f533536f565b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_a57c2025-c2cd-405b-85f1-107bdbf4c003" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_45266271-a604-4964-835d-30c53dc41309" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_a57c2025-c2cd-405b-85f1-107bdbf4c003" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.contexttherapeutics.com/role/StockholdersEquityNarrativeDetails" xlink:type="simple" xlink:href="cntx-20230331.xsd#StockholdersEquityNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.contexttherapeutics.com/role/StockholdersEquityNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityDisclosureAbstract_9e3ed33d-eba5-467b-a5cf-720a9a7025e5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightTable_fa3eb0b9-ce6c-48bb-96ad-2f1fae1e16bc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TemporaryEquityDisclosureAbstract_9e3ed33d-eba5-467b-a5cf-720a9a7025e5" xlink:to="loc_us-gaap_ClassOfWarrantOrRightTable_fa3eb0b9-ce6c-48bb-96ad-2f1fae1e16bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_926e21c9-3d82-4fdc-befe-66a4271a9aaa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_fa3eb0b9-ce6c-48bb-96ad-2f1fae1e16bc" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_926e21c9-3d82-4fdc-befe-66a4271a9aaa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_8a07fd9d-f63d-489f-b9a6-241db22b6ef3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_926e21c9-3d82-4fdc-befe-66a4271a9aaa" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_8a07fd9d-f63d-489f-b9a6-241db22b6ef3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cntx_IssuedForProfessionalConsultingServicesMember_fb01f542-8e0f-4381-83b5-e9487bb9b275" xlink:href="cntx-20230331.xsd#cntx_IssuedForProfessionalConsultingServicesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_8a07fd9d-f63d-489f-b9a6-241db22b6ef3" xlink:to="loc_cntx_IssuedForProfessionalConsultingServicesMember_fb01f542-8e0f-4381-83b5-e9487bb9b275" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightLineItems_d5a2cc6b-78af-4c0b-9206-2615c08cdd97" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_fa3eb0b9-ce6c-48bb-96ad-2f1fae1e16bc" xlink:to="loc_us-gaap_ClassOfWarrantOrRightLineItems_d5a2cc6b-78af-4c0b-9206-2615c08cdd97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_d2bd5d1c-4e0a-45cb-aa28-943d5ea6523b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_d5a2cc6b-78af-4c0b-9206-2615c08cdd97" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_d2bd5d1c-4e0a-45cb-aa28-943d5ea6523b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_18735b2a-9a3b-4ccf-aec7-b13521484ce9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_d5a2cc6b-78af-4c0b-9206-2615c08cdd97" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_18735b2a-9a3b-4ccf-aec7-b13521484ce9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingTerm_f2d47658-6733-40dd-ae54-02076d9adae5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantsAndRightsOutstandingTerm"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_d5a2cc6b-78af-4c0b-9206-2615c08cdd97" xlink:to="loc_us-gaap_WarrantsAndRightsOutstandingTerm_f2d47658-6733-40dd-ae54-02076d9adae5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAdjustmentOfWarrants_62406061-f498-48ac-9df1-f61b45a9bc51" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAdjustmentOfWarrants"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_d5a2cc6b-78af-4c0b-9206-2615c08cdd97" xlink:to="loc_us-gaap_FairValueAdjustmentOfWarrants_62406061-f498-48ac-9df1-f61b45a9bc51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.contexttherapeutics.com/role/StockholdersEquityScheduleofWarrantsOutstandingDetails" xlink:type="simple" xlink:href="cntx-20230331.xsd#StockholdersEquityScheduleofWarrantsOutstandingDetails"/>
  <link:presentationLink xlink:role="http://www.contexttherapeutics.com/role/StockholdersEquityScheduleofWarrantsOutstandingDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityDisclosureAbstract_7d7201e6-af06-4018-9266-58bc6b83810a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightTable_1d7671b9-f37c-408c-8288-4aa42dd5d8fa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TemporaryEquityDisclosureAbstract_7d7201e6-af06-4018-9266-58bc6b83810a" xlink:to="loc_us-gaap_ClassOfWarrantOrRightTable_1d7671b9-f37c-408c-8288-4aa42dd5d8fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_e3c96551-1b3a-4123-8f17-82109bfd7c89" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_1d7671b9-f37c-408c-8288-4aa42dd5d8fa" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_e3c96551-1b3a-4123-8f17-82109bfd7c89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_3201483b-839a-4fa2-abdb-c2943f78b1b4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_e3c96551-1b3a-4123-8f17-82109bfd7c89" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_3201483b-839a-4fa2-abdb-c2943f78b1b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cntx_IssuedToPlacementAgentsMember_0a0418e6-bc59-458a-83d9-1888ab1bc5b1" xlink:href="cntx-20230331.xsd#cntx_IssuedToPlacementAgentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_3201483b-839a-4fa2-abdb-c2943f78b1b4" xlink:to="loc_cntx_IssuedToPlacementAgentsMember_0a0418e6-bc59-458a-83d9-1888ab1bc5b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cntx_December2021PrivatePlacementAgentWarrantsMember_8b6f877c-33af-48d2-a3b7-d49033bcf61f" xlink:href="cntx-20230331.xsd#cntx_December2021PrivatePlacementAgentWarrantsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_3201483b-839a-4fa2-abdb-c2943f78b1b4" xlink:to="loc_cntx_December2021PrivatePlacementAgentWarrantsMember_8b6f877c-33af-48d2-a3b7-d49033bcf61f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cntx_IssuedForProfessionalConsultingServicesMember_bb5bffde-46f3-4552-83af-fd5bf5fdef43" xlink:href="cntx-20230331.xsd#cntx_IssuedForProfessionalConsultingServicesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_3201483b-839a-4fa2-abdb-c2943f78b1b4" xlink:to="loc_cntx_IssuedForProfessionalConsultingServicesMember_bb5bffde-46f3-4552-83af-fd5bf5fdef43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightLineItems_cec57d9b-9429-4e75-bc73-3839eabc2acf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_1d7671b9-f37c-408c-8288-4aa42dd5d8fa" xlink:to="loc_us-gaap_ClassOfWarrantOrRightLineItems_cec57d9b-9429-4e75-bc73-3839eabc2acf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_de616651-bfe5-4aa6-b350-4d7fa19f1fc9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_cec57d9b-9429-4e75-bc73-3839eabc2acf" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_de616651-bfe5-4aa6-b350-4d7fa19f1fc9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_a6c47959-d798-481d-950e-addc3be35fc6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_cec57d9b-9429-4e75-bc73-3839eabc2acf" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_a6c47959-d798-481d-950e-addc3be35fc6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.contexttherapeutics.com/role/ShareBasedCompensationAdditionalInformationDetails" xlink:type="simple" xlink:href="cntx-20230331.xsd#ShareBasedCompensationAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.contexttherapeutics.com/role/ShareBasedCompensationAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_b9e154ce-72eb-4c60-98ac-faf899ac3879" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7745bcd3-ced1-4d68-9bf3-d62583b0c7a7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_b9e154ce-72eb-4c60-98ac-faf899ac3879" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7745bcd3-ced1-4d68-9bf3-d62583b0c7a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_76fb3c45-37e3-4d34-b1a8-d159f30db58d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7745bcd3-ced1-4d68-9bf3-d62583b0c7a7" xlink:to="loc_us-gaap_StatementClassOfStockAxis_76fb3c45-37e3-4d34-b1a8-d159f30db58d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_0a3bfbd4-c603-4ca2-a171-fc98e6605279" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_76fb3c45-37e3-4d34-b1a8-d159f30db58d" xlink:to="loc_us-gaap_ClassOfStockDomain_0a3bfbd4-c603-4ca2-a171-fc98e6605279" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassAMember_a8490597-4312-44f8-9555-f775dc1f0aa5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonClassAMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_0a3bfbd4-c603-4ca2-a171-fc98e6605279" xlink:to="loc_us-gaap_CommonClassAMember_a8490597-4312-44f8-9555-f775dc1f0aa5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_81bfc743-701d-4eca-ab73-61c58201588c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_0a3bfbd4-c603-4ca2-a171-fc98e6605279" xlink:to="loc_us-gaap_EmployeeStockOptionMember_81bfc743-701d-4eca-ab73-61c58201588c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_eb230aab-ef98-4278-82ca-5e38cd40333a" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7745bcd3-ced1-4d68-9bf3-d62583b0c7a7" xlink:to="loc_srt_RangeAxis_eb230aab-ef98-4278-82ca-5e38cd40333a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_5e3b10cb-755f-4afe-ac86-7b85c458b865" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_eb230aab-ef98-4278-82ca-5e38cd40333a" xlink:to="loc_srt_RangeMember_5e3b10cb-755f-4afe-ac86-7b85c458b865" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_fa92cfd7-7756-4500-be81-a7dd2c6a219f" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_5e3b10cb-755f-4afe-ac86-7b85c458b865" xlink:to="loc_srt_MinimumMember_fa92cfd7-7756-4500-be81-a7dd2c6a219f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_ac75b4e4-106a-4d3c-a204-57c8ce2ce74a" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_5e3b10cb-755f-4afe-ac86-7b85c458b865" xlink:to="loc_srt_MaximumMember_ac75b4e4-106a-4d3c-a204-57c8ce2ce74a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3629a71e-46f2-45ef-a2fa-1a3debc213f9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7745bcd3-ced1-4d68-9bf3-d62583b0c7a7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3629a71e-46f2-45ef-a2fa-1a3debc213f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_947f10fd-46af-4f4f-afac-893f46c0da72" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3629a71e-46f2-45ef-a2fa-1a3debc213f9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_947f10fd-46af-4f4f-afac-893f46c0da72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cntx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedAsAPercentageOfOutstandingStock_0a5fc451-4e87-49e4-a848-5af27a613861" xlink:href="cntx-20230331.xsd#cntx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedAsAPercentageOfOutstandingStock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3629a71e-46f2-45ef-a2fa-1a3debc213f9" xlink:to="loc_cntx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedAsAPercentageOfOutstandingStock_0a5fc451-4e87-49e4-a848-5af27a613861" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_769e98da-08d3-429a-b3a1-2b5474d85c6a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3629a71e-46f2-45ef-a2fa-1a3debc213f9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_769e98da-08d3-429a-b3a1-2b5474d85c6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_f39233a8-4a2e-469b-84f0-1302455a864a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3629a71e-46f2-45ef-a2fa-1a3debc213f9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_f39233a8-4a2e-469b-84f0-1302455a864a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_e22b18ae-6806-4285-b1b0-5d6a86f0c63c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3629a71e-46f2-45ef-a2fa-1a3debc213f9" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_e22b18ae-6806-4285-b1b0-5d6a86f0c63c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_53561f42-f282-4330-b005-370e6b420352" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3629a71e-46f2-45ef-a2fa-1a3debc213f9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_53561f42-f282-4330-b005-370e6b420352" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_cdc0dbde-17c4-4615-95a3-019b1d90b95d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3629a71e-46f2-45ef-a2fa-1a3debc213f9" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_cdc0dbde-17c4-4615-95a3-019b1d90b95d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_ba8b24c7-4a0c-4280-9c94-12623872e496" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3629a71e-46f2-45ef-a2fa-1a3debc213f9" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_ba8b24c7-4a0c-4280-9c94-12623872e496" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.contexttherapeutics.com/role/SharebasedCompensationScheduleofSharebasedCompensationExpenseDetails" xlink:type="simple" xlink:href="cntx-20230331.xsd#SharebasedCompensationScheduleofSharebasedCompensationExpenseDetails"/>
  <link:presentationLink xlink:role="http://www.contexttherapeutics.com/role/SharebasedCompensationScheduleofSharebasedCompensationExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_9166f7f6-74d2-4cf7-aaf9-f22f6f13d402" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_94366b31-570b-4bd4-9f3b-a38ea72de285" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_9166f7f6-74d2-4cf7-aaf9-f22f6f13d402" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_94366b31-570b-4bd4-9f3b-a38ea72de285" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_3ffea33f-9eb3-49c1-8cee-9620884b3044" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_94366b31-570b-4bd4-9f3b-a38ea72de285" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_3ffea33f-9eb3-49c1-8cee-9620884b3044" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_f76ebd7e-78e1-44a1-8b26-7efe40369620" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_3ffea33f-9eb3-49c1-8cee-9620884b3044" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_f76ebd7e-78e1-44a1-8b26-7efe40369620" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_a3f6fda1-6faa-457b-9cd3-a31c5d9b95e5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_f76ebd7e-78e1-44a1-8b26-7efe40369620" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_a3f6fda1-6faa-457b-9cd3-a31c5d9b95e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_ebdf239a-456e-45fd-b273-f5cfe3915ca2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_f76ebd7e-78e1-44a1-8b26-7efe40369620" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_ebdf239a-456e-45fd-b273-f5cfe3915ca2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_3d7adad0-161e-40cb-aa23-044bdf9a38c0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_94366b31-570b-4bd4-9f3b-a38ea72de285" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_3d7adad0-161e-40cb-aa23-044bdf9a38c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_16843367-da26-402d-85dd-d78cd64e0457" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_3d7adad0-161e-40cb-aa23-044bdf9a38c0" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_16843367-da26-402d-85dd-d78cd64e0457" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.contexttherapeutics.com/role/ShareBasedCompensationScheduleofAssumptionsUsedtoDetermineFairValueofShareBasedAwardsDetails" xlink:type="simple" xlink:href="cntx-20230331.xsd#ShareBasedCompensationScheduleofAssumptionsUsedtoDetermineFairValueofShareBasedAwardsDetails"/>
  <link:presentationLink xlink:role="http://www.contexttherapeutics.com/role/ShareBasedCompensationScheduleofAssumptionsUsedtoDetermineFairValueofShareBasedAwardsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_d0c476eb-5553-4e17-80cb-87a54af65d1a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_47759f05-c4e7-405d-85e8-059cb33e9649" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_d0c476eb-5553-4e17-80cb-87a54af65d1a" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_47759f05-c4e7-405d-85e8-059cb33e9649" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_58008832-b54b-4588-8f76-6e71179124fe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_47759f05-c4e7-405d-85e8-059cb33e9649" xlink:to="loc_us-gaap_AwardTypeAxis_58008832-b54b-4588-8f76-6e71179124fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_fceab3a3-b9bd-49bc-ae2d-3578bf82fb44" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_58008832-b54b-4588-8f76-6e71179124fe" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_fceab3a3-b9bd-49bc-ae2d-3578bf82fb44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_c2e55c19-0fef-4954-a22d-3d19e313a6d5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_fceab3a3-b9bd-49bc-ae2d-3578bf82fb44" xlink:to="loc_us-gaap_EmployeeStockOptionMember_c2e55c19-0fef-4954-a22d-3d19e313a6d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7888107b-e6a3-4300-8089-0493c9b70840" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_47759f05-c4e7-405d-85e8-059cb33e9649" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7888107b-e6a3-4300-8089-0493c9b70840" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_230fbb74-c852-41ab-a559-4651178873f3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7888107b-e6a3-4300-8089-0493c9b70840" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_230fbb74-c852-41ab-a559-4651178873f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_6019963a-f783-4e0d-bae1-5978fbec0568" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7888107b-e6a3-4300-8089-0493c9b70840" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_6019963a-f783-4e0d-bae1-5978fbec0568" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_f4e9574e-8814-44c8-81fa-6cc107469005" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7888107b-e6a3-4300-8089-0493c9b70840" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_f4e9574e-8814-44c8-81fa-6cc107469005" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_8139351a-81cd-4b35-b9dd-bad693935605" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7888107b-e6a3-4300-8089-0493c9b70840" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_8139351a-81cd-4b35-b9dd-bad693935605" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.contexttherapeutics.com/role/ShareBasedCompensationScheduleofShareBasedActivityDetails" xlink:type="simple" xlink:href="cntx-20230331.xsd#ShareBasedCompensationScheduleofShareBasedActivityDetails"/>
  <link:presentationLink xlink:role="http://www.contexttherapeutics.com/role/ShareBasedCompensationScheduleofShareBasedActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_316ffae6-dcea-456a-9538-2ba871cb7899" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_c812ac71-ebb5-49ad-bb40-c06ce9ac5a27" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_316ffae6-dcea-456a-9538-2ba871cb7899" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_c812ac71-ebb5-49ad-bb40-c06ce9ac5a27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_36b21fe6-3118-466d-a06d-3ec4f6968e5e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_c812ac71-ebb5-49ad-bb40-c06ce9ac5a27" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_36b21fe6-3118-466d-a06d-3ec4f6968e5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_d3c83767-02d1-45c4-b9c7-92dd092915fc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_c812ac71-ebb5-49ad-bb40-c06ce9ac5a27" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_d3c83767-02d1-45c4-b9c7-92dd092915fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_3d7c8567-bdf1-4954-8754-0d2d0654102d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_c812ac71-ebb5-49ad-bb40-c06ce9ac5a27" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_3d7c8567-bdf1-4954-8754-0d2d0654102d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_62d392a6-7381-4026-a2db-575f2b1db519" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_c812ac71-ebb5-49ad-bb40-c06ce9ac5a27" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_62d392a6-7381-4026-a2db-575f2b1db519" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_3361f4e0-3c3c-45cd-8d2d-335cd60bed2e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_316ffae6-dcea-456a-9538-2ba871cb7899" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_3361f4e0-3c3c-45cd-8d2d-335cd60bed2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_6ed6bf1d-663a-4fc7-a151-e557e3f0d615" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_316ffae6-dcea-456a-9538-2ba871cb7899" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_6ed6bf1d-663a-4fc7-a151-e557e3f0d615" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_7cf84def-3927-4255-8ed1-cf1d85907915" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_316ffae6-dcea-456a-9538-2ba871cb7899" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_7cf84def-3927-4255-8ed1-cf1d85907915" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_5e70561b-da59-49ed-92b8-d120cd7ab3c0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_7cf84def-3927-4255-8ed1-cf1d85907915" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_5e70561b-da59-49ed-92b8-d120cd7ab3c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_ef693fea-a445-405c-bf3e-aabe888ad2db" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_7cf84def-3927-4255-8ed1-cf1d85907915" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_ef693fea-a445-405c-bf3e-aabe888ad2db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_025f5dfa-b5fe-4363-b4bc-e0aa289803ee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_7cf84def-3927-4255-8ed1-cf1d85907915" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_025f5dfa-b5fe-4363-b4bc-e0aa289803ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_5e469a25-5f5d-4bc6-adce-ee74fd680ea7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_7cf84def-3927-4255-8ed1-cf1d85907915" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_5e469a25-5f5d-4bc6-adce-ee74fd680ea7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_9e71144c-a8a4-4a44-85eb-5cbb655ef525" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_316ffae6-dcea-456a-9538-2ba871cb7899" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_9e71144c-a8a4-4a44-85eb-5cbb655ef525" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_a48e0dd2-c264-4488-bcff-b8be51fba800" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_316ffae6-dcea-456a-9538-2ba871cb7899" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_a48e0dd2-c264-4488-bcff-b8be51fba800" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_9c92dfcb-61fb-4c32-9f39-52e5a9c28bba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_316ffae6-dcea-456a-9538-2ba871cb7899" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_9c92dfcb-61fb-4c32-9f39-52e5a9c28bba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_a64c0808-8903-4d94-9731-04dd4df544de" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_9c92dfcb-61fb-4c32-9f39-52e5a9c28bba" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_a64c0808-8903-4d94-9731-04dd4df544de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_0e6a9c38-b900-4aba-9801-f92a817fd489" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_9c92dfcb-61fb-4c32-9f39-52e5a9c28bba" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_0e6a9c38-b900-4aba-9801-f92a817fd489" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_a8510716-fd18-4d99-b884-f24b9daba01d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_9c92dfcb-61fb-4c32-9f39-52e5a9c28bba" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_a8510716-fd18-4d99-b884-f24b9daba01d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_9b9ea629-16cc-452c-8d51-df283cc26602" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_9c92dfcb-61fb-4c32-9f39-52e5a9c28bba" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_9b9ea629-16cc-452c-8d51-df283cc26602" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.contexttherapeutics.com/role/CommitmentandContingenciesOperatingLeaseDetails" xlink:type="simple" xlink:href="cntx-20230331.xsd#CommitmentandContingenciesOperatingLeaseDetails"/>
  <link:presentationLink xlink:role="http://www.contexttherapeutics.com/role/CommitmentandContingenciesOperatingLeaseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_48760f0c-6056-4b4e-9686-e50fe2a80fbc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_2256c166-0659-4eaa-b885-922b1415ab1d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_48760f0c-6056-4b4e-9686-e50fe2a80fbc" xlink:to="loc_us-gaap_LeasesAbstract_2256c166-0659-4eaa-b885-922b1415ab1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_fbfc2bae-a19b-4fa5-a59e-38d177bb4b6e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_2256c166-0659-4eaa-b885-922b1415ab1d" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_fbfc2bae-a19b-4fa5-a59e-38d177bb4b6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_8e6abfce-fce5-4b26-ab4d-646e08d1b05d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_2256c166-0659-4eaa-b885-922b1415ab1d" xlink:to="loc_us-gaap_OperatingLeaseLiability_8e6abfce-fce5-4b26-ab4d-646e08d1b05d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_862e0cb3-cd8d-4429-9036-5e31ab0a4d55" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_2256c166-0659-4eaa-b885-922b1415ab1d" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_862e0cb3-cd8d-4429-9036-5e31ab0a4d55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_71d570df-ea40-4dcd-b14d-f7e5beeb0a5a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseRemainingLeaseTerm"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_2256c166-0659-4eaa-b885-922b1415ab1d" xlink:to="loc_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_71d570df-ea40-4dcd-b14d-f7e5beeb0a5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceived_c8c2812a-cbb9-4765-a85f-ceadeaaa0b98" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceived"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_2256c166-0659-4eaa-b885-922b1415ab1d" xlink:to="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceived_c8c2812a-cbb9-4765-a85f-ceadeaaa0b98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost_50114478-3bde-4c31-a837-2b8e049f00e6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseCost"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_2256c166-0659-4eaa-b885-922b1415ab1d" xlink:to="loc_us-gaap_OperatingLeaseCost_50114478-3bde-4c31-a837-2b8e049f00e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_0823b55d-7cd0-419e-9ff6-e64e5f6205e2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_2256c166-0659-4eaa-b885-922b1415ab1d" xlink:to="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_0823b55d-7cd0-419e-9ff6-e64e5f6205e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.contexttherapeutics.com/role/CommitmentandContingenciesEmployeeBenefitPlansDetails" xlink:type="simple" xlink:href="cntx-20230331.xsd#CommitmentandContingenciesEmployeeBenefitPlansDetails"/>
  <link:presentationLink xlink:role="http://www.contexttherapeutics.com/role/CommitmentandContingenciesEmployeeBenefitPlansDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_0d457ded-6b6e-443c-a637-3f596d525fde" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_f52f57bb-a94c-4908-9959-b848501af0a8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_0d457ded-6b6e-443c-a637-3f596d525fde" xlink:to="loc_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_f52f57bb-a94c-4908-9959-b848501af0a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_46f3cafc-3c1c-4793-8663-32738fafef5b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_0d457ded-6b6e-443c-a637-3f596d525fde" xlink:to="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_46f3cafc-3c1c-4793-8663-32738fafef5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_fe5fa83e-3dbe-4d5e-b3aa-bebcc0f81c63" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_0d457ded-6b6e-443c-a637-3f596d525fde" xlink:to="loc_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_fe5fa83e-3dbe-4d5e-b3aa-bebcc0f81c63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.contexttherapeutics.com/role/CommitmentandContingenciesCollaborationAgreementsDetails" xlink:type="simple" xlink:href="cntx-20230331.xsd#CommitmentandContingenciesCollaborationAgreementsDetails"/>
  <link:presentationLink xlink:role="http://www.contexttherapeutics.com/role/CommitmentandContingenciesCollaborationAgreementsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_856f1e89-6c4e-4d3c-89f7-2cd42b5f8343" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_5e984f17-d8d4-4506-9fc1-0b70cff290fd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_856f1e89-6c4e-4d3c-89f7-2cd42b5f8343" xlink:to="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_5e984f17-d8d4-4506-9fc1-0b70cff290fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_d0835cbb-2398-4e8e-aa91-1e90e51170a5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_5e984f17-d8d4-4506-9fc1-0b70cff290fd" xlink:to="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_d0835cbb-2398-4e8e-aa91-1e90e51170a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProjectMember_49b193da-a8cc-42f2-a63e-8332dd1e4192" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProjectMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_d0835cbb-2398-4e8e-aa91-1e90e51170a5" xlink:to="loc_us-gaap_ProjectMember_49b193da-a8cc-42f2-a63e-8332dd1e4192" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cntx_ScaleUp100KilogramsOfGMPGradeCompoundMember_620f7849-4065-4b23-98c1-be28ef20fde6" xlink:href="cntx-20230331.xsd#cntx_ScaleUp100KilogramsOfGMPGradeCompoundMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProjectMember_49b193da-a8cc-42f2-a63e-8332dd1e4192" xlink:to="loc_cntx_ScaleUp100KilogramsOfGMPGradeCompoundMember_620f7849-4065-4b23-98c1-be28ef20fde6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cntx_ScaleUp300KilogramsOfGMPGradeCompoundMember_e0ca2d72-8091-4f5b-8565-9fc1c335571f" xlink:href="cntx-20230331.xsd#cntx_ScaleUp300KilogramsOfGMPGradeCompoundMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProjectMember_49b193da-a8cc-42f2-a63e-8332dd1e4192" xlink:to="loc_cntx_ScaleUp300KilogramsOfGMPGradeCompoundMember_e0ca2d72-8091-4f5b-8565-9fc1c335571f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_86abd820-31a9-4925-b189-943eae080463" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_5e984f17-d8d4-4506-9fc1-0b70cff290fd" xlink:to="loc_srt_CounterpartyNameAxis_86abd820-31a9-4925-b189-943eae080463" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_925b5ce6-f39b-4041-a92d-ddc89996c11b" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_86abd820-31a9-4925-b189-943eae080463" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_925b5ce6-f39b-4041-a92d-ddc89996c11b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cntx_TyligandBioscienceShanghaiLimitedMember_d1935e37-9eb4-4d74-bf97-5131627a6a2e" xlink:href="cntx-20230331.xsd#cntx_TyligandBioscienceShanghaiLimitedMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_925b5ce6-f39b-4041-a92d-ddc89996c11b" xlink:to="loc_cntx_TyligandBioscienceShanghaiLimitedMember_d1935e37-9eb4-4d74-bf97-5131627a6a2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cntx_IntegralMolecularIncMember_4e256769-b07a-40f2-bc7c-665ce54b75b4" xlink:href="cntx-20230331.xsd#cntx_IntegralMolecularIncMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_925b5ce6-f39b-4041-a92d-ddc89996c11b" xlink:to="loc_cntx_IntegralMolecularIncMember_4e256769-b07a-40f2-bc7c-665ce54b75b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_16fa9325-8fb1-4891-b6bc-b4ad7a2b42fa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_5e984f17-d8d4-4506-9fc1-0b70cff290fd" xlink:to="loc_us-gaap_TypeOfArrangementAxis_16fa9325-8fb1-4891-b6bc-b4ad7a2b42fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_adfc0a37-c585-42dc-82ca-207f31b1a8ae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_16fa9325-8fb1-4891-b6bc-b4ad7a2b42fa" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_adfc0a37-c585-42dc-82ca-207f31b1a8ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember_3c97a234-ed11-4d02-ad68-2b4756eae2fc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_adfc0a37-c585-42dc-82ca-207f31b1a8ae" xlink:to="loc_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember_3c97a234-ed11-4d02-ad68-2b4756eae2fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_2c67f88e-1072-41c1-bf83-d887f8383632" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_5e984f17-d8d4-4506-9fc1-0b70cff290fd" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_2c67f88e-1072-41c1-bf83-d887f8383632" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cntx_CollaborativeArrangementRightsAndObligationsMilestonePayment_42404fc8-a8a4-4420-8213-76fd7e04cf3a" xlink:href="cntx-20230331.xsd#cntx_CollaborativeArrangementRightsAndObligationsMilestonePayment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_2c67f88e-1072-41c1-bf83-d887f8383632" xlink:to="loc_cntx_CollaborativeArrangementRightsAndObligationsMilestonePayment_42404fc8-a8a4-4420-8213-76fd7e04cf3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cntx_CollaborativeArrangementRightsAndObligationsQuarterlySalesPaymentsPercent_a09ec128-46cb-4188-8f05-a5ff0261b0a3" xlink:href="cntx-20230331.xsd#cntx_CollaborativeArrangementRightsAndObligationsQuarterlySalesPaymentsPercent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_2c67f88e-1072-41c1-bf83-d887f8383632" xlink:to="loc_cntx_CollaborativeArrangementRightsAndObligationsQuarterlySalesPaymentsPercent_a09ec128-46cb-4188-8f05-a5ff0261b0a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cntx_CollaborativeArrangementRightsAndObligationsSalesPaymentPeriod_a3763cb8-4660-4287-8316-a47234ddb8a5" xlink:href="cntx-20230331.xsd#cntx_CollaborativeArrangementRightsAndObligationsSalesPaymentPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_2c67f88e-1072-41c1-bf83-d887f8383632" xlink:to="loc_cntx_CollaborativeArrangementRightsAndObligationsSalesPaymentPeriod_a3763cb8-4660-4287-8316-a47234ddb8a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cntx_CollaborativeArrangementRightsAndObligationsDevelopmentAndRegulatoryMilestonePaymentsMaximum_365b1b89-e414-4e51-b8f5-aa1eec82bb91" xlink:href="cntx-20230331.xsd#cntx_CollaborativeArrangementRightsAndObligationsDevelopmentAndRegulatoryMilestonePaymentsMaximum"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_2c67f88e-1072-41c1-bf83-d887f8383632" xlink:to="loc_cntx_CollaborativeArrangementRightsAndObligationsDevelopmentAndRegulatoryMilestonePaymentsMaximum_365b1b89-e414-4e51-b8f5-aa1eec82bb91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cntx_CollaborativeArrangementRightsAndObligationsSalesMilestonePaymentsMaximum_88b8bf1a-53a4-4c29-aa85-e4cb78479835" xlink:href="cntx-20230331.xsd#cntx_CollaborativeArrangementRightsAndObligationsSalesMilestonePaymentsMaximum"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_2c67f88e-1072-41c1-bf83-d887f8383632" xlink:to="loc_cntx_CollaborativeArrangementRightsAndObligationsSalesMilestonePaymentsMaximum_88b8bf1a-53a4-4c29-aa85-e4cb78479835" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cntx_CollaborativeArrangementRightsAndObligationsTieredRoyaltyPercent_7a512ce4-88ac-4368-8445-b3807ffa21c4" xlink:href="cntx-20230331.xsd#cntx_CollaborativeArrangementRightsAndObligationsTieredRoyaltyPercent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_2c67f88e-1072-41c1-bf83-d887f8383632" xlink:to="loc_cntx_CollaborativeArrangementRightsAndObligationsTieredRoyaltyPercent_7a512ce4-88ac-4368-8445-b3807ffa21c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139811475862160">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover - shares<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>May 05, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Mar. 31,  2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-40654<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">CONTEXT THERAPEUTICS INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">86-3738787<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">2001 Market Street,<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 3915, Unit #15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Philadelphia,<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">PA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">19103<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">267<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">225-7416<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, par value $0.001 per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">CNTX<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Entity Ex Transition Period</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,966,053<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001842952<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139811479229856">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets - USD ($)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 29,768,990<span></span>
</td>
<td class="nump">$ 35,497,445<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">2,116,737<span></span>
</td>
<td class="nump">2,356,213<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">31,885,727<span></span>
</td>
<td class="nump">37,853,658<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use asset</a></td>
<td class="nump">29,892<span></span>
</td>
<td class="nump">51,967<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">24,375<span></span>
</td>
<td class="nump">27,568<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">26,188<span></span>
</td>
<td class="nump">32,750<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">31,966,182<span></span>
</td>
<td class="nump">37,965,943<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">1,210,261<span></span>
</td>
<td class="nump">936,330<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses and other current liabilities</a></td>
<td class="nump">1,991,442<span></span>
</td>
<td class="nump">2,216,169<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liability - current</a></td>
<td class="nump">31,669<span></span>
</td>
<td class="nump">55,078<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">3,233,372<span></span>
</td>
<td class="nump">3,207,577<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">3,233,372<span></span>
</td>
<td class="nump">3,207,577<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and Contingencies</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, $0.001 par value; 10,000,000 shares authorized; no shares issued or outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.001 par value; 100,000,000 shares authorized; 15,966,053 shares issued and outstanding at March&#160;31, 2023 and December&#160;31, 2022</a></td>
<td class="nump">15,966<span></span>
</td>
<td class="nump">15,966<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">79,115,541<span></span>
</td>
<td class="nump">78,832,779<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(50,398,697)<span></span>
</td>
<td class="num">(44,090,379)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders' equity</a></td>
<td class="nump">28,732,810<span></span>
</td>
<td class="nump">34,758,366<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders' equity</a></td>
<td class="nump">$ 31,966,182<span></span>
</td>
<td class="nump">$ 37,965,943<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6904-107765<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139811476112816">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in shares)</a></td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="nump">100,000,000<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued (in shares)</a></td>
<td class="nump">15,966,053<span></span>
</td>
<td class="nump">15,966,053<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding (in shares)</a></td>
<td class="nump">15,966,053<span></span>
</td>
<td class="nump">15,966,053<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139811478281936">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Operations (Unaudited) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost', window );">Research and development</a></td>
<td class="nump">$ 4,534,676<span></span>
</td>
<td class="nump">$ 1,351,495<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">2,131,872<span></span>
</td>
<td class="nump">2,091,467<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(6,666,548)<span></span>
</td>
<td class="num">(3,442,962)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestIncomeExpenseNet', window );">Interest income</a></td>
<td class="nump">355,542<span></span>
</td>
<td class="nump">5,864<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Other income (expense)</a></td>
<td class="nump">2,688<span></span>
</td>
<td class="num">(1,239)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (6,308,318)<span></span>
</td>
<td class="num">$ (3,438,337)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net income (loss) per share - basic (in dollars per share)</a></td>
<td class="num">$ (0.40)<span></span>
</td>
<td class="num">$ (0.22)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net income (loss) per share - diluted (in dollars per share)</a></td>
<td class="num">$ (0.40)<span></span>
</td>
<td class="num">$ (0.22)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average common shares outstanding - basic (in shares)</a></td>
<td class="nump">15,966,053<span></span>
</td>
<td class="nump">15,966,053<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average common shares outstanding - diluted (in shares)</a></td>
<td class="nump">15,966,053<span></span>
</td>
<td class="nump">15,966,053<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeExpenseNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net amount of operating interest income (expense).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.10)<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeExpenseNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The costs incurred in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, excluding in-process research and development acquired in a business combination consummated during the period. Excludes software research and development, which has a separate concept.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139811473965024">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Changes in Stockholders' Equity (Unaudited) - USD ($)<br></strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Common&#160;Stock</div></th>
<th class="th"><div>Additional Paid-in Capital</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,966,053<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2021</a></td>
<td class="nump">$ 48,272,335<span></span>
</td>
<td class="nump">$ 15,966<span></span>
</td>
<td class="nump">$ 77,510,809<span></span>
</td>
<td class="num">$ (29,254,440)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued', window );">Fair value of warrants issued for services</a></td>
<td class="nump">345,530<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">345,530<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation expense</a></td>
<td class="nump">214,958<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">214,958<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(3,438,337)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,438,337)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Mar. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,966,053<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Mar. 31, 2022</a></td>
<td class="nump">45,394,486<span></span>
</td>
<td class="nump">$ 15,966<span></span>
</td>
<td class="nump">78,071,297<span></span>
</td>
<td class="num">(32,692,777)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,966,053<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2022</a></td>
<td class="nump">34,758,366<span></span>
</td>
<td class="nump">$ 15,966<span></span>
</td>
<td class="nump">78,832,779<span></span>
</td>
<td class="num">(44,090,379)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation expense</a></td>
<td class="nump">282,762<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">282,762<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(6,308,318)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(6,308,318)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Mar. 31, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,966,053<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Mar. 31, 2023</a></td>
<td class="nump">$ 28,732,810<span></span>
</td>
<td class="nump">$ 15,966<span></span>
</td>
<td class="nump">$ 79,115,541<span></span>
</td>
<td class="num">$ (50,398,697)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=126964447&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126964447&amp;loc=d3e11178-113907<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126961718&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 25<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=123466302&amp;loc=d3e4724-112606<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139811471716000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statement of Cash Flows (Unaudited) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (6,308,318)<span></span>
</td>
<td class="num">$ (3,438,337)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share-based compensation expense</a></td>
<td class="nump">282,762<span></span>
</td>
<td class="nump">214,958<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization expense</a></td>
<td class="nump">3,193<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense', window );">Reduction in the carrying amount of operating lease right-of-use asset</a></td>
<td class="nump">22,075<span></span>
</td>
<td class="nump">14,021<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">239,476<span></span>
</td>
<td class="nump">491,053<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets', window );">Other assets</a></td>
<td class="nump">6,562<span></span>
</td>
<td class="num">(24,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="nump">273,931<span></span>
</td>
<td class="num">(1,269,389)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Accrued expenses and other current liabilities</a></td>
<td class="num">(224,727)<span></span>
</td>
<td class="nump">198,324<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability', window );">Operating lease liability</a></td>
<td class="num">(23,409)<span></span>
</td>
<td class="num">(6,911)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Cash used in operating activities</a></td>
<td class="num">(5,728,455)<span></span>
</td>
<td class="num">(3,820,281)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchase of property and equipment</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(34,999)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Cash used in investing activities</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(34,999)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Cash used in financing activities</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(102,071)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net decrease in cash, cash equivalents and restricted cash</a></td>
<td class="num">(5,728,455)<span></span>
</td>
<td class="num">(3,957,351)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash at beginning of period</a></td>
<td class="nump">35,497,445<span></span>
</td>
<td class="nump">49,685,586<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents at end of period</a></td>
<td class="nump">29,768,990<span></span>
</td>
<td class="nump">45,728,235<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowElementsAbstract', window );"><strong>Supplemental disclosure of non-cash activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Right-of-use asset obtained in exchange for lease obligation</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">130,488<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember', window );">Private Placement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Payments for offering costs related to the private placement sale of common stock</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(102,071)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=cntx_IssuedForServicesMember', window );">Issued for services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowElementsAbstract', window );"><strong>Supplemental disclosure of non-cash activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cntx_WarrantsIssued', window );">Issuance of warrants for services provided</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 345,530<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cntx_WarrantsIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Warrants Issued</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cntx_WarrantsIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherNoncurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for right-of-use asset from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowElementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowElementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=cntx_IssuedForServicesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=cntx_IssuedForServicesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139811471786416">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Description of Business<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NatureOfOperations', window );">Organization and Description of Business</a></td>
<td class="text">Organization and Description of Business<div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Context Therapeutics Inc. (the &#8220;Company&#8221;) is a biopharmaceutical company dedicated to improving the lives of patients living with cancer. The Company&#8217;s preclinical product candidate, CTIM-76, is an anti-CD3 x anti-Claudin 6 (&#8220;CLDN6&#8221;) antigen bispecific monoclonal antibody (&#8220;bsAb&#8221;) that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company had also been developing onapristone extended release (&#8220;ONA-XR&#8221;). However, in March 2023, the Company announced its plan to discontinue the development of this product candidate and focus its efforts on the development of CTIM-76. All estimated closeout costs associated with the ONA-XR program were recognized in research and development expense during the first quarter of 2023. The Company does not expect to incur future material expenses related to this program.</span></div>The Company was organized in April 2015 under the laws of the State of Delaware. The Company&#8217;s headquarters are located in Philadelphia, Pennsylvania.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NatureOfOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI https://asc.fasb.org/topic&amp;trid=2134479<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NatureOfOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139811477318336">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Risks and Liquidity<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cntx_RisksAndLiquidityAbstract', window );"><strong>Risks And Liquidity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cntx_RisksAndLiquidityTextBlock', window );">Risks and Liquidity</a></td>
<td class="text">Risks and Liquidity <div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company has incurred losses and negative cash flows from operations since inception and had an accumulated deficit of $50.4&#160;million as of March&#160;31, 2023. The Company anticipates incurring additional losses until such time, if ever, that it can generate significant revenues from its current or any future product candidates. The Company believes its cash and cash equivalents of $29.8 million as of March&#160;31, 2023 are sufficient to fund its projected operations for at least the next 12 months from the issuance date of these condensed consolidated financial statements. However, substantial additional financing will be needed by the Company to fund its operations and to commercially develop its current and any future product candidates. There is no assurance that such financing will be available when needed or on acceptable terms.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company plans to seek additional capital in the future through equity and/or debt financings, partnerships, collaborations, or other sources to carry out the Company&#8217;s planned development activities. If additional capital is not available when required, the Company may need to delay or curtail its operations until such funding is received. Various internal and external factors will affect whether and when the Company&#8217;s current or any future product candidates become approved for marketing and successful commercialization. The regulatory approval and market acceptance of the Company&#8217;s current and any future product candidates, length of time and cost of developing and commercializing these product candidates and/or failure of them at any stage of the approval process will materially affect the Company&#8217;s financial condition and future operations. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company faces risks associated with companies whose products are in development. These risks include the need for additional financing to complete its research and development, achieving its research and development objectives, defending its intellectual property rights, recruiting and retaining skilled personnel, and dependence on key members of management, among others. </span></div>The spread of COVID-19 has caused worldwide economic downturn and significant volatility in the financial markets. There is significant uncertainty as to the likely effects of this disease should novel outbreaks emerge, which may, among other things, materially impact the Company&#8217;s planned clinical trials. This pandemic and/or periodic outbreaks could result in difficulty securing clinical trial site locations, contract research organizations, and/or trial monitors and other critical vendors and consultants supporting the trials. In addition, outbreaks or the perception of an outbreak near a clinical trial site location could impact the Company&#8217;s ability to enroll patients. These situations, or others associated with&#160;COVID-19,&#160;could cause delays in the Company&#8217;s clinical trial plans and could increase expected costs, all of which could have a material adverse effect on the Company&#8217;s business and its financial condition. At the current time, the Company is unable to quantify the potential effects of this pandemic on its future consolidated financial statements.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cntx_RisksAndLiquidityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Risks And Liquidity</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cntx_RisksAndLiquidityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cntx_RisksAndLiquidityTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Risks And Liquidity</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cntx_RisksAndLiquidityTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139811477631104">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation and Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock', window );">Basis of Presentation and Summary of Significant Accounting Policies</a></td>
<td class="text">Basis of Presentation and Summary of Significant Accounting Policies <div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Basis of Presentation and Principles of Consolidation </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The accompanying unaudited condensed consolidated financial statements have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission (&#8220;SEC&#8221;). Certain information and note disclosures normally included in annual financial statements prepared in accordance with U.S. generally accepted accounting principles (&#8220;GAAP&#8221;) have been condensed or omitted pursuant to those rules and regulations, although the Company believes that the disclosures made are adequate to make the information not misleading. Any reference in these notes to applicable guidance is meant to refer to GAAP as found in the Accounting Standards Codification and Accounting Standards Updates (&#8220;ASU&#8221;) of the Financial Accounting Standards Board (&#8220;FASB&#8221;).</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In the opinion of management, the accompanying unaudited condensed consolidated financial statements include all normal and recurring adjustments (which consist primarily of accruals and estimates that impact the financial statements) considered necessary to present fairly the Company&#8217;s financial position as of March&#160;31, 2023, and its results of operations and cash flows for the three months ended March&#160;31, 2023 and 2022. Operating results for the three months ended March&#160;31, 2023 are not necessarily indicative of the results that may be expected for the year ending December&#160;31, 2023. The unaudited condensed consolidated financial statements, presented herein, do not contain the required disclosures under GAAP for annual financial statements. The accompanying unaudited condensed consolidated financial statements should be read in conjunction with the annual audited consolidated financial statements and related notes as of and for the year ended December&#160;31, 2022. The consolidated financial information as of December&#160;31, 2022 included herein has been derived from the annual audited consolidated financial statements. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The unaudited condensed consolidated financial statements include the accounts of the Company, Context Therapeutics LLC, Context Biopharma, Inc. and Context Ireland Ltd., the Company&#8217;s wholly-owned subsidiaries. All intercompany accounts and transactions have been eliminated in consolidation. </span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Use of Estimates </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The preparation of condensed consolidated financial statements in conformity with GAAP&#160;requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and contingent liabilities at the date of the condensed consolidated financial statements and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Estimates and assumptions are periodically reviewed, and the effects of the revisions are reflected in the accompanying unaudited condensed consolidated financial statements in the period they are determined to be necessary. Significant estimates and assumptions made in the accompanying unaudited condensed consolidated financial statements include, but are not limited to, share-based compensation arrangements, the fair value of warrants, and in recording the prepayments, accruals and associated expense for research and development activities performed for the Company by third parties. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Concentrations of Credit Risk </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash and cash equivalents. The Company maintains deposits in federally insured financial institutions in excess of federally insured limits. The Company has not experienced any losses in such accounts. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Fair Value of Financial Instruments</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The carrying amount of the Company&#8217;s financial instruments, which include cash and cash equivalents, restricted cash, and accounts payable, approximate their fair values given their short-term nature.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Cash, Cash Equivalents and Restricted Cash</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company considers all highly liquid investments that have original maturities of three months or less when acquired to be cash equivalents. Cash equivalents consist of amounts invested in money market accounts. At March&#160;31, 2023, the Company's cash and cash equivalent balances exceeded federally insured limits by approximately $29.5 million.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company maintained approximately $50,000 as collateral for the Company&#8217;s credit card program at December 31, 2021, which was previously reported as restricted cash on its consolidated balance sheets. There were no amounts restricted as of March 31, 2023 and December 31, 2022, as the collateral was released to the Company in the first quarter of 2022.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> <br/></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Deferred Offering Costs </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company capitalizes certain legal, professional, accounting and other third-party fees that are directly associated with in-process equity financings as deferred offering costs until such financings are consummated. After consummation of an equity financing, the costs are recorded as a reduction of additional paid-in capital generated as a result of such offering. Should an in-process equity financing be abandoned, the deferred offering costs will be expensed immediately as a charge to operating expenses in the condensed consolidated statements of operations. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Property and Equipmen</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">t</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Property and equipment consist of office equipment, furniture, and leasehold improvements and are recorded at cost. Property and equipment are depreciated on a straight-line basis over their estimated useful lives. Leasehold improvements are amortized over the shorter of their economic lives or the remaining lease term. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Acquired In-Process Research and Development Costs</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Acquired in-process research and development (IPR&amp;D) expense consists of payments incurred in connection with the acquisition or licensing of products or technologies that do not meet the definition of a business under FASB ASC Topic 805, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Business Combinations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">. Payments for product development milestones are initially treated as the acquisition of an asset but then immediately expensed as there is no future alternative use for the asset. These development milestone payments are reflected as an investing activity outflow on the Company&#8217;s consolidated statements of cash flows due to the nature of the underlying acquisition of an asset. See Note 8 for further discussion.</span></div><div><span><br/></span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Research and Development Costs </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Research and development costs are expensed as incurred. Research and development costs include external costs of outside vendors engaged to conduct clinical studies and other research and development activities, salaries, share-based compensation, and other operational costs related to the Company&#8217;s research and development activities. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Costs for certain development activities, such as the provision of services for product candidate development, clinical and preclinical development and related supply and manufacturing costs, are estimated based on an evaluation of the progress to completion of specific tasks using data such as patient enrollment, clinical site activations or information provided to the Company by its vendors with respect to their actual costs incurred. Payments for these activities are based on the terms of the individual arrangements, which may differ from the pattern of costs incurred, and are reflected in the condensed consolidated financial statements as prepaid or accrued research and development expense, as the case may be. The estimates are adjusted to reflect the best information available at the time of the financial statement issuance. Although the Company does not expect its estimates to be materially different from amounts actually incurred, the Company&#8217;s estimate of the status and timing of services performed relative to the actual status and timing of services performed may vary.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Nonrefundable advance payments for goods and services, including fees for clinical trial expenses, process development or manufacturing and distribution of clinical supplies that will be used in future research and development activities, are deferred and recognized as expense in the period that the related goods are consumed or services are performed.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Patent Costs </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Costs related to filing and pursuing patent applications are recorded as general and administrative expense and expensed as incurred since recoverability of such expenditures is uncertain.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Share-Based Compensation </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company measures and recognizes share-based compensation expense for both employee and non-employee awards based on the grant date fair value of the awards. The Company recognizes share-based compensation expense on a straight-line basis over the requisite service period of the awards, which is generally the vesting period. The Company recognizes forfeitures as they occur. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company classifies share-based compensation expense in its unaudited condensed consolidated statements of operations in the same manner in which the award recipients&#8217; payroll costs are classified or in which the award recipients&#8217; service payments are classified. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company estimates the fair value of employee and non-employee stock awards as of the date of grant using the Black-Scholes option pricing model. The Company lacks Company-specific historical and implied volatility information. Therefore, management estimates the expected share price volatility based on the historical volatility of a publicly traded set of peer companies and expects to continue to do so until such time as it has adequate historical data regarding the volatility of its own publicly traded share price. The expected term of the Company&#8217;s stock awards has been determined utilizing the &#8220;simplified&#8221; method for awards that qualify as &#8220;plain-vanilla&#8221; stock awards. The risk-free interest rate is determined by reference to the yield curve of a zero-coupon U.S. Treasury bond on the date of grant of the award for time periods approximately equal to the expected term of the award. Expected dividend yield is based on the fact that the Company has never paid cash dividends on common stock and does not expect to pay any cash dividends in the foreseeable future. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Net Loss Per Share </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Basic net loss per share of common stock is computed by dividing net loss by the weighted-average number of shares of common stock outstanding during each period. Diluted net loss per share of common stock includes the effect, if any, from the potential exercise or conversion of securities, such as convertible promissory notes, preferred stock, warrants and share-based awards, which would result in the issuance of incremental shares of common stock. For diluted net loss per share, the weighted-average number of shares of common stock is the same for basic net loss per share due to the fact that when a net loss exists, dilutive securities are not included in the calculation as the impact is anti-dilutive. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The following potentially dilutive securities have been excluded from the computation of diluted weighted-average shares of common stock outstanding, as they would be anti-dilutive:</span></div><div><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:59.210%"><tr><td style="width:1.0%"/><td style="width:55.937%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.887%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.787%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.889%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:125%">March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:125%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:125%">2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Stock options</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">2,165,646&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">1,180,222&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Warrants</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">5,860,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">5,860,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">8,025,646&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">7,040,222&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Amounts in the above table reflect common stock equivalents.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Emerging Growth Company Status </span></div>The Company is an emerging growth company, as defined in the Jumpstart Our Business Startups Act of 2012 (the &#8220;JOBS Act&#8221;). Under the JOBS Act, emerging growth companies can delay adopting new or revised accounting standards issued subsequent to the enactment of the JOBS Act, until such time as those standards apply to private companies. The Company has elected to use this extended transition period for complying with new or revised accounting standards that have different effective dates for public and private companies until the earlier of the date that it (i)&#160;is no longer an emerging growth company or (ii)&#160;affirmatively and irrevocably opts out of the extended transition period provided in the JOBS Act. As a result, these condensed consolidated financial statements may not be comparable to companies that comply with the new or revised accounting pronouncements as of public company effective dates.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). Accounting policies describe all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI https://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139811481012064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value Measurements</a></td>
<td class="text">Fair Value Measurements <div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company utilizes a valuation hierarchy that prioritizes fair value measurements based on the types of inputs used for the various valuation techniques related to its financial assets and financial liabilities. The three levels of inputs used to measure fair value are described as follows: </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Level&#160;1 &#8211; Observable inputs such as quoted prices in active markets. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Level&#160;2 &#8211; Inputs, other than the quoted prices in active markets, that are observable either directly or indirectly. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Level&#160;3 &#8211; Unobservable inputs for which there is little or no market data, which require the reporting entity to develop its own assumptions. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In accordance with the fair value hierarchy described above, the following table sets forth the Company&#8217;s assets and liabilities measured at fair value on a recurring basis: </span></div><div style="margin-top:12pt"><span><br/></span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:34.237%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.829%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.386%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.495%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.386%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.589%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.386%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.592%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.57pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:125%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:125%">March 31, 2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.57pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:125%">Total </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:125%">Quoted&#160;Prices&#160;in&#160;Active<br/>Markets for Identical<br/>Assets (Level 1) </span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:125%">Significant&#160;Other<br/>Observable&#160;Inputs<br/>(Level 2) </span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:125%">Significant<br/>Unobservable&#160;Inputs<br/>(Level 3) </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">Financial assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 5.57pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 5.57pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 5.57pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 5.57pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.08pt;padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Cash equivalents <br/>(Money Market Accounts)</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 5.57pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">2,150,810</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 5.57pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">2,150,810</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 5.57pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 5.57pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8212;</span></td></tr></table></div><div><span><br/></span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:34.771%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.369%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.385%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.469%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.385%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.566%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.385%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.570%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.57pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%">&#160;</span></td><td colspan="3" style="padding:2px 1pt 2px 5.57pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.57pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:125%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:125%">Quoted&#160;Prices&#160;in&#160;Active<br/>Markets for Identical<br/>Assets (Level 1)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:125%">Significant&#160;Other<br/>Observable&#160;Inputs<br/>(Level 2)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:125%">Significant<br/>Unobservable&#160;Inputs<br/>(Level 3)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">Financial assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 5.57pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 5.57pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 5.57pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 5.57pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Cash equivalents </span><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(Money Market Accounts)</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 5.57pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">1,723,893</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 5.57pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">1,723,893</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 5.57pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 5.57pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8212;</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139811477596784">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Expenses and Other Current Liabilities<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock', window );">Accrued Expenses and Other Current Liabilities</a></td>
<td class="text">Accrued Expenses and Other Current Liabilities<div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Accrued expenses and other current liabilities consisted of the following:</span></div><div><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:77.046%"><tr><td style="width:1.0%"/><td style="width:49.184%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.077%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.620%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">March 31, 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;text-indent:-12pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Compensation and benefits</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">215,050&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">770,055&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;text-indent:-12pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Research and development costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">1,629,014&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">1,358,707&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;text-indent:-12pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Professional fees</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">103,131&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">3,951&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;text-indent:-12pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">44,247&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">83,456&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;text-indent:-12pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">1,991,442&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">2,216,169&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable, accrued expenses, and other liabilities that are classified as current at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139811477631104">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityDisclosureAbstract', window );"><strong>Temporary Equity Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Stockholders' Equity</a></td>
<td class="text">Stockholders' Equity<div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Warrants for Common Stock </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In connection with the Company's initial public offering (&#8220;IPO&#8221;) and private placement in 2021, the Company issued warrants to purchase shares of common stock.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In March 2022, the Company issued 360,000 warrants to purchase common stock with an exercise price of $10.00 per share and a term of 5.76 years as compensation for professional consulting services performed in 2021. The estimated fair value of the warrants of $0.3&#160;million was recorded in general and administrative expense during the year ended December 31, 2021 and was also reflected as a liability on the condensed consolidated balance sheets as of December 31, 2021. The liability was reclassified into additional paid-in capital in March 2022 upon the issuance of the warrants.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">At March&#160;31, 2023, the Company had the following warrants outstanding to acquire common stock: </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#160;</span></div><div style="margin-bottom:6pt;padding-left:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.274%"><tr><td style="width:1.0%"/><td style="width:42.787%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.849%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.426%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.103%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.426%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.609%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:125%">Outstanding </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:125%">Exercise&#160;price </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:125%">Expiration&#160;dates </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Issued in connection with 2021 IPO</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 5.57pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">250,000</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 5.57pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">6.25</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">October 2026</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Issued in connection with 2021 private placement</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 5.57pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">5,250,000</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 5.57pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">6.25</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">June 2027</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Issued in 2022 for consulting services</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 5.57pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">360,000</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 5.57pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">10.00</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">December 2027</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 5.57pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">5,860,000</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI https://asc.fasb.org/topic&amp;trid=2208762<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496180-112644<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126731327&amp;loc=SL126733271-114008<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139811477318336">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Share-Based Compensation</a></td>
<td class="text">Share-based Compensation <div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In April 2021, the Company adopted the 2021 Long-Term Performance Incentive Plan (&#8220;2021 Incentive Plan&#8221;). Under the 2021 Incentive Plan, the Company can grant stock options, stock appreciation rights, restricted stock, restricted stock units (&#8220;RSUs&#8221;) and stock grants. The 2021 Incentive Plan allows for the issuance of up to 1,266,092 shares of common stock (the &#8220;Share Limit&#8221;).  The Share Limit automatically increases on January 1st of each year, during the term of the 2021 Incentive Plan, commencing on January 1 of the year following the year in which the effective date occurs, in an amount equal to four percent (4%) of the total number of shares of the Company&#8217;s common stock outstanding on December 31st of the preceding calendar year; provided that the Board may determine that there will be no such increase or a smaller increase for any particular year. As of March&#160;31, 2023, 361,035 shares remained available for future grants. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:115%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Share-based awards generally vest over a period of one year to four years, and share-based awards that lapse or are forfeited are available to be granted again. The contractual life of all share-based awards is ten years. The expiration dates of the outstanding share-based awards range from January 2028 to February 2033. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company measures share-based awards at their grant-date fair value and records compensation expense on a straight-line basis over the service period of the awards. Share-based compensation is allocated to employees and consultants based on their respective departments. All board of directors&#8217; compensation is charged to general and administrative expense. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Share-based compensation expense related to the issuance of stock options was as follows for the three months ended March&#160;31, 2023 and 2022: </span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:61.842%"><tr><td style="width:1.0%"/><td style="width:49.018%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.540%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.745%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.197%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">Three months ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Research and development</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">21,087&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">32,960&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">General and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">261,675&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">181,998&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">282,762&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">214,958&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The weighted average assumptions used in the Black-Scholes option pricing model to determine the fair value of share-based awards granted to employees during the three months ended March&#160;31, 2023 and 2022 were as follows: </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#160;</span></div><div style="margin-bottom:6pt;padding-left:51.3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:81.286%"><tr><td style="width:1.0%"/><td style="width:66.525%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.519%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.367%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.519%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.370%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.57pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:125%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:125%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Expected stock price volatility</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">91.85%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">86.86%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">3.88%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">1.91%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Expected term (in years)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">6.08</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">6.03</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Expected dividend yield</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8212;&#160;&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8212;</span></td></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The following table summarizes the share-based award activity for the periods presented: </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#160;</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:53.870%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.524%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.57pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.08pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:125%">Number&#160;of&#160;Shares</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:125%">Weighted&#160;Average<br/>Exercise&#160;Price&#160;Per<br/>Share </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:125%">Weighted&#160;Average<br/>Remaining<br/>Contractual&#160;Term<br/>(years) </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Outstanding at January 1, 2023</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 5.57pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">1,341,504</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">3.27&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 5.57pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">8.9</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 5.57pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">824,142</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">0.84&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 5.57pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.05pt;margin-top:0.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;&#160;&#160;&#160;&#160;Forfeited</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 5.57pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.08pt;padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Outstanding at March&#160;31, 2023</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 5.57pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">2,165,646</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">2.35&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 5.57pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">9.1</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.08pt;padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Vested and exercisable at March&#160;31, 2023</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 5.57pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">526,574</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">4.43&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 5.57pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">8.3</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.08pt;padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Vested and expected to vest at March&#160;31, 2023</span></div></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 5.57pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">2,165,646</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">2.35&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 5.57pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">9.1</span></td></tr></table></div>The weighted average fair value of share-based awards granted during the three months ended March&#160;31, 2023 and 2022 was $0.65 and $1.33, respectively. As of March&#160;31, 2023, the unrecognized compensation cost related to outstanding share-based awards was $1.9&#160;million and is expected to be recognized as expense over a weighted-average period of approximately 2.49 years.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI https://asc.fasb.org/topic&amp;trid=2228938<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139811477511552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitment and Contingencies<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text">Commitments and Contingencies <div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Operating Lease</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In January 2022, the Company entered into a noncancellable operating sublease for corporate office space in Philadelphia, Pennsylvania. The sublease for this space commenced on February 1, 2022 and is set to expire on July 31, 2023. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As of March&#160;31, 2023, the operating lease right-of-use asset and the operating lease liabilities were $29,892 and $31,669, respectively. The discount rate used to account for the Company&#8217;s operating leases was the Company&#8217;s estimated incremental borrowing rate of 5.0%. The remaining term of the Company&#8217;s noncancellable operating lease is 0.33 years. Future minimum lease payments under the sublease are $32,000 at March&#160;31, 2023.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Rent expense related to the Company&#8217;s operating lease was approximately $23,000 and $15,000 for the three months ended March&#160;31, 2023 and 2022, respectively. The Company recognizes rent expense on a straight-line basis over the lease period and accrues for rent expense incurred but not yet paid.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In March 2023, the Company entered into a direct lease for this same office space that commences on August 1, 2023 and is set to expire on August 31, 2024, pursuant to which the Company retains the right to renew the lease for an additional one-year term.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Employee Benefit Plans</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In the first quarter of 2022, the Company established a defined contribution 401(k) plan in which employees may contribute up to 100% of their salary and bonus, subject to statutory maximum contribution amounts. The Company contributes a safe harbor minimum contribution equivalent to 3% of employees&#8217; compensation. The Company generally assumes all administrative costs of the plan. For the three months ended March&#160;31, 2023 and 2022, the Company provided contributions of approximately $40,000 and $25,000, respectively.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Collaboration Agreement with Tyligand Bioscience </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In March 2020, the Company entered into a process development agreement (the &#8220;Tyligand Process Development Agreement&#8221;) with Tyligand Bioscience (Shanghai) Limited (&#8220;Tyligand&#8221;) for the development, manufacturing, registration and future commercialization of ONA-XR. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Under the terms of the Tyligand Process Development Agreement, Tyligand was solely responsible for the design and optimization of an improved manufacturing process for ONA-XR. Upon completion of specific performance-based milestones, Tyligand and the Company entered into a license agreement (the &#8220;Tyligand License Agreement&#8221;) whereby Tyligand was granted the exclusive right to ONA-XR and is solely responsible for the development and commercialization of ONA-XR in China, Hong Kong and Macau (the &#8220;Territory&#8221;). The Company retains rights in the rest of the world to commercialize ONA-XR. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Under the Tyligand Process Development Agreement, the Company paid Tyligand certain milestone payments upon successful completion of the manufacturing development plan in 2021.  In addition, $2.0 million will be payable upon the completion of scale-up of the first cumulative 100 kilograms of the Good Manufacturing Practices (&#8220;GMP&#8221;)-grade compound and $3.0 million upon the Company&#8217;s completion of scale-up of the first cumulative 300&#160;kilograms of the GMP-grade compound. In consideration of and upon Tyligand&#8217;s successful completion of the development plan, within 30 days at the end of each calendar quarter, the Company shall pay Tyligand 1% of net sales of finished product utilizing the compound substantially manufactured in accordance with the process and specifications outlined in the Tyligand Process Development Agreement. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Per the Tyligand License Agreement, Tyligand shall pay the Company a non-refundable, non-creditable royalty at a rate in the mid-single digits of the net sales of each product in the Territory in each calendar quarter commencing with the first commercial sale of such product in the field in the Territory and ending upon the latest of (i) the sale of a generic product in the Territory and (ii) 15 years after the date of the first commercial sale of product in the Territory. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Collaboration and Licensing Agreement with Integral Molecular </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In April 2021, the Company entered into a collaboration and licensing agreement with Integral Molecular, Inc. (&#8220;Integral&#8221;) (the &#8220;Integral License Agreement&#8221;) for the development of a CLDN6 bispecific monoclonal antibody for cancer therapy. Under the terms of the agreement, Integral and the Company will develop CLDN6 bispecific antibodies that trigger the activation of T cells and eliminate cancer cells displaying CLND6. The Company will conduct preclinical and all clinical development, as well as regulatory and commercial activities through exclusive worldwide rights to develop and commercialize the novel CLDN6 candidates. The payment for the initial upfront license fee as well as subsequent payments for milestones achieved were expensed to acquired in-process research and development. See Note 3. As a part of the agreement, Integral will be eligible to receive remaining development and regulatory milestone payments totaling approximately $55&#160;million, sales milestone payments totaling up to $130.0 million, and tiered royalties of up to 12% of net sales of certain products developed under this agreement. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On March 20, 2023, the Company amended the Integral License Agreement to remove the previously agreed to second milestone payment and to change the amount of the third milestone payment to increase such payment by the amount of the prior second milestone payment and to add payment for third party research funding obtained and used by Integral in connection with the development of CTIM-76.</span></div><div><span><br/></span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Research and Development Arrangements</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In the course of normal business operations, the Company enters into agreements with universities and contract research organizations to assist in the performance of research and development activities and contract manufacturers to assist with chemistry, manufacturing, and controls related expenses. Expenditures to contract research organizations represent a significant cost in clinical development for the Company. The Company could also enter into additional collaborative research, contract research, manufacturing, and supplier agreements in the future, which may</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">require upfront payments and long-term commitments of cash.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI https://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 440<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6491277&amp;loc=d3e6429-115629<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI https://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139811478056736">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation and Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Basis of Presentation and Principles of Consolidation </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The accompanying unaudited condensed consolidated financial statements have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission (&#8220;SEC&#8221;). Certain information and note disclosures normally included in annual financial statements prepared in accordance with U.S. generally accepted accounting principles (&#8220;GAAP&#8221;) have been condensed or omitted pursuant to those rules and regulations, although the Company believes that the disclosures made are adequate to make the information not misleading. Any reference in these notes to applicable guidance is meant to refer to GAAP as found in the Accounting Standards Codification and Accounting Standards Updates (&#8220;ASU&#8221;) of the Financial Accounting Standards Board (&#8220;FASB&#8221;).</span></div>In the opinion of management, the accompanying unaudited condensed consolidated financial statements include all normal and recurring adjustments (which consist primarily of accruals and estimates that impact the financial statements) considered necessary to present fairly the Company&#8217;s financial position as of March&#160;31, 2023, and its results of operations and cash flows for the three months ended March&#160;31, 2023 and 2022. Operating results for the three months ended March&#160;31, 2023 are not necessarily indicative of the results that may be expected for the year ending December&#160;31, 2023. The unaudited condensed consolidated financial statements, presented herein, do not contain the required disclosures under GAAP for annual financial statements. The accompanying unaudited condensed consolidated financial statements should be read in conjunction with the annual audited consolidated financial statements and related notes as of and for the year ended December&#160;31, 2022. The consolidated financial information as of December&#160;31, 2022 included herein has been derived from the annual audited consolidated financial statements.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Principles of Consolidation</a></td>
<td class="text">The unaudited condensed consolidated financial statements include the accounts of the Company, Context Therapeutics LLC, Context Biopharma, Inc. and Context Ireland Ltd., the Company&#8217;s wholly-owned subsidiaries. All intercompany accounts and transactions have been eliminated in consolidation.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Use of Estimates </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The preparation of condensed consolidated financial statements in conformity with GAAP&#160;requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and contingent liabilities at the date of the condensed consolidated financial statements and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates. </span></div>Estimates and assumptions are periodically reviewed, and the effects of the revisions are reflected in the accompanying unaudited condensed consolidated financial statements in the period they are determined to be necessary. Significant estimates and assumptions made in the accompanying unaudited condensed consolidated financial statements include, but are not limited to, share-based compensation arrangements, the fair value of warrants, and in recording the prepayments, accruals and associated expense for research and development activities performed for the Company by third parties.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentrations of Credit Risk</a></td>
<td class="text">Concentrations of Credit Risk Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash and cash equivalents. The Company maintains deposits in federally insured financial institutions in excess of federally insured limits. The Company has not experienced any losses in such accounts.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueOfFinancialInstrumentsPolicy', window );">Fair Value of Financial Instruments</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Fair Value of Financial Instruments</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The carrying amount of the Company&#8217;s financial instruments, which include cash and cash equivalents, restricted cash, and accounts payable, approximate their fair values given their short-term nature.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash, Cash Equivalents and Restricted Cash</a></td>
<td class="text">Cash, Cash Equivalents and Restricted CashThe Company considers all highly liquid investments that have original maturities of three months or less when acquired to be cash equivalents. Cash equivalents consist of amounts invested in money market accounts.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredChargesPolicyTextBlock', window );">Deferred Offering Costs</a></td>
<td class="text">Deferred Offering Costs The Company capitalizes certain legal, professional, accounting and other third-party fees that are directly associated with in-process equity financings as deferred offering costs until such financings are consummated. After consummation of an equity financing, the costs are recorded as a reduction of additional paid-in capital generated as a result of such offering. Should an in-process equity financing be abandoned, the deferred offering costs will be expensed immediately as a charge to operating expenses in the condensed consolidated statements of operations.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and Equipment</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Property and Equipmen</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">t</span>Property and equipment consist of office equipment, furniture, and leasehold improvements and are recorded at cost. Property and equipment are depreciated on a straight-line basis over their estimated useful lives. Leasehold improvements are amortized over the shorter of their economic lives or the remaining lease term.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InProcessResearchAndDevelopmentPolicy', window );">Acquired In-Process Research and Development Costs</a></td>
<td class="text">Acquired In-Process Research and Development Costs<span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Acquired in-process research and development (IPR&amp;D) expense consists of payments incurred in connection with the acquisition or licensing of products or technologies that do not meet the definition of a business under FASB ASC Topic 805, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Business Combinations</span>. Payments for product development milestones are initially treated as the acquisition of an asset but then immediately expensed as there is no future alternative use for the asset. These development milestone payments are reflected as an investing activity outflow on the Company&#8217;s consolidated statements of cash flows due to the nature of the underlying acquisition of an asset.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Costs</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Research and Development Costs </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Research and development costs are expensed as incurred. Research and development costs include external costs of outside vendors engaged to conduct clinical studies and other research and development activities, salaries, share-based compensation, and other operational costs related to the Company&#8217;s research and development activities. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Costs for certain development activities, such as the provision of services for product candidate development, clinical and preclinical development and related supply and manufacturing costs, are estimated based on an evaluation of the progress to completion of specific tasks using data such as patient enrollment, clinical site activations or information provided to the Company by its vendors with respect to their actual costs incurred. Payments for these activities are based on the terms of the individual arrangements, which may differ from the pattern of costs incurred, and are reflected in the condensed consolidated financial statements as prepaid or accrued research and development expense, as the case may be. The estimates are adjusted to reflect the best information available at the time of the financial statement issuance. Although the Company does not expect its estimates to be materially different from amounts actually incurred, the Company&#8217;s estimate of the status and timing of services performed relative to the actual status and timing of services performed may vary.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Nonrefundable advance payments for goods and services, including fees for clinical trial expenses, process development or manufacturing and distribution of clinical supplies that will be used in future research and development activities, are deferred and recognized as expense in the period that the related goods are consumed or services are performed.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cntx_PatentCostsPolicyPolicyTextBlock', window );">Patent Costs</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Patent Costs </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Costs related to filing and pursuing patent applications are recorded as general and administrative expense and expensed as incurred since recoverability of such expenditures is uncertain.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Share-based Compensation</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Share-Based Compensation </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company measures and recognizes share-based compensation expense for both employee and non-employee awards based on the grant date fair value of the awards. The Company recognizes share-based compensation expense on a straight-line basis over the requisite service period of the awards, which is generally the vesting period. The Company recognizes forfeitures as they occur. </span></div>The Company classifies share-based compensation expense in its unaudited condensed consolidated statements of operations in the same manner in which the award recipients&#8217; payroll costs are classified or in which the award recipients&#8217; service payments are classified. The Company estimates the fair value of employee and non-employee stock awards as of the date of grant using the Black-Scholes option pricing model. The Company lacks Company-specific historical and implied volatility information. Therefore, management estimates the expected share price volatility based on the historical volatility of a publicly traded set of peer companies and expects to continue to do so until such time as it has adequate historical data regarding the volatility of its own publicly traded share price. The expected term of the Company&#8217;s stock awards has been determined utilizing the &#8220;simplified&#8221; method for awards that qualify as &#8220;plain-vanilla&#8221; stock awards. The risk-free interest rate is determined by reference to the yield curve of a zero-coupon U.S. Treasury bond on the date of grant of the award for time periods approximately equal to the expected term of the award. Expected dividend yield is based on the fact that the Company has never paid cash dividends on common stock and does not expect to pay any cash dividends in the foreseeable future.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net Loss Per Share</a></td>
<td class="text">Net Loss Per Share Basic net loss per share of common stock is computed by dividing net loss by the weighted-average number of shares of common stock outstanding during each period. Diluted net loss per share of common stock includes the effect, if any, from the potential exercise or conversion of securities, such as convertible promissory notes, preferred stock, warrants and share-based awards, which would result in the issuance of incremental shares of common stock. For diluted net loss per share, the weighted-average number of shares of common stock is the same for basic net loss per share due to the fact that when a net loss exists, dilutive securities are not included in the calculation as the impact is anti-dilutive.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cntx_PatentCostsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Patent Costs, Policy</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cntx_PatentCostsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4273-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126941378&amp;loc=d3e61044-112788<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18823-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=d3e5614-111684<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredChargesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for deferral and amortization of significant deferred charges.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredChargesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfFinancialInstrumentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the fair value of financial instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 60<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=7493716&amp;loc=d3e21868-110260<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13279-108611<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOfFinancialInstrumentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InProcessResearchAndDevelopmentPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs assigned to identifiable tangible and intangible assets of an acquired entity to be used in the research and development activities of the combined enterprise. An entity also may disclose the appraisal method or significant assumptions used to value acquired research and development assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420387&amp;loc=d3e23199-108380<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InProcessResearchAndDevelopmentPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99779-112916<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99893-112916<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI https://asc.fasb.org/topic&amp;trid=2228938<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2.Q6)<br> -URI https://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139811477631104">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation and Summary of Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The following potentially dilutive securities have been excluded from the computation of diluted weighted-average shares of common stock outstanding, as they would be anti-dilutive:</span></div><div><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:59.210%"><tr><td style="width:1.0%"/><td style="width:55.937%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.887%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.787%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.889%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:125%">March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:125%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:125%">2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Stock options</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">2,165,646&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">1,180,222&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Warrants</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">5,860,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">5,860,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">8,025,646&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">7,040,222&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139811566069024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock', window );">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In accordance with the fair value hierarchy described above, the following table sets forth the Company&#8217;s assets and liabilities measured at fair value on a recurring basis: </span></div><div style="margin-top:12pt"><span><br/></span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:34.237%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.829%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.386%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.495%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.386%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.589%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.386%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.592%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.57pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:125%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:125%">March 31, 2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.57pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:125%">Total </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:125%">Quoted&#160;Prices&#160;in&#160;Active<br/>Markets for Identical<br/>Assets (Level 1) </span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:125%">Significant&#160;Other<br/>Observable&#160;Inputs<br/>(Level 2) </span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:125%">Significant<br/>Unobservable&#160;Inputs<br/>(Level 3) </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">Financial assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 5.57pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 5.57pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 5.57pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 5.57pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.08pt;padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Cash equivalents <br/>(Money Market Accounts)</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 5.57pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">2,150,810</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 5.57pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">2,150,810</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 5.57pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 5.57pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8212;</span></td></tr></table></div><div><span><br/></span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:34.771%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.369%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.385%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.469%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.385%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.566%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.385%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.570%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.57pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%">&#160;</span></td><td colspan="3" style="padding:2px 1pt 2px 5.57pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.57pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:125%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:125%">Quoted&#160;Prices&#160;in&#160;Active<br/>Markets for Identical<br/>Assets (Level 1)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:125%">Significant&#160;Other<br/>Observable&#160;Inputs<br/>(Level 2)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:125%">Significant<br/>Unobservable&#160;Inputs<br/>(Level 3)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">Financial assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 5.57pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 5.57pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 5.57pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 5.57pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Cash equivalents </span><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(Money Market Accounts)</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 5.57pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">1,723,893</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 5.57pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">1,723,893</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 5.57pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 5.57pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8212;</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139811480257504">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Expenses and Other Current Liabilities (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Schedule of Accrued Liabilities</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Accrued expenses and other current liabilities consisted of the following:</span></div><div><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:77.046%"><tr><td style="width:1.0%"/><td style="width:49.184%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.077%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.620%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">March 31, 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;text-indent:-12pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Compensation and benefits</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">215,050&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">770,055&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;text-indent:-12pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Research and development costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">1,629,014&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">1,358,707&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;text-indent:-12pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Professional fees</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">103,131&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">3,951&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;text-indent:-12pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">44,247&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">83,456&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;text-indent:-12pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">1,991,442&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">2,216,169&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139811476700624">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityDisclosureAbstract', window );"><strong>Temporary Equity Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock', window );">Schedule of Warrants Outstanding</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">At March&#160;31, 2023, the Company had the following warrants outstanding to acquire common stock: </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#160;</span></div><div style="margin-bottom:6pt;padding-left:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.274%"><tr><td style="width:1.0%"/><td style="width:42.787%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.849%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.426%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.103%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.426%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.609%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:125%">Outstanding </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:125%">Exercise&#160;price </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:125%">Expiration&#160;dates </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Issued in connection with 2021 IPO</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 5.57pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">250,000</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 5.57pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">6.25</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">October 2026</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Issued in connection with 2021 private placement</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 5.57pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">5,250,000</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 5.57pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">6.25</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">June 2027</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Issued in 2022 for consulting services</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 5.57pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">360,000</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 5.57pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">10.00</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">December 2027</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 5.57pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">5,860,000</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 50<br> -Section S99<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6784392&amp;loc=d3e188667-122775<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139811478250096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Share-Based Payment Arrangement, Expensed and Capitalized, Amount</a></td>
<td class="text">Share-based compensation expense related to the issuance of stock options was as follows for the three months ended March&#160;31, 2023 and 2022: <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:61.842%"><tr><td style="width:1.0%"/><td style="width:49.018%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.540%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.745%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.197%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">Three months ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Research and development</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">21,087&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">32,960&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">General and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">261,675&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">181,998&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">282,762&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">214,958&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of Assumptions Used to Determine Fair Value of Share-Based Awards</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The weighted average assumptions used in the Black-Scholes option pricing model to determine the fair value of share-based awards granted to employees during the three months ended March&#160;31, 2023 and 2022 were as follows: </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#160;</span></div><div style="margin-bottom:6pt;padding-left:51.3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:81.286%"><tr><td style="width:1.0%"/><td style="width:66.525%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.519%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.367%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.519%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.370%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.57pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:125%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:125%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Expected stock price volatility</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">91.85%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">86.86%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">3.88%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">1.91%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Expected term (in years)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">6.08</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">6.03</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Expected dividend yield</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8212;&#160;&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8212;</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Schedule of Share-Based Award Activity</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The following table summarizes the share-based award activity for the periods presented: </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#160;</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:53.870%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.524%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.57pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.08pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:125%">Number&#160;of&#160;Shares</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:125%">Weighted&#160;Average<br/>Exercise&#160;Price&#160;Per<br/>Share </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:125%">Weighted&#160;Average<br/>Remaining<br/>Contractual&#160;Term<br/>(years) </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Outstanding at January 1, 2023</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 5.57pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">1,341,504</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">3.27&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 5.57pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">8.9</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 5.57pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">824,142</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">0.84&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 5.57pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.05pt;margin-top:0.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;&#160;&#160;&#160;&#160;Forfeited</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 5.57pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.08pt;padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Outstanding at March&#160;31, 2023</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 5.57pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">2,165,646</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">2.35&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 5.57pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">9.1</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.08pt;padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Vested and exercisable at March&#160;31, 2023</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 5.57pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">526,574</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">4.43&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 5.57pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">8.3</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.08pt;padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Vested and expected to vest at March&#160;31, 2023</span></div></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 5.57pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">2,165,646</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">2.35&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 5.57pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">9.1</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139811477971264">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Risks and Liquidity - Narrative (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cntx_RisksAndLiquidityAbstract', window );"><strong>Risks And Liquidity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="nump">$ 50,398,697<span></span>
</td>
<td class="nump">$ 44,090,379<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 29,768,990<span></span>
</td>
<td class="nump">$ 35,497,445<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cntx_RisksAndLiquidityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Risks And Liquidity</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cntx_RisksAndLiquidityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139811475853936">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Basis of Presentation and Summary of Significant Accounting Policies - Narrative (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashUninsuredAmount', window );">Uninsured amount</a></td>
<td class="nump">$ 29,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashNoncurrent', window );">Restricted cash</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 50,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashUninsuredAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash as of the balance sheet date that is not insured by the Federal Deposit Insurance Corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashUninsuredAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 210<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=120413173&amp;loc=SL116631458-115580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139811472785008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation and Summary of Significant Accounting Policies - Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share (Details) - shares<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of diluted weighted-average shares of common stock outstanding</a></td>
<td class="nump">8,025,646<span></span>
</td>
<td class="nump">7,040,222<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of diluted weighted-average shares of common stock outstanding</a></td>
<td class="nump">2,165,646<span></span>
</td>
<td class="nump">1,180,222<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember', window );">Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of diluted weighted-average shares of common stock outstanding</a></td>
<td class="nump">5,860,000<span></span>
</td>
<td class="nump">5,860,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139811479189632">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements - Schedule of assets and liabilities measured at fair value on a recurring basis (Details) - Recurring - Money market funds - USD ($)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Financial assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">$ 2,150,810<span></span>
</td>
<td class="nump">$ 1,723,893<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Financial assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">2,150,810<span></span>
</td>
<td class="nump">1,723,893<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Financial assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Financial assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139811478488288">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Accrued Expenses and Other Current Liabilities (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Compensation and benefits</a></td>
<td class="nump">$ 215,050<span></span>
</td>
<td class="nump">$ 770,055<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cntx_AccruedResearchAndDevelopmentCostsCurrent', window );">Research and development costs</a></td>
<td class="nump">1,629,014<span></span>
</td>
<td class="nump">1,358,707<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedProfessionalFeesCurrent', window );">Professional fees</a></td>
<td class="nump">103,131<span></span>
</td>
<td class="nump">3,951<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other</a></td>
<td class="nump">44,247<span></span>
</td>
<td class="nump">83,456<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses and other current liabilities</a></td>
<td class="nump">$ 1,991,442<span></span>
</td>
<td class="nump">$ 2,216,169<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cntx_AccruedResearchAndDevelopmentCostsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued Research and Development Costs, Current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cntx_AccruedResearchAndDevelopmentCostsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedProfessionalFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedProfessionalFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139811471711120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity - Narrative (Details) - USD ($)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants prior to conversion (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,860,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=cntx_IssuedForProfessionalConsultingServicesMember', window );">Issued in 2022 for consulting services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants prior to conversion (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">360,000<span></span>
</td>
<td class="nump">360,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10.00<span></span>
</td>
<td class="nump">$ 10.00<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Warrants, term from date of issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years 9 months 3 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Fair value adjustment of warrants</a></td>
<td class="nump">$ 0.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section 25<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=109262497&amp;loc=d3e20148-110875<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=cntx_IssuedForProfessionalConsultingServicesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=cntx_IssuedForProfessionalConsultingServicesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139811478098624">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Stockholders' Equity - Schedule of Warrants Outstanding (Details) - $ / shares<br></strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants prior to conversion (in shares)</a></td>
<td class="nump">5,860,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=cntx_IssuedToPlacementAgentsMember', window );">Issued in connection with 2021 IPO</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants prior to conversion (in shares)</a></td>
<td class="nump">250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price (in dollars per share)</a></td>
<td class="nump">$ 6.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=cntx_December2021PrivatePlacementAgentWarrantsMember', window );">Issued in connection with 2021 private placement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants prior to conversion (in shares)</a></td>
<td class="nump">5,250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price (in dollars per share)</a></td>
<td class="nump">$ 6.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=cntx_IssuedForProfessionalConsultingServicesMember', window );">Issued in 2022 for consulting services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants prior to conversion (in shares)</a></td>
<td class="nump">360,000<span></span>
</td>
<td class="nump">360,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price (in dollars per share)</a></td>
<td class="nump">$ 10.00<span></span>
</td>
<td class="nump">$ 10.00<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=cntx_IssuedToPlacementAgentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=cntx_IssuedToPlacementAgentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=cntx_December2021PrivatePlacementAgentWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=cntx_December2021PrivatePlacementAgentWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=cntx_IssuedForProfessionalConsultingServicesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=cntx_IssuedForProfessionalConsultingServicesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139811476109616">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation - Additional Information (Details) - USD ($)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Apr. 30, 2021</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cntx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedAsAPercentageOfOutstandingStock', window );">Annual rate at which authorized shares of common stock increase</a></td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Share-based award contractual life</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average fair value of grants during period (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.65<span></span>
</td>
<td class="nump">$ 1.33<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Unrecognized compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Share-based awards vesting period</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Share-based awards vesting period</a></td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Total shares of common stock authorized for issuance (in shares)</a></td>
<td class="nump">1,266,092<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Shares of common stock available for grant (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">361,035<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Expected period for recognition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 5 months 26 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cntx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedAsAPercentageOfOutstandingStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Additional Shares Authorized As A Percentage Of Outstanding Stock</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cntx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedAsAPercentageOfOutstandingStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139811479232576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-based Compensation - Schedule of Share-based Compensation Expense (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="nump">$ 282,762<span></span>
</td>
<td class="nump">$ 214,958<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="nump">21,087<span></span>
</td>
<td class="nump">32,960<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="nump">$ 261,675<span></span>
</td>
<td class="nump">$ 181,998<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139811471705504">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation - Schedule of Assumptions Used to Determine Fair Value of Share-Based Awards (Details) - Stock options<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected stock price volatility</a></td>
<td class="nump">91.85%<span></span>
</td>
<td class="nump">86.86%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">3.88%<span></span>
</td>
<td class="nump">1.91%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
<td class="text">6 years 29 days<span></span>
</td>
<td class="text">6 years 10 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139811475971648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation - Schedule of Share-Based Activity (Details) - $ / shares<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Number of Options</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding at beginning of period ( in shares)</a></td>
<td class="nump">1,341,504<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted during the period (in shares)</a></td>
<td class="nump">824,142<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Forfeited (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding at period end (in shares)</a></td>
<td class="nump">2,165,646<span></span>
</td>
<td class="nump">1,341,504<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Exercisable at period end (in shares)</a></td>
<td class="nump">526,574<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Vested and expected to vest at period end (in shares)</a></td>
<td class="nump">2,165,646<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted Average Exercise Price Per Share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding at beginning of period (in dollars per share)</a></td>
<td class="nump">$ 3.27<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted (in dollars per share)</a></td>
<td class="nump">0.84<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Forfeited (in dollars per share)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding at period end (in dollars per share)</a></td>
<td class="nump">2.35<span></span>
</td>
<td class="nump">$ 3.27<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Exercisable at period end (in dollars per share)</a></td>
<td class="nump">4.43<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Vested and expected to vest at period end (in dollars per share)</a></td>
<td class="nump">$ 2.35<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract', window );"><strong>Weighted Average Remaining Contractual Term (years)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Outstanding at beginning of period</a></td>
<td class="text">9 years 1 month 6 days<span></span>
</td>
<td class="text">8 years 10 months 24 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Outstanding at end of period</a></td>
<td class="text">9 years 1 month 6 days<span></span>
</td>
<td class="text">8 years 10 months 24 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Vested and exercisable at March&#160;31, 2023</a></td>
<td class="text">8 years 3 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1', window );">Vested and expected to vest at March&#160;31, 2023</a></td>
<td class="text">9 years 1 month 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139811478569248">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitment and Contingencies - Operating Lease (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use asset</a></td>
<td class="nump">$ 29,892<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 51,967<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Operating lease liabilities</a></td>
<td class="nump">$ 31,669<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted average discount rate</a></td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm', window );">Remaining lease term</a></td>
<td class="text">3 months 29 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LessorOperatingLeasePaymentsToBeReceived', window );">Future minimum payments due</a></td>
<td class="nump">$ 32,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Rent expense</a></td>
<td class="nump">$ 23,000<span></span>
</td>
<td class="nump">$ 15,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Additional renewal term</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Remaining lease term of operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseRemainingLeaseTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseRenewalTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseRenewalTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LessorOperatingLeasePaymentsToBeReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lease payments to be received by lessor for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 30<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=124258985&amp;loc=SL77919396-209981<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LessorOperatingLeasePaymentsToBeReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139811478203296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitment and Contingencies - Employee Benefit Plans (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent', window );">Maximum annual contributions per employee, percent</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent', window );">Employer matching contribution, percent of employees compensation</a></td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount', window );">Employer contribution amount</a></td>
<td class="nump">$ 40,000<span></span>
</td>
<td class="nump">$ 25,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of discretionary contributions made by an employer to a defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of employees' gross pay for which the employer contributes a matching contribution to a defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum percentage of employee gross pay the employee may contribute to a defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139811478055664">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitment and Contingencies - Collaboration Agreements (Details) - Collaborative Arrangement, Transaction with Party to Collaborative Arrangement - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Apr. 30, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=cntx_TyligandBioscienceShanghaiLimitedMember', window );">Tyligand</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cntx_CollaborativeArrangementRightsAndObligationsQuarterlySalesPaymentsPercent', window );">Quarterly sales payment due upon completion, percentage</a></td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cntx_CollaborativeArrangementRightsAndObligationsSalesPaymentPeriod', window );">Quarterly sales payment due upon completion, period of payment</a></td>
<td class="text">15 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=cntx_IntegralMolecularIncMember', window );">Integral</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cntx_CollaborativeArrangementRightsAndObligationsDevelopmentAndRegulatoryMilestonePaymentsMaximum', window );">Maximum development and regulatory milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 55.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cntx_CollaborativeArrangementRightsAndObligationsSalesMilestonePaymentsMaximum', window );">Maximum sales milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 130.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cntx_CollaborativeArrangementRightsAndObligationsTieredRoyaltyPercent', window );">Tiered royalty payment, percent (up to)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=cntx_ScaleUp100KilogramsOfGMPGradeCompoundMember', window );">Scale-up, 100 kilograms of GMP-grade compound | Tyligand</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cntx_CollaborativeArrangementRightsAndObligationsMilestonePayment', window );">Milestone payment</a></td>
<td class="nump">$ 2.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=cntx_ScaleUp300KilogramsOfGMPGradeCompoundMember', window );">Scale-up, 300 kilograms of GMP-grade compound | Tyligand</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cntx_CollaborativeArrangementRightsAndObligationsMilestonePayment', window );">Milestone payment</a></td>
<td class="nump">$ 3.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cntx_CollaborativeArrangementRightsAndObligationsDevelopmentAndRegulatoryMilestonePaymentsMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Rights and Obligations, Development And Regulatory Milestone Payments, Maximum</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cntx_CollaborativeArrangementRightsAndObligationsDevelopmentAndRegulatoryMilestonePaymentsMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cntx_CollaborativeArrangementRightsAndObligationsMilestonePayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Rights and Obligations, Milestone Payment</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cntx_CollaborativeArrangementRightsAndObligationsMilestonePayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cntx_CollaborativeArrangementRightsAndObligationsQuarterlySalesPaymentsPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Rights and Obligations, Quarterly Sales Payments, Percent</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cntx_CollaborativeArrangementRightsAndObligationsQuarterlySalesPaymentsPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cntx_CollaborativeArrangementRightsAndObligationsSalesMilestonePaymentsMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Rights and Obligations, Sales Milestone Payments, Maximum</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cntx_CollaborativeArrangementRightsAndObligationsSalesMilestonePaymentsMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cntx_CollaborativeArrangementRightsAndObligationsSalesPaymentPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Research And Development Arrangement, Contract To Perform For Others, Upon Completion, Sales Payment Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cntx_CollaborativeArrangementRightsAndObligationsSalesPaymentPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cntx_CollaborativeArrangementRightsAndObligationsTieredRoyaltyPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Rights and Obligations, Tiered Royalty, Percent</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cntx_CollaborativeArrangementRightsAndObligationsTieredRoyaltyPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=cntx_TyligandBioscienceShanghaiLimitedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=cntx_TyligandBioscienceShanghaiLimitedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=cntx_IntegralMolecularIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=cntx_IntegralMolecularIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=cntx_ScaleUp100KilogramsOfGMPGradeCompoundMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=cntx_ScaleUp100KilogramsOfGMPGradeCompoundMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=cntx_ScaleUp300KilogramsOfGMPGradeCompoundMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=cntx_ScaleUp300KilogramsOfGMPGradeCompoundMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>cntx-20230331_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:cntx="http://www.contexttherapeutics.com/20230331"
  xmlns:dei="http://xbrl.sec.gov/dei/2022"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2022"
  xmlns:us-gaap="http://fasb.org/us-gaap/2022"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="cntx-20230331.xsd" xlink:type="simple"/>
    <context id="ie35b115501ca468f8cadb8213304a30b_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001842952</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="ia277388742eb471f9d42d799adb36d70_I20230505">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001842952</identifier>
        </entity>
        <period>
            <instant>2023-05-05</instant>
        </period>
    </context>
    <context id="i9e6ffce2c2d247f491e046febe8251cd_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001842952</identifier>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i4b1713eab7d84494b3b43202a26fc3c4_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001842952</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i3baf3250062d4a79a9b120fc56f1b18c_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001842952</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i943d13fd1b9f4197ae5a210a64adb3ab_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001842952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ifaa2a5dd56c843d9a857de26b952bcfb_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001842952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ic501c165e10e47e080880f65f01c1d5b_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001842952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="icd5ebf0042ac4aac81eeac59d3a7522d_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001842952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i8d193fa8f7974372bd0db6d8ebed8675_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001842952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i9f9455c0d0e74c97a9a53955ed07377f_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001842952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="ib8f0e2696e0648f880780a1ad638027a_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001842952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="if64ea5a878c145cdb5ea7e8156bc0335_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001842952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="ifd24ec169b5741408f1f292b74c4c8e7_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001842952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="id6056ac1137049ecbf03cbd976238e74_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001842952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ia7a50df0f70a4507a6bc3fee39e5d9c3_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001842952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i7970953f78074175b146df53757b2465_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001842952</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ic40bb4943d7c476c9169444151149747_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001842952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ibf6fa1d37c03414bbe62bf55d335f4fe_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001842952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i81afc8f1d52c4facbecee4956dd23cfd_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001842952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i3bf77d6bc24e42a48e050108be77d852_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001842952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i6c6c3dc5639243a9bea9f8bc22ea83db_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001842952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="iafab01d20e1847b5b62b10c7e70e7bc8_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001842952</identifier>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i426de1e79cbb451489bfc39d312e71c9_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001842952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i0353d0309620461ab7aee7ea14ec31ba_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001842952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="id8892bb22a7e45e7ab17a6a179589967_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001842952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cntx:IssuedForServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="ie79fb9e8979b4831b96adca175266f37_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001842952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cntx:IssuedForServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="iacc367c186494022944e99aa683971ef_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001842952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i56a00969dd024778bc570050ee58a725_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001842952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i8c99fb13d0f54109a9578b166514e149_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001842952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i8db471e9da7749b2b45d29dfa213f4cc_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001842952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i3062cc15f83f4cdfb396a7b04a1c52fc_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001842952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i4d1a753ee70a4fd2bfd93f0e3636aa04_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001842952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="ibcafe063c5b44faf99d7d8aa71157121_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001842952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i1badbe53200740efb2a4bd341a6746ea_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001842952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i32dbf7cfaa0f452aae81b03367cca49f_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001842952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="id0fabbbc724b4914bb823640a0a66913_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001842952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i226a9d11b9184048a101065b542aff08_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001842952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i71991571d44349a9b2f3d9678cc16557_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001842952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i123230c41d4a4b6cb51151a89a8800c3_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001842952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cntx:IssuedForProfessionalConsultingServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i1be90ca5530f4a1d914f1a6103d21bd1_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001842952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cntx:IssuedForProfessionalConsultingServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i68c87024c26f44ab8263dbd0a7fa6a4f_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001842952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cntx:IssuedToPlacementAgentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="id3ed5205e2ed4995a41973b9bf8be2de_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001842952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cntx:December2021PrivatePlacementAgentWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i4ab77790f64945ee9a78ac502ec36b66_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001842952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cntx:IssuedForProfessionalConsultingServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="ib10d0ed1d1274880b8a73ff00fe229ab_I20210430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001842952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-30</instant>
        </period>
    </context>
    <context id="i37c7d2f5e060456d835ba44ccd4b0c9b_D20210401-20210430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001842952</identifier>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-04-30</endDate>
        </period>
    </context>
    <context id="i4ac2f469b04f49ea9a783619785adc82_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001842952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="ibac63907709f43e8bb17c649e92f3e4d_D20210401-20210430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001842952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-04-30</endDate>
        </period>
    </context>
    <context id="i902a704c36e04459a8ef415c67f74f48_D20210401-20210430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001842952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-04-30</endDate>
        </period>
    </context>
    <context id="i70f641b88b5a48aeb3fe1ce75baa1362_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001842952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i4799146a2fb14bd8b37fc240a795004c_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001842952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="iaf92495d8d6b4b9a9ec33d201a161246_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001842952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i7503ba5b2ff64139bbe478fa4ceedf80_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001842952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i56df8626827b4508b71d14c260351355_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001842952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="ia22a5f1f807740beb36572d3ab1f91c8_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001842952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i626f38146e594fbca5a1d17b96610d86_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001842952</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i247dcebb8f8f491b838555cf4a897045_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001842952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="ie4f3b47997974a9c92cf0116fb61189f_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001842952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cntx:TyligandBioscienceShanghaiLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">cntx:ScaleUp100KilogramsOfGMPGradeCompoundMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i4798e3c1b6ca496686ec4fd693e57cd8_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001842952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cntx:TyligandBioscienceShanghaiLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">cntx:ScaleUp300KilogramsOfGMPGradeCompoundMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i6b2d762a98f94d569b10a0723338a465_D20200301-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001842952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cntx:TyligandBioscienceShanghaiLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-03-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="icadec7fbbc8a431cbf67adac36bb34b1_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001842952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cntx:IntegralMolecularIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="ibffbea9aff4c4a0a9c67a9e90540390f_I20210430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001842952</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cntx:IntegralMolecularIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-30</instant>
        </period>
    </context>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <dei:AmendmentFlag
      contextRef="ie35b115501ca468f8cadb8213304a30b_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY180L2ZyYWc6YjZjY2Y5NDk4NDAwNDcwNzkzNjFjODFjMTRjNjk5Y2EvdGFibGU6YzU1NDc2MjFmMjIxNDJhOWFjNjBlMTBkZmVkY2I4OGIvdGFibGVyYW5nZTpjNTU0NzYyMWYyMjE0MmE5YWM2MGUxMGRmZWRjYjg4Yl8zLTEtMS0xLTY5OTQ5_ffe7bd93-01a8-4251-b365-68f6ba042ad5">false</dei:AmendmentFlag>
    <dei:DocumentFiscalYearFocus
      contextRef="ie35b115501ca468f8cadb8213304a30b_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY180L2ZyYWc6YjZjY2Y5NDk4NDAwNDcwNzkzNjFjODFjMTRjNjk5Y2EvdGFibGU6YzU1NDc2MjFmMjIxNDJhOWFjNjBlMTBkZmVkY2I4OGIvdGFibGVyYW5nZTpjNTU0NzYyMWYyMjE0MmE5YWM2MGUxMGRmZWRjYjg4Yl80LTEtMS0xLTY5OTQ5_d55726b2-fe29-401f-8316-1db6c693b16e">2023</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="ie35b115501ca468f8cadb8213304a30b_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY180L2ZyYWc6YjZjY2Y5NDk4NDAwNDcwNzkzNjFjODFjMTRjNjk5Y2EvdGFibGU6YzU1NDc2MjFmMjIxNDJhOWFjNjBlMTBkZmVkY2I4OGIvdGFibGVyYW5nZTpjNTU0NzYyMWYyMjE0MmE5YWM2MGUxMGRmZWRjYjg4Yl81LTEtMS0xLTY5OTQ5_d4001128-e34e-4c90-b224-73590c75e5ea">Q1</dei:DocumentFiscalPeriodFocus>
    <dei:EntityCentralIndexKey
      contextRef="ie35b115501ca468f8cadb8213304a30b_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY180L2ZyYWc6YjZjY2Y5NDk4NDAwNDcwNzkzNjFjODFjMTRjNjk5Y2EvdGFibGU6YzU1NDc2MjFmMjIxNDJhOWFjNjBlMTBkZmVkY2I4OGIvdGFibGVyYW5nZTpjNTU0NzYyMWYyMjE0MmE5YWM2MGUxMGRmZWRjYjg4Yl82LTEtMS0xLTY5OTQ5_8829ec5b-3941-4cd8-b582-88978e032d39">0001842952</dei:EntityCentralIndexKey>
    <dei:CurrentFiscalYearEndDate
      contextRef="ie35b115501ca468f8cadb8213304a30b_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY180L2ZyYWc6YjZjY2Y5NDk4NDAwNDcwNzkzNjFjODFjMTRjNjk5Y2EvdGFibGU6YzU1NDc2MjFmMjIxNDJhOWFjNjBlMTBkZmVkY2I4OGIvdGFibGVyYW5nZTpjNTU0NzYyMWYyMjE0MmE5YWM2MGUxMGRmZWRjYjg4Yl83LTEtMS0xLTY5OTQ5_c27488d6-0f8f-477a-be0b-ce621837419b">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentType
      contextRef="ie35b115501ca468f8cadb8213304a30b_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY18xL2ZyYWc6ZWRiMzM5MDJkYzdlNGY5NTllOGNkNjRiYTExZDQ0NWYvdGV4dHJlZ2lvbjplZGIzMzkwMmRjN2U0Zjk1OWU4Y2Q2NGJhMTFkNDQ1Zl8yMTU5_9ad6a1fc-7d74-4c3f-bb94-d6713f9be2ce">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport
      contextRef="ie35b115501ca468f8cadb8213304a30b_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY18xL2ZyYWc6ZWRiMzM5MDJkYzdlNGY5NTllOGNkNjRiYTExZDQ0NWYvdGFibGU6ODBhZGExMGIwYWIzNDY2Yzk1ZTY4MjMxNzZiNTk5NTUvdGFibGVyYW5nZTo4MGFkYTEwYjBhYjM0NjZjOTVlNjgyMzE3NmI1OTk1NV8wLTEtMS0xLTY5OTQ5_4f173ca4-a011-407b-b21a-57369debc2ed">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate
      contextRef="ie35b115501ca468f8cadb8213304a30b_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY18xL2ZyYWc6ZWRiMzM5MDJkYzdlNGY5NTllOGNkNjRiYTExZDQ0NWYvdGV4dHJlZ2lvbjplZGIzMzkwMmRjN2U0Zjk1OWU4Y2Q2NGJhMTFkNDQ1Zl8yMTM_6dd1a57d-adaf-4fa6-b47f-8611b2f92485">2023-03-31</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport
      contextRef="ie35b115501ca468f8cadb8213304a30b_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY18xL2ZyYWc6ZWRiMzM5MDJkYzdlNGY5NTllOGNkNjRiYTExZDQ0NWYvdGFibGU6ZmY0ZmZkNmM3YzI3NGNjYzk0MjQ1NTc4ZDlkMmU3MzQvdGFibGVyYW5nZTpmZjRmZmQ2YzdjMjc0Y2NjOTQyNDU1NzhkOWQyZTczNF8wLTEtMS0xLTY5OTQ5_edb83cbd-5f79-4baf-838d-a8da54d71cd2">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="ie35b115501ca468f8cadb8213304a30b_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY18xL2ZyYWc6ZWRiMzM5MDJkYzdlNGY5NTllOGNkNjRiYTExZDQ0NWYvdGV4dHJlZ2lvbjplZGIzMzkwMmRjN2U0Zjk1OWU4Y2Q2NGJhMTFkNDQ1Zl8yMTYw_c51bd763-885f-4123-85ca-356849923e5c">001-40654</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="ie35b115501ca468f8cadb8213304a30b_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY18xL2ZyYWc6ZWRiMzM5MDJkYzdlNGY5NTllOGNkNjRiYTExZDQ0NWYvdGV4dHJlZ2lvbjplZGIzMzkwMmRjN2U0Zjk1OWU4Y2Q2NGJhMTFkNDQ1Zl8yMTU0_30014f1f-7bb3-4ecc-a6a5-3bf861d4e30d">CONTEXT THERAPEUTICS INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="ie35b115501ca468f8cadb8213304a30b_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY18xL2ZyYWc6ZWRiMzM5MDJkYzdlNGY5NTllOGNkNjRiYTExZDQ0NWYvdGFibGU6YzRjYzcwYTFkMTA0NDY0MGFmYWFhZWE4ZDc5ZDM0M2IvdGFibGVyYW5nZTpjNGNjNzBhMWQxMDQ0NjQwYWZhYWFlYThkNzlkMzQzYl8wLTAtMS0xLTY5OTQ5_8241fd1f-c417-4c75-bf60-0aab61c6cf8e">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="ie35b115501ca468f8cadb8213304a30b_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY18xL2ZyYWc6ZWRiMzM5MDJkYzdlNGY5NTllOGNkNjRiYTExZDQ0NWYvdGFibGU6YzRjYzcwYTFkMTA0NDY0MGFmYWFhZWE4ZDc5ZDM0M2IvdGFibGVyYW5nZTpjNGNjNzBhMWQxMDQ0NjQwYWZhYWFlYThkNzlkMzQzYl8wLTEtMS0xLTY5OTQ5_3cace272-1a40-418b-9e66-f5be8779c348">86-3738787</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="ie35b115501ca468f8cadb8213304a30b_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY18xL2ZyYWc6ZWRiMzM5MDJkYzdlNGY5NTllOGNkNjRiYTExZDQ0NWYvdGV4dHJlZ2lvbjplZGIzMzkwMmRjN2U0Zjk1OWU4Y2Q2NGJhMTFkNDQ1Zl8yMTYx_c1ed7ca1-f5de-4df4-9673-051c7b1e21a6">2001 Market Street,</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2
      contextRef="ie35b115501ca468f8cadb8213304a30b_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY18xL2ZyYWc6ZWRiMzM5MDJkYzdlNGY5NTllOGNkNjRiYTExZDQ0NWYvdGV4dHJlZ2lvbjplZGIzMzkwMmRjN2U0Zjk1OWU4Y2Q2NGJhMTFkNDQ1Zl8yMTU2_97e44a65-6226-4609-98aa-f23684b0851e">Suite 3915, Unit #15</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown
      contextRef="ie35b115501ca468f8cadb8213304a30b_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY18xL2ZyYWc6ZWRiMzM5MDJkYzdlNGY5NTllOGNkNjRiYTExZDQ0NWYvdGV4dHJlZ2lvbjplZGIzMzkwMmRjN2U0Zjk1OWU4Y2Q2NGJhMTFkNDQ1Zl8yMTQ5_322c2f35-675d-4448-8e53-7b189d0bf4e4">Philadelphia,</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="ie35b115501ca468f8cadb8213304a30b_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY18xL2ZyYWc6ZWRiMzM5MDJkYzdlNGY5NTllOGNkNjRiYTExZDQ0NWYvdGV4dHJlZ2lvbjplZGIzMzkwMmRjN2U0Zjk1OWU4Y2Q2NGJhMTFkNDQ1Zl8yMTUw_17c4ddf8-9556-44a8-944f-5008b317b502">PA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="ie35b115501ca468f8cadb8213304a30b_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY18xL2ZyYWc6ZWRiMzM5MDJkYzdlNGY5NTllOGNkNjRiYTExZDQ0NWYvdGV4dHJlZ2lvbjplZGIzMzkwMmRjN2U0Zjk1OWU4Y2Q2NGJhMTFkNDQ1Zl81MTE_7d2b6e59-6fb3-415c-9ee3-d47a97fcb15d">19103</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="ie35b115501ca468f8cadb8213304a30b_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY18xL2ZyYWc6ZWRiMzM5MDJkYzdlNGY5NTllOGNkNjRiYTExZDQ0NWYvdGV4dHJlZ2lvbjplZGIzMzkwMmRjN2U0Zjk1OWU4Y2Q2NGJhMTFkNDQ1Zl81Nzg_9aae1081-4592-4282-91fd-8bbbbcc1323c">267</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="ie35b115501ca468f8cadb8213304a30b_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY18xL2ZyYWc6ZWRiMzM5MDJkYzdlNGY5NTllOGNkNjRiYTExZDQ0NWYvdGV4dHJlZ2lvbjplZGIzMzkwMmRjN2U0Zjk1OWU4Y2Q2NGJhMTFkNDQ1Zl8yMTU4_1d10f036-964c-494e-a4c1-6496d64ebcfa">225-7416</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="ie35b115501ca468f8cadb8213304a30b_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY18xL2ZyYWc6ZWRiMzM5MDJkYzdlNGY5NTllOGNkNjRiYTExZDQ0NWYvdGFibGU6MGQxMmIyNGRlODQ0NDQyMDg0YmFlNTg1MGFkYmExZTkvdGFibGVyYW5nZTowZDEyYjI0ZGU4NDQ0NDIwODRiYWU1ODUwYWRiYTFlOV8yLTAtMS0xLTY5OTQ5_e877d5e2-5847-4c7d-98cf-a2a168645710">Common Stock, par value $0.001 per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="ie35b115501ca468f8cadb8213304a30b_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY18xL2ZyYWc6ZWRiMzM5MDJkYzdlNGY5NTllOGNkNjRiYTExZDQ0NWYvdGFibGU6MGQxMmIyNGRlODQ0NDQyMDg0YmFlNTg1MGFkYmExZTkvdGFibGVyYW5nZTowZDEyYjI0ZGU4NDQ0NDIwODRiYWU1ODUwYWRiYTFlOV8yLTEtMS0xLTY5OTQ5_ee4edf38-a460-4a73-b16f-d9161943c7b6">CNTX</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="ie35b115501ca468f8cadb8213304a30b_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY18xL2ZyYWc6ZWRiMzM5MDJkYzdlNGY5NTllOGNkNjRiYTExZDQ0NWYvdGFibGU6MGQxMmIyNGRlODQ0NDQyMDg0YmFlNTg1MGFkYmExZTkvdGFibGVyYW5nZTowZDEyYjI0ZGU4NDQ0NDIwODRiYWU1ODUwYWRiYTFlOV8yLTItMS0xLTY5OTQ5_2d833a4f-ce2e-4d72-9ce4-277dabe1ca25">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus
      contextRef="ie35b115501ca468f8cadb8213304a30b_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY18xL2ZyYWc6ZWRiMzM5MDJkYzdlNGY5NTllOGNkNjRiYTExZDQ0NWYvdGV4dHJlZ2lvbjplZGIzMzkwMmRjN2U0Zjk1OWU4Y2Q2NGJhMTFkNDQ1Zl8yMTUx_5ccc640b-d5c7-493e-9fee-4150586bcb9e">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="ie35b115501ca468f8cadb8213304a30b_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY18xL2ZyYWc6ZWRiMzM5MDJkYzdlNGY5NTllOGNkNjRiYTExZDQ0NWYvdGV4dHJlZ2lvbjplZGIzMzkwMmRjN2U0Zjk1OWU4Y2Q2NGJhMTFkNDQ1Zl8yMTYy_d23f6224-f41c-4bdb-bf88-ad3af5f68108">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="ie35b115501ca468f8cadb8213304a30b_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY18xL2ZyYWc6ZWRiMzM5MDJkYzdlNGY5NTllOGNkNjRiYTExZDQ0NWYvdGFibGU6YzRhNzhhMzE5N2E3NDYyM2JiZTEyMzA4MjViZTRhMjgvdGFibGVyYW5nZTpjNGE3OGEzMTk3YTc0NjIzYmJlMTIzMDgyNWJlNGEyOF8xLTAtMS0xLTY5OTQ5_05560ba9-56b6-44b4-8a4c-15bc7580036b">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="ie35b115501ca468f8cadb8213304a30b_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY18xL2ZyYWc6ZWRiMzM5MDJkYzdlNGY5NTllOGNkNjRiYTExZDQ0NWYvdGFibGU6YzRhNzhhMzE5N2E3NDYyM2JiZTEyMzA4MjViZTRhMjgvdGFibGVyYW5nZTpjNGE3OGEzMTk3YTc0NjIzYmJlMTIzMDgyNWJlNGEyOF8xLTQtMS0xLTY5OTQ5_7a158280-d9c7-4fd0-ac26-8408167ea694">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="ie35b115501ca468f8cadb8213304a30b_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY18xL2ZyYWc6ZWRiMzM5MDJkYzdlNGY5NTllOGNkNjRiYTExZDQ0NWYvdGFibGU6YzRhNzhhMzE5N2E3NDYyM2JiZTEyMzA4MjViZTRhMjgvdGFibGVyYW5nZTpjNGE3OGEzMTk3YTc0NjIzYmJlMTIzMDgyNWJlNGEyOF8yLTQtMS0xLTY5OTQ5_fc032777-bb4f-4b30-8ff1-ed548e0bf30c">true</dei:EntityEmergingGrowthCompany>
    <dei:EntityExTransitionPeriod
      contextRef="ie35b115501ca468f8cadb8213304a30b_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY18xL2ZyYWc6ZWRiMzM5MDJkYzdlNGY5NTllOGNkNjRiYTExZDQ0NWYvdGV4dHJlZ2lvbjplZGIzMzkwMmRjN2U0Zjk1OWU4Y2Q2NGJhMTFkNDQ1Zl8yMTUy_45038ad0-e47e-477f-9b94-41c5b1e065c6">false</dei:EntityExTransitionPeriod>
    <dei:EntityShellCompany
      contextRef="ie35b115501ca468f8cadb8213304a30b_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY18xL2ZyYWc6ZWRiMzM5MDJkYzdlNGY5NTllOGNkNjRiYTExZDQ0NWYvdGV4dHJlZ2lvbjplZGIzMzkwMmRjN2U0Zjk1OWU4Y2Q2NGJhMTFkNDQ1Zl8yMTYz_0f43825d-30ae-4c53-9743-8e180a7f55a5">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="ia277388742eb471f9d42d799adb36d70_I20230505"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY18xL2ZyYWc6ZWRiMzM5MDJkYzdlNGY5NTllOGNkNjRiYTExZDQ0NWYvdGV4dHJlZ2lvbjplZGIzMzkwMmRjN2U0Zjk1OWU4Y2Q2NGJhMTFkNDQ1Zl8yMTM4_38a3734a-96fd-4aa6-9415-16defbc3058b"
      unitRef="shares">15966053</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i9e6ffce2c2d247f491e046febe8251cd_I20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY18yMi9mcmFnOjAwMGYzZjEyOTA1NzRkM2ZhZmY0N2ZmZGFmY2YyNjRhL3RhYmxlOjQ4MDNhMzdjMjkzMDRkNDE4NDQ1ZTA5ZTY3ZGZlNmY1L3RhYmxlcmFuZ2U6NDgwM2EzN2MyOTMwNGQ0MTg0NDVlMDllNjdkZmU2ZjVfNC0xLTEtMS02OTk0OQ_4070c089-2066-4a2f-851b-dca5988c5370"
      unitRef="usd">29768990</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i4b1713eab7d84494b3b43202a26fc3c4_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY18yMi9mcmFnOjAwMGYzZjEyOTA1NzRkM2ZhZmY0N2ZmZGFmY2YyNjRhL3RhYmxlOjQ4MDNhMzdjMjkzMDRkNDE4NDQ1ZTA5ZTY3ZGZlNmY1L3RhYmxlcmFuZ2U6NDgwM2EzN2MyOTMwNGQ0MTg0NDVlMDllNjdkZmU2ZjVfNC0zLTEtMS02OTk0OQ_574ad9d5-7f63-46c8-8a7a-72445b497551"
      unitRef="usd">35497445</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i9e6ffce2c2d247f491e046febe8251cd_I20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY18yMi9mcmFnOjAwMGYzZjEyOTA1NzRkM2ZhZmY0N2ZmZGFmY2YyNjRhL3RhYmxlOjQ4MDNhMzdjMjkzMDRkNDE4NDQ1ZTA5ZTY3ZGZlNmY1L3RhYmxlcmFuZ2U6NDgwM2EzN2MyOTMwNGQ0MTg0NDVlMDllNjdkZmU2ZjVfNS0xLTEtMS02OTk0OQ_fa438ce4-f1ba-4fd6-8272-35d07e138b56"
      unitRef="usd">2116737</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i4b1713eab7d84494b3b43202a26fc3c4_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY18yMi9mcmFnOjAwMGYzZjEyOTA1NzRkM2ZhZmY0N2ZmZGFmY2YyNjRhL3RhYmxlOjQ4MDNhMzdjMjkzMDRkNDE4NDQ1ZTA5ZTY3ZGZlNmY1L3RhYmxlcmFuZ2U6NDgwM2EzN2MyOTMwNGQ0MTg0NDVlMDllNjdkZmU2ZjVfNS0zLTEtMS02OTk0OQ_b4a0f957-39ad-4090-9a9c-1e73a7fa6632"
      unitRef="usd">2356213</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i9e6ffce2c2d247f491e046febe8251cd_I20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY18yMi9mcmFnOjAwMGYzZjEyOTA1NzRkM2ZhZmY0N2ZmZGFmY2YyNjRhL3RhYmxlOjQ4MDNhMzdjMjkzMDRkNDE4NDQ1ZTA5ZTY3ZGZlNmY1L3RhYmxlcmFuZ2U6NDgwM2EzN2MyOTMwNGQ0MTg0NDVlMDllNjdkZmU2ZjVfNi0xLTEtMS02OTk0OQ_6189e66a-a02a-4416-9f0b-0af6fb19cfab"
      unitRef="usd">31885727</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i4b1713eab7d84494b3b43202a26fc3c4_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY18yMi9mcmFnOjAwMGYzZjEyOTA1NzRkM2ZhZmY0N2ZmZGFmY2YyNjRhL3RhYmxlOjQ4MDNhMzdjMjkzMDRkNDE4NDQ1ZTA5ZTY3ZGZlNmY1L3RhYmxlcmFuZ2U6NDgwM2EzN2MyOTMwNGQ0MTg0NDVlMDllNjdkZmU2ZjVfNi0zLTEtMS02OTk0OQ_59f4397b-85a7-446c-b967-3e3154d7a3f9"
      unitRef="usd">37853658</us-gaap:AssetsCurrent>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i9e6ffce2c2d247f491e046febe8251cd_I20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY18yMi9mcmFnOjAwMGYzZjEyOTA1NzRkM2ZhZmY0N2ZmZGFmY2YyNjRhL3RhYmxlOjQ4MDNhMzdjMjkzMDRkNDE4NDQ1ZTA5ZTY3ZGZlNmY1L3RhYmxlcmFuZ2U6NDgwM2EzN2MyOTMwNGQ0MTg0NDVlMDllNjdkZmU2ZjVfNy0xLTEtMS02OTk0OQ_a330497b-03dc-4e93-b9a9-bbb3fd2b3909"
      unitRef="usd">29892</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i4b1713eab7d84494b3b43202a26fc3c4_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY18yMi9mcmFnOjAwMGYzZjEyOTA1NzRkM2ZhZmY0N2ZmZGFmY2YyNjRhL3RhYmxlOjQ4MDNhMzdjMjkzMDRkNDE4NDQ1ZTA5ZTY3ZGZlNmY1L3RhYmxlcmFuZ2U6NDgwM2EzN2MyOTMwNGQ0MTg0NDVlMDllNjdkZmU2ZjVfNy0zLTEtMS02OTk0OQ_2ba56837-5758-4f36-b324-41ca2c2a92be"
      unitRef="usd">51967</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i9e6ffce2c2d247f491e046febe8251cd_I20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY18yMi9mcmFnOjAwMGYzZjEyOTA1NzRkM2ZhZmY0N2ZmZGFmY2YyNjRhL3RhYmxlOjQ4MDNhMzdjMjkzMDRkNDE4NDQ1ZTA5ZTY3ZGZlNmY1L3RhYmxlcmFuZ2U6NDgwM2EzN2MyOTMwNGQ0MTg0NDVlMDllNjdkZmU2ZjVfOC0xLTEtMS02OTk0OQ_9782a10e-4bf1-4b42-8dd0-f1af746cfab5"
      unitRef="usd">24375</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i4b1713eab7d84494b3b43202a26fc3c4_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY18yMi9mcmFnOjAwMGYzZjEyOTA1NzRkM2ZhZmY0N2ZmZGFmY2YyNjRhL3RhYmxlOjQ4MDNhMzdjMjkzMDRkNDE4NDQ1ZTA5ZTY3ZGZlNmY1L3RhYmxlcmFuZ2U6NDgwM2EzN2MyOTMwNGQ0MTg0NDVlMDllNjdkZmU2ZjVfOC0zLTEtMS02OTk0OQ_eaceb49b-0123-4753-8527-067ec0938c9b"
      unitRef="usd">27568</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i9e6ffce2c2d247f491e046febe8251cd_I20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY18yMi9mcmFnOjAwMGYzZjEyOTA1NzRkM2ZhZmY0N2ZmZGFmY2YyNjRhL3RhYmxlOjQ4MDNhMzdjMjkzMDRkNDE4NDQ1ZTA5ZTY3ZGZlNmY1L3RhYmxlcmFuZ2U6NDgwM2EzN2MyOTMwNGQ0MTg0NDVlMDllNjdkZmU2ZjVfOS0xLTEtMS02OTk0OQ_9fcc2f97-3e79-40ad-a747-67d275fe2bfd"
      unitRef="usd">26188</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i4b1713eab7d84494b3b43202a26fc3c4_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY18yMi9mcmFnOjAwMGYzZjEyOTA1NzRkM2ZhZmY0N2ZmZGFmY2YyNjRhL3RhYmxlOjQ4MDNhMzdjMjkzMDRkNDE4NDQ1ZTA5ZTY3ZGZlNmY1L3RhYmxlcmFuZ2U6NDgwM2EzN2MyOTMwNGQ0MTg0NDVlMDllNjdkZmU2ZjVfOS0zLTEtMS02OTk0OQ_baaacad0-2707-4142-b58a-61b1278e4321"
      unitRef="usd">32750</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="i9e6ffce2c2d247f491e046febe8251cd_I20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY18yMi9mcmFnOjAwMGYzZjEyOTA1NzRkM2ZhZmY0N2ZmZGFmY2YyNjRhL3RhYmxlOjQ4MDNhMzdjMjkzMDRkNDE4NDQ1ZTA5ZTY3ZGZlNmY1L3RhYmxlcmFuZ2U6NDgwM2EzN2MyOTMwNGQ0MTg0NDVlMDllNjdkZmU2ZjVfMTEtMS0xLTEtNjk5NDk_2bcd2281-f4f7-496e-a9bf-d9e672e1e666"
      unitRef="usd">31966182</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="i4b1713eab7d84494b3b43202a26fc3c4_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY18yMi9mcmFnOjAwMGYzZjEyOTA1NzRkM2ZhZmY0N2ZmZGFmY2YyNjRhL3RhYmxlOjQ4MDNhMzdjMjkzMDRkNDE4NDQ1ZTA5ZTY3ZGZlNmY1L3RhYmxlcmFuZ2U6NDgwM2EzN2MyOTMwNGQ0MTg0NDVlMDllNjdkZmU2ZjVfMTEtMy0xLTEtNjk5NDk_8dcd2d70-20b3-4bc8-8091-4244d6b94d53"
      unitRef="usd">37965943</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="i9e6ffce2c2d247f491e046febe8251cd_I20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY18yMi9mcmFnOjAwMGYzZjEyOTA1NzRkM2ZhZmY0N2ZmZGFmY2YyNjRhL3RhYmxlOjQ4MDNhMzdjMjkzMDRkNDE4NDQ1ZTA5ZTY3ZGZlNmY1L3RhYmxlcmFuZ2U6NDgwM2EzN2MyOTMwNGQ0MTg0NDVlMDllNjdkZmU2ZjVfMTQtMS0xLTEtNjk5NDk_05f476a7-10f3-43b1-abd1-dab007002eb0"
      unitRef="usd">1210261</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="i4b1713eab7d84494b3b43202a26fc3c4_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY18yMi9mcmFnOjAwMGYzZjEyOTA1NzRkM2ZhZmY0N2ZmZGFmY2YyNjRhL3RhYmxlOjQ4MDNhMzdjMjkzMDRkNDE4NDQ1ZTA5ZTY3ZGZlNmY1L3RhYmxlcmFuZ2U6NDgwM2EzN2MyOTMwNGQ0MTg0NDVlMDllNjdkZmU2ZjVfMTQtMy0xLTEtNjk5NDk_77f9bb42-645d-4920-a282-0d68dc4ecb45"
      unitRef="usd">936330</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i9e6ffce2c2d247f491e046febe8251cd_I20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY18yMi9mcmFnOjAwMGYzZjEyOTA1NzRkM2ZhZmY0N2ZmZGFmY2YyNjRhL3RhYmxlOjQ4MDNhMzdjMjkzMDRkNDE4NDQ1ZTA5ZTY3ZGZlNmY1L3RhYmxlcmFuZ2U6NDgwM2EzN2MyOTMwNGQ0MTg0NDVlMDllNjdkZmU2ZjVfMTUtMS0xLTEtNjk5NDk_d09b9cc6-5740-4026-8813-235b1b0e98ff"
      unitRef="usd">1991442</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i4b1713eab7d84494b3b43202a26fc3c4_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY18yMi9mcmFnOjAwMGYzZjEyOTA1NzRkM2ZhZmY0N2ZmZGFmY2YyNjRhL3RhYmxlOjQ4MDNhMzdjMjkzMDRkNDE4NDQ1ZTA5ZTY3ZGZlNmY1L3RhYmxlcmFuZ2U6NDgwM2EzN2MyOTMwNGQ0MTg0NDVlMDllNjdkZmU2ZjVfMTUtMy0xLTEtNjk5NDk_20bcd61a-ab25-4481-9a01-86e5c0d14aa7"
      unitRef="usd">2216169</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i9e6ffce2c2d247f491e046febe8251cd_I20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY18yMi9mcmFnOjAwMGYzZjEyOTA1NzRkM2ZhZmY0N2ZmZGFmY2YyNjRhL3RhYmxlOjQ4MDNhMzdjMjkzMDRkNDE4NDQ1ZTA5ZTY3ZGZlNmY1L3RhYmxlcmFuZ2U6NDgwM2EzN2MyOTMwNGQ0MTg0NDVlMDllNjdkZmU2ZjVfMTYtMS0xLTEtNjk5NDk_80dfde25-c4a1-4462-a996-baf606a5fd34"
      unitRef="usd">31669</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i4b1713eab7d84494b3b43202a26fc3c4_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY18yMi9mcmFnOjAwMGYzZjEyOTA1NzRkM2ZhZmY0N2ZmZGFmY2YyNjRhL3RhYmxlOjQ4MDNhMzdjMjkzMDRkNDE4NDQ1ZTA5ZTY3ZGZlNmY1L3RhYmxlcmFuZ2U6NDgwM2EzN2MyOTMwNGQ0MTg0NDVlMDllNjdkZmU2ZjVfMTYtMy0xLTEtNjk5NDk_4bc32cb6-b2ae-4e2e-8ef4-fd98a7c4d55d"
      unitRef="usd">55078</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i9e6ffce2c2d247f491e046febe8251cd_I20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY18yMi9mcmFnOjAwMGYzZjEyOTA1NzRkM2ZhZmY0N2ZmZGFmY2YyNjRhL3RhYmxlOjQ4MDNhMzdjMjkzMDRkNDE4NDQ1ZTA5ZTY3ZGZlNmY1L3RhYmxlcmFuZ2U6NDgwM2EzN2MyOTMwNGQ0MTg0NDVlMDllNjdkZmU2ZjVfMTctMS0xLTEtNjk5NDk_625dbac6-e920-4991-88dd-5cfdf70b6205"
      unitRef="usd">3233372</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i4b1713eab7d84494b3b43202a26fc3c4_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY18yMi9mcmFnOjAwMGYzZjEyOTA1NzRkM2ZhZmY0N2ZmZGFmY2YyNjRhL3RhYmxlOjQ4MDNhMzdjMjkzMDRkNDE4NDQ1ZTA5ZTY3ZGZlNmY1L3RhYmxlcmFuZ2U6NDgwM2EzN2MyOTMwNGQ0MTg0NDVlMDllNjdkZmU2ZjVfMTctMy0xLTEtNjk5NDk_c6d1eccb-670e-4dd5-b690-2b2c0387f742"
      unitRef="usd">3207577</us-gaap:LiabilitiesCurrent>
    <us-gaap:Liabilities
      contextRef="i9e6ffce2c2d247f491e046febe8251cd_I20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY18yMi9mcmFnOjAwMGYzZjEyOTA1NzRkM2ZhZmY0N2ZmZGFmY2YyNjRhL3RhYmxlOjQ4MDNhMzdjMjkzMDRkNDE4NDQ1ZTA5ZTY3ZGZlNmY1L3RhYmxlcmFuZ2U6NDgwM2EzN2MyOTMwNGQ0MTg0NDVlMDllNjdkZmU2ZjVfMTgtMS0xLTEtNjk5NDk_1d1907b7-ed3b-4dfa-9159-23159f170adb"
      unitRef="usd">3233372</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="i4b1713eab7d84494b3b43202a26fc3c4_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY18yMi9mcmFnOjAwMGYzZjEyOTA1NzRkM2ZhZmY0N2ZmZGFmY2YyNjRhL3RhYmxlOjQ4MDNhMzdjMjkzMDRkNDE4NDQ1ZTA5ZTY3ZGZlNmY1L3RhYmxlcmFuZ2U6NDgwM2EzN2MyOTMwNGQ0MTg0NDVlMDllNjdkZmU2ZjVfMTgtMy0xLTEtNjk5NDk_a77cf86e-1544-44a8-aec0-a36f6edfeb76"
      unitRef="usd">3207577</us-gaap:Liabilities>
    <us-gaap:CommitmentsAndContingencies
      contextRef="i9e6ffce2c2d247f491e046febe8251cd_I20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY18yMi9mcmFnOjAwMGYzZjEyOTA1NzRkM2ZhZmY0N2ZmZGFmY2YyNjRhL3RhYmxlOjQ4MDNhMzdjMjkzMDRkNDE4NDQ1ZTA5ZTY3ZGZlNmY1L3RhYmxlcmFuZ2U6NDgwM2EzN2MyOTMwNGQ0MTg0NDVlMDllNjdkZmU2ZjVfMTktMS0xLTEtNjk5NDk_b2034094-3169-4886-9df2-acdbd396ad7f"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="i4b1713eab7d84494b3b43202a26fc3c4_I20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY18yMi9mcmFnOjAwMGYzZjEyOTA1NzRkM2ZhZmY0N2ZmZGFmY2YyNjRhL3RhYmxlOjQ4MDNhMzdjMjkzMDRkNDE4NDQ1ZTA5ZTY3ZGZlNmY1L3RhYmxlcmFuZ2U6NDgwM2EzN2MyOTMwNGQ0MTg0NDVlMDllNjdkZmU2ZjVfMTktMy0xLTEtNjk5NDk_590b10d4-4d07-4e7a-8e6a-81d3568f0ffd"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="i4b1713eab7d84494b3b43202a26fc3c4_I20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY18yMi9mcmFnOjAwMGYzZjEyOTA1NzRkM2ZhZmY0N2ZmZGFmY2YyNjRhL3RhYmxlOjQ4MDNhMzdjMjkzMDRkNDE4NDQ1ZTA5ZTY3ZGZlNmY1L3RhYmxlcmFuZ2U6NDgwM2EzN2MyOTMwNGQ0MTg0NDVlMDllNjdkZmU2ZjVfMjEtMC0xLTEtNjk5NDkvdGV4dHJlZ2lvbjozOGE4NGUzMDJmMTM0MzJhYTM5YWI4NTExYTMzNmQ4OV8yMQ_7a038add-a5c5-4afb-b18d-cf84d017ef51"
      unitRef="usdPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="i9e6ffce2c2d247f491e046febe8251cd_I20230331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY18yMi9mcmFnOjAwMGYzZjEyOTA1NzRkM2ZhZmY0N2ZmZGFmY2YyNjRhL3RhYmxlOjQ4MDNhMzdjMjkzMDRkNDE4NDQ1ZTA5ZTY3ZGZlNmY1L3RhYmxlcmFuZ2U6NDgwM2EzN2MyOTMwNGQ0MTg0NDVlMDllNjdkZmU2ZjVfMjEtMC0xLTEtNjk5NDkvdGV4dHJlZ2lvbjozOGE4NGUzMDJmMTM0MzJhYTM5YWI4NTExYTMzNmQ4OV8yMQ_98e23a0e-cef7-47ec-95be-3183a7456b6a"
      unitRef="usdPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="i4b1713eab7d84494b3b43202a26fc3c4_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY18yMi9mcmFnOjAwMGYzZjEyOTA1NzRkM2ZhZmY0N2ZmZGFmY2YyNjRhL3RhYmxlOjQ4MDNhMzdjMjkzMDRkNDE4NDQ1ZTA5ZTY3ZGZlNmY1L3RhYmxlcmFuZ2U6NDgwM2EzN2MyOTMwNGQ0MTg0NDVlMDllNjdkZmU2ZjVfMjEtMC0xLTEtNjk5NDkvdGV4dHJlZ2lvbjozOGE4NGUzMDJmMTM0MzJhYTM5YWI4NTExYTMzNmQ4OV8zNQ_251cb4f0-3e97-4a3b-bac1-4658107ae42a"
      unitRef="shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="i9e6ffce2c2d247f491e046febe8251cd_I20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY18yMi9mcmFnOjAwMGYzZjEyOTA1NzRkM2ZhZmY0N2ZmZGFmY2YyNjRhL3RhYmxlOjQ4MDNhMzdjMjkzMDRkNDE4NDQ1ZTA5ZTY3ZGZlNmY1L3RhYmxlcmFuZ2U6NDgwM2EzN2MyOTMwNGQ0MTg0NDVlMDllNjdkZmU2ZjVfMjEtMC0xLTEtNjk5NDkvdGV4dHJlZ2lvbjozOGE4NGUzMDJmMTM0MzJhYTM5YWI4NTExYTMzNmQ4OV8zNQ_e5d60299-2060-40d1-9840-3271fb2aea1b"
      unitRef="shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i9e6ffce2c2d247f491e046febe8251cd_I20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY18yMi9mcmFnOjAwMGYzZjEyOTA1NzRkM2ZhZmY0N2ZmZGFmY2YyNjRhL3RhYmxlOjQ4MDNhMzdjMjkzMDRkNDE4NDQ1ZTA5ZTY3ZGZlNmY1L3RhYmxlcmFuZ2U6NDgwM2EzN2MyOTMwNGQ0MTg0NDVlMDllNjdkZmU2ZjVfMjEtMC0xLTEtNjk5NDkvdGV4dHJlZ2lvbjozOGE4NGUzMDJmMTM0MzJhYTM5YWI4NTExYTMzNmQ4OV81Nw_39ab2906-4f52-4864-8aa8-4a41c4eb443b"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i4b1713eab7d84494b3b43202a26fc3c4_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY18yMi9mcmFnOjAwMGYzZjEyOTA1NzRkM2ZhZmY0N2ZmZGFmY2YyNjRhL3RhYmxlOjQ4MDNhMzdjMjkzMDRkNDE4NDQ1ZTA5ZTY3ZGZlNmY1L3RhYmxlcmFuZ2U6NDgwM2EzN2MyOTMwNGQ0MTg0NDVlMDllNjdkZmU2ZjVfMjEtMC0xLTEtNjk5NDkvdGV4dHJlZ2lvbjozOGE4NGUzMDJmMTM0MzJhYTM5YWI4NTExYTMzNmQ4OV81Nw_4d9796fa-c968-4aef-8036-b29f64b3c466"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="i9e6ffce2c2d247f491e046febe8251cd_I20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY18yMi9mcmFnOjAwMGYzZjEyOTA1NzRkM2ZhZmY0N2ZmZGFmY2YyNjRhL3RhYmxlOjQ4MDNhMzdjMjkzMDRkNDE4NDQ1ZTA5ZTY3ZGZlNmY1L3RhYmxlcmFuZ2U6NDgwM2EzN2MyOTMwNGQ0MTg0NDVlMDllNjdkZmU2ZjVfMjEtMC0xLTEtNjk5NDkvdGV4dHJlZ2lvbjozOGE4NGUzMDJmMTM0MzJhYTM5YWI4NTExYTMzNmQ4OV81Nw_abbcea6b-23c8-41d2-bfe8-5be891aa85fd"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued
      contextRef="i4b1713eab7d84494b3b43202a26fc3c4_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY18yMi9mcmFnOjAwMGYzZjEyOTA1NzRkM2ZhZmY0N2ZmZGFmY2YyNjRhL3RhYmxlOjQ4MDNhMzdjMjkzMDRkNDE4NDQ1ZTA5ZTY3ZGZlNmY1L3RhYmxlcmFuZ2U6NDgwM2EzN2MyOTMwNGQ0MTg0NDVlMDllNjdkZmU2ZjVfMjEtMC0xLTEtNjk5NDkvdGV4dHJlZ2lvbjozOGE4NGUzMDJmMTM0MzJhYTM5YWI4NTExYTMzNmQ4OV81Nw_bc1908e3-2dd7-4014-a2dd-6079d703127b"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockValue
      contextRef="i9e6ffce2c2d247f491e046febe8251cd_I20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY18yMi9mcmFnOjAwMGYzZjEyOTA1NzRkM2ZhZmY0N2ZmZGFmY2YyNjRhL3RhYmxlOjQ4MDNhMzdjMjkzMDRkNDE4NDQ1ZTA5ZTY3ZGZlNmY1L3RhYmxlcmFuZ2U6NDgwM2EzN2MyOTMwNGQ0MTg0NDVlMDllNjdkZmU2ZjVfMjEtMS0xLTEtNjk5NDk_faa30cf5-4aab-4eaa-8275-1fad5eb0432d"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue
      contextRef="i4b1713eab7d84494b3b43202a26fc3c4_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY18yMi9mcmFnOjAwMGYzZjEyOTA1NzRkM2ZhZmY0N2ZmZGFmY2YyNjRhL3RhYmxlOjQ4MDNhMzdjMjkzMDRkNDE4NDQ1ZTA5ZTY3ZGZlNmY1L3RhYmxlcmFuZ2U6NDgwM2EzN2MyOTMwNGQ0MTg0NDVlMDllNjdkZmU2ZjVfMjEtMy0xLTEtNjk5NDk_ebca4a28-bf2d-4a0e-91ff-20be7b262722"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i9e6ffce2c2d247f491e046febe8251cd_I20230331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY18yMi9mcmFnOjAwMGYzZjEyOTA1NzRkM2ZhZmY0N2ZmZGFmY2YyNjRhL3RhYmxlOjQ4MDNhMzdjMjkzMDRkNDE4NDQ1ZTA5ZTY3ZGZlNmY1L3RhYmxlcmFuZ2U6NDgwM2EzN2MyOTMwNGQ0MTg0NDVlMDllNjdkZmU2ZjVfMjItMC0xLTEtNjk5NDkvdGV4dHJlZ2lvbjo2MGFkYjdjNjA3OGU0ZGIxODI3ZTdjODZkYjQyMzViM18xOA_414e7e02-74fd-4aea-bbde-c798fc98bbf9"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i4b1713eab7d84494b3b43202a26fc3c4_I20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY18yMi9mcmFnOjAwMGYzZjEyOTA1NzRkM2ZhZmY0N2ZmZGFmY2YyNjRhL3RhYmxlOjQ4MDNhMzdjMjkzMDRkNDE4NDQ1ZTA5ZTY3ZGZlNmY1L3RhYmxlcmFuZ2U6NDgwM2EzN2MyOTMwNGQ0MTg0NDVlMDllNjdkZmU2ZjVfMjItMC0xLTEtNjk5NDkvdGV4dHJlZ2lvbjo2MGFkYjdjNjA3OGU0ZGIxODI3ZTdjODZkYjQyMzViM18xOA_c708108d-b32e-4990-964d-3e5937e0e4b4"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i4b1713eab7d84494b3b43202a26fc3c4_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY18yMi9mcmFnOjAwMGYzZjEyOTA1NzRkM2ZhZmY0N2ZmZGFmY2YyNjRhL3RhYmxlOjQ4MDNhMzdjMjkzMDRkNDE4NDQ1ZTA5ZTY3ZGZlNmY1L3RhYmxlcmFuZ2U6NDgwM2EzN2MyOTMwNGQ0MTg0NDVlMDllNjdkZmU2ZjVfMjItMC0xLTEtNjk5NDkvdGV4dHJlZ2lvbjo2MGFkYjdjNjA3OGU0ZGIxODI3ZTdjODZkYjQyMzViM18zMg_9a485a77-dbb2-471c-96d7-0076153c0aac"
      unitRef="shares">100000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i9e6ffce2c2d247f491e046febe8251cd_I20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY18yMi9mcmFnOjAwMGYzZjEyOTA1NzRkM2ZhZmY0N2ZmZGFmY2YyNjRhL3RhYmxlOjQ4MDNhMzdjMjkzMDRkNDE4NDQ1ZTA5ZTY3ZGZlNmY1L3RhYmxlcmFuZ2U6NDgwM2EzN2MyOTMwNGQ0MTg0NDVlMDllNjdkZmU2ZjVfMjItMC0xLTEtNjk5NDkvdGV4dHJlZ2lvbjo2MGFkYjdjNjA3OGU0ZGIxODI3ZTdjODZkYjQyMzViM18zMg_e0a61d51-aeac-4981-a834-1060f20d82df"
      unitRef="shares">100000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i9e6ffce2c2d247f491e046febe8251cd_I20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY18yMi9mcmFnOjAwMGYzZjEyOTA1NzRkM2ZhZmY0N2ZmZGFmY2YyNjRhL3RhYmxlOjQ4MDNhMzdjMjkzMDRkNDE4NDQ1ZTA5ZTY3ZGZlNmY1L3RhYmxlcmFuZ2U6NDgwM2EzN2MyOTMwNGQ0MTg0NDVlMDllNjdkZmU2ZjVfMjItMC0xLTEtNjk5NDkvdGV4dHJlZ2lvbjo2MGFkYjdjNjA3OGU0ZGIxODI3ZTdjODZkYjQyMzViM181NA_2dab8fa4-a840-46fe-bd3d-6ed7895b75a1"
      unitRef="shares">15966053</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="i4b1713eab7d84494b3b43202a26fc3c4_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY18yMi9mcmFnOjAwMGYzZjEyOTA1NzRkM2ZhZmY0N2ZmZGFmY2YyNjRhL3RhYmxlOjQ4MDNhMzdjMjkzMDRkNDE4NDQ1ZTA5ZTY3ZGZlNmY1L3RhYmxlcmFuZ2U6NDgwM2EzN2MyOTMwNGQ0MTg0NDVlMDllNjdkZmU2ZjVfMjItMC0xLTEtNjk5NDkvdGV4dHJlZ2lvbjo2MGFkYjdjNjA3OGU0ZGIxODI3ZTdjODZkYjQyMzViM181NA_5674aa2a-8ad6-4260-b1c5-e6e4a784648a"
      unitRef="shares">15966053</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued
      contextRef="i9e6ffce2c2d247f491e046febe8251cd_I20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY18yMi9mcmFnOjAwMGYzZjEyOTA1NzRkM2ZhZmY0N2ZmZGFmY2YyNjRhL3RhYmxlOjQ4MDNhMzdjMjkzMDRkNDE4NDQ1ZTA5ZTY3ZGZlNmY1L3RhYmxlcmFuZ2U6NDgwM2EzN2MyOTMwNGQ0MTg0NDVlMDllNjdkZmU2ZjVfMjItMC0xLTEtNjk5NDkvdGV4dHJlZ2lvbjo2MGFkYjdjNjA3OGU0ZGIxODI3ZTdjODZkYjQyMzViM181NA_69f43160-2d8d-4f8b-9ec7-1699b97d1368"
      unitRef="shares">15966053</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i4b1713eab7d84494b3b43202a26fc3c4_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY18yMi9mcmFnOjAwMGYzZjEyOTA1NzRkM2ZhZmY0N2ZmZGFmY2YyNjRhL3RhYmxlOjQ4MDNhMzdjMjkzMDRkNDE4NDQ1ZTA5ZTY3ZGZlNmY1L3RhYmxlcmFuZ2U6NDgwM2EzN2MyOTMwNGQ0MTg0NDVlMDllNjdkZmU2ZjVfMjItMC0xLTEtNjk5NDkvdGV4dHJlZ2lvbjo2MGFkYjdjNjA3OGU0ZGIxODI3ZTdjODZkYjQyMzViM181NA_84de4c18-0660-49a2-80d5-1657f319cf66"
      unitRef="shares">15966053</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="i9e6ffce2c2d247f491e046febe8251cd_I20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY18yMi9mcmFnOjAwMGYzZjEyOTA1NzRkM2ZhZmY0N2ZmZGFmY2YyNjRhL3RhYmxlOjQ4MDNhMzdjMjkzMDRkNDE4NDQ1ZTA5ZTY3ZGZlNmY1L3RhYmxlcmFuZ2U6NDgwM2EzN2MyOTMwNGQ0MTg0NDVlMDllNjdkZmU2ZjVfMjItMS0xLTEtNjk5NDk_633b2f1e-b1b7-4a34-aa97-6e91fde9e206"
      unitRef="usd">15966</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="i4b1713eab7d84494b3b43202a26fc3c4_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY18yMi9mcmFnOjAwMGYzZjEyOTA1NzRkM2ZhZmY0N2ZmZGFmY2YyNjRhL3RhYmxlOjQ4MDNhMzdjMjkzMDRkNDE4NDQ1ZTA5ZTY3ZGZlNmY1L3RhYmxlcmFuZ2U6NDgwM2EzN2MyOTMwNGQ0MTg0NDVlMDllNjdkZmU2ZjVfMjItMy0xLTEtNjk5NDk_a3e29b4e-96f9-4633-b7ce-641a4498cfb2"
      unitRef="usd">15966</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="i9e6ffce2c2d247f491e046febe8251cd_I20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY18yMi9mcmFnOjAwMGYzZjEyOTA1NzRkM2ZhZmY0N2ZmZGFmY2YyNjRhL3RhYmxlOjQ4MDNhMzdjMjkzMDRkNDE4NDQ1ZTA5ZTY3ZGZlNmY1L3RhYmxlcmFuZ2U6NDgwM2EzN2MyOTMwNGQ0MTg0NDVlMDllNjdkZmU2ZjVfMjMtMS0xLTEtNjk5NDk_87c65f55-4027-4f87-8b98-96190eadb3d4"
      unitRef="usd">79115541</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="i4b1713eab7d84494b3b43202a26fc3c4_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY18yMi9mcmFnOjAwMGYzZjEyOTA1NzRkM2ZhZmY0N2ZmZGFmY2YyNjRhL3RhYmxlOjQ4MDNhMzdjMjkzMDRkNDE4NDQ1ZTA5ZTY3ZGZlNmY1L3RhYmxlcmFuZ2U6NDgwM2EzN2MyOTMwNGQ0MTg0NDVlMDllNjdkZmU2ZjVfMjMtMy0xLTEtNjk5NDk_7d106c30-0b67-4b9e-b9ff-789992f77eaa"
      unitRef="usd">78832779</us-gaap:AdditionalPaidInCapital>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i9e6ffce2c2d247f491e046febe8251cd_I20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY18yMi9mcmFnOjAwMGYzZjEyOTA1NzRkM2ZhZmY0N2ZmZGFmY2YyNjRhL3RhYmxlOjQ4MDNhMzdjMjkzMDRkNDE4NDQ1ZTA5ZTY3ZGZlNmY1L3RhYmxlcmFuZ2U6NDgwM2EzN2MyOTMwNGQ0MTg0NDVlMDllNjdkZmU2ZjVfMjQtMS0xLTEtNjk5NDk_8cb4939c-d5d2-439b-9f63-d23cc91434d0"
      unitRef="usd">-50398697</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i4b1713eab7d84494b3b43202a26fc3c4_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY18yMi9mcmFnOjAwMGYzZjEyOTA1NzRkM2ZhZmY0N2ZmZGFmY2YyNjRhL3RhYmxlOjQ4MDNhMzdjMjkzMDRkNDE4NDQ1ZTA5ZTY3ZGZlNmY1L3RhYmxlcmFuZ2U6NDgwM2EzN2MyOTMwNGQ0MTg0NDVlMDllNjdkZmU2ZjVfMjQtMy0xLTEtNjk5NDk_fc808d05-e40c-4fd0-8978-40d713885736"
      unitRef="usd">-44090379</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="i9e6ffce2c2d247f491e046febe8251cd_I20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY18yMi9mcmFnOjAwMGYzZjEyOTA1NzRkM2ZhZmY0N2ZmZGFmY2YyNjRhL3RhYmxlOjQ4MDNhMzdjMjkzMDRkNDE4NDQ1ZTA5ZTY3ZGZlNmY1L3RhYmxlcmFuZ2U6NDgwM2EzN2MyOTMwNGQ0MTg0NDVlMDllNjdkZmU2ZjVfMjUtMS0xLTEtNjk5NDk_1be63065-388d-4029-befd-1f1292c4dee3"
      unitRef="usd">28732810</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i4b1713eab7d84494b3b43202a26fc3c4_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY18yMi9mcmFnOjAwMGYzZjEyOTA1NzRkM2ZhZmY0N2ZmZGFmY2YyNjRhL3RhYmxlOjQ4MDNhMzdjMjkzMDRkNDE4NDQ1ZTA5ZTY3ZGZlNmY1L3RhYmxlcmFuZ2U6NDgwM2EzN2MyOTMwNGQ0MTg0NDVlMDllNjdkZmU2ZjVfMjUtMy0xLTEtNjk5NDk_d960f2de-96c1-4a7f-a52e-12565aec0c2d"
      unitRef="usd">34758366</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i9e6ffce2c2d247f491e046febe8251cd_I20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY18yMi9mcmFnOjAwMGYzZjEyOTA1NzRkM2ZhZmY0N2ZmZGFmY2YyNjRhL3RhYmxlOjQ4MDNhMzdjMjkzMDRkNDE4NDQ1ZTA5ZTY3ZGZlNmY1L3RhYmxlcmFuZ2U6NDgwM2EzN2MyOTMwNGQ0MTg0NDVlMDllNjdkZmU2ZjVfMjYtMS0xLTEtNjk5NDk_945bbaff-fc40-40ad-921c-b4a1bb70b767"
      unitRef="usd">31966182</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i4b1713eab7d84494b3b43202a26fc3c4_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY18yMi9mcmFnOjAwMGYzZjEyOTA1NzRkM2ZhZmY0N2ZmZGFmY2YyNjRhL3RhYmxlOjQ4MDNhMzdjMjkzMDRkNDE4NDQ1ZTA5ZTY3ZGZlNmY1L3RhYmxlcmFuZ2U6NDgwM2EzN2MyOTMwNGQ0MTg0NDVlMDllNjdkZmU2ZjVfMjYtMy0xLTEtNjk5NDk_b2806cb5-6e15-4c42-a561-61c8c3a35379"
      unitRef="usd">37965943</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="ie35b115501ca468f8cadb8213304a30b_D20230101-20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY18yNS9mcmFnOjA5ZGZjMGNmNmE4YjQ1Nzk5MzY0MTllYjNjYjczZGI3L3RhYmxlOmRlNzUzZDM1MGI1MDQzMGY5YTY4NjdkMjI1MTEwNjliL3RhYmxlcmFuZ2U6ZGU3NTNkMzUwYjUwNDMwZjlhNjg2N2QyMjUxMTA2OWJfNC0xLTEtMS02OTk0OQ_ee47d727-11ca-48d0-8764-ecf9b2359980"
      unitRef="usd">4534676</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="i3baf3250062d4a79a9b120fc56f1b18c_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY18yNS9mcmFnOjA5ZGZjMGNmNmE4YjQ1Nzk5MzY0MTllYjNjYjczZGI3L3RhYmxlOmRlNzUzZDM1MGI1MDQzMGY5YTY4NjdkMjI1MTEwNjliL3RhYmxlcmFuZ2U6ZGU3NTNkMzUwYjUwNDMwZjlhNjg2N2QyMjUxMTA2OWJfNC0zLTEtMS02OTk0OQ_69c2e11e-d9d9-4a12-b188-53660d5027c5"
      unitRef="usd">1351495</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="ie35b115501ca468f8cadb8213304a30b_D20230101-20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY18yNS9mcmFnOjA5ZGZjMGNmNmE4YjQ1Nzk5MzY0MTllYjNjYjczZGI3L3RhYmxlOmRlNzUzZDM1MGI1MDQzMGY5YTY4NjdkMjI1MTEwNjliL3RhYmxlcmFuZ2U6ZGU3NTNkMzUwYjUwNDMwZjlhNjg2N2QyMjUxMTA2OWJfNS0xLTEtMS02OTk0OQ_ff6ee6a5-ee08-410b-8005-c77200aa3469"
      unitRef="usd">2131872</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i3baf3250062d4a79a9b120fc56f1b18c_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY18yNS9mcmFnOjA5ZGZjMGNmNmE4YjQ1Nzk5MzY0MTllYjNjYjczZGI3L3RhYmxlOmRlNzUzZDM1MGI1MDQzMGY5YTY4NjdkMjI1MTEwNjliL3RhYmxlcmFuZ2U6ZGU3NTNkMzUwYjUwNDMwZjlhNjg2N2QyMjUxMTA2OWJfNS0zLTEtMS02OTk0OQ_da6359cd-0d6a-473c-a782-809f7530ba21"
      unitRef="usd">2091467</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingIncomeLoss
      contextRef="ie35b115501ca468f8cadb8213304a30b_D20230101-20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY18yNS9mcmFnOjA5ZGZjMGNmNmE4YjQ1Nzk5MzY0MTllYjNjYjczZGI3L3RhYmxlOmRlNzUzZDM1MGI1MDQzMGY5YTY4NjdkMjI1MTEwNjliL3RhYmxlcmFuZ2U6ZGU3NTNkMzUwYjUwNDMwZjlhNjg2N2QyMjUxMTA2OWJfNi0xLTEtMS02OTk0OQ_27f5afb3-7773-40f3-9fbb-1f29f5bc63fa"
      unitRef="usd">-6666548</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i3baf3250062d4a79a9b120fc56f1b18c_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY18yNS9mcmFnOjA5ZGZjMGNmNmE4YjQ1Nzk5MzY0MTllYjNjYjczZGI3L3RhYmxlOmRlNzUzZDM1MGI1MDQzMGY5YTY4NjdkMjI1MTEwNjliL3RhYmxlcmFuZ2U6ZGU3NTNkMzUwYjUwNDMwZjlhNjg2N2QyMjUxMTA2OWJfNi0zLTEtMS02OTk0OQ_b38c0909-ab13-47bc-8b0b-99b5dda42c3f"
      unitRef="usd">-3442962</us-gaap:OperatingIncomeLoss>
    <us-gaap:InterestIncomeExpenseNet
      contextRef="ie35b115501ca468f8cadb8213304a30b_D20230101-20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY18yNS9mcmFnOjA5ZGZjMGNmNmE4YjQ1Nzk5MzY0MTllYjNjYjczZGI3L3RhYmxlOmRlNzUzZDM1MGI1MDQzMGY5YTY4NjdkMjI1MTEwNjliL3RhYmxlcmFuZ2U6ZGU3NTNkMzUwYjUwNDMwZjlhNjg2N2QyMjUxMTA2OWJfNy0xLTEtMS02OTk0OQ_5bc9409b-dd47-4a6a-ab4f-487cf3586441"
      unitRef="usd">355542</us-gaap:InterestIncomeExpenseNet>
    <us-gaap:InterestIncomeExpenseNet
      contextRef="i3baf3250062d4a79a9b120fc56f1b18c_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY18yNS9mcmFnOjA5ZGZjMGNmNmE4YjQ1Nzk5MzY0MTllYjNjYjczZGI3L3RhYmxlOmRlNzUzZDM1MGI1MDQzMGY5YTY4NjdkMjI1MTEwNjliL3RhYmxlcmFuZ2U6ZGU3NTNkMzUwYjUwNDMwZjlhNjg2N2QyMjUxMTA2OWJfNy0zLTEtMS02OTk0OQ_d4f47199-9885-448d-9bd2-888041ccf38a"
      unitRef="usd">5864</us-gaap:InterestIncomeExpenseNet>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="ie35b115501ca468f8cadb8213304a30b_D20230101-20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY18yNS9mcmFnOjA5ZGZjMGNmNmE4YjQ1Nzk5MzY0MTllYjNjYjczZGI3L3RhYmxlOmRlNzUzZDM1MGI1MDQzMGY5YTY4NjdkMjI1MTEwNjliL3RhYmxlcmFuZ2U6ZGU3NTNkMzUwYjUwNDMwZjlhNjg2N2QyMjUxMTA2OWJfOS0xLTEtMS02OTk0OQ_529b593b-d982-499c-b319-787bbb055448"
      unitRef="usd">2688</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="i3baf3250062d4a79a9b120fc56f1b18c_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY18yNS9mcmFnOjA5ZGZjMGNmNmE4YjQ1Nzk5MzY0MTllYjNjYjczZGI3L3RhYmxlOmRlNzUzZDM1MGI1MDQzMGY5YTY4NjdkMjI1MTEwNjliL3RhYmxlcmFuZ2U6ZGU3NTNkMzUwYjUwNDMwZjlhNjg2N2QyMjUxMTA2OWJfOS0zLTEtMS02OTk0OQ_8b44c428-3142-4e55-834d-bc62b7fe2796"
      unitRef="usd">-1239</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NetIncomeLoss
      contextRef="ie35b115501ca468f8cadb8213304a30b_D20230101-20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY18yNS9mcmFnOjA5ZGZjMGNmNmE4YjQ1Nzk5MzY0MTllYjNjYjczZGI3L3RhYmxlOmRlNzUzZDM1MGI1MDQzMGY5YTY4NjdkMjI1MTEwNjliL3RhYmxlcmFuZ2U6ZGU3NTNkMzUwYjUwNDMwZjlhNjg2N2QyMjUxMTA2OWJfMTAtMS0xLTEtNjk5NDk_71955604-afa2-4f8e-805c-5e0d08e53572"
      unitRef="usd">-6308318</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i3baf3250062d4a79a9b120fc56f1b18c_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY18yNS9mcmFnOjA5ZGZjMGNmNmE4YjQ1Nzk5MzY0MTllYjNjYjczZGI3L3RhYmxlOmRlNzUzZDM1MGI1MDQzMGY5YTY4NjdkMjI1MTEwNjliL3RhYmxlcmFuZ2U6ZGU3NTNkMzUwYjUwNDMwZjlhNjg2N2QyMjUxMTA2OWJfMTAtMy0xLTEtNjk5NDk_1b5e9a69-58f3-4d7c-a416-b6dd60171adc"
      unitRef="usd">-3438337</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareDiluted
      contextRef="ie35b115501ca468f8cadb8213304a30b_D20230101-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY18yNS9mcmFnOjA5ZGZjMGNmNmE4YjQ1Nzk5MzY0MTllYjNjYjczZGI3L3RhYmxlOmRlNzUzZDM1MGI1MDQzMGY5YTY4NjdkMjI1MTEwNjliL3RhYmxlcmFuZ2U6ZGU3NTNkMzUwYjUwNDMwZjlhNjg2N2QyMjUxMTA2OWJfMTEtMS0xLTEtNjk5NDk_407902ed-d759-4227-932b-27ef141c1e85"
      unitRef="usdPerShare">-0.40</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="ie35b115501ca468f8cadb8213304a30b_D20230101-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY18yNS9mcmFnOjA5ZGZjMGNmNmE4YjQ1Nzk5MzY0MTllYjNjYjczZGI3L3RhYmxlOmRlNzUzZDM1MGI1MDQzMGY5YTY4NjdkMjI1MTEwNjliL3RhYmxlcmFuZ2U6ZGU3NTNkMzUwYjUwNDMwZjlhNjg2N2QyMjUxMTA2OWJfMTEtMS0xLTEtNjk5NDk_e7895dd6-2456-4b4b-9b37-0bc1ba53b741"
      unitRef="usdPerShare">-0.40</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i3baf3250062d4a79a9b120fc56f1b18c_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY18yNS9mcmFnOjA5ZGZjMGNmNmE4YjQ1Nzk5MzY0MTllYjNjYjczZGI3L3RhYmxlOmRlNzUzZDM1MGI1MDQzMGY5YTY4NjdkMjI1MTEwNjliL3RhYmxlcmFuZ2U6ZGU3NTNkMzUwYjUwNDMwZjlhNjg2N2QyMjUxMTA2OWJfMTEtMy0xLTEtNjk5NDk_7396cab6-1e12-4e87-a923-1a05b31cf986"
      unitRef="usdPerShare">-0.22</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="i3baf3250062d4a79a9b120fc56f1b18c_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY18yNS9mcmFnOjA5ZGZjMGNmNmE4YjQ1Nzk5MzY0MTllYjNjYjczZGI3L3RhYmxlOmRlNzUzZDM1MGI1MDQzMGY5YTY4NjdkMjI1MTEwNjliL3RhYmxlcmFuZ2U6ZGU3NTNkMzUwYjUwNDMwZjlhNjg2N2QyMjUxMTA2OWJfMTEtMy0xLTEtNjk5NDk_ba60692c-621e-419e-aab9-a08f34cd2aee"
      unitRef="usdPerShare">-0.22</us-gaap:EarningsPerShareBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="ie35b115501ca468f8cadb8213304a30b_D20230101-20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY18yNS9mcmFnOjA5ZGZjMGNmNmE4YjQ1Nzk5MzY0MTllYjNjYjczZGI3L3RhYmxlOmRlNzUzZDM1MGI1MDQzMGY5YTY4NjdkMjI1MTEwNjliL3RhYmxlcmFuZ2U6ZGU3NTNkMzUwYjUwNDMwZjlhNjg2N2QyMjUxMTA2OWJfMTMtMS0xLTEtNjk5NDk_46ac0094-41af-4981-b4c6-2cd431a10fef"
      unitRef="shares">15966053</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="ie35b115501ca468f8cadb8213304a30b_D20230101-20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY18yNS9mcmFnOjA5ZGZjMGNmNmE4YjQ1Nzk5MzY0MTllYjNjYjczZGI3L3RhYmxlOmRlNzUzZDM1MGI1MDQzMGY5YTY4NjdkMjI1MTEwNjliL3RhYmxlcmFuZ2U6ZGU3NTNkMzUwYjUwNDMwZjlhNjg2N2QyMjUxMTA2OWJfMTMtMS0xLTEtNjk5NDk_bb30c879-7bf3-463a-8a9e-1f0a08494d3e"
      unitRef="shares">15966053</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i3baf3250062d4a79a9b120fc56f1b18c_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY18yNS9mcmFnOjA5ZGZjMGNmNmE4YjQ1Nzk5MzY0MTllYjNjYjczZGI3L3RhYmxlOmRlNzUzZDM1MGI1MDQzMGY5YTY4NjdkMjI1MTEwNjliL3RhYmxlcmFuZ2U6ZGU3NTNkMzUwYjUwNDMwZjlhNjg2N2QyMjUxMTA2OWJfMTMtMy0xLTEtNjk5NDk_fa06dd43-ee69-4d8d-98b3-0989d2bcb762"
      unitRef="shares">15966053</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i3baf3250062d4a79a9b120fc56f1b18c_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY18yNS9mcmFnOjA5ZGZjMGNmNmE4YjQ1Nzk5MzY0MTllYjNjYjczZGI3L3RhYmxlOmRlNzUzZDM1MGI1MDQzMGY5YTY4NjdkMjI1MTEwNjliL3RhYmxlcmFuZ2U6ZGU3NTNkMzUwYjUwNDMwZjlhNjg2N2QyMjUxMTA2OWJfMTMtMy0xLTEtNjk5NDk_fb3695d2-eea5-4dea-8222-296c98cdbfbc"
      unitRef="shares">15966053</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:SharesOutstanding
      contextRef="i943d13fd1b9f4197ae5a210a64adb3ab_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY18yOC9mcmFnOjVkNjAyMjg2NTk0NjQyZmU4M2ZmYmFmODZkYWVlMjc5L3RhYmxlOmExNWQ1Yjk0MTIzZDRjODNiYmQwYjdmMjJiZDkyOWJjL3RhYmxlcmFuZ2U6YTE1ZDViOTQxMjNkNGM4M2JiZDBiN2YyMmJkOTI5YmNfMy0xLTEtMS03MjMxMg_38bae8c2-a109-4049-974d-18732c646a28"
      unitRef="shares">15966053</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i943d13fd1b9f4197ae5a210a64adb3ab_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY18yOC9mcmFnOjVkNjAyMjg2NTk0NjQyZmU4M2ZmYmFmODZkYWVlMjc5L3RhYmxlOmExNWQ1Yjk0MTIzZDRjODNiYmQwYjdmMjJiZDkyOWJjL3RhYmxlcmFuZ2U6YTE1ZDViOTQxMjNkNGM4M2JiZDBiN2YyMmJkOTI5YmNfMy0zLTEtMS03MjMxMg_1920dc30-4596-4fa8-91a8-2b26c3f85e3b"
      unitRef="usd">15966</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ifaa2a5dd56c843d9a857de26b952bcfb_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY18yOC9mcmFnOjVkNjAyMjg2NTk0NjQyZmU4M2ZmYmFmODZkYWVlMjc5L3RhYmxlOmExNWQ1Yjk0MTIzZDRjODNiYmQwYjdmMjJiZDkyOWJjL3RhYmxlcmFuZ2U6YTE1ZDViOTQxMjNkNGM4M2JiZDBiN2YyMmJkOTI5YmNfMy01LTEtMS03MjMxMg_78af1677-9767-4603-86ab-6e0a35d7eff5"
      unitRef="usd">78832779</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ic501c165e10e47e080880f65f01c1d5b_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY18yOC9mcmFnOjVkNjAyMjg2NTk0NjQyZmU4M2ZmYmFmODZkYWVlMjc5L3RhYmxlOmExNWQ1Yjk0MTIzZDRjODNiYmQwYjdmMjJiZDkyOWJjL3RhYmxlcmFuZ2U6YTE1ZDViOTQxMjNkNGM4M2JiZDBiN2YyMmJkOTI5YmNfMy03LTEtMS03MjMxMg_d2eb9377-2cd2-46d4-9658-628991d1e55f"
      unitRef="usd">-44090379</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i4b1713eab7d84494b3b43202a26fc3c4_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY18yOC9mcmFnOjVkNjAyMjg2NTk0NjQyZmU4M2ZmYmFmODZkYWVlMjc5L3RhYmxlOmExNWQ1Yjk0MTIzZDRjODNiYmQwYjdmMjJiZDkyOWJjL3RhYmxlcmFuZ2U6YTE1ZDViOTQxMjNkNGM4M2JiZDBiN2YyMmJkOTI5YmNfMy05LTEtMS03MjMxMg_5d6e004c-b120-4302-b93b-5d6dec3c6c7a"
      unitRef="usd">34758366</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="icd5ebf0042ac4aac81eeac59d3a7522d_D20230101-20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY18yOC9mcmFnOjVkNjAyMjg2NTk0NjQyZmU4M2ZmYmFmODZkYWVlMjc5L3RhYmxlOmExNWQ1Yjk0MTIzZDRjODNiYmQwYjdmMjJiZDkyOWJjL3RhYmxlcmFuZ2U6YTE1ZDViOTQxMjNkNGM4M2JiZDBiN2YyMmJkOTI5YmNfNC01LTEtMS03MjMxMg_34e546e7-ecfe-4c06-9638-5164d9e717a5"
      unitRef="usd">282762</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="ie35b115501ca468f8cadb8213304a30b_D20230101-20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY18yOC9mcmFnOjVkNjAyMjg2NTk0NjQyZmU4M2ZmYmFmODZkYWVlMjc5L3RhYmxlOmExNWQ1Yjk0MTIzZDRjODNiYmQwYjdmMjJiZDkyOWJjL3RhYmxlcmFuZ2U6YTE1ZDViOTQxMjNkNGM4M2JiZDBiN2YyMmJkOTI5YmNfNC05LTEtMS03MjMxMg_df178b95-1e45-4edc-a8e4-81430127bf9d"
      unitRef="usd">282762</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss
      contextRef="i8d193fa8f7974372bd0db6d8ebed8675_D20230101-20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY18yOC9mcmFnOjVkNjAyMjg2NTk0NjQyZmU4M2ZmYmFmODZkYWVlMjc5L3RhYmxlOmExNWQ1Yjk0MTIzZDRjODNiYmQwYjdmMjJiZDkyOWJjL3RhYmxlcmFuZ2U6YTE1ZDViOTQxMjNkNGM4M2JiZDBiN2YyMmJkOTI5YmNfNS03LTEtMS03MjMxMg_34d883ee-1512-47ba-a239-3984acc44a34"
      unitRef="usd">-6308318</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ie35b115501ca468f8cadb8213304a30b_D20230101-20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY18yOC9mcmFnOjVkNjAyMjg2NTk0NjQyZmU4M2ZmYmFmODZkYWVlMjc5L3RhYmxlOmExNWQ1Yjk0MTIzZDRjODNiYmQwYjdmMjJiZDkyOWJjL3RhYmxlcmFuZ2U6YTE1ZDViOTQxMjNkNGM4M2JiZDBiN2YyMmJkOTI5YmNfNS05LTEtMS03MjMxMg_0a398734-ca5a-4dcb-80bf-26d16575b3bd"
      unitRef="usd">-6308318</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="i9f9455c0d0e74c97a9a53955ed07377f_I20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY18yOC9mcmFnOjVkNjAyMjg2NTk0NjQyZmU4M2ZmYmFmODZkYWVlMjc5L3RhYmxlOmExNWQ1Yjk0MTIzZDRjODNiYmQwYjdmMjJiZDkyOWJjL3RhYmxlcmFuZ2U6YTE1ZDViOTQxMjNkNGM4M2JiZDBiN2YyMmJkOTI5YmNfNi0xLTEtMS03MjU5MQ_9a439f6c-451e-48da-a940-e78ca6566113"
      unitRef="shares">15966053</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i9f9455c0d0e74c97a9a53955ed07377f_I20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY18yOC9mcmFnOjVkNjAyMjg2NTk0NjQyZmU4M2ZmYmFmODZkYWVlMjc5L3RhYmxlOmExNWQ1Yjk0MTIzZDRjODNiYmQwYjdmMjJiZDkyOWJjL3RhYmxlcmFuZ2U6YTE1ZDViOTQxMjNkNGM4M2JiZDBiN2YyMmJkOTI5YmNfNi0zLTEtMS03MjU5MQ_9f1daffb-afea-47c2-817c-6e56bf7d7e21"
      unitRef="usd">15966</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ib8f0e2696e0648f880780a1ad638027a_I20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY18yOC9mcmFnOjVkNjAyMjg2NTk0NjQyZmU4M2ZmYmFmODZkYWVlMjc5L3RhYmxlOmExNWQ1Yjk0MTIzZDRjODNiYmQwYjdmMjJiZDkyOWJjL3RhYmxlcmFuZ2U6YTE1ZDViOTQxMjNkNGM4M2JiZDBiN2YyMmJkOTI5YmNfNi01LTEtMS03MjU5MQ_c363b810-74fe-4e27-ae21-10b8b31142a2"
      unitRef="usd">79115541</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="if64ea5a878c145cdb5ea7e8156bc0335_I20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY18yOC9mcmFnOjVkNjAyMjg2NTk0NjQyZmU4M2ZmYmFmODZkYWVlMjc5L3RhYmxlOmExNWQ1Yjk0MTIzZDRjODNiYmQwYjdmMjJiZDkyOWJjL3RhYmxlcmFuZ2U6YTE1ZDViOTQxMjNkNGM4M2JiZDBiN2YyMmJkOTI5YmNfNi03LTEtMS03MjU5MQ_066baac9-30a4-4e14-bf8b-3c16120a2ab4"
      unitRef="usd">-50398697</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i9e6ffce2c2d247f491e046febe8251cd_I20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY18yOC9mcmFnOjVkNjAyMjg2NTk0NjQyZmU4M2ZmYmFmODZkYWVlMjc5L3RhYmxlOmExNWQ1Yjk0MTIzZDRjODNiYmQwYjdmMjJiZDkyOWJjL3RhYmxlcmFuZ2U6YTE1ZDViOTQxMjNkNGM4M2JiZDBiN2YyMmJkOTI5YmNfNi05LTEtMS03MjU5MQ_0295ed17-5eee-491f-8d54-047b81c5c293"
      unitRef="usd">28732810</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="ifd24ec169b5741408f1f292b74c4c8e7_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY18yOC9mcmFnOjVkNjAyMjg2NTk0NjQyZmU4M2ZmYmFmODZkYWVlMjc5L3RhYmxlOmExNWQ1Yjk0MTIzZDRjODNiYmQwYjdmMjJiZDkyOWJjL3RhYmxlcmFuZ2U6YTE1ZDViOTQxMjNkNGM4M2JiZDBiN2YyMmJkOTI5YmNfMTItMS0xLTEtNzA3ODc_03aa510d-de77-4117-b3bd-30c4a2b16655"
      unitRef="shares">15966053</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="ifd24ec169b5741408f1f292b74c4c8e7_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY18yOC9mcmFnOjVkNjAyMjg2NTk0NjQyZmU4M2ZmYmFmODZkYWVlMjc5L3RhYmxlOmExNWQ1Yjk0MTIzZDRjODNiYmQwYjdmMjJiZDkyOWJjL3RhYmxlcmFuZ2U6YTE1ZDViOTQxMjNkNGM4M2JiZDBiN2YyMmJkOTI5YmNfMTItMy0xLTEtNzA3ODc_a75c52e2-937d-4b40-9fca-ded93f85d85c"
      unitRef="usd">15966</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="id6056ac1137049ecbf03cbd976238e74_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY18yOC9mcmFnOjVkNjAyMjg2NTk0NjQyZmU4M2ZmYmFmODZkYWVlMjc5L3RhYmxlOmExNWQ1Yjk0MTIzZDRjODNiYmQwYjdmMjJiZDkyOWJjL3RhYmxlcmFuZ2U6YTE1ZDViOTQxMjNkNGM4M2JiZDBiN2YyMmJkOTI5YmNfMTItNS0xLTEtNzA3ODc_b762bf15-9d02-43e2-aeb5-60f34b02dc43"
      unitRef="usd">77510809</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ia7a50df0f70a4507a6bc3fee39e5d9c3_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY18yOC9mcmFnOjVkNjAyMjg2NTk0NjQyZmU4M2ZmYmFmODZkYWVlMjc5L3RhYmxlOmExNWQ1Yjk0MTIzZDRjODNiYmQwYjdmMjJiZDkyOWJjL3RhYmxlcmFuZ2U6YTE1ZDViOTQxMjNkNGM4M2JiZDBiN2YyMmJkOTI5YmNfMTItNy0xLTEtNzA3ODc_542fbc30-4f46-4f5c-9d8a-e45d664df3a4"
      unitRef="usd">-29254440</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i7970953f78074175b146df53757b2465_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY18yOC9mcmFnOjVkNjAyMjg2NTk0NjQyZmU4M2ZmYmFmODZkYWVlMjc5L3RhYmxlOmExNWQ1Yjk0MTIzZDRjODNiYmQwYjdmMjJiZDkyOWJjL3RhYmxlcmFuZ2U6YTE1ZDViOTQxMjNkNGM4M2JiZDBiN2YyMmJkOTI5YmNfMTItOS0xLTEtNzA3ODc_9636ce17-360c-4e8b-bf2b-e92cdb267924"
      unitRef="usd">48272335</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="ic40bb4943d7c476c9169444151149747_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY18yOC9mcmFnOjVkNjAyMjg2NTk0NjQyZmU4M2ZmYmFmODZkYWVlMjc5L3RhYmxlOmExNWQ1Yjk0MTIzZDRjODNiYmQwYjdmMjJiZDkyOWJjL3RhYmxlcmFuZ2U6YTE1ZDViOTQxMjNkNGM4M2JiZDBiN2YyMmJkOTI5YmNfMTMtNS0xLTEtNzIzMTk_7df1794b-d64b-483a-87bc-dba9570aeceb"
      unitRef="usd">345530</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="i3baf3250062d4a79a9b120fc56f1b18c_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY18yOC9mcmFnOjVkNjAyMjg2NTk0NjQyZmU4M2ZmYmFmODZkYWVlMjc5L3RhYmxlOmExNWQ1Yjk0MTIzZDRjODNiYmQwYjdmMjJiZDkyOWJjL3RhYmxlcmFuZ2U6YTE1ZDViOTQxMjNkNGM4M2JiZDBiN2YyMmJkOTI5YmNfMTMtOS0xLTEtNzIzMTk_7dcf0f58-a53a-4283-aa9a-430812f8f7f6"
      unitRef="usd">345530</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="ic40bb4943d7c476c9169444151149747_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY18yOC9mcmFnOjVkNjAyMjg2NTk0NjQyZmU4M2ZmYmFmODZkYWVlMjc5L3RhYmxlOmExNWQ1Yjk0MTIzZDRjODNiYmQwYjdmMjJiZDkyOWJjL3RhYmxlcmFuZ2U6YTE1ZDViOTQxMjNkNGM4M2JiZDBiN2YyMmJkOTI5YmNfMTQtNS0xLTEtNzA5MTI_303fb82a-b98d-4917-a355-f21f7493de7a"
      unitRef="usd">214958</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i3baf3250062d4a79a9b120fc56f1b18c_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY18yOC9mcmFnOjVkNjAyMjg2NTk0NjQyZmU4M2ZmYmFmODZkYWVlMjc5L3RhYmxlOmExNWQ1Yjk0MTIzZDRjODNiYmQwYjdmMjJiZDkyOWJjL3RhYmxlcmFuZ2U6YTE1ZDViOTQxMjNkNGM4M2JiZDBiN2YyMmJkOTI5YmNfMTMtOS0xLTEtNzA3ODc_2716e18e-b51d-4b7b-a2db-23a0a772b743"
      unitRef="usd">214958</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss
      contextRef="ibf6fa1d37c03414bbe62bf55d335f4fe_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY18yOC9mcmFnOjVkNjAyMjg2NTk0NjQyZmU4M2ZmYmFmODZkYWVlMjc5L3RhYmxlOmExNWQ1Yjk0MTIzZDRjODNiYmQwYjdmMjJiZDkyOWJjL3RhYmxlcmFuZ2U6YTE1ZDViOTQxMjNkNGM4M2JiZDBiN2YyMmJkOTI5YmNfMTUtNy0xLTEtNzIzMTk_1984bc21-3423-47da-adad-995e3a8350ec"
      unitRef="usd">-3438337</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i3baf3250062d4a79a9b120fc56f1b18c_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY18yOC9mcmFnOjVkNjAyMjg2NTk0NjQyZmU4M2ZmYmFmODZkYWVlMjc5L3RhYmxlOmExNWQ1Yjk0MTIzZDRjODNiYmQwYjdmMjJiZDkyOWJjL3RhYmxlcmFuZ2U6YTE1ZDViOTQxMjNkNGM4M2JiZDBiN2YyMmJkOTI5YmNfMTQtOS0xLTEtNzA3ODc_6efb316d-5081-4c82-908f-b16887ea3928"
      unitRef="usd">-3438337</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="i81afc8f1d52c4facbecee4956dd23cfd_I20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY18yOC9mcmFnOjVkNjAyMjg2NTk0NjQyZmU4M2ZmYmFmODZkYWVlMjc5L3RhYmxlOmExNWQ1Yjk0MTIzZDRjODNiYmQwYjdmMjJiZDkyOWJjL3RhYmxlcmFuZ2U6YTE1ZDViOTQxMjNkNGM4M2JiZDBiN2YyMmJkOTI5YmNfMTUtMS0xLTEtNzA3ODc_937adab4-a993-4d9e-a987-847b77d5154d"
      unitRef="shares">15966053</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i81afc8f1d52c4facbecee4956dd23cfd_I20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY18yOC9mcmFnOjVkNjAyMjg2NTk0NjQyZmU4M2ZmYmFmODZkYWVlMjc5L3RhYmxlOmExNWQ1Yjk0MTIzZDRjODNiYmQwYjdmMjJiZDkyOWJjL3RhYmxlcmFuZ2U6YTE1ZDViOTQxMjNkNGM4M2JiZDBiN2YyMmJkOTI5YmNfMTUtMy0xLTEtNzA3ODc_ba6879a9-9bb1-41a6-841b-7ed23bd991e0"
      unitRef="usd">15966</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i3bf77d6bc24e42a48e050108be77d852_I20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY18yOC9mcmFnOjVkNjAyMjg2NTk0NjQyZmU4M2ZmYmFmODZkYWVlMjc5L3RhYmxlOmExNWQ1Yjk0MTIzZDRjODNiYmQwYjdmMjJiZDkyOWJjL3RhYmxlcmFuZ2U6YTE1ZDViOTQxMjNkNGM4M2JiZDBiN2YyMmJkOTI5YmNfMTUtNS0xLTEtNzA3ODc_c6afff8d-eca7-4aa0-9378-458c4a72706f"
      unitRef="usd">78071297</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i6c6c3dc5639243a9bea9f8bc22ea83db_I20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY18yOC9mcmFnOjVkNjAyMjg2NTk0NjQyZmU4M2ZmYmFmODZkYWVlMjc5L3RhYmxlOmExNWQ1Yjk0MTIzZDRjODNiYmQwYjdmMjJiZDkyOWJjL3RhYmxlcmFuZ2U6YTE1ZDViOTQxMjNkNGM4M2JiZDBiN2YyMmJkOTI5YmNfMTUtNy0xLTEtNzA3ODc_d19d9539-eecc-481c-83f7-9057008369e8"
      unitRef="usd">-32692777</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="iafab01d20e1847b5b62b10c7e70e7bc8_I20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY18yOC9mcmFnOjVkNjAyMjg2NTk0NjQyZmU4M2ZmYmFmODZkYWVlMjc5L3RhYmxlOmExNWQ1Yjk0MTIzZDRjODNiYmQwYjdmMjJiZDkyOWJjL3RhYmxlcmFuZ2U6YTE1ZDViOTQxMjNkNGM4M2JiZDBiN2YyMmJkOTI5YmNfMTUtOS0xLTEtNzA3ODc_36655e70-445e-4024-8bdd-f9570a7984dc"
      unitRef="usd">45394486</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="ie35b115501ca468f8cadb8213304a30b_D20230101-20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY18zNC9mcmFnOmE1Mjg2MzYzYjkyYjRjZGFhODllMjhiZjU0N2UyZTc3L3RhYmxlOjdiYmUwMjhjYmQ0MDRjZGViNWQyZTE2MzYwOTBjNDkxL3RhYmxlcmFuZ2U6N2JiZTAyOGNiZDQwNGNkZWI1ZDJlMTYzNjA5MGM0OTFfNC0xLTEtMS02OTk0OQ_bfbe42b3-e52c-4f62-b5a4-ff0350fd790f"
      unitRef="usd">-6308318</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i3baf3250062d4a79a9b120fc56f1b18c_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY18zNC9mcmFnOmE1Mjg2MzYzYjkyYjRjZGFhODllMjhiZjU0N2UyZTc3L3RhYmxlOjdiYmUwMjhjYmQ0MDRjZGViNWQyZTE2MzYwOTBjNDkxL3RhYmxlcmFuZ2U6N2JiZTAyOGNiZDQwNGNkZWI1ZDJlMTYzNjA5MGM0OTFfNC0zLTEtMS02OTk0OQ_dccac528-3dd1-494d-93eb-16bff1e28528"
      unitRef="usd">-3438337</us-gaap:NetIncomeLoss>
    <us-gaap:ShareBasedCompensation
      contextRef="ie35b115501ca468f8cadb8213304a30b_D20230101-20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY18zNC9mcmFnOmE1Mjg2MzYzYjkyYjRjZGFhODllMjhiZjU0N2UyZTc3L3RhYmxlOjdiYmUwMjhjYmQ0MDRjZGViNWQyZTE2MzYwOTBjNDkxL3RhYmxlcmFuZ2U6N2JiZTAyOGNiZDQwNGNkZWI1ZDJlMTYzNjA5MGM0OTFfOC0xLTEtMS02OTk0OQ_71abd3c7-4057-4948-a73e-f362cc1cef84"
      unitRef="usd">282762</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="i3baf3250062d4a79a9b120fc56f1b18c_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY18zNC9mcmFnOmE1Mjg2MzYzYjkyYjRjZGFhODllMjhiZjU0N2UyZTc3L3RhYmxlOjdiYmUwMjhjYmQ0MDRjZGViNWQyZTE2MzYwOTBjNDkxL3RhYmxlcmFuZ2U6N2JiZTAyOGNiZDQwNGNkZWI1ZDJlMTYzNjA5MGM0OTFfOC0zLTEtMS02OTk0OQ_d5809538-241e-4e56-96c0-b924b97bb203"
      unitRef="usd">214958</us-gaap:ShareBasedCompensation>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="ie35b115501ca468f8cadb8213304a30b_D20230101-20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY18zNC9mcmFnOmE1Mjg2MzYzYjkyYjRjZGFhODllMjhiZjU0N2UyZTc3L3RhYmxlOjdiYmUwMjhjYmQ0MDRjZGViNWQyZTE2MzYwOTBjNDkxL3RhYmxlcmFuZ2U6N2JiZTAyOGNiZDQwNGNkZWI1ZDJlMTYzNjA5MGM0OTFfOS0xLTEtMS02OTk0OQ_1cc65b52-72c7-4df1-896a-253f2dc56d35"
      unitRef="usd">3193</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i3baf3250062d4a79a9b120fc56f1b18c_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY18zNC9mcmFnOmE1Mjg2MzYzYjkyYjRjZGFhODllMjhiZjU0N2UyZTc3L3RhYmxlOjdiYmUwMjhjYmQ0MDRjZGViNWQyZTE2MzYwOTBjNDkxL3RhYmxlcmFuZ2U6N2JiZTAyOGNiZDQwNGNkZWI1ZDJlMTYzNjA5MGM0OTFfOS0zLTEtMS02OTk0OQ_a262c1b0-aa6d-4d16-8255-5393a78bd942"
      unitRef="usd">0</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense
      contextRef="ie35b115501ca468f8cadb8213304a30b_D20230101-20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY18zNC9mcmFnOmE1Mjg2MzYzYjkyYjRjZGFhODllMjhiZjU0N2UyZTc3L3RhYmxlOjdiYmUwMjhjYmQ0MDRjZGViNWQyZTE2MzYwOTBjNDkxL3RhYmxlcmFuZ2U6N2JiZTAyOGNiZDQwNGNkZWI1ZDJlMTYzNjA5MGM0OTFfMTItMS0xLTEtNjk5NDk_f6e42c13-783e-4b13-a301-62a3e2dccfae"
      unitRef="usd">22075</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense
      contextRef="i3baf3250062d4a79a9b120fc56f1b18c_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY18zNC9mcmFnOmE1Mjg2MzYzYjkyYjRjZGFhODllMjhiZjU0N2UyZTc3L3RhYmxlOjdiYmUwMjhjYmQ0MDRjZGViNWQyZTE2MzYwOTBjNDkxL3RhYmxlcmFuZ2U6N2JiZTAyOGNiZDQwNGNkZWI1ZDJlMTYzNjA5MGM0OTFfMTItMy0xLTEtNjk5NDk_79bc9915-3a54-4679-8f6f-55a1217ff68d"
      unitRef="usd">14021</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="ie35b115501ca468f8cadb8213304a30b_D20230101-20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY18zNC9mcmFnOmE1Mjg2MzYzYjkyYjRjZGFhODllMjhiZjU0N2UyZTc3L3RhYmxlOjdiYmUwMjhjYmQ0MDRjZGViNWQyZTE2MzYwOTBjNDkxL3RhYmxlcmFuZ2U6N2JiZTAyOGNiZDQwNGNkZWI1ZDJlMTYzNjA5MGM0OTFfMTUtMS0xLTEtNjk5NDk_8af7999f-c46d-4fa2-b0e9-b4c7b7126c0c"
      unitRef="usd">-239476</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="i3baf3250062d4a79a9b120fc56f1b18c_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY18zNC9mcmFnOmE1Mjg2MzYzYjkyYjRjZGFhODllMjhiZjU0N2UyZTc3L3RhYmxlOjdiYmUwMjhjYmQ0MDRjZGViNWQyZTE2MzYwOTBjNDkxL3RhYmxlcmFuZ2U6N2JiZTAyOGNiZDQwNGNkZWI1ZDJlMTYzNjA5MGM0OTFfMTUtMy0xLTEtNjk5NDk_345012e8-ef9c-4e20-be20-965ee963eac9"
      unitRef="usd">-491053</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentAssets
      contextRef="ie35b115501ca468f8cadb8213304a30b_D20230101-20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY18zNC9mcmFnOmE1Mjg2MzYzYjkyYjRjZGFhODllMjhiZjU0N2UyZTc3L3RhYmxlOjdiYmUwMjhjYmQ0MDRjZGViNWQyZTE2MzYwOTBjNDkxL3RhYmxlcmFuZ2U6N2JiZTAyOGNiZDQwNGNkZWI1ZDJlMTYzNjA5MGM0OTFfMTYtMS0xLTEtNjk5NDk_fee8c164-c29c-4822-be7f-11e28fe6f3c5"
      unitRef="usd">-6562</us-gaap:IncreaseDecreaseInOtherNoncurrentAssets>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentAssets
      contextRef="i3baf3250062d4a79a9b120fc56f1b18c_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY18zNC9mcmFnOmE1Mjg2MzYzYjkyYjRjZGFhODllMjhiZjU0N2UyZTc3L3RhYmxlOjdiYmUwMjhjYmQ0MDRjZGViNWQyZTE2MzYwOTBjNDkxL3RhYmxlcmFuZ2U6N2JiZTAyOGNiZDQwNGNkZWI1ZDJlMTYzNjA5MGM0OTFfMTYtMy0xLTEtNjk5NDk_28403db4-aec6-4f0e-9012-c7fe34105827"
      unitRef="usd">24000</us-gaap:IncreaseDecreaseInOtherNoncurrentAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="ie35b115501ca468f8cadb8213304a30b_D20230101-20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY18zNC9mcmFnOmE1Mjg2MzYzYjkyYjRjZGFhODllMjhiZjU0N2UyZTc3L3RhYmxlOjdiYmUwMjhjYmQ0MDRjZGViNWQyZTE2MzYwOTBjNDkxL3RhYmxlcmFuZ2U6N2JiZTAyOGNiZDQwNGNkZWI1ZDJlMTYzNjA5MGM0OTFfMTctMS0xLTEtNjk5NDk_b4556200-d048-4f1b-a42f-0277fe389b32"
      unitRef="usd">273931</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="i3baf3250062d4a79a9b120fc56f1b18c_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY18zNC9mcmFnOmE1Mjg2MzYzYjkyYjRjZGFhODllMjhiZjU0N2UyZTc3L3RhYmxlOjdiYmUwMjhjYmQ0MDRjZGViNWQyZTE2MzYwOTBjNDkxL3RhYmxlcmFuZ2U6N2JiZTAyOGNiZDQwNGNkZWI1ZDJlMTYzNjA5MGM0OTFfMTctMy0xLTEtNjk5NDk_9f70c36a-0130-4ad6-a361-f9b18415b748"
      unitRef="usd">-1269389</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="ie35b115501ca468f8cadb8213304a30b_D20230101-20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY18zNC9mcmFnOmE1Mjg2MzYzYjkyYjRjZGFhODllMjhiZjU0N2UyZTc3L3RhYmxlOjdiYmUwMjhjYmQ0MDRjZGViNWQyZTE2MzYwOTBjNDkxL3RhYmxlcmFuZ2U6N2JiZTAyOGNiZDQwNGNkZWI1ZDJlMTYzNjA5MGM0OTFfMTgtMS0xLTEtNjk5NDk_663a0997-0be2-465b-9998-e9ce5665852d"
      unitRef="usd">-224727</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="i3baf3250062d4a79a9b120fc56f1b18c_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY18zNC9mcmFnOmE1Mjg2MzYzYjkyYjRjZGFhODllMjhiZjU0N2UyZTc3L3RhYmxlOjdiYmUwMjhjYmQ0MDRjZGViNWQyZTE2MzYwOTBjNDkxL3RhYmxlcmFuZ2U6N2JiZTAyOGNiZDQwNGNkZWI1ZDJlMTYzNjA5MGM0OTFfMTgtMy0xLTEtNjk5NDk_4a547442-c8c9-4615-aacb-ac7c958b5653"
      unitRef="usd">198324</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="ie35b115501ca468f8cadb8213304a30b_D20230101-20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY18zNC9mcmFnOmE1Mjg2MzYzYjkyYjRjZGFhODllMjhiZjU0N2UyZTc3L3RhYmxlOjdiYmUwMjhjYmQ0MDRjZGViNWQyZTE2MzYwOTBjNDkxL3RhYmxlcmFuZ2U6N2JiZTAyOGNiZDQwNGNkZWI1ZDJlMTYzNjA5MGM0OTFfMTktMS0xLTEtNjk5NDk_956ae906-da2b-4b54-b044-cbd93d247207"
      unitRef="usd">-23409</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="i3baf3250062d4a79a9b120fc56f1b18c_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY18zNC9mcmFnOmE1Mjg2MzYzYjkyYjRjZGFhODllMjhiZjU0N2UyZTc3L3RhYmxlOjdiYmUwMjhjYmQ0MDRjZGViNWQyZTE2MzYwOTBjNDkxL3RhYmxlcmFuZ2U6N2JiZTAyOGNiZDQwNGNkZWI1ZDJlMTYzNjA5MGM0OTFfMTktMy0xLTEtNjk5NDk_7ad7b8c6-80d1-4011-a26f-1e4487b0b139"
      unitRef="usd">-6911</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="ie35b115501ca468f8cadb8213304a30b_D20230101-20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY18zNC9mcmFnOmE1Mjg2MzYzYjkyYjRjZGFhODllMjhiZjU0N2UyZTc3L3RhYmxlOjdiYmUwMjhjYmQ0MDRjZGViNWQyZTE2MzYwOTBjNDkxL3RhYmxlcmFuZ2U6N2JiZTAyOGNiZDQwNGNkZWI1ZDJlMTYzNjA5MGM0OTFfMjAtMS0xLTEtNjk5NDk_a9f09a81-43d5-48b5-9cab-3e4a5b70ba2d"
      unitRef="usd">-5728455</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i3baf3250062d4a79a9b120fc56f1b18c_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY18zNC9mcmFnOmE1Mjg2MzYzYjkyYjRjZGFhODllMjhiZjU0N2UyZTc3L3RhYmxlOjdiYmUwMjhjYmQ0MDRjZGViNWQyZTE2MzYwOTBjNDkxL3RhYmxlcmFuZ2U6N2JiZTAyOGNiZDQwNGNkZWI1ZDJlMTYzNjA5MGM0OTFfMjAtMy0xLTEtNjk5NDk_0f2c1575-7f4d-4920-825e-560ae99290fc"
      unitRef="usd">-3820281</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="ie35b115501ca468f8cadb8213304a30b_D20230101-20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY18zNC9mcmFnOmE1Mjg2MzYzYjkyYjRjZGFhODllMjhiZjU0N2UyZTc3L3RhYmxlOjdiYmUwMjhjYmQ0MDRjZGViNWQyZTE2MzYwOTBjNDkxL3RhYmxlcmFuZ2U6N2JiZTAyOGNiZDQwNGNkZWI1ZDJlMTYzNjA5MGM0OTFfMjMtMS0xLTEtNjk5NDk_5b0d6139-9fbd-49a7-9737-248bd32dcc39"
      unitRef="usd">0</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i3baf3250062d4a79a9b120fc56f1b18c_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY18zNC9mcmFnOmE1Mjg2MzYzYjkyYjRjZGFhODllMjhiZjU0N2UyZTc3L3RhYmxlOjdiYmUwMjhjYmQ0MDRjZGViNWQyZTE2MzYwOTBjNDkxL3RhYmxlcmFuZ2U6N2JiZTAyOGNiZDQwNGNkZWI1ZDJlMTYzNjA5MGM0OTFfMjMtMy0xLTEtNjk5NDk_ff0c8dbb-146a-4cc3-9fcf-46c640fd9df7"
      unitRef="usd">34999</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="ie35b115501ca468f8cadb8213304a30b_D20230101-20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY18zNC9mcmFnOmE1Mjg2MzYzYjkyYjRjZGFhODllMjhiZjU0N2UyZTc3L3RhYmxlOjdiYmUwMjhjYmQ0MDRjZGViNWQyZTE2MzYwOTBjNDkxL3RhYmxlcmFuZ2U6N2JiZTAyOGNiZDQwNGNkZWI1ZDJlMTYzNjA5MGM0OTFfMjQtMS0xLTEtNjk5NDk_b910060c-5b28-4c13-8c87-fafba6a8be16"
      unitRef="usd">0</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i3baf3250062d4a79a9b120fc56f1b18c_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY18zNC9mcmFnOmE1Mjg2MzYzYjkyYjRjZGFhODllMjhiZjU0N2UyZTc3L3RhYmxlOjdiYmUwMjhjYmQ0MDRjZGViNWQyZTE2MzYwOTBjNDkxL3RhYmxlcmFuZ2U6N2JiZTAyOGNiZDQwNGNkZWI1ZDJlMTYzNjA5MGM0OTFfMjQtMy0xLTEtNjk5NDk_4c8a01b8-9ce6-4c6f-bfaf-27340f94062b"
      unitRef="usd">-34999</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="i426de1e79cbb451489bfc39d312e71c9_D20230101-20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY18zNC9mcmFnOmE1Mjg2MzYzYjkyYjRjZGFhODllMjhiZjU0N2UyZTc3L3RhYmxlOjdiYmUwMjhjYmQ0MDRjZGViNWQyZTE2MzYwOTBjNDkxL3RhYmxlcmFuZ2U6N2JiZTAyOGNiZDQwNGNkZWI1ZDJlMTYzNjA5MGM0OTFfMjYtMS0xLTEtNjk5NDk_fe7890ae-4260-4854-9a43-fc3450e04e4a"
      unitRef="usd">0</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="i0353d0309620461ab7aee7ea14ec31ba_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY18zNC9mcmFnOmE1Mjg2MzYzYjkyYjRjZGFhODllMjhiZjU0N2UyZTc3L3RhYmxlOjdiYmUwMjhjYmQ0MDRjZGViNWQyZTE2MzYwOTBjNDkxL3RhYmxlcmFuZ2U6N2JiZTAyOGNiZDQwNGNkZWI1ZDJlMTYzNjA5MGM0OTFfMjYtMy0xLTEtNjk5NDk_18877593-e060-47ff-8b49-9b8d2ed20704"
      unitRef="usd">102071</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="ie35b115501ca468f8cadb8213304a30b_D20230101-20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY18zNC9mcmFnOmE1Mjg2MzYzYjkyYjRjZGFhODllMjhiZjU0N2UyZTc3L3RhYmxlOjdiYmUwMjhjYmQ0MDRjZGViNWQyZTE2MzYwOTBjNDkxL3RhYmxlcmFuZ2U6N2JiZTAyOGNiZDQwNGNkZWI1ZDJlMTYzNjA5MGM0OTFfMjktMS0xLTEtNjk5NDk_85f774f4-8c87-4b6c-bd2f-4d979eee991b"
      unitRef="usd">0</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i3baf3250062d4a79a9b120fc56f1b18c_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY18zNC9mcmFnOmE1Mjg2MzYzYjkyYjRjZGFhODllMjhiZjU0N2UyZTc3L3RhYmxlOjdiYmUwMjhjYmQ0MDRjZGViNWQyZTE2MzYwOTBjNDkxL3RhYmxlcmFuZ2U6N2JiZTAyOGNiZDQwNGNkZWI1ZDJlMTYzNjA5MGM0OTFfMjktMy0xLTEtNjk5NDk_a2477158-b25a-4171-9630-a5902b20f1db"
      unitRef="usd">-102071</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="ie35b115501ca468f8cadb8213304a30b_D20230101-20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY18zNC9mcmFnOmE1Mjg2MzYzYjkyYjRjZGFhODllMjhiZjU0N2UyZTc3L3RhYmxlOjdiYmUwMjhjYmQ0MDRjZGViNWQyZTE2MzYwOTBjNDkxL3RhYmxlcmFuZ2U6N2JiZTAyOGNiZDQwNGNkZWI1ZDJlMTYzNjA5MGM0OTFfMzAtMS0xLTEtNjk5NDk_c7b4ca77-d98a-4b2d-999e-d91094e5a2b7"
      unitRef="usd">-5728455</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i3baf3250062d4a79a9b120fc56f1b18c_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY18zNC9mcmFnOmE1Mjg2MzYzYjkyYjRjZGFhODllMjhiZjU0N2UyZTc3L3RhYmxlOjdiYmUwMjhjYmQ0MDRjZGViNWQyZTE2MzYwOTBjNDkxL3RhYmxlcmFuZ2U6N2JiZTAyOGNiZDQwNGNkZWI1ZDJlMTYzNjA5MGM0OTFfMzAtMy0xLTEtNjk5NDk_cb230086-be4a-4690-832f-b89798ff6811"
      unitRef="usd">-3957351</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i4b1713eab7d84494b3b43202a26fc3c4_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY18zNC9mcmFnOmE1Mjg2MzYzYjkyYjRjZGFhODllMjhiZjU0N2UyZTc3L3RhYmxlOjdiYmUwMjhjYmQ0MDRjZGViNWQyZTE2MzYwOTBjNDkxL3RhYmxlcmFuZ2U6N2JiZTAyOGNiZDQwNGNkZWI1ZDJlMTYzNjA5MGM0OTFfMzEtMS0xLTEtNjk5NDk_ee5584be-43b1-4b1f-bd62-d99751b1186f"
      unitRef="usd">35497445</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i7970953f78074175b146df53757b2465_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY18zNC9mcmFnOmE1Mjg2MzYzYjkyYjRjZGFhODllMjhiZjU0N2UyZTc3L3RhYmxlOjdiYmUwMjhjYmQ0MDRjZGViNWQyZTE2MzYwOTBjNDkxL3RhYmxlcmFuZ2U6N2JiZTAyOGNiZDQwNGNkZWI1ZDJlMTYzNjA5MGM0OTFfMzEtMy0xLTEtNjk5NDk_cd79887f-05b5-4009-91d2-00e8bd31c750"
      unitRef="usd">49685586</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i9e6ffce2c2d247f491e046febe8251cd_I20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY18zNC9mcmFnOmE1Mjg2MzYzYjkyYjRjZGFhODllMjhiZjU0N2UyZTc3L3RhYmxlOjdiYmUwMjhjYmQ0MDRjZGViNWQyZTE2MzYwOTBjNDkxL3RhYmxlcmFuZ2U6N2JiZTAyOGNiZDQwNGNkZWI1ZDJlMTYzNjA5MGM0OTFfMzItMS0xLTEtNjk5NDk_4d1afb00-cbde-4f8e-9e49-72acb41ece7e"
      unitRef="usd">29768990</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="iafab01d20e1847b5b62b10c7e70e7bc8_I20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY18zNC9mcmFnOmE1Mjg2MzYzYjkyYjRjZGFhODllMjhiZjU0N2UyZTc3L3RhYmxlOjdiYmUwMjhjYmQ0MDRjZGViNWQyZTE2MzYwOTBjNDkxL3RhYmxlcmFuZ2U6N2JiZTAyOGNiZDQwNGNkZWI1ZDJlMTYzNjA5MGM0OTFfMzItMy0xLTEtNjk5NDk_c55daca7-33d5-4239-836e-26133f15529b"
      unitRef="usd">45728235</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <cntx:WarrantsIssued
      contextRef="id8892bb22a7e45e7ab17a6a179589967_D20230101-20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY18zNC9mcmFnOmE1Mjg2MzYzYjkyYjRjZGFhODllMjhiZjU0N2UyZTc3L3RhYmxlOjdiYmUwMjhjYmQ0MDRjZGViNWQyZTE2MzYwOTBjNDkxL3RhYmxlcmFuZ2U6N2JiZTAyOGNiZDQwNGNkZWI1ZDJlMTYzNjA5MGM0OTFfMzktMS0xLTEtNjk5NDk_a046c390-e40a-413d-ab40-7cbb479084be"
      unitRef="usd">0</cntx:WarrantsIssued>
    <cntx:WarrantsIssued
      contextRef="ie79fb9e8979b4831b96adca175266f37_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY18zNC9mcmFnOmE1Mjg2MzYzYjkyYjRjZGFhODllMjhiZjU0N2UyZTc3L3RhYmxlOjdiYmUwMjhjYmQ0MDRjZGViNWQyZTE2MzYwOTBjNDkxL3RhYmxlcmFuZ2U6N2JiZTAyOGNiZDQwNGNkZWI1ZDJlMTYzNjA5MGM0OTFfMzktMy0xLTEtNjk5NDk_be63ef49-bbb6-403b-b0f3-74755a759d8f"
      unitRef="usd">345530</cntx:WarrantsIssued>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="ie35b115501ca468f8cadb8213304a30b_D20230101-20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY18zNC9mcmFnOmE1Mjg2MzYzYjkyYjRjZGFhODllMjhiZjU0N2UyZTc3L3RhYmxlOjdiYmUwMjhjYmQ0MDRjZGViNWQyZTE2MzYwOTBjNDkxL3RhYmxlcmFuZ2U6N2JiZTAyOGNiZDQwNGNkZWI1ZDJlMTYzNjA5MGM0OTFfNDAtMS0xLTEtNjk5NDk_8ec6386e-49fe-417c-b478-dd128d98316d"
      unitRef="usd">0</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="i3baf3250062d4a79a9b120fc56f1b18c_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY18zNC9mcmFnOmE1Mjg2MzYzYjkyYjRjZGFhODllMjhiZjU0N2UyZTc3L3RhYmxlOjdiYmUwMjhjYmQ0MDRjZGViNWQyZTE2MzYwOTBjNDkxL3RhYmxlcmFuZ2U6N2JiZTAyOGNiZDQwNGNkZWI1ZDJlMTYzNjA5MGM0OTFfNDAtMy0xLTEtNjk5NDk_9b02dc21-d2cc-4b12-8b44-b3a5f7b066ab"
      unitRef="usd">130488</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:NatureOfOperations
      contextRef="ie35b115501ca468f8cadb8213304a30b_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY180MC9mcmFnOjA5MGM5YjQyYzhlNzQyZjNiZmYxY2E1OTlkYTJhNTU4L3RleHRyZWdpb246MDkwYzliNDJjOGU3NDJmM2JmZjFjYTU5OWRhMmE1NThfMTIzMw_180bbc19-0a42-466c-a8b8-bb627d6be466">Organization and Description of Business&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Context Therapeutics Inc. (the &#x201c;Company&#x201d;) is a biopharmaceutical company dedicated to improving the lives of patients living with cancer. The Company&#x2019;s preclinical product candidate, CTIM-76, is an anti-CD3 x anti-Claudin 6 (&#x201c;CLDN6&#x201d;) antigen bispecific monoclonal antibody (&#x201c;bsAb&#x201d;) that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The Company had also been developing onapristone extended release (&#x201c;ONA-XR&#x201d;). However, in March 2023, the Company announced its plan to discontinue the development of this product candidate and focus its efforts on the development of CTIM-76. All estimated closeout costs associated with the ONA-XR program were recognized in research and development expense during the first quarter of 2023. The Company does not expect to incur future material expenses related to this program.&lt;/span&gt;&lt;/div&gt;The Company was organized in April 2015 under the laws of the State of Delaware. The Company&#x2019;s headquarters are located in Philadelphia, Pennsylvania.</us-gaap:NatureOfOperations>
    <cntx:RisksAndLiquidityTextBlock
      contextRef="ie35b115501ca468f8cadb8213304a30b_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY180My9mcmFnOjQxZDU2YmVjZjA4YzQ1NjQ5OTQ0YWM3MDc2ODJlMmEyL3RleHRyZWdpb246NDFkNTZiZWNmMDhjNDU2NDk5NDRhYzcwNzY4MmUyYTJfNDcxMQ_b2168143-d414-4042-8ad6-e19a533b96dc">Risks and Liquidity &lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company has incurred losses and negative cash flows from operations since inception and had an accumulated deficit of $50.4&#160;million as of March&#160;31, 2023. The Company anticipates incurring additional losses until such time, if ever, that it can generate significant revenues from its current or any future product candidates. The Company believes its cash and cash equivalents of $29.8 million as of March&#160;31, 2023 are sufficient to fund its projected operations for at least the next 12 months from the issuance date of these condensed consolidated financial statements. However, substantial additional financing will be needed by the Company to fund its operations and to commercially develop its current and any future product candidates. There is no assurance that such financing will be available when needed or on acceptable terms.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company plans to seek additional capital in the future through equity and/or debt financings, partnerships, collaborations, or other sources to carry out the Company&#x2019;s planned development activities. If additional capital is not available when required, the Company may need to delay or curtail its operations until such funding is received. Various internal and external factors will affect whether and when the Company&#x2019;s current or any future product candidates become approved for marketing and successful commercialization. The regulatory approval and market acceptance of the Company&#x2019;s current and any future product candidates, length of time and cost of developing and commercializing these product candidates and/or failure of them at any stage of the approval process will materially affect the Company&#x2019;s financial condition and future operations. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company faces risks associated with companies whose products are in development. These risks include the need for additional financing to complete its research and development, achieving its research and development objectives, defending its intellectual property rights, recruiting and retaining skilled personnel, and dependence on key members of management, among others. &lt;/span&gt;&lt;/div&gt;The spread of COVID-19 has caused worldwide economic downturn and significant volatility in the financial markets. There is significant uncertainty as to the likely effects of this disease should novel outbreaks emerge, which may, among other things, materially impact the Company&#x2019;s planned clinical trials. This pandemic and/or periodic outbreaks could result in difficulty securing clinical trial site locations, contract research organizations, and/or trial monitors and other critical vendors and consultants supporting the trials. In addition, outbreaks or the perception of an outbreak near a clinical trial site location could impact the Company&#x2019;s ability to enroll patients. These situations, or others associated with&#160;COVID-19,&#160;could cause delays in the Company&#x2019;s clinical trial plans and could increase expected costs, all of which could have a material adverse effect on the Company&#x2019;s business and its financial condition. At the current time, the Company is unable to quantify the potential effects of this pandemic on its future consolidated financial statements.</cntx:RisksAndLiquidityTextBlock>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i9e6ffce2c2d247f491e046febe8251cd_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY180My9mcmFnOjQxZDU2YmVjZjA4YzQ1NjQ5OTQ0YWM3MDc2ODJlMmEyL3RleHRyZWdpb246NDFkNTZiZWNmMDhjNDU2NDk5NDRhYzcwNzY4MmUyYTJfMTUy_bc35397d-78f8-4da7-8f0b-7eaf0c1eb991"
      unitRef="usd">-50400000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i9e6ffce2c2d247f491e046febe8251cd_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY180My9mcmFnOjQxZDU2YmVjZjA4YzQ1NjQ5OTQ0YWM3MDc2ODJlMmEyL3RleHRyZWdpb246NDFkNTZiZWNmMDhjNDU2NDk5NDRhYzcwNzY4MmUyYTJfMzkz_6066ee05-aa21-4bd2-8fe4-6d89cc46a15c"
      unitRef="usd">29800000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock
      contextRef="ie35b115501ca468f8cadb8213304a30b_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY180Ni9mcmFnOjhjODU4NmNiZTA4YzQ2MDA5Y2YzNDQyOWE5OGI4MzZkL3RleHRyZWdpb246OGM4NTg2Y2JlMDhjNDYwMDljZjM0NDI5YTk4YjgzNmRfMTI5MjA_dfbf2bfc-14f1-4d6b-88ee-befbad8c0efc">Basis of Presentation and Summary of Significant Accounting Policies &lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Basis of Presentation and Principles of Consolidation &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The accompanying unaudited condensed consolidated financial statements have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission (&#x201c;SEC&#x201d;). Certain information and note disclosures normally included in annual financial statements prepared in accordance with U.S. generally accepted accounting principles (&#x201c;GAAP&#x201d;) have been condensed or omitted pursuant to those rules and regulations, although the Company believes that the disclosures made are adequate to make the information not misleading. Any reference in these notes to applicable guidance is meant to refer to GAAP as found in the Accounting Standards Codification and Accounting Standards Updates (&#x201c;ASU&#x201d;) of the Financial Accounting Standards Board (&#x201c;FASB&#x201d;).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In the opinion of management, the accompanying unaudited condensed consolidated financial statements include all normal and recurring adjustments (which consist primarily of accruals and estimates that impact the financial statements) considered necessary to present fairly the Company&#x2019;s financial position as of March&#160;31, 2023, and its results of operations and cash flows for the three months ended March&#160;31, 2023 and 2022. Operating results for the three months ended March&#160;31, 2023 are not necessarily indicative of the results that may be expected for the year ending December&#160;31, 2023. The unaudited condensed consolidated financial statements, presented herein, do not contain the required disclosures under GAAP for annual financial statements. The accompanying unaudited condensed consolidated financial statements should be read in conjunction with the annual audited consolidated financial statements and related notes as of and for the year ended December&#160;31, 2022. The consolidated financial information as of December&#160;31, 2022 included herein has been derived from the annual audited consolidated financial statements. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The unaudited condensed consolidated financial statements include the accounts of the Company, Context Therapeutics LLC, Context Biopharma, Inc. and Context Ireland Ltd., the Company&#x2019;s wholly-owned subsidiaries. All intercompany accounts and transactions have been eliminated in consolidation. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Use of Estimates &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The preparation of condensed consolidated financial statements in conformity with GAAP&#160;requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and contingent liabilities at the date of the condensed consolidated financial statements and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Estimates and assumptions are periodically reviewed, and the effects of the revisions are reflected in the accompanying unaudited condensed consolidated financial statements in the period they are determined to be necessary. Significant estimates and assumptions made in the accompanying unaudited condensed consolidated financial statements include, but are not limited to, share-based compensation arrangements, the fair value of warrants, and in recording the prepayments, accruals and associated expense for research and development activities performed for the Company by third parties. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Concentrations of Credit Risk &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash and cash equivalents. The Company maintains deposits in federally insured financial institutions in excess of federally insured limits. The Company has not experienced any losses in such accounts. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Fair Value of Financial Instruments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The carrying amount of the Company&#x2019;s financial instruments, which include cash and cash equivalents, restricted cash, and accounts payable, approximate their fair values given their short-term nature.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Cash, Cash Equivalents and Restricted Cash&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company considers all highly liquid investments that have original maturities of three months or less when acquired to be cash equivalents. Cash equivalents consist of amounts invested in money market accounts. At March&#160;31, 2023, the Company's cash and cash equivalent balances exceeded federally insured limits by approximately $29.5 million.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company maintained approximately $50,000 as collateral for the Company&#x2019;s credit card program at December 31, 2021, which was previously reported as restricted cash on its consolidated balance sheets. There were no amounts restricted as of March 31, 2023 and December 31, 2022, as the collateral was released to the Company in the first quarter of 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt; &lt;br/&gt;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Deferred Offering Costs &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company capitalizes certain legal, professional, accounting and other third-party fees that are directly associated with in-process equity financings as deferred offering costs until such financings are consummated. After consummation of an equity financing, the costs are recorded as a reduction of additional paid-in capital generated as a result of such offering. Should an in-process equity financing be abandoned, the deferred offering costs will be expensed immediately as a charge to operating expenses in the condensed consolidated statements of operations. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Property and Equipmen&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;t&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Property and equipment consist of office equipment, furniture, and leasehold improvements and are recorded at cost. Property and equipment are depreciated on a straight-line basis over their estimated useful lives. Leasehold improvements are amortized over the shorter of their economic lives or the remaining lease term. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Acquired In-Process Research and Development Costs&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Acquired in-process research and development (IPR&amp;amp;D) expense consists of payments incurred in connection with the acquisition or licensing of products or technologies that do not meet the definition of a business under FASB ASC Topic 805, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;Business Combinations&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;. Payments for product development milestones are initially treated as the acquisition of an asset but then immediately expensed as there is no future alternative use for the asset. These development milestone payments are reflected as an investing activity outflow on the Company&#x2019;s consolidated statements of cash flows due to the nature of the underlying acquisition of an asset. See Note 8 for further discussion.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Research and Development Costs &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Research and development costs are expensed as incurred. Research and development costs include external costs of outside vendors engaged to conduct clinical studies and other research and development activities, salaries, share-based compensation, and other operational costs related to the Company&#x2019;s research and development activities. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Costs for certain development activities, such as the provision of services for product candidate development, clinical and preclinical development and related supply and manufacturing costs, are estimated based on an evaluation of the progress to completion of specific tasks using data such as patient enrollment, clinical site activations or information provided to the Company by its vendors with respect to their actual costs incurred. Payments for these activities are based on the terms of the individual arrangements, which may differ from the pattern of costs incurred, and are reflected in the condensed consolidated financial statements as prepaid or accrued research and development expense, as the case may be. The estimates are adjusted to reflect the best information available at the time of the financial statement issuance. Although the Company does not expect its estimates to be materially different from amounts actually incurred, the Company&#x2019;s estimate of the status and timing of services performed relative to the actual status and timing of services performed may vary.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Nonrefundable advance payments for goods and services, including fees for clinical trial expenses, process development or manufacturing and distribution of clinical supplies that will be used in future research and development activities, are deferred and recognized as expense in the period that the related goods are consumed or services are performed.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Patent Costs &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Costs related to filing and pursuing patent applications are recorded as general and administrative expense and expensed as incurred since recoverability of such expenditures is uncertain.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Share-Based Compensation &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company measures and recognizes share-based compensation expense for both employee and non-employee awards based on the grant date fair value of the awards. The Company recognizes share-based compensation expense on a straight-line basis over the requisite service period of the awards, which is generally the vesting period. The Company recognizes forfeitures as they occur. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company classifies share-based compensation expense in its unaudited condensed consolidated statements of operations in the same manner in which the award recipients&#x2019; payroll costs are classified or in which the award recipients&#x2019; service payments are classified. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company estimates the fair value of employee and non-employee stock awards as of the date of grant using the Black-Scholes option pricing model. The Company lacks Company-specific historical and implied volatility information. Therefore, management estimates the expected share price volatility based on the historical volatility of a publicly traded set of peer companies and expects to continue to do so until such time as it has adequate historical data regarding the volatility of its own publicly traded share price. The expected term of the Company&#x2019;s stock awards has been determined utilizing the &#x201c;simplified&#x201d; method for awards that qualify as &#x201c;plain-vanilla&#x201d; stock awards. The risk-free interest rate is determined by reference to the yield curve of a zero-coupon U.S. Treasury bond on the date of grant of the award for time periods approximately equal to the expected term of the award. Expected dividend yield is based on the fact that the Company has never paid cash dividends on common stock and does not expect to pay any cash dividends in the foreseeable future. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Net Loss Per Share &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Basic net loss per share of common stock is computed by dividing net loss by the weighted-average number of shares of common stock outstanding during each period. Diluted net loss per share of common stock includes the effect, if any, from the potential exercise or conversion of securities, such as convertible promissory notes, preferred stock, warrants and share-based awards, which would result in the issuance of incremental shares of common stock. For diluted net loss per share, the weighted-average number of shares of common stock is the same for basic net loss per share due to the fact that when a net loss exists, dilutive securities are not included in the calculation as the impact is anti-dilutive. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The following potentially dilutive securities have been excluded from the computation of diluted weighted-average shares of common stock outstanding, as they would be anti-dilutive:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:59.210%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:55.937%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:19.887%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.787%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:19.889%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:125%"&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:125%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:125%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;Stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;2,165,646&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;1,180,222&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;Warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;5,860,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;5,860,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;8,025,646&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;7,040,222&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Amounts in the above table reflect common stock equivalents.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Emerging Growth Company Status &lt;/span&gt;&lt;/div&gt;The Company is an emerging growth company, as defined in the Jumpstart Our Business Startups Act of 2012 (the &#x201c;JOBS Act&#x201d;). Under the JOBS Act, emerging growth companies can delay adopting new or revised accounting standards issued subsequent to the enactment of the JOBS Act, until such time as those standards apply to private companies. The Company has elected to use this extended transition period for complying with new or revised accounting standards that have different effective dates for public and private companies until the earlier of the date that it (i)&#160;is no longer an emerging growth company or (ii)&#160;affirmatively and irrevocably opts out of the extended transition period provided in the JOBS Act. As a result, these condensed consolidated financial statements may not be comparable to companies that comply with the new or revised accounting pronouncements as of public company effective dates.</us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock
      contextRef="ie35b115501ca468f8cadb8213304a30b_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY180Ni9mcmFnOjhjODU4NmNiZTA4YzQ2MDA5Y2YzNDQyOWE5OGI4MzZkL3RleHRyZWdpb246OGM4NTg2Y2JlMDhjNDYwMDljZjM0NDI5YTk4YjgzNmRfMTI5MTQ_a5302759-12a4-4534-acb1-bc0236a83b60">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Basis of Presentation and Principles of Consolidation &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The accompanying unaudited condensed consolidated financial statements have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission (&#x201c;SEC&#x201d;). Certain information and note disclosures normally included in annual financial statements prepared in accordance with U.S. generally accepted accounting principles (&#x201c;GAAP&#x201d;) have been condensed or omitted pursuant to those rules and regulations, although the Company believes that the disclosures made are adequate to make the information not misleading. Any reference in these notes to applicable guidance is meant to refer to GAAP as found in the Accounting Standards Codification and Accounting Standards Updates (&#x201c;ASU&#x201d;) of the Financial Accounting Standards Board (&#x201c;FASB&#x201d;).&lt;/span&gt;&lt;/div&gt;In the opinion of management, the accompanying unaudited condensed consolidated financial statements include all normal and recurring adjustments (which consist primarily of accruals and estimates that impact the financial statements) considered necessary to present fairly the Company&#x2019;s financial position as of March&#160;31, 2023, and its results of operations and cash flows for the three months ended March&#160;31, 2023 and 2022. Operating results for the three months ended March&#160;31, 2023 are not necessarily indicative of the results that may be expected for the year ending December&#160;31, 2023. The unaudited condensed consolidated financial statements, presented herein, do not contain the required disclosures under GAAP for annual financial statements. The accompanying unaudited condensed consolidated financial statements should be read in conjunction with the annual audited consolidated financial statements and related notes as of and for the year ended December&#160;31, 2022. The consolidated financial information as of December&#160;31, 2022 included herein has been derived from the annual audited consolidated financial statements.</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:ConsolidationPolicyTextBlock
      contextRef="ie35b115501ca468f8cadb8213304a30b_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY180Ni9mcmFnOjhjODU4NmNiZTA4YzQ2MDA5Y2YzNDQyOWE5OGI4MzZkL3RleHRyZWdpb246OGM4NTg2Y2JlMDhjNDYwMDljZjM0NDI5YTk4YjgzNmRfMTI5MTU_1fe473fa-863a-444a-9bfa-683d438cfa03">The unaudited condensed consolidated financial statements include the accounts of the Company, Context Therapeutics LLC, Context Biopharma, Inc. and Context Ireland Ltd., the Company&#x2019;s wholly-owned subsidiaries. All intercompany accounts and transactions have been eliminated in consolidation.</us-gaap:ConsolidationPolicyTextBlock>
    <us-gaap:UseOfEstimates
      contextRef="ie35b115501ca468f8cadb8213304a30b_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY180Ni9mcmFnOjhjODU4NmNiZTA4YzQ2MDA5Y2YzNDQyOWE5OGI4MzZkL3RleHRyZWdpb246OGM4NTg2Y2JlMDhjNDYwMDljZjM0NDI5YTk4YjgzNmRfMTI5MDY_daf4b0a4-f3d1-4fe1-b618-5b5413176c01">&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Use of Estimates &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The preparation of condensed consolidated financial statements in conformity with GAAP&#160;requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and contingent liabilities at the date of the condensed consolidated financial statements and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates. &lt;/span&gt;&lt;/div&gt;Estimates and assumptions are periodically reviewed, and the effects of the revisions are reflected in the accompanying unaudited condensed consolidated financial statements in the period they are determined to be necessary. Significant estimates and assumptions made in the accompanying unaudited condensed consolidated financial statements include, but are not limited to, share-based compensation arrangements, the fair value of warrants, and in recording the prepayments, accruals and associated expense for research and development activities performed for the Company by third parties.</us-gaap:UseOfEstimates>
    <us-gaap:ConcentrationRiskCreditRisk
      contextRef="ie35b115501ca468f8cadb8213304a30b_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY180Ni9mcmFnOjhjODU4NmNiZTA4YzQ2MDA5Y2YzNDQyOWE5OGI4MzZkL3RleHRyZWdpb246OGM4NTg2Y2JlMDhjNDYwMDljZjM0NDI5YTk4YjgzNmRfMTI5MTY_0e53b7e4-6a36-4b2d-8153-1790563f9c8d">Concentrations of Credit Risk Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash and cash equivalents. The Company maintains deposits in federally insured financial institutions in excess of federally insured limits. The Company has not experienced any losses in such accounts.</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:FairValueOfFinancialInstrumentsPolicy
      contextRef="ie35b115501ca468f8cadb8213304a30b_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY180Ni9mcmFnOjhjODU4NmNiZTA4YzQ2MDA5Y2YzNDQyOWE5OGI4MzZkL3RleHRyZWdpb246OGM4NTg2Y2JlMDhjNDYwMDljZjM0NDI5YTk4YjgzNmRfMTI5MjE_123fd042-e462-4954-868c-c69f415638ae">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Fair Value of Financial Instruments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The carrying amount of the Company&#x2019;s financial instruments, which include cash and cash equivalents, restricted cash, and accounts payable, approximate their fair values given their short-term nature.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueOfFinancialInstrumentsPolicy>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock
      contextRef="ie35b115501ca468f8cadb8213304a30b_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY180Ni9mcmFnOjhjODU4NmNiZTA4YzQ2MDA5Y2YzNDQyOWE5OGI4MzZkL3RleHRyZWdpb246OGM4NTg2Y2JlMDhjNDYwMDljZjM0NDI5YTk4YjgzNmRfMTI5MTc_12b92361-03e2-497f-987c-dd6950aeadbf">Cash, Cash Equivalents and Restricted CashThe Company considers all highly liquid investments that have original maturities of three months or less when acquired to be cash equivalents. Cash equivalents consist of amounts invested in money market accounts.</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:CashUninsuredAmount
      contextRef="i9e6ffce2c2d247f491e046febe8251cd_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY180Ni9mcmFnOjhjODU4NmNiZTA4YzQ2MDA5Y2YzNDQyOWE5OGI4MzZkL3RleHRyZWdpb246OGM4NTg2Y2JlMDhjNDYwMDljZjM0NDI5YTk4YjgzNmRfMzI5ODUzNDg5NzI3Mg_7fdbe4f6-2f1c-46a4-931a-952c3b5556d3"
      unitRef="usd">29500000</us-gaap:CashUninsuredAmount>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="i7970953f78074175b146df53757b2465_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY180Ni9mcmFnOjhjODU4NmNiZTA4YzQ2MDA5Y2YzNDQyOWE5OGI4MzZkL3RleHRyZWdpb246OGM4NTg2Y2JlMDhjNDYwMDljZjM0NDI5YTk4YjgzNmRfMTY0OTI2NzQ2MDUxOQ_7bff8df6-98da-4e64-93b8-257d045aeb70"
      unitRef="usd">50000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="i9e6ffce2c2d247f491e046febe8251cd_I20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY180Ni9mcmFnOjhjODU4NmNiZTA4YzQ2MDA5Y2YzNDQyOWE5OGI4MzZkL3RleHRyZWdpb246OGM4NTg2Y2JlMDhjNDYwMDljZjM0NDI5YTk4YjgzNmRfMTY0OTI2NzQ2MDUyNw_3197330f-db6a-4e1f-a0fc-f4c608b8bcb1"
      unitRef="usd">0</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="i4b1713eab7d84494b3b43202a26fc3c4_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY180Ni9mcmFnOjhjODU4NmNiZTA4YzQ2MDA5Y2YzNDQyOWE5OGI4MzZkL3RleHRyZWdpb246OGM4NTg2Y2JlMDhjNDYwMDljZjM0NDI5YTk4YjgzNmRfMTY0OTI2NzQ2MDUyNw_bd45b5d0-c519-4f53-98f2-af13a000d7d6"
      unitRef="usd">0</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:DeferredChargesPolicyTextBlock
      contextRef="ie35b115501ca468f8cadb8213304a30b_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY180Ni9mcmFnOjhjODU4NmNiZTA4YzQ2MDA5Y2YzNDQyOWE5OGI4MzZkL3RleHRyZWdpb246OGM4NTg2Y2JlMDhjNDYwMDljZjM0NDI5YTk4YjgzNmRfMTI5MjI_a6d9dedc-c935-4b5a-a36a-a0d8a65b7b2e">Deferred Offering Costs The Company capitalizes certain legal, professional, accounting and other third-party fees that are directly associated with in-process equity financings as deferred offering costs until such financings are consummated. After consummation of an equity financing, the costs are recorded as a reduction of additional paid-in capital generated as a result of such offering. Should an in-process equity financing be abandoned, the deferred offering costs will be expensed immediately as a charge to operating expenses in the condensed consolidated statements of operations.</us-gaap:DeferredChargesPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock
      contextRef="ie35b115501ca468f8cadb8213304a30b_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY180Ni9mcmFnOjhjODU4NmNiZTA4YzQ2MDA5Y2YzNDQyOWE5OGI4MzZkL3RleHRyZWdpb246OGM4NTg2Y2JlMDhjNDYwMDljZjM0NDI5YTk4YjgzNmRfMTI5MDc_6a2caee9-642e-46fa-a600-f14f883bbf60">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Property and Equipmen&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;t&lt;/span&gt;Property and equipment consist of office equipment, furniture, and leasehold improvements and are recorded at cost. Property and equipment are depreciated on a straight-line basis over their estimated useful lives. Leasehold improvements are amortized over the shorter of their economic lives or the remaining lease term.</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <us-gaap:InProcessResearchAndDevelopmentPolicy
      contextRef="ie35b115501ca468f8cadb8213304a30b_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY180Ni9mcmFnOjhjODU4NmNiZTA4YzQ2MDA5Y2YzNDQyOWE5OGI4MzZkL3RleHRyZWdpb246OGM4NTg2Y2JlMDhjNDYwMDljZjM0NDI5YTk4YjgzNmRfMTY0OTI2NzQ2MDUzNg_e57e41cc-a384-4a7c-a353-f4dace1d5c80">Acquired In-Process Research and Development Costs&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Acquired in-process research and development (IPR&amp;amp;D) expense consists of payments incurred in connection with the acquisition or licensing of products or technologies that do not meet the definition of a business under FASB ASC Topic 805, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;Business Combinations&lt;/span&gt;. Payments for product development milestones are initially treated as the acquisition of an asset but then immediately expensed as there is no future alternative use for the asset. These development milestone payments are reflected as an investing activity outflow on the Company&#x2019;s consolidated statements of cash flows due to the nature of the underlying acquisition of an asset.</us-gaap:InProcessResearchAndDevelopmentPolicy>
    <us-gaap:ResearchAndDevelopmentExpensePolicy
      contextRef="ie35b115501ca468f8cadb8213304a30b_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY180Ni9mcmFnOjhjODU4NmNiZTA4YzQ2MDA5Y2YzNDQyOWE5OGI4MzZkL3RleHRyZWdpb246OGM4NTg2Y2JlMDhjNDYwMDljZjM0NDI5YTk4YjgzNmRfMTI5MDg_8d3ac5e9-97a5-435e-bcc9-8e3af78249ff">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Research and Development Costs &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Research and development costs are expensed as incurred. Research and development costs include external costs of outside vendors engaged to conduct clinical studies and other research and development activities, salaries, share-based compensation, and other operational costs related to the Company&#x2019;s research and development activities. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Costs for certain development activities, such as the provision of services for product candidate development, clinical and preclinical development and related supply and manufacturing costs, are estimated based on an evaluation of the progress to completion of specific tasks using data such as patient enrollment, clinical site activations or information provided to the Company by its vendors with respect to their actual costs incurred. Payments for these activities are based on the terms of the individual arrangements, which may differ from the pattern of costs incurred, and are reflected in the condensed consolidated financial statements as prepaid or accrued research and development expense, as the case may be. The estimates are adjusted to reflect the best information available at the time of the financial statement issuance. Although the Company does not expect its estimates to be materially different from amounts actually incurred, the Company&#x2019;s estimate of the status and timing of services performed relative to the actual status and timing of services performed may vary.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Nonrefundable advance payments for goods and services, including fees for clinical trial expenses, process development or manufacturing and distribution of clinical supplies that will be used in future research and development activities, are deferred and recognized as expense in the period that the related goods are consumed or services are performed.&lt;/span&gt;&lt;/div&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <cntx:PatentCostsPolicyPolicyTextBlock
      contextRef="ie35b115501ca468f8cadb8213304a30b_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY180Ni9mcmFnOjhjODU4NmNiZTA4YzQ2MDA5Y2YzNDQyOWE5OGI4MzZkL3RleHRyZWdpb246OGM4NTg2Y2JlMDhjNDYwMDljZjM0NDI5YTk4YjgzNmRfMTI5MTg_7ceb5688-7db3-4426-96bd-ebaf63fe8e05">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Patent Costs &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Costs related to filing and pursuing patent applications are recorded as general and administrative expense and expensed as incurred since recoverability of such expenditures is uncertain.&lt;/span&gt;&lt;/div&gt;</cntx:PatentCostsPolicyPolicyTextBlock>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy
      contextRef="ie35b115501ca468f8cadb8213304a30b_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY180Ni9mcmFnOjhjODU4NmNiZTA4YzQ2MDA5Y2YzNDQyOWE5OGI4MzZkL3RleHRyZWdpb246OGM4NTg2Y2JlMDhjNDYwMDljZjM0NDI5YTk4YjgzNmRfMTI5MDk_8a659fe0-74ce-451c-bd5c-7a23677319d3">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Share-Based Compensation &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company measures and recognizes share-based compensation expense for both employee and non-employee awards based on the grant date fair value of the awards. The Company recognizes share-based compensation expense on a straight-line basis over the requisite service period of the awards, which is generally the vesting period. The Company recognizes forfeitures as they occur. &lt;/span&gt;&lt;/div&gt;The Company classifies share-based compensation expense in its unaudited condensed consolidated statements of operations in the same manner in which the award recipients&#x2019; payroll costs are classified or in which the award recipients&#x2019; service payments are classified. The Company estimates the fair value of employee and non-employee stock awards as of the date of grant using the Black-Scholes option pricing model. The Company lacks Company-specific historical and implied volatility information. Therefore, management estimates the expected share price volatility based on the historical volatility of a publicly traded set of peer companies and expects to continue to do so until such time as it has adequate historical data regarding the volatility of its own publicly traded share price. The expected term of the Company&#x2019;s stock awards has been determined utilizing the &#x201c;simplified&#x201d; method for awards that qualify as &#x201c;plain-vanilla&#x201d; stock awards. The risk-free interest rate is determined by reference to the yield curve of a zero-coupon U.S. Treasury bond on the date of grant of the award for time periods approximately equal to the expected term of the award. Expected dividend yield is based on the fact that the Company has never paid cash dividends on common stock and does not expect to pay any cash dividends in the foreseeable future.</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:EarningsPerSharePolicyTextBlock
      contextRef="ie35b115501ca468f8cadb8213304a30b_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY180Ni9mcmFnOjhjODU4NmNiZTA4YzQ2MDA5Y2YzNDQyOWE5OGI4MzZkL3RleHRyZWdpb246OGM4NTg2Y2JlMDhjNDYwMDljZjM0NDI5YTk4YjgzNmRfMTI5MTI_740e3eea-3baa-423e-83fc-22dc77a8fb1d">Net Loss Per Share Basic net loss per share of common stock is computed by dividing net loss by the weighted-average number of shares of common stock outstanding during each period. Diluted net loss per share of common stock includes the effect, if any, from the potential exercise or conversion of securities, such as convertible promissory notes, preferred stock, warrants and share-based awards, which would result in the issuance of incremental shares of common stock. For diluted net loss per share, the weighted-average number of shares of common stock is the same for basic net loss per share due to the fact that when a net loss exists, dilutive securities are not included in the calculation as the impact is anti-dilutive.</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock
      contextRef="ie35b115501ca468f8cadb8213304a30b_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY180Ni9mcmFnOjhjODU4NmNiZTA4YzQ2MDA5Y2YzNDQyOWE5OGI4MzZkL3RleHRyZWdpb246OGM4NTg2Y2JlMDhjNDYwMDljZjM0NDI5YTk4YjgzNmRfMTI5MTM_af9f43d8-5017-4304-9974-8767b4e26074">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The following potentially dilutive securities have been excluded from the computation of diluted weighted-average shares of common stock outstanding, as they would be anti-dilutive:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:59.210%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:55.937%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:19.887%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.787%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:19.889%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:125%"&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:125%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:125%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;Stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;2,165,646&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;1,180,222&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;Warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;5,860,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;5,860,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;8,025,646&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;7,040,222&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="iacc367c186494022944e99aa683971ef_D20230101-20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY180Ni9mcmFnOjhjODU4NmNiZTA4YzQ2MDA5Y2YzNDQyOWE5OGI4MzZkL3RhYmxlOmUxOGVjMzA1ZmJhNDQzMGJiN2EzMGUwYmM4NjE5ZGJkL3RhYmxlcmFuZ2U6ZTE4ZWMzMDVmYmE0NDMwYmI3YTMwZTBiYzg2MTlkYmRfNS0xLTEtMS02OTk0OQ_c1605c67-2baa-496e-87e1-cd379acbfc09"
      unitRef="shares">2165646</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i56a00969dd024778bc570050ee58a725_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY180Ni9mcmFnOjhjODU4NmNiZTA4YzQ2MDA5Y2YzNDQyOWE5OGI4MzZkL3RhYmxlOmUxOGVjMzA1ZmJhNDQzMGJiN2EzMGUwYmM4NjE5ZGJkL3RhYmxlcmFuZ2U6ZTE4ZWMzMDVmYmE0NDMwYmI3YTMwZTBiYzg2MTlkYmRfNS0zLTEtMS02OTk0OQ_0c22f84d-be25-435e-abc0-2a2afb14b059"
      unitRef="shares">1180222</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i8c99fb13d0f54109a9578b166514e149_D20230101-20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY180Ni9mcmFnOjhjODU4NmNiZTA4YzQ2MDA5Y2YzNDQyOWE5OGI4MzZkL3RhYmxlOmUxOGVjMzA1ZmJhNDQzMGJiN2EzMGUwYmM4NjE5ZGJkL3RhYmxlcmFuZ2U6ZTE4ZWMzMDVmYmE0NDMwYmI3YTMwZTBiYzg2MTlkYmRfNy0xLTEtMS02OTk0OQ_75d5d811-8dfb-4757-b017-55ca0e1524a7"
      unitRef="shares">5860000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i8db471e9da7749b2b45d29dfa213f4cc_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY180Ni9mcmFnOjhjODU4NmNiZTA4YzQ2MDA5Y2YzNDQyOWE5OGI4MzZkL3RhYmxlOmUxOGVjMzA1ZmJhNDQzMGJiN2EzMGUwYmM4NjE5ZGJkL3RhYmxlcmFuZ2U6ZTE4ZWMzMDVmYmE0NDMwYmI3YTMwZTBiYzg2MTlkYmRfNy0zLTEtMS02OTk0OQ_c4f3e5df-7d2f-45e8-bd04-f8c59e13c186"
      unitRef="shares">5860000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ie35b115501ca468f8cadb8213304a30b_D20230101-20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY180Ni9mcmFnOjhjODU4NmNiZTA4YzQ2MDA5Y2YzNDQyOWE5OGI4MzZkL3RhYmxlOmUxOGVjMzA1ZmJhNDQzMGJiN2EzMGUwYmM4NjE5ZGJkL3RhYmxlcmFuZ2U6ZTE4ZWMzMDVmYmE0NDMwYmI3YTMwZTBiYzg2MTlkYmRfOC0xLTEtMS02OTk0OQ_cfeb02c5-ccdf-4c90-af63-e4088c6b7bed"
      unitRef="shares">8025646</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i3baf3250062d4a79a9b120fc56f1b18c_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY180Ni9mcmFnOjhjODU4NmNiZTA4YzQ2MDA5Y2YzNDQyOWE5OGI4MzZkL3RhYmxlOmUxOGVjMzA1ZmJhNDQzMGJiN2EzMGUwYmM4NjE5ZGJkL3RhYmxlcmFuZ2U6ZTE4ZWMzMDVmYmE0NDMwYmI3YTMwZTBiYzg2MTlkYmRfOC0zLTEtMS02OTk0OQ_66097b0a-aad1-4061-98b8-88962a815a24"
      unitRef="shares">7040222</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="ie35b115501ca468f8cadb8213304a30b_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY180OS9mcmFnOmEyOGFhZmExODFjOTQxMGZhZTFiMjcyMTQxNWU5NTFhL3RleHRyZWdpb246YTI4YWFmYTE4MWM5NDEwZmFlMWIyNzIxNDE1ZTk1MWFfODQ0_cb617dea-c5f2-4644-8f25-0ec929196a69">Fair Value Measurements &lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company utilizes a valuation hierarchy that prioritizes fair value measurements based on the types of inputs used for the various valuation techniques related to its financial assets and financial liabilities. The three levels of inputs used to measure fair value are described as follows: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Level&#160;1 &#x2013; Observable inputs such as quoted prices in active markets. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Level&#160;2 &#x2013; Inputs, other than the quoted prices in active markets, that are observable either directly or indirectly. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Level&#160;3 &#x2013; Unobservable inputs for which there is little or no market data, which require the reporting entity to develop its own assumptions. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In accordance with the fair value hierarchy described above, the following table sets forth the Company&#x2019;s assets and liabilities measured at fair value on a recurring basis: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:34.237%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.829%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.386%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.495%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.386%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.589%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.386%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.592%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 5.57pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:125%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:125%"&gt;March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 5.57pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:125%"&gt;Total &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:125%"&gt;Quoted&#160;Prices&#160;in&#160;Active&lt;br/&gt;Markets for Identical&lt;br/&gt;Assets (Level 1) &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:125%"&gt;Significant&#160;Other&lt;br/&gt;Observable&#160;Inputs&lt;br/&gt;(Level 2) &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:125%"&gt;Significant&lt;br/&gt;Unobservable&#160;Inputs&lt;br/&gt;(Level 3) &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%"&gt;Financial assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 5.57pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 5.57pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 5.57pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 5.57pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="margin-bottom:0.08pt;padding-left:18pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;Cash equivalents &lt;br/&gt;(Money Market Accounts)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 5.57pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;2,150,810&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 5.57pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;2,150,810&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 5.57pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 5.57pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:34.771%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.369%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.385%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.469%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.385%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.566%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.385%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.570%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 5.57pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 5.57pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 5.57pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:125%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:125%"&gt;Quoted&#160;Prices&#160;in&#160;Active&lt;br/&gt;Markets for Identical&lt;br/&gt;Assets (Level 1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:125%"&gt;Significant&#160;Other&lt;br/&gt;Observable&#160;Inputs&lt;br/&gt;(Level 2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:125%"&gt;Significant&lt;br/&gt;Unobservable&#160;Inputs&lt;br/&gt;(Level 3)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%"&gt;Financial assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 5.57pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 5.57pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 5.57pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 5.57pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;Cash equivalents &lt;/span&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;(Money Market Accounts)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 5.57pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;1,723,893&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 5.57pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;1,723,893&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 5.57pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 5.57pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock
      contextRef="ie35b115501ca468f8cadb8213304a30b_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY180OS9mcmFnOmEyOGFhZmExODFjOTQxMGZhZTFiMjcyMTQxNWU5NTFhL3RleHRyZWdpb246YTI4YWFmYTE4MWM5NDEwZmFlMWIyNzIxNDE1ZTk1MWFfODQ1_f64b8169-f568-4130-9df5-07dfc3171b28">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In accordance with the fair value hierarchy described above, the following table sets forth the Company&#x2019;s assets and liabilities measured at fair value on a recurring basis: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:34.237%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.829%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.386%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.495%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.386%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.589%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.386%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.592%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 5.57pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:125%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:125%"&gt;March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 5.57pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:125%"&gt;Total &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:125%"&gt;Quoted&#160;Prices&#160;in&#160;Active&lt;br/&gt;Markets for Identical&lt;br/&gt;Assets (Level 1) &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:125%"&gt;Significant&#160;Other&lt;br/&gt;Observable&#160;Inputs&lt;br/&gt;(Level 2) &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:125%"&gt;Significant&lt;br/&gt;Unobservable&#160;Inputs&lt;br/&gt;(Level 3) &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%"&gt;Financial assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 5.57pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 5.57pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 5.57pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 5.57pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="margin-bottom:0.08pt;padding-left:18pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;Cash equivalents &lt;br/&gt;(Money Market Accounts)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 5.57pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;2,150,810&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 5.57pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;2,150,810&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 5.57pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 5.57pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:34.771%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.369%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.385%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.469%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.385%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.566%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.385%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.570%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 5.57pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 5.57pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 5.57pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:125%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:125%"&gt;Quoted&#160;Prices&#160;in&#160;Active&lt;br/&gt;Markets for Identical&lt;br/&gt;Assets (Level 1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:125%"&gt;Significant&#160;Other&lt;br/&gt;Observable&#160;Inputs&lt;br/&gt;(Level 2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:125%"&gt;Significant&lt;br/&gt;Unobservable&#160;Inputs&lt;br/&gt;(Level 3)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%"&gt;Financial assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 5.57pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 5.57pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 5.57pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 5.57pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;Cash equivalents &lt;/span&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;(Money Market Accounts)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 5.57pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;1,723,893&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 5.57pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;1,723,893&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 5.57pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 5.57pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i3062cc15f83f4cdfb396a7b04a1c52fc_I20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY180OS9mcmFnOmEyOGFhZmExODFjOTQxMGZhZTFiMjcyMTQxNWU5NTFhL3RhYmxlOmIzYWJiZmQ4ODM5NDQ3ZmFiZTZiM2QyM2UxODkyODgwL3RhYmxlcmFuZ2U6YjNhYmJmZDg4Mzk0NDdmYWJlNmIzZDIzZTE4OTI4ODBfMy0xLTEtMS02OTk0OQ_d96eddbe-08a1-4310-80c2-c5543c5011b3"
      unitRef="usd">2150810</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i4d1a753ee70a4fd2bfd93f0e3636aa04_I20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY180OS9mcmFnOmEyOGFhZmExODFjOTQxMGZhZTFiMjcyMTQxNWU5NTFhL3RhYmxlOmIzYWJiZmQ4ODM5NDQ3ZmFiZTZiM2QyM2UxODkyODgwL3RhYmxlcmFuZ2U6YjNhYmJmZDg4Mzk0NDdmYWJlNmIzZDIzZTE4OTI4ODBfMy0zLTEtMS02OTk0OQ_3b7b5277-d935-4afd-a298-9721aec85e22"
      unitRef="usd">2150810</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="ibcafe063c5b44faf99d7d8aa71157121_I20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY180OS9mcmFnOmEyOGFhZmExODFjOTQxMGZhZTFiMjcyMTQxNWU5NTFhL3RhYmxlOmIzYWJiZmQ4ODM5NDQ3ZmFiZTZiM2QyM2UxODkyODgwL3RhYmxlcmFuZ2U6YjNhYmJmZDg4Mzk0NDdmYWJlNmIzZDIzZTE4OTI4ODBfMy01LTEtMS02OTk0OQ_e498e6ce-ed87-42c2-81ec-d8163fc7711e"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i1badbe53200740efb2a4bd341a6746ea_I20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY180OS9mcmFnOmEyOGFhZmExODFjOTQxMGZhZTFiMjcyMTQxNWU5NTFhL3RhYmxlOmIzYWJiZmQ4ODM5NDQ3ZmFiZTZiM2QyM2UxODkyODgwL3RhYmxlcmFuZ2U6YjNhYmJmZDg4Mzk0NDdmYWJlNmIzZDIzZTE4OTI4ODBfMy03LTEtMS02OTk0OQ_972524ba-c280-47c2-97de-d9ff55855a36"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i32dbf7cfaa0f452aae81b03367cca49f_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY180OS9mcmFnOmEyOGFhZmExODFjOTQxMGZhZTFiMjcyMTQxNWU5NTFhL3RhYmxlOjViYjE5NjkyYmQ1NjQ4MDhiZTFlYzdhNjYwMzIyY2FiL3RhYmxlcmFuZ2U6NWJiMTk2OTJiZDU2NDgwOGJlMWVjN2E2NjAzMjJjYWJfMy0xLTEtMS02OTk0OQ_47a0ae7a-1b54-4549-b8a2-b7c938e43ddb"
      unitRef="usd">1723893</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="id0fabbbc724b4914bb823640a0a66913_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY180OS9mcmFnOmEyOGFhZmExODFjOTQxMGZhZTFiMjcyMTQxNWU5NTFhL3RhYmxlOjViYjE5NjkyYmQ1NjQ4MDhiZTFlYzdhNjYwMzIyY2FiL3RhYmxlcmFuZ2U6NWJiMTk2OTJiZDU2NDgwOGJlMWVjN2E2NjAzMjJjYWJfMy0zLTEtMS02OTk0OQ_537f4bab-3afe-4872-bfbd-7d04081fb348"
      unitRef="usd">1723893</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i226a9d11b9184048a101065b542aff08_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY180OS9mcmFnOmEyOGFhZmExODFjOTQxMGZhZTFiMjcyMTQxNWU5NTFhL3RhYmxlOjViYjE5NjkyYmQ1NjQ4MDhiZTFlYzdhNjYwMzIyY2FiL3RhYmxlcmFuZ2U6NWJiMTk2OTJiZDU2NDgwOGJlMWVjN2E2NjAzMjJjYWJfMy01LTEtMS02OTk0OQ_e55c5a7a-f76b-4335-bc3d-93af5195da52"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i71991571d44349a9b2f3d9678cc16557_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY180OS9mcmFnOmEyOGFhZmExODFjOTQxMGZhZTFiMjcyMTQxNWU5NTFhL3RhYmxlOjViYjE5NjkyYmQ1NjQ4MDhiZTFlYzdhNjYwMzIyY2FiL3RhYmxlcmFuZ2U6NWJiMTk2OTJiZDU2NDgwOGJlMWVjN2E2NjAzMjJjYWJfMy03LTEtMS02OTk0OQ_28b1ceee-36e3-4922-8994-9d50d7d00b52"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock
      contextRef="ie35b115501ca468f8cadb8213304a30b_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY181Mi9mcmFnOmEzYWJjNmJkN2M1ZTQ4MjViNjFiMWRkMDUxY2RkNzAxL3RleHRyZWdpb246YTNhYmM2YmQ3YzVlNDgyNWI2MWIxZGQwNTFjZGQ3MDFfMTMz_3fbaf32c-3413-44b4-bcfd-f7ebb0d9130e">Accrued Expenses and Other Current Liabilities&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Accrued expenses and other current liabilities consisted of the following:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:77.046%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:49.184%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.077%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.620%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%"&gt;March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;text-indent:-12pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Compensation and benefits&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;215,050&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;770,055&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;text-indent:-12pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Research and development costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;1,629,014&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;1,358,707&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;text-indent:-12pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Professional fees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;103,131&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;3,951&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;text-indent:-12pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;44,247&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;83,456&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;text-indent:-12pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;1,991,442&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;2,216,169&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock>
    <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock
      contextRef="ie35b115501ca468f8cadb8213304a30b_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY181Mi9mcmFnOmEzYWJjNmJkN2M1ZTQ4MjViNjFiMWRkMDUxY2RkNzAxL3RleHRyZWdpb246YTNhYmM2YmQ3YzVlNDgyNWI2MWIxZGQwNTFjZGQ3MDFfMTM0_c4dbdd85-26d7-410e-b261-261a23bec2aa">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Accrued expenses and other current liabilities consisted of the following:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:77.046%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:49.184%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.077%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.620%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%"&gt;March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;text-indent:-12pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Compensation and benefits&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;215,050&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;770,055&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;text-indent:-12pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Research and development costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;1,629,014&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;1,358,707&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;text-indent:-12pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Professional fees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;103,131&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;3,951&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;text-indent:-12pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;44,247&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;83,456&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;text-indent:-12pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;1,991,442&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;2,216,169&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="i9e6ffce2c2d247f491e046febe8251cd_I20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY181Mi9mcmFnOmEzYWJjNmJkN2M1ZTQ4MjViNjFiMWRkMDUxY2RkNzAxL3RhYmxlOmZjNzg2Mzc5YTI2MDQ1ODU5OTUzZWM0MTkzZmE4NzQwL3RhYmxlcmFuZ2U6ZmM3ODYzNzlhMjYwNDU4NTk5NTNlYzQxOTNmYTg3NDBfMS0xLTEtMS02OTk0OQ_fc2bd34a-f588-40b1-b9a0-a703927e6920"
      unitRef="usd">215050</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="i4b1713eab7d84494b3b43202a26fc3c4_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY181Mi9mcmFnOmEzYWJjNmJkN2M1ZTQ4MjViNjFiMWRkMDUxY2RkNzAxL3RhYmxlOmZjNzg2Mzc5YTI2MDQ1ODU5OTUzZWM0MTkzZmE4NzQwL3RhYmxlcmFuZ2U6ZmM3ODYzNzlhMjYwNDU4NTk5NTNlYzQxOTNmYTg3NDBfMS0zLTEtMS02OTk0OQ_cf321c9d-966a-44e3-8349-08377e6302ce"
      unitRef="usd">770055</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <cntx:AccruedResearchAndDevelopmentCostsCurrent
      contextRef="i9e6ffce2c2d247f491e046febe8251cd_I20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY181Mi9mcmFnOmEzYWJjNmJkN2M1ZTQ4MjViNjFiMWRkMDUxY2RkNzAxL3RhYmxlOmZjNzg2Mzc5YTI2MDQ1ODU5OTUzZWM0MTkzZmE4NzQwL3RhYmxlcmFuZ2U6ZmM3ODYzNzlhMjYwNDU4NTk5NTNlYzQxOTNmYTg3NDBfMi0xLTEtMS02OTk0OQ_77178f09-0c25-48ae-97cd-72bb413e1aa7"
      unitRef="usd">1629014</cntx:AccruedResearchAndDevelopmentCostsCurrent>
    <cntx:AccruedResearchAndDevelopmentCostsCurrent
      contextRef="i4b1713eab7d84494b3b43202a26fc3c4_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY181Mi9mcmFnOmEzYWJjNmJkN2M1ZTQ4MjViNjFiMWRkMDUxY2RkNzAxL3RhYmxlOmZjNzg2Mzc5YTI2MDQ1ODU5OTUzZWM0MTkzZmE4NzQwL3RhYmxlcmFuZ2U6ZmM3ODYzNzlhMjYwNDU4NTk5NTNlYzQxOTNmYTg3NDBfMi0zLTEtMS02OTk0OQ_edabaa09-f349-43f0-aaa2-bc73705bb370"
      unitRef="usd">1358707</cntx:AccruedResearchAndDevelopmentCostsCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="i9e6ffce2c2d247f491e046febe8251cd_I20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY181Mi9mcmFnOmEzYWJjNmJkN2M1ZTQ4MjViNjFiMWRkMDUxY2RkNzAxL3RhYmxlOmZjNzg2Mzc5YTI2MDQ1ODU5OTUzZWM0MTkzZmE4NzQwL3RhYmxlcmFuZ2U6ZmM3ODYzNzlhMjYwNDU4NTk5NTNlYzQxOTNmYTg3NDBfMy0xLTEtMS02OTk0OQ_77d0662f-c152-4c9b-8ad3-5197d2f3e5ab"
      unitRef="usd">103131</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="i4b1713eab7d84494b3b43202a26fc3c4_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY181Mi9mcmFnOmEzYWJjNmJkN2M1ZTQ4MjViNjFiMWRkMDUxY2RkNzAxL3RhYmxlOmZjNzg2Mzc5YTI2MDQ1ODU5OTUzZWM0MTkzZmE4NzQwL3RhYmxlcmFuZ2U6ZmM3ODYzNzlhMjYwNDU4NTk5NTNlYzQxOTNmYTg3NDBfMy0zLTEtMS02OTk0OQ_b389d6ed-c3f3-48c6-a88a-22c475176fd3"
      unitRef="usd">3951</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="i9e6ffce2c2d247f491e046febe8251cd_I20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY181Mi9mcmFnOmEzYWJjNmJkN2M1ZTQ4MjViNjFiMWRkMDUxY2RkNzAxL3RhYmxlOmZjNzg2Mzc5YTI2MDQ1ODU5OTUzZWM0MTkzZmE4NzQwL3RhYmxlcmFuZ2U6ZmM3ODYzNzlhMjYwNDU4NTk5NTNlYzQxOTNmYTg3NDBfNC0xLTEtMS02OTk0OQ_5c92bb13-d70f-41fe-8699-3ddddb9482c0"
      unitRef="usd">44247</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="i4b1713eab7d84494b3b43202a26fc3c4_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY181Mi9mcmFnOmEzYWJjNmJkN2M1ZTQ4MjViNjFiMWRkMDUxY2RkNzAxL3RhYmxlOmZjNzg2Mzc5YTI2MDQ1ODU5OTUzZWM0MTkzZmE4NzQwL3RhYmxlcmFuZ2U6ZmM3ODYzNzlhMjYwNDU4NTk5NTNlYzQxOTNmYTg3NDBfNC0zLTEtMS02OTk0OQ_c5749ccb-85b4-487d-8783-86b5f0d15c72"
      unitRef="usd">83456</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i9e6ffce2c2d247f491e046febe8251cd_I20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY181Mi9mcmFnOmEzYWJjNmJkN2M1ZTQ4MjViNjFiMWRkMDUxY2RkNzAxL3RhYmxlOmZjNzg2Mzc5YTI2MDQ1ODU5OTUzZWM0MTkzZmE4NzQwL3RhYmxlcmFuZ2U6ZmM3ODYzNzlhMjYwNDU4NTk5NTNlYzQxOTNmYTg3NDBfNS0xLTEtMS02OTk0OQ_1accdba5-ccc7-4a2a-9488-022906feba02"
      unitRef="usd">1991442</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i4b1713eab7d84494b3b43202a26fc3c4_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY181Mi9mcmFnOmEzYWJjNmJkN2M1ZTQ4MjViNjFiMWRkMDUxY2RkNzAxL3RhYmxlOmZjNzg2Mzc5YTI2MDQ1ODU5OTUzZWM0MTkzZmE4NzQwL3RhYmxlcmFuZ2U6ZmM3ODYzNzlhMjYwNDU4NTk5NTNlYzQxOTNmYTg3NDBfNS0zLTEtMS02OTk0OQ_3d762f74-5881-43a0-ac4d-000ae057723b"
      unitRef="usd">2216169</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock
      contextRef="ie35b115501ca468f8cadb8213304a30b_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY181OC9mcmFnOmRhYTM0ODIxMjc2MjQ2YjBiY2ZiODBlY2E3YTQzYWUzL3RleHRyZWdpb246ZGFhMzQ4MjEyNzYyNDZiMGJjZmI4MGVjYTdhNDNhZTNfMjY1Mg_b7a1f568-fb8e-4048-818d-efec6a60d520">Stockholders' Equity&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Warrants for Common Stock &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In connection with the Company's initial public offering (&#x201c;IPO&#x201d;) and private placement in 2021, the Company issued warrants to purchase shares of common stock.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In March 2022, the Company issued 360,000 warrants to purchase common stock with an exercise price of $10.00 per share and a term of 5.76 years as compensation for professional consulting services performed in 2021. The estimated fair value of the warrants of $0.3&#160;million was recorded in general and administrative expense during the year ended December 31, 2021 and was also reflected as a liability on the condensed consolidated balance sheets as of December 31, 2021. The liability was reclassified into additional paid-in capital in March 2022 upon the issuance of the warrants.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;At March&#160;31, 2023, the Company had the following warrants outstanding to acquire common stock: &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;padding-left:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.274%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:42.787%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.849%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.426%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.103%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.426%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:24.609%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:125%"&gt;Outstanding &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:125%"&gt;Exercise&#160;price &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:125%"&gt;Expiration&#160;dates &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;Issued in connection with 2021 IPO&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 5.57pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;250,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 5.57pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;6.25&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;October 2026&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;Issued in connection with 2021 private placement&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 5.57pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;5,250,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 5.57pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;6.25&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;June 2027&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;Issued in 2022 for consulting services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 5.57pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;360,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 5.57pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;10.00&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;December 2027&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 5.57pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;5,860,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="i123230c41d4a4b6cb51151a89a8800c3_I20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY181OC9mcmFnOmRhYTM0ODIxMjc2MjQ2YjBiY2ZiODBlY2E3YTQzYWUzL3RleHRyZWdpb246ZGFhMzQ4MjEyNzYyNDZiMGJjZmI4MGVjYTdhNDNhZTNfMTY0OTI2NzQ1MDI5OQ_b7c84d8f-a023-4836-8f46-f220cd5fc72b"
      unitRef="shares">360000</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i123230c41d4a4b6cb51151a89a8800c3_I20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY181OC9mcmFnOmRhYTM0ODIxMjc2MjQ2YjBiY2ZiODBlY2E3YTQzYWUzL3RleHRyZWdpb246ZGFhMzQ4MjEyNzYyNDZiMGJjZmI4MGVjYTdhNDNhZTNfMTY0OTI2NzQ1MDMyMw_48e3e72e-e392-416a-aaa7-5bd56e367791"
      unitRef="usdPerShare">10.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="i123230c41d4a4b6cb51151a89a8800c3_I20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY181OC9mcmFnOmRhYTM0ODIxMjc2MjQ2YjBiY2ZiODBlY2E3YTQzYWUzL3RleHRyZWdpb246ZGFhMzQ4MjEyNzYyNDZiMGJjZmI4MGVjYTdhNDNhZTNfMTY0OTI2NzQ1MDMwNw_0081463c-2a10-4d59-a0b2-77674454e1c4">P5Y9M3D</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="i1be90ca5530f4a1d914f1a6103d21bd1_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY181OC9mcmFnOmRhYTM0ODIxMjc2MjQ2YjBiY2ZiODBlY2E3YTQzYWUzL3RleHRyZWdpb246ZGFhMzQ4MjEyNzYyNDZiMGJjZmI4MGVjYTdhNDNhZTNfMTY0OTI2NzQ1MDMwOQ_76a5b1bd-8612-4dae-bfc1-05ca0442d286"
      unitRef="usd">300000</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock
      contextRef="ie35b115501ca468f8cadb8213304a30b_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY181OC9mcmFnOmRhYTM0ODIxMjc2MjQ2YjBiY2ZiODBlY2E3YTQzYWUzL3RleHRyZWdpb246ZGFhMzQ4MjEyNzYyNDZiMGJjZmI4MGVjYTdhNDNhZTNfMjY1Mw_8d32400c-5cb6-4936-9c4f-4328f15ddc35">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;At March&#160;31, 2023, the Company had the following warrants outstanding to acquire common stock: &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;padding-left:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.274%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:42.787%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.849%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.426%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.103%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.426%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:24.609%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:125%"&gt;Outstanding &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:125%"&gt;Exercise&#160;price &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:125%"&gt;Expiration&#160;dates &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;Issued in connection with 2021 IPO&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 5.57pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;250,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 5.57pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;6.25&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;October 2026&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;Issued in connection with 2021 private placement&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 5.57pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;5,250,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 5.57pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;6.25&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;June 2027&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;Issued in 2022 for consulting services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 5.57pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;360,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 5.57pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;10.00&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;December 2027&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 5.57pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;5,860,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="i68c87024c26f44ab8263dbd0a7fa6a4f_I20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY181OC9mcmFnOmRhYTM0ODIxMjc2MjQ2YjBiY2ZiODBlY2E3YTQzYWUzL3RhYmxlOmMzYzQ5NTc0MzE4MzRjYmI5MGIxNmI4ZTc4NGQyMTg5L3RhYmxlcmFuZ2U6YzNjNDk1NzQzMTgzNGNiYjkwYjE2YjhlNzg0ZDIxODlfMS0xLTEtMS02OTk0OQ_50184511-15fc-4840-8926-50e006e9c550"
      unitRef="shares">250000</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i68c87024c26f44ab8263dbd0a7fa6a4f_I20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY181OC9mcmFnOmRhYTM0ODIxMjc2MjQ2YjBiY2ZiODBlY2E3YTQzYWUzL3RhYmxlOmMzYzQ5NTc0MzE4MzRjYmI5MGIxNmI4ZTc4NGQyMTg5L3RhYmxlcmFuZ2U6YzNjNDk1NzQzMTgzNGNiYjkwYjE2YjhlNzg0ZDIxODlfMS0zLTEtMS02OTk0OQ_bfed624d-ec25-4392-b7bc-1876a2826a5c"
      unitRef="usdPerShare">6.25</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="id3ed5205e2ed4995a41973b9bf8be2de_I20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY181OC9mcmFnOmRhYTM0ODIxMjc2MjQ2YjBiY2ZiODBlY2E3YTQzYWUzL3RhYmxlOmMzYzQ5NTc0MzE4MzRjYmI5MGIxNmI4ZTc4NGQyMTg5L3RhYmxlcmFuZ2U6YzNjNDk1NzQzMTgzNGNiYjkwYjE2YjhlNzg0ZDIxODlfMi0xLTEtMS02OTk0OQ_d5051517-9768-4d1c-87a3-b3e2e84839bb"
      unitRef="shares">5250000</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="id3ed5205e2ed4995a41973b9bf8be2de_I20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY181OC9mcmFnOmRhYTM0ODIxMjc2MjQ2YjBiY2ZiODBlY2E3YTQzYWUzL3RhYmxlOmMzYzQ5NTc0MzE4MzRjYmI5MGIxNmI4ZTc4NGQyMTg5L3RhYmxlcmFuZ2U6YzNjNDk1NzQzMTgzNGNiYjkwYjE2YjhlNzg0ZDIxODlfMi0zLTEtMS02OTk0OQ_9246c5cf-b4a2-4a2c-8637-2292f910a4f8"
      unitRef="usdPerShare">6.25</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="i4ab77790f64945ee9a78ac502ec36b66_I20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY181OC9mcmFnOmRhYTM0ODIxMjc2MjQ2YjBiY2ZiODBlY2E3YTQzYWUzL3RhYmxlOmMzYzQ5NTc0MzE4MzRjYmI5MGIxNmI4ZTc4NGQyMTg5L3RhYmxlcmFuZ2U6YzNjNDk1NzQzMTgzNGNiYjkwYjE2YjhlNzg0ZDIxODlfMy0xLTEtMS02OTk0OQ_0be65e25-3e49-4262-a392-a4d8877f76ad"
      unitRef="shares">360000</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i4ab77790f64945ee9a78ac502ec36b66_I20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY181OC9mcmFnOmRhYTM0ODIxMjc2MjQ2YjBiY2ZiODBlY2E3YTQzYWUzL3RhYmxlOmMzYzQ5NTc0MzE4MzRjYmI5MGIxNmI4ZTc4NGQyMTg5L3RhYmxlcmFuZ2U6YzNjNDk1NzQzMTgzNGNiYjkwYjE2YjhlNzg0ZDIxODlfMy0zLTEtMS02OTk0OQ_1fbfd698-b48a-4223-a772-cdcfb66ecc5a"
      unitRef="usdPerShare">10.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="i9e6ffce2c2d247f491e046febe8251cd_I20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY181OC9mcmFnOmRhYTM0ODIxMjc2MjQ2YjBiY2ZiODBlY2E3YTQzYWUzL3RhYmxlOmMzYzQ5NTc0MzE4MzRjYmI5MGIxNmI4ZTc4NGQyMTg5L3RhYmxlcmFuZ2U6YzNjNDk1NzQzMTgzNGNiYjkwYjE2YjhlNzg0ZDIxODlfNC0xLTEtMS02OTk0OQ_0775dbff-ace0-40cd-be5a-e1efe9b60104"
      unitRef="shares">5860000</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="ie35b115501ca468f8cadb8213304a30b_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY182MS9mcmFnOmY0MWY3ZGYxZWMzYTQ3N2FhOWY1NmI1ZGJjMzIyOTMzL3RleHRyZWdpb246ZjQxZjdkZjFlYzNhNDc3YWE5ZjU2YjVkYmMzMjI5MzNfMjk4MA_ac717a96-ae8c-4906-ba14-65784d291d1b">Share-based Compensation &lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In April 2021, the Company adopted the 2021 Long-Term Performance Incentive Plan (&#x201c;2021 Incentive Plan&#x201d;). Under the 2021 Incentive Plan, the Company can grant stock options, stock appreciation rights, restricted stock, restricted stock units (&#x201c;RSUs&#x201d;) and stock grants. The 2021 Incentive Plan allows for the issuance of up to 1,266,092 shares of common stock (the &#x201c;Share Limit&#x201d;).  The Share Limit automatically increases on January 1st of each year, during the term of the 2021 Incentive Plan, commencing on January 1 of the year following the year in which the effective date occurs, in an amount equal to four percent (4%) of the total number of shares of the Company&#x2019;s common stock outstanding on December 31st of the preceding calendar year; provided that the Board may determine that there will be no such increase or a smaller increase for any particular year. As of March&#160;31, 2023, 361,035 shares remained available for future grants. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:115%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Share-based awards generally vest over a period of one year to four years, and share-based awards that lapse or are forfeited are available to be granted again. The contractual life of all share-based awards is ten years. The expiration dates of the outstanding share-based awards range from January 2028 to February 2033. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company measures share-based awards at their grant-date fair value and records compensation expense on a straight-line basis over the service period of the awards. Share-based compensation is allocated to employees and consultants based on their respective departments. All board of directors&#x2019; compensation is charged to general and administrative expense. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Share-based compensation expense related to the issuance of stock options was as follows for the three months ended March&#160;31, 2023 and 2022: &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:61.842%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:49.018%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.540%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.745%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:24.197%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%"&gt;Three months ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;21,087&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;32,960&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;General and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;261,675&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;181,998&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;282,762&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;214,958&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The weighted average assumptions used in the Black-Scholes option pricing model to determine the fair value of share-based awards granted to employees during the three months ended March&#160;31, 2023 and 2022 were as follows: &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;padding-left:51.3pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:81.286%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:66.525%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.367%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.370%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 5.57pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:125%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:125%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Expected stock price volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;91.85%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;86.86%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;3.88%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;1.91%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Expected term (in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;6.08&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;6.03&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Expected dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;&#x2014;&#160;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The following table summarizes the share-based award activity for the periods presented: &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:53.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.524%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 5.57pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:0.08pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:125%"&gt;Number&#160;of&#160;Shares&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:125%"&gt;Weighted&#160;Average&lt;br/&gt;Exercise&#160;Price&#160;Per&lt;br/&gt;Share &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:125%"&gt;Weighted&#160;Average&lt;br/&gt;Remaining&lt;br/&gt;Contractual&#160;Term&lt;br/&gt;(years) &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;Outstanding at January 1, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 5.57pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;1,341,504&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;3.27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 5.57pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;8.9&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 5.57pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;824,142&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;0.84&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 5.57pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="margin-bottom:0.05pt;margin-top:0.05pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#160;&#160;&#160;&#160;&#160;Forfeited&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 5.57pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="margin-bottom:0.08pt;padding-left:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;Outstanding at March&#160;31, 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 5.57pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;2,165,646&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;2.35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 5.57pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;9.1&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="margin-bottom:0.08pt;padding-left:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;Vested and exercisable at March&#160;31, 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 5.57pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;526,574&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;4.43&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 5.57pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;8.3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="margin-bottom:0.08pt;padding-left:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;Vested and expected to vest at March&#160;31, 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 5.57pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;2,165,646&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;2.35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 5.57pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;9.1&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;The weighted average fair value of share-based awards granted during the three months ended March&#160;31, 2023 and 2022 was $0.65 and $1.33, respectively. As of March&#160;31, 2023, the unrecognized compensation cost related to outstanding share-based awards was $1.9&#160;million and is expected to be recognized as expense over a weighted-average period of approximately 2.49 years.</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="ib10d0ed1d1274880b8a73ff00fe229ab_I20210430"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY182MS9mcmFnOmY0MWY3ZGYxZWMzYTQ3N2FhOWY1NmI1ZGJjMzIyOTMzL3RleHRyZWdpb246ZjQxZjdkZjFlYzNhNDc3YWE5ZjU2YjVkYmMzMjI5MzNfMzYx_63df7442-2c45-4565-b5a2-eab19add99a8"
      unitRef="shares">1266092</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <cntx:ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedAsAPercentageOfOutstandingStock
      contextRef="i37c7d2f5e060456d835ba44ccd4b0c9b_D20210401-20210430"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY182MS9mcmFnOmY0MWY3ZGYxZWMzYTQ3N2FhOWY1NmI1ZGJjMzIyOTMzL3RleHRyZWdpb246ZjQxZjdkZjFlYzNhNDc3YWE5ZjU2YjVkYmMzMjI5MzNfNjUz_2f3faabf-71bd-4edc-9b0a-15c6d38ab7ef"
      unitRef="number">0.04</cntx:ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedAsAPercentageOfOutstandingStock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="i4ac2f469b04f49ea9a783619785adc82_I20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY182MS9mcmFnOmY0MWY3ZGYxZWMzYTQ3N2FhOWY1NmI1ZGJjMzIyOTMzL3RleHRyZWdpb246ZjQxZjdkZjFlYzNhNDc3YWE5ZjU2YjVkYmMzMjI5MzNfOTA5_dfaeb34f-687b-4512-93cc-89c66f461e86"
      unitRef="shares">361035</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="ibac63907709f43e8bb17c649e92f3e4d_D20210401-20210430"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY182MS9mcmFnOmY0MWY3ZGYxZWMzYTQ3N2FhOWY1NmI1ZGJjMzIyOTMzL3RleHRyZWdpb246ZjQxZjdkZjFlYzNhNDc3YWE5ZjU2YjVkYmMzMjI5MzNfMTAxMQ_383e6cd1-d847-417d-8ad5-e2d54df4277a">P1Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="i902a704c36e04459a8ef415c67f74f48_D20210401-20210430"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY182MS9mcmFnOmY0MWY3ZGYxZWMzYTQ3N2FhOWY1NmI1ZGJjMzIyOTMzL3RleHRyZWdpb246ZjQxZjdkZjFlYzNhNDc3YWE5ZjU2YjVkYmMzMjI5MzNfMTAxNw_268f54dd-73f5-4732-8350-60ace136fadf">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="i37c7d2f5e060456d835ba44ccd4b0c9b_D20210401-20210430"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY182MS9mcmFnOmY0MWY3ZGYxZWMzYTQ3N2FhOWY1NmI1ZGJjMzIyOTMzL3RleHRyZWdpb246ZjQxZjdkZjFlYzNhNDc3YWE5ZjU2YjVkYmMzMjI5MzNfMTE1Nw_741a0fea-72c4-4867-a298-e309d15622a0">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock
      contextRef="ie35b115501ca468f8cadb8213304a30b_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY182MS9mcmFnOmY0MWY3ZGYxZWMzYTQ3N2FhOWY1NmI1ZGJjMzIyOTMzL3RleHRyZWdpb246ZjQxZjdkZjFlYzNhNDc3YWE5ZjU2YjVkYmMzMjI5MzNfMjk3Nw_f5c3cab1-263a-40f3-bedb-e82068235a9a">Share-based compensation expense related to the issuance of stock options was as follows for the three months ended March&#160;31, 2023 and 2022: &lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:61.842%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:49.018%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.540%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.745%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:24.197%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%"&gt;Three months ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;21,087&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;32,960&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;General and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;261,675&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;181,998&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;282,762&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;214,958&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i70f641b88b5a48aeb3fe1ce75baa1362_D20230101-20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY182MS9mcmFnOmY0MWY3ZGYxZWMzYTQ3N2FhOWY1NmI1ZGJjMzIyOTMzL3RhYmxlOjZmNzZmYjQ2YzM4ZjQ2ZDc5YTI5OThhMGY5NDgyOTc5L3RhYmxlcmFuZ2U6NmY3NmZiNDZjMzhmNDZkNzlhMjk5OGEwZjk0ODI5NzlfMy0xLTEtMS02OTk0OQ_3dcd75bb-0022-4b51-85e2-91809f34f62b"
      unitRef="usd">21087</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i4799146a2fb14bd8b37fc240a795004c_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY182MS9mcmFnOmY0MWY3ZGYxZWMzYTQ3N2FhOWY1NmI1ZGJjMzIyOTMzL3RhYmxlOjZmNzZmYjQ2YzM4ZjQ2ZDc5YTI5OThhMGY5NDgyOTc5L3RhYmxlcmFuZ2U6NmY3NmZiNDZjMzhmNDZkNzlhMjk5OGEwZjk0ODI5NzlfMy0zLTEtMS02OTk0OQ_a5662161-1ad9-435a-8e7f-748d765ef208"
      unitRef="usd">32960</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="iaf92495d8d6b4b9a9ec33d201a161246_D20230101-20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY182MS9mcmFnOmY0MWY3ZGYxZWMzYTQ3N2FhOWY1NmI1ZGJjMzIyOTMzL3RhYmxlOjZmNzZmYjQ2YzM4ZjQ2ZDc5YTI5OThhMGY5NDgyOTc5L3RhYmxlcmFuZ2U6NmY3NmZiNDZjMzhmNDZkNzlhMjk5OGEwZjk0ODI5NzlfNC0xLTEtMS02OTk0OQ_6c797015-d750-4559-9b6b-07747297d7af"
      unitRef="usd">261675</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i7503ba5b2ff64139bbe478fa4ceedf80_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY182MS9mcmFnOmY0MWY3ZGYxZWMzYTQ3N2FhOWY1NmI1ZGJjMzIyOTMzL3RhYmxlOjZmNzZmYjQ2YzM4ZjQ2ZDc5YTI5OThhMGY5NDgyOTc5L3RhYmxlcmFuZ2U6NmY3NmZiNDZjMzhmNDZkNzlhMjk5OGEwZjk0ODI5NzlfNC0zLTEtMS02OTk0OQ_b75cd246-00c8-40c0-b049-bac4bd6d8280"
      unitRef="usd">181998</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ie35b115501ca468f8cadb8213304a30b_D20230101-20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY182MS9mcmFnOmY0MWY3ZGYxZWMzYTQ3N2FhOWY1NmI1ZGJjMzIyOTMzL3RhYmxlOjZmNzZmYjQ2YzM4ZjQ2ZDc5YTI5OThhMGY5NDgyOTc5L3RhYmxlcmFuZ2U6NmY3NmZiNDZjMzhmNDZkNzlhMjk5OGEwZjk0ODI5NzlfNS0xLTEtMS02OTk0OQ_795f6362-7ca5-4638-9183-9f8702192ed7"
      unitRef="usd">282762</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i3baf3250062d4a79a9b120fc56f1b18c_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY182MS9mcmFnOmY0MWY3ZGYxZWMzYTQ3N2FhOWY1NmI1ZGJjMzIyOTMzL3RhYmxlOjZmNzZmYjQ2YzM4ZjQ2ZDc5YTI5OThhMGY5NDgyOTc5L3RhYmxlcmFuZ2U6NmY3NmZiNDZjMzhmNDZkNzlhMjk5OGEwZjk0ODI5NzlfNS0zLTEtMS02OTk0OQ_a09226f2-6b6f-4ba5-be6a-feb817b1b446"
      unitRef="usd">214958</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
      contextRef="ie35b115501ca468f8cadb8213304a30b_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY182MS9mcmFnOmY0MWY3ZGYxZWMzYTQ3N2FhOWY1NmI1ZGJjMzIyOTMzL3RleHRyZWdpb246ZjQxZjdkZjFlYzNhNDc3YWE5ZjU2YjVkYmMzMjI5MzNfMjk4MQ_50134cef-5ff5-47aa-b9d5-34a63bd734ed">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The weighted average assumptions used in the Black-Scholes option pricing model to determine the fair value of share-based awards granted to employees during the three months ended March&#160;31, 2023 and 2022 were as follows: &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;padding-left:51.3pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:81.286%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:66.525%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.367%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.370%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 5.57pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:125%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:125%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Expected stock price volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;91.85%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;86.86%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;3.88%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;1.91%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Expected term (in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;6.08&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;6.03&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Expected dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;&#x2014;&#160;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="i56df8626827b4508b71d14c260351355_D20230101-20230331"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY182MS9mcmFnOmY0MWY3ZGYxZWMzYTQ3N2FhOWY1NmI1ZGJjMzIyOTMzL3RhYmxlOmU3NDIyMTI5NjZmMDQyZWE5ODA2ZTA2YzJkZWEyY2Y0L3RhYmxlcmFuZ2U6ZTc0MjIxMjk2NmYwNDJlYTk4MDZlMDZjMmRlYTJjZjRfMS0yLTEtMS02OTk0OQ_64f166ee-935b-412f-a356-1c72ccfa118c"
      unitRef="number">0.9185</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="ia22a5f1f807740beb36572d3ab1f91c8_D20220101-20220331"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY182MS9mcmFnOmY0MWY3ZGYxZWMzYTQ3N2FhOWY1NmI1ZGJjMzIyOTMzL3RhYmxlOmU3NDIyMTI5NjZmMDQyZWE5ODA2ZTA2YzJkZWEyY2Y0L3RhYmxlcmFuZ2U6ZTc0MjIxMjk2NmYwNDJlYTk4MDZlMDZjMmRlYTJjZjRfMS00LTEtMS02OTk0OQ_590027da-e916-4771-ba4a-abea22a4052d"
      unitRef="number">0.8686</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="i56df8626827b4508b71d14c260351355_D20230101-20230331"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY182MS9mcmFnOmY0MWY3ZGYxZWMzYTQ3N2FhOWY1NmI1ZGJjMzIyOTMzL3RhYmxlOmU3NDIyMTI5NjZmMDQyZWE5ODA2ZTA2YzJkZWEyY2Y0L3RhYmxlcmFuZ2U6ZTc0MjIxMjk2NmYwNDJlYTk4MDZlMDZjMmRlYTJjZjRfMi0yLTEtMS02OTk0OQ_2dbafd88-18f7-499d-a7da-9b972d202a3e"
      unitRef="number">0.0388</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="ia22a5f1f807740beb36572d3ab1f91c8_D20220101-20220331"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY182MS9mcmFnOmY0MWY3ZGYxZWMzYTQ3N2FhOWY1NmI1ZGJjMzIyOTMzL3RhYmxlOmU3NDIyMTI5NjZmMDQyZWE5ODA2ZTA2YzJkZWEyY2Y0L3RhYmxlcmFuZ2U6ZTc0MjIxMjk2NmYwNDJlYTk4MDZlMDZjMmRlYTJjZjRfMi00LTEtMS02OTk0OQ_30ae6e17-c4e9-4993-91b0-2680c4eca68f"
      unitRef="number">0.0191</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i56df8626827b4508b71d14c260351355_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY182MS9mcmFnOmY0MWY3ZGYxZWMzYTQ3N2FhOWY1NmI1ZGJjMzIyOTMzL3RhYmxlOmU3NDIyMTI5NjZmMDQyZWE5ODA2ZTA2YzJkZWEyY2Y0L3RhYmxlcmFuZ2U6ZTc0MjIxMjk2NmYwNDJlYTk4MDZlMDZjMmRlYTJjZjRfMy0yLTEtMS02OTk0OQ_98c038ca-bb79-443a-891b-a5ff03adb790">P6Y29D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="ia22a5f1f807740beb36572d3ab1f91c8_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY182MS9mcmFnOmY0MWY3ZGYxZWMzYTQ3N2FhOWY1NmI1ZGJjMzIyOTMzL3RhYmxlOmU3NDIyMTI5NjZmMDQyZWE5ODA2ZTA2YzJkZWEyY2Y0L3RhYmxlcmFuZ2U6ZTc0MjIxMjk2NmYwNDJlYTk4MDZlMDZjMmRlYTJjZjRfMy00LTEtMS02OTk0OQ_d87c2f33-29c7-4214-9d92-581a22647d7e">P6Y10D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="i56df8626827b4508b71d14c260351355_D20230101-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY182MS9mcmFnOmY0MWY3ZGYxZWMzYTQ3N2FhOWY1NmI1ZGJjMzIyOTMzL3RhYmxlOmU3NDIyMTI5NjZmMDQyZWE5ODA2ZTA2YzJkZWEyY2Y0L3RhYmxlcmFuZ2U6ZTc0MjIxMjk2NmYwNDJlYTk4MDZlMDZjMmRlYTJjZjRfNC0yLTEtMS02OTk0OQ_13cccaa5-fcc3-4962-9777-f06702cc2896"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="ia22a5f1f807740beb36572d3ab1f91c8_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY182MS9mcmFnOmY0MWY3ZGYxZWMzYTQ3N2FhOWY1NmI1ZGJjMzIyOTMzL3RhYmxlOmU3NDIyMTI5NjZmMDQyZWE5ODA2ZTA2YzJkZWEyY2Y0L3RhYmxlcmFuZ2U6ZTc0MjIxMjk2NmYwNDJlYTk4MDZlMDZjMmRlYTJjZjRfNC00LTEtMS02OTk0OQ_57de793f-027b-4b22-a145-cc3724227bfa"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
      contextRef="ie35b115501ca468f8cadb8213304a30b_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY182MS9mcmFnOmY0MWY3ZGYxZWMzYTQ3N2FhOWY1NmI1ZGJjMzIyOTMzL3RleHRyZWdpb246ZjQxZjdkZjFlYzNhNDc3YWE5ZjU2YjVkYmMzMjI5MzNfMjk3OA_3e8e07c9-d4a2-4a0c-80bb-e0b598bc031b">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The following table summarizes the share-based award activity for the periods presented: &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:53.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.524%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 5.57pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:0.08pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:125%"&gt;Number&#160;of&#160;Shares&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:125%"&gt;Weighted&#160;Average&lt;br/&gt;Exercise&#160;Price&#160;Per&lt;br/&gt;Share &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:125%"&gt;Weighted&#160;Average&lt;br/&gt;Remaining&lt;br/&gt;Contractual&#160;Term&lt;br/&gt;(years) &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;Outstanding at January 1, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 5.57pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;1,341,504&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;3.27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 5.57pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;8.9&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 5.57pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;824,142&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;0.84&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 5.57pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="margin-bottom:0.05pt;margin-top:0.05pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#160;&#160;&#160;&#160;&#160;Forfeited&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 5.57pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="margin-bottom:0.08pt;padding-left:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;Outstanding at March&#160;31, 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 5.57pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;2,165,646&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;2.35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 5.57pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;9.1&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="margin-bottom:0.08pt;padding-left:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;Vested and exercisable at March&#160;31, 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 5.57pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;526,574&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;4.43&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 5.57pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;8.3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="margin-bottom:0.08pt;padding-left:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;Vested and expected to vest at March&#160;31, 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 5.57pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;2,165,646&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;2.35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 5.57pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%"&gt;9.1&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i4b1713eab7d84494b3b43202a26fc3c4_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY182MS9mcmFnOmY0MWY3ZGYxZWMzYTQ3N2FhOWY1NmI1ZGJjMzIyOTMzL3RhYmxlOjIxNDU5MjBhMDZlYzRkOGZiYzRhMjg5YmM1MTYwNThmL3RhYmxlcmFuZ2U6MjE0NTkyMGEwNmVjNGQ4ZmJjNGEyODliYzUxNjA1OGZfMS0xLTEtMS02OTk0OQ_00944b93-d5cc-4d95-99e6-f0b6e064b906"
      unitRef="shares">1341504</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i4b1713eab7d84494b3b43202a26fc3c4_I20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY182MS9mcmFnOmY0MWY3ZGYxZWMzYTQ3N2FhOWY1NmI1ZGJjMzIyOTMzL3RhYmxlOjIxNDU5MjBhMDZlYzRkOGZiYzRhMjg5YmM1MTYwNThmL3RhYmxlcmFuZ2U6MjE0NTkyMGEwNmVjNGQ4ZmJjNGEyODliYzUxNjA1OGZfMS0zLTEtMS02OTk0OQ_a90736ae-25aa-4ad8-9f37-6343ab99a9f7"
      unitRef="usdPerShare">3.27</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="i626f38146e594fbca5a1d17b96610d86_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY182MS9mcmFnOmY0MWY3ZGYxZWMzYTQ3N2FhOWY1NmI1ZGJjMzIyOTMzL3RhYmxlOjIxNDU5MjBhMDZlYzRkOGZiYzRhMjg5YmM1MTYwNThmL3RhYmxlcmFuZ2U6MjE0NTkyMGEwNmVjNGQ4ZmJjNGEyODliYzUxNjA1OGZfMS01LTEtMS02OTk0OQ_3880556f-eec1-4d6d-8973-e64dcb16dafb">P8Y10M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="ie35b115501ca468f8cadb8213304a30b_D20230101-20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY182MS9mcmFnOmY0MWY3ZGYxZWMzYTQ3N2FhOWY1NmI1ZGJjMzIyOTMzL3RhYmxlOjIxNDU5MjBhMDZlYzRkOGZiYzRhMjg5YmM1MTYwNThmL3RhYmxlcmFuZ2U6MjE0NTkyMGEwNmVjNGQ4ZmJjNGEyODliYzUxNjA1OGZfMi0xLTEtMS02OTk0OQ_959c99f3-37e7-41c0-bdbe-2b8741b81ae6"
      unitRef="shares">824142</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="ie35b115501ca468f8cadb8213304a30b_D20230101-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY182MS9mcmFnOmY0MWY3ZGYxZWMzYTQ3N2FhOWY1NmI1ZGJjMzIyOTMzL3RhYmxlOjIxNDU5MjBhMDZlYzRkOGZiYzRhMjg5YmM1MTYwNThmL3RhYmxlcmFuZ2U6MjE0NTkyMGEwNmVjNGQ4ZmJjNGEyODliYzUxNjA1OGZfMi0zLTEtMS02OTk0OQ_3c9c47d0-21af-4b54-9072-80429f42efee"
      unitRef="usdPerShare">0.84</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="ie35b115501ca468f8cadb8213304a30b_D20230101-20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY182MS9mcmFnOmY0MWY3ZGYxZWMzYTQ3N2FhOWY1NmI1ZGJjMzIyOTMzL3RhYmxlOjIxNDU5MjBhMDZlYzRkOGZiYzRhMjg5YmM1MTYwNThmL3RhYmxlcmFuZ2U6MjE0NTkyMGEwNmVjNGQ4ZmJjNGEyODliYzUxNjA1OGZfMy0xLTEtMS02OTk0OQ_d771d579-d25a-4b58-b7de-c0a78951e99c"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="ie35b115501ca468f8cadb8213304a30b_D20230101-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY182MS9mcmFnOmY0MWY3ZGYxZWMzYTQ3N2FhOWY1NmI1ZGJjMzIyOTMzL3RhYmxlOjIxNDU5MjBhMDZlYzRkOGZiYzRhMjg5YmM1MTYwNThmL3RhYmxlcmFuZ2U6MjE0NTkyMGEwNmVjNGQ4ZmJjNGEyODliYzUxNjA1OGZfMy0zLTEtMS02OTk0OQ_b3c99700-2ea9-4fc3-85b8-46ecc65c7441"
      unitRef="usdPerShare">0</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i9e6ffce2c2d247f491e046febe8251cd_I20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY182MS9mcmFnOmY0MWY3ZGYxZWMzYTQ3N2FhOWY1NmI1ZGJjMzIyOTMzL3RhYmxlOjIxNDU5MjBhMDZlYzRkOGZiYzRhMjg5YmM1MTYwNThmL3RhYmxlcmFuZ2U6MjE0NTkyMGEwNmVjNGQ4ZmJjNGEyODliYzUxNjA1OGZfNC0xLTEtMS02OTk0OQ_04eb7f87-35a1-4c87-a2f8-5a47b6281b02"
      unitRef="shares">2165646</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i9e6ffce2c2d247f491e046febe8251cd_I20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY182MS9mcmFnOmY0MWY3ZGYxZWMzYTQ3N2FhOWY1NmI1ZGJjMzIyOTMzL3RhYmxlOjIxNDU5MjBhMDZlYzRkOGZiYzRhMjg5YmM1MTYwNThmL3RhYmxlcmFuZ2U6MjE0NTkyMGEwNmVjNGQ4ZmJjNGEyODliYzUxNjA1OGZfNC0zLTEtMS02OTk0OQ_5ef0f588-0466-4a64-a05b-cb7613bb843b"
      unitRef="usdPerShare">2.35</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="ie35b115501ca468f8cadb8213304a30b_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY182MS9mcmFnOmY0MWY3ZGYxZWMzYTQ3N2FhOWY1NmI1ZGJjMzIyOTMzL3RhYmxlOjIxNDU5MjBhMDZlYzRkOGZiYzRhMjg5YmM1MTYwNThmL3RhYmxlcmFuZ2U6MjE0NTkyMGEwNmVjNGQ4ZmJjNGEyODliYzUxNjA1OGZfNC01LTEtMS02OTk0OQ_a5780a09-b803-4cb1-b029-f98709a2e7e5">P9Y1M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="i9e6ffce2c2d247f491e046febe8251cd_I20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY182MS9mcmFnOmY0MWY3ZGYxZWMzYTQ3N2FhOWY1NmI1ZGJjMzIyOTMzL3RhYmxlOjIxNDU5MjBhMDZlYzRkOGZiYzRhMjg5YmM1MTYwNThmL3RhYmxlcmFuZ2U6MjE0NTkyMGEwNmVjNGQ4ZmJjNGEyODliYzUxNjA1OGZfNS0xLTEtMS02OTk0OQ_1397c8a5-bf7b-473c-a3bb-deaac7a296de"
      unitRef="shares">526574</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="i9e6ffce2c2d247f491e046febe8251cd_I20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY182MS9mcmFnOmY0MWY3ZGYxZWMzYTQ3N2FhOWY1NmI1ZGJjMzIyOTMzL3RhYmxlOjIxNDU5MjBhMDZlYzRkOGZiYzRhMjg5YmM1MTYwNThmL3RhYmxlcmFuZ2U6MjE0NTkyMGEwNmVjNGQ4ZmJjNGEyODliYzUxNjA1OGZfNS0zLTEtMS02OTk0OQ_42e465c3-1f4c-49c7-b784-956da6643151"
      unitRef="usdPerShare">4.43</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="ie35b115501ca468f8cadb8213304a30b_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY182MS9mcmFnOmY0MWY3ZGYxZWMzYTQ3N2FhOWY1NmI1ZGJjMzIyOTMzL3RhYmxlOjIxNDU5MjBhMDZlYzRkOGZiYzRhMjg5YmM1MTYwNThmL3RhYmxlcmFuZ2U6MjE0NTkyMGEwNmVjNGQ4ZmJjNGEyODliYzUxNjA1OGZfNS01LTEtMS02OTk0OQ_e07aa49a-69ae-4713-9f52-f564b84e0511">P8Y3M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
      contextRef="i9e6ffce2c2d247f491e046febe8251cd_I20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY182MS9mcmFnOmY0MWY3ZGYxZWMzYTQ3N2FhOWY1NmI1ZGJjMzIyOTMzL3RhYmxlOjIxNDU5MjBhMDZlYzRkOGZiYzRhMjg5YmM1MTYwNThmL3RhYmxlcmFuZ2U6MjE0NTkyMGEwNmVjNGQ4ZmJjNGEyODliYzUxNjA1OGZfNi0xLTEtMS02OTk0OQ_13369237-d6e3-40e9-b802-2f4c0a00cef0"
      unitRef="shares">2165646</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
      contextRef="i9e6ffce2c2d247f491e046febe8251cd_I20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY182MS9mcmFnOmY0MWY3ZGYxZWMzYTQ3N2FhOWY1NmI1ZGJjMzIyOTMzL3RhYmxlOjIxNDU5MjBhMDZlYzRkOGZiYzRhMjg5YmM1MTYwNThmL3RhYmxlcmFuZ2U6MjE0NTkyMGEwNmVjNGQ4ZmJjNGEyODliYzUxNjA1OGZfNi0zLTEtMS02OTk0OQ_0c40f77b-5752-49e5-94a6-c71cc05c73d4"
      unitRef="usdPerShare">2.35</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
      contextRef="ie35b115501ca468f8cadb8213304a30b_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY182MS9mcmFnOmY0MWY3ZGYxZWMzYTQ3N2FhOWY1NmI1ZGJjMzIyOTMzL3RhYmxlOjIxNDU5MjBhMDZlYzRkOGZiYzRhMjg5YmM1MTYwNThmL3RhYmxlcmFuZ2U6MjE0NTkyMGEwNmVjNGQ4ZmJjNGEyODliYzUxNjA1OGZfNi01LTEtMS02OTk0OQ_c46c573d-7171-4f92-9266-2f39bfabe1be">P9Y1M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="ie35b115501ca468f8cadb8213304a30b_D20230101-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY182MS9mcmFnOmY0MWY3ZGYxZWMzYTQ3N2FhOWY1NmI1ZGJjMzIyOTMzL3RleHRyZWdpb246ZjQxZjdkZjFlYzNhNDc3YWE5ZjU2YjVkYmMzMjI5MzNfMjIwMw_a61973b9-0296-41ed-8aac-db0b2d4af307"
      unitRef="usdPerShare">0.65</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i3baf3250062d4a79a9b120fc56f1b18c_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY182MS9mcmFnOmY0MWY3ZGYxZWMzYTQ3N2FhOWY1NmI1ZGJjMzIyOTMzL3RleHRyZWdpb246ZjQxZjdkZjFlYzNhNDc3YWE5ZjU2YjVkYmMzMjI5MzNfMjIxMA_b3415585-b1e3-4568-8597-f501598f4410"
      unitRef="usdPerShare">1.33</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
      contextRef="i9e6ffce2c2d247f491e046febe8251cd_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY182MS9mcmFnOmY0MWY3ZGYxZWMzYTQ3N2FhOWY1NmI1ZGJjMzIyOTMzL3RleHRyZWdpb246ZjQxZjdkZjFlYzNhNDc3YWE5ZjU2YjVkYmMzMjI5MzNfMjMxOQ_72a1e4ed-a15a-4b30-bf1e-14f9e79bc194"
      unitRef="usd">1900000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="i247dcebb8f8f491b838555cf4a897045_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY182MS9mcmFnOmY0MWY3ZGYxZWMzYTQ3N2FhOWY1NmI1ZGJjMzIyOTMzL3RleHRyZWdpb246ZjQxZjdkZjFlYzNhNDc3YWE5ZjU2YjVkYmMzMjI5MzNfMjQxNA_429e3698-6c94-4c1c-bf46-eb75202b6295">P2Y5M26D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="ie35b115501ca468f8cadb8213304a30b_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY182NC9mcmFnOjIwYTRiZDM4N2RmYjRiOGJhZTc0ZWY1MjNmZGYyY2M0L3RleHRyZWdpb246MjBhNGJkMzg3ZGZiNGI4YmFlNzRlZjUyM2ZkZjJjYzRfNjA1Mw_6e338bed-2e11-46f7-a579-390fbe87620b">Commitments and Contingencies &lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Operating Lease&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In January 2022, the Company entered into a noncancellable operating sublease for corporate office space in Philadelphia, Pennsylvania. The sublease for this space commenced on February 1, 2022 and is set to expire on July 31, 2023. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;As of March&#160;31, 2023, the operating lease right-of-use asset and the operating lease liabilities were $29,892 and $31,669, respectively. The discount rate used to account for the Company&#x2019;s operating leases was the Company&#x2019;s estimated incremental borrowing rate of 5.0%. The remaining term of the Company&#x2019;s noncancellable operating lease is 0.33 years. Future minimum lease payments under the sublease are $32,000 at March&#160;31, 2023.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Rent expense related to the Company&#x2019;s operating lease was approximately $23,000 and $15,000 for the three months ended March&#160;31, 2023 and 2022, respectively. The Company recognizes rent expense on a straight-line basis over the lease period and accrues for rent expense incurred but not yet paid.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In March 2023, the Company entered into a direct lease for this same office space that commences on August 1, 2023 and is set to expire on August 31, 2024, pursuant to which the Company retains the right to renew the lease for an additional one-year term.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Employee Benefit Plans&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In the first quarter of 2022, the Company established a defined contribution 401(k) plan in which employees may contribute up to 100% of their salary and bonus, subject to statutory maximum contribution amounts. The Company contributes a safe harbor minimum contribution equivalent to 3% of employees&#x2019; compensation. The Company generally assumes all administrative costs of the plan. For the three months ended March&#160;31, 2023 and 2022, the Company provided contributions of approximately $40,000 and $25,000, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Collaboration Agreement with Tyligand Bioscience &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In March 2020, the Company entered into a process development agreement (the &#x201c;Tyligand Process Development Agreement&#x201d;) with Tyligand Bioscience (Shanghai) Limited (&#x201c;Tyligand&#x201d;) for the development, manufacturing, registration and future commercialization of ONA-XR. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Under the terms of the Tyligand Process Development Agreement, Tyligand was solely responsible for the design and optimization of an improved manufacturing process for ONA-XR. Upon completion of specific performance-based milestones, Tyligand and the Company entered into a license agreement (the &#x201c;Tyligand License Agreement&#x201d;) whereby Tyligand was granted the exclusive right to ONA-XR and is solely responsible for the development and commercialization of ONA-XR in China, Hong Kong and Macau (the &#x201c;Territory&#x201d;). The Company retains rights in the rest of the world to commercialize ONA-XR. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Under the Tyligand Process Development Agreement, the Company paid Tyligand certain milestone payments upon successful completion of the manufacturing development plan in 2021.  In addition, $2.0 million will be payable upon the completion of scale-up of the first cumulative 100 kilograms of the Good Manufacturing Practices (&#x201c;GMP&#x201d;)-grade compound and $3.0 million upon the Company&#x2019;s completion of scale-up of the first cumulative 300&#160;kilograms of the GMP-grade compound. In consideration of and upon Tyligand&#x2019;s successful completion of the development plan, within 30 days at the end of each calendar quarter, the Company shall pay Tyligand 1% of net sales of finished product utilizing the compound substantially manufactured in accordance with the process and specifications outlined in the Tyligand Process Development Agreement. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Per the Tyligand License Agreement, Tyligand shall pay the Company a non-refundable, non-creditable royalty at a rate in the mid-single digits of the net sales of each product in the Territory in each calendar quarter commencing with the first commercial sale of such product in the field in the Territory and ending upon the latest of (i) the sale of a generic product in the Territory and (ii) 15 years after the date of the first commercial sale of product in the Territory. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Collaboration and Licensing Agreement with Integral Molecular &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;In April 2021, the Company entered into a collaboration and licensing agreement with Integral Molecular, Inc. (&#x201c;Integral&#x201d;) (the &#x201c;Integral License Agreement&#x201d;) for the development of a CLDN6 bispecific monoclonal antibody for cancer therapy. Under the terms of the agreement, Integral and the Company will develop CLDN6 bispecific antibodies that trigger the activation of T cells and eliminate cancer cells displaying CLND6. The Company will conduct preclinical and all clinical development, as well as regulatory and commercial activities through exclusive worldwide rights to develop and commercialize the novel CLDN6 candidates. The payment for the initial upfront license fee as well as subsequent payments for milestones achieved were expensed to acquired in-process research and development. See Note 3. As a part of the agreement, Integral will be eligible to receive remaining development and regulatory milestone payments totaling approximately $55&#160;million, sales milestone payments totaling up to $130.0 million, and tiered royalties of up to 12% of net sales of certain products developed under this agreement. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;On March 20, 2023, the Company amended the Integral License Agreement to remove the previously agreed to second milestone payment and to change the amount of the third milestone payment to increase such payment by the amount of the prior second milestone payment and to add payment for third party research funding obtained and used by Integral in connection with the development of CTIM-76.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%"&gt;Research and Development Arrangements&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In the course of normal business operations, the Company enters into agreements with universities and contract research organizations to assist in the performance of research and development activities and contract manufacturers to assist with chemistry, manufacturing, and controls related expenses. Expenditures to contract research organizations represent a significant cost in clinical development for the Company. The Company could also enter into additional collaborative research, contract research, manufacturing, and supplier agreements in the future, which may&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;require upfront payments and long-term commitments of cash.&lt;/span&gt;&lt;/div&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i9e6ffce2c2d247f491e046febe8251cd_I20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY182NC9mcmFnOjIwYTRiZDM4N2RmYjRiOGJhZTc0ZWY1MjNmZGYyY2M0L3RleHRyZWdpb246MjBhNGJkMzg3ZGZiNGI4YmFlNzRlZjUyM2ZkZjJjYzRfMzgy_7dcd5cd6-58a9-4c63-9339-b580497b9466"
      unitRef="usd">29892</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiability
      contextRef="i9e6ffce2c2d247f491e046febe8251cd_I20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY182NC9mcmFnOjIwYTRiZDM4N2RmYjRiOGJhZTc0ZWY1MjNmZGYyY2M0L3RleHRyZWdpb246MjBhNGJkMzg3ZGZiNGI4YmFlNzRlZjUyM2ZkZjJjYzRfMzg5_89a4b63a-a436-4d69-b29d-cac2ba242637"
      unitRef="usd">31669</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="i9e6ffce2c2d247f491e046febe8251cd_I20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY182NC9mcmFnOjIwYTRiZDM4N2RmYjRiOGJhZTc0ZWY1MjNmZGYyY2M0L3RleHRyZWdpb246MjBhNGJkMzg3ZGZiNGI4YmFlNzRlZjUyM2ZkZjJjYzRfNTY2_8024d9bd-30ae-4e95-8b0f-4bbd1adc3e0e"
      unitRef="number">0.050</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:LesseeOperatingLeaseRemainingLeaseTerm
      contextRef="i9e6ffce2c2d247f491e046febe8251cd_I20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY182NC9mcmFnOjIwYTRiZDM4N2RmYjRiOGJhZTc0ZWY1MjNmZGYyY2M0L3RleHRyZWdpb246MjBhNGJkMzg3ZGZiNGI4YmFlNzRlZjUyM2ZkZjJjYzRfNjQw_b1a8b410-9d43-4dd6-a119-ea5450053314">P0Y3M29D</us-gaap:LesseeOperatingLeaseRemainingLeaseTerm>
    <us-gaap:LessorOperatingLeasePaymentsToBeReceived
      contextRef="i9e6ffce2c2d247f491e046febe8251cd_I20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY182NC9mcmFnOjIwYTRiZDM4N2RmYjRiOGJhZTc0ZWY1MjNmZGYyY2M0L3RleHRyZWdpb246MjBhNGJkMzg3ZGZiNGI4YmFlNzRlZjUyM2ZkZjJjYzRfMzg0ODI5MDcwMzQ2Mg_c779abe8-8845-4236-bbcb-ebf39ea88390"
      unitRef="usd">32000</us-gaap:LessorOperatingLeasePaymentsToBeReceived>
    <us-gaap:OperatingLeaseCost
      contextRef="ie35b115501ca468f8cadb8213304a30b_D20230101-20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY182NC9mcmFnOjIwYTRiZDM4N2RmYjRiOGJhZTc0ZWY1MjNmZGYyY2M0L3RleHRyZWdpb246MjBhNGJkMzg3ZGZiNGI4YmFlNzRlZjUyM2ZkZjJjYzRfNzE3_8596d5cd-9082-4766-bb46-7c7a76deaba9"
      unitRef="usd">23000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="i3baf3250062d4a79a9b120fc56f1b18c_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY182NC9mcmFnOjIwYTRiZDM4N2RmYjRiOGJhZTc0ZWY1MjNmZGYyY2M0L3RleHRyZWdpb246MjBhNGJkMzg3ZGZiNGI4YmFlNzRlZjUyM2ZkZjJjYzRfNzI0_d979ffa6-5df7-4c17-b400-fd17c35a9ceb"
      unitRef="usd">15000</us-gaap:OperatingLeaseCost>
    <us-gaap:LesseeOperatingLeaseRenewalTerm
      contextRef="i9e6ffce2c2d247f491e046febe8251cd_I20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY182NC9mcmFnOjIwYTRiZDM4N2RmYjRiOGJhZTc0ZWY1MjNmZGYyY2M0L3RleHRyZWdpb246MjBhNGJkMzg3ZGZiNGI4YmFlNzRlZjUyM2ZkZjJjYzRfMTY0OTI2NzQ1MTcxNA_b75b2521-75c9-45e4-aca7-2f728257b3d9">P1Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent
      contextRef="ie35b115501ca468f8cadb8213304a30b_D20230101-20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY182NC9mcmFnOjIwYTRiZDM4N2RmYjRiOGJhZTc0ZWY1MjNmZGYyY2M0L3RleHRyZWdpb246MjBhNGJkMzg3ZGZiNGI4YmFlNzRlZjUyM2ZkZjJjYzRfMTE1NA_b833c3c7-824e-4215-8399-573f16091f7e"
      unitRef="number">1</us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent>
    <us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent
      contextRef="ie35b115501ca468f8cadb8213304a30b_D20230101-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY182NC9mcmFnOjIwYTRiZDM4N2RmYjRiOGJhZTc0ZWY1MjNmZGYyY2M0L3RleHRyZWdpb246MjBhNGJkMzg3ZGZiNGI4YmFlNzRlZjUyM2ZkZjJjYzRfMTMwOA_82c9a380-3a09-45cb-8f67-1630cc15ac2a"
      unitRef="number">0.03</us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent>
    <us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount
      contextRef="ie35b115501ca468f8cadb8213304a30b_D20230101-20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY182NC9mcmFnOjIwYTRiZDM4N2RmYjRiOGJhZTc0ZWY1MjNmZGYyY2M0L3RleHRyZWdpb246MjBhNGJkMzg3ZGZiNGI4YmFlNzRlZjUyM2ZkZjJjYzRfMTQ5OQ_bb5c0180-4c78-461c-9c1a-58530bf419a1"
      unitRef="usd">40000</us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount>
    <us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount
      contextRef="i3baf3250062d4a79a9b120fc56f1b18c_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY182NC9mcmFnOjIwYTRiZDM4N2RmYjRiOGJhZTc0ZWY1MjNmZGYyY2M0L3RleHRyZWdpb246MjBhNGJkMzg3ZGZiNGI4YmFlNzRlZjUyM2ZkZjJjYzRfMTUwNg_50ac228b-e808-4dcd-b075-3014e43b16b6"
      unitRef="usd">25000</us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount>
    <cntx:CollaborativeArrangementRightsAndObligationsMilestonePayment
      contextRef="ie4f3b47997974a9c92cf0116fb61189f_I20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY182NC9mcmFnOjIwYTRiZDM4N2RmYjRiOGJhZTc0ZWY1MjNmZGYyY2M0L3RleHRyZWdpb246MjBhNGJkMzg3ZGZiNGI4YmFlNzRlZjUyM2ZkZjJjYzRfMjg4Mw_3555c3e6-bc20-41ee-bd65-3afcac3ac404"
      unitRef="usd">2000000</cntx:CollaborativeArrangementRightsAndObligationsMilestonePayment>
    <cntx:CollaborativeArrangementRightsAndObligationsMilestonePayment
      contextRef="i4798e3c1b6ca496686ec4fd693e57cd8_I20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY182NC9mcmFnOjIwYTRiZDM4N2RmYjRiOGJhZTc0ZWY1MjNmZGYyY2M0L3RleHRyZWdpb246MjBhNGJkMzg3ZGZiNGI4YmFlNzRlZjUyM2ZkZjJjYzRfMzAzNQ_8b85cc74-39ad-4210-b8a2-3b5ec989f286"
      unitRef="usd">3000000</cntx:CollaborativeArrangementRightsAndObligationsMilestonePayment>
    <cntx:CollaborativeArrangementRightsAndObligationsQuarterlySalesPaymentsPercent
      contextRef="i6b2d762a98f94d569b10a0723338a465_D20200301-20200331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY182NC9mcmFnOjIwYTRiZDM4N2RmYjRiOGJhZTc0ZWY1MjNmZGYyY2M0L3RleHRyZWdpb246MjBhNGJkMzg3ZGZiNGI4YmFlNzRlZjUyM2ZkZjJjYzRfMzMxNQ_40235db2-6cd6-4a52-9e50-c1621f90a494"
      unitRef="number">0.01</cntx:CollaborativeArrangementRightsAndObligationsQuarterlySalesPaymentsPercent>
    <cntx:CollaborativeArrangementRightsAndObligationsSalesPaymentPeriod
      contextRef="i6b2d762a98f94d569b10a0723338a465_D20200301-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY182NC9mcmFnOjIwYTRiZDM4N2RmYjRiOGJhZTc0ZWY1MjNmZGYyY2M0L3RleHRyZWdpb246MjBhNGJkMzg3ZGZiNGI4YmFlNzRlZjUyM2ZkZjJjYzRfMzkwNA_cdebf6e1-07c6-41ee-960f-0c58d6ca24d3">P15Y</cntx:CollaborativeArrangementRightsAndObligationsSalesPaymentPeriod>
    <cntx:CollaborativeArrangementRightsAndObligationsDevelopmentAndRegulatoryMilestonePaymentsMaximum
      contextRef="icadec7fbbc8a431cbf67adac36bb34b1_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY182NC9mcmFnOjIwYTRiZDM4N2RmYjRiOGJhZTc0ZWY1MjNmZGYyY2M0L3RleHRyZWdpb246MjBhNGJkMzg3ZGZiNGI4YmFlNzRlZjUyM2ZkZjJjYzRfNTA1Ng_8b4710d9-386b-4bb1-93d1-0a9c08e9c323"
      unitRef="usd">55000000</cntx:CollaborativeArrangementRightsAndObligationsDevelopmentAndRegulatoryMilestonePaymentsMaximum>
    <cntx:CollaborativeArrangementRightsAndObligationsSalesMilestonePaymentsMaximum
      contextRef="ibffbea9aff4c4a0a9c67a9e90540390f_I20210430"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY182NC9mcmFnOjIwYTRiZDM4N2RmYjRiOGJhZTc0ZWY1MjNmZGYyY2M0L3RleHRyZWdpb246MjBhNGJkMzg3ZGZiNGI4YmFlNzRlZjUyM2ZkZjJjYzRfNTEwMA_67796fe2-95da-4a1d-bf88-91dd7cd4b255"
      unitRef="usd">130000000</cntx:CollaborativeArrangementRightsAndObligationsSalesMilestonePaymentsMaximum>
    <cntx:CollaborativeArrangementRightsAndObligationsTieredRoyaltyPercent
      contextRef="ibffbea9aff4c4a0a9c67a9e90540390f_I20210430"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMTRlMDFhOTdiMTQ2M2I5MTUxOTJhOWVmZjkzZjBjL3NlYzpiZDE0ZTAxYTk3YjE0NjNiOTE1MTkyYTllZmY5M2YwY182NC9mcmFnOjIwYTRiZDM4N2RmYjRiOGJhZTc0ZWY1MjNmZGYyY2M0L3RleHRyZWdpb246MjBhNGJkMzg3ZGZiNGI4YmFlNzRlZjUyM2ZkZjJjYzRfNTEzNA_7806f709-8521-4839-b191-6a8fa5d92a74"
      unitRef="number">0.12</cntx:CollaborativeArrangementRightsAndObligationsTieredRoyaltyPercent>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>45
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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MFE&/"74 _+[D7!XWU!_(_X?"X']02P,$%     @ 6X2J5H)/4T0C!0  .10
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MAFE0N^]4NQLCZ_93SYTT1I;MY98S@&X-X/U&2O-Z8[\>=5\+5_\"4$L#!!0
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M0AO _)IS=>CH!?I?">DW4$L#!!0    ( %N$JE:)H-LYNP0  ' 8   8
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M8'F2*0'Y?,68>+]0GX3K?S+,_P%02P,$%     @ 6X2J5A8>^.]E!@  3QP
M !@   !X;"]W;W)K<VAE971S+W-H965T-BYX;6RU65MOVS84_BN$-PPM4-<B
MJ6N6&$C<%>M#5R-!MV=:HFVNDNB2M)/LUX^D;,N6*#8!W)=$D@^/OG/]#L7K
M1RZ^R36E"CQ592UO1FNE-E>3B<S7M"+R/=_06O^RY*(B2M^*U41N!"6%7525
M$Q0$\:0BK!Y-K^VSN9A>\ZTJ64WG LAM51'Q?$=+_G@S@J/#@WNV6BOS8#*]
MWI 5?:#JZV8N]-WDJ*5@%:TEXS40='DSNH57,VP76(F_&7V4)]? F++@_)NY
M^53<C *#B)8T5T8%T?]V=$;+TFC2.+[OE8Z.[S0+3Z\/VC]:X[4Q"R+IC)?_
ML$*M;T;I"!1T2;:ENN>/?]*]09'1E_-2VK_@<2\;C$"^E8I7^\4:0<7JYC]Y
MVCOB9('6XUZ ]@M0=T$XL #O%V!K:(/,FO6!*#*]%OP1"".MM9D+ZQN[6EO#
M:A/&!R7TKTRO4],9KPL=%%H ?25YR0JB],V#TO]TM!3@2S C<@T^ZH!+\.9K
M3;8%TR)OP1A\??@ WOSZ]GJB-!*C;Y+OWWK7O!4-O!6#S[Q6:PG^T&\OSM=/
MM 5',]#!C#OD5?B9B/< PW< !0@[\,Q>OAQYX."C5['5AX>\:CRVM!Y;"EX!
M776"*%:OFK1EBE%YY7);HS9TJS4E?24W)*<W(UVSDHH='4U_^P7&P>\NFR^D
M[,P#X=$#H4_[]"_=@4HNI<O(9F5L5YHVLYN.8QRD&*;7D]VI 0Y!'.(4X^0H
M> 8N.H*+O.&Y+?[5E6726P+%=3?*>9VSDH)ZC]H\-=>YB>/65 >K7Q[$Z))!
MO)"R,S_%1S_%WB ^K(F@8],E"Y#S2E.')+;YTB=S35W&-QJCDYBA%"4QZH36
M(0;#+$K=@4V.@!,OX ]4>R%G#4A2%X!47"CVWP]1)STX&&:X@[DO%+CAID>X
MJ1?N/2VV#9OI]%)KJO--B&>;817?-LVWS;J2ZD  87AIS)=CG9: 2$F5RYZT
M[UX4)%''H+X4# ,$W49E1Z,R?^];DWI%9:=B#%!I0U(RLF#E</5DEZR>"RD[
M<P0,6FX-O/&="[HAK#@D7F,_UX$6FMJ%,/3:.,;)H$$_AC@+D[@31(=<F,$@
MPNXPPI/) 'K1?[% /0!A[\5QU"MTA]08A4$P4#H0M?"0%]YMGIL:D6!#GLFB
M=);U7L69#Q.<8=@%V9<;0Q1G.,T&8+:3 /32K($IMM2; R<5X30".SR(P@0E
M72OZ@C!+,0H';&BY'/K)_$NG!QT /SOAA@ZX. RR+EJ'7)S!@>X#6VZ'7DIL
M9B\?9SM!1WTP48+2,.KV3)<D3O7<F XA;]D6QJ^:&EF]H_(E P?TTOAK>^:E
MM)U[H:5PZ.?P^5;D:Y-EFOPVP@10/=NBH=^W;&.&-J<+?.2\MZLOHL?)+!LJ
M\9;%H9_&SS+.%30GX#[Y]@#W1;R 6X:&/Z#H3J(M64WT /R"1+LH.5]*V_F.
ML65GY&?GL["Y7.#R .JS;3=L#I$Q#/3X-= @4,O(R,_(9E-5T%S8)JQ!F^W)
MNV:38HIC1TJ[I3'%HAVF!,O-7M[\[C3%P<SNGN>2Q%F4X&C(I);%D9_%9R\V
M 1 %%G3%ZMI$R30'*A@OG);UZ1Q'89:$8<^ROF28Q6D4I?& 92WQ(S_QV_0R
M=O2-4X":(<!K0I_+49;$:9;UTJTO&9HP(AP-F-#R/@J]?>)AN]F4]C,0*4'!
M9*[WQEMA.W/-ZW$3%7_'0-[)XK4=XU+:SOW1CA;(/UK<]_9>@"\4T5*VA]"G
MW.Y]P)*+_:3$%R5;V=VGTSG]6:(7W;X(Q$&8#FR443ML(/_>?BYT/BH*YJ7V
MUQ"K^G6\.GH_8[! [6"!DI_#>L@[L+S:"Q?2=NZ%=EA!_F%E3IZ;#U\F2?ER
MJ3N0]D#.I7XD:&F__BINOT9L]BFR.:0(D+J#F>K/>57Q&DC%\V].C_UXN'&(
M^%FRG6Z0=VZ8?I+2;+B,?<9]+!]@\HO.,I?2=OZYN9UE</"S.S7V3DNO_O9\
M(6WG_F@G)>R?E$P.Z.*V#G@D0I!#QA\RPFPM=JQW^+!W!>Q]>.ZFKT,$Z\$)
M=S]K3$Z.9BHJ5O;$2@+[Z:(YWC@^/9Z*W=JSH,[S.W@U:\ZV6C7-4=MG(O14
M)#7C++7*X'VB:THTIU?-C>(;>P"TX$KQREZN*2FH, +Z]R7GZG!C7G \0YS^
M#U!+ P04    " !;A*I6R:\?0/,#  "A"   &    'AL+W=O<FMS:&5E=',O
M<VAE970W+GAM;*U6;6_;-A#^*P<5*#H@L?R2)D5B&W"2%0W0M$'2O0##/M#D
M22)*D2I)Q<Y^_>ZHER98%A38OE@B=??<\]P=>5[NG/\:*L0(^]K8L,JJ&)O3
M/ ^RPEJ$B6O0TI?"^5I$6OHR#XU'H9)3;?+Y='J<UT+;;+U,>S=^O71M--KB
MC8?0UK7P#^=HW&Z5S;)AXU:75>2-?+UL1(EW&']I;CRM\A%%Z1IMT,Z"QV*5
M;6:GYT=LGPQ^U;@+C]Z!E6R=^\J+*[7*IDP(#<K("((>]WB!QC 0T?C68V9C
M2'9\_#Z@OT_:2<M6!+QPYC>M8K7*WF6@L!"MB;=N]P%[/6\93SH3TB_L>MMI
M!K(-T=6],S&HM>V>8M_GX4<<YKW#//'N B66ER**]=*['7BV)C1^25*3-Y'3
MEHMR%SU]U>07UY]]*:S^2W0IL@HN,4BOF[1V!9RW@3Q"6.:1HK%/+GOD\PYY
M_B_("[AV-E8!?K8*U5/_G%B.5.<#U?/YBX#7PD]@,3N ^72^> %O,4I?)+S%
M#T@_@ MG@S-:?<_$C<> -HHA%>^U%59J8>".-I$Z,P;X8[,-T5-O_?E<ACH"
M1\\3X/-V&AHA<94U',O?8[9^_6IV/#U[0=[1*._H)?3_5-G_!YES&G$?X4N%
M7C381BT#7%DY@3>Q0GC]ZMU\/CV[<'4C[$-:S<Y^ AU P%:[IA)T[&1RHZ3+
MSHR.G*)U1 71@:X;[^ZU+8$!#1WPP P:XI;*0SO\<:=C!9*JA]1"Q 8>Q9R=
MG 6@_$N2F0(1HFIE9'O%_8#4'%^NK@]/C@\2-]8<]>'%Y0+V_:L1K=(6CN'-
MH.GCY:?C41$;E6A)5&A0ZD)+J)UUTCA+\?CKUJF'T7D;-MO1-U8B<EA-J>2#
MQ*H]I8 (4V(/)=UGAS6M4T;,0R#3Z';"*[HEC"ZI94D)&07 /7=9X'PD>D\R
M 950($QPL$5BJO">[NN&;8ECXS5=1!8)HB?AZ5JENW"D_/G3YO#WVX'T!#ZX
M'2%X2I@%.K>R2H?V(%5IB"BL=2V51(&F2C6&$DO:E Z2VD;;%I-USX1/&U<V
M5CK\LT*I"PM']V7"PH*F%3VI'9^!Z(LY@8TQ@"'J.N6.JA&0QA8U6B!?$8*3
M7593]S!0IY+#EU[4L$./E GI2CH-+(/'5, DEPD]CDO)ITE&7%H_=&NA?8CP
MK14^HF=BG**G15&.^MFZSIT$<\=;V7HHVMA2<&;N^4;JX0,79C@;0ZJ8Z^2Y
M"R5_-#9J]&4:CH'TMS9V$V3<'>?OIAL[W\V[X4TU+K6E\X8%N4XG)V\S\-U
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MQY+R\QKU^\AM94K11-@]H$RE+]VCXB(H("HEX6 IK;S6+:_Z-4R&^MH5Y[G
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M?Q.LVJ?PT;S]H"!J&V6HAV%-KI/QR7$D7/M(MQ.T=7@8,XOTS(9A2=\UX-B
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M6;JHN<\EO9E1,P&=SY6R[8(5=*_PBW\!4$L#!!0    ( %N$JE;Z!$3.W H
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MJFS./S.%6<;1 GQ?6A2!^$ ,VIO:B_\ 4$L#!!0    ( %N$JE:RK(V59 P
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M5O(HA7.+__+Z]V=7Y]G()ES\67;Q9Y.^.>&!8XX^38Q<]MN\--D^RR/9:O;
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M6G=04-I865,'-]FS-CH[EEBVH$.'0'$,OZ5B5)Q=78A?;:,+\?+XV4R<=U,
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M.;F?!#8M3>T$&$C"P60<3D83&(2#:1PF%/' M"8B ^-P.HG#.(Z/1M,P3EK
M51B/6L"IFX^.WG2%>N<[EP%?C>WS[E?[YKAL>\)K>-M9R<6.DU:!!4'CRZMQ
M +KM5NW$JMIWB*VRU&_\L*0&C]H%T'ZAZ+ZZB4O0_V6D_P!02P,$%     @
M6X2J5L/Y/F$! P  V08  !D   !X;"]W;W)K<VAE971S+W-H965T,3<N>&UL
MM55=3]LP%/TK5]F$0*I(FO+1E;92"T-#&EH'C#U,>W"2V\;"L8/MM/3?[]I)
M0V'0/>TEL9U[SSW']CT9KI1^,#FBA:="2#,*<FO+01B:-,>"F4-5HJ0O<Z4+
M9FFJ%Z$I-;+,)Q4BC*/H)"P8E\%XZ-=F>CQ4E15<XDR#J8J"Z?44A5J-@FZP
M6;CAB]RZA7 \+-D";]'^*&>:9F&+DO$"I>%*@L;Y*)AT!],C%^\#[CFNS-88
MG))$J0<WN<I&0>0(H<#4.@1&KR6>HQ .B&@\-IA!6](E;H\WZ)=>.VE)F,%S
M)7[RS.:CH!] AG-6"7NC5E^PT7/L\%(EC'_"JHX]/0X@K8Q519-,# HNZS=[
M:O9A*Z$?O9,0-PFQYUT7\BPOF&7CH58KT"Z:T-S 2_791(Y+=RBW5M-73GEV
M?,FXAGLF*H1K9*;22#MN#>S?L42@.1B&EJJXV#!M$*<U8OP.8@^NE;2Y@<\R
MP^QE?DCL6HKQAN(TW@EXS?0A]+H=B*.XMP.OUTKN>;S>OR5?<),*Y50;^#5)
MC-5T2WZ_I;F&/'H;TG7.P)0LQ5% K6%0+S$8[WWHGD1G.P@?M82/=J&/;ZD3
MLTH@J#D\D^_ Q!BDHV(R@Z^<)5QPRTE(<XX9T*6_P;32FLL%3)GAYBUENVM?
MN<9)E<Z83)'NILW!Y@AS1V/I]S#GJ)E.\S4U@TDU3Z@R2]22"/I():CQ'0/K
M;A1XRF0F#="Y*DHFUWL?^G'W](S$/&L26YJ*C29FMVN[MB9KV&A,G,8!7#LZ
M[8V!.V69@.^5LI0_TSPE/"YAXOT ;OE"\CE/F;3PC1CI%RN77))P3OD-L7-F
M<L#'BA,!WR@?(>YTCZ-.OQN]&GM-\=G6Z )3+!(JT7"+_S.W?>I$7+O]>"![
MG] Y5K1\0(RZG=.XU^E_ZKT:_\7YK>L;;ME-@7KA3=6 1Z^=IUUM?7M2V]5S
M>&WZ1&W!I0&!<TJ-#IU-ZMI(ZXE5I3>O1%FR0C_,Z=^#V@70][FBK6LFKD#[
M-QO_ 5!+ P04    " !;A*I67%(;',L"  #X!0  &0   'AL+W=O<FMS:&5E
M=',O<VAE970Q."YX;6Q]5&UOTS 0_BNG,"&0HN6];[25V@X$$A/5-N #XH.;
M7!IK3EQL=]W^/6<G#47J^B4YVW?//?<Z/4CUJ"M$ \^U:/3,JXS938) YQ76
M3%_+'3;T4DI5,T-'M0WT3B$KG%$M@C@,!T'->./-I^YNK>93N3>"-[A6H/=U
MS=3+$H4\S+S(.U[<\6UE[$4PG^[8%N_1?-^M%9V"'J7@-3::RP84EC-O$4V6
MJ=5W"C\X'O2)##:2C92/]O"EF'FA)80"<V,1&/V><(5"6""B\:?#]'J7UO!4
M/J)_<K%3+!NF<27%3UZ8:N:-/"BP9'MA[N3A,W;Q9!8OET*[+QQ:W6S@0;[7
M1M:=,3&H>=/^V7.7AQ.#4?B*0=P9Q(YWZ\BQO&&&S:=*'D!9;4*S@@O561,Y
MWMBBW!M%KYSLS'R1YVJ/!7Q\IC)KU,": KZ9"A6L]DIA8^ K9QLNN.'T^NZ!
M;03J]]/ D',+$>2=HV7K*'[%40*WLC&5AH]-@<7_]@&1[IG'1^;+^"+@+5/7
MD$0^Q&&<7,!+^DPD#B]Y!6_-7EQL+@,N+4QH^+78:*.H=WZ?"[E%3,\CVGF:
MZ!W+<>;1P&A43^C-W[Z)!N&'"WS3GF]Z"7U^3_-9[ 6"+.%8Q9-2G:-[$? \
MW2,RGO:'=/V1=_TA3OHCES2NVI !L2(M**6@N>?-=@)4L+SJ*P8WF&.](9SN
M)H:5K*T3UHXK^=E@@R4W&JX@CC(_S$*2AL.0I SNB*)#M)H%/M%^V=663RXU
MF43^(![[8922E&0C?Q@.8:UDB=KN$R:@1.(;A8D?)1$D_CB+NKY/4S].AS!*
M_#0;P(,TI'Q%*.-QY*=I;,GX<33PH\$8SM4Q.)G&&M76[1R;FGUCVL'L;_NU
MMFBG^9]ZNQ,I95O>:!!8DFEX/<P\4.V>:0]&[MQL;Z2A3>'$BE8S*JM [Z64
MYGBP#OIE/_\+4$L#!!0    ( %N$JE8QIL+QT0(  !4&   9    >&PO=V]R
M:W-H965T<R]S:&5E=#$Y+GAM;(55VV[;, S]%<(;=@&"V'$N[;(D0'H9U@%%
M@Z9;'X8]*#83"Y4E3Z*;]N]'V8Z;#6GV8HD2>7@HZ="3K;$/+D,D>,J5=M,@
M(RK&8>B2#'/ANJ9 S3MK8W-!;-I-Z J+(JV"<A7&430*<R%U,)M4:PL[FYB2
ME-2XL.#*/!?V^0R5V4Z#7K!;N)6;C/Q".)L48H-+I._%PK(5MBBIS%$[:318
M7$^#>6]\-O#^E<,/B5NW-P=?R<J8!V]<I=,@\H1084(>0?#PB.>HE =B&K\;
MS*!-Z0/WYSOT+U7M7,M*.#PWZEZFE$V#TP!27(M2T:W9?L6FGJ''2XQRU1>V
MM6__4P!)Z<CD33 SR*6N1_'4G,->P&GT2D#<!,05[SI1Q?)"D)A-K-F"]=Z,
MYB=5J54TDY/:7\J2+.]*CJ/9DDSRD!F5HG7OX?)W*>D9/MR)E4+W<1(2I_".
M8=+ G=5P\2MP?;@VFC('ESK%]._XD*FU_.(=O[/X*."UL%WH]SH01W'_"%Z_
MK;=?X?5?P;O#O#"6G]^NU@OI$F5<:1%^SE>.++^37X<*KW$'AW&]=L:N$ E.
M Q:'0_N(P>S=F]XH^GR$]:!E/3B&/ENR%M-2(9@UW MKA28'-R4Y$CJ5>G.(
M[W'$.0$?;9*U9]L!RA#.35X(_0R92"M[;13+EC/ =I?6O*0%,BPK/D<^O,3D
M.:O,^?<TWN<&ET]H$^D0"BL39+.05E223 6A@ROG2DQ!:L;0NE'K5E+F>?7@
M:G$#\3#J1%$$;V'4C8=PDY!9H?7[H_^%<])'3@.%XLOA;D(P[/P#]ZW4Z)U/
M]K#8C+EZZT$=*]P7XF^5*W#0'^WB>U&7QPMDZ(;0">.?UON'+C[<DVJ.=E,U
M),=92DVU:MO5MN?-:ZF_N-<-D^]O([4#A6L.C;HGPP!LW81J@TQ1"7]EB-M(
M-<VX;Z/U#KR_-H9VAD_0_@EF?P!02P,$%     @ 6X2J5GTP@=AE!   CPH
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M<B@G#N_ .!X8Q\$O><1O#-F/RY6QVIWZGV-T.K]TW,]7@@O34@8SW/I=TUO
M^:L7D_/HPQBKYS0KGLGL@&,R<$R.N>=+R:79:"@1;3S0,7*=PWEP\"5OF\?O
MIY'_962[3^7HJ_Z7RC.9'5!)!RKI42HWX X29]9A8=348U#2!U#^IO'/B.)A
MQ/2 :I<[V:M$_MIP'_+:;1H24#E==/9VBI'N2G'7L:H-Q6FEK"MUH5F[VPNT
M#W#SE5+VON/KW7 ?YG\ 4$L#!!0    ( %N$JE9C4!>D0 ,  .X,   9
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MT,/?B]QX@V$I@[M3.68@E[:@5L26>&515(_61?O$EJHOQJ>FF+<5Z3--^26
M)<^2<4526""E=]Y'KV197)<=+7);GSX(C=6N;:[P@P2D,<#YA1!ZVS$+U)\X
MX_]02P,$%     @ 6X2J5E)46[[] @  JPP  !D   !X;"]W;W)K<VAE971S
M+W-H965T,C0N>&ULK5=K3]LP%/TK5C9-( WRZI.UD48KQ*0A(2K89S>Y:2T<
MN]A."_]^=A),,T)6U'QI_+CGY)[KD^9FLN/B4:X!%'K.*)-39ZW4YL)U9;R&
M#,MSO@&F=U(N,JST5*Q<N1& DP*443?PO(&;8<*<:%*LW8IHPG-%"8-;@62>
M95B\7 +ENZGC.Z\+=V2U5F;!C28;O((%J/O-K= SU[(D) ,F"6=(0#IU?OH7
M,S\P@"+B@<!.[HV1D;+D_-%,?B53QS,9 858&0JL+UN8 :6&2>?Q5)$Z]IX&
MN#]^9;\JQ&LQ2RQAQND?DJCUU!DY*($4YU3=\=TU5(+ZAB_F5!:_:%?%>@Z*
M<ZEX5H%U!AEAY14_5X78 _B]#P!!!0@.!805("R$EID5LN98X6@B^ X)$ZW9
MS*"H38'6:@@SQ[A00N\2C5/1%28"/6": [H!+',!^HR41&=HH1V3Y!003Q&6
M$O0B9@FB!"\))8J 1%F)2!!6*#5$VX+(G(X^XC@7@K"5J3*1Z&0."A,J3S7U
MG=T[0S><P8M6)!ZU9].<)>;>]XLY.OEZ.G&5EF@2=>-*SF4I)_A S@T6YRCT
MOZ/ "\(&^*P=/H?8PH,ZW-6%M=4-;'6#@B_\J+J$81833*L*-@DJ&7K-#.8I
MOI ;',/4T8^I!+$%)_KVQ1]X/YKD=416$QM:L6$;>S3#<HW@*2?:!<9#36)+
MAD'!8/YAME'@][V1[TW<[;Z.]W'^, A'X]#&U5+LV11[K2G^ABU0Y#=EU@K\
M[#%T1%;3V+<:^T=[KM^EV([(:F('5NS@:,^5#/W_>NY]7*OGAC;%X0&>"YHR
M:P5^]A@Z(JMI'%F-HZ,]-^I2;$=D-;%C*W9\M.?&[[STK]O:(FII^=[;J]P[
MP&E-K[W+=N1GJ]\56UWG7LOB'^VVBJ(KP1VQU06_=1%^ZWO[(,=5%(,6R[6&
ME*FY>YVD:>-U/[4B3"(*J<9XYT-M6%%VQN5$\4W17"ZYTJUJ,5SKKPD0)D#O
MIYRKUXGI5^WW2?074$L#!!0    ( %N$JE:?Q<$WU (  +P'   9    >&PO
M=V]R:W-H965T<R]S:&5E=#(U+GAM;*U576_3,!3]*U9 :)-@B?.YCC;2UH)
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M3PI\K3M"@73P+(H^H5JMNLZI[K6.UF>J&]4MU3-,T<IB%[".,T$26"&D=3[
M5XT7W6$QD2S7#=8]D]BNZ6&$'35P%8#/5XS)_41M4/7H_E]02P,$%     @
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M2-,;V4S!FFG1*)_E9MX?M,2O#'$Z'@O.F<:)U(3F*1F+7+-\#GG"0)$+\J4
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M D\CCF .P .&Q+%]#^Z\CZ+5>RI:_W]O]!M02P,$%     @ 6X2J5I>*NQS
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M;%!+ 0(4 Q0    ( %N$JE;8]I#G[P   "L"   1              "  :\
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M2P$"% ,4    " !;A*I6D;E,5/8"  !A"@  &               @(&J$P
M>&PO=V]R:W-H965T<R]S:&5E=#,N>&UL4$L! A0#%     @ 6X2J5H#0V#*[
M P  ,0P  !@              ("!UA8  'AL+W=O<FMS:&5E=',O<VAE970T
M+GAM;%!+ 0(4 Q0    ( %N$JE:)H-LYNP0  ' 8   8              "
M@<<:  !X;"]W;W)K<VAE971S+W-H965T-2YX;6Q02P$"% ,4    " !;A*I6
M%A[X[V4&  !/'   &               @(&X'P  >&PO=V]R:W-H965T<R]S
M:&5E=#8N>&UL4$L! A0#%     @ 6X2J5LFO'T#S P  H0@  !@
M     ("!4R8  'AL+W=O<FMS:&5E=',O<VAE970W+GAM;%!+ 0(4 Q0    (
M %N$JE8N'\#N9P4  /0,   8              " @7PJ  !X;"]W;W)K<VAE
M971S+W-H965T."YX;6Q02P$"% ,4    " !;A*I6YP\1J!<1  "',0  &
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M970Q,RYX;6Q02P$"% ,4    " !;A*I6^@1$SMP*  "U'0  &0
M    @(%J4P  >&PO=V]R:W-H965T<R]S:&5E=#$T+GAM;%!+ 0(4 Q0    (
M %N$JE:RK(V59 P  'TE   9              " @7U>  !X;"]W;W)K<VAE
M971S+W-H965T,34N>&UL4$L! A0#%     @ 6X2J5M<BI6K> @  /@8  !D
M             ("!&&L  'AL+W=O<FMS:&5E=',O<VAE970Q-BYX;6Q02P$"
M% ,4    " !;A*I6P_D^80$#  #9!@  &0              @($M;@  >&PO
M=V]R:W-H965T<R]S:&5E=#$W+GAM;%!+ 0(4 Q0    ( %N$JE9<4AL<RP(
M /@%   9              " @65Q  !X;"]W;W)K<VAE971S+W-H965T,3@N
M>&UL4$L! A0#%     @ 6X2J5C&FPO'1 @  %08  !D              ("!
M9W0  'AL+W=O<FMS:&5E=',O<VAE970Q.2YX;6Q02P$"% ,4    " !;A*I6
M?3"!V&4$  "/"@  &0              @(%O=P  >&PO=V]R:W-H965T<R]S
M:&5E=#(P+GAM;%!+ 0(4 Q0    ( %N$JE8&L0B?6 (  +$%   9
M      " @0M\  !X;"]W;W)K<VAE971S+W-H965T,C$N>&UL4$L! A0#%
M  @ 6X2J5NW<,A1Q @  &P<  !D              ("!FGX  'AL+W=O<FMS
M:&5E=',O<VAE970R,BYX;6Q02P$"% ,4    " !;A*I68U 7I$ #  #N#
M&0              @(%"@0  >&PO=V]R:W-H965T<R]S:&5E=#(S+GAM;%!+
M 0(4 Q0    ( %N$JE925%N^_0(  *L,   9              " @;F$  !X
M;"]W;W)K<VAE971S+W-H965T,C0N>&UL4$L! A0#%     @ 6X2J5I_%P3?4
M @  O <  !D              ("![8<  'AL+W=O<FMS:&5E=',O<VAE970R
M-2YX;6Q02P$"% ,4    " !;A*I6632W-(L#   9#@  &0
M@('XB@  >&PO=V]R:W-H965T<R]S:&5E=#(V+GAM;%!+ 0(4 Q0    ( %N$
MJE;_%QL1; ,  ($0   9              " @;J.  !X;"]W;W)K<VAE971S
M+W-H965T,C<N>&UL4$L! A0#%     @ 6X2J5F=/U:3O!   .QP  !D
M         ("!79(  'AL+W=O<FMS:&5E=',O<VAE970R."YX;6Q02P$"% ,4
M    " !;A*I6F]YW+AD#  "O"P  &0              @(&#EP  >&PO=V]R
M:W-H965T<R]S:&5E=#(Y+GAM;%!+ 0(4 Q0    ( %N$JE;QF)#9! ,  %0(
M   9              " @=.:  !X;"]W;W)K<VAE971S+W-H965T,S N>&UL
M4$L! A0#%     @ 6X2J5BIA+?Y\!   M!4  !D              ("!#IX
M 'AL+W=O<FMS:&5E=',O<VAE970S,2YX;6Q02P$"% ,4    " !;A*I6L]LG
MT70#  !F#0  &0              @('!H@  >&PO=V]R:W-H965T<R]S:&5E
M=#,R+GAM;%!+ 0(4 Q0    ( %N$JE9,/ZL=PP(  +$'   9
M  " @6RF  !X;"]W;W)K<VAE971S+W-H965T,S,N>&UL4$L! A0#%     @
M6X2J5F&<-)]W!   /Q@  !D              ("!9JD  'AL+W=O<FMS:&5E
M=',O<VAE970S-"YX;6Q02P$"% ,4    " !;A*I6]+7(*S@#  #L$P  #0
M            @ $4K@  >&PO<W1Y;&5S+GAM;%!+ 0(4 Q0    ( %N$JE:7
MBKL<P    !,"   +              "  7>Q  !?<F5L<R\N<F5L<U!+ 0(4
M Q0    ( %N$JE9149LO0P,  &X7   /              "  6"R  !X;"]W
M;W)K8F]O:RYX;6Q02P$"% ,4    " !;A*I6C-]?K6X!  #=%   &@
M        @ '0M0  >&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'-02P$"% ,4
M    " !;A*I6!E="=X\!  !P%0  $P              @ %VMP  6T-O;G1E
C;G1?5'EP97-=+GAM;%!+!08     *@ J %T+   VN0     !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.23.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>62</ContextCount>
  <ElementCount>169</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>27</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>4</UnitCount>
  <MyReports>
    <Report instance="cntx-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.contexttherapeutics.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="cntx-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>0000002 - Statement - Condensed Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.contexttherapeutics.com/role/CondensedConsolidatedBalanceSheets</Role>
      <ShortName>Condensed Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="cntx-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>0000003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.contexttherapeutics.com/role/CondensedConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>Condensed Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="cntx-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>0000004 - Statement - Condensed Consolidated Statements of Operations (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.contexttherapeutics.com/role/CondensedConsolidatedStatementsofOperationsUnaudited</Role>
      <ShortName>Condensed Consolidated Statements of Operations (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="cntx-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>0000005 - Statement - Condensed Consolidated Statements of Changes in Stockholders' Equity (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.contexttherapeutics.com/role/CondensedConsolidatedStatementsofChangesinStockholdersEquityUnaudited</Role>
      <ShortName>Condensed Consolidated Statements of Changes in Stockholders' Equity (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="cntx-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>0000006 - Statement - Condensed Consolidated Statement of Cash Flows (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.contexttherapeutics.com/role/CondensedConsolidatedStatementofCashFlowsUnaudited</Role>
      <ShortName>Condensed Consolidated Statement of Cash Flows (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="cntx-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>0000007 - Disclosure - Organization and Description of Business</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.contexttherapeutics.com/role/OrganizationandDescriptionofBusiness</Role>
      <ShortName>Organization and Description of Business</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="cntx-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>0000008 - Disclosure - Risks and Liquidity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.contexttherapeutics.com/role/RisksandLiquidity</Role>
      <ShortName>Risks and Liquidity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="cntx-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>0000009 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.contexttherapeutics.com/role/BasisofPresentationandSummaryofSignificantAccountingPolicies</Role>
      <ShortName>Basis of Presentation and Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="cntx-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>0000010 - Disclosure - Fair Value Measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.contexttherapeutics.com/role/FairValueMeasurements</Role>
      <ShortName>Fair Value Measurements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="cntx-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>0000011 - Disclosure - Accrued Expenses and Other Current Liabilities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.contexttherapeutics.com/role/AccruedExpensesandOtherCurrentLiabilities</Role>
      <ShortName>Accrued Expenses and Other Current Liabilities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="cntx-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>0000012 - Disclosure - Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.contexttherapeutics.com/role/StockholdersEquity</Role>
      <ShortName>Stockholders' Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="cntx-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>0000013 - Disclosure - Share-Based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.contexttherapeutics.com/role/ShareBasedCompensation</Role>
      <ShortName>Share-Based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="cntx-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>0000014 - Disclosure - Commitment and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.contexttherapeutics.com/role/CommitmentandContingencies</Role>
      <ShortName>Commitment and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="cntx-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>0000015 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.contexttherapeutics.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Basis of Presentation and Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.contexttherapeutics.com/role/BasisofPresentationandSummaryofSignificantAccountingPolicies</ParentRole>
      <Position>15</Position>
    </Report>
    <Report instance="cntx-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>0000016 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.contexttherapeutics.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesTables</Role>
      <ShortName>Basis of Presentation and Summary of Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.contexttherapeutics.com/role/BasisofPresentationandSummaryofSignificantAccountingPolicies</ParentRole>
      <Position>16</Position>
    </Report>
    <Report instance="cntx-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>0000017 - Disclosure - Fair Value Measurements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.contexttherapeutics.com/role/FairValueMeasurementsTables</Role>
      <ShortName>Fair Value Measurements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.contexttherapeutics.com/role/FairValueMeasurements</ParentRole>
      <Position>17</Position>
    </Report>
    <Report instance="cntx-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>0000018 - Disclosure - Accrued Expenses and Other Current Liabilities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.contexttherapeutics.com/role/AccruedExpensesandOtherCurrentLiabilitiesTables</Role>
      <ShortName>Accrued Expenses and Other Current Liabilities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.contexttherapeutics.com/role/AccruedExpensesandOtherCurrentLiabilities</ParentRole>
      <Position>18</Position>
    </Report>
    <Report instance="cntx-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>0000019 - Disclosure - Stockholders' Equity (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.contexttherapeutics.com/role/StockholdersEquityTables</Role>
      <ShortName>Stockholders' Equity (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.contexttherapeutics.com/role/StockholdersEquity</ParentRole>
      <Position>19</Position>
    </Report>
    <Report instance="cntx-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>0000020 - Disclosure - Share-Based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.contexttherapeutics.com/role/ShareBasedCompensationTables</Role>
      <ShortName>Share-Based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.contexttherapeutics.com/role/ShareBasedCompensation</ParentRole>
      <Position>20</Position>
    </Report>
    <Report instance="cntx-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>0000021 - Disclosure - Risks and Liquidity - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.contexttherapeutics.com/role/RisksandLiquidityNarrativeDetails</Role>
      <ShortName>Risks and Liquidity - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="cntx-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>0000022 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.contexttherapeutics.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails</Role>
      <ShortName>Basis of Presentation and Summary of Significant Accounting Policies - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.contexttherapeutics.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesTables</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="cntx-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>0000023 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies - Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.contexttherapeutics.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesScheduleofAntidilutiveSecuritiesExcludedfromComputationofEarningsPerShareDetails</Role>
      <ShortName>Basis of Presentation and Summary of Significant Accounting Policies - Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="cntx-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>0000024 - Disclosure - Fair Value Measurements - Schedule of assets and liabilities measured at fair value on a recurring basis (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.contexttherapeutics.com/role/FairValueMeasurementsScheduleofassetsandliabilitiesmeasuredatfairvalueonarecurringbasisDetails</Role>
      <ShortName>Fair Value Measurements - Schedule of assets and liabilities measured at fair value on a recurring basis (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="cntx-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>0000025 - Disclosure - Accrued Expenses and Other Current Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.contexttherapeutics.com/role/AccruedExpensesandOtherCurrentLiabilitiesDetails</Role>
      <ShortName>Accrued Expenses and Other Current Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.contexttherapeutics.com/role/AccruedExpensesandOtherCurrentLiabilitiesTables</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="cntx-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>0000026 - Disclosure - Stockholders' Equity - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.contexttherapeutics.com/role/StockholdersEquityNarrativeDetails</Role>
      <ShortName>Stockholders' Equity - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>26</Position>
    </Report>
    <Report instance="cntx-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>0000027 - Disclosure - Stockholders' Equity - Schedule of Warrants Outstanding (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.contexttherapeutics.com/role/StockholdersEquityScheduleofWarrantsOutstandingDetails</Role>
      <ShortName>Stockholders' Equity - Schedule of Warrants Outstanding (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>27</Position>
    </Report>
    <Report instance="cntx-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>0000028 - Disclosure - Share-Based Compensation - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.contexttherapeutics.com/role/ShareBasedCompensationAdditionalInformationDetails</Role>
      <ShortName>Share-Based Compensation - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>28</Position>
    </Report>
    <Report instance="cntx-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>0000029 - Disclosure - Share-based Compensation - Schedule of Share-based Compensation Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.contexttherapeutics.com/role/SharebasedCompensationScheduleofSharebasedCompensationExpenseDetails</Role>
      <ShortName>Share-based Compensation - Schedule of Share-based Compensation Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>29</Position>
    </Report>
    <Report instance="cntx-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>0000030 - Disclosure - Share-Based Compensation - Schedule of Assumptions Used to Determine Fair Value of Share-Based Awards (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.contexttherapeutics.com/role/ShareBasedCompensationScheduleofAssumptionsUsedtoDetermineFairValueofShareBasedAwardsDetails</Role>
      <ShortName>Share-Based Compensation - Schedule of Assumptions Used to Determine Fair Value of Share-Based Awards (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report instance="cntx-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>0000031 - Disclosure - Share-Based Compensation - Schedule of Share-Based Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.contexttherapeutics.com/role/ShareBasedCompensationScheduleofShareBasedActivityDetails</Role>
      <ShortName>Share-Based Compensation - Schedule of Share-Based Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report instance="cntx-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>0000032 - Disclosure - Commitment and Contingencies - Operating Lease (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.contexttherapeutics.com/role/CommitmentandContingenciesOperatingLeaseDetails</Role>
      <ShortName>Commitment and Contingencies - Operating Lease (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>32</Position>
    </Report>
    <Report instance="cntx-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>0000033 - Disclosure - Commitment and Contingencies - Employee Benefit Plans (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.contexttherapeutics.com/role/CommitmentandContingenciesEmployeeBenefitPlansDetails</Role>
      <ShortName>Commitment and Contingencies - Employee Benefit Plans (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="cntx-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>0000034 - Disclosure - Commitment and Contingencies - Collaboration Agreements (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.contexttherapeutics.com/role/CommitmentandContingenciesCollaborationAgreementsDetails</Role>
      <ShortName>Commitment and Contingencies - Collaboration Agreements (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-Q" original="cntx-20230331.htm">cntx-20230331.htm</File>
    <File>cntx-20230331.xsd</File>
    <File>cntx-20230331_cal.xml</File>
    <File>cntx-20230331_def.xml</File>
    <File>cntx-20230331_lab.xml</File>
    <File>cntx-20230331_pre.xml</File>
    <File>cntx2023-033110xqexhibit311.htm</File>
    <File>cntx2023033110-qexhibit312.htm</File>
    <File>cntx2023033110-qexhibit321.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="256">http://fasb.org/us-gaap/2022</BaseTaxonomy>
    <BaseTaxonomy items="31">http://xbrl.sec.gov/dei/2022</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>50
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "cntx-20230331.htm": {
   "axisCustom": 0,
   "axisStandard": 14,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2022": 256,
    "http://xbrl.sec.gov/dei/2022": 31
   },
   "contextCount": 62,
   "dts": {
    "calculationLink": {
     "local": [
      "cntx-20230331_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "cntx-20230331_def.xml"
     ]
    },
    "inline": {
     "local": [
      "cntx-20230331.htm"
     ]
    },
    "labelLink": {
     "local": [
      "cntx-20230331_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "cntx-20230331_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "cntx-20230331.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd",
      "https://xbrl.sec.gov/country/2022/country-2022.xsd",
      "https://xbrl.sec.gov/dei/2022/dei-2022.xsd"
     ]
    }
   },
   "elementCount": 267,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2022": 5,
    "total": 5
   },
   "keyCustom": 11,
   "keyStandard": 158,
   "memberCustom": 8,
   "memberStandard": 17,
   "nsprefix": "cntx",
   "nsuri": "http://www.contexttherapeutics.com/20230331",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cntx-20230331.htm",
      "contextRef": "ie35b115501ca468f8cadb8213304a30b_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0000001 - Document - Cover",
     "menuCat": "Cover",
     "order": "1",
     "role": "http://www.contexttherapeutics.com/role/Cover",
     "shortName": "Cover",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cntx-20230331.htm",
      "contextRef": "ie35b115501ca468f8cadb8213304a30b_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cntx-20230331.htm",
      "contextRef": "ie35b115501ca468f8cadb8213304a30b_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000010 - Disclosure - Fair Value Measurements",
     "menuCat": "Notes",
     "order": "10",
     "role": "http://www.contexttherapeutics.com/role/FairValueMeasurements",
     "shortName": "Fair Value Measurements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cntx-20230331.htm",
      "contextRef": "ie35b115501ca468f8cadb8213304a30b_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cntx-20230331.htm",
      "contextRef": "ie35b115501ca468f8cadb8213304a30b_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000011 - Disclosure - Accrued Expenses and Other Current Liabilities",
     "menuCat": "Notes",
     "order": "11",
     "role": "http://www.contexttherapeutics.com/role/AccruedExpensesandOtherCurrentLiabilities",
     "shortName": "Accrued Expenses and Other Current Liabilities",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cntx-20230331.htm",
      "contextRef": "ie35b115501ca468f8cadb8213304a30b_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cntx-20230331.htm",
      "contextRef": "ie35b115501ca468f8cadb8213304a30b_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000012 - Disclosure - Stockholders' Equity",
     "menuCat": "Notes",
     "order": "12",
     "role": "http://www.contexttherapeutics.com/role/StockholdersEquity",
     "shortName": "Stockholders' Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cntx-20230331.htm",
      "contextRef": "ie35b115501ca468f8cadb8213304a30b_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cntx-20230331.htm",
      "contextRef": "ie35b115501ca468f8cadb8213304a30b_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000013 - Disclosure - Share-Based Compensation",
     "menuCat": "Notes",
     "order": "13",
     "role": "http://www.contexttherapeutics.com/role/ShareBasedCompensation",
     "shortName": "Share-Based Compensation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cntx-20230331.htm",
      "contextRef": "ie35b115501ca468f8cadb8213304a30b_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cntx-20230331.htm",
      "contextRef": "ie35b115501ca468f8cadb8213304a30b_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000014 - Disclosure - Commitment and Contingencies",
     "menuCat": "Notes",
     "order": "14",
     "role": "http://www.contexttherapeutics.com/role/CommitmentandContingencies",
     "shortName": "Commitment and Contingencies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cntx-20230331.htm",
      "contextRef": "ie35b115501ca468f8cadb8213304a30b_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cntx-20230331.htm",
      "contextRef": "ie35b115501ca468f8cadb8213304a30b_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000015 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Policies)",
     "menuCat": "Policies",
     "order": "15",
     "role": "http://www.contexttherapeutics.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies",
     "shortName": "Basis of Presentation and Summary of Significant Accounting Policies (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cntx-20230331.htm",
      "contextRef": "ie35b115501ca468f8cadb8213304a30b_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cntx-20230331.htm",
      "contextRef": "ie35b115501ca468f8cadb8213304a30b_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000016 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Tables)",
     "menuCat": "Tables",
     "order": "16",
     "role": "http://www.contexttherapeutics.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesTables",
     "shortName": "Basis of Presentation and Summary of Significant Accounting Policies (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cntx-20230331.htm",
      "contextRef": "ie35b115501ca468f8cadb8213304a30b_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cntx-20230331.htm",
      "contextRef": "ie35b115501ca468f8cadb8213304a30b_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000017 - Disclosure - Fair Value Measurements (Tables)",
     "menuCat": "Tables",
     "order": "17",
     "role": "http://www.contexttherapeutics.com/role/FairValueMeasurementsTables",
     "shortName": "Fair Value Measurements (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cntx-20230331.htm",
      "contextRef": "ie35b115501ca468f8cadb8213304a30b_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cntx-20230331.htm",
      "contextRef": "ie35b115501ca468f8cadb8213304a30b_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000018 - Disclosure - Accrued Expenses and Other Current Liabilities (Tables)",
     "menuCat": "Tables",
     "order": "18",
     "role": "http://www.contexttherapeutics.com/role/AccruedExpensesandOtherCurrentLiabilitiesTables",
     "shortName": "Accrued Expenses and Other Current Liabilities (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cntx-20230331.htm",
      "contextRef": "ie35b115501ca468f8cadb8213304a30b_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cntx-20230331.htm",
      "contextRef": "ie35b115501ca468f8cadb8213304a30b_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000019 - Disclosure - Stockholders' Equity (Tables)",
     "menuCat": "Tables",
     "order": "19",
     "role": "http://www.contexttherapeutics.com/role/StockholdersEquityTables",
     "shortName": "Stockholders' Equity (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cntx-20230331.htm",
      "contextRef": "ie35b115501ca468f8cadb8213304a30b_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cntx-20230331.htm",
      "contextRef": "i9e6ffce2c2d247f491e046febe8251cd_I20230331",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000002 - Statement - Condensed Consolidated Balance Sheets",
     "menuCat": "Statements",
     "order": "2",
     "role": "http://www.contexttherapeutics.com/role/CondensedConsolidatedBalanceSheets",
     "shortName": "Condensed Consolidated Balance Sheets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cntx-20230331.htm",
      "contextRef": "i9e6ffce2c2d247f491e046febe8251cd_I20230331",
      "decimals": "0",
      "lang": "en-US",
      "name": "us-gaap:PrepaidExpenseAndOtherAssetsCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cntx-20230331.htm",
      "contextRef": "ie35b115501ca468f8cadb8213304a30b_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000020 - Disclosure - Share-Based Compensation (Tables)",
     "menuCat": "Tables",
     "order": "20",
     "role": "http://www.contexttherapeutics.com/role/ShareBasedCompensationTables",
     "shortName": "Share-Based Compensation (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cntx-20230331.htm",
      "contextRef": "ie35b115501ca468f8cadb8213304a30b_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cntx-20230331.htm",
      "contextRef": "i9e6ffce2c2d247f491e046febe8251cd_I20230331",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RetainedEarningsAccumulatedDeficit",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000021 - Disclosure - Risks and Liquidity - Narrative (Details)",
     "menuCat": "Details",
     "order": "21",
     "role": "http://www.contexttherapeutics.com/role/RisksandLiquidityNarrativeDetails",
     "shortName": "Risks and Liquidity - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cntx-20230331.htm",
      "contextRef": "i9e6ffce2c2d247f491e046febe8251cd_I20230331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashUninsuredAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000022 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies - Narrative (Details)",
     "menuCat": "Details",
     "order": "22",
     "role": "http://www.contexttherapeutics.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails",
     "shortName": "Basis of Presentation and Summary of Significant Accounting Policies - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cntx-20230331.htm",
      "contextRef": "i9e6ffce2c2d247f491e046febe8251cd_I20230331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashUninsuredAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cntx-20230331.htm",
      "contextRef": "ie35b115501ca468f8cadb8213304a30b_D20230101-20230331",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000023 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies - Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share (Details)",
     "menuCat": "Details",
     "order": "23",
     "role": "http://www.contexttherapeutics.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesScheduleofAntidilutiveSecuritiesExcludedfromComputationofEarningsPerShareDetails",
     "shortName": "Basis of Presentation and Summary of Significant Accounting Policies - Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cntx-20230331.htm",
      "contextRef": "ie35b115501ca468f8cadb8213304a30b_D20230101-20230331",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cntx-20230331.htm",
      "contextRef": "i3062cc15f83f4cdfb396a7b04a1c52fc_I20230331",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000024 - Disclosure - Fair Value Measurements - Schedule of assets and liabilities measured at fair value on a recurring basis (Details)",
     "menuCat": "Details",
     "order": "24",
     "role": "http://www.contexttherapeutics.com/role/FairValueMeasurementsScheduleofassetsandliabilitiesmeasuredatfairvalueonarecurringbasisDetails",
     "shortName": "Fair Value Measurements - Schedule of assets and liabilities measured at fair value on a recurring basis (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cntx-20230331.htm",
      "contextRef": "i3062cc15f83f4cdfb396a7b04a1c52fc_I20230331",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cntx-20230331.htm",
      "contextRef": "i9e6ffce2c2d247f491e046febe8251cd_I20230331",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000025 - Disclosure - Accrued Expenses and Other Current Liabilities (Details)",
     "menuCat": "Details",
     "order": "25",
     "role": "http://www.contexttherapeutics.com/role/AccruedExpensesandOtherCurrentLiabilitiesDetails",
     "shortName": "Accrued Expenses and Other Current Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cntx-20230331.htm",
      "contextRef": "i9e6ffce2c2d247f491e046febe8251cd_I20230331",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cntx-20230331.htm",
      "contextRef": "i9e6ffce2c2d247f491e046febe8251cd_I20230331",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ClassOfWarrantOrRightOutstanding",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000026 - Disclosure - Stockholders' Equity - Narrative (Details)",
     "menuCat": "Details",
     "order": "26",
     "role": "http://www.contexttherapeutics.com/role/StockholdersEquityNarrativeDetails",
     "shortName": "Stockholders' Equity - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cntx-20230331.htm",
      "contextRef": "i123230c41d4a4b6cb51151a89a8800c3_I20220331",
      "decimals": null,
      "lang": "en-US",
      "name": "us-gaap:WarrantsAndRightsOutstandingTerm",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cntx-20230331.htm",
      "contextRef": "i9e6ffce2c2d247f491e046febe8251cd_I20230331",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ClassOfWarrantOrRightOutstanding",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000027 - Disclosure - Stockholders' Equity - Schedule of Warrants Outstanding (Details)",
     "menuCat": "Details",
     "order": "27",
     "role": "http://www.contexttherapeutics.com/role/StockholdersEquityScheduleofWarrantsOutstandingDetails",
     "shortName": "Stockholders' Equity - Schedule of Warrants Outstanding (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cntx-20230331.htm",
      "contextRef": "i68c87024c26f44ab8263dbd0a7fa6a4f_I20230331",
      "decimals": "0",
      "lang": "en-US",
      "name": "us-gaap:ClassOfWarrantOrRightOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cntx-20230331.htm",
      "contextRef": "i37c7d2f5e060456d835ba44ccd4b0c9b_D20210401-20210430",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "cntx:ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedAsAPercentageOfOutstandingStock",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000028 - Disclosure - Share-Based Compensation - Additional Information (Details)",
     "menuCat": "Details",
     "order": "28",
     "role": "http://www.contexttherapeutics.com/role/ShareBasedCompensationAdditionalInformationDetails",
     "shortName": "Share-Based Compensation - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cntx-20230331.htm",
      "contextRef": "i37c7d2f5e060456d835ba44ccd4b0c9b_D20210401-20210430",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "cntx:ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedAsAPercentageOfOutstandingStock",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cntx-20230331.htm",
      "contextRef": "ie35b115501ca468f8cadb8213304a30b_D20230101-20230331",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000029 - Disclosure - Share-based Compensation - Schedule of Share-based Compensation Expense (Details)",
     "menuCat": "Details",
     "order": "29",
     "role": "http://www.contexttherapeutics.com/role/SharebasedCompensationScheduleofSharebasedCompensationExpenseDetails",
     "shortName": "Share-based Compensation - Schedule of Share-based Compensation Expense (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cntx-20230331.htm",
      "contextRef": "ie35b115501ca468f8cadb8213304a30b_D20230101-20230331",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:PreferredStockParOrStatedValuePerShare",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cntx-20230331.htm",
      "contextRef": "i9e6ffce2c2d247f491e046febe8251cd_I20230331",
      "decimals": "3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)",
     "menuCat": "Statements",
     "order": "3",
     "role": "http://www.contexttherapeutics.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
     "shortName": "Condensed Consolidated Balance Sheets (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:PreferredStockParOrStatedValuePerShare",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cntx-20230331.htm",
      "contextRef": "i9e6ffce2c2d247f491e046febe8251cd_I20230331",
      "decimals": "3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cntx-20230331.htm",
      "contextRef": "i56df8626827b4508b71d14c260351355_D20230101-20230331",
      "decimals": "4",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000030 - Disclosure - Share-Based Compensation - Schedule of Assumptions Used to Determine Fair Value of Share-Based Awards (Details)",
     "menuCat": "Details",
     "order": "30",
     "role": "http://www.contexttherapeutics.com/role/ShareBasedCompensationScheduleofAssumptionsUsedtoDetermineFairValueofShareBasedAwardsDetails",
     "shortName": "Share-Based Compensation - Schedule of Assumptions Used to Determine Fair Value of Share-Based Awards (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cntx-20230331.htm",
      "contextRef": "i56df8626827b4508b71d14c260351355_D20230101-20230331",
      "decimals": "4",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cntx-20230331.htm",
      "contextRef": "i4b1713eab7d84494b3b43202a26fc3c4_I20221231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000031 - Disclosure - Share-Based Compensation - Schedule of Share-Based Activity (Details)",
     "menuCat": "Details",
     "order": "31",
     "role": "http://www.contexttherapeutics.com/role/ShareBasedCompensationScheduleofShareBasedActivityDetails",
     "shortName": "Share-Based Compensation - Schedule of Share-Based Activity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cntx-20230331.htm",
      "contextRef": "ie35b115501ca468f8cadb8213304a30b_D20230101-20230331",
      "decimals": "0",
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cntx-20230331.htm",
      "contextRef": "i9e6ffce2c2d247f491e046febe8251cd_I20230331",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseRightOfUseAsset",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000032 - Disclosure - Commitment and Contingencies - Operating Lease (Details)",
     "menuCat": "Details",
     "order": "32",
     "role": "http://www.contexttherapeutics.com/role/CommitmentandContingenciesOperatingLeaseDetails",
     "shortName": "Commitment and Contingencies - Operating Lease (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cntx-20230331.htm",
      "contextRef": "i9e6ffce2c2d247f491e046febe8251cd_I20230331",
      "decimals": "0",
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseLiability",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cntx-20230331.htm",
      "contextRef": "ie35b115501ca468f8cadb8213304a30b_D20230101-20230331",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000033 - Disclosure - Commitment and Contingencies - Employee Benefit Plans (Details)",
     "menuCat": "Details",
     "order": "33",
     "role": "http://www.contexttherapeutics.com/role/CommitmentandContingenciesEmployeeBenefitPlansDetails",
     "shortName": "Commitment and Contingencies - Employee Benefit Plans (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cntx-20230331.htm",
      "contextRef": "ie35b115501ca468f8cadb8213304a30b_D20230101-20230331",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cntx-20230331.htm",
      "contextRef": "i6b2d762a98f94d569b10a0723338a465_D20200301-20200331",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "cntx:CollaborativeArrangementRightsAndObligationsQuarterlySalesPaymentsPercent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000034 - Disclosure - Commitment and Contingencies - Collaboration Agreements (Details)",
     "menuCat": "Details",
     "order": "34",
     "role": "http://www.contexttherapeutics.com/role/CommitmentandContingenciesCollaborationAgreementsDetails",
     "shortName": "Commitment and Contingencies - Collaboration Agreements (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cntx-20230331.htm",
      "contextRef": "i6b2d762a98f94d569b10a0723338a465_D20200301-20200331",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "cntx:CollaborativeArrangementRightsAndObligationsQuarterlySalesPaymentsPercent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cntx-20230331.htm",
      "contextRef": "ie35b115501ca468f8cadb8213304a30b_D20230101-20230331",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000004 - Statement - Condensed Consolidated Statements of Operations (Unaudited)",
     "menuCat": "Statements",
     "order": "4",
     "role": "http://www.contexttherapeutics.com/role/CondensedConsolidatedStatementsofOperationsUnaudited",
     "shortName": "Condensed Consolidated Statements of Operations (Unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cntx-20230331.htm",
      "contextRef": "ie35b115501ca468f8cadb8213304a30b_D20230101-20230331",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cntx-20230331.htm",
      "contextRef": "ifd24ec169b5741408f1f292b74c4c8e7_I20211231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharesOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000005 - Statement - Condensed Consolidated Statements of Changes in Stockholders' Equity (Unaudited)",
     "menuCat": "Statements",
     "order": "5",
     "role": "http://www.contexttherapeutics.com/role/CondensedConsolidatedStatementsofChangesinStockholdersEquityUnaudited",
     "shortName": "Condensed Consolidated Statements of Changes in Stockholders' Equity (Unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cntx-20230331.htm",
      "contextRef": "ifd24ec169b5741408f1f292b74c4c8e7_I20211231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharesOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cntx-20230331.htm",
      "contextRef": "ie35b115501ca468f8cadb8213304a30b_D20230101-20230331",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000006 - Statement - Condensed Consolidated Statement of Cash Flows (Unaudited)",
     "menuCat": "Statements",
     "order": "6",
     "role": "http://www.contexttherapeutics.com/role/CondensedConsolidatedStatementofCashFlowsUnaudited",
     "shortName": "Condensed Consolidated Statement of Cash Flows (Unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cntx-20230331.htm",
      "contextRef": "ie35b115501ca468f8cadb8213304a30b_D20230101-20230331",
      "decimals": "0",
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cntx-20230331.htm",
      "contextRef": "ie35b115501ca468f8cadb8213304a30b_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NatureOfOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000007 - Disclosure - Organization and Description of Business",
     "menuCat": "Notes",
     "order": "7",
     "role": "http://www.contexttherapeutics.com/role/OrganizationandDescriptionofBusiness",
     "shortName": "Organization and Description of Business",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cntx-20230331.htm",
      "contextRef": "ie35b115501ca468f8cadb8213304a30b_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NatureOfOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cntx-20230331.htm",
      "contextRef": "ie35b115501ca468f8cadb8213304a30b_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "cntx:RisksAndLiquidityTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000008 - Disclosure - Risks and Liquidity",
     "menuCat": "Notes",
     "order": "8",
     "role": "http://www.contexttherapeutics.com/role/RisksandLiquidity",
     "shortName": "Risks and Liquidity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cntx-20230331.htm",
      "contextRef": "ie35b115501ca468f8cadb8213304a30b_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "cntx:RisksAndLiquidityTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cntx-20230331.htm",
      "contextRef": "ie35b115501ca468f8cadb8213304a30b_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000009 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies",
     "menuCat": "Notes",
     "order": "9",
     "role": "http://www.contexttherapeutics.com/role/BasisofPresentationandSummaryofSignificantAccountingPolicies",
     "shortName": "Basis of Presentation and Summary of Significant Accounting Policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cntx-20230331.htm",
      "contextRef": "ie35b115501ca468f8cadb8213304a30b_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 27,
   "tag": {
    "cntx_AccruedResearchAndDevelopmentCostsCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.contexttherapeutics.com/role/AccruedExpensesandOtherCurrentLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued Research and Development Costs, Current",
        "label": "Accrued Research and Development Costs, Current",
        "terseLabel": "Research and development costs"
       }
      }
     },
     "localname": "AccruedResearchAndDevelopmentCostsCurrent",
     "nsuri": "http://www.contexttherapeutics.com/20230331",
     "presentation": [
      "http://www.contexttherapeutics.com/role/AccruedExpensesandOtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cntx_CollaborativeArrangementRightsAndObligationsDevelopmentAndRegulatoryMilestonePaymentsMaximum": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, Rights and Obligations, Development And Regulatory Milestone Payments, Maximum",
        "label": "Collaborative Arrangement, Rights and Obligations, Development And Regulatory Milestone Payments, Maximum",
        "terseLabel": "Maximum development and regulatory milestone payments"
       }
      }
     },
     "localname": "CollaborativeArrangementRightsAndObligationsDevelopmentAndRegulatoryMilestonePaymentsMaximum",
     "nsuri": "http://www.contexttherapeutics.com/20230331",
     "presentation": [
      "http://www.contexttherapeutics.com/role/CommitmentandContingenciesCollaborationAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cntx_CollaborativeArrangementRightsAndObligationsMilestonePayment": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, Rights and Obligations, Milestone Payment",
        "label": "Collaborative Arrangement, Rights and Obligations, Milestone Payment",
        "terseLabel": "Milestone payment"
       }
      }
     },
     "localname": "CollaborativeArrangementRightsAndObligationsMilestonePayment",
     "nsuri": "http://www.contexttherapeutics.com/20230331",
     "presentation": [
      "http://www.contexttherapeutics.com/role/CommitmentandContingenciesCollaborationAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cntx_CollaborativeArrangementRightsAndObligationsQuarterlySalesPaymentsPercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, Rights and Obligations, Quarterly Sales Payments, Percent",
        "label": "Collaborative Arrangement, Rights and Obligations, Quarterly Sales Payments, Percent",
        "terseLabel": "Quarterly sales payment due upon completion, percentage"
       }
      }
     },
     "localname": "CollaborativeArrangementRightsAndObligationsQuarterlySalesPaymentsPercent",
     "nsuri": "http://www.contexttherapeutics.com/20230331",
     "presentation": [
      "http://www.contexttherapeutics.com/role/CommitmentandContingenciesCollaborationAgreementsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "cntx_CollaborativeArrangementRightsAndObligationsSalesMilestonePaymentsMaximum": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, Rights and Obligations, Sales Milestone Payments, Maximum",
        "label": "Collaborative Arrangement, Rights and Obligations, Sales Milestone Payments, Maximum",
        "terseLabel": "Maximum sales milestone payments"
       }
      }
     },
     "localname": "CollaborativeArrangementRightsAndObligationsSalesMilestonePaymentsMaximum",
     "nsuri": "http://www.contexttherapeutics.com/20230331",
     "presentation": [
      "http://www.contexttherapeutics.com/role/CommitmentandContingenciesCollaborationAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cntx_CollaborativeArrangementRightsAndObligationsSalesPaymentPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research And Development Arrangement, Contract To Perform For Others, Upon Completion, Sales Payment Period",
        "label": "Collaborative Arrangement, Rights and Obligations, Sales Payment Period",
        "terseLabel": "Quarterly sales payment due upon completion, period of payment"
       }
      }
     },
     "localname": "CollaborativeArrangementRightsAndObligationsSalesPaymentPeriod",
     "nsuri": "http://www.contexttherapeutics.com/20230331",
     "presentation": [
      "http://www.contexttherapeutics.com/role/CommitmentandContingenciesCollaborationAgreementsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "cntx_CollaborativeArrangementRightsAndObligationsTieredRoyaltyPercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, Rights and Obligations, Tiered Royalty, Percent",
        "label": "Collaborative Arrangement, Rights and Obligations, Tiered Royalty, Percent",
        "terseLabel": "Tiered royalty payment, percent (up to)"
       }
      }
     },
     "localname": "CollaborativeArrangementRightsAndObligationsTieredRoyaltyPercent",
     "nsuri": "http://www.contexttherapeutics.com/20230331",
     "presentation": [
      "http://www.contexttherapeutics.com/role/CommitmentandContingenciesCollaborationAgreementsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "cntx_December2021PrivatePlacementAgentWarrantsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "December 2021 Private Placement Agent Warrants",
        "label": "December 2021 Private Placement Agent Warrants [Member]",
        "terseLabel": "Issued in connection with 2021 private placement"
       }
      }
     },
     "localname": "December2021PrivatePlacementAgentWarrantsMember",
     "nsuri": "http://www.contexttherapeutics.com/20230331",
     "presentation": [
      "http://www.contexttherapeutics.com/role/StockholdersEquityScheduleofWarrantsOutstandingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cntx_IntegralMolecularIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Integral Molecular, Inc.",
        "label": "Integral Molecular, Inc. [Member]",
        "terseLabel": "Integral"
       }
      }
     },
     "localname": "IntegralMolecularIncMember",
     "nsuri": "http://www.contexttherapeutics.com/20230331",
     "presentation": [
      "http://www.contexttherapeutics.com/role/CommitmentandContingenciesCollaborationAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cntx_IssuedForProfessionalConsultingServicesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Issued for Professional Consulting Services",
        "label": "Issued for Professional Consulting Services [Member]",
        "terseLabel": "Issued in 2022 for consulting services"
       }
      }
     },
     "localname": "IssuedForProfessionalConsultingServicesMember",
     "nsuri": "http://www.contexttherapeutics.com/20230331",
     "presentation": [
      "http://www.contexttherapeutics.com/role/StockholdersEquityNarrativeDetails",
      "http://www.contexttherapeutics.com/role/StockholdersEquityScheduleofWarrantsOutstandingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cntx_IssuedForServicesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Issued for Services",
        "label": "Issued for Services [Member]",
        "terseLabel": "Issued for services"
       }
      }
     },
     "localname": "IssuedForServicesMember",
     "nsuri": "http://www.contexttherapeutics.com/20230331",
     "presentation": [
      "http://www.contexttherapeutics.com/role/CondensedConsolidatedStatementofCashFlowsUnaudited"
     ],
     "xbrltype": "domainItemType"
    },
    "cntx_IssuedToPlacementAgentsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Issued to Placement Agents",
        "label": "Issued to Placement Agents [Member]",
        "terseLabel": "Issued in connection with 2021 IPO"
       }
      }
     },
     "localname": "IssuedToPlacementAgentsMember",
     "nsuri": "http://www.contexttherapeutics.com/20230331",
     "presentation": [
      "http://www.contexttherapeutics.com/role/StockholdersEquityScheduleofWarrantsOutstandingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cntx_PatentCostsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Patent Costs, Policy",
        "label": "Patent Costs, Policy [Policy Text Block]",
        "terseLabel": "Patent Costs"
       }
      }
     },
     "localname": "PatentCostsPolicyPolicyTextBlock",
     "nsuri": "http://www.contexttherapeutics.com/20230331",
     "presentation": [
      "http://www.contexttherapeutics.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "cntx_RisksAndLiquidityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Risks And Liquidity",
        "label": "Risks And Liquidity [Abstract]"
       }
      }
     },
     "localname": "RisksAndLiquidityAbstract",
     "nsuri": "http://www.contexttherapeutics.com/20230331",
     "xbrltype": "stringItemType"
    },
    "cntx_RisksAndLiquidityTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Risks And Liquidity",
        "label": "Risks And Liquidity [Text Block]",
        "terseLabel": "Risks and Liquidity"
       }
      }
     },
     "localname": "RisksAndLiquidityTextBlock",
     "nsuri": "http://www.contexttherapeutics.com/20230331",
     "presentation": [
      "http://www.contexttherapeutics.com/role/RisksandLiquidity"
     ],
     "xbrltype": "textBlockItemType"
    },
    "cntx_ScaleUp100KilogramsOfGMPGradeCompoundMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Scale-Up, 100 kilograms of GMP-Grade Compound",
        "label": "Scale-Up, 100 kilograms of GMP-Grade Compound [Member]",
        "terseLabel": "Scale-up, 100 kilograms of GMP-grade compound"
       }
      }
     },
     "localname": "ScaleUp100KilogramsOfGMPGradeCompoundMember",
     "nsuri": "http://www.contexttherapeutics.com/20230331",
     "presentation": [
      "http://www.contexttherapeutics.com/role/CommitmentandContingenciesCollaborationAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cntx_ScaleUp300KilogramsOfGMPGradeCompoundMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Scale-Up, 300 kilograms of GMP-Grade Compound",
        "label": "Scale-Up, 300 kilograms of GMP-Grade Compound [Member]",
        "terseLabel": "Scale-up, 300 kilograms of GMP-grade compound"
       }
      }
     },
     "localname": "ScaleUp300KilogramsOfGMPGradeCompoundMember",
     "nsuri": "http://www.contexttherapeutics.com/20230331",
     "presentation": [
      "http://www.contexttherapeutics.com/role/CommitmentandContingenciesCollaborationAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cntx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedAsAPercentageOfOutstandingStock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Additional Shares Authorized As A Percentage Of Outstanding Stock",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Additional Shares Authorized As A Percentage Of Outstanding Stock",
        "terseLabel": "Annual rate at which authorized shares of common stock increase"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedAsAPercentageOfOutstandingStock",
     "nsuri": "http://www.contexttherapeutics.com/20230331",
     "presentation": [
      "http://www.contexttherapeutics.com/role/ShareBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "cntx_TyligandBioscienceShanghaiLimitedMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tyligand Bioscience (Shanghai) Limited",
        "label": "Tyligand Bioscience (Shanghai) Limited [Member]",
        "terseLabel": "Tyligand"
       }
      }
     },
     "localname": "TyligandBioscienceShanghaiLimitedMember",
     "nsuri": "http://www.contexttherapeutics.com/20230331",
     "presentation": [
      "http://www.contexttherapeutics.com/role/CommitmentandContingenciesCollaborationAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cntx_WarrantsIssued": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Warrants Issued",
        "label": "Warrants Issued",
        "verboseLabel": "Issuance of warrants for services provided"
       }
      }
     },
     "localname": "WarrantsIssued",
     "nsuri": "http://www.contexttherapeutics.com/20230331",
     "presentation": [
      "http://www.contexttherapeutics.com/role/CondensedConsolidatedStatementofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/Cover"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/Cover"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/Cover"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r304"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report",
        "terseLabel": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r305"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/Cover"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two",
        "terseLabel": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/Cover"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r302"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/Cover"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/Cover"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r302"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityExTransitionPeriod": {
     "auth_ref": [
      "r307"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.",
        "label": "Entity Ex Transition Period",
        "terseLabel": "Entity Ex Transition Period"
       }
      }
     },
     "localname": "EntityExTransitionPeriod",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/Cover"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r302"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/Cover"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/Cover"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r306"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r302"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r302"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r302"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r302"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/Cover"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r301"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r303"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/Cover"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/Cover"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "srt_CounterpartyNameAxis": {
     "auth_ref": [
      "r96",
      "r97",
      "r157",
      "r161",
      "r281",
      "r283"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Axis]",
        "terseLabel": "Counterparty Name [Axis]"
       }
      }
     },
     "localname": "CounterpartyNameAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/CommitmentandContingenciesCollaborationAgreementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r144",
      "r145",
      "r146",
      "r147",
      "r183",
      "r262",
      "r267",
      "r277",
      "r278",
      "r290",
      "r294",
      "r300",
      "r325",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/ShareBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r144",
      "r145",
      "r146",
      "r147",
      "r183",
      "r262",
      "r267",
      "r277",
      "r278",
      "r290",
      "r294",
      "r300",
      "r325",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/ShareBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r144",
      "r145",
      "r146",
      "r147",
      "r176",
      "r183",
      "r213",
      "r214",
      "r215",
      "r261",
      "r262",
      "r267",
      "r277",
      "r278",
      "r290",
      "r294",
      "r300",
      "r321",
      "r325",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]",
        "terseLabel": "Statistical Measurement [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/ShareBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r144",
      "r145",
      "r146",
      "r147",
      "r176",
      "r183",
      "r213",
      "r214",
      "r215",
      "r261",
      "r262",
      "r267",
      "r277",
      "r278",
      "r290",
      "r294",
      "r300",
      "r321",
      "r325",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]",
        "terseLabel": "Statistical Measurement [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/ShareBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "auth_ref": [
      "r96",
      "r97",
      "r157",
      "r161",
      "r282",
      "r283"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Domain]",
        "terseLabel": "Counterparty Name [Domain]"
       }
      }
     },
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/CommitmentandContingenciesCollaborationAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for accounts payable, accrued expenses, and other liabilities that are classified as current at the end of the reporting period.",
        "label": "Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block]",
        "terseLabel": "Accrued Expenses and Other Current Liabilities"
       }
      }
     },
     "localname": "AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/AccruedExpensesandOtherCurrentLiabilities"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r7",
      "r299"
     ],
     "calculation": {
      "http://www.contexttherapeutics.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r9"
     ],
     "calculation": {
      "http://www.contexttherapeutics.com/role/AccruedExpensesandOtherCurrentLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.contexttherapeutics.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Liabilities, Current",
        "terseLabel": "Accrued expenses and other current liabilities",
        "totalLabel": "Accrued expenses and other current liabilities"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/AccruedExpensesandOtherCurrentLiabilitiesDetails",
      "http://www.contexttherapeutics.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedProfessionalFeesCurrent": {
     "auth_ref": [
      "r9"
     ],
     "calculation": {
      "http://www.contexttherapeutics.com/role/AccruedExpensesandOtherCurrentLiabilitiesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Professional Fees, Current",
        "terseLabel": "Professional fees"
       }
      }
     },
     "localname": "AccruedProfessionalFeesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/AccruedExpensesandOtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapital": {
     "auth_ref": [
      "r2",
      "r299"
     ],
     "calculation": {
      "http://www.contexttherapeutics.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.",
        "label": "Additional Paid in Capital",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapital",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r222",
      "r223",
      "r224",
      "r316",
      "r317",
      "r318",
      "r329"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional Paid-in Capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/CondensedConsolidatedStatementsofChangesinStockholdersEquityUnaudited"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r51",
      "r52",
      "r185"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
        "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition",
        "terseLabel": "Share-based compensation expense"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/CondensedConsolidatedStatementsofChangesinStockholdersEquityUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued": {
     "auth_ref": [
      "r36",
      "r38",
      "r39"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants.",
        "label": "Adjustments to Additional Paid in Capital, Warrant Issued",
        "terseLabel": "Fair value of warrants issued for services"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalWarrantIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/CondensedConsolidatedStatementsofChangesinStockholdersEquityUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/CondensedConsolidatedStatementofCashFlowsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r217"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Share-Based Payment Arrangement, Expense",
        "terseLabel": "Share-based compensation expense"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/SharebasedCompensationScheduleofSharebasedCompensationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r119"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Antidilutive securities excluded from computation of diluted weighted-average shares of common stock outstanding"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesScheduleofAntidilutiveSecuritiesExcludedfromComputationofEarningsPerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "auth_ref": [
      "r28"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of antidilutive security.",
        "label": "Antidilutive Securities [Axis]",
        "terseLabel": "Antidilutive Securities [Axis]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesScheduleofAntidilutiveSecuritiesExcludedfromComputationofEarningsPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesScheduleofAntidilutiveSecuritiesExcludedfromComputationofEarningsPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "auth_ref": [
      "r28"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.",
        "label": "Antidilutive Securities, Name [Domain]",
        "terseLabel": "Antidilutive Securities, Name [Domain]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesScheduleofAntidilutiveSecuritiesExcludedfromComputationofEarningsPerShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]"
       }
      }
     },
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/CommitmentandContingenciesCollaborationAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r64",
      "r70",
      "r82",
      "r95",
      "r132",
      "r134",
      "r136",
      "r138",
      "r148",
      "r149",
      "r150",
      "r151",
      "r152",
      "r153",
      "r154",
      "r155",
      "r156",
      "r229",
      "r231",
      "r244",
      "r299",
      "r323",
      "r324",
      "r335"
     ],
     "calculation": {
      "http://www.contexttherapeutics.com/role/CondensedConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "Assets"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r78",
      "r86",
      "r95",
      "r138",
      "r148",
      "r149",
      "r150",
      "r151",
      "r152",
      "r153",
      "r154",
      "r155",
      "r156",
      "r229",
      "r231",
      "r244",
      "r299",
      "r323",
      "r324",
      "r335"
     ],
     "calculation": {
      "http://www.contexttherapeutics.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsFairValueDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Fair Value Disclosure [Abstract]",
        "terseLabel": "Financial assets"
       }
      }
     },
     "localname": "AssetsFairValueDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/FairValueMeasurementsScheduleofassetsandliabilitiesmeasuredatfairvalueonarecurringbasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r188",
      "r189",
      "r190",
      "r192",
      "r193",
      "r194",
      "r195",
      "r196",
      "r197",
      "r198",
      "r199",
      "r200",
      "r201",
      "r202",
      "r203",
      "r204",
      "r205",
      "r206",
      "r207",
      "r208",
      "r209",
      "r212",
      "r213",
      "r214",
      "r215",
      "r216"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/ShareBasedCompensationScheduleofAssumptionsUsedtoDetermineFairValueofShareBasedAwardsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "terseLabel": "Basis of Presentation"
       }
      }
     },
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r27"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). Accounting policies describe all significant accounting policies of the reporting entity.",
        "label": "Basis of Presentation and Significant Accounting Policies [Text Block]",
        "terseLabel": "Basis of Presentation and Summary of Significant Accounting Policies"
       }
      }
     },
     "localname": "BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/BasisofPresentationandSummaryofSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis": {
     "auth_ref": [
      "r60",
      "r61",
      "r62"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by project.",
        "label": "Project [Axis]",
        "terseLabel": "Project [Axis]"
       }
      }
     },
     "localname": "CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/CommitmentandContingenciesCollaborationAgreementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r24",
      "r80",
      "r280"
     ],
     "calculation": {
      "http://www.contexttherapeutics.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.contexttherapeutics.com/role/RisksandLiquidityNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAxis": {
     "auth_ref": [
      "r80"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of cash and cash equivalent balance.",
        "label": "Cash and Cash Equivalents [Axis]",
        "terseLabel": "Cash and Cash Equivalents [Axis]"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/FairValueMeasurementsScheduleofassetsandliabilitiesmeasuredatfairvalueonarecurringbasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashAndCashEquivalentsFairValueDisclosure": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash and Cash Equivalents, Fair Value Disclosure",
        "terseLabel": "Cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/FairValueMeasurementsScheduleofassetsandliabilitiesmeasuredatfairvalueonarecurringbasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "auth_ref": [
      "r25"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.",
        "label": "Cash and Cash Equivalents, Policy [Policy Text Block]",
        "terseLabel": "Cash, Cash Equivalents and Restricted Cash"
       }
      }
     },
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r19",
      "r24",
      "r26"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents",
        "periodEndLabel": "Cash and cash equivalents at end of period",
        "periodStartLabel": "Cash, cash equivalents and restricted cash at beginning of period"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/CondensedConsolidatedStatementofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r19",
      "r59"
     ],
     "calculation": {
      "http://www.contexttherapeutics.com/role/CondensedConsolidatedStatementofCashFlowsUnaudited": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Net decrease in cash, cash equivalents and restricted cash"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/CondensedConsolidatedStatementofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashUninsuredAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of cash as of the balance sheet date that is not insured by the Federal Deposit Insurance Corporation.",
        "label": "Cash, Uninsured Amount",
        "terseLabel": "Uninsured amount"
       }
      }
     },
     "localname": "CashUninsuredAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ClassOfStockDomain": {
     "auth_ref": [
      "r83",
      "r84",
      "r85",
      "r95",
      "r113",
      "r114",
      "r116",
      "r118",
      "r122",
      "r123",
      "r138",
      "r148",
      "r150",
      "r151",
      "r152",
      "r155",
      "r156",
      "r159",
      "r160",
      "r163",
      "r167",
      "r173",
      "r244",
      "r279",
      "r308",
      "r314",
      "r319"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.",
        "label": "Class of Stock [Domain]",
        "terseLabel": "Class of Stock [Domain]"
       }
      }
     },
     "localname": "ClassOfStockDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/ShareBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfWarrantOrRightAxis": {
     "auth_ref": [
      "r40",
      "r42"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of warrant or right issued.",
        "label": "Class of Warrant or Right [Axis]",
        "terseLabel": "Class of Warrant or Right [Axis]"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/CondensedConsolidatedStatementofCashFlowsUnaudited",
      "http://www.contexttherapeutics.com/role/StockholdersEquityNarrativeDetails",
      "http://www.contexttherapeutics.com/role/StockholdersEquityScheduleofWarrantsOutstandingDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfWarrantOrRightDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months.",
        "label": "Class of Warrant or Right [Domain]",
        "terseLabel": "Class of Warrant or Right [Domain]"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/CondensedConsolidatedStatementofCashFlowsUnaudited",
      "http://www.contexttherapeutics.com/role/StockholdersEquityNarrativeDetails",
      "http://www.contexttherapeutics.com/role/StockholdersEquityScheduleofWarrantsOutstandingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "auth_ref": [
      "r174"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding.",
        "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights",
        "terseLabel": "Warrant exercise price (in dollars per share)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/StockholdersEquityNarrativeDetails",
      "http://www.contexttherapeutics.com/role/StockholdersEquityScheduleofWarrantsOutstandingDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ClassOfWarrantOrRightLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Class of Warrant or Right [Line Items]",
        "terseLabel": "Class of Warrant or Right [Line Items]"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/StockholdersEquityNarrativeDetails",
      "http://www.contexttherapeutics.com/role/StockholdersEquityScheduleofWarrantsOutstandingDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfWarrantOrRightOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of warrants or rights outstanding.",
        "label": "Class of Warrant or Right, Outstanding",
        "terseLabel": "Warrants prior to conversion (in shares)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/StockholdersEquityNarrativeDetails",
      "http://www.contexttherapeutics.com/role/StockholdersEquityScheduleofWarrantsOutstandingDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ClassOfWarrantOrRightTable": {
     "auth_ref": [
      "r40",
      "r42"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure for warrants or rights issued, which includes the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.",
        "label": "Class of Warrant or Right [Table]",
        "terseLabel": "Class of Warrant or Right [Table]"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/StockholdersEquityNarrativeDetails",
      "http://www.contexttherapeutics.com/role/StockholdersEquityScheduleofWarrantsOutstandingDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember": {
     "auth_ref": [
      "r328"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement transaction between parties to collaborative arrangement.",
        "label": "Collaborative Arrangement, Transaction with Party to Collaborative Arrangement [Member]",
        "terseLabel": "Collaborative Arrangement, Transaction with Party to Collaborative Arrangement"
       }
      }
     },
     "localname": "CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/CommitmentandContingenciesCollaborationAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r11",
      "r66",
      "r74"
     ],
     "calculation": {
      "http://www.contexttherapeutics.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and Contingencies",
        "terseLabel": "Commitments and Contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r35",
      "r142",
      "r143",
      "r274",
      "r322"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "Commitments and Contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/CommitmentandContingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonClassAMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Classification of common stock representing ownership interest in a corporation.",
        "label": "Common Class A [Member]",
        "terseLabel": "Common Stock"
       }
      }
     },
     "localname": "CommonClassAMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/ShareBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r316",
      "r317",
      "r329"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common\u00a0Stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/CondensedConsolidatedStatementsofChangesinStockholdersEquityUnaudited"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common stock, par value (in dollars per share)"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common stock, shares authorized (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "terseLabel": "Common stock, shares issued (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r1",
      "r38"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "terseLabel": "Common stock, shares outstanding (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r1",
      "r299"
     ],
     "calculation": {
      "http://www.contexttherapeutics.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "terseLabel": "Common stock, $0.001 par value; 100,000,000 shares authorized; 15,966,053 shares issued and outstanding at March\u00a031, 2023 and December\u00a031, 2022"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "auth_ref": [
      "r69",
      "r127"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for credit risk.",
        "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]",
        "terseLabel": "Concentrations of Credit Risk"
       }
      }
     },
     "localname": "ConcentrationRiskCreditRisk",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConsolidationPolicyTextBlock": {
     "auth_ref": [
      "r56",
      "r284"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.",
        "label": "Consolidation, Policy [Policy Text Block]",
        "terseLabel": "Principles of Consolidation"
       }
      }
     },
     "localname": "ConsolidationPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DeferredChargesPolicyTextBlock": {
     "auth_ref": [
      "r81"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for deferral and amortization of significant deferred charges.",
        "label": "Deferred Charges, Policy [Policy Text Block]",
        "terseLabel": "Deferred Offering Costs"
       }
      }
     },
     "localname": "DeferredChargesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of discretionary contributions made by an employer to a defined contribution plan.",
        "label": "Defined Contribution Plan, Employer Discretionary Contribution Amount",
        "terseLabel": "Employer contribution amount"
       }
      }
     },
     "localname": "DefinedContributionPlanEmployerDiscretionaryContributionAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/CommitmentandContingenciesEmployeeBenefitPlansDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of employees' gross pay for which the employer contributes a matching contribution to a defined contribution plan.",
        "label": "Defined Contribution Plan, Employer Matching Contribution, Percent of Employees' Gross Pay",
        "terseLabel": "Employer matching contribution, percent of employees compensation"
       }
      }
     },
     "localname": "DefinedContributionPlanEmployerMatchingContributionPercent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/CommitmentandContingenciesEmployeeBenefitPlansDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum percentage of employee gross pay the employee may contribute to a defined contribution plan.",
        "label": "Defined Contribution Plan, Maximum Annual Contributions Per Employee, Percent",
        "terseLabel": "Maximum annual contributions per employee, percent"
       }
      }
     },
     "localname": "DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/CommitmentandContingenciesEmployeeBenefitPlansDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "auth_ref": [
      "r22",
      "r131"
     ],
     "calculation": {
      "http://www.contexttherapeutics.com/role/CondensedConsolidatedStatementofCashFlowsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.",
        "label": "Depreciation, Depletion and Amortization",
        "terseLabel": "Depreciation and amortization expense"
       }
      }
     },
     "localname": "DepreciationDepletionAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/CondensedConsolidatedStatementofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r187",
      "r218",
      "r219",
      "r221",
      "r226",
      "r295"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement [Text Block]",
        "terseLabel": "Share-Based Compensation"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/ShareBasedCompensation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r92",
      "r103",
      "r104",
      "r105",
      "r106",
      "r107",
      "r111",
      "r113",
      "r116",
      "r117",
      "r118",
      "r120",
      "r235",
      "r236",
      "r264",
      "r266",
      "r285"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic",
        "terseLabel": "Net income (loss) per share - basic (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/CondensedConsolidatedStatementsofOperationsUnaudited"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r92",
      "r103",
      "r104",
      "r105",
      "r106",
      "r107",
      "r113",
      "r116",
      "r117",
      "r118",
      "r120",
      "r235",
      "r236",
      "r264",
      "r266",
      "r285"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Diluted",
        "terseLabel": "Net income (loss) per share - diluted (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/CondensedConsolidatedStatementsofOperationsUnaudited"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "auth_ref": [
      "r28",
      "r29"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.",
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "terseLabel": "Net Loss Per Share"
       }
      }
     },
     "localname": "EarningsPerSharePolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "auth_ref": [
      "r9"
     ],
     "calculation": {
      "http://www.contexttherapeutics.com/role/AccruedExpensesandOtherCurrentLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Employee-related Liabilities, Current",
        "terseLabel": "Compensation and benefits"
       }
      }
     },
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/AccruedExpensesandOtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]",
        "terseLabel": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/SharebasedCompensationScheduleofSharebasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "auth_ref": [
      "r220"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "terseLabel": "Expected period for recognition"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/ShareBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": {
     "auth_ref": [
      "r327"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost to be recognized for option under share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount",
        "terseLabel": "Unrecognized compensation expense"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/ShareBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Share-Based Payment Arrangement, Option [Member]",
        "terseLabel": "Stock options"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesScheduleofAntidilutiveSecuritiesExcludedfromComputationofEarningsPerShareDetails",
      "http://www.contexttherapeutics.com/role/ShareBasedCompensationAdditionalInformationDetails",
      "http://www.contexttherapeutics.com/role/ShareBasedCompensationScheduleofAssumptionsUsedtoDetermineFairValueofShareBasedAwardsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r38",
      "r76",
      "r89",
      "r90",
      "r91",
      "r98",
      "r99",
      "r100",
      "r102",
      "r108",
      "r110",
      "r121",
      "r139",
      "r175",
      "r222",
      "r223",
      "r224",
      "r227",
      "r228",
      "r234",
      "r245",
      "r246",
      "r247",
      "r248",
      "r249",
      "r250",
      "r257",
      "r268",
      "r269",
      "r270"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/CondensedConsolidatedStatementsofChangesinStockholdersEquityUnaudited"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueAdjustmentOfWarrants": {
     "auth_ref": [
      "r22",
      "r37"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense (income) related to adjustment to fair value of warrant liability.",
        "label": "Fair Value Adjustment of Warrants",
        "terseLabel": "Fair value adjustment of warrants"
       }
      }
     },
     "localname": "FairValueAdjustmentOfWarrants",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/FairValueMeasurementsScheduleofassetsandliabilitiesmeasuredatfairvalueonarecurringbasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "auth_ref": [
      "r237",
      "r238",
      "r242"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.",
        "label": "Fair Value, Recurring and Nonrecurring [Table]",
        "terseLabel": "Fair Value, Recurring and Nonrecurring [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/FairValueMeasurementsScheduleofassetsandliabilitiesmeasuredatfairvalueonarecurringbasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r158",
      "r177",
      "r178",
      "r179",
      "r180",
      "r181",
      "r182",
      "r238",
      "r258",
      "r259",
      "r260",
      "r288",
      "r289",
      "r291",
      "r292",
      "r293"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "terseLabel": "Fair Value Hierarchy and NAV [Axis]"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/FairValueMeasurementsScheduleofassetsandliabilitiesmeasuredatfairvalueonarecurringbasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "auth_ref": [
      "r237",
      "r238",
      "r239",
      "r240",
      "r243"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by measurement frequency.",
        "label": "Measurement Frequency [Axis]",
        "terseLabel": "Measurement Frequency [Axis]"
       }
      }
     },
     "localname": "FairValueByMeasurementFrequencyAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/FairValueMeasurementsScheduleofassetsandliabilitiesmeasuredatfairvalueonarecurringbasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "localname": "FairValueDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "auth_ref": [
      "r241"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.",
        "label": "Fair Value Disclosures [Text Block]",
        "terseLabel": "Fair Value Measurements"
       }
      }
     },
     "localname": "FairValueDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/FairValueMeasurements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r158",
      "r177",
      "r182",
      "r238",
      "r258",
      "r291",
      "r292",
      "r293"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "terseLabel": "Level 1"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/FairValueMeasurementsScheduleofassetsandliabilitiesmeasuredatfairvalueonarecurringbasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r158",
      "r177",
      "r182",
      "r238",
      "r259",
      "r288",
      "r289",
      "r291",
      "r292",
      "r293"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "terseLabel": "Level 2"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/FairValueMeasurementsScheduleofassetsandliabilitiesmeasuredatfairvalueonarecurringbasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "auth_ref": [
      "r158",
      "r177",
      "r178",
      "r179",
      "r180",
      "r181",
      "r182",
      "r238",
      "r260",
      "r288",
      "r289",
      "r291",
      "r292",
      "r293"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "terseLabel": "Level 3"
       }
      }
     },
     "localname": "FairValueInputsLevel3Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/FairValueMeasurementsScheduleofassetsandliabilitiesmeasuredatfairvalueonarecurringbasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement frequency.",
        "label": "Measurement Frequency [Domain]",
        "terseLabel": "Measurement Frequency [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementFrequencyDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/FairValueMeasurementsScheduleofassetsandliabilitiesmeasuredatfairvalueonarecurringbasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r158",
      "r177",
      "r178",
      "r179",
      "r180",
      "r181",
      "r182",
      "r258",
      "r259",
      "r260",
      "r288",
      "r289",
      "r291",
      "r292",
      "r293"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "terseLabel": "Fair Value Hierarchy and NAV [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/FairValueMeasurementsScheduleofassetsandliabilitiesmeasuredatfairvalueonarecurringbasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "auth_ref": [
      "r241",
      "r243"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.",
        "label": "Fair Value, Recurring [Member]",
        "terseLabel": "Recurring"
       }
      }
     },
     "localname": "FairValueMeasurementsRecurringMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/FairValueMeasurementsScheduleofassetsandliabilitiesmeasuredatfairvalueonarecurringbasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueOfFinancialInstrumentsPolicy": {
     "auth_ref": [
      "r57",
      "r58"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments.",
        "label": "Fair Value of Financial Instruments, Policy [Policy Text Block]",
        "terseLabel": "Fair Value of Financial Instruments"
       }
      }
     },
     "localname": "FairValueOfFinancialInstrumentsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r15"
     ],
     "calculation": {
      "http://www.contexttherapeutics.com/role/CondensedConsolidatedStatementsofOperationsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "General and Administrative Expense",
        "terseLabel": "General and administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/CondensedConsolidatedStatementsofOperationsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing general and administrative expense.",
        "label": "General and Administrative Expense [Member]",
        "terseLabel": "General and administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/SharebasedCompensationScheduleofSharebasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_InProcessResearchAndDevelopmentPolicy": {
     "auth_ref": [
      "r54"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for costs assigned to identifiable tangible and intangible assets of an acquired entity to be used in the research and development activities of the combined enterprise. An entity also may disclose the appraisal method or significant assumptions used to value acquired research and development assets.",
        "label": "In Process Research and Development, Policy [Policy Text Block]",
        "terseLabel": "Acquired In-Process Research and Development Costs"
       }
      }
     },
     "localname": "InProcessResearchAndDevelopmentPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r140",
      "r141"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]",
        "terseLabel": "Income Statement Location [Axis]"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/SharebasedCompensationScheduleofSharebasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [
      "r141"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]",
        "terseLabel": "Income Statement Location [Domain]"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/SharebasedCompensationScheduleofSharebasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "auth_ref": [
      "r21"
     ],
     "calculation": {
      "http://www.contexttherapeutics.com/role/CondensedConsolidatedStatementofCashFlowsUnaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.",
        "label": "Increase (Decrease) in Accounts Payable",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/CondensedConsolidatedStatementofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilities": {
     "auth_ref": [
      "r21"
     ],
     "calculation": {
      "http://www.contexttherapeutics.com/role/CondensedConsolidatedStatementofCashFlowsUnaudited": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.",
        "label": "Increase (Decrease) in Accrued Liabilities",
        "terseLabel": "Accrued expenses and other current liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/CondensedConsolidatedStatementofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Changes in operating assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/CondensedConsolidatedStatementofCashFlowsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingLeaseLiability": {
     "auth_ref": [
      "r311",
      "r334"
     ],
     "calculation": {
      "http://www.contexttherapeutics.com/role/CondensedConsolidatedStatementofCashFlowsUnaudited": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in obligation for operating lease.",
        "label": "Increase (Decrease) in Operating Lease Liability",
        "terseLabel": "Operating lease liability"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/CondensedConsolidatedStatementofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherNoncurrentAssets": {
     "auth_ref": [
      "r311"
     ],
     "calculation": {
      "http://www.contexttherapeutics.com/role/CondensedConsolidatedStatementofCashFlowsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in noncurrent assets classified as other.",
        "label": "Increase (Decrease) in Other Noncurrent Assets",
        "negatedTerseLabel": "Other assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherNoncurrentAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/CondensedConsolidatedStatementofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "auth_ref": [
      "r21"
     ],
     "calculation": {
      "http://www.contexttherapeutics.com/role/CondensedConsolidatedStatementofCashFlowsUnaudited": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "negatedTerseLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/CondensedConsolidatedStatementofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]"
       }
      }
     },
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/CondensedConsolidatedStatementsofChangesinStockholdersEquityUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InterestIncomeExpenseNet": {
     "auth_ref": [
      "r68"
     ],
     "calculation": {
      "http://www.contexttherapeutics.com/role/CondensedConsolidatedStatementsofOperationsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net amount of operating interest income (expense).",
        "label": "Interest Income (Expense), Net",
        "terseLabel": "Interest income"
       }
      }
     },
     "localname": "InterestIncomeExpenseNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/CondensedConsolidatedStatementsofOperationsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeasesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases [Abstract]",
        "terseLabel": "Leases [Abstract]"
       }
      }
     },
     "localname": "LeasesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/CommitmentandContingenciesOperatingLeaseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeOperatingLeaseRemainingLeaseTerm": {
     "auth_ref": [
      "r332"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Remaining lease term of operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Operating Lease, Remaining Lease Term",
        "terseLabel": "Remaining lease term"
       }
      }
     },
     "localname": "LesseeOperatingLeaseRemainingLeaseTerm",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/CommitmentandContingenciesOperatingLeaseDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LesseeOperatingLeaseRenewalTerm": {
     "auth_ref": [
      "r333"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Operating Lease, Renewal Term",
        "terseLabel": "Additional renewal term"
       }
      }
     },
     "localname": "LesseeOperatingLeaseRenewalTerm",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/CommitmentandContingenciesOperatingLeaseDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LessorOperatingLeasePaymentsToBeReceived": {
     "auth_ref": [
      "r256"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lease payments to be received by lessor for operating lease.",
        "label": "Lessor, Operating Lease, Payments to be Received",
        "terseLabel": "Future minimum payments due"
       }
      }
     },
     "localname": "LessorOperatingLeasePaymentsToBeReceived",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/CommitmentandContingenciesOperatingLeaseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r8",
      "r95",
      "r138",
      "r148",
      "r149",
      "r150",
      "r151",
      "r152",
      "r153",
      "r154",
      "r155",
      "r156",
      "r230",
      "r231",
      "r232",
      "r244",
      "r286",
      "r323",
      "r335",
      "r336"
     ],
     "calculation": {
      "http://www.contexttherapeutics.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r6",
      "r65",
      "r72",
      "r299",
      "r315",
      "r320",
      "r331"
     ],
     "calculation": {
      "http://www.contexttherapeutics.com/role/CondensedConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and stockholders' equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "Liabilities and Stockholders' Equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r10",
      "r79",
      "r95",
      "r138",
      "r148",
      "r149",
      "r150",
      "r151",
      "r152",
      "r153",
      "r154",
      "r155",
      "r156",
      "r230",
      "r231",
      "r232",
      "r244",
      "r299",
      "r323",
      "r335",
      "r336"
     ],
     "calculation": {
      "http://www.contexttherapeutics.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_MoneyMarketFundsMember": {
     "auth_ref": [
      "r326"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.",
        "label": "Money Market Funds [Member]",
        "terseLabel": "Money market funds"
       }
      }
     },
     "localname": "MoneyMarketFundsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/FairValueMeasurementsScheduleofassetsandliabilitiesmeasuredatfairvalueonarecurringbasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NatureOfOperations": {
     "auth_ref": [
      "r124",
      "r130"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.",
        "label": "Nature of Operations [Text Block]",
        "terseLabel": "Organization and Description of Business"
       }
      }
     },
     "localname": "NatureOfOperations",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/OrganizationandDescriptionofBusiness"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r93"
     ],
     "calculation": {
      "http://www.contexttherapeutics.com/role/CondensedConsolidatedStatementofCashFlowsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Cash used in financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/CondensedConsolidatedStatementofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "terseLabel": "Cash flows from financing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/CondensedConsolidatedStatementofCashFlowsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r93"
     ],
     "calculation": {
      "http://www.contexttherapeutics.com/role/CondensedConsolidatedStatementofCashFlowsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Cash used in investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/CondensedConsolidatedStatementofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "Cash flows from investing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/CondensedConsolidatedStatementofCashFlowsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r19",
      "r20",
      "r23"
     ],
     "calculation": {
      "http://www.contexttherapeutics.com/role/CondensedConsolidatedStatementofCashFlowsUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Cash used in operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/CondensedConsolidatedStatementofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Cash flows from operating activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/CondensedConsolidatedStatementofCashFlowsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r13",
      "r23",
      "r67",
      "r75",
      "r77",
      "r87",
      "r88",
      "r91",
      "r95",
      "r101",
      "r103",
      "r104",
      "r105",
      "r106",
      "r109",
      "r110",
      "r115",
      "r132",
      "r133",
      "r135",
      "r137",
      "r138",
      "r148",
      "r149",
      "r150",
      "r151",
      "r152",
      "r153",
      "r154",
      "r155",
      "r156",
      "r236",
      "r244",
      "r287",
      "r323"
     ],
     "calculation": {
      "http://www.contexttherapeutics.com/role/CondensedConsolidatedStatementofCashFlowsUnaudited": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.contexttherapeutics.com/role/CondensedConsolidatedStatementsofOperationsUnaudited": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "terseLabel": "Net loss",
        "totalLabel": "Net loss"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/CondensedConsolidatedStatementofCashFlowsUnaudited",
      "http://www.contexttherapeutics.com/role/CondensedConsolidatedStatementsofChangesinStockholdersEquityUnaudited",
      "http://www.contexttherapeutics.com/role/CondensedConsolidatedStatementsofOperationsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "auth_ref": [
      "r16"
     ],
     "calculation": {
      "http://www.contexttherapeutics.com/role/CondensedConsolidatedStatementsofOperationsUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).",
        "label": "Nonoperating Income (Expense)",
        "terseLabel": "Other income (expense)"
       }
      }
     },
     "localname": "NonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/CondensedConsolidatedStatementsofOperationsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses [Abstract]",
        "terseLabel": "Operating expenses:"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/CondensedConsolidatedStatementsofOperationsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r132",
      "r133",
      "r135",
      "r137",
      "r287"
     ],
     "calculation": {
      "http://www.contexttherapeutics.com/role/CondensedConsolidatedStatementsofOperationsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "Loss from operations"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/CondensedConsolidatedStatementsofOperationsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseCost": {
     "auth_ref": [
      "r253",
      "r298"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.",
        "label": "Operating Lease, Cost",
        "terseLabel": "Rent expense"
       }
      }
     },
     "localname": "OperatingLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/CommitmentandContingenciesOperatingLeaseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiability": {
     "auth_ref": [
      "r252"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.",
        "label": "Operating Lease, Liability",
        "terseLabel": "Operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/CommitmentandContingenciesOperatingLeaseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r252"
     ],
     "calculation": {
      "http://www.contexttherapeutics.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease, Liability, Current",
        "terseLabel": "Operating lease liability - current"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r251"
     ],
     "calculation": {
      "http://www.contexttherapeutics.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease, Right-of-Use Asset",
        "terseLabel": "Operating lease right-of-use asset"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/CommitmentandContingenciesOperatingLeaseDetails",
      "http://www.contexttherapeutics.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense": {
     "auth_ref": [
      "r312"
     ],
     "calculation": {
      "http://www.contexttherapeutics.com/role/CondensedConsolidatedStatementofCashFlowsUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization expense for right-of-use asset from operating lease.",
        "label": "Operating Lease, Right-of-Use Asset, Amortization Expense",
        "terseLabel": "Reduction in the carrying amount of operating lease right-of-use asset"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAssetAmortizationExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/CondensedConsolidatedStatementofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "auth_ref": [
      "r255",
      "r298"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average discount rate for operating lease calculated at point in time.",
        "label": "Operating Lease, Weighted Average Discount Rate, Percent",
        "terseLabel": "Weighted average discount rate"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/CommitmentandContingenciesOperatingLeaseDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r9"
     ],
     "calculation": {
      "http://www.contexttherapeutics.com/role/AccruedExpensesandOtherCurrentLiabilitiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Accrued Liabilities, Current",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "OtherAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/AccruedExpensesandOtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r81"
     ],
     "calculation": {
      "http://www.contexttherapeutics.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets, Noncurrent",
        "terseLabel": "Other assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PayablesAndAccrualsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payables and Accruals [Abstract]"
       }
      }
     },
     "localname": "PayablesAndAccrualsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PaymentsOfStockIssuanceCosts": {
     "auth_ref": [
      "r18"
     ],
     "calculation": {
      "http://www.contexttherapeutics.com/role/CondensedConsolidatedStatementofCashFlowsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security.",
        "label": "Payments of Stock Issuance Costs",
        "negatedTerseLabel": "Payments for offering costs related to the private placement sale of common stock"
       }
      }
     },
     "localname": "PaymentsOfStockIssuanceCosts",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/CondensedConsolidatedStatementofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r17"
     ],
     "calculation": {
      "http://www.contexttherapeutics.com/role/CondensedConsolidatedStatementofCashFlowsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedTerseLabel": "Purchase of property and equipment"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/CondensedConsolidatedStatementofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r0",
      "r159"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "terseLabel": "Preferred stock, par value (in dollars per share)"
       }
      }
     },
     "localname": "PreferredStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred Stock, Shares Authorized",
        "terseLabel": "Preferred stock, shares authorized (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesIssued": {
     "auth_ref": [
      "r0",
      "r159"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.",
        "label": "Preferred Stock, Shares Issued",
        "terseLabel": "Preferred stock, shares issued (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.",
        "label": "Preferred Stock, Shares Outstanding",
        "terseLabel": "Preferred stock, shares outstanding (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockValue": {
     "auth_ref": [
      "r0",
      "r299"
     ],
     "calculation": {
      "http://www.contexttherapeutics.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Preferred Stock, Value, Issued",
        "terseLabel": "Preferred stock, $0.001 par value; 10,000,000 shares authorized; no shares issued or outstanding"
       }
      }
     },
     "localname": "PreferredStockValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r310"
     ],
     "calculation": {
      "http://www.contexttherapeutics.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense and Other Assets, Current",
        "terseLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrivatePlacementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A private placement is a direct offering of securities to a limited number of sophisticated investors such as insurance companies, pension funds, mezzanine funds, stock funds and trusts.",
        "label": "Private Placement [Member]",
        "terseLabel": "Private Placement"
       }
      }
     },
     "localname": "PrivatePlacementMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/CondensedConsolidatedStatementofCashFlowsUnaudited"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ProjectMember": {
     "auth_ref": [
      "r63"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Planned program of work.",
        "label": "Project [Domain]",
        "terseLabel": "Project [Domain]"
       }
      }
     },
     "localname": "ProjectMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/CommitmentandContingenciesCollaborationAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r34",
      "r73",
      "r265",
      "r299"
     ],
     "calculation": {
      "http://www.contexttherapeutics.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Property and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "auth_ref": [
      "r34",
      "r275",
      "r276"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property, Plant and Equipment, Policy [Policy Text Block]",
        "terseLabel": "Property and Equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Research and Development Arrangement, Contract to Perform for Others [Line Items]",
        "terseLabel": "Research and Development Arrangement, Contract to Perform for Others [Line Items]"
       }
      }
     },
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/CommitmentandContingenciesCollaborationAgreementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost": {
     "auth_ref": [
      "r53"
     ],
     "calculation": {
      "http://www.contexttherapeutics.com/role/CondensedConsolidatedStatementsofOperationsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The costs incurred in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, excluding in-process research and development acquired in a business combination consummated during the period. Excludes software research and development, which has a separate concept.",
        "label": "Research and Development Expense (Excluding Acquired in Process Cost)",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/CondensedConsolidatedStatementsofOperationsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research and Development Expense [Member]",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/SharebasedCompensationScheduleofSharebasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "auth_ref": [
      "r53"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.",
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "terseLabel": "Research and Development Costs"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember": {
     "auth_ref": [
      "r80"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of cash and cash equivalent. Cash is currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash and Cash Equivalents [Domain]",
        "terseLabel": "Cash and Cash Equivalents [Domain]"
       }
      }
     },
     "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/FairValueMeasurementsScheduleofassetsandliabilitiesmeasuredatfairvalueonarecurringbasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestrictedCashNoncurrent": {
     "auth_ref": [
      "r273",
      "r309",
      "r313"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.",
        "label": "Restricted Cash, Noncurrent",
        "terseLabel": "Restricted cash"
       }
      }
     },
     "localname": "RestrictedCashNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r3",
      "r39",
      "r71",
      "r271",
      "r272",
      "r299"
     ],
     "calculation": {
      "http://www.contexttherapeutics.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "negatedTerseLabel": "Accumulated deficit",
        "terseLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.contexttherapeutics.com/role/RisksandLiquidityNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r76",
      "r98",
      "r99",
      "r100",
      "r102",
      "r108",
      "r110",
      "r139",
      "r222",
      "r223",
      "r224",
      "r227",
      "r228",
      "r234",
      "r268",
      "r270"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated Deficit"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/CondensedConsolidatedStatementsofChangesinStockholdersEquityUnaudited"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
     "auth_ref": [
      "r254",
      "r298"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.",
        "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability",
        "terseLabel": "Right-of-use asset obtained in exchange for lease obligation"
       }
      }
     },
     "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/CondensedConsolidatedStatementofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.",
        "label": "Sale of Stock [Domain]",
        "terseLabel": "Sale of Stock [Domain]"
       }
      }
     },
     "localname": "SaleOfStockNameOfTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/CondensedConsolidatedStatementofCashFlowsUnaudited"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of accrued liabilities.",
        "label": "Schedule of Accrued Liabilities [Table Text Block]",
        "terseLabel": "Schedule of Accrued Liabilities"
       }
      }
     },
     "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/AccruedExpensesandOtherCurrentLiabilitiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "auth_ref": [
      "r28"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]",
        "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesScheduleofAntidilutiveSecuritiesExcludedfromComputationofEarningsPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "auth_ref": [
      "r28"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": {
     "auth_ref": [
      "r48",
      "r50"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements.",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]",
        "terseLabel": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/SharebasedCompensationScheduleofSharebasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "auth_ref": [
      "r48"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]",
        "terseLabel": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/ShareBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": {
     "auth_ref": [
      "r237",
      "r238"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).",
        "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]",
        "terseLabel": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis"
       }
      }
     },
     "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/FairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable": {
     "auth_ref": [
      "r54",
      "r55"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A schedule reflecting the terms of significant agreements under research and development arrangements accounted for as a contract to perform research and development for others (including royalty arrangements, purchase provisions, license agreements, and commitments to provide additional funding), aggregated by similar arrangements or individually if necessary to understand the effects on the financial statements.",
        "label": "Schedule of Research and Development Arrangement, Contract to Perform for Others [Table]",
        "terseLabel": "Schedule of Research and Development Arrangement, Contract to Perform for Others [Table]"
       }
      }
     },
     "localname": "ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/CommitmentandContingenciesCollaborationAgreementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r184",
      "r186",
      "r188",
      "r189",
      "r190",
      "r192",
      "r193",
      "r194",
      "r195",
      "r196",
      "r197",
      "r198",
      "r199",
      "r200",
      "r201",
      "r202",
      "r203",
      "r204",
      "r205",
      "r206",
      "r207",
      "r208",
      "r209",
      "r212",
      "r213",
      "r214",
      "r215",
      "r216"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]",
        "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/ShareBasedCompensationAdditionalInformationDetails",
      "http://www.contexttherapeutics.com/role/ShareBasedCompensationScheduleofAssumptionsUsedtoDetermineFairValueofShareBasedAwardsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "auth_ref": [
      "r43",
      "r44",
      "r45"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
        "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]",
        "terseLabel": "Schedule of Share-Based Award Activity"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/ShareBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "auth_ref": [
      "r47"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "terseLabel": "Schedule of Assumptions Used to Determine Fair Value of Share-Based Awards"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/ShareBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock": {
     "auth_ref": [
      "r40",
      "r42"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.",
        "label": "Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]",
        "terseLabel": "Schedule of Warrants Outstanding"
       }
      }
     },
     "localname": "ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/StockholdersEquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r21"
     ],
     "calculation": {
      "http://www.contexttherapeutics.com/role/CondensedConsolidatedStatementofCashFlowsUnaudited": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement, Noncash Expense",
        "terseLabel": "Share-based compensation expense"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/CondensedConsolidatedStatementofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "auth_ref": [
      "r295"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period",
        "terseLabel": "Share-based awards vesting period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/ShareBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "auth_ref": [
      "r214"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "terseLabel": "Expected dividend yield"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/ShareBasedCompensationScheduleofAssumptionsUsedtoDetermineFairValueofShareBasedAwardsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "auth_ref": [
      "r213"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate",
        "terseLabel": "Expected stock price volatility"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/ShareBasedCompensationScheduleofAssumptionsUsedtoDetermineFairValueofShareBasedAwardsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "auth_ref": [
      "r215"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "terseLabel": "Risk-free interest rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/ShareBasedCompensationScheduleofAssumptionsUsedtoDetermineFairValueofShareBasedAwardsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]",
        "verboseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/ShareBasedCompensationAdditionalInformationDetails",
      "http://www.contexttherapeutics.com/role/ShareBasedCompensationScheduleofAssumptionsUsedtoDetermineFairValueofShareBasedAwardsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": {
     "auth_ref": [
      "r297"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares authorized for issuance under share-based payment arrangement.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized",
        "terseLabel": "Total shares of common stock authorized for issuance (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/ShareBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "auth_ref": [
      "r49"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant",
        "terseLabel": "Shares of common stock available for grant (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/ShareBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures [Abstract]",
        "terseLabel": "Weighted Average Remaining Contractual Term (years)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/ShareBasedCompensationScheduleofShareBasedActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "auth_ref": [
      "r194"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number",
        "terseLabel": "Exercisable at period end (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/ShareBasedCompensationScheduleofShareBasedActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r194"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "terseLabel": "Exercisable at period end (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/ShareBasedCompensationScheduleofShareBasedActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "auth_ref": [
      "r198"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period",
        "negatedTerseLabel": "Forfeited (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/ShareBasedCompensationScheduleofShareBasedActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [
      "r196"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross",
        "terseLabel": "Granted during the period (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/ShareBasedCompensationScheduleofShareBasedActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r206"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted average fair value of grants during period (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/ShareBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r192",
      "r193"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Outstanding at period end (in shares)",
        "periodStartLabel": "Outstanding at beginning of period ( in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/ShareBasedCompensationScheduleofShareBasedActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]",
        "terseLabel": "Number of Options"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/ShareBasedCompensationScheduleofShareBasedActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r192",
      "r193"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Outstanding at period end (in dollars per share)",
        "periodStartLabel": "Outstanding at beginning of period (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/ShareBasedCompensationScheduleofShareBasedActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]",
        "terseLabel": "Weighted Average Exercise Price Per Share"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/ShareBasedCompensationScheduleofShareBasedActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": {
     "auth_ref": [
      "r208"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number",
        "terseLabel": "Vested and expected to vest at period end (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/ShareBasedCompensationScheduleofShareBasedActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r208"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price",
        "terseLabel": "Vested and expected to vest at period end (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/ShareBasedCompensationScheduleofShareBasedActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r188",
      "r189",
      "r190",
      "r192",
      "r193",
      "r194",
      "r195",
      "r196",
      "r197",
      "r198",
      "r199",
      "r200",
      "r201",
      "r202",
      "r203",
      "r204",
      "r205",
      "r206",
      "r207",
      "r208",
      "r209",
      "r212",
      "r213",
      "r214",
      "r215",
      "r216"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Award Type [Domain]",
        "terseLabel": "Award Type [Domain]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/ShareBasedCompensationScheduleofAssumptionsUsedtoDetermineFairValueofShareBasedAwardsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r198"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price",
        "terseLabel": "Forfeited (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/ShareBasedCompensationScheduleofShareBasedActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r196"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "terseLabel": "Granted (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/ShareBasedCompensationScheduleofShareBasedActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "auth_ref": [
      "r191",
      "r210",
      "r211",
      "r212",
      "r213",
      "r216",
      "r225",
      "r226"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.",
        "label": "Share-Based Payment Arrangement [Policy Text Block]",
        "terseLabel": "Share-based Compensation"
       }
      }
     },
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": {
     "auth_ref": [
      "r296"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period",
        "terseLabel": "Share-based award contractual life"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/ShareBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "auth_ref": [
      "r212"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term",
        "terseLabel": "Expected term (in years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/ShareBasedCompensationScheduleofAssumptionsUsedtoDetermineFairValueofShareBasedAwardsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r49"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term",
        "terseLabel": "Vested and exercisable at March\u00a031, 2023"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/ShareBasedCompensationScheduleofShareBasedActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r46"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Outstanding at beginning of period",
        "verboseLabel": "Outstanding at end of period"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/ShareBasedCompensationScheduleofShareBasedActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r208"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Vested and expected to vest at March\u00a031, 2023"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/ShareBasedCompensationScheduleofShareBasedActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.",
        "label": "Shares, Outstanding",
        "periodEndLabel": "Ending balance (in shares)",
        "periodStartLabel": "Beginning balance (in shares)"
       }
      }
     },
     "localname": "SharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/CondensedConsolidatedStatementsofChangesinStockholdersEquityUnaudited"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StatementClassOfStockAxis": {
     "auth_ref": [
      "r83",
      "r84",
      "r85",
      "r95",
      "r113",
      "r114",
      "r116",
      "r118",
      "r122",
      "r123",
      "r138",
      "r148",
      "r150",
      "r151",
      "r152",
      "r155",
      "r156",
      "r159",
      "r160",
      "r163",
      "r167",
      "r173",
      "r244",
      "r279",
      "r308",
      "r314",
      "r319"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by the different classes of stock of the entity.",
        "label": "Class of Stock [Axis]",
        "terseLabel": "Class of Stock [Axis]"
       }
      }
     },
     "localname": "StatementClassOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/ShareBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r12",
      "r38",
      "r76",
      "r89",
      "r90",
      "r91",
      "r98",
      "r99",
      "r100",
      "r102",
      "r108",
      "r110",
      "r121",
      "r139",
      "r175",
      "r222",
      "r223",
      "r224",
      "r227",
      "r228",
      "r234",
      "r245",
      "r246",
      "r247",
      "r248",
      "r249",
      "r250",
      "r257",
      "r268",
      "r269",
      "r270"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/CondensedConsolidatedStatementsofChangesinStockholdersEquityUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/CondensedConsolidatedStatementofCashFlowsUnaudited",
      "http://www.contexttherapeutics.com/role/CondensedConsolidatedStatementsofChangesinStockholdersEquityUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r98",
      "r99",
      "r100",
      "r121",
      "r263"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/CondensedConsolidatedStatementofCashFlowsUnaudited",
      "http://www.contexttherapeutics.com/role/CondensedConsolidatedStatementsofChangesinStockholdersEquityUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r1",
      "r4",
      "r5",
      "r33",
      "r299",
      "r315",
      "r320",
      "r331"
     ],
     "calculation": {
      "http://www.contexttherapeutics.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance",
        "totalLabel": "Total stockholders' equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.contexttherapeutics.com/role/CondensedConsolidatedStatementsofChangesinStockholdersEquityUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent [Abstract]",
        "verboseLabel": "Stockholders' equity:"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r41",
      "r94",
      "r160",
      "r162",
      "r163",
      "r164",
      "r165",
      "r166",
      "r167",
      "r168",
      "r169",
      "r170",
      "r171",
      "r172",
      "r175",
      "r233"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
        "label": "Stockholders' Equity Note Disclosure [Text Block]",
        "terseLabel": "Stockholders' Equity"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/StockholdersEquity"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of sale of the entity's stock.",
        "label": "Sale of Stock [Axis]",
        "terseLabel": "Sale of Stock [Axis]"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/CondensedConsolidatedStatementofCashFlowsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SupplementalCashFlowElementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental Cash Flow Elements [Abstract]",
        "terseLabel": "Supplemental disclosure of non-cash activities:"
       }
      }
     },
     "localname": "SupplementalCashFlowElementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/CondensedConsolidatedStatementofCashFlowsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TemporaryEquityDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Temporary Equity Disclosure [Abstract]"
       }
      }
     },
     "localname": "TemporaryEquityDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_TypeOfArrangementAxis": {
     "auth_ref": [
      "r328"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]"
       }
      }
     },
     "localname": "TypeOfArrangementAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/CommitmentandContingenciesCollaborationAgreementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r30",
      "r31",
      "r32",
      "r125",
      "r126",
      "r128",
      "r129"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "terseLabel": "Use of Estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_WarrantMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.",
        "label": "Warrant [Member]",
        "terseLabel": "Warrants"
       }
      }
     },
     "localname": "WarrantMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesScheduleofAntidilutiveSecuritiesExcludedfromComputationofEarningsPerShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WarrantsAndRightsOutstandingTerm": {
     "auth_ref": [
      "r330"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Warrants and Rights Outstanding, Term",
        "terseLabel": "Warrants, term from date of issuance"
       }
      }
     },
     "localname": "WarrantsAndRightsOutstandingTerm",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r112",
      "r118"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "Weighted average common shares outstanding - diluted (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/CondensedConsolidatedStatementsofOperationsUnaudited"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r111",
      "r118"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Weighted average common shares outstanding - basic (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.contexttherapeutics.com/role/CondensedConsolidatedStatementsofOperationsUnaudited"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 4
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1448-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1505-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1278-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1337-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e3842-109258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "275",
   "URI": "https://asc.fasb.org/topic&trid=2134479",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(4))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496180-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=SL116886442-113899",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4534-113899",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4549-113899",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(v)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(l)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.D.2.Q6)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "https://asc.fasb.org/topic&trid=2228938",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=SL126733271-114008",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(4)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(1)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3044-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19279-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=SL6742756-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4273-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(2)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(4)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=124258985&loc=SL77919396-209981",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "https://asc.fasb.org/extlink&oid=126937589&loc=SL119991595-234733",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "https://asc.fasb.org/topic&trid=2122369",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "210",
   "Topic": "954",
   "URI": "https://asc.fasb.org/extlink&oid=120413173&loc=SL116631458-115580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "440",
   "Subparagraph": "(a)",
   "Topic": "954",
   "URI": "https://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Subparagraph": "(d)",
   "Topic": "958",
   "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99779-112916",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99893-112916",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(c)",
   "Topic": "976",
   "URI": "https://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "978",
   "URI": "https://asc.fasb.org/extlink&oid=126945304&loc=d3e27327-108691",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r279": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1402",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226049-175313",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e4984-109258",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117819544-158441",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r301": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r302": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r303": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r304": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "308",
   "Subsection": "a",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r305": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r306": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r307": {
   "Name": "Securities Act",
   "Number": "7A",
   "Publisher": "SEC",
   "Section": "B",
   "Subsection": "2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054",
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(17))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(9))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(d))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "55",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e2626-109256",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "410",
   "URI": "https://asc.fasb.org/extlink&oid=6393242&loc=d3e13237-110859",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "https://asc.fasb.org/topic&trid=2127136",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "808",
   "URI": "https://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(1)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918673-209980",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918673-209980",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(1)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "https://asc.fasb.org/topic&trid=2144648",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466302&loc=d3e4724-112606",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "10",
   "Topic": "480",
   "URI": "https://asc.fasb.org/extlink&oid=109262497&loc=d3e20148-110875",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "50",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=6784392&loc=d3e188667-122775",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "https://asc.fasb.org/topic&trid=2208762",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5047-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.F)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11149-113907",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11178-113907",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "https://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "730",
   "URI": "https://asc.fasb.org/extlink&oid=6420387&loc=d3e23199-108380",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "730",
   "URI": "https://asc.fasb.org/extlink&oid=6420387&loc=d3e23221-108380",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=d3e5614-111684",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "60",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=7493716&loc=d3e21868-110260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13279-108611",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-10(a)(32))",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126954596&loc=d3e511914-122862",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-10(c)(3)(ii)(A))",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126954596&loc=d3e511914-122862",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-10(c)(7)(ii))",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126954596&loc=d3e511914-122862",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=SL6806780-109447",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.10)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126941378&loc=d3e61044-112788",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(17))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(18))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(9))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(2)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  }
 },
 "version": "2.2"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>51
<FILENAME>0001842952-23-000054-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001842952-23-000054-xbrl.zip
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MZ<W>,+6823ABC>";.QKP'X@]?FWUE8+ A]1MDVQG9\O)MQ\C4(YW8*QP0JQ
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M0"8B(DI$&!+L=)FPL($1F='EI_#9EO,>67 ^T,[<ENTY3/U5)]S/FU^3@EN
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M-^S%DZ7T&I,Y+V#%QG#0R7(+Q;KV4RRH(%ZVOOYPT")I @$QW JB(!;.A$*
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M@I$59Y:*<EVA8;%#P@=C(Q=UPK*[#4Q76",P94^#RRNL5O@&S+P?KBBF!_>
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M:_MBVNM4R.? 78&>E-DK;7>HVB&XN>M=3'8)?TTDDXPS_^.).PHG[N>)=U7
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M0V-_V_[X^?]5)Z=_;OT^BJ4ML;8L>7(^"@,N9+R+8/Z.F\WZ"W<M,TC#F3%
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MKCV]88:/]ZN_T,@Q>@2F1K<W<MVV3H*;PDZ7&1NYT<H$'?C;-2:U[J8?>"1
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MV!WJQX1"RU$I/U80*,\S8EL:(U7-XLAF@D)/.PS.9NI^QB/0JJQ[V*I#Y<A
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M;_!>)O+5-S;?H)(]E<;2#;9\"N<:-%:2I2Z[9*;AY+D,VV!\0>CM@QR.SB;
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M7;!7!<'DSQJ%:A1:*Q3"6@&A9QE)TU 5Q&NBJ+89Q2KG-'>J1J'U1*%L!H6
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M60%+J,^S$NBY"?AEG'?7CM83_W=-AKV*X&14PZ)BBK")<<XQ;DD-K[*:5?;
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MHIMW#CN225$PZ=N$<C<;IY+*E,92JEUZ_'F&&>&2:)]0;)%:B;;X,L&NJY9
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M$\Q^GC:=]3.- (?,YUP=Z)DX4 FF1J]:SPEE@9K767K!9G.T@N23"9" 4/+
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M6?SS@CR+XH74+RA-M3E2*?\?+1W!:@GR1DN@^!G,E8;ZM_KO3.D)UDH]D"W
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M&.F@^5')YY1R^SQS\CFG81"SA'D>EW$ PT10B *>PI2D$0P8CQ*?28RYYR
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M2"WBGB=@RE,&"=<5V9,HIAZ>K98K,C=;Q'=:MUI'-WT,QY!*.#!7<MFMCKN
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MC,U(PPUR W-&?]#<%&G=P6/(*JU51]<OT[JCL%&=UMTW7#C?-B=ZK[-0>K%
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M#=\^JO\4C;L&1CP,)5)0IAPB%C%(4UUV*(X#XB')!3*Z>CO?U>1(HRHQD2V
M&M*%:)6845^5#^X>[FT<8CI![F8-M] -31H5:JLEV$@**E%[^1%U?YL6KD2N
MX!O+F^@DC*[\B4P Z78IZFQA1*\B$TUV'8N,WNAG@7T01;',=P^0:C._^++\
M17P23"B3C\]8&L<IPI%"-HP@PD$,J< 8<F6/"2S"V)-6YIAIQU.CV??KE0Z*
M?<X6V?/Z&;S4(@/>4='T,N3-;+0A\!R8>RN1=7C-WN%Q([?F$RI ([H[ \X6
M+$?6G'&WHYIVMF#LVWG6[_<\CE9[3Y[-UWH'6GMP9:)X]XW-UUSP]THMO6M=
M5RO=O7Q'<IV*LW@0>;6O?3W>0+D-BFB4^%'D08*8SB,C(D@Y$9!@]3]*N42!
M58G* 66=&A^V)05;47OM5(<<8L/S^6D,W-"'_OW&S/XR8'@T7=TP#"CIN-<6
MPT-^<!<R0I<]W9](\?2;ZDPGR."W9?*K&9:$>#I;6!)SI"M4,8B%%T-!)?>Q
M9))[=M6(#_N8&D5OQ*L3@%GZ-QT!T8Q,+X1F8!+4TMV +3:WW=C8NS&=UMZ5
M_]*1'L9U7#JMXH''4L>C/7>N6U^<VP4_S$ZX<=WE.!3$YP+Z)! 0Q8)"2H0/
M4QX&J?H7'T5&$3.V'4^-!EIREYZ_EV<X-1X"PRWL , .O87=P[3.<#J$+[4M
M.J[VK*;=CKMGM03C8,]J^W[//>M!9/2;*EO 3 ?Q!8%(81C$:L<91"$DA$D8
M"1)Z**(H(5:D=+*GJ;'0D)D43L/MB9@H6T]")H@'=:DVB!/D0RPYBV2*4^)+
M*R<V)W"/X-=V';@--]LN0!QZJWR8B^(&U&(ZW"B?0\+5-O=D/^-N4L^I>[#%
M//O"0%G4BC-9>?Y2UE6Z6U1A:%VU)V?<9R1&GHX"374N1<X@I3&%?DA)G'H<
M1Q0[3:WF3O:IK2&EY&I2ZEI ?#F?D[P +XK1RKI ?<H"C?0)F-'B1 =V8*(U
M2=-6F.9IJQ#0OA 5!F<+((^8OLW]Z(V5T\VAY!-PD1QT2*RSOPT@PH75J2H7
M=[4[:JVZ=8$:?K_XI,]I\VSQJ![XN%SDS8]*_JRHHA^3B'B!1"F,A:00A;H,
M(!>A3H7 N*^60DEEKQI6ETHVM>5LFW;[!FRD+PWUMOS]HE/=#:?9XG6501IX
M:7(T/OVK:KG"TG7MK8OENDZ%+E=PGJSCY:R#'NZQGQF9B]]>?,_[O[/Y\C$G
MS\6]_,NO#VH!X4(O/LOU@M<.B;Z'&8^(A#R2'"(O]* ^>())*C!&(?)8:IY/
MSZ+CJ1%P*3I<O]P )3WX>R.^#G=7"L!'K0%@M0H6[J V8]%-KT,B/+1A7X+[
MVREP2^%!(WT?IUL;E"U<< =">R2'7"O4'?GH]D"LTV/7IKWQ_'=[:+GCS=OG
M_7ZF_$>QTM>N#_GR:\8%_^7U-[6WN%O4]7'4^L-6V=<JO3!*9,(%$3# C.FB
M00G$Q LAIKZ/8Q$0HO,[F)^/FW<]M0-S+398%U4DA6SD!60CL)W];3$&9@;V
M,,@.O 8HH4$);".V/LCY\;<*Y9_ 1GAP>QYF:S/:'C%'=K)%QZ,:PO: [%NZ
M/5KH?8&J7454DV6\J;ZNM2S#=;*!"4V/K9"@D7*8JEMGP7!WSW2JH[$OFLXH
M?.2FZ=P;_;[D=\\O\^6K$)_$G*R.7IH*CL,DUD7>19Q E 2BRAH:1X%:A%-,
M:&1U7G:VQZEMPW:._?7Q"A4+(3/;A"SGD3:C#J?X#<P@C:PPKX0=^+[:&!I'
M?'*^OU%IQ5C]?78Q?_&BY;*H,TINF"6AOD=C @,9<8C"5!GV22R@2!@-$46<
MID9!T=W=3(U.&BEUC)X6T]JYY1B45E;'!0"-8W$4H)9P&)^6#@S<&AK[G5S#
MR#BAZ D#X]33/?U83KO>"L_W>"022'&:0D2I!PD+*411A +)4ID@//LJ<KHT
M=CQQXIC;[G+ 8[ ='V=12OMG2P>12]V:OPM'YF/.X.!VM<HSNE[I#[6,[2>E
MP^ 06Y/1_)FGXL%L[[,\F)?R0RY>2,;K N6W"WZO_4.K2ZQFW0M9E$BI# <B
M(D4>@:*1U$,^%)()+R!^R(A5NFB#/J=F3]0B=[G2]LD?:8*^&=$XQG1@QFG@
MK,4MT2P%!DTY<N<FB05 KM+2&_0X;GIZ<P@.TM1;O-K3C&%/@J_GXEX>]X4J
M&;!VB-(7[94355&LGZO?E9?G.A%AF8=P%C/FT31)8"QPHDLE"9B2!$&?2B*T
MYS^65@<J;L6;&KTUVNDKPI;0H#RE5XO_6Z&D>,X6 FS]8?2S;7_,$@;;ZL=N
M!]W0)KO:4 Y^V[X=Q0Y/V5*_K;_L1L6=D:\<F@;*[#G( +BR$=T*-ZY=.0BP
M![;H,+WTO.<F.B73O:Q3T*CF9S*)PC0B"!*?<IW0A4*J;=:0IQY+?$2"P.K$
MZ["+J='W??Y(%MD_MH?G;T7!\JR$6Y/!+^M"<7=A>WU]"*WA-?5%@ U]'5T*
MIU'9BJ?8;@B>.XV#JTOFPP[&O4P^J>#!I?'I)_O-^[K\2>W:Y2%.6(2HKDY"
M(,)^#%/A2^CYNCA)J.Q F=A,^9W6IS;;:^$L9_,N8&83N3<, \_AI@[168=!
MZRE[5&-'LW6W[5$GZE&U]N?H\8?Z9]]1NT3]ASZN^DKF.LZERAN^M==1Z'/A
M4P1CJ4^E4Z&F;2@]*#&B(6))'(96@?!&O4YM.E>Y:$H/J9;0Y3+^212K/&/Z
M3E?_NWWNGO-#8$8$SH$=F"!*-#6"^[#>@+IDP:"E"ZS@<I@0Z'R?HZ<(,H;A
M6-(@\Y=[ER#(=<;*MZ+Z\VYQJE87DM(G,4T44[$8(@\)2,-8,94R+Z0,/9+X
M5D?@QCU/C:U.546SS!YDCKP900V"Y\ DU<@,?FRD_DG['>]EQ!VBFIHU6NXJ
M&ACV.W9] SLXCE0[L&S OMKXN\5*-? ^FXO\#5F)QV7^.O/"*)6)VNPD@NKR
M;)@J^XG$,&()ER+D# NC;<^)]J?&/96(H)01-$*:EQD_AF WNSC 96 .L8/$
MJKYXA^*]JHL?:V^TVN(=RK0KBW<]UO.<8C=:_^-:;Z[JD]/B?KTJ5LI,K0-
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M>F>^T_+4C(E:.%!)9WXKO@O7^7OPWB ,/,T-];>ZZ3ZJ:Z^[[=V61KO-/JI
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M1HI\:SXM<)JHD# !]#\<P AC0)G @-,HDS$DD5!.JYB6MN9FMD^@EC*U%=;
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M-]L%0CSCC,4@22D",&8AP+&@($*<)C"D<>Q>"^B\D;F]#P_%;EZ !A52]V)
M%X2VOW]\T33R6Z$'0[W* 351,*@>T,5-)R\(U-2M:Q6!&K_K/LG?:<Z7CY_7
M*_E^5\H <2P2EJ4,4.U# Z@$!BR-,)"(I8F,DH@(ZR(8YS>?VZ0N\04EP*!"
M:#^9+XCKGL1#Z!AY\CHPX31IF[K<:[)>W&RR2=K4C>/)V?B=?JOK?43UI_4]
M_V.7;_3KW*@2;)\?]<!MC3N@?_K5?&6!<$85%R$@RI3Q5% "AA@!),(IQ#@1
M&>6+E7RBQGFP7Q#;([!ZD$GU(%_@&.^A?M0W^FQ" M<J^%ICKU:T>^!NJU2'
M(;%;47IF>!I3L0=MEFDU[&"/^RXHD=]5Z[E.EIV79NZ$>5I&.30\Z9+'G9#S
MY4F/._3<+NPHL5XF:M9KGCI^^KDLJ?X2.D<11PS*"&2A2;P.(P4()AG VL(E
MBL$49TX*2L,AS<VCV?>HS#\^VGXI%Y3[!(1GQ\VYX0-GN<$VZ7#<.JJIZLC=
M85""?Y9]&2=8TA^UOO:EA@.:=F_)&X$7^T/^[CPPMZ02NS*QSXL$84&$*?=,
M8@F@C"- >9B ,&1A%$(10[,*7&_ITL[27FG#R70>6AIS"52<5G/5?/?,'#DB
MTL[R#:1G9%/VDB6R%Z4S #TJTK5TWW<^R%$+M\D"N>QB8^['E:_VF^$?9"&-
M-H[VYGXVZCCKTI^KPVEK^>>8"$X$PT!0/<]A%'' N"FS$.I59):98N].HC86
M;<[->=I#+E<OX@6TFQ6P(=O.*GBF<&0K<<+>$=Y]V':W@KFSW7 @R),=L6EQ
M4KOB0,&YG7&Y= K-G-I+KB+E%I*+!%'%@4JC%$ D%, QI@!S* G4W@F)D_&$
M<DZPS,U._7U'-[J=Y7.MCU.KX@1B)X/=U_6JS#A9RFIY44=JF"VPZFMC:J^<
M#F&[E9MX8$:V?KU55?9KPZI'TPW.F&HXO0=I(@F<PZOJ_NQ5=3)NK]:K,G4_
M^+0VHZ/6FR_!F_4F*.6L]?C]9J;:JZ.IYC2@(ROC7!T"OW(XITW,6 /G*A?#
MA&^NW[*G=WZ:W?W MC1?&3F)U]_Y9X-$/W2G^>#O<LKR9;Y]7B@I%),D PG%
M#, TP0!G^J49I0HC:**]N5-VY0 L<WM+'J0,#CH0P;KNCDDYD76'RBHPE7+$
M^C#(CA[_@ &T7 E,,RQCKQ NQ"6"AZ,1>7T\(F?*%,&A/QY7#\-)];6J&(!D
MVM7&<,HN5B$>;MG/[KY=\8VYW\^R^O?MZG$CO])<[.N#U$LA8_[-*[^J>+E(
MA4S2%(<@49E>F(0I!TS&$% A$<\8C),H['':W@_-7$_>*^C[;/?*^5V794#X
M3G=&NT>T1VW:GB-F9V-''(")JLG5'0A^VG?ASV5N93T6^VV8<AU2#D5'>6!G
M@SJ,04^VM">(2<WH,*+.+>C N_7,-%Q_^5*?397'5L>%.A<)9AE*.00QEAC
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M+;[NAP_<"<Z%2*5;E@"A,PI.F0S4\DRYY#GKVG[R9FJ&S??TH_W-$#M$%0V
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M3\=%>F6RV9K94=241$,YH,.)\4PV :PM,;*F+N5H"'FR"_<^8'R&I&$3^OT
MKJ86&@#5M9!69\2;V6(Q4K@G&#$>;$B=YTG!H9# &!I4XA&%5#N_^@@9PX*G
MUR-S3UDW4+'3#51,B^6*@S7F2\\A0CS#4!?!S@,O+=0$.!05:&5-9EHQDFH;
MGTVT#'O/TP=PJDB] 6/S=C:=W=T#5U8S,RF5-A22TPY$RAP,%PZX(YERKS+:
MT,KPV4C,L#<Z?>"GCMQ; %!:WK*=)',BF5*@LT7;F31:49$)D)!0'BY07_U%
MS1T"AKV7Z04H>\NW@;/IJHSZZM+H5[<8AQ%EB21N'/IZ+.(!BTZ^T[FX?M$G
M:T5RH?;K\T<)&?:BI0^P'"[O!BS*?29>CB<7RQ1'VB3&DB9H#FT H6( HZ,&
MFKQA5C'/4^V;X VD#'NK<@S@["/S!J#S]U0:MZ9X]@V/UL_I[<6Y3_-W^4$F
M?[4OT%9RFC :)#SB22MD!F>D 2.SL<0Q2UAM!WDG H>]:ND#9OWIIUWPK;?2
MP]LDPYC*"27GG6,H2*/!.4. !R8X,29Q7MN>[4CB5@"L/LEM  !6T=&/<./W
MXHN;?DZ+\?3A$Y-^KP"W6OCH=X*[BZ/^PXPG7A09:US29<R!R*J$BHA3[BUH
M$[77/BI7O1O\5H0=_F9QO<BGT@UPQ+PBAH4,E!D#PA.*[D@6D'$+*L.]X+IV
M5?Q="IIY:E$)"P^?+>XM[P;.W6OJ5Q(I4\!GTZX3SO?Q8J2<(%3S,M"/E[$S
M28"5*4!0EG'&#4%[WA=X'B.H$2SMH>E-H#E8[ U@Z!X/+V?G;CP=*2$=Y]8#
MNA<H'BM*'PH2H61R1=+,!U*[+O110AK!S.&*OA]U'BSU!J!SJV+L]U3<R9'(
M1,2L*0A:JEAS1@:20^%P2;S0(B(C_57LK8@8%C(5%+NY+F\/*3< DPW=2M;,
M.*JSB)$"53R!<+F;_J" )"&#+]7/JG;>_$F"AKWIK0^?>M)O $KWFY2LN6"4
M,<<EAU3NC$3D96X]BQ!#E$P*E6WUMAZ/4S+L;6]]\%20=P.HN3[&,5Q.K_'+
MQ8BB^Y=B\.6"L<R^9@J,X (P;)=*18L,U'[;_I"*1IX85W2(]Q-P Q!Y/0WS
MTO'Z95K]]_4C>8\/L\GDU6S^AYO'TK&6:^T5!,LS^GX6]Q/N*F#:>VVE]5+5
MSC_L2&(CGO.>B'A0<]*?>AI W\/L:T8KBMO1@K&Z3/4D#AS3%H*QGEN#//#J
ML?M>.? ^R\3[4_E]^W60_/<&T-<T'\]*UG6^[*OA&1[TBI1[@LX#$-+@X1^]
M!9:$MCHZ9DWM4J8]NU3U63QY/" =IH%FD'06_^-BL6JJ_6FV(8+XNYO/W72Y
M?G>87/94*PE4IQ)(Q)(601,?I!0\X*8)U1LU[DSDX+681\-AO_IKX,3<AL'.
MJGO777*=EPK#3M4?$DIZ,5ZFCVG^;1S*JW[<.A]2F'V>=I^RGMG.O+1*I%(J
MA-+7J )O&,>]*Z+,02@;:AO.OGD:O)2T*?@?#1T-[):[E91<6\,DNC7:,-SJ
MWEK<ZEW3@9 L%X105GN@6UN5JD?#X?YR;P T#YUB9FG6DE'PC"H\(QP%2ZF&
M'$(F(647775G<J^@I,_*U0&#DEWD?Z K^=LT]A621,X9B9R!-,*B[90*3&E4
MH(V0.FC'E*^=\-\S).FSCG7(D&07#53%T5#E7;/\PBV^O)K,_NBSG<.CJQRW
M<.MY1NM7:5VO>%V00PRWS$@"A'+$5PH&O'<>>%8\46]BZ&&';Z:G<DV6#5H$
MXCD05^Y<RVV9]PP#IZ2%XIH0$6L_2&VT)NLPS3]3BK6+F!OPEEY,W&+Q+J^#
MZG?S#Z7:=E4F0HV6!L,$320:;S368'WI41BBXVC!,Y&U\;*1F$:@LX>&[Q=%
M5!%WJ[A9W]QR9<J![T&1C +RFH*)/D(D3$E. S6\>G.^S>0,BYU*"M\&1GM(
M?T @%2]EM$KBH;NX3EM<7=13'WDDU(-D3H/("1W'\E<6T&/$;R66Z'-.SU,+
M-(B)?;0WJRS*!NS*QPN_&,>QFU]^=).TKI_N]DLP)F2>+40K2_58<F"UTD!L
M2#$197U,M?V73<0T50%QR'E41]PMX.:&_+?N'+_\A'MK@;X=ZF2]M;1$063-
M(+A(T,QZ [84W5N1E,\B><9KYP^?IVI@SZ:.^N^#JJXN&D#7^_GX&^ZY]Q,7
MNHVWMJW6$.,-"6!RJ4+,1(,G2H'$/6<#US16'R_Y."4#HZBROA]T3S]8^ U
MZ)'*(ATSISF57A#E:$X!/4"%YW.6GB8,2(4(O47D;W8JYNM_H$.%H^PP 3<
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M,6P7@)MM]AN"9W:9TL<T_S8.Z7'-G4VZC^S23!A0S3Y/Q_]$HKI)-1VEMZX
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M#"TSQR(+RC%JM[H2>D;E=Q8=6.G[J&Q60WY#*]Y]OT6X"UIZD0104KH$1Q[
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M@KMA>QK?3]STK3M/5[%Z2,YSQ\%;'T%8'\ E],:XU,9GP[*O?DG0!Q_#@OL
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MMN6"PX&F)SW/>A;ZT$!ZC1+"TWOR.WYFN)BX^>MIN/(-$I-**PN>:(=R0M_
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M RN>N7&LF%UPU#+/*9Y0E]*REBW24BTYT#8*\!5\T3(1S!W<=3'6@@FJA U
M^(KKF#>S(Q7:5D&W [0KF8Z7I.9P"$=VURF'P!-AD5!+IPC+.;&HINCA:_.R
MI,"W,;>&8#STYVP]PST$BQ<"IO%=,#UZ@ZY@ZO%;^]'0 APG@EG$4"TS:CF,
M:J#-JBL+(ZK8/*4 F:!CD0@SLY5MW;06X"[[+K$>F[=,E]29H\KK,J"\4#F
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M,#,S,3$P+7%E>&AI8FET,S(Q+FAT;>U967/:2!!^WU_1BVL=NPJ=@+&!N(H
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M,S,Q+FAT;5!+ 0(4 Q0    ( %N$JE8L@Z=".0H  +Y?   1
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M8FET,S$Q+FAT;5!+ 0(4 Q0    ( %N$JE:UD_XQ1@@  .(I   >
M      "  3+] 0!C;G1X,C R,S S,S$Q,"UQ97AH:6)I=#,Q,BYH=&U02P$"
M% ,4    " !;A*I6CJ6L?]D%  !'&0  '@              @ &T!0( 8VYT
M>#(P,C,P,S,Q,3 M<65X:&EB:70S,C$N:'1M4$L%!@     )  D ;P(  ,D+
$ @    $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
